Torsade B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
de B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pointes B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ventricular B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tachycardia B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
during O
low O
dose O
intermittent O
dobutamine O
treatment O
in O
a O
patient O
with O
dilated B_DISEASE
cardiomyopathy I_DISEASE
and O
congestive B_DISEASE/B_LOCATION
heart I_DISEASE/I_LOCATION
failure I_DISEASE/I_LOCATION
. O

The O
authors O
describe O
the O
case O
of O
a O
56 O
- O
year O
- O
old O
woman O
with O
chronic O
, O
severe O
heart B_DISEASE
failure I_DISEASE
secondary O
to O
dilated B_DISEASE
cardiomyopathy I_DISEASE
and O
absence O
of O
significant O
ventricular B_DISEASE
arrhythmias I_DISEASE
who O
developed O
QT B_DISEASE
prolongation I_DISEASE
and O
torsade B_DISEASE
de I_DISEASE
pointes I_DISEASE
ventricular I_DISEASE
tachycardia I_DISEASE
during O
one O
cycle O
of O
intermittent O
low O
dose O
( O
2 O
. O
5 O
mcg O
/ O
kg O
per O
min O
) O
dobutamine O
. O

This O
report O
of O
torsade B_DISEASE
de I_DISEASE
pointes I_DISEASE
ventricular I_DISEASE
tachycardia I_DISEASE
during O
intermittent O
dobutamine O
supports O
the O
hypothesis O
that O
unpredictable O
fatal O
arrhythmias B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
may O
occur O
even O
with O
low O
doses O
and O
in O
patients O
with O
no O
history O
of O
significant O
rhythm O
disturbances O
. O

The O
mechanisms B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
proarrhythmic B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
effects B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
Dubutamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
are O
discussed O
. O

Positive B_DISEASE_ADJECTIVE[DISEASE]
skin I_DISEASE_ADJECTIVE[DISEASE]
tests I_DISEASE_ADJECTIVE[DISEASE]
in O
late B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
reactions I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
to O
radiographic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
contrast I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
media I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O

In O
the O
last B_TIME[MEASURE]/B_BODY_PART_OR_ORGAN_COMPONENT
few B_TIME[MEASURE]/I_BODY_PART_OR_ORGAN_COMPONENT
years B_TIME[MEASURE]/I_BODY_PART_OR_ORGAN_COMPONENT
delayed O
reactions B_TIME[MEASURE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
several B_TIME[MEASURE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hours B_TIME[MEASURE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
after O
the O
injection B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
of O
radiographic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
contrast B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
materials I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
PRC B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O
have O
been O
described O
with O
increasing O
frequency B_MEASURE
. O

The O
authors B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
report O
two B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
observations I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
patients B_PERSON/B_BIO
with O
delayed O
reactions B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
whom O
intradermoreactions B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O
IDR B_LOCATION/B_ORGANIZATION
) O
and O
patch B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
tests I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
to O
a O
series B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
ionic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
non B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ionic I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
PRC I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
studied O
. O

After O
angiography O
by O
the O
venous O
route O
in O
patient O
n O
degree O
1 O
a O
biphasic O
reaction O
with O
an O
immediate O
reaction O
( O
dyspnea B_DISEASE
, O
loss B_DISEASE
of I_DISEASE
consciousness I_DISEASE
) O
and O
delayed O
macro B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- B_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
papular B_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
rash B_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
appeared O
, O
whilst O
patient O
n O
degree O
2 O
developed O
a O
generalised O
sensation O
of O
heat O
, O
persistent O
pain B_DISEASE
at O
the O
site O
of O
injection O
immediately O
and O
a O
generalised O
macro O
- O
papular O
reaction O
after O
24 O
hours O
. O

The O
skin B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
tests I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
revealed O
positive B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
delayed O
reactions B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
24 B_MEASURE/B_SPORT[ENT]
hours I_MEASURE/I_SPORT[ENT]
and O
48 B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
hours B_TIME[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
by O
IDR B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O
patch B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
tests B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
to O
only O
some O
PRC B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
common B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
chains B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
their O
structures B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O

The O
positive O
skin O
tests O
are O
in O
favour O
of O
immunological O
reactions O
and O
may O
help O
in O
diagnosis O
of O
allergy B_DISEASE
in O
the O
patients O
. O

Risk O
of O
transient O
hyperammonemic B_DISEASE
encephalopathy I_DISEASE
in O
cancer B_DISEASE/B_PERSON
patients O
who O
received O
continuous O
infusion O
of O
5 O
- O
fluorouracil O
with O
the O
complication O
of O
dehydration B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
infection B_DISEASE
. O

From O
1986 O
to O
1998 O
, O
29 O
cancer B_DISEASE/B_PERSON
patients O
who O
had O
32 O
episodes O
of O
transient O
hyperammonemic B_DISEASE
encephalopathy I_DISEASE
related O
to O
continuous O
infusion O
of O
5 O
- O
fluorouracil O
( O
5 O
- O
Fu O
) O
were O
identified O
. O

None O
of O
the O
patients O
had O
decompensated O
liver B_DISEASE/B_GENE
disease I_DISEASE/I_GENE
. O

onset O
of O
hyperammonemic B_DISEASE
encephalopathy I_DISEASE
varied O
from O
0 O
. O
5 O
to O
5 O
days O
( O
mean O
: O
2 O
. O
6 O
+ O
/ O
- O
1 O
. O
3 O
days O
) O
after O
the O
initiation O
of O
chemotherapy O
. O

Plasma B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
ammonium I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
level I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
ranged O
from O
248 B_MEASURE
to O
2387 B_MEASURE
microg I_MEASURE
% I_MEASURE
( O
mean B_MEASURE
: O
626 B_MEASURE/B_LOCATION
+ I_MEASURE/I_LOCATION
/ O
- O
431 B_MEASURE
microg I_MEASURE
% I_MEASURE
) O
. O

Among O
the O
32 O
episodes O
, O
26 O
( O
81 O
% O
) O
had O
various O
degrees O
of O
azotemia B_DISEASE
, O
18 O
( O
56 O
% O
) O
occurred O
during O
bacterial B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
infections I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
14 O
( O
44 O
% O
) O
without O
infection B_DISEASE/B_PERSON
occurred O
during O
periods O
of O
dehydration B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Higher O
plasma O
ammonium O
levels O
and O
more O
rapid O
onset O
of O
hyperammonemia B_DISEASE
were O
seen O
in O
18 O
patients O
with O
bacterial B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
infections B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
p O
= O
0 O
. O
003 O
and O
0 O
. O
0006 O
, O
respectively O
) O
and O
in O
nine O
patients O
receiving O
high O
daily O
doses O
( O
2600 O
or O
1800 O
mg O
/ O
m2 O
) O
of O
5 O
- O
Fu O
( O
p O
= O
0 O
. O
0001 O
and O
< O
0 O
. O
0001 O
, O
respectively O
) O
. O

In O
25 B_MEASURE
out O
of O
32 B_MEASURE
episodes I_MEASURE
( O
78 B_MEASURE/B_LOCATION
% I_MEASURE/I_LOCATION
) O
, O
plasma B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
ammonium I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
levels I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
and O
mental B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
status I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
returned O
to O
normal B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
within O
2 B_TIME[MEASURE]/B_ENT
days I_TIME[MEASURE]/I_ENT
after O
adequate B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
management I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
. O

In O
conclusion O
, O
hyperammonemic B_DISEASE
encephalopathy I_DISEASE
can O
occur O
in O
patients O
receiving O
continuous O
infusion O
of O
5 O
- O
Fu O
. O

Azotemia B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
, O
body O
fluid O
insufficiency O
and O
bacterial B_DISEASE
infections I_DISEASE
were O
frequently O
found O
in O
these O
patients O
. O

It O
is O
therefore O
important B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
recognize O
this O
condition B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
in O
patients B_PERSON/B_BIO
receiving O
continuous B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
infusion I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
of O
5 B_MEASURE/B_PERSON
- O
FU B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
. O

The O
effects B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
quinine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
and O
4 B_MEASURE
- O
aminopyridine B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
conditioned B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
place I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
preference I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
changes B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
motor B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
activity I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
induced O
by O
morphine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
in O
rats B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

1 B_NUMBER[MEASURE]
. O

The O
effects B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
two B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
unselective I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
potassium I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
K B_PROTEIN[GENE]/B_LOCATION
( O
+ B_PROTEIN[GENE]/B_DISEASE
) O
- O
) O
channel B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
blockers I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
quinine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
( O
12 B_MEASURE
. O
5 B_MEASURE
, O
25 B_MEASURE
and O
50 B_MEASURE
mg I_MEASURE
/ O
kg B_MEASURE
) O
and O
4 B_MEASURE
- O
aminopyridine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
( O
1 B_MEASURE
and O
2 B_MEASURE
mg I_MEASURE
/ O
kg B_MEASURE
) O
, O
on O
conditioned O
place B_DISEASE_ADJECTIVE[DISEASE]
preference I_DISEASE_ADJECTIVE[DISEASE]
and O
biphasic B_DISEASE_ADJECTIVE[DISEASE]
changes I_DISEASE_ADJECTIVE[DISEASE]
in O
motor B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
activity I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
induced O
by O
morphine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
10 B_MEASURE
mg I_MEASURE
/ O
kg B_MEASURE
) O
were O
tested O
in O
Wistar B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
rats I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Quinine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
is O
known O
to O
block O
voltage B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
, O
calcium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
- O
and O
ATP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
sensitive B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
K I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
+ B_PROTEIN[GENE]/B_DISEASE
) O
- O
channels B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
while O
4 B_MEASURE
- O
aminopyridine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
is O
known O
to O
block O
voltage B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
sensitive B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
K B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
+ B_PROTEIN[GENE]/B_DISEASE
) O
- O
channels B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O

2 B_NUMBER[MEASURE]
. O

In O
the O
counterbalanced B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
method B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
, O
quinine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
attenuated I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
morphine I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
- O
induced O
place B_DISEASE
preference I_DISEASE
, O
whereas O
4 B_MEASURE
- O
aminopyridine B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
ineffective B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O

In O
the O
motor O
activity O
test O
measured O
with O
an O
Animex O
- O
activity O
meter O
neither O
of O
the O
K O
( O
+ O
) O
- O
channel O
blockers O
affected O
morphine O
- O
induced O
hypoactivity B_DISEASE
, O
but O
both O
K O
( O
+ O
) O
- O
channel O
blockers O
prevented O
morphine O
- O
induced O
secondary O
hyperactivity B_DISEASE
. O

3 B_NUMBER[MEASURE]
. O

These O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggest O
the O
involvement B_PERSON/B_DISEASE
of O
quinine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O
sensitive B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
but O
not O
4 B_MEASURE
- O
aminopyridine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O
sensitive B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
K B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
( O
+ B_PROTEIN[GENE]/B_DISEASE
) O
- O
channels B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
in O
morphine B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reward I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

It O
is O
also O
suggested O
that O
the O
blockade O
of O
K O
( O
+ O
) O
- O
channels O
sensitive O
to O
these O
blockers O
is O
not O
sufficient O
to O
prevent O
morphine O
- O
induced O
hypoactivity B_DISEASE
whereas O
morphine O
- O
induced O
hyperactivity B_DISEASE
seems O
to O
be O
connected O
to O
both O
quinine O
- O
and O
4 O
- O
aminopyridine O
- O
sensitive O
K O
( O
+ O
) O
- O
channels O
. O

Nociceptin O
/ O
orphanin O
FQ O
and O
nocistatin O
on O
learning B_DISEASE
and I_DISEASE
memory I_DISEASE
impairment I_DISEASE
induced O
by O
scopolamine O
in O
mice O
. O

1 B_NUMBER[MEASURE]
. O

Nociceptin B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
also O
known O
as O
orphanin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
FQ I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O
is O
an O
endogenous B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
ligand I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
for O
the O
orphan B_GENE
opioid I_GENE
receptor I_GENE
- O
like B_PROTEIN[GENE]
receptor I_PROTEIN[GENE]
1 I_PROTEIN[GENE]
( O
ORL1 B_GENE/B_DISEASE
) O
and O
involves O
in O
various B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
functions B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
in O
the O
central B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
nervous I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
system I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
( O
CNS B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
) O
. O

On O
the O
other O
hand O
, O
nocistatin O
is O
recently O
isolated O
from O
the O
same O
precursor O
as O
nociceptin O
and O
blocks O
nociceptin O
- O
induced O
allodynia B_DISEASE
and O
hyperalgesia B_DISEASE
. O

2 B_NUMBER[MEASURE]
. O

Although O
ORL1 B_GENE
receptors I_GENE
which O
display O
a O
high B_MEASURE/B_LOCATION
degree I_MEASURE/I_LOCATION
of O
sequence B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
homology I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
with O
classical B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
opioid I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptors I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
are O
abundant B_DISEASE_ADJECTIVE[DISEASE]
in O
the O
hippocampus B_BODY_PART_OR_ORGAN_COMPONENT
, O
little B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
is O
known O
regarding O
their O
role B_TIME[MEASURE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
learning B_DISEASE
and O
memory B_DISEASE
. O

3 B_NUMBER[MEASURE]
. O

The O
present O
study O
was O
designed O
to O
investigate O
whether O
nociceptin O
/ O
orphanin O
FQ O
and O
nocistatin O
could O
modulate O
impairment B_DISEASE
of I_DISEASE
learning I_DISEASE
and I_DISEASE
memory I_DISEASE
induced O
by O
scopolamine O
, O
a O
muscarinic O
cholinergic O
receptor O
antagonist O
, O
using O
spontaneous O
alternation O
of O
Y O
- O
maze O
and O
step O
- O
down O
type O
passive O
avoidance O
tasks O
in O
mice O
. O

4 B_NUMBER[MEASURE]
. O

While O
nocistatin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O
0 B_NUMBER[MEASURE]
. O
5 B_MEASURE
- O
5 B_MEASURE
. O
0 B_MEASURE/B_PERSON
nmol I_MEASURE/I_PERSON
mouse I_MEASURE/I_PERSON
- O
1 B_NUMBER[MEASURE]
, O
i O
. O
c O
. O
v B_PROTEIN[GENE]/B_MEASURE
. O
) O
administered O
30 B_TIME[MEASURE]/B_LOCATION
min I_TIME[MEASURE]/I_LOCATION
before O
spontaneous B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
alternation I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
performance I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
or O
the O
training B_TIME[MEASURE]/B_LOCATION
session I_TIME[MEASURE]/I_LOCATION
of O
the O
passive B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
avoidance I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
task I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
had O
no O
effect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
spontaneous B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
alternation I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
or O
passive B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
avoidance B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
behaviours B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
a O
lower B_MEASURE
per O
cent B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
alternation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
and O
shorter B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
median B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
step O
- O
down O
latency B_MEASURE
in O
the O
retention B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
test I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
were O
obtained O
in O
nociceptin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
1 B_MEASURE/B_LOCATION
. O
5 B_MEASURE
and O
/ O
or O
5 B_MEASURE
. O
0 B_MEASURE/B_PERSON
nmol I_MEASURE/I_PERSON
mouse I_MEASURE/I_PERSON
- O
1 B_NUMBER[MEASURE]
, O
i O
. O
c O
. O
v O
. O
) O
- O
treated O
normal B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mice I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

5 B_NUMBER[MEASURE]
. O

Administration B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
nocistatin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O
1 B_MEASURE
. O
5 B_MEASURE
and O
/ O
or O
5 B_MEASURE
. O
0 B_MEASURE/B_PERSON
nmol I_MEASURE/I_PERSON
mouse I_MEASURE/I_PERSON
- O
1 B_MEASURE
, O
i O
. O
c O
. O
v B_PROTEIN[GENE]/B_LOCATION
. O
) O
30 B_TIME[MEASURE]/B_LOCATION
min I_TIME[MEASURE]/I_LOCATION
before O
spontaneous B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
alternation I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
performance I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
or O
the O
training B_TIME[MEASURE]/B_LOCATION
session I_TIME[MEASURE]/I_LOCATION
of O
the O
passive B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
avoidance I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
task I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
attenuated O
the O
scopolamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
induced O
impairment B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
spontaneous B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alternation I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
passive B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
avoidance B_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
behaviours B_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

6 B_NUMBER[MEASURE]
. O

These O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
indicated O
that O
nocistatin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
a O
new B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
biologically O
active B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
peptide I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
ameliorates O
impairments B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
spontaneous B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
alternation B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
passive B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
avoidance I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
induced O
by O
scopolamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O
and O
suggested O
that O
these O
peptides B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
play O
opposite B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
roles I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O
learning B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
memory B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Meloxicam O
- O
induced O
liver B_DISEASE
toxicity I_DISEASE
. O

We O
report O
the O
case O
of O
a O
female O
patient O
with O
rheumatoid B_DISEASE
arthritis I_DISEASE
who O
developed O
acute O
cytolytic O
hepatitis B_DISEASE
due O
to O
meloxicam O
. O

Recently O
introduced O
in O
Belgium B_LOCATION/B_MEASURE
, O
meloxicam B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
the O
first B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
nonsteroidal I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antiinflammatory I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
drug I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
selective B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
action I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
on O
the O
inducible B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
form I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
cyclooxygenase B_GENE
2 I_GENE
. O

The O
acute O
cytolytic O
hepatitis B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
occurred O
rapidly O
after O
meloxicam O
administration O
and O
was O
associated O
with O
the O
development O
of O
antinuclear O
antibodies O
suggesting O
a O
hypersensitivity B_DISEASE
mechanism O
. O

This O
first O
case O
of O
meloxicam O
related O
liver B_DISEASE
toxicity I_DISEASE
demonstrates O
the O
potential O
of O
this O
drug O
to O
induce O
hepatic B_DISEASE
damage I_DISEASE
. O

induction O
of O
apoptosis O
by O
remoxipride O
metabolites O
in O
HL60 O
and O
CD34 O
+ O
/ O
CD19 O
- O
human O
bone O
marrow O
progenitor O
cells O
: O
potential O
relevance O
to O
remoxipride O
- O
induced O
aplastic B_DISEASE
anemia I_DISEASE
. O

The O
antipsychotic O
agent O
, O
remoxipride O
[ O
( O
S O
) O
- O
( O
- O
) O
- O
3 O
- O
bromo O
- O
N O
- O
[ O
( O
1 O
- O
ethyl O
- O
2 O
- O
pyrrolidinyl O
) O
methyl O
] O
- O
2 O
, O
6 O
- O
dimethoxybenz O
amide O
] O
has O
been O
associated O
with O
acquired O
aplastic B_DISEASE
anemia I_DISEASE
. O

We O
have O
examined O
the O
ability B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
remoxipride B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
three B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
pyrrolidine I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
ring I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
metabolites I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
five B_MEASURE/B_LOCATION
aromatic B_MEASURE/I_LOCATION
ring B_MEASURE/I_LOCATION
metabolites B_MEASURE/I_LOCATION
of O
the O
parent B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
compound I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
to O
induce O
apoptosis B_DISEASE/B_GENE
in O
HL60 B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_SPECIES[BIO]
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_SPECIES[BIO]
and O
human B_CELL_LINE[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
bone I_CELL_LINE[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE
marrow I_CELL_LINE[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE
progenitor I_CELL_LINE[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE
( O
HBMP B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
cells B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

cells B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
were O
treated O
for O
0 B_MEASURE
- O
24 B_MEASURE
h I_MEASURE
with O
each O
compound B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
0 B_MEASURE
- O
200 B_MEASURE
microM I_MEASURE
) O
. O

Apoptosis B_DISEASE/B_GENE
was O
assessed O
by O
fluorescence B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
microscopy I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
in O
Hoechst B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
33342 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
and O
propidium B_TIME[MEASURE]/B_COLOR
iodide I_TIME[MEASURE]/I_COLOR
stained O
cell B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
samples I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

Results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
were O
confirmed O
by O
determination B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
internucleosomal B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
DNA I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
fragmentation I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
using O
gel B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
electrophoresis I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
for O
HL60 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
cell B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
samples B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O
terminal B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
deoxynucleotidyl I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
transferase I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
assay I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
in O
HBMP B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
catechol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
hydroquinone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
metabolites I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
NCQ436 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O
NCQ344 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
induced B_DISEASE_ADJECTIVE[DISEASE]
apoptosis I_DISEASE_ADJECTIVE[DISEASE]
in O
HL60 B_GENE/B_CELL_LINE[BODY_PART_OR_ORGAN_COMPONENT]
and O
HBMP B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
in O
a O
time B_MEASURE/B_LOCATION
- O
and O
concentration B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dependent B_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
manner B_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
while O
the O
phenols B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O
NCR181 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
FLA873 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
FLA797 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
and O
the O
derivatives B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
formed O
by O
oxidation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
the O
pyrrolidine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ring I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
FLA838 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
NCM001 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
and O
NCL118 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
had O
no O
effect B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O

No O
necrosis B_DISEASE
was O
observed O
in O
cells O
treated O
with O
NCQ436 O
but O
NCQ344 O
had O
a O
biphasic O
effect O
in O
both O
cell O
types O
, O
inducing O
apoptosis O
at O
lower O
concentrations O
and O
necrosis B_DISEASE/B_GENE
at O
higher O
concentrations O
. O

These O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
show O
that O
the O
catechol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
hydroquinone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
metabolites I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
remoxipride B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
have O
direct B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
toxic B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
HL60 B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
and O
HBMP B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
, O
leading O
to O
apoptosis B_DISEASE/B_GENE
, O
while O
the O
phenol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
metabolites I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
were O
inactive B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Similarly O
, O
benzene B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
derived O
catechol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
hydroquinone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
, O
but O
not O
phenol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
induce O
apoptosis B_DISEASE/B_GENE
in O
HBMP B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
[ O
Moran B_PERSON/B_LOCATION
et I_PERSON/I_LOCATION
al O
. O
, O
Mol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O
Pharmacol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O
, O
50 B_MEASURE
( O
1996 B_MEASURE
) O
610 B_MEASURE
- O
615 B_MEASURE
] I_MEASURE
. O

We O
propose O
that O
remoxipride O
and O
benzene O
may O
induce O
aplastic B_DISEASE/B_GENE
anemia I_DISEASE/I_GENE
via O
production O
of O
similar O
reactive O
metabolites O
and O
that O
the O
ability O
of O
NCQ436 O
and O
NCQ344 O
to O
induce O
apoptosis O
in O
HBMP O
cells O
may O
contribute O
to O
the O
mechanism O
underlying O
acquired O
aplastic B_DISEASE
anemia I_DISEASE
that O
has O
been O
associated O
with O
remoxipride O
. O

synthesis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O
preliminary B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
pharmacological I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
investigations I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
of O
1 B_MEASURE
- O
( O
1 B_NUMBER[MEASURE]
, O
2 B_MEASURE
- O
dihydro B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
2 B_MEASURE
- O
acenaphthylenyl B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
piperazine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
derivatives I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O
potential B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
atypical I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
antipsychotic I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
agents I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
mice B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

In O
research B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
towards O
the O
development B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O
new B_DISEASE
atypical I_DISEASE
antipsychotic I_DISEASE
agents I_DISEASE
, O
one B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
strategy I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
is O
that O
the O
dopaminergic B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
system I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
can O
be O
modulated O
through O
manipulation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
the O
serotonergic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
system B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
. O

The O
synthesis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O
preliminary B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pharmacological I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
evaluation I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
a O
series B_SPORT[ENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
potential B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
atypical I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
antipsychotic I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
agents I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
based O
on O
the O
structure B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
1 B_MEASURE
- O
( O
1 B_MEASURE/B_LOCATION
, O
2 B_MEASURE
- O
dihydro B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
2 B_MEASURE
- O
acenaphthylenyl B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
piperazine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
7 B_TIME[MEASURE]/B_LOCATION
) O
is O
described O
. O

Compound B_LOCATION/B_TIME[MEASURE]
7e B_LOCATION/I_TIME[MEASURE]
, O
5 B_MEASURE
- O
{ O
2 B_NUMBER[MEASURE]
- O
[ B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
4 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
- O
( O
1 B_NUMBER[MEASURE]
, O
2 B_NUMBER[MEASURE]
- O
dihydro B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
2 B_MEASURE
- O
acenaphthylenyl B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
piperazinyl B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ethyl I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
} O
- O
2 B_NUMBER[MEASURE]
, O
3 B_NUMBER[MEASURE]
- O
dihy B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
dro I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
- O
1H B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
indol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
2 B_NUMBER[MEASURE]
- O
one B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
from O
this O
series B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
showed O
significant B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
affinities B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O
the O
5 B_MEASURE
- O
HT1A B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
5 B_MEASURE
- O
HT2A B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
receptors I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
moderate B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
affinity I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
at O
the O
D2 B_PROTEIN[GENE]
receptor I_PROTEIN[GENE]
. O

7e O
exhibits O
a O
high O
reversal O
of O
catalepsy B_DISEASE
induced O
by O
haloperidol O
indicating O
its O
atypical O
antipsychotic O
nature O
. O

Sub O
- O
chronic O
inhibition O
of O
nitric O
- O
oxide O
synthesis O
modifies O
haloperidol O
- O
induced O
catalepsy B_DISEASE
and O
the O
number O
of O
NADPH O
- O
diaphorase O
neurons O
in O
mice O
. O

RATIONALE O
: O
Ng O
- O
nitro O
- O
L O
- O
arginine O
( O
L O
- O
NOARG O
) O
, O
an O
inhibitor O
of O
nitric O
- O
oxide O
synthase O
( O
NOS O
) O
, O
induces O
catalepsy B_DISEASE
in O
mice O
. O

This O
effect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
undergoes O
rapid B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
tolerance I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
, O
showing O
a O
significant B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
decrease B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
after O
2 B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
days B_TIME[MEASURE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
sub B_DISEASE/B_MEASURE
- O
chronic B_DISEASE_ADJECTIVE[DISEASE]/B_PROTEIN[GENE]
L B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
- O
NOARG B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
treatment I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

Nitric B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
oxide I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
NO B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
) O
has O
been O
shown O
to O
influence O
dopaminergic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
neurotransmission I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
striatum B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
. O

Neuroleptic O
drugs O
such O
as O
haloperidol O
, O
which O
block O
dopamine O
receptors O
, O
also O
cause O
catalepsy B_DISEASE
in O
rodents O
. O

objectives O
: O
To O
investigate O
the O
effects O
of O
subchronic O
L O
- O
NOARG O
treatment O
in O
haloperidol O
- O
induced O
catalepsy B_DISEASE
and O
the O
number O
of O
NOS O
neurons O
in O
areas O
related O
to O
motor O
control O
. O

methods B_MEASURE
: O
Male B_PERSON
albino I_PERSON
Swiss I_PERSON
mice I_PERSON
were O
treated O
sub O
- O
chronically O
( O
twice O
a O
day B_TIME[MEASURE]
for O
4 B_TIME[MEASURE]
days I_TIME[MEASURE]
) O
with O
L B_PROTEIN[GENE]/B_MEASURE
- O
NOARG B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O
40 B_MEASURE
mg I_MEASURE
/ O
kg B_MEASURE
i O
. O
p B_MEASURE/B_LOCATION
. O
) O
or O
haloperidol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
1 B_MEASURE
mg I_MEASURE
/ O
kg B_MEASURE
i O
. O
p B_MEASURE/B_LOCATION
. O
) O
. O

Catalepsy B_DISEASE_ADJECTIVE[DISEASE]
was O
evaluated O
at O
the O
beginning O
and O
the O
end O
of O
the O
treatments O
. O

reduced O
nicotinamide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
adenine I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
dinucleotide I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
phosphate I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
- O
diaphorase B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
( O
NADPH B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
d B_PROTEIN[GENE]/B_DISEASE
) O
histochemistry B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
was O
also O
employed O
to O
visualize O
NOS B_DISEASE/B_GENE
as O
an O
index B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
enzyme B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expression I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
mice B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
brain I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
regions I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
related O
to O
motor B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
control I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Results O
: O
L O
- O
NOARG O
sub O
- O
chronic O
administration O
produced O
tolerance O
of O
L O
- O
NOARG O
and O
of O
haloperidol O
- O
induced O
catalepsy B_DISEASE
. O

It O
also O
induced O
an O
increase B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
the O
number B_MEASURE/B_ENT
of O
NADPH B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O
d B_ENZYME[GENE]/B_DISEASE
- O
positive B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
cells I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
the O
dorsal B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
part I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
of O
the O
caudate B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
and O
accumbens B_BODY_PART_OR_ORGAN_COMPONENT
nuclei I_BODY_PART_OR_ORGAN_COMPONENT
compared O
with O
haloperidol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
in O
the O
pedunculopontine B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
tegmental I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
nucleus I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
compared O
with O
saline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

In O
contrast B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
there O
was O
a O
decrease B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O
NADPH B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
d B_MEASURE/B_ENT
neuron I_MEASURE/I_ENT
number I_MEASURE/I_ENT
in O
the O
substantia B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
nigra I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
, O
pars O
compacta B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
in O
both O
haloperidol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
treated O
and O
L B_PROTEIN[GENE]/B_MEASURE
- O
NOARG B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
treated O
animals B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

CONCLUSIONS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O
The O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
give O
further B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
support I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
to O
the O
hypothesis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
that O
NO O
plays O
a O
role B_MEASURE/B_PERSON
in O
motor B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
behavior I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
control I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
suggest O
that O
it O
may O
take O
part B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
synaptic B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
changes I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
produced O
by O
antipsychotic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
treatment I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O

prolonged O
left B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
ventricular I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
dysfunction I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
occurs O
in O
patients O
with O
coronary B_DISEASE/B_LOCATION
artery I_DISEASE/I_LOCATION
disease I_DISEASE/I_LOCATION
after O
both O
dobutamine O
and O
exercise O
induced O
myocardial B_DISEASE_ADJECTIVE[DISEASE]
ischaemia I_DISEASE_ADJECTIVE[DISEASE]
. O

objective O
: O
To O
determine O
whether O
pharmacological O
stress O
leads O
to O
prolonged O
but O
reversible O
left B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
ventricular I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
dysfunction I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
patients O
with O
coronary B_DISEASE
artery I_DISEASE
disease I_DISEASE
, O
similar O
to O
that O
seen O
after O
exercise O
. O

Design O
: O
A O
randomised O
crossover O
study O
of O
recovery O
time O
of O
systolic O
and O
diastolic O
left O
ventricular O
function O
after O
exercise O
and O
dobutamine O
induced O
ischaemia B_DISEASE
. O

subjects O
: O
10 O
patients O
with O
stable B_DISEASE_ADJECTIVE[DISEASE]
angina I_DISEASE_ADJECTIVE[DISEASE]
, O
angiographically O
proven O
coronary B_DISEASE/B_LOCATION
artery I_DISEASE/I_LOCATION
disease I_DISEASE/I_LOCATION
, O
and O
normal O
left O
ventricular O
function O
. O

Interventions B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O
treadmill B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
exercise I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
dobutamine B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
stress I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
were O
performed O
on O
different B_TIME[MEASURE]/B_ENT
days I_TIME[MEASURE]/I_ENT
. O

Quantitative B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
assessment I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
systolic B_BODY_PART_OR_ORGAN_COMPONENT
and O
diastolic B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
left O
ventricular B_BODY_PART_OR_ORGAN_COMPONENT/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
function I_BODY_PART_OR_ORGAN_COMPONENT/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
performed O
using O
transthoracic B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
echocardiography I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O
baseline B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O
at O
regular B_TIME[MEASURE]/B_LOCATION
intervals I_TIME[MEASURE]/I_LOCATION
after O
each O
test B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

RESULTS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O
Both O
forms B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O
stress B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
led O
to O
prolonged O
but O
reversible B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
systolic B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
and O
diastolic B_DISEASE
dysfunction I_DISEASE
. O

There O
was O
no O
difference O
in O
the O
maximum O
double O
product O
( O
p O
= O
0 O
. O
53 O
) O
or O
ST O
depression B_TIME[MEASURE]/B_DISEASE
( O
p O
= O
0 O
. O
63 O
) O
with O
either O
form O
of O
stress O
. O

After O
exercise B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
ejection B_MEASURE/B_DISEASE
fraction B_MEASURE/I_DISEASE
was O
reduced O
at O
15 B_MEASURE
and O
30 B_MEASURE/B_ENT
minutes I_MEASURE/I_ENT
compared O
with O
baseline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
( O
mean B_MEASURE/B_LOCATION
( O
SEM B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
, O
- O
5 B_MEASURE
. O
6 B_MEASURE
( O
1 B_MEASURE
. O
5 B_MEASURE
) O
% B_MEASURE/B_OTHER
, O
p O
< B_MEASURE
0 I_MEASURE
. O
05 B_MEASURE
; O
and O
- O
6 B_MEASURE
. O
1 B_MEASURE
( O
2 B_NUMBER[MEASURE]
. O
2 B_MEASURE
) O
% B_MEASURE/B_OTHER
, O
p O
< O
0 B_NUMBER[MEASURE]
. O
01 B_MEASURE
) O
, O
and O
at O
30 B_MEASURE
and O
45 B_MEASURE/B_ENT
minutes I_MEASURE/I_ENT
after O
dobutamine B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
( O
- O
10 B_NUMBER[MEASURE]
. O
8 B_MEASURE
( O
1 B_MEASURE
. O
8 B_MEASURE
) O
% B_MEASURE/B_OTHER
and O
- O
5 B_MEASURE
. O
5 B_MEASURE
( O
1 B_NUMBER[MEASURE]
. O
8 B_MEASURE
) O
% B_MEASURE/B_OTHER
, O
both O
p B_MEASURE/B_LOCATION
< O
0 B_NUMBER[MEASURE]
. O
01 B_MEASURE
) O
. O

Regional B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
analysis I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
showed O
a O
reduction B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O
the O
worst B_TIME[MEASURE]
affected I_TIME[MEASURE]
segment I_TIME[MEASURE]
15 I_TIME[MEASURE]
and O
30 B_MEASURE/B_ENT
minutes I_MEASURE/I_ENT
after O
exercise B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
- O
27 B_MEASURE
. O
9 B_MEASURE
( O
7 B_MEASURE
. O
2 B_MEASURE
) O
% B_OTHER/B_MEASURE
and O
- O
28 B_MEASURE
. O
6 B_MEASURE
( O
5 B_MEASURE
. O
7 B_MEASURE
) O
% B_MEASURE/B_OTHER
, O
both O
p B_MEASURE/B_PROTEIN[GENE]
< O
0 B_MEASURE
. O
01 B_MEASURE
) O
, O
and O
at O
30 B_TIME[MEASURE]/B_ENT
minutes I_TIME[MEASURE]/I_ENT
after O
dobutamine B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
( O
- O
32 B_MEASURE
( O
5 B_MEASURE
. O
3 B_MEASURE
) O
% B_MEASURE/B_OTHER
, O
p B_MEASURE/B_PROTEIN[GENE]
< O
0 B_MEASURE
. O
01 B_MEASURE
) O
. O

The O
isovolumic B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
relaxation B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
period B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
was O
prolonged O
45 B_TIME[MEASURE]/B_ENT
minutes I_TIME[MEASURE]/I_ENT
after O
each O
form B_TIME[MEASURE]/B_LOCATION
of O
stress B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O
p B_PROTEIN[GENE]/B_LOCATION
< O
0 B_MEASURE
. O
05 B_MEASURE
) O
. O

conclusions O
: O
In O
patients O
with O
coronary B_DISEASE
artery I_DISEASE
disease I_DISEASE
, O
dobutamine O
induced O
ischaemia B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
results O
in O
prolonged O
reversible O
left B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
ventricular I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
dysfunction I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
presumed O
to O
be O
myocardial B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
stunning I_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
, O
similar O
to O
that O
seen O
after O
exercise O
. O

Dobutamine O
induced O
ischaemia B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
could O
therefore O
be O
used O
to O
study O
the O
pathophysiology O
of O
this O
phenomenon O
further O
in O
patients O
with O
coronary B_DISEASE
artery I_DISEASE
disease I_DISEASE
. O

Anorexigens O
and O
pulmonary B_DISEASE/B_PERSON
hypertension I_DISEASE/I_PERSON
in O
the O
United O
States O
: O
results O
from O
the O
surveillance O
of O
North O
American O
pulmonary B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
hypertension B_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
. O

Background O
: O
The O
use O
of O
appetite O
suppressants O
in O
Europe O
has O
been O
associated O
with O
the O
development O
of O
primary B_DISEASE
pulmonary I_DISEASE
hypertension I_DISEASE
( O
PPH B_DISEASE/B_GENE
) O
. O

Recently O
, O
fenfluramine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
appetite I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
suppressants I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
became O
widely O
used O
in O
the O
United B_LOCATION/B_ORGANIZATION
States I_LOCATION/I_ORGANIZATION
but O
were O
withdrawn O
in O
September B_TIME[MEASURE]/B_LOCATION
1997 I_TIME[MEASURE]/I_LOCATION
because O
of O
concerns B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
over O
adverse B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Materials O
AND O
methods O
: O
We O
conducted O
a O
prospective O
surveillance O
study O
on O
patients O
diagnosed O
with O
pulmonary B_DISEASE
hypertension I_DISEASE
at O
12 O
large O
referral O
centers O
in O
North O
America O
. O

Data O
collected O
on O
patients O
seen O
from O
September O
1 O
, O
1996 O
, O
to O
December O
31 O
, O
1997 O
, O
included O
the O
cause O
of O
the O
pulmonary B_DISEASE_ADJECTIVE[DISEASE]
hypertension I_DISEASE_ADJECTIVE[DISEASE]
and O
its O
severity O
. O

patients O
with O
no O
identifiable O
cause O
of O
pulmonary B_DISEASE/B_GENE
hypertension I_DISEASE/I_GENE
were O
classed O
as O
PPH B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
. O

A O
history B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
drug B_DISEASE
exposure I_DISEASE
also O
was O
taken O
with O
special B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
attention I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
on O
the O
use B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
antidepressants B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
anorexigens B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
, O
and O
amphetamines B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O

Results O
: O
Five O
hundred O
seventy O
- O
nine O
patients O
were O
studied O
, O
205 O
with O
PPH B_DISEASE/B_GENE
and O
374 O
with O
pulmonary B_DISEASE
hypertension I_DISEASE
from O
other O
causes O
( O
secondary O
pulmonary B_DISEASE
hypertension I_DISEASE
[ O
SPH O
] O
) O
. O

The O
use B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
anorexigens B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
was O
common B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O
both O
groups B_ORGANIZATION/B_LOCATION
. O

However O
, O
of O
the O
medications O
surveyed O
, O
only O
the O
fenfluramines O
had O
a O
significant O
preferential O
association O
with O
PPH B_DISEASE/B_LOCATION
as O
compared O
with O
SPH O
( O
adjusted O
odds O
ratio O
for O
use O
> O
6 O
months O
, O
7 O
. O
5 O
; O
95 O
% O
confidence O
interval O
, O
1 O
. O
7 O
to O
32 O
. O
4 O
) O
. O

The O
association B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
was O
stronger B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
longer B_TIME[MEASURE]
duration I_TIME[MEASURE]
of O
use B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
when O
compared O
to O
shorter B_TIME[MEASURE]
duration I_TIME[MEASURE]
of O
use B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
and O
was O
more O
pronounced B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
recent B_PERSON/B_LOCATION
users I_PERSON/I_LOCATION
than O
in O
remote B_PERSON/B_ORGANIZATION
users I_PERSON/I_ORGANIZATION
. O

An O
unexpectedly O
high B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
( O
11 B_MEASURE
. O
4 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
number B_MEASURE/B_PERSON
of O
patients B_PERSON
with O
Sph B_DISEASE/B_GENE
had O
used O
anorexigens B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
. O

conclusion O
: O
The O
magnitude O
of O
the O
association O
with O
PPH B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
the O
increase O
of O
association O
with O
increasing O
duration O
of O
use O
, O
and O
the O
specificity O
for O
fenfluramines O
are O
consistent O
with O
previous O
studies O
indicating O
that O
fenfluramines O
are O
causally O
related O
to O
PPH B_DISEASE
. O

The O
high O
prevalence O
of O
anorexigen O
use O
in O
patients O
with O
SPH O
also O
raises O
the O
possibility O
that O
these O
drugs O
precipitate O
pulmonary B_DISEASE
hypertension I_DISEASE
in O
patients O
with O
underlying O
conditions O
associated O
with O
SPH O
. O

Clinical O
aspects O
of O
heparin O
- O
induced O
thrombocytopenia B_DISEASE
and O
thrombosis B_DISEASE
and O
other O
side O
effects O
of O
heparin O
therapy O
. O

Heparin O
, O
first O
used O
to O
prevent O
the O
clotting O
of O
blood O
in O
vitro O
, O
has O
been O
clinically O
used O
to O
treat O
thrombosis B_DISEASE
for O
more O
than O
50 O
years O
. O

Although O
several O
new O
anticoagulant O
drugs O
are O
in O
development O
, O
heparin O
remains O
the O
anticoagulant O
of O
choice O
to O
treat O
acute O
thrombotic B_DISEASE
episodes O
. O

The O
clinical B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
effects I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
of O
heparin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
meritorious B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
, O
but O
side B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
effects I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
do O
exist O
. O

Bleeding B_DISEASE
is O
the O
primary O
untoward O
effect O
of O
heparin O
. O

Major O
bleeding B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
is O
of O
primary O
concern O
in O
patients O
receiving O
heparin O
therapy O
. O

However O
, O
additional O
important O
untoward O
effects O
of O
heparin O
therapy O
include O
heparin O
- O
induced O
thrombocytopenia B_DISEASE
, O
heparin O
- O
associated O
osteoporosis B_DISEASE
, O
eosinophilia B_DISEASE
, O
skin B_DISEASE
reactions I_DISEASE
, O
allergic B_DISEASE_ADJECTIVE[DISEASE]
reactions I_DISEASE_ADJECTIVE[DISEASE]
other O
than O
thrombocytopenia B_DISEASE
, O
alopecia B_DISEASE
, O
transaminasemia O
, O
hyperkalemia B_DISEASE
, O
hypoaldosteronism B_DISEASE
, O
and O
priapism B_DISEASE
. O

These O
side O
effects O
are O
relatively O
rare O
in O
a O
given O
individual O
, O
but O
given O
the O
extremely O
widespread O
use O
of O
heparin O
, O
some O
are O
quite O
common O
, O
particularly O
HITT B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
osteoporosis B_DISEASE
. O

Although O
reasonable B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
incidences I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
many B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
these O
side B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
effects B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
can O
be O
' O
softly O
' O
deduced O
from O
current B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
reports I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
dealing O
with O
unfractionated B_DISEASE
heparin I_DISEASE
, O
at O
present B_TIME[MEASURE]
the O
incidences B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
these O
side B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
effects I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
with O
newer B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
low I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
molecular I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
weight I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
heparins I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
appear O
to O
be O
much O
less O
common B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
. O

However O
, O
only O
longer B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
experience I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
will O
more O
clearly O
define O
the O
incidence B_DISEASE_ADJECTIVE[DISEASE]
of O
each O
side B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effect I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
low B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
molecular I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
weight I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
preparations I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

A O
case O
of O
bilateral O
optic B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
neuropathy I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
a O
patient O
on O
tacrolimus O
( O
FK506 O
) O
therapy O
after O
liver O
transplantation O
. O

purpose O
: O
To O
report O
a O
case O
of O
bilateral O
optic B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
neuropathy I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
a O
patient O
receiving O
tacrolimus O
( O
FK O
506 O
, O
Prograf O
; O
Fujisawa O
USA O
, O
Inc O
, O
Deerfield O
, O
Illinois O
) O
for O
immunosuppression O
after O
orthotropic O
liver O
transplantation O
. O

Method B_MEASURE/B_LOCATION
: O
Case B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
report I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

In O
a O
58 B_MEASURE
- O
year B_TIME[MEASURE]
- O
old B_PERSON
man I_PERSON
receiving O
tacrolimus B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
after O
orthotropic B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
liver I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
transplantation I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
, O
serial B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
neuro B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
- O
ophthalmologic B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
examinations I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
laboratory B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
studies I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
performed O
. O

Results O
: O
The O
patient O
had O
episodic O
deterioration O
of O
vision O
in O
both O
eyes O
, O
with O
clinical O
features O
resembling O
ischemic B_DISEASE
optic I_DISEASE
neuropathies I_DISEASE
. O

Deterioration B_DISEASE/B_PERSON
of I_DISEASE/I_PERSON
vision I_DISEASE/I_PERSON
occurred O
despite O
discontinuation O
of O
the O
tacrolimus O
. O

conclusion O
: O
Tacrolimus O
and O
other O
immunosuppressive O
agents O
may O
be O
associated O
with O
optic B_DISEASE/B_GENE
nerve I_DISEASE/I_GENE
toxicity I_DISEASE/I_GENE
. O

Hypercalcemia B_DISEASE
, O
arrhythmia B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
mood O
stabilizers O
. O

Recent O
findings O
in O
a O
bipolar B_DISEASE/B_PERSON
patient O
receiving O
maintenance O
lithium O
therapy O
who O
developed O
hypercalcemia B_DISEASE
and O
severe O
bradyarrhythmia B_DISEASE
prompted O
the O
authors O
to O
conduct O
a O
retrospective O
study O
of O
bipolar B_NUMBER[MEASURE]
patients O
with O
lithium O
- O
associated O
hypercalcemia B_DISEASE
. O

A O
printout O
of O
all O
cases O
of O
hypercalcemia B_DISEASE
that O
presented O
during O
a O
1 O
- O
year O
period O
was O
generated O
. O

After O
eliminating O
spurious O
hypercalcemias B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O
those O
associated O
with O
intravenous O
fluids O
, O
the O
authors O
identified O
18 O
non O
- O
lithium O
- O
treated O
patients O
with O
hypercalcemias B_DISEASE
related O
to O
malignancies B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
and O
other O
medical O
conditions O
( O
group O
A O
) O
and O
12 O
patients O
with O
lithium O
- O
associated O
hypercalcemia B_DISEASE
( O
group O
B O
) O
. O

patients B_PERSON
in O
group B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
B I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
were O
not O
comparable B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
those O
in O
group B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
A I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
, O
as O
the O
latter B_NUMBER[MEASURE]/B_PERSON
were O
medically O
compromised O
and O
were O
receiving O
multiple B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pharmacotherapies I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Thus O
, O
two O
control O
groups O
were O
generated O
: O
group O
C1 O
, O
which O
included O
age O
- O
and O
sex O
- O
comparable O
lithium O
- O
treated O
bipolar B_DISEASE/B_PERSON
normocalcemic O
patients O
, O
and O
group O
C2 O
, O
which O
included O
bipolar B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
normocalcemic O
patients O
treated O
with O
anticonvulsant O
mood O
stabilizers O
. O

The O
electrocardiographic B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
( O
ECG B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O
findings B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
for O
patients B_PERSON/B_DISEASE
in O
group B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
B I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
compared O
with O
those O
of O
patients B_PERSON
in O
groups B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
C1 I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
C2 B_PROTEIN[GENE]
. O

It O
was O
found O
that O
these O
groups B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
did O
not O
differ O
in O
their O
overall B_MEASURE
frequency I_MEASURE
of O
ECG B_DISEASE_ADJECTIVE[DISEASE]
abnormalities I_DISEASE_ADJECTIVE[DISEASE]
; O
however O
, O
there O
were O
significant B_DISEASE_ADJECTIVE[DISEASE]
differences I_DISEASE_ADJECTIVE[DISEASE]
in O
the O
frequency B_MEASURE
of O
conduction B_DISEASE/B_LOCATION
defects I_DISEASE/I_LOCATION
. O

patients O
with O
hypercalcemia B_DISEASE
resulting O
from O
medical O
diseases O
and O
bipolar B_DISEASE/B_MEASURE
patients O
with O
lithium O
- O
associated O
hypercalcemia B_DISEASE
had O
significantly O
higher O
frequencies O
of O
conduction O
defects O
. O

patients B_PERSON
in O
group B_NUMBER[MEASURE]/B_LOCATION
A I_NUMBER[MEASURE]/I_LOCATION
had O
significant B_DISEASE/B_MEASURE
mortality I_DISEASE/I_MEASURE
at O
2 B_NUMBER[MEASURE]
- O
year B_TIME[MEASURE]/B_LOCATION
follow I_TIME[MEASURE]/I_LOCATION
- O
up B_TIME[MEASURE]/B_LOCATION
( O
28 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
, O
in O
contrast B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O
zero B_PERSON/B_DISEASE
mortality I_PERSON/I_DISEASE
in O
the O
other B_MEASURE/B_LOCATION
three B_MEASURE/I_LOCATION
groups B_MEASURE/I_LOCATION
. O

The O
clinical B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
implications I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O
these O
findings B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
discussed O
. O

Attenuation O
of O
nephrotoxicity B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O
a O
novel O
lipid O
nanosphere O
( O
NS O
- O
718 O
) O
incorporating O
amphotericin O
B O
. O

NS O
- O
718 O
, O
a O
lipid O
nanosphere O
incorporating O
amphotericin O
B O
, O
is O
effective O
against O
pathogenic O
fungi O
and O
has O
low O
toxicity B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

We O
compared O
the O
toxicity B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O
NS O
- O
718 O
with O
that O
of O
Fungizone O
( O
amphotericin O
B O
- O
sodium O
deoxycholate O
; O
D O
- O
AmB O
) O
in O
vitro O
using O
renal O
cell O
cultures O
and O
in O
vivo O
by O
biochemical O
analysis O
, O
histopathological O
study O
of O
the O
kidney O
and O
pharmacokinetic O
study O
of O
amphotericin O
B O
following O
intravenous O
infusion O
of O
the O
formulation O
in O
rats O
. O

Incubation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
with O
NS B_PROTEIN[GENE]/B_DISEASE
- O
718 B_MEASURE/B_LOCATION
resulted O
in O
significantly O
less B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
damage I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
cultured B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
human I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
renal I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
proximal I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tubular I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
epithelial I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
compared O
with O
D B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
Amb B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O

Serum B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
blood B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
urea B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O
creatinine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
concentrations I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
increased O
significantly O
in O
rats B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
given O
an O
iv B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
infusion I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
of O
D B_OTHER/B_PROTEIN[GENE]
- O
AmB B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
3 I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mg I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
kg B_TIME[MEASURE]
but O
not O
in O
those O
given O
the O
same B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
dose I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
of O
NS B_DISEASE/B_PROTEIN[GENE]
- O
718 B_NUMBER[MEASURE]
. O

Histopathological O
examination O
of O
the O
kidney O
showed O
tubular B_DISEASE
necrosis I_DISEASE
in O
D O
- O
AmB O
- O
treated O
rats O
but O
no O
change O
in O
NS O
- O
718 O
- O
treated O
rats O
. O

amphotericin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
B I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
concentrations I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
in O
the O
kidney B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
in O
NS B_PROTEIN[GENE]/B_DISEASE
- O
718 B_TIME[MEASURE]/B_LOCATION
- O
treated O
rats B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
higher B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
than O
those O
in O
D B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
AmB B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
treated O
rats B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Our O
in O
vitro O
and O
in O
vivo O
results O
suggest O
that O
incorporation O
of O
amphotericin O
B O
into O
lipid O
nanospheres O
of O
NS O
- O
718 O
attenuates O
the O
nephrotoxicity B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O
amphotericin O
B O
. O

patterns O
of O
sulfadiazine O
acute B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
nephrotoxicity B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Sulfadiazine O
acute B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
nephrotoxicity I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
is O
reviving O
specially O
because O
of O
its O
use O
in O
toxoplasmosis B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
in O
HIV O
- O
positive O
patients O
. O

We O
report O
4 B_NUMBER[MEASURE]/B_PERSON
cases I_NUMBER[MEASURE]/I_PERSON
, O
one B_NUMBER[MEASURE]
of O
them O
in O
a O
previously O
healthy B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
person I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
. O

Under O
treatment O
with O
sulfadiazine O
they O
developed O
oliguria B_DISEASE
, O
abdominal B_DISEASE
pain I_DISEASE
, O
renal B_DISEASE
failure I_DISEASE
and O
showed O
multiple O
radiolucent O
renal B_DISEASE/B_LOCATION
calculi I_DISEASE/I_LOCATION
in O
echography O
. O

All O
patients B_PERSON
recovered O
their O
previous B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
normal B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
renal B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
function B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
after O
adequate B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
hydration I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
and O
alcalinization B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
. O

A O
nephrostomy O
tube O
had O
to O
be O
placed O
in O
one O
of O
the O
patients O
for O
ureteral B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
lithiasis I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
in O
a O
single O
functional O
kidney O
. O

None B_PERSON/B_NUMBER[MEASURE]
of O
them O
needed O
dialysis B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
or O
a O
renal B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
biopsy I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
because O
of O
a O
typical B_DISEASE
benign I_DISEASE
course I_DISEASE
. O

Treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O
sulfadiazine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
requires O
exquisite B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
control I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
renal B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
function I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
an O
increase B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
water B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ingestion B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
possibly O
the O
alcalinization B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O
the O
urine B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

We O
communicate O
a O
case B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
a O
previously O
healthy B_PERSON/B_TIME[MEASURE]
person B_PERSON/I_TIME[MEASURE]
, O
a O
fact B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
not O
found O
in O
the O
recent B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
literature I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

Probably O
many B_PERSON
more I_PERSON
cases I_PERSON
are O
not O
detected O
. O

We O
think O
that O
a O
prospective B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
would O
be O
useful B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O

Downbeat B_DISEASE_ADJECTIVE[DISEASE]
nystagmus I_DISEASE_ADJECTIVE[DISEASE]
associated O
with O
intravenous O
patient O
- O
controlled O
administration O
of O
morphine O
. O

implications O
: O
This O
case O
documents O
a O
patient O
who O
developed O
dizziness B_DISEASE
with O
downbeating B_DISEASE/B_MEASURE
nystagmus I_DISEASE/I_MEASURE
while O
receiving O
a O
relatively O
large O
dose O
of O
IV O
patient O
- O
controlled O
analgesia O
morphine O
. O

Although O
there O
have O
been O
case B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
reports I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
of O
epidural B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
morphine I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
with O
these O
symptoms B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
signs B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O
this O
has O
not O
been O
previously O
documented O
with O
IV B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O
patient B_PERSON/B_LOCATION
- O
controlled O
analgesia B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
morphine I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Hemodynamic O
and O
antiadrenergic O
effects O
of O
dronedarone O
and O
amiodarone O
in O
animals O
with O
a O
healed O
myocardial B_DISEASE
infarction I_DISEASE
. O

The O
hemodynamic O
and O
antiadrenergic O
effects O
of O
dronedarone O
, O
a O
noniodinated O
compound O
structurally O
related O
to O
amiodarone O
, O
were O
compared O
with O
those O
of O
amiodarone O
after O
prolonged O
oral O
administration O
, O
both O
at O
rest O
and O
during O
sympathetic O
stimulation O
in O
conscious O
dogs O
with O
a O
healed O
myocardial B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
infarction I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
. O

All O
dogs B_BIO/B_PERSON
( O
n B_OTHER/B_MEASURE
= O
6 B_MEASURE
) O
randomly O
received O
orally B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dronedarone I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
10 B_MEASURE
and O
30 B_MEASURE
mg I_MEASURE
/ O
kg B_MEASURE
) O
, O
amiodarone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
10 B_MEASURE
and O
30 B_MEASURE
mg I_MEASURE
/ O
kg B_MEASURE
) O
, O
and O
placebo B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
twice O
daily O
for O
7 B_TIME[MEASURE]
days I_TIME[MEASURE]
, O
with O
a O
3 B_NUMBER[MEASURE]
- O
week B_TIME[MEASURE]/B_ENT
washout I_TIME[MEASURE]/I_ENT
between O
consecutive B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treatments I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Heart B_MEASURE/B_DISEASE
rate I_MEASURE/I_DISEASE
( O
HR B_LOCATION
) O
, O
mean B_MEASURE/B_DISEASE
arterial I_MEASURE/I_DISEASE
pressure I_MEASURE/I_DISEASE
( O
MBP B_LOCATION/B_ORGANIZATION
) O
, O
positive B_MEASURE
rate I_MEASURE
of O
increase B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
left B_DISEASE/B_GENE
ventricular B_DISEASE/I_GENE
pressure B_DISEASE/I_GENE
( O
+ B_PROTEIN[GENE]
LVdP I_PROTEIN[GENE]
/ O
dt B_MEASURE/B_PROTEIN[GENE]
) O
, O
echocardiographically O
assessed O
left O
ventricular B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
ejection B_MEASURE/I_BODY_PART_OR_ORGAN_COMPONENT
fraction B_MEASURE/I_BODY_PART_OR_ORGAN_COMPONENT
( O
LVEF B_LOCATION/B_MEASURE
) O
, O
and O
fractional B_MEASURE/B_DISEASE
shortening I_MEASURE/I_DISEASE
( O
FS B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
, O
as O
well O
as O
chronotropic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
response B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
to O
isoproterenol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O
exercise B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
induced O
sympathetic B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
stimulation I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
were O
evaluated O
under O
baseline B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
and O
posttreatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
conditions I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
. O

resting O
values B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
LVEF B_LOCATION
, O
FS B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
, O
+ B_LOCATION/B_PROTEIN[GENE]
LVdP I_LOCATION/I_PROTEIN[GENE]
/ O
dt B_PROTEIN[GENE]/B_LOCATION
, O
and O
MBP B_LOCATION
remained O
unchanged B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
whatever O
the O
drug B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
the O
dosing B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
regimen I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O
whereas O
resting O
HR B_PROTEIN[GENE]/B_BODY_PART_OR_ORGAN_COMPONENT
was O
significantly O
and O
dose B_MEASURE
- O
dependently O
lowered O
after O
dronedarone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
to O
a O
lesser B_MEASURE/B_LOCATION
extent I_MEASURE/I_LOCATION
after O
amiodarone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Both O
dronedarone O
and O
amiodarone O
significantly O
reduced O
the O
exercise O
- O
induced O
tachycardia B_DISEASE
and O
, O
at O
the O
highest O
dose O
, O
decreased O
the O
isoproterenol O
- O
induced O
tachycardia B_DISEASE
. O

Thus O
, O
dronedarone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
amiodarone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
displayed O
a O
similar B_MEASURE
level I_MEASURE
of O
antiadrenergic B_DISEASE/B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effect B_DISEASE/I_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
did O
not O
impair O
the O
resting B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
left O
ventricular B_BODY_PART_OR_ORGAN_COMPONENT/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
function I_BODY_PART_OR_ORGAN_COMPONENT/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Consequently O
, O
dronedarone O
might O
be O
particularly O
suitable O
for O
the O
treatment O
and O
prevention O
of O
various O
clinical O
arrhythmias B_DISEASE
, O
without O
compromising O
the O
left O
ventricular O
function O
. O

Phase O
2 O
trial O
of O
liposomal O
doxorubicin O
( O
40 O
mg O
/ O
m O
( O
2 O
) O
) O
in O
platinum O
/ O
paclitaxel O
- O
refractory O
ovarian B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
and I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
fallopian I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
tube I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
cancers I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
and O
primary O
carcinoma B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
of I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
the I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
peritoneum I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
. O

Background O
: O
Several O
studies O
have O
demonstrated O
liposomal O
doxorubicin O
( O
Doxil O
) O
to O
be O
an O
active O
antineoplastic O
agent O
in O
platinum O
- O
resistant O
ovarian B_DISEASE
cancer I_DISEASE
, O
with O
dose O
limiting O
toxicity B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O
the O
standard O
dosing O
regimen O
( O
50 O
mg O
/ O
m O
( O
2 O
) O
q O
4 O
weeks O
) O
being O
severe O
erythrodysesthesia B_DISEASE
( O
' O
hand B_DISEASE
- I_DISEASE
foot I_DISEASE
syndrome I_DISEASE
' O
) O
and O
stomatitis B_DISEASE
. O

We O
wished O
to O
develop O
a O
more O
tolerable B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
liposomal I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
doxorubicin I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treatment I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
regimen I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
document O
its O
level B_MEASURE/B_LOCATION
of O
activity B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
in O
a O
well O
- O
defined O
patient B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
population I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
with O
platinum B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
paclitaxel B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
refractory B_DISEASE
disease I_DISEASE
. O

methods O
AND O
Materials O
: O
patients O
with O
ovarian B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
or I_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
fallopian I_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
tube I_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
cancers I_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
or O
primary O
peritoneal B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
carcinoma I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
with O
platinum O
/ O
paclitaxel O
- O
refractory O
disease O
( O
stable O
or O
progressive O
disease O
following O
treatment O
with O
these O
agents O
or O
previous O
objective O
response O
< O
3 O
months O
in O
duration O
) O
were O
treated O
with O
liposomal O
doxorubicin O
at O
a O
dose O
of O
40 O
mg O
/ O
m O
( O
2 O
) O
q O
4 O
weeks O
. O

RESULTS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O
A O
total B_MEASURE
of O
49 B_TIME[MEASURE]
patients I_TIME[MEASURE]
( O
median B_MEASURE/B_PERSON
age I_MEASURE/I_PERSON
: O
60 B_MEASURE
; O
range B_MEASURE/B_LOCATION
41 I_MEASURE/I_LOCATION
- O
81 B_MEASURE
) O
entered O
this O
phase B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
trial I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
median B_MEASURE/B_LOCATION
number I_MEASURE/I_LOCATION
of O
prior B_PERSON/B_ORGANIZATION
regimens I_PERSON/I_ORGANIZATION
was O
2 B_MEASURE
( O
range B_MEASURE/B_LOCATION
: O
1 B_NUMBER[MEASURE]
- O
6 B_MEASURE
) O
. O

Six O
( O
12 O
% O
) O
and O
4 O
( O
8 O
% O
) O
patients O
experienced O
grade O
2 O
hand B_DISEASE
- I_DISEASE
foot I_DISEASE
syndrome I_DISEASE
and O
stomatitis B_DISEASE
, O
respectively O
( O
no O
episodes O
of O
grade O
3 O
) O
. O

One O
patient O
developed O
grade O
3 O
diarrhea B_DISEASE
requiring O
hospitalization O
for O
hydration O
. O

Six B_NUMBER[MEASURE]
( O
12 B_NUMBER[MEASURE]
% I_NUMBER[MEASURE]
) O
individuals B_PERSON/B_LOCATION
required O
dose B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
reductions I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
median B_MEASURE/B_LOCATION
number I_MEASURE/I_LOCATION
of O
courses B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
liposomal B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
doxorubicin I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
administered O
on O
this O
protocol B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
2 B_MEASURE
( O
range B_MEASURE/B_LOCATION
: O
1 B_NUMBER[MEASURE]
- O
12 B_MEASURE
) O
. O

Four B_NUMBER[MEASURE]
of O
44 B_NUMBER[MEASURE]/B_PERSON
patients I_NUMBER[MEASURE]/I_PERSON
( O
9 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
evaluable B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
response B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
exhibited O
objective B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
subjective B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
evidence I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
an O
antineoplastic B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
effect I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
of O
therapy B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

conclusion O
: O
This O
modified O
liposomal O
doxorubicin O
regimen O
results O
in O
less O
toxicity B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
stomatitis B_DISEASE
, O
hand B_DISEASE
- I_DISEASE
foot I_DISEASE
syndrome I_DISEASE
) O
than O
the O
standard O
FDA O
- O
approved O
dose O
schedule O
. O

definite O
, O
although O
limited O
, O
antineoplastic O
activity O
is O
observed O
in O
patients O
with O
well O
- O
defined O
platinum O
- O
and O
paclitaxel O
- O
refractory O
ovarian B_DISEASE
cancer I_DISEASE
. O

efficacy O
of O
olanzapine O
in O
acute O
bipolar B_DISEASE
mania I_DISEASE
: O
a O
double O
- O
blind O
, O
placebo O
- O
controlled O
study O
. O

The O
Olanzipine B_PERSON/B_LOCATION
HGGW I_PERSON/I_LOCATION
Study I_PERSON/I_LOCATION
Group I_PERSON/I_LOCATION
. O

Background O
: O
We O
compared O
the O
efficacy O
and O
safety O
of O
olanzapine O
vs O
placebo O
for O
the O
treatment O
of O
acute O
bipolar B_DISEASE
mania I_DISEASE
. O

METHODS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O
Four B_NUMBER[MEASURE]
- O
week B_TIME[MEASURE]/B_PERSON
, O
randomized O
, O
double B_MEASURE/B_COLOR
- O
blind B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
parallel B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

A O
total O
of O
115 O
patients O
with O
a O
DSM O
- O
IV O
diagnosis O
of O
bipolar B_DISEASE/B_LOCATION
disorder I_DISEASE/I_LOCATION
, O
manic B_DISEASE
or O
mixed O
, O
were O
randomized O
to O
olanzapine O
, O
5 O
to O
20 O
mg O
/ O
d O
( O
n O
= O
55 O
) O
, O
or O
placebo O
( O
n O
= O
60 O
) O
. O

The O
primary O
efficacy O
measure O
was O
the O
Young O
- O
Mania B_PERSON
rating O
Scale O
( O
Y O
- O
Mrs O
) O
total O
score O
. O

Response B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
euthymia B_DISEASE_ADJECTIVE[DISEASE]
were O
defined O
, O
a O
priori B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O
as O
at O
least O
a O
50 B_MEASURE
% I_MEASURE
improvement I_MEASURE
from O
baseline B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O
end B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
point B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
and O
as O
a O
score B_MEASURE
of O
no O
less B_MEASURE
than O
12 B_NUMBER[MEASURE]
at O
end B_LOCATION/B_MEASURE
point I_LOCATION/I_MEASURE
in O
the O
Y B_OTHER/B_LOCATION
- O
Mrs B_MEASURE/B_LOCATION
total I_MEASURE/I_LOCATION
score I_MEASURE/I_LOCATION
, O
respectively O
. O

Safety O
was O
assessed O
using O
adverse O
events O
, O
Extrapyramidal B_DISEASE
Symptom I_DISEASE
( O
EPS B_LOCATION
) O
rating O
scales O
, O
laboratory O
values O
, O
electrocardiograms O
, O
vital O
signs O
, O
and O
weight O
change O
. O

RESULTS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O
olanzapine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
treated O
patients B_PERSON/B_BIO
demonstrated O
a O
statistically O
significant B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
greater B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
mean B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
( O
+ B_MEASURE/B_DISEASE
/ O
- O
SD B_DISEASE/B_PROTEIN[GENE]
) O
improvement B_DISEASE_ADJECTIVE[DISEASE]
in O
Y B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
Mrs B_MEASURE
total I_MEASURE
score I_MEASURE
than O
placebo B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
treated O
patients B_PERSON/B_BIO
( O
- O
14 B_MEASURE
. O
8 B_MEASURE
+ I_MEASURE
/ O
- O
12 B_MEASURE
. O
5 B_MEASURE
and O
- O
8 B_MEASURE
. O
1 B_MEASURE/B_LOCATION
+ I_MEASURE/I_LOCATION
/ O
- O
12 B_MEASURE
. O
7 B_MEASURE
, O
respectively O
; O
P B_MEASURE/B_LOCATION
< I_MEASURE/I_LOCATION
. O
001 B_MEASURE
) O
, O
which O
was O
evident B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O
the O
first B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
postbaseline B_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
observation B_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 B_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
week B_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
after O
randomization B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
and O
was O
maintained O
throughout O
the O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
last B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
observation I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
carried O
forward O
) O
. O

olanzapine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
treated O
patients B_PERSON/B_BIO
demonstrated O
a O
higher B_MEASURE
rate I_MEASURE
of O
response B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
65 B_MEASURE
% I_MEASURE
vs I_MEASURE
43 I_MEASURE
% I_MEASURE
, O
respectively O
; O
P B_OTHER/B_LOCATION
= O
. O
02 B_MEASURE
) O
and O
euthymia B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O
61 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
vs O
36 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
, O
respectively O
; O
P B_OTHER/B_LOCATION
= O
. O
01 B_MEASURE
) O
than O
placebo B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
treated O
patients B_PERSON/B_BIO
. O

There O
were O
no O
statistically O
significant O
differences O
in O
EPSs B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O
groups O
. O

However O
, O
olanzapine O
- O
treated O
patients O
had O
a O
statistically O
significant O
greater O
mean O
( O
+ O
/ O
- O
SD O
) O
weight B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
gain B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
than O
placebo O
- O
treated O
patients O
( O
2 O
. O
1 O
+ O
/ O
- O
2 O
. O
8 O
vs O
0 O
. O
45 O
+ O
/ O
- O
2 O
. O
3 O
kg O
, O
respectively O
) O
and O
also O
experienced O
more O
treatment O
- O
emergent O
somnolence B_DISEASE
( O
21 O
patients O
[ O
38 O
. O
2 O
% O
] O
vs O
5 O
[ O
8 O
. O
3 O
% O
] O
, O
respectively O
) O
. O

conclusion O
: O
Olanzapine O
demonstrated O
greater O
efficacy O
than O
placebo O
in O
the O
treatment O
of O
acute O
bipolar B_DISEASE
mania I_DISEASE
and O
was O
generally O
well O
tolerated O
. O

The O
effect O
of O
pupil B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
dilation I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
with O
tropicamide O
on O
vision O
and O
driving O
simulator O
performance O
. O

purpose O
: O
To O
assess O
the O
effect O
of O
pupil B_DISEASE
dilation I_DISEASE
on O
vision O
and O
driving O
ability O
. O

methods O
: O
A O
series O
of O
tests O
on O
various O
parameters O
of O
visual O
function O
and O
driving O
simulator O
performance O
were O
performed O
on O
12 O
healthy O
drivers O
, O
before O
and O
after O
pupil B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
dilation I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
using O
guttae O
tropicamide O
1 O
% O
. O

A O
driving O
simulator B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
Transport B_LOCATION/B_ORGANIZATION
Research I_LOCATION/I_ORGANIZATION
Laboratory I_LOCATION/I_ORGANIZATION
) O
was O
used O
to O
measure O
reaction B_MEASURE
time I_MEASURE
( O
RT B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
) O
, O
speed B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
maintenance B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
and O
steering B_MEASURE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
accuracy B_MEASURE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Tests B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
basic B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
visual I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
function I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
included O
high B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
- O
and O
low B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O
contrast B_MEASURE
visual I_MEASURE
acuity I_MEASURE
( O
HCVA B_LOCATION/B_ORGANIZATION
and O
LCVA B_LOCATION/B_ORGANIZATION
) O
, O
Pelli B_PERSON
- O
Robson B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
contrast B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
threshold B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O
CT B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
) O
and O
Goldmann B_MEASURE
perimetry I_MEASURE
( O
Fields B_LOCATION/B_ORGANIZATION
) O
. O

useful B_LOCATION/B_PERSON
Field I_LOCATION/I_PERSON
of O
view B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
( O
UFOV B_TIME[MEASURE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
- O
a O
test B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
visual B_DISEASE/B_ORGANISM_FUNCTION
attention I_DISEASE/I_ORGANISM_FUNCTION
) O
was O
also O
undertaken O
. O

The O
mean B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
differences I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
in O
the O
pre B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
and O
post B_LOCATION/B_DISEASE
- O
dilatation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
measurements I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
tested O
for O
statistical B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
significance I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
at O
the O
95 B_MEASURE/B_LOCATION
% I_MEASURE/I_LOCATION
level I_MEASURE/I_LOCATION
using O
one B_NUMBER[MEASURE]/B_BODY_PART_OR_ORGAN_COMPONENT
- O
tail B_BODY_PART_OR_ORGAN_COMPONENT/B_MEASURE
paired O
t B_OTHER/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
tests B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O

Results O
: O
Pupillary B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
dilation I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
resulted O
in O
a O
statistically O
significant O
deterioration O
in O
CT O
and O
HCVA O
only O
. O

Five B_NUMBER[MEASURE]/B_LOCATION
of O
12 B_PERSON
drivers I_PERSON
also O
exhibited O
deterioration B_DISEASE_ADJECTIVE[DISEASE]
in O
LCVA B_LOCATION/B_ORGANIZATION
, O
CT B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
and O
RT B_LOCATION
. O

Little B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
evidence I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
emerged O
for O
deterioration B_DISEASE_ADJECTIVE[DISEASE]
in O
fields B_DISEASE/B_PROTEIN[GENE]
and O
UFOV B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O

Also O
, O
7 B_NUMBER[MEASURE]/B_ORGANIZATION
of O
12 B_MEASURE/B_PERSON
drivers B_MEASURE/I_PERSON
appeared O
to O
adjust O
their O
driving O
behaviour B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
by O
reducing O
their O
speed B_MEASURE/B_SPORT[ENT]
on O
the O
driving O
simulator B_LOCATION/B_PERSON
, O
leading O
to O
improved B_DISEASE/B_LOCATION
steering I_DISEASE/I_LOCATION
accuracy I_DISEASE/I_LOCATION
. O

conclusions O
: O
Pupillary B_DISEASE/B_PERSON
dilation I_DISEASE/I_PERSON
may O
lead O
to O
a O
decrease O
in O
vision O
and O
daylight O
driving O
performance O
in O
young O
people O
. O

A O
larger B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
including O
a O
broader B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
spectrum B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
subjects B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
is O
warranted O
before O
guidelines B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
can O
be O
recommended O
. O

A O
case O
of O
isotretinoin B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
embryopathy B_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
with O
bilateral O
anotia B_DISEASE/B_BACTERIUM[BIO]
and O
Taussig B_DISEASE
- I_DISEASE
Bing I_DISEASE
malformation I_DISEASE
. O

We O
report O
a O
newborn O
infant O
with O
multiple O
congenital O
anomalies O
( O
anotia B_PERSON/B_DISEASE
and O
Taussig B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
- I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
Bing I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
malformation I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
) O
due O
to O
exposure O
to O
isotretinoin O
within O
the O
first O
trimester O
. O

In O
this O
paper B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PRODUCT[OBJECT]
we O
aim O
to O
draw O
to O
the O
fact B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
that O
caution B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
is O
needed O
when O
prescribing O
vitamin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
A I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
containing O
drugs B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
women B_PERSON
of O
childbearing O
years B_TIME[MEASURE]/B_PERSON
. O

Effect O
of O
methoxamine O
on O
maximum O
urethral O
pressure O
in O
women O
with O
genuine O
stress B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
incontinence I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
: O
a O
placebo O
- O
controlled O
, O
double O
- O
blind O
crossover O
study O
. O

The O
aim O
of O
the O
study O
was O
to O
evaluate O
the O
potential O
role O
for O
a O
selective O
alpha1 O
- O
adrenoceptor O
agonist O
in O
the O
treatment O
of O
urinary B_DISEASE/B_LOCATION
stress I_DISEASE/I_LOCATION
incontinence I_DISEASE/I_LOCATION
. O

A O
randomised B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O
double B_MEASURE/B_COLOR
- O
blind B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
placebo B_LOCATION/B_PERSON
- O
controlled O
, O
crossover B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
design I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
employed O
. O

Half O
log O
incremental O
doses O
of O
intravenous O
methoxamine O
or O
placebo O
( O
saline O
) O
were O
administered O
to O
a O
group O
of O
women O
with O
genuine O
stress B_DISEASE
incontinence I_DISEASE
while O
measuring O
maximum O
urethral O
pressure O
( O
MUP O
) O
, O
blood O
pressure O
, O
heart O
rate O
, O
and O
symptomatic O
side O
effects O
. O

Methoxamine O
evoked O
non O
- O
significant O
increases O
in O
MUP O
and O
diastolic O
blood O
pressure O
but O
caused O
a B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
significant I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
rise I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
systolic I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
blood I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pressure I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
significant O
fall O
in O
heart O
rate O
at O
maximum O
dosage O
. O

systemic O
side O
effects O
including O
piloerection O
, O
headache B_DISEASE
, O
and O
cold O
extremities O
were O
experienced O
in O
all O
subjects O
. O

The O
results O
indicate O
that O
the O
clinical O
usefulness O
of O
direct O
, O
peripherally O
acting O
sub O
- O
type O
- O
selective O
alpha1 O
- O
adrenoceptor O
agonists O
in O
the O
medical O
treatment O
of O
stress B_DISEASE/B_LOCATION
incontinence I_DISEASE/I_LOCATION
may O
be O
limited O
by O
associated O
piloerection O
and O
cardiovascular O
side O
effects O
. O

Hyperglycemic B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effect O
of O
amino O
compounds O
structurally O
related O
to O
caproate O
in O
rats O
. O

The O
chronic O
feeding O
of O
small O
amounts O
( O
0 O
. O
3 O
- O
3 O
% O
of O
diet O
weight O
) O
of O
certain O
amino O
derivatives O
of O
caproate O
resulted O
in O
hyperglycemia B_DISEASE
, O
an O
elevated O
glucose O
tolerance O
curve O
and O
, O
occasionally O
, O
glucosuria B_DISEASE
. O

Effective B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
compounds I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
included O
norleucine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
norvaline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
glutamate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
epsilon B_PROTEIN[GENE]/B_MEASURE
- O
aminocaproate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
methionine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
leucine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Toleration O
of O
high O
doses O
of O
angiotensin O
- O
converting O
enzyme O
inhibitors O
in O
patients O
with O
chronic O
heart B_DISEASE
failure I_DISEASE
: O
results O
from O
the O
Atlas O
trial O
. O

The O
Assessment B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
Treatment B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
with O
Lisinopril B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
Survival B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O

Background O
: O
Treatment O
with O
angiotensin O
- O
converting O
enzyme O
( O
ace O
) O
inhibitors O
reduces O
mortality O
and O
morbidity O
in O
patients O
with O
chronic O
heart B_DISEASE
failure I_DISEASE
( O
CHF B_LOCATION/B_ORGANIZATION
) O
, O
but O
most O
affected O
patients O
are O
not O
receiving O
these O
agents O
or O
are O
being O
treated O
with O
doses O
lower O
than O
those O
found O
to O
be O
efficacious O
in O
trials O
, O
primarily O
because O
of O
concerns O
about O
the O
safety O
and O
tolerability O
of O
these O
agents O
, O
especially O
at O
the O
recommended O
doses O
. O

The O
present O
study O
examines O
the O
safety O
and O
tolerability O
of O
high O
- O
compared O
with O
low O
- O
dose O
lisinopril O
in O
CHF B_DISEASE/B_PERSON
. O

METHODS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O
The O
Assessment B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
Lisinopril B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O
Survival B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
study I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
was O
a O
multicenter B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O
randomized B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
double B_MEASURE/B_COLOR
- O
blind B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
trial I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
in O
which O
patients B_PERSON/B_BIO
with O
or O
without O
previous B_DISEASE/B_GENE
ACE I_DISEASE/I_GENE
inhibitor I_DISEASE/I_GENE
treatment I_DISEASE/I_GENE
were O
stabilized O
receiving O
medium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O
dose B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
lisinopril I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
( O
12 B_MEASURE
. O
5 B_MEASURE
or O
15 B_MEASURE
. O
0 B_MEASURE
mg I_MEASURE
once O
daily O
[ O
OD B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
for O
2 B_NUMBER[MEASURE]/B_LOCATION
to O
4 B_TIME[MEASURE]/B_ENT
weeks I_TIME[MEASURE]/I_ENT
and O
then O
randomized O
to O
high B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
- O
( O
35 B_MEASURE
. O
0 B_MEASURE
or O
32 B_MEASURE
. O
5 B_MEASURE
mg I_MEASURE
OD I_MEASURE
) O
or O
low B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O
dose B_MEASURE
( O
5 B_MEASURE
. O
0 B_MEASURE
or O
2 B_MEASURE
. O
5 B_MEASURE
mg I_MEASURE
OD I_MEASURE
) O
groups B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

patients O
with O
New O
York O
Heart O
Association O
classes O
II O
to O
IV O
CHF B_DISEASE
and O
left O
ventricular O
ejection O
fractions O
of O
no O
greater O
than O
0 O
. O
30 O
( O
n O
= O
3164 O
) O
were O
randomized O
and O
followed O
up O
for O
a O
median O
of O
46 O
months O
. O

We O
examined O
the O
occurrence O
of O
adverse O
events O
and O
the O
need O
for O
discontinuation O
and O
dose O
reduction O
during O
treatment O
, O
with O
a O
focus O
on O
hypotension B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
and O
renal B_DISEASE
dysfunction I_DISEASE
. O

Results O
: O
Of O
405 O
patients O
not O
previously O
receiving O
an O
ace O
inhibitor O
, O
doses O
in O
only O
4 O
. O
2 O
% O
could O
not O
be O
titrated O
to O
the O
medium O
doses O
required O
for O
randomization O
because O
of O
symptoms O
possibly O
related O
to O
hypotension B_DISEASE
( O
2 O
. O
0 O
% O
) O
or O
because O
of O
renal B_DISEASE
dysfunction I_DISEASE
or O
hyperkalemia B_DISEASE
( O
2 O
. O
3 O
% O
) O
. O

doses B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
more B_MEASURE
than O
90 B_NUMBER[MEASURE]/B_LOCATION
% I_NUMBER[MEASURE]/I_LOCATION
of O
randomized B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
patients B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
in O
the O
high B_MEASURE/B_LOCATION
- O
and O
low B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O
dose B_MEASURE/B_LOCATION
groups B_MEASURE/I_LOCATION
were O
titrated O
to O
their O
assigned O
target B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
, O
and O
the O
mean B_MEASURE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
doses B_MEASURE/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
blinded B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
medication I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
both O
groups B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
remained O
similar B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
throughout O
the O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Withdrawals B_DISEASE
occurred O
in O
27 B_MEASURE
. O
1 B_MEASURE
% I_MEASURE
of O
the O
high B_MEASURE/B_LOCATION
- O
and O
30 B_MEASURE
. O
7 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
of O
the O
low B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O
dose B_MEASURE/B_LOCATION
groups B_MEASURE/I_LOCATION
. O

Subgroups O
presumed O
to O
be O
at O
higher O
risk O
for O
ace O
inhibitor O
intolerance O
( O
blood O
pressure O
, O
< O
120 O
mm O
Hg O
; O
creatinine O
, O
> O
or O
= O
132 O
. O
6 O
micromol O
/ O
L O
[ O
> O
or O
= O
1 O
. O
5 O
mg O
/ O
DL O
] O
; O
age O
, O
> O
or O
= O
70 O
years O
; O
and O
patients O
with O
diabetes B_DISEASE/B_GENE
) O
generally O
tolerated O
the O
high O
- O
dose O
strategy O
. O

conclusions O
: O
These O
findings O
demonstrate O
that O
ace O
inhibitor O
therapy O
in O
most O
patients O
with O
CHF B_DISEASE
can O
be O
successfully O
titrated O
to O
and O
maintained O
at O
high O
doses O
, O
and O
that O
more O
aggressive O
use O
of O
these O
agents O
is O
warranted O
. O

cocaine O
, O
ethanol O
, O
and O
cocaethylene O
cardiotoxity B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
an O
animal O
model O
of O
cocaine B_DISEASE/B_LOCATION
and I_DISEASE/I_LOCATION
ethanol I_DISEASE/I_LOCATION
abuse I_DISEASE/I_LOCATION
. O

objectives O
: O
simultaneous O
abuse B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cocaine I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ethanol I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
affects O
12 O
million O
Americans O
annually O
. O

In O
combination B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
these O
substances B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
substantially O
more O
toxic B_DISEASE_ADJECTIVE[DISEASE]
than O
either O
drug B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
alone O
. O

Their O
combined O
cardiac B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
toxicity I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
may O
be O
due O
to O
independent O
effects O
of O
each O
drug O
; O
however O
, O
they O
may O
also O
be O
due O
to O
cocaethylene O
( O
CE O
) O
, O
a O
cocaine O
metabolite O
formed O
only O
in O
the O
presence O
of O
ethanol O
. O

The O
purpose O
of O
this O
study O
was O
to O
delineate O
the O
role O
of O
CE O
in O
the O
combined O
cardiotoxicity B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
cocaine O
and O
ethanol O
in O
a O
model O
simulating O
their O
abuse O
. O

METHODS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O
Twenty B_NUMBER[MEASURE]
- O
three B_NUMBER[MEASURE]/B_ENT
dogs I_NUMBER[MEASURE]/I_ENT
were O
randomized O
to O
receive O
either O
1 B_NUMBER[MEASURE]/B_LOCATION
) O
three B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BODY_PART_OR_ORGAN_COMPONENT
intravenous B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_BODY_PART_OR_ORGAN_COMPONENT
( O
IV B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
boluses B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
of O
cocaine B_MEASURE
7 I_MEASURE
. O
5 B_MEASURE
mg I_MEASURE
/ O
kg B_MEASURE
with O
ethanol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
1 B_MEASURE/B_LOCATION
g I_MEASURE/I_LOCATION
/ O
kg B_MEASURE
) O
as O
an O
IV B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
infusion I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O
C B_OTHER/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
+ O
E B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
n B_MEASURE/B_PROTEIN[GENE]
= O
8 B_MEASURE
) O
, O
2 B_NUMBER[MEASURE]
) O
three B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cocaine I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
boluses I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
only O
( O
C B_PROTEIN[GENE]/B_LOCATION
, O
n B_MEASURE/B_LOCATION
= O
6 B_MEASURE
) O
, O
3 B_NUMBER[MEASURE]
) O
ethanol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
infusion I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
only O
( O
E B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
n B_MEASURE/B_LOCATION
= O
5 B_MEASURE
) O
, O
or O
4 B_NUMBER[MEASURE]/B_LOCATION
) O
placebo B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
boluses I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
infusion B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
n B_OTHER/B_MEASURE
= O
4 B_MEASURE
) O
. O

hemodynamic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
measurements I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
, O
electrocardiograms B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O
and O
serum B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
drug I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
concentrations I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
obtained O
at O
baseline B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
, O
and O
then O
at O
fixed O
time B_MEASURE/B_LOCATION
intervals I_MEASURE/I_LOCATION
after O
each O
drug B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
administered O
. O

Results O
: O
Two O
of O
eight O
dogs O
in O
the O
C O
+ O
E O
group O
experienced O
cardiovascular B_DISEASE
collapse I_DISEASE
. O

The O
most O
dramatic B_DISEASE_ADJECTIVE[DISEASE]
hemodynamic I_DISEASE_ADJECTIVE[DISEASE]
changes I_DISEASE_ADJECTIVE[DISEASE]
occurred O
after O
each O
cocaine B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
bolus I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
the O
C B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
+ B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
E B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
and O
C B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
only B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
groups B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
; O
however O
, O
persistent B_NUMBER[MEASURE]/B_PERSON
hemodynamic I_NUMBER[MEASURE]/I_PERSON
changes I_NUMBER[MEASURE]/I_PERSON
occurred O
in O
the O
C B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SEQUENCE[MEASURE]
+ I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_SEQUENCE[MEASURE]
E I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_SEQUENCE[MEASURE]
group I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_SEQUENCE[MEASURE]
. O

Peak O
CE O
levels O
were O
associated O
with O
a O
45 O
% O
( O
SD O
+ O
/ O
- O
22 O
% O
, O
95 O
% O
CI O
= O
22 O
% O
to O
69 O
% O
) O
decrease B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
cardiac I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
output I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O
p O
< O
0 O
. O
05 O
) O
, O
a O
56 O
% O
( O
SD O
+ O
/ O
- O
23 O
% O
, O
95 O
% O
CI O
= O
32 O
% O
to O
80 O
% O
) O
decrease O
in O
dP O
/ O
dt O
( O
Max O
) O
( O
p O
< O
. O
006 O
) O
, O
and O
a O
23 O
% O
( O
SD O
+ O
/ O
- O
15 O
% O
, O
95 O
% O
CI O
= O
7 O
% O
to O
49 O
% O
) O
decrease O
in O
SVO O
( O
2 O
) O
( O
p O
< O
0 O
. O
025 O
) O
. O

Ventricular B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
arrhythmias I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
were O
primarily O
observed O
in O
the O
C O
+ O
E O
group O
, O
in O
which O
four O
of O
eight O
dogs O
experienced O
ventricular B_DISEASE
tachycardia I_DISEASE
. O

CONCLUSIONS B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
: O
cocaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O
ethanol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
combination B_MEASURE/B_ORGANIZATION
were O
more O
toxic B_DISEASE_ADJECTIVE[DISEASE]
than O
either O
substance B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
alone O
. O

Co O
- O
administration O
resulted O
in O
prolonged O
cardiac B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
toxicity I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
was O
dysrhythmogenic O
. O

Peak O
serum O
cocaethylene O
concentrations O
were O
associated O
with O
prolonged O
myocardial B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
depression I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Worsening O
of O
Parkinsonism B_DISEASE
after O
the O
use O
of O
veralipride O
for O
treatment O
of O
menopause O
: O
case O
report O
. O

We O
describe O
a O
female O
patient O
with O
stable O
Parkinson B_DISEASE
' I_DISEASE
s I_DISEASE
disease I_DISEASE
who O
has O
shown O
a O
marked O
worsening O
of O
her O
motor O
functions O
following O
therapy O
of O
menopause O
related O
symptoms O
with O
veralipride O
, O
as O
well O
as O
the O
improvement O
of O
her O
symptoms O
back O
to O
baseline O
after O
discontinuation O
of O
the O
drug O
. O

We O
emphasize O
the O
anti B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
- O
dopaminergic B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effect I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
veralipride B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Viracept O
and O
irregular B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANIZATION
heartbeat I_DISEASE_ADJECTIVE[DISEASE]/I_ORGANIZATION
warning O
. O

A O
group O
of O
doctors O
in O
Boston O
warn O
that O
the O
protease O
inhibitor O
Viracept O
may O
cause O
an O
irregular B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
heart I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
beat I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
known O
as O
bradycardia B_DISEASE
, O
in O
people O
with O
HIV O
. O

Bradycardia B_DISEASE/B_PERSON
occurred O
in O
a O
45 O
- O
year O
- O
old O
male O
patient O
who O
was O
Viracept O
in O
combination O
with O
other O
anti O
- O
HIV O
drugs O
. O

The O
symptoms B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ceased O
after O
switching O
to O
another O
drug B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
combination I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

frequency O
of O
appearance O
of O
myeloperoxidase O
- O
antineutrophil O
cytoplasmic O
antibody O
( O
MPO O
- O
ANCA O
) O
in O
Graves B_DISEASE/B_PERSON
' I_DISEASE/I_PERSON
disease I_DISEASE/I_PERSON
patients O
treated O
with O
propylthiouracil O
and O
the O
relationship O
between O
MPO O
- O
ANCA O
and O
clinical O
manifestations O
. O

objective O
: O
Myeloperoxidase O
antineutrophil O
cytoplasmic O
antibody O
( O
MPO O
- O
ANCA O
) O
- O
positive O
vasculitis B_DISEASE
has O
been O
reported O
in O
patients O
with O
Graves B_DISEASE
' I_DISEASE
disease I_DISEASE
who O
were O
treated O
with O
propylthiouracil O
( O
PTU O
) O
. O

The O
appearance B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
of O
MPO B_LOCATION
- O
ANCA B_DISEASE/B_LOCATION
in O
these O
cases B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
suspected O
of O
being O
related O
to O
PTU B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
because O
the O
titres B_MEASURE/B_GENE
of O
MPO B_LOCATION
- O
ANCA B_LOCATION/B_DISEASE
decreased O
when O
PTU B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
stopped O
. O

Nevertheless O
, O
there O
have O
been O
no O
studies O
on O
the O
temporal O
relationship O
between O
the O
appearance O
of O
MPO O
- O
ANCA O
and O
vasculitis B_DISEASE
during O
PTU O
therapy O
, O
or O
on O
the O
incidence O
of O
MPO O
- O
ANCA O
in O
untreated O
Graves B_DISEASE/B_LOCATION
' I_DISEASE/I_LOCATION
disease I_DISEASE/I_LOCATION
patients O
. O

Therefore O
, O
we O
sought O
to O
address O
these O
parameters O
in O
patients O
with O
Graves B_DISEASE/B_LOCATION
' I_DISEASE/I_LOCATION
disease I_DISEASE/I_LOCATION
. O

patients O
: O
We O
investigated O
102 O
untreated O
patients O
with O
hyperthyroidism B_DISEASE/B_LOCATION
due O
to O
Graves B_DISEASE/B_LOCATION
' I_DISEASE/I_LOCATION
disease I_DISEASE/I_LOCATION
for O
the O
presence O
of O
MPO O
- O
ANCA O
, O
and O
for O
the O
development O
vasculitis B_DISEASE/B_TIME[MEASURE]
after O
starting O
PTU O
therapy O
. O

Twenty B_NUMBER[MEASURE]
- O
nine B_NUMBER[MEASURE]
of O
them O
were O
later O
excluded O
because O
of O
adverse B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
PTU B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O
because O
the O
observation B_TIME[MEASURE]
period I_TIME[MEASURE]
was O
less B_MEASURE
than O
3 B_TIME[MEASURE]
months I_TIME[MEASURE]
. O

The O
remaining O
73 B_NUMBER[MEASURE]/B_PERSON
patients I_NUMBER[MEASURE]/I_PERSON
( O
55 B_MEASURE/B_SPORT[ENT]
women I_MEASURE/I_SPORT[ENT]
and O
18 B_PERSON
men I_PERSON
) O
, O
all O
of O
whom O
were O
examined O
for O
more B_TIME[MEASURE]
than O
3 B_TIME[MEASURE]
months I_TIME[MEASURE]
, O
were O
adopted O
as O
the O
subjects B_PERSON
of O
the O
investigation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
median B_TIME[MEASURE]/B_LOCATION
observation I_TIME[MEASURE]/I_LOCATION
period I_TIME[MEASURE]/I_LOCATION
was O
23 B_MEASURE
. O
6 B_TIME[MEASURE]
months I_TIME[MEASURE]
( O
range B_LOCATION/B_MEASURE
: O
3 B_MEASURE
- O
37 B_TIME[MEASURE]
months I_TIME[MEASURE]
) O
. O

Measurements B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
: O
MPO B_MEASURE/B_PROTEIN[GENE]
- O
ANCA B_MEASURE/B_DISEASE
was O
measured O
at O
intervals B_MEASURE/B_LOCATION
of O
2 B_NUMBER[MEASURE]
- O
6 B_TIME[MEASURE]
months I_TIME[MEASURE]
. O

Results O
: O
Before O
treatment O
, O
the O
MPO O
- O
ANCA O
titres O
of O
all O
102 O
untreated O
Graves B_DISEASE/B_LOCATION
' I_DISEASE/I_LOCATION
disease I_DISEASE/I_LOCATION
patients O
were O
within O
the O
reference O
range O
( O
below O
10 O
U O
/ O
ml O
) O
. O

Three B_NUMBER[MEASURE]
( O
4 B_MEASURE
. O
1 B_MEASURE
% I_MEASURE
) O
of O
the O
73 B_PERSON/B_BIO
patients I_PERSON/I_BIO
were O
positive B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
for O
MPO B_PROTEIN[GENE]/B_LOCATION
- O
ANCA B_MEASURE/B_DISEASE
at O
13 B_NUMBER[MEASURE]
, O
16 B_NUMBER[MEASURE]
and O
17 B_TIME[MEASURE]
months I_TIME[MEASURE]
, O
respectively O
, O
after O
the O
start B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
PTU B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
therapy I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O

In O
two O
of O
them O
, O
the O
MPO O
- O
ANCA O
titres O
transiently O
increased O
to O
12 O
. O
8 O
and O
15 O
. O
0 O
U O
/ O
ml O
, O
respectively O
, O
despite O
continued O
PTU O
therapy O
, O
but O
no O
vasculitic B_DISEASE
disorders I_DISEASE
developed O
. O

In O
the O
third O
patient O
, O
the O
MPO O
- O
ANCA O
titre O
increased O
to O
204 O
U O
/ O
ml O
and O
she O
developed O
a O
higher O
fever B_DISEASE/B_MEASURE
, O
oral B_DISEASE
ulcers I_DISEASE
and O
polyarthralgia B_DISEASE
, O
but O
the O
symptoms O
resolved O
2 O
weeks O
after O
stopping O
PTU O
therapy O
, O
and O
the O
MPO O
- O
ANCA O
titre O
decreased O
to O
20 O
. O
7 O
U O
/ O
ml O
by O
4 O
months O
after O
discontinuing O
PTU O
. O

conclusions O
: O
PTU O
therapy O
may O
be O
related O
to O
the O
appearance O
of O
MPO O
- O
ANCA O
, O
but O
MPO O
- O
ANCA O
does O
not O
appear O
to O
be O
closely O
related O
to O
vasculitis B_DISEASE
. O

prevalence O
of O
heart B_DISEASE/B_LOCATION
disease I_DISEASE/I_LOCATION
in O
asymptomatic O
chronic O
cocaine O
users O
. O

To O
determine O
the O
prevalence O
of O
heart B_DISEASE/B_LOCATION
disease I_DISEASE/I_LOCATION
in O
outpatient O
young O
asymptomatic O
chronic O
cocaine O
users O
, O
35 O
cocaine O
users O
and O
32 O
age O
- O
matched O
controls O
underwent O
resting O
and O
exercise O
electrocardiography O
( O
ECG O
) O
and O
Doppler O
echocardiography O
. O

findings O
consistent O
with O
coronary B_DISEASE/B_LOCATION
artery I_DISEASE/I_LOCATION
disease I_DISEASE/I_LOCATION
were O
detected O
in O
12 O
( O
34 O
% O
) O
patients O
and O
3 O
( O
9 O
% O
) O
controls O
( O
p O
= O
0 O
. O
01 O
) O
. O

decreased O
left O
ventricular B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
systolic I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
function I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
demonstrated O
in O
5 B_NUMBER[MEASURE]
( O
14 B_NUMBER[MEASURE]/B_PERSON
% I_NUMBER[MEASURE]/I_PERSON
) O
patients B_PERSON
, O
but O
in O
none B_NUMBER[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
controls B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
p B_OTHER/B_PROTEIN[GENE]
= O
0 B_MEASURE
. O
055 B_MEASURE
) O
. O

Finally O
, O
resting O
and O
peak O
exercise O
abnormal B_DISEASE
left I_DISEASE
ventricular I_DISEASE
filling I_DISEASE
was O
detected O
in O
38 O
and O
35 O
% O
of O
patients O
as O
compared O
to O
19 O
and O
9 O
% O
of O
controls O
, O
respectively O
( O
p O
= O
0 O
. O
11 O
and O
0 O
. O
02 O
, O
respectively O
) O
. O

We O
conclude O
that O
coronary B_DISEASE
artery I_DISEASE
or I_DISEASE
myocardial I_DISEASE
disease I_DISEASE
is O
common O
( O
38 O
% O
) O
in O
young O
asymptomatic O
chronic O
cocaine O
users O
. O

Therefore O
, O
screening O
ECG B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O
echocardiography B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
may O
be O
warranted O
in O
these O
patients B_PERSON/B_LOCATION
. O

cardioprotective B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
Picrorrhiza B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
kurroa I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
against O
isoproterenol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
myocardial I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stress I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
rats B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
cardioprotective O
effect O
of O
the O
ethanol O
extract O
of O
Picrorrhiza O
kurroa O
rhizomes O
and O
roots O
( O
PK O
) O
on O
isoproterenol O
- O
induced O
myocardial B_DISEASE
infarction I_DISEASE
in O
rats O
with O
respect O
to O
lipid O
metabolism O
in O
serum O
and O
heart O
tissue O
has O
been O
investigated O
. O

Oral O
pre O
- O
treatment O
with O
PK O
( O
80 O
mg O
kg O
( O
- O
1 O
) O
day O
( O
- O
1 O
) O
for O
15 O
days O
) O
significantly O
prevented O
the O
isoproterenol O
- O
induced O
myocardial B_DISEASE
infarction I_DISEASE
and O
maintained O
the O
rats O
at O
near O
normal O
status O
. O

Phase O
2 O
early O
afterdepolarization O
as O
a O
trigger O
of O
polymorphic O
ventricular B_DISEASE
tachycardia I_DISEASE
in O
acquired O
long B_DISEASE_ADJECTIVE[DISEASE]/B_SPECIES[BIO]
- B_DISEASE_ADJECTIVE[DISEASE]/I_SPECIES[BIO]
QT B_DISEASE_ADJECTIVE[DISEASE]/I_SPECIES[BIO]
syndrome B_DISEASE_ADJECTIVE[DISEASE]/I_SPECIES[BIO]
: O
direct O
evidence O
from O
intracellular O
recordings O
in O
the O
intact O
left O
ventricular O
wall O
. O

Background O
: O
This O
study O
examined O
the O
role O
of O
phase O
2 O
early O
afterdepolarization O
( O
EAD O
) O
in O
producing O
a O
trigger O
to O
initiate O
torsade B_DISEASE
de I_DISEASE
pointes I_DISEASE
( O
TdP B_LOCATION/B_ORGANIZATION
) O
with O
QT B_DISEASE
prolongation I_DISEASE
induced O
by O
DL O
- O
sotalol O
and O
azimilide O
. O

The O
contribution O
of O
transmural O
dispersion O
of O
repolarization O
( O
TDR O
) O
to O
transmural O
propagation O
of O
EAD O
and O
the O
maintenance O
of O
TdP B_PROTEIN[GENE]/B_DISEASE
was O
also O
evaluated O
. O

METHODS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
AND O
RESULTS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
transmembrane B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
action I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
potentials I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
from O
epicardium B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
, O
midmyocardium B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
, O
and O
endocardium B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
were O
recorded O
simultaneously O
, O
together O
with O
a O
transmural B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ECG I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
in O
arterially O
perfused O
canine B_SPECIES[BIO]
and O
rabbit B_SPECIES[BIO]
left O
ventricular B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
preparations I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O

DL O
- O
Sotalol O
preferentially O
prolonged O
action O
potential O
duration O
( O
APD O
) O
in O
M O
cells O
dose O
- O
dependently O
( O
1 O
to O
100 O
micromol O
/ O
L O
) O
, O
leading O
to O
QT B_DISEASE
prolongation I_DISEASE
and O
an O
increase O
in O
TDR O
. O

Azimilide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
however O
, O
significantly O
prolonged O
APD B_DISEASE/B_PROTEIN[GENE]
and O
QT B_PROTEIN[GENE]/B_LOCATION
interval I_PROTEIN[GENE]/I_LOCATION
at O
concentrations B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
from O
0 B_MEASURE
. O
1 B_MEASURE
to O
10 B_MEASURE
micromol I_MEASURE
/ O
L B_OTHER/B_MEASURE
but O
shortened O
them O
at O
30 B_MEASURE/B_LOCATION
micromol I_MEASURE/I_LOCATION
/ O
L B_OTHER/B_MEASURE
. O

Unlike O
dl B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
sotalol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
azimilide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
> O
3 B_MEASURE/B_LOCATION
micromol I_MEASURE/I_LOCATION
/ O
L B_OTHER/B_MEASURE
) O
increased O
epicardial B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
APD I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
markedly O
, O
causing O
a O
diminished B_DISEASE
TDR I_DISEASE
. O

Although O
both O
DL O
- O
sotalol O
and O
azimilide O
rarely O
induced O
EADs O
in O
canine O
left O
ventricles O
, O
they O
produced O
frequent O
EADs O
in O
rabbits O
, O
in O
which O
more O
pronounced O
QT B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
prolongation I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O
seen O
. O

An O
increase O
in O
TDR O
by O
DL O
- O
sotalol O
facilitated O
transmural O
propagation O
of O
EADs O
that O
initiated O
multiple O
episodes O
of O
spontaneous O
TdP B_DISEASE/B_GENE
in O
3 O
of O
6 O
rabbit O
left O
ventricles O
. O

Of O
note B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
, O
although O
azimilide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
3 B_MEASURE/B_LOCATION
to O
10 B_MEASURE
micromol I_MEASURE
/ O
L B_OTHER/B_MEASURE
) O
increased O
APD B_DISEASE
more I_DISEASE
than O
dl B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
sotalol B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
its O
EADs B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
often O
failed O
to O
propagate O
transmurally O
, O
probably O
because O
of O
a O
diminished B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
TDR I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

conclusions O
: O
This O
study O
provides O
the O
first O
direct O
evidence O
from O
intracellular O
action O
potential O
recordings O
that O
phase O
2 O
EAD O
can O
be O
generated O
from O
intact O
ventricular O
wall O
and O
produce O
a O
trigger O
to O
initiate O
the O
onset O
of O
TdP B_PROTEIN[GENE]/B_DISEASE
under O
QT B_DISEASE
prolongation I_DISEASE
. O

A O
pilot O
study O
to O
assess O
the O
safety O
of O
dobutamine O
stress O
echocardiography O
in O
the O
emergency O
department O
evaluation O
of O
cocaine O
- O
associated O
chest B_DISEASE/B_LOCATION
pain I_DISEASE/I_LOCATION
. O

Study O
objective O
: O
Chest B_DISEASE
pain I_DISEASE
in O
the O
setting O
of O
cocaine O
use O
poses O
a O
diagnostic O
dilemma O
. O

Dobutamine O
stress O
echocardiography O
( O
DSE O
) O
is O
a O
widely O
available O
and O
sensitive O
test O
for O
evaluating O
cardiac O
ischemia B_DISEASE/B_LOCATION
. O

Because O
of O
the O
theoretical O
concern O
regarding O
administration O
of O
dobutamine O
in O
the O
setting O
of O
cocaine O
use O
, O
we O
conducted O
a O
pilot O
study O
to O
assess O
the O
safety O
of O
DSE O
in O
emergency O
department O
patients O
with O
cocaine O
- O
associated O
chest B_DISEASE/B_LOCATION
pain I_DISEASE/I_LOCATION
. O

methods B_MEASURE
: O
A O
prospective B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
case I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
series I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
conducted O
in O
the O
intensive B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
diagnostic I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
and O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
unit I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_LOCATION
in O
the O
Ed B_PERSON/B_LOCATION
of O
an O
urban B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
tertiary I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
- O
care B_LOCATION/B_ORGANIZATION
teaching I_LOCATION/I_ORGANIZATION
hospital I_LOCATION/I_ORGANIZATION
. O

patients O
were O
eligible O
for O
DSE O
if O
they O
had O
used O
cocaine O
within O
24 O
hours O
preceding O
the O
onset O
of O
chest B_DISEASE
pain I_DISEASE
and O
had O
a O
normal O
ECG O
and O
tropinin O
I O
level O
. O

patients O
exhibiting O
signs O
of O
continuing O
cocaine O
toxicity B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
excluded O
from O
the O
study O
. O

All O
patients B_PERSON
were O
admitted O
to O
the O
hospital B_LOCATION/B_ORGANIZATION
for O
serial B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
testing I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
after O
the O
DSE B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
testing I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_LOCATION
in O
the O
intensive B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
diagnostic I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
and O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
unit I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_LOCATION
. O

RESULTS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O
Twenty B_NUMBER[MEASURE]
- O
four B_NUMBER[MEASURE]
patients I_NUMBER[MEASURE]
were O
enrolled O
. O

Two O
patients O
had O
inadequate O
resting O
images O
, O
one O
DSE O
was O
terminated O
because O
of O
inferior O
hypokinesis B_DISEASE_ADJECTIVE[DISEASE]
, O
another O
DSE O
was O
terminated O
because O
of O
a O
rate O
- O
related O
atrial O
conduction O
deficit O
, O
and O
1 O
patient O
did O
not O
reach O
the O
target O
heart O
rate O
. O

Thus O
, O
19 B_PERSON
patients I_PERSON
completed O
a O
DSE B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
reached O
their O
target B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
heart I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
rates I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

None O
of O
the O
patients O
experienced O
signs O
of O
exaggerated O
adrenergic O
response O
, O
which O
was O
defined O
as O
a O
systolic O
blood O
pressure O
of O
greater O
than O
200 O
mm O
Hg O
or O
the O
occurrence O
of O
tachydysrhythmias B_DISEASE
( O
excluding O
sinus B_DISEASE
tachycardia I_DISEASE
) O
. O

Further B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
suggesting I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
lack I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O
exaggerated B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
adrenergic B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
response B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
13 B_NUMBER[MEASURE]
( O
65 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
of O
20 B_PERSON/B_BIO
patients I_PERSON/I_BIO
required O
supplemental B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
atropine I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
to O
reach O
their O
target B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
heart I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
rates I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O

conclusion O
: O
No O
exaggerated O
adrenergic O
response O
was O
detected O
when O
dobutamine O
was O
administered O
to O
patients O
with O
cocaine O
- O
related O
chest B_DISEASE/B_LOCATION
pain I_DISEASE/I_LOCATION
. O

Prenatal O
cocaine O
exposure O
and O
cranial O
sonographic O
findings O
in O
preterm B_PERSON/B_BIO
infants I_PERSON/I_BIO
. O

purpose O
: O
Prenatal O
cocaine O
exposure O
has O
been O
linked O
with O
subependymal O
hemorrhage B_DISEASE
and O
the O
formation O
of O
cysts B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
that O
are O
detectable O
on O
cranial O
sonography O
in O
neonates O
born O
at O
term O
. O

We O
sought O
to O
determine O
if O
prenatal O
cocaine O
exposure O
increases O
the O
incidence O
of O
subependymal B_DISEASE
cysts I_DISEASE
in O
preterm B_PERSON/B_BIO
infants I_PERSON/I_BIO
. O

methods O
: O
We O
retrospectively O
reviewed O
the O
medical O
records O
and O
cranial O
sonograms O
obtained O
during O
a O
1 O
- O
year O
period O
on O
122 O
premature B_TIME[MEASURE]/B_PERSON
( I_TIME[MEASURE]/I_PERSON
< I_TIME[MEASURE]/I_PERSON
36 I_TIME[MEASURE]/I_PERSON
weeks I_TIME[MEASURE]/I_PERSON
of I_TIME[MEASURE]/I_PERSON
gestation I_TIME[MEASURE]/I_PERSON
) I_TIME[MEASURE]/I_PERSON
infants I_TIME[MEASURE]/I_PERSON
. O

infants B_PERSON
were O
categorized O
into O
1 B_NUMBER[MEASURE]/B_LOCATION
of O
2 B_NUMBER[MEASURE]/B_PERSON
groups I_NUMBER[MEASURE]/I_PERSON
: O
those O
exposed O
to O
cocaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
those O
not O
exposed O
to O
cocaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O

infants O
were O
assigned O
to O
the O
cocaine O
- O
exposed O
group O
if O
there O
was O
a O
maternal O
history O
of O
cocaine B_DISEASE
abuse I_DISEASE
during O
pregnancy O
or O
if O
maternal O
or O
neonatal O
urine O
toxicology O
results O
were O
positive O
at O
the O
time O
of O
delivery O
. O

RESULTS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O
Five B_NUMBER[MEASURE]
of O
the O
122 B_PERSON
infants I_PERSON
were O
excluded O
from O
the O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
because O
of O
insufficient B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
medical B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
and O
drug B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
histories I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
incidence O
of O
subependymal B_DISEASE
cysts I_DISEASE
in O
the O
117 O
remaining O
infants O
was O
14 O
% O
( O
16 O
of O
117 O
) O
. O

The O
incidence O
of O
subependymal B_DISEASE
cysts I_DISEASE
in O
infants O
exposed O
to O
cocaine O
prenatally O
was O
44 O
% O
( O
8 O
of O
18 O
) O
compared O
with O
8 O
% O
( O
8 O
of O
99 O
) O
in O
the O
unexposed O
group O
( O
p O
< O
0 O
. O
01 O
) O
. O

conclusions O
: O
We O
found O
an O
increased O
incidence O
of O
subependymal B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
cyst I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
formation O
in O
preterm B_PERSON
infants I_PERSON
who O
were O
exposed O
to O
cocaine O
prenatally O
. O

This O
result B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
is O
consistent B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
with O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O
similar B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
studies I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
in O
term B_LOCATION
infants I_LOCATION
. O

Thalidomide O
neuropathy B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
patients O
treated O
for O
metastatic O
prostate B_DISEASE
cancer I_DISEASE
. O

We O
prospectively O
evaluated O
thalidomide O
- O
induced O
neuropathy B_DISEASE
using O
electrodiagnostic O
studies O
. O

sixty O
- O
seven O
men O
with O
metastatic O
androgen O
- O
independent O
prostate B_DISEASE
cancer I_DISEASE
in O
an O
open O
- O
label O
trial O
of O
oral O
thalidomide O
underwent O
neurologic O
examinations O
and O
nerve O
conduction O
studies O
( O
NCS O
) O
prior O
to O
and O
at O
3 O
- O
month O
intervals O
during O
treatment O
. O

NCS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
included O
recording B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
sensory B_DISEASE/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
nerve B_DISEASE/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
action B_DISEASE/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
potentials B_DISEASE/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
snaps B_DISEASE
) O
from O
median B_BODY_PART_OR_ORGAN_COMPONENT/B_MEASURE
, O
radial B_BODY_PART_OR_ORGAN_COMPONENT
, O
ulnar B_BODY_PART_OR_ORGAN_COMPONENT
, O
and O
sural B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
nerves I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O

SNAP B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
amplitudes B_MEASURE/B_ENT
for O
each O
nerve B_BODY_PART_OR_ORGAN_COMPONENT/B_PERSON
were O
expressed O
as O
the O
percentage B_MEASURE
of O
its O
baseline B_MEASURE/B_LOCATION
, O
and O
the O
mean B_MEASURE
of O
the O
four B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
was O
termed O
the O
snap B_MEASURE/B_LOCATION
index I_MEASURE/I_LOCATION
. O

A O
40 B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
% I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
decline I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O
the O
SNAP B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
index I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
considered O
clinically O
significant B_DISEASE_ADJECTIVE[DISEASE]
. O

thalidomide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
discontinued O
in O
55 B_TIME[MEASURE]
patients I_TIME[MEASURE]
for O
lack B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O
therapeutic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
response I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Of O
67 B_PERSON
patients I_PERSON
initially O
enrolled O
, O
24 B_MEASURE
remained O
on O
thalidomide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
3 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
months I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
, O
8 B_MEASURE
remained O
at O
6 B_MEASURE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
months I_MEASURE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
and O
3 B_NUMBER[MEASURE]
remained O
at O
9 B_MEASURE/B_LOCATION
months I_MEASURE/I_LOCATION
. O

Six O
patients O
developed O
neuropathy B_DISEASE
. O

Clinical B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
symptoms I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
a O
decline B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O
the O
SNAP B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
index I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
occurred O
concurrently O
. O

Older B_MEASURE
age I_MEASURE
and O
cumulative B_MEASURE/B_PERSON
dose B_MEASURE/I_PERSON
were O
possible B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
contributing O
factors B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
. O

Neuropathy B_DISEASE
may O
thus O
be O
a O
common O
complication O
of O
thalidomide O
in O
older O
patients O
. O

The O
snap O
index O
can O
be O
used O
to O
monitor O
peripheral B_DISEASE_ADJECTIVE[DISEASE]
neuropathy I_DISEASE_ADJECTIVE[DISEASE]
, O
but O
not O
for O
early O
detection O
. O

Overexpression O
of O
copper O
/ O
zinc O
- O
superoxide O
dismutase O
protects O
from O
kanamycin O
- O
induced O
hearing B_DISEASE/B_GENE
loss I_DISEASE/I_GENE
. O

The O
participation O
of O
reactive O
oxygen O
species O
in O
aminoglycoside O
- O
induced O
ototoxicity B_DISEASE
has O
been O
deduced O
from O
observations O
that O
aminoglycoside O
- O
iron O
complexes O
catalyze O
the O
formation O
of O
superoxide O
radicals O
in O
vitro O
and O
that O
antioxidants O
attenuate O
ototoxicity B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
vivo O
. O

We O
therefore O
hypothesized O
that O
overexpression O
of O
cu O
/ O
Zn O
- O
superoxide O
dismutase O
( O
h O
- O
SOD1 O
) O
should O
protect O
transgenic O
mice O
from O
ototoxicity B_DISEASE/B_GENE
. O

immunocytochemistry B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
confirmed O
expression B_GENE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
h O
- O
SOD1 B_GENE
in O
inner B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
ear I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
tissues I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
of O
transgenic B_GENE/B_MEASURE
C57BL I_GENE/I_MEASURE
/ O
6 B_MEASURE
- O
TgN B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
SOD1 I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] O
3Cje B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
mice I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
. O

Transgenic B_PERSON
and O
nontransgenic B_PERSON/B_SPECIES[BIO]
littermates I_PERSON/I_SPECIES[BIO]
received O
kanamycin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
( O
400 B_MEASURE
mg I_MEASURE
/ O
kg B_MEASURE
body I_MEASURE
weight I_MEASURE
/ O
day B_TIME[MEASURE]/B_PERSON
) O
for O
10 B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
days B_TIME[MEASURE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
beginning O
on O
day B_TIME[MEASURE]/B_LOCATION
10 I_TIME[MEASURE]/I_LOCATION
after O
birth B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O

Auditory B_PERSON/B_ORGANIZATION
thresholds I_PERSON/I_ORGANIZATION
were O
tested O
by O
evoked B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
auditory I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
brain I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
stem O
responses B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
at O
1 B_TIME[MEASURE]/B_LOCATION
month I_TIME[MEASURE]/I_LOCATION
after O
birth B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O

In O
nontransgenic B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
animals I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
the O
threshold B_DISEASE/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
kanamycin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
- O
treated O
group B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
was O
45 B_MEASURE
- O
50 B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
DB B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
higher B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
than O
in O
saline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
injected O
controls B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
. O

In O
the O
transgenic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
group I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
, O
kanamycin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
increased O
the O
threshold B_MEASURE/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O
only O
15 B_TIME[MEASURE]/B_LOCATION
DB I_TIME[MEASURE]/I_LOCATION
over O
the O
respective B_TIME[MEASURE]/B_LOCATION
controls I_TIME[MEASURE]/I_LOCATION
. O

The O
effects B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
were O
similar B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
at O
12 B_MEASURE
and O
24 B_MEASURE/B_LOCATION
kHz I_MEASURE/I_LOCATION
. O

The O
protection O
by O
overexpression O
of O
superoxide O
dismutase O
supports O
the O
hypothesis O
that O
oxidant O
stress O
plays O
a O
significant O
role O
in O
aminoglycoside O
- O
induced O
ototoxicity B_DISEASE
. O

The O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
also O
suggest O
transgenic B_SPECIES[BIO]/B_PERSON
animals I_SPECIES[BIO]/I_PERSON
as O
suitable B_PERSON/B_LOCATION
models I_PERSON/I_LOCATION
to O
investigate O
the O
underlying O
mechanisms B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
possible B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
strategies I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_LOCATION
for O
prevention B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Fatty B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
liver I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
induced O
by O
tetracycline O
in O
the O
rat O
. O

dose B_TIME[MEASURE]/B_PERSON
- O
response B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
relationships I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
and O
effect B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
sex B_PERSON/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

dose O
- O
response O
relationships O
, O
biochemical O
mechanisms O
, O
and O
sex O
differences O
in O
the O
experimental O
fatty B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
liver I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
induced O
by O
tetracycline O
were O
studied O
in O
the O
intact O
rat O
and O
with O
the O
isolated O
perfused O
rat O
liver O
in O
vitro O
. O

In O
the O
intact B_PERSON/B_BIO
male I_PERSON/I_BIO
and O
female B_PERSON/B_BIO
rat I_PERSON/I_BIO
, O
no O
direct B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
relationship I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
was O
observed O
between O
dose B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
tetracycline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O
hepatic B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
accumulation B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O
triglyceride B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

With O
provision O
of O
adequate O
oleic O
acid O
as O
a O
substrate O
for O
the O
isolated O
perfused O
liver O
, O
a O
direct O
relationship O
was O
observed O
between O
dose O
of O
tetracycline O
and O
both O
accumulation O
of O
triglyceride O
in O
the O
liver O
and O
depression B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O
output O
of O
triglyceride O
by O
livers O
from O
male O
and O
female O
rats O
. O

marked O
differences B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
observed O
between O
female B_PERSON/B_BIO
and O
male B_PERSON
rats I_PERSON
with O
regard B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
base B_MEASURE/B_LOCATION
line I_MEASURE/I_LOCATION
( O
control B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
) O
hepatic B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
concentration I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
triglyceride B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O
output B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
of O
triglyceride B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

accumulation B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O
hepatic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
triglyceride I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
as O
a O
per O
cent B_MEASURE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
control B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
values I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O
in O
response B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O
graded O
doses B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
of O
tetracycline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
did O
not O
differ O
significantly O
between O
male B_PERSON
, O
female B_PERSON/B_BIO
and O
pregnant B_PERSON
rat I_PERSON
livers I_PERSON
. O

However O
, O
livers O
from O
female O
, O
and O
especially O
pregnant O
female O
rats O
, O
were O
strikingly O
resistant O
to O
the O
effects O
of O
tetracycline O
on O
depression B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O
output O
of O
triglyceride O
under O
these O
experimental O
conditions O
. O

These O
differences B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O
the O
sexes B_BIO/B_PERSON
could O
not O
be O
related O
to O
altered O
disposition B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
of O
tetracycline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
or O
altered O
uptake B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
of O
oleic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acid I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

depressed O
hepatic O
secretion O
of O
triglyceride O
accounted O
only O
for O
30 O
to O
50 O
% O
of O
accumulated O
hepatic O
triglyceride O
, O
indicating O
that O
additional O
mechanisms O
must O
be O
involved O
in O
the O
production O
of O
the O
triglyceride O
- O
rich O
fatty B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
liver I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
response O
to O
tetracycline O
. O

Prednisone O
induces O
anxiety B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
and O
glial O
cerebral O
changes O
in O
rats O
. O

objective O
: O
To O
assess O
whether O
prednisone O
( O
PDN O
) O
produces O
anxiety B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
and O
/ O
or O
cerebral O
glial O
changes O
in O
rats O
. O

METHODS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O
Male B_BIO/B_GENE
Wistar I_BIO/I_GENE
rats I_BIO/I_GENE
were O
studied O
and O
3 B_ORGANIZATION/B_PERSON
groups I_ORGANIZATION/I_PERSON
were O
formed O
( O
8 B_NUMBER[MEASURE]
rats I_NUMBER[MEASURE]
per O
group B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
. O

The O
moderate B_PERSON/B_MEASURE
- O
dose B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
group I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
received O
5 B_MEASURE
mg I_MEASURE
/ O
kg B_MEASURE
/ O
day B_TIME[MEASURE]
PDN I_TIME[MEASURE]
released O
from O
a O
subcutaneous B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
implant I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

In O
the O
high B_NUMBER[MEASURE]/B_PERSON
- O
dose B_MEASURE/B_LOCATION
group B_MEASURE/I_LOCATION
, O
implants B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
containing O
PDN B_MEASURE/B_LOCATION
equivalent I_MEASURE/I_LOCATION
to O
60 B_MEASURE
mg I_MEASURE
/ O
kg B_MEASURE
/ O
day B_MEASURE/B_LOCATION
were O
applied O
. O

In O
the O
control B_PRODUCT[OBJECT]/B_LOCATION
group B_PRODUCT[OBJECT]/I_LOCATION
implants B_PRODUCT[OBJECT]/I_LOCATION
contained O
no O
PDN B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Anxiety B_DISEASE
was O
assessed O
using O
an O
open O
field O
and O
elevated O
plus O
- O
maze O
devices O
. O

The O
number B_MEASURE/B_LOCATION
of O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
and O
cytoplasmic B_MEASURE/B_LOCATION
transformation I_MEASURE/I_LOCATION
of O
astrocytes B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O
microglia B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
were O
assessed O
by O
immunohistochemical B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analyses I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Results O
: O
Anxiety B_DISEASE/B_GENE
was O
documented O
in O
both O
groups O
of O
PDN O
treated O
rats O
compared O
with O
controls O
. O

The O
magnitude B_MEASURE
of O
transformation B_DISEASE
of O
the O
microglia B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
assessed O
by O
the O
number B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
intersections B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
significantly O
higher B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
in O
the O
PDN B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
groups I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
than O
in O
controls B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
prefrontal B_BODY_PART_OR_ORGAN_COMPONENT
cortex I_BODY_PART_OR_ORGAN_COMPONENT
( O
moderate B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O
dose B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
, O
24 B_MEASURE
. O
1 B_MEASURE
; O
high B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
- O
dose B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
, O
23 B_MEASURE
. O
6 B_MEASURE
; O
controls B_MEASURE/B_PERSON
18 I_MEASURE/I_PERSON
. O
7 B_NUMBER[MEASURE]
; O
p O
< O
0 B_MEASURE
. O
01 B_MEASURE
) O
and O
striatum B_BODY_PART_OR_ORGAN_COMPONENT
( O
moderate B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O
dose B_MEASURE
25 I_MEASURE
. O
6 B_MEASURE
; O
high B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
- O
dose B_MEASURE
26 I_MEASURE
. O
3 B_MEASURE
; O
controls B_MEASURE/B_PERSON
18 I_MEASURE/I_PERSON
. O
9 B_MEASURE
; O
p O
< O
0 B_MEASURE
. O
01 B_MEASURE
) O
, O
but O
not O
in O
hippocampus B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
. O

The O
number B_MEASURE
of O
stained B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
microglia I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
was O
significantly O
higher B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
in O
the O
PDN B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
treated O
groups B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
in O
the O
prefrontal B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
cortex I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
than O
in O
controls B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
( O
moderate B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O
dose B_MEASURE
, O
29 B_MEASURE
. O
1 B_MEASURE
; O
high B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
- O
dose B_MEASURE/B_DISEASE
, O
28 B_MEASURE
. O
4 B_MEASURE
; O
control B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O
17 B_MEASURE
. O
7 B_MEASURE
cells I_MEASURE
per O
field B_LOCATION/B_TIME[MEASURE]
; O
p O
< O
0 B_MEASURE
. O
01 B_MEASURE
) O
. O

stained O
microglia B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
cells I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
were O
significantly O
more O
numerous B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
striatum I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
and O
hippocampus B_BODY_PART_OR_ORGAN_COMPONENT
in O
the O
high B_MEASURE/B_LOCATION
- O
dose B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
group I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
compared O
to O
controls B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
. O

conclusion O
: O
Subacute O
exposure O
to O
PDN O
induced O
anxiety B_DISEASE
and O
reactivity O
of O
microglia O
. O

The O
relevance B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
these O
features B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
for O
patients B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
using O
PDN B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
remains O
to O
be O
elucidated O
. O

Phase O
II O
study O
of O
carboplatin O
and O
liposomal O
doxorubicin O
in O
patients O
with O
recurrent O
squamous B_DISEASE
cell I_DISEASE
carcinoma I_DISEASE
of I_DISEASE
the I_DISEASE
cervix I_DISEASE
. O

Background O
: O
The O
activity O
of O
the O
combination O
of O
carboplatin O
and O
liposomal O
doxorubicin O
was O
tested O
in O
a O
Phase O
II O
study O
of O
patients O
with O
recurrent O
cervical B_DISEASE
carcinoma I_DISEASE
. O

methods O
: O
The O
combination O
of O
carboplatin O
( O
area O
under O
the O
concentration O
curve O
[ O
AUC O
] O
, O
5 O
) O
and O
liposomal O
doxorubicin O
( O
Doxil O
; O
starting O
dose O
, O
40 O
mg O
/ O
m O
( O
2 O
) O
) O
was O
administered O
intravenously O
every O
28 O
days O
to O
37 O
patients O
with O
recurrent O
squamous B_DISEASE
cell I_DISEASE
cervical I_DISEASE
carcinoma I_DISEASE
to O
determine O
antitumor O
activity O
and O
toxicity B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
profile O
. O

Results O
: O
Twenty O
- O
nine O
patients O
were O
assessable O
for O
response O
, O
and O
35 O
patients O
were O
assessable O
for O
toxicity B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
overall B_MEASURE
response I_MEASURE
rate I_MEASURE
was O
38 B_MEASURE
% I_MEASURE
, O
the O
median B_MEASURE/B_LOCATION
time I_MEASURE/I_LOCATION
to O
response O
was O
10 B_MEASURE/B_ENT
weeks I_MEASURE/I_ENT
, O
the O
median B_MEASURE/B_LOCATION
duration I_MEASURE/I_LOCATION
of O
response B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
was O
26 B_MEASURE/B_ENT
weeks I_MEASURE/I_ENT
, O
and O
the O
median B_MEASURE
survival I_MEASURE
was O
37 B_MEASURE/B_ENT
weeks I_MEASURE/I_ENT
. O

The O
main O
toxic O
effect O
was O
myelosuppression B_DISEASE
, O
with O
Grade O
3 O
and O
4 O
neutropenia B_DISEASE
in O
16 O
patients O
, O
anemia B_DISEASE
in O
12 O
patients O
, O
thrombocytopenia B_DISEASE
in O
11 O
patients O
, O
and O
neutropenic B_DISEASE
fever I_DISEASE
in O
3 O
patients O
. O

Four B_PERSON
patients I_PERSON
had O
five B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
infusion I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
- O
related O
reactions B_DISEASE
during O
the O
infusion B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
liposomal B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
doxorubicin I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
leading O
to O
treatment B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
discontinuation I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
three B_TIME[MEASURE]/B_PERSON
patients I_TIME[MEASURE]/I_PERSON
. O

Grade O
> O
or O
= O
2 O
nonhematologic O
toxicity B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
included O
nausea B_DISEASE
in O
17 O
patients O
, O
emesis B_DISEASE
in O
14 O
patients O
, O
fatigue B_DISEASE
in O
9 O
patients O
, O
mucositis B_DISEASE
and O
/ O
or O
stomatitis B_DISEASE
in O
8 O
patients O
, O
constipation B_DISEASE
in O
6 O
patients O
, O
weight B_DISEASE
loss I_DISEASE
in O
5 O
patients O
, O
hand B_DISEASE
- I_DISEASE
foot I_DISEASE
syndrome I_DISEASE
in O
2 O
patients O
, O
and O
skin B_DISEASE
reactions I_DISEASE
in O
3 O
patients O
. O

conclusions O
: O
The O
combination O
of O
carboplatin O
and O
liposomal O
doxorubicin O
has O
modest O
activity O
in O
patients O
with O
recurrent O
cervical B_DISEASE
carcinoma I_DISEASE
. O

Antimicrobial O
- O
induced O
mania B_DISEASE
( O
antibiomania B_DISEASE/B_MEASURE
) O
: O
a O
review O
of O
spontaneous O
reports O
. O

The O
authors O
reviewed O
reported O
cases O
of O
antibiotic O
- O
induced O
manic B_DISEASE
episodes O
by O
means O
of O
a O
MEDLINE O
and O
PsychLit O
search O
for O
reports O
of O
antibiotic O
- O
induced O
mania B_DISEASE
. O

Unpublished B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
reports I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
were O
requested O
from O
the O
World B_ORGANIZATION/B_PERSON
Health I_ORGANIZATION/I_PERSON
Organization I_ORGANIZATION/I_PERSON
( O
WHO B_ORGANIZATION/B_LOCATION
) O
and O
the O
Food B_ORGANIZATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
Drug B_ORGANIZATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Administration I_ORGANIZATION/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
FDA B_ORGANIZATION/B_LOCATION
) O
. O

Twenty O
- O
one O
reports O
of O
antimicrobial O
- O
induced O
mania B_DISEASE
were O
found O
in O
the O
literature O
. O

There O
were O
6 B_NUMBER[MEASURE]
cases I_NUMBER[MEASURE]
implicating O
clarithromycin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
13 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
implicating I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
isoniazid I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
1 B_NUMBER[MEASURE]/B_LOCATION
case O
each O
implicating B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
erythromycin I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
amoxicillin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
WHO O
reported O
82 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
cases I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

Of O
these O
, O
clarithromycin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
implicated O
in O
23 B_MEASURE
( O
27 B_MEASURE
. O
6 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
cases B_PERSON
, O
ciprofloxacin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
12 B_MEASURE
( O
14 B_MEASURE
. O
4 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
cases B_PERSON
, O
and O
ofloxacin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O
10 B_MEASURE
( O
12 B_MEASURE
% I_MEASURE
) O
cases B_PERSON
. O

Cotrimoxazole O
, O
metronidazole O
, O
and O
erythromycin O
were O
involved O
in O
15 O
reported O
manic B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
episodes O
. O

cases O
reported O
by O
the O
FDA O
showed O
clarithromycin O
and O
ciprofloxacin O
to O
be O
the O
most O
frequently O
associated O
with O
the O
development O
of O
mania B_DISEASE/B_GENE
. O

Statistical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
would O
not O
have O
demonstrated O
a O
significant B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
statistical I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
correlative I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
risk I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
and O
was O
therefore O
not O
undertaken O
. O

patients O
have O
an O
increased O
risk O
of O
developing O
mania B_DISEASE
while O
being O
treated O
with O
antimicrobials O
. O

Although O
this O
is O
not O
a O
statistically O
significant B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
risk I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
physicians B_PERSON
must O
be O
aware B_PERSON
of O
the O
effect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
and O
reversibility B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Further O
research O
clearly O
is O
required O
to O
determine O
the O
incidence O
of O
antimicrobial O
- O
induced O
mania B_DISEASE
, O
the O
relative O
risk O
factors O
of O
developing O
an O
antimicrobial O
- O
induced O
manic B_DISEASE
episode O
among O
various O
demographic O
populations O
, O
and O
the O
incidence O
of O
patients O
who O
continue O
to O
have O
persistent O
affective O
disorders O
once O
the O
initial O
episode O
, O
which O
occurs O
while O
the O
patient O
is O
taking O
antibiotics O
, O
subsides O
. O

The O
authors O
elected O
to O
name O
this O
syndrome O
' O
antibiomania B_BACTERIUM[BIO]/B_GENE
. O
' O
. O

Levodopa O
- O
induced O
ocular B_DISEASE
dyskinesias I_DISEASE
in O
Parkinson B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
' B_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
s B_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
disease B_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
. O

Levodopa O
- O
induced O
ocular B_DISEASE_ADJECTIVE[DISEASE]
dyskinesias I_DISEASE_ADJECTIVE[DISEASE]
are O
very O
uncommon O
. O

Usually O
they O
occur O
simultaneously O
with O
limb O
peak O
- O
dose O
choreatic B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
dyskinesias I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

We O
report O
on O
a O
patient O
with O
leftward O
and O
upward O
deviations O
of O
gaze O
during O
the O
peak O
effect O
of O
levodopa O
, O
and O
hypothesize O
that O
a O
severe O
dopaminergic O
denervation O
in O
the O
caudate O
nucleus O
is O
needed O
for O
the O
appearance O
of O
these O
levodopa O
- O
induce O
ocular B_DISEASE_ADJECTIVE[DISEASE]
dyskinesias I_DISEASE_ADJECTIVE[DISEASE]
. O

A O
comparison O
of O
glyceryl O
trinitrate O
with O
diclofenac O
for O
the O
treatment O
of O
primary O
dysmenorrhea B_DISEASE
: O
an O
open O
, O
randomized O
, O
cross O
- O
over O
trial O
. O

Primary O
dysmenorrhea B_DISEASE/B_ORGANISM_FUNCTION
is O
a O
syndrome O
characterized O
by O
painful O
uterine O
contractility O
caused O
by O
a O
hypersecretion O
of O
endometrial O
prostaglandins O
; O
non O
- O
steroidal O
anti O
- O
inflammatory O
drugs O
are O
the O
first O
choice O
for O
its O
treatment O
. O

However O
, O
in O
vivo B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
and O
in O
vitro B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
studies I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
have O
demonstrated O
that O
myometrial B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
are O
also O
targets B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
of O
the O
relaxant B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
nitric B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
oxide I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
NO B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
) O
. O

The O
aim O
of O
the O
present O
study O
was O
to O
determine O
the O
efficacy O
of O
glyceryl O
trinitrate O
( O
GTN O
) O
, O
an O
NO O
donor O
, O
in O
the O
resolution O
of O
primary O
dysmenorrhea B_DISEASE
in O
comparison O
with O
diclofenac O
( O
DCF O
) O
. O

A O
total O
of O
24 O
patients O
with O
the O
diagnosis O
of O
severe O
primary O
dysmenorrhea B_DISEASE/B_GENE
were O
studied O
during O
two O
consecutive O
menstrual O
cycles O
. O

In O
an O
open B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
cross O
- O
over O
, O
controlled O
design B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
patients B_PERSON/B_BIO
were O
randomized O
to O
receive O
either O
DCF B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
per O
OS B_TIME[MEASURE]/B_PERSON
or O
GTN B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
patches O
the O
first B_TIME[MEASURE]/B_ENT
days I_TIME[MEASURE]/I_ENT
of O
menses B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
when O
menstrual B_DISEASE_ADJECTIVE[DISEASE]
cramps I_DISEASE_ADJECTIVE[DISEASE]
became O
unendurable B_DISEASE_ADJECTIVE[DISEASE]
. O

In O
the O
subsequent B_TIME[MEASURE]/B_LOCATION
cycle I_TIME[MEASURE]/I_LOCATION
the O
other B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
treatment I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
was O
used O
. O

patients B_PERSON/B_BIO
received O
up O
to O
3 B_MEASURE
doses I_MEASURE
/ O
day B_TIME[MEASURE]
of O
50 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
mg I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
DCF I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
or O
2 B_MEASURE
. O
5 B_MEASURE
mg I_MEASURE
/ O
24 B_MEASURE
h O
transdermal B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
GTN I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
for O
the O
first B_MEASURE/B_ENT
3 I_MEASURE/I_ENT
days I_MEASURE/I_ENT
of O
the O
cycle B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
according O
to O
their O
needs B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O

The O
participants B_PERSON
recorded O
menstrual B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
symptoms I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
and O
possible B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
side B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
effects B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
at O
different B_MEASURE/B_ENT
times I_MEASURE/I_ENT
( O
0 B_MEASURE
, O
30 B_MEASURE
, O
60 B_MEASURE
, O
120 B_MEASURE/B_ENT
minutes I_MEASURE/I_ENT
) O
after O
the O
first B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
dose I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
of O
medication B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
on O
the O
first B_SEQUENCE[MEASURE]/B_LOCATION
day I_SEQUENCE[MEASURE]/I_LOCATION
of O
the O
cycle B_TIME[MEASURE]
, O
with O
both O
drugs B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
. O

The O
difference O
in O
pain B_DISEASE
intensity O
score O
( O
DPI O
) O
was O
the O
main O
outcome O
variable O
. O

Both O
treatments B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
significantly O
reduced O
DPI B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O
the O
30th B_TIME[MEASURE]/B_PERSON
minute B_TIME[MEASURE]/I_PERSON
( O
GTN B_LOCATION
, O
- O
12 B_MEASURE
. O
8 B_MEASURE
+ I_MEASURE
/ O
- O
17 B_MEASURE
. O
9 B_MEASURE
; O
DCF B_LOCATION/B_ORGANIZATION
, O
- O
18 B_MEASURE
. O
9 B_MEASURE
+ I_MEASURE
/ O
- O
16 B_MEASURE
. O
6 B_MEASURE
) O
. O

However O
, O
DCF O
continued O
to O
be O
effective O
in O
reducing O
pelvic B_DISEASE/B_GENE
pain I_DISEASE/I_GENE
for O
two O
hours O
, O
whereas O
GTN O
scores O
remained O
more O
or O
less O
stable O
after O
30 O
min O
and O
significantly O
higher O
than O
those O
for O
DFC O
( O
after O
one O
hour O
: O
GTN O
, O
- O
12 O
. O
8 O
+ O
/ O
- O
17 O
. O
9 O
; O
DFC O
, O
- O
18 O
. O
9 O
+ O
/ O
- O
16 O
. O
6 O
and O
after O
two O
hours O
: O
GTN O
, O
- O
23 O
. O
7 O
+ O
/ O
- O
20 O
. O
5 O
; O
DFC O
, O
- O
59 O
. O
7 O
+ O
/ O
- O
17 O
. O
9 O
, O
p O
= O
0 O
. O
0001 O
) O
. O

Low B_DISEASE/B_PERSON
back I_DISEASE/I_PERSON
pain I_DISEASE/I_PERSON
was O
also O
relieved O
by O
both O
drugs O
. O

Headache B_DISEASE
was O
significantly O
increased O
by O
GTN O
but O
not O
by O
DCF O
. O

Eight O
patients O
stopped O
using O
GTN O
because O
headache B_DISEASE
- O
- O
attributed O
to O
its O
use O
- O
- O
became O
intolerable O
. O

These O
findings O
indicate O
that O
GTN O
has O
a O
reduced O
efficacy O
and O
tolerability O
by O
comparison O
with O
DCF O
in O
the O
treatment O
of O
primary O
dysmenorrhea B_DISEASE/B_LOCATION
. O

Temocapril O
, O
a O
long O
- O
acting O
non O
- O
SH O
group O
angiotensin O
converting O
enzyme O
inhibitor O
, O
modulates O
glomerular B_DISEASE
injury I_DISEASE
in O
chronic O
puromycin O
aminonucleoside O
nephrosis B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

The O
purpose O
of O
the O
present O
study O
was O
to O
determine O
whether O
chronic O
administration O
of O
temocapril O
, O
a O
long O
- O
acting O
non O
- O
SH O
group O
angiotensin O
converting O
enzyme O
( O
ace O
) O
inhibitor O
, O
reduced O
proteinuria B_DISEASE/B_GENE
, O
inhibited O
glomerular O
hypertrophy B_DISEASE
and O
prevented O
glomerulosclerosis B_DISEASE/B_GENE
in O
chronic O
puromycin O
aminonucleoside O
( O
pan O
) O
- O
induced O
nephrotic B_DISEASE
rats O
. O

Nephrosis B_DISEASE
was O
induced O
by O
injection O
of O
pan O
( O
15mg O
/ O
100g O
body O
weight O
) O
in O
male O
Sprague O
- O
Dawley O
( O
SD O
) O
rats O
. O

Four B_NUMBER[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
groups I_NUMBER[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
used O
, O
i O
) O
the O
Pan B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
group I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
( O
14 B_MEASURE
) O
, O
ii B_NUMBER[MEASURE]/B_PROTEIN[GENE]
) O
Pan B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
/ O
temocapril B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
13 B_MEASURE
) O
, O
III B_NUMBER[MEASURE]/B_PROTEIN[GENE]
) O
temocapril B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
( O
14 B_NUMBER[MEASURE]
) O
and O
IV B_SEQUENCE[MEASURE]/B_PROTEIN[GENE]
) O
untreated B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
controls I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O
15 B_NUMBER[MEASURE]
) O
. O

Temocapril B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O
8 B_MEASURE
mg I_MEASURE
/ O
kg B_MEASURE
/ O
day B_MEASURE
) O
was O
administered O
to O
the O
rats B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
which O
were O
killed O
at O
weeks B_NUMBER[MEASURE]/B_ENT
4 I_NUMBER[MEASURE]/I_ENT
, O
14 B_NUMBER[MEASURE]
or O
20 B_MEASURE
. O

At O
each O
time B_MEASURE/B_LOCATION
point B_MEASURE/I_LOCATION
, O
systolic B_DISEASE/B_GENE
blood I_DISEASE/I_GENE
pressure I_DISEASE/I_GENE
( O
BP B_DISEASE/B_GENE
) O
, O
urinary B_BODY_PART_OR_ORGAN_COMPONENT
protein I_BODY_PART_OR_ORGAN_COMPONENT
excretion I_BODY_PART_OR_ORGAN_COMPONENT
and O
renal B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
histopathological B_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
findings B_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
evaluated O
, O
and O
morphometric B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
image I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
done O
. O

Systolic B_DISEASE/B_GENE
BP I_DISEASE/I_GENE
in O
the O
Pan B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
group I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
was O
significantly O
high B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
at O
4 B_MEASURE
, O
14 B_NUMBER[MEASURE]
and O
20 B_MEASURE/B_ENT
weeks I_MEASURE/I_ENT
, O
but O
was O
normal B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
Pan B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
/ O
temocapril B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
group B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
. O

Urinary B_DISEASE/B_PERSON
protein I_DISEASE/I_PERSON
excretion I_DISEASE/I_PERSON
in O
the O
Pan B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
group I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
increased O
significantly O
, O
peaking O
at O
8 B_MEASURE/B_ENT
days I_MEASURE/I_ENT
, O
then O
decreased O
at O
4 B_TIME[MEASURE]/B_ENT
weeks I_TIME[MEASURE]/I_ENT
, O
but O
rose O
again O
significantly O
at O
14 B_MEASURE
and O
20 B_MEASURE/B_ENT
weeks I_MEASURE/I_ENT
. O

Temocapril O
did O
not O
attenuate O
proteinuria B_DISEASE/B_GENE
at O
8 O
days O
, O
but O
it O
did O
markedly O
lower O
it O
from O
weeks O
4 O
to O
20 O
. O

The O
glomerulosclerosis B_DISEASE_ADJECTIVE[DISEASE]
index O
( O
GSI O
) O
was O
6 O
. O
21 O
% O
at O
4 O
weeks O
and O
respectively O
25 O
. O
35 O
% O
and O
30 O
. O
49 O
% O
at O
14 O
and O
20 O
weeks O
in O
the O
pan O
group O
. O

There O
was O
a O
significant B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
correlation B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O
urinary B_LOCATION/B_ORGANIZATION
protein I_LOCATION/I_ORGANIZATION
excretion I_LOCATION/I_ORGANIZATION
and O
GSI B_DISEASE/B_GENE
( O
r B_OTHER/B_MEASURE
= O
0 B_MEASURE/B_LOCATION
. O
808 B_MEASURE
, O
p O
< O
0 B_MEASURE
. O
0001 B_MEASURE
) O
. O

The O
ratio B_MEASURE/B_PERSON
of O
glomerular B_MEASURE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tuft B_MEASURE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
area B_MEASURE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
the O
area B_LOCATION/B_MEASURE
of O
Bowman B_DISEASE/B_LOCATION
' B_DISEASE/I_LOCATION
s B_DISEASE/I_LOCATION
capsules B_DISEASE/I_LOCATION
( O
GT B_ORGANIZATION/B_LOCATION
/ O
BC B_LOCATION/B_ORGANIZATION
) O
in O
the O
Pan B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
group I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
was O
significantly O
increased O
, O
but O
it O
was O
significantly O
lower B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O
the O
Pan B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
/ O
temocapril B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
group I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

It O
appears O
that O
temocapril O
was O
effective O
in O
retarding O
renal O
progression O
and O
protected O
renal O
function O
in O
pan O
neprotic B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
rats O
. O

Pulmonary B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hypertension B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
after O
ibuprofen O
prophylaxis O
in O
very O
preterm O
infants O
. O

We O
report O
three O
cases O
of O
severe O
hypoxaemia B_DISEASE
after O
ibuprofen O
administration O
during O
a O
randomised O
controlled O
trial O
of O
prophylactic O
treatment O
of O
patent B_DISEASE/B_PERSON
ductus I_DISEASE/I_PERSON
arteriosus I_DISEASE/I_PERSON
with O
ibuprofen O
in O
premature O
infants O
born O
at O
less O
than O
28 O
weeks O
of O
gestation O
. O

echocardiography B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
showed O
severely O
decreased O
pulmonary B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
blood B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
flow B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Hypoxaemia B_PERSON
resolved O
quickly O
on O
inhaled O
nitric O
oxide O
therapy O
. O

We O
suggest O
that O
investigators O
involved O
in O
similar O
trials O
pay O
close O
attention O
to O
pulmonary O
pressure O
if O
hypoxaemia B_DISEASE/B_LOCATION
occurs O
after O
prophylactic O
administration O
of O
ibuprofen O
. O

Hyponatremia B_DISEASE
and O
syndrome B_DISEASE
of I_DISEASE
inappropriate I_DISEASE
anti I_DISEASE
- I_DISEASE
diuretic I_DISEASE
hormone I_DISEASE
reported O
with O
the O
use O
of O
Vincristine O
: O
an O
over O
- O
representation O
of O
Asians O
. O

purpose O
: O
This O
retrospective O
study O
used O
a O
pharmaceutical O
company O
' O
s O
global O
safety O
database O
to O
determine O
the O
reporting O
rate O
of O
hyponatremia B_DISEASE
and O
/ O
or O
syndrome B_DISEASE
of I_DISEASE
inappropriate I_DISEASE
secretion I_DISEASE
of I_DISEASE
anti I_DISEASE
- I_DISEASE
diuretic I_DISEASE
hormone I_DISEASE
( O
SIADH B_DISEASE/B_GENE
) O
among O
vincristine O
- O
treated O
patients O
and O
to O
explore O
the O
possibility O
of O
at O
- O
risk O
population O
subgroups O
. O

Method O
: O
We O
searched O
the O
Eli O
Lilly O
and O
Company O
' O
s O
computerized O
adverse O
event O
database O
for O
all O
reported O
cases O
of O
hyponatremia B_DISEASE
and O
/ O
or O
SIADH B_DISEASE
as O
of O
1 O
November O
1999 O
that O
had O
been O
reported O
during O
the O
use O
of O
vincristine O
. O

Results O
: O
A O
total O
of O
76 O
cases O
of O
hyponatremia B_DISEASE/B_LOCATION
and O
/ O
or O
SIADH B_DISEASE
associated O
with O
vincristine O
use O
were O
identified O
. O

The O
overall B_MEASURE/B_PERSON
reporting I_MEASURE/I_PERSON
rate I_MEASURE/I_PERSON
was O
estimated O
to O
be O
1 B_MEASURE
. O
3 B_MEASURE
/ O
100 B_MEASURE
, O
000 B_MEASURE
treated O
patients B_PERSON/B_LOCATION
. O

The O
average B_MEASURE/B_PERSON
age I_MEASURE/I_PERSON
of O
patients B_PERSON/B_LOCATION
was O
35 B_MEASURE
. O
6 B_MEASURE
+ I_MEASURE
/ O
- O
28 B_MEASURE
. O
3 B_MEASURE/B_ENT
years I_MEASURE/I_ENT
, O
and O
62 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
were O
males B_PERSON
. O

Approximately O
75 O
% O
of O
the O
patients O
were O
receiving O
treatment O
for O
leukemia B_DISEASE
or O
lymphoma B_DISEASE
. O

Among O
the O
39 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reports I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
included O
information B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
on O
race B_SPORT[ENT]/B_PERSON
, O
the O
racial B_MEASURE/B_PERSON
distribution I_MEASURE/I_PERSON
was O
: O
1 B_PERSON/B_NUMBER[MEASURE]
Black B_PERSON/I_NUMBER[MEASURE]
, O
3 B_PERSON/B_COLOR
Caucasian I_PERSON/I_COLOR
, O
and O
35 B_NUMBER[MEASURE]/B_PERSON
Asian I_NUMBER[MEASURE]/I_PERSON
. O

conclusion O
: O
Our O
data O
suggest O
that O
Asian O
patients O
may O
be O
at O
increased O
risk O
of O
hyponatremia B_DISEASE/B_LOCATION
and O
/ O
or O
SIADH B_DISEASE
associated O
with O
vincristine O
use O
. O

Although O
the O
overall O
reported O
rate O
of O
SIADH B_DISEASE
associated O
with O
vincristine O
is O
very O
low O
, O
physicians O
caring O
for O
Asian O
oncology O
patients O
should O
be O
aware O
of O
this O
potential O
serious O
but O
reversible O
adverse O
event O
. O

delayed O
toxicity B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O
cyclophosphamide O
on O
the O
bladder O
of O
DBA O
/ O
2 O
and O
C57BL O
/ O
6 O
female O
mouse O
. O

The O
present B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
describes O
the O
delayed B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
development I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
a O
severe B_DISEASE
bladder I_DISEASE
pathology I_DISEASE
in O
a O
susceptible B_MEASURE/B_BIO
strain I_MEASURE/I_BIO
of O
mice B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
DBA B_LOCATION/B_ORGANIZATION
/ O
2 B_MEASURE
) O
but O
not O
in O
a O
resistant B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
strain I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
( O
C57BL B_PROTEIN[GENE]/B_BIO
/ O
6 B_NUMBER[MEASURE]
) O
when O
both O
were O
treated O
with O
a O
single B_MEASURE
300 I_MEASURE
mg I_MEASURE
/ O
kg B_MEASURE
dose I_MEASURE
of O
cyclophosphamide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
CY B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O
. O

Inbred B_LOCATION/B_PERSON
DBA I_LOCATION/I_PERSON
/ O
2 B_MEASURE
and O
C57BL B_PROTEIN[GENE]/B_BIO
/ O
6 B_NUMBER[MEASURE]/B_PERSON
female I_NUMBER[MEASURE]/I_PERSON
mice I_NUMBER[MEASURE]/I_PERSON
were O
injected O
with O
CY B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O
and O
the O
effect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
drug B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
on O
the O
bladder B_BODY_PART_OR_ORGAN_COMPONENT
was O
assessed O
during O
100 B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
days I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
by O
light B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
microscopy I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
using O
different B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
staining I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
procedures I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
and O
after O
30 B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
days I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
by O
conventional B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
electron I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
microscopy I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Early O
Cy O
toxicity B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
caused O
a O
typical O
haemorrhagic B_DISEASE_ADJECTIVE[DISEASE]
cystitis I_DISEASE_ADJECTIVE[DISEASE]
in O
both O
strains O
that O
was O
completely O
repaired O
in O
about O
7 O
- O
10 O
days O
. O

After O
30 O
days O
of O
Cy O
injection O
ulcerous O
and O
non O
- O
ulcerous O
forms O
of O
chronic O
cystitis B_DISEASE
appeared O
in O
86 O
% O
of O
DBA O
/ O
2 O
mice O
but O
only O
in O
4 O
% O
of O
C57BL O
/ O
6 O
mice O
. O

delayed O
cystitis B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O
characterized O
by O
infiltration O
and O
transepithelial O
passage O
into O
the O
lumen O
of O
inflammatory O
cells O
and O
by O
frequent O
exfoliation O
of O
the O
urothelium O
. O

mast B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
appeared O
in O
the O
connective B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
and O
muscular B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
layers I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
of O
the O
bladder B_BODY_PART_OR_ORGAN_COMPONENT
at O
a O
much O
higher B_MEASURE
number I_MEASURE
in O
DBA B_PROTEIN[GENE]/B_DISEASE
/ O
2 B_MEASURE/B_PROTEIN[GENE]
mice I_MEASURE/I_PROTEIN[GENE]
than O
in O
C57BL B_PROTEIN[GENE]/B_BIO
/ O
6 B_MEASURE
mice I_MEASURE
or O
untreated B_PERSON/B_MEASURE
controls I_PERSON/I_MEASURE
. O

Electron B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
microscopy I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
disclosed O
the O
absence B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
typical B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
discoidal I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
vesicles I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
normally O
present B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O
the O
cytoplasm B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
of O
surface B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Instead O
, O
numerous B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
abnormal B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
vesicles B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
containing O
one B_NUMBER[MEASURE]
or O
several B_NUMBER[MEASURE]/B_PERSON
dark I_NUMBER[MEASURE]/I_PERSON
granules I_NUMBER[MEASURE]/I_PERSON
were O
observed O
in O
the O
cytoplasm B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
of O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
from O
all O
the O
epithelial B_LOCATION/B_DISEASE
layers I_LOCATION/I_DISEASE
. O

delayed O
cystitis B_DISEASE
still O
persisted O
in O
DBA O
/ O
2 O
mice O
100 O
days O
after O
treatment O
. O

These O
results O
indicate O
that O
delayed O
toxicity B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O
Cy O
in O
female O
DBA O
/ O
2 O
mice O
causes O
a O
bladder O
pathology O
that O
is O
not O
observed O
in O
C57BL O
/ O
6 O
mice O
. O

This O
pathology O
resembles O
interstitial B_DISEASE/B_LOCATION
cystitis I_DISEASE/I_LOCATION
in O
humans O
and O
could O
perhaps O
be O
used O
as O
an O
animal O
model O
for O
studies O
on O
the O
disease O
. O

High O
- O
dose O
5 O
- O
fluorouracil O
/ O
folinic O
acid O
in O
combination O
with O
three O
- O
weekly O
mitomycin O
C O
in O
the O
treatment O
of O
advanced O
gastric B_DISEASE
cancer I_DISEASE
. O

A O
phase B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
II I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

Background O
: O
The O
24 O
- O
hour O
continuous O
infusion O
of O
5 O
- O
fluorouracil O
( O
5 O
- O
Fu O
) O
and O
folinic O
acid O
( O
FA O
) O
as O
part O
of O
several O
new O
multidrug O
chemotherapy O
regimens O
in O
advanced O
gastric B_DISEASE
cancer I_DISEASE
( O
AGC B_DISEASE/B_LOCATION
) O
has O
shown O
to O
be O
effective O
, O
with O
low O
toxicity B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

In O
a O
previous O
phase O
II O
study O
with O
3 O
- O
weekly O
bolus O
5 O
- O
Fu O
, O
FA O
and O
mitomycin O
C O
( O
MMC O
) O
we O
found O
a O
low O
toxicity B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
rate O
and O
response O
rates O
comparable O
to O
those O
of O
regimens O
such O
as O
ELF O
, O
FAM O
or O
FAMTX O
, O
and O
a O
promising O
median O
overall O
survival O
. O

In O
order B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
improve O
this O
MMC B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
- O
dependent B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
schedule I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
we O
initiated O
a O
phase B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
II I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
high B_NUMBER[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O
dose B_MEASURE/B_LOCATION
5 B_MEASURE/I_LOCATION
- O
FU B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
FA B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
3 B_NUMBER[MEASURE]/B_LOCATION
- O
weekly B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
bolus I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
MMC I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

patients O
AND O
methods O
: O
From O
February O
, O
1998 O
to O
September O
, O
2000 O
we O
recruited O
33 O
patients O
with O
AGC B_DISEASE/B_GENE
to O
receive O
weekly O
24 O
- O
hour O
5 O
- O
Fu O
2 O
, O
600 O
mg O
/ O
m O
( O
2 O
) O
preceded O
by O
2 O
- O
hour O
FA O
500 O
mg O
/ O
m O
( O
2 O
) O
for O
6 O
weeks O
, O
followed O
by O
a O
2 O
- O
week O
rest O
period O
. O

bolus B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
MMC I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
10 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
mg I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
/ O
m B_OTHER/B_MEASURE
( O
2 B_MEASURE/B_LOCATION
) O
was O
added O
in O
3 B_NUMBER[MEASURE]/B_LOCATION
- O
weekly B_TIME[MEASURE]/B_LOCATION
intervals I_TIME[MEASURE]/I_LOCATION
. O

Treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
given O
on O
an O
outpatient B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
basis B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_LOCATION
, O
using O
portable B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pump I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
systems I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
was O
repeated O
on O
day B_TIME[MEASURE]/B_LOCATION
57 I_TIME[MEASURE]/I_LOCATION
. O

Patients B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
' I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
characteristics I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
were O
: O
male B_PERSON
/ O
female B_MEASURE/B_PERSON
ratio I_MEASURE/I_PERSON
20 I_MEASURE/I_PERSON
/ O
13 B_MEASURE
; O
median B_MEASURE/B_PERSON
age I_MEASURE/I_PERSON
57 I_MEASURE/I_PERSON
( O
27 B_MEASURE
- O
75 B_MEASURE
) O
years B_TIME[MEASURE]/B_ORGANIZATION
; O
median B_LOCATION/B_MEASURE
WHO O
status B_MEASURE
1 I_MEASURE
( O
0 B_MEASURE
- O
2 B_MEASURE
) O
. O

18 O
patients O
had O
a O
primary O
AGC B_DISEASE/B_LOCATION
, O
and O
15 O
showed O
a O
relapsed O
AGC B_DISEASE
. O

median B_TIME[MEASURE]/B_PERSON
follow I_TIME[MEASURE]/I_PERSON
- O
up B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
11 B_MEASURE
. O
8 B_TIME[MEASURE]
months I_TIME[MEASURE]
( O
range B_MEASURE/B_LOCATION
of O
those O
surviving O
: O
2 B_MEASURE
. O
7 B_MEASURE
- O
11 B_MEASURE
. O
8 B_TIME[MEASURE]
months I_TIME[MEASURE]
) O
. O

RESULTS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
32 B_PERSON/B_TIME[MEASURE]
patients I_PERSON/I_TIME[MEASURE]
were O
evaluable B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
response B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
complete B_MEASURE
remission I_MEASURE
9 I_MEASURE
. O
1 B_MEASURE
% I_MEASURE
( O
n B_MEASURE/B_PROTEIN[GENE]
= O
3 B_MEASURE
) O
, O
partial B_TIME[MEASURE]
remission I_TIME[MEASURE]
45 I_TIME[MEASURE]
. O
5 B_MEASURE
% I_MEASURE
( O
n B_OTHER/B_MEASURE
= O
15 B_MEASURE
) O
, O
no O
change B_TIME[MEASURE]
27 I_TIME[MEASURE]
. O
3 B_MEASURE
% I_MEASURE
( O
n B_OTHER/B_MEASURE
= O
9 B_MEASURE
) O
, O
progressive B_MEASURE
disease I_MEASURE
15 I_MEASURE
. O
1 B_MEASURE
% I_MEASURE
( O
n B_OTHER/B_MEASURE
= O
5 B_MEASURE
) O
. O

median B_TIME[MEASURE]/B_PERSON
overall I_TIME[MEASURE]/I_PERSON
survival I_TIME[MEASURE]/I_PERSON
time I_TIME[MEASURE]/I_PERSON
was O
10 B_MEASURE
. O
2 B_MEASURE
months I_MEASURE
[ I_MEASURE
95 I_MEASURE
% I_MEASURE
confidence I_MEASURE
interval I_MEASURE
( O
CI B_LOCATION
) O
: O
8 B_MEASURE
. O
7 B_MEASURE
- O
11 B_MEASURE
. O
6 B_MEASURE
] I_MEASURE
, O
and O
median B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
progression I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
- O
free B_TIME[MEASURE]/B_LOCATION
survival I_TIME[MEASURE]/I_LOCATION
time I_TIME[MEASURE]/I_LOCATION
was O
7 B_MEASURE
. O
6 B_TIME[MEASURE]
months I_TIME[MEASURE]
( O
95 B_TIME[MEASURE]/B_LOCATION
% I_TIME[MEASURE]/I_LOCATION
CI I_TIME[MEASURE]/I_LOCATION
: O
4 B_MEASURE
. O
4 B_MEASURE
- O
10 B_MEASURE
. O
9 B_MEASURE
) O
. O

The O
worst O
toxicities B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
% O
) O
observed O
were O
( O
CTC O
- O
NCI O
1 O
/ O
2 O
/ O
3 O
) O
: O
leukopenia B_DISEASE
45 O
. O
5 O
/ O
18 O
. O
2 O
/ O
6 O
. O
1 O
, O
thrombocytopenia B_DISEASE
33 O
. O
3 O
/ O
9 O
. O
1 O
/ O
6 O
. O
1 O
, O
vomitus B_DISEASE
24 O
. O
2 O
/ O
9 O
. O
1 O
/ O
0 O
, O
diarrhea B_DISEASE
36 O
. O
4 O
/ O
6 O
. O
1 O
/ O
3 O
. O
0 O
, O
stomatitis B_DISEASE
18 O
. O
2 O
/ O
9 O
. O
1 O
/ O
0 O
, O
hand B_DISEASE
- I_DISEASE
foot I_DISEASE
syndrome I_DISEASE
12 O
. O
1 O
/ O
0 O
/ O
0 O
. O

Two O
patients O
developed O
hemolytic B_DISEASE
- I_DISEASE
uremic I_DISEASE
syndrome I_DISEASE
( O
HUS B_MEASURE/B_DISEASE
) O
. O

conclusions O
: O
High O
- O
dose O
5 O
- O
Fu O
/ O
FA O
/ O
MMC O
is O
an O
effective O
and O
well O
- O
tolerated O
outpatient O
regimen O
for O
AGC B_DISEASE
( O
objective O
response O
rate O
54 O
. O
6 O
% O
) O
. O

It O
may O
serve O
as O
an O
alternative O
to O
cisplatin O
- O
containing O
regimens O
; O
however O
, O
it O
has O
to O
be O
considered O
that O
possibly O
HUS B_DISEASE
may O
occur O
. O

persistent O
sterile O
leukocyturia B_DISEASE
is O
associated O
with O
impaired B_DISEASE
renal I_DISEASE
function I_DISEASE
in O
human B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
immunodeficiency I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
virus I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
type I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
1 I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
- I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
infected I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
children O
treated O
with O
indinavir O
. O

Background B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
Prolonged B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
administration B_ORGANIZATION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
indinavir B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
is O
associated O
with O
the O
occurrence B_DISEASE_ADJECTIVE[DISEASE]
of O
a O
variety B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
renal B_DISEASE_ADJECTIVE[DISEASE]
complications I_DISEASE_ADJECTIVE[DISEASE]
in O
adults B_PERSON/B_BIO
. O

These O
well O
- O
documented O
side B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
effects B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
have O
restricted O
the O
use B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
of O
this O
potent B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
protease I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
inhibitor I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
children B_PERSON/B_DISEASE
. O

Design O
: O
A O
prospective O
study O
to O
monitor O
indinavir O
- O
related O
nephrotoxicity B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
a O
cohort O
of O
30 O
human B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
immunodeficiency I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
virus I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
type I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
1 I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
- I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
infected I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
children O
treated O
with O
indinavir O
. O

METHODS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O
Urinary B_BODY_PART_OR_ORGAN_COMPONENT/B_MEASURE
pH O
, O
albumin B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
creatinine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
the O
presence B_MEASURE/B_DISEASE
of O
erythrocytes B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O
leukocytes B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
, O
bacteria B_BACTERIUM[BIO]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O
crystals B_SPECIES[BIO]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O
and O
culture B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
were O
analyzed O
every O
3 B_TIME[MEASURE]
months I_TIME[MEASURE]
for O
96 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
weeks I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Serum B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
creatinine I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
levels I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
were O
routinely O
determined O
at O
the O
same B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
time I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
points I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

steady B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
- O
state B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pharmacokinetics I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
indinavir B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
were O
done O
at O
week B_TIME[MEASURE]/B_LOCATION
4 I_TIME[MEASURE]/I_LOCATION
after O
the O
initiation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O
indinavir B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O

Results O
: O
The O
cumulative O
incidence O
of O
persistent O
sterile O
leukocyturia B_DISEASE_ADJECTIVE[DISEASE]
( O
> O
or O
= O
75 O
cells O
/ O
micro O
L O
in O
at O
least O
2 O
consecutive O
visits O
) O
after O
96 O
weeks O
was O
53 O
% O
. O

persistent O
sterile O
leukocyturia B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
was O
frequently O
associated O
with O
a O
mild O
increase O
in O
the O
urine O
albumin O
/ O
creatinine O
ratio O
and O
by O
microscopic O
hematuria B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
cumulative B_MEASURE
incidence I_MEASURE
of O
serum B_MEASURE/B_GENE
creatinine B_MEASURE/I_GENE
levels B_MEASURE/I_GENE
> O
50 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
above O
normal B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
was O
33 B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
% B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
after O
96 B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
weeks I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Children O
with O
persistent O
sterile O
leukocyturia B_DISEASE
more O
frequently O
had O
serum O
creatinine O
levels O
of O
50 O
% O
above O
normal O
than O
those O
children O
without O
persistent O
sterile O
leukocyturia B_DISEASE_ADJECTIVE[DISEASE]
. O

In O
children O
younger O
than O
5 O
. O
6 O
years O
, O
persistent O
sterile O
leukocyturia B_DISEASE
was O
significantly O
more O
frequent O
than O
in O
older O
children O
. O

A O
higher O
cumulative O
incidence O
of O
persistent O
leukocyturia B_DISEASE
was O
found O
in O
children O
with O
an O
area O
under O
the O
curve O
> O
19 O
mg O
/ O
L O
x O
h O
or O
a O
peak O
serum O
level O
of O
indinavir O
> O
12 O
mg O
/ O
L O
. O

In O
4 O
children O
, O
indinavir O
was O
discontinued O
because O
of O
nephrotoxicity B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Subsequently O
, O
the O
serum O
creatinine O
levels O
decreased O
, O
the O
urine O
albumin O
/ O
creatinine O
ratios O
returned O
to O
zero O
, O
and O
the O
leukocyturia B_DISEASE
disappeared O
within O
3 O
months O
. O

conclusions O
: O
Children O
treated O
with O
indinavir O
have O
a O
high O
cumulative O
incidence O
of O
persistent O
sterile O
leukocyturia B_DISEASE_ADJECTIVE[DISEASE]
. O

Children O
with O
persistent O
sterile O
leukocyturia B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
more O
frequently O
had O
an O
increase O
in O
serum O
creatinine O
levels O
of O
> O
50 O
% O
above O
normal O
. O

Younger B_PERSON/B_ENT
children I_PERSON/I_ENT
have O
an O
additional B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
risk I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
for O
renal B_DISEASE
complications I_DISEASE
. O

The O
impairment B_DISEASE
of I_DISEASE
the I_DISEASE
renal I_DISEASE
function I_DISEASE
in O
these O
children O
occurred O
in O
the O
absence O
of O
clinical O
symptoms O
of O
nephrolithiasis B_DISEASE/B_GENE
. O

Indinavir O
- O
associated O
nephrotoxicity B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
must O
be O
monitored O
closely O
, O
especially O
in O
children O
with O
risk O
factors O
such O
as O
persistent O
sterile O
leukocyturia B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
age O
< O
5 O
. O
6 O
years O
, O
an O
area O
under O
the O
curve O
of O
indinavir O
> O
19 O
mg O
/ O
L O
x O
h O
, O
and O
a O
C O
( O
Max O
) O
> O
12 O
mg O
/ O
L O
. O

utility O
of O
troponin O
I O
in O
patients O
with O
cocaine O
- O
associated O
chest B_DISEASE/B_LOCATION
pain I_DISEASE/I_LOCATION
. O

Baseline O
electrocardiogram O
abnormalities O
and O
market O
elevations O
not O
associated O
with O
myocardial B_DISEASE
necrosis I_DISEASE
make O
accurate O
diagnosis O
of O
myocardial B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
infarction I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
( O
MI B_LOCATION/B_ORGANIZATION
) O
difficult O
in O
patients O
with O
cocaine O
- O
associated O
chest B_DISEASE/B_LOCATION
pain I_DISEASE/I_LOCATION
. O

troponin B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
sampling I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
may O
offer O
greater B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
diagnostic I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
utility I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
these O
patients B_PERSON/B_LOCATION
. O

objective O
: O
To O
assess O
outcomes O
based O
on O
troponin O
positivity O
in O
patients O
with O
cocaine O
chest B_DISEASE_ADJECTIVE[DISEASE]
pain I_DISEASE_ADJECTIVE[DISEASE]
admitted O
for O
exclusion O
of O
MI B_DISEASE/B_LOCATION
. O

methods O
: O
outcomes O
were O
examined O
in O
patients O
admitted O
for O
possible O
MI B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
after O
cocaine O
use O
. O

All O
patients B_PERSON
underwent O
a O
rapid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
rule I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
- O
in O
protocol B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
included O
serial B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
sampling I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
creatine B_ENZYME[GENE]
kinase I_ENZYME[GENE]
( O
CK B_LOCATION/B_ORGANIZATION
) O
, O
CK B_GENE
- O
MB B_PROTEIN[GENE]/B_MEASURE
, O
and O
cardiac B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
troponin B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
( O
cTnI B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
) O
over O
eight B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
hours B_TIME[MEASURE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

outcomes O
included O
CK O
- O
MB O
MI B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
( O
CK O
- O
MB O
> O
or O
= O
8 O
ng O
/ O
mL O
with O
a O
relative O
index O
[ O
( O
CK O
- O
MB O
x O
100 O
) O
/ O
total O
CK O
] O
> O
or O
= O
4 O
, O
cardiac B_DISEASE
death I_DISEASE
, O
and O
significant O
coronary B_DISEASE/B_LOCATION
disease I_DISEASE/I_LOCATION
( O
> O
or O
= O
50 O
% O
) O
. O

Results O
: O
Of O
the O
246 O
admitted O
patients O
, O
34 O
( O
14 O
% O
) O
met O
CK O
- O
MB O
criteria O
for O
MI B_DISEASE/B_LOCATION
and O
38 O
( O
16 O
% O
) O
had O
cTnI O
elevations O
. O

angiography B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
was O
performed O
in O
29 B_NUMBER[MEASURE]
of O
38 B_TIME[MEASURE]/B_PERSON
patients B_TIME[MEASURE]/I_PERSON
who O
were O
cTnI B_DISEASE/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
positive B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
with O
significant B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
disease I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
present I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
in O
25 B_NUMBER[MEASURE]/B_PERSON
( O
86 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
. O

Three O
of O
the O
four O
patients O
without O
significant O
disease O
who O
had O
cTnI O
elevations O
met O
CK O
- O
MB O
criteria O
for O
MI B_DISEASE/B_LOCATION
, O
and O
the O
other O
had O
a O
peak O
CK O
- O
MB O
level O
of O
13 O
ng O
/ O
mL O
. O

Sensitivities O
, O
specificities O
, O
and O
positive O
and O
negative O
likelihood O
ratios O
for O
predicting O
cardiac B_DISEASE_ADJECTIVE[DISEASE]
death I_DISEASE_ADJECTIVE[DISEASE]
or O
significant O
disease O
were O
high O
for O
both O
CK O
- O
MB O
MI B_DISEASE/B_PROTEIN[GENE]
and O
cTnI O
and O
were O
not O
significantly O
different O
. O

conclusions O
: O
Most O
patients O
with O
cTnI O
elevations O
meet O
CK O
- O
MB O
criteria O
for O
MI B_DISEASE/B_LOCATION
, O
as O
well O
as O
have O
a O
high O
incidence O
of O
underlying O
significant O
disease O
. O

Troponin O
appears O
to O
have O
an O
equivalent O
diagnostic O
accuracy O
compared O
with O
CK O
- O
MB O
for O
diagnosing O
necrosis B_DISEASE/B_LOCATION
in O
patients O
with O
cocaine O
- O
associated O
chest B_DISEASE/B_LOCATION
pain I_DISEASE/I_LOCATION
and O
suspected O
MI B_DISEASE
. O

acute O
interstitial B_DISEASE
nephritis I_DISEASE
due O
to O
nicergoline O
( O
Sermion O
) O
. O

We O
report O
a O
case O
of O
acute O
interstitial B_DISEASE
nephritis I_DISEASE
( O
AIN B_TIME[MEASURE]/B_LOCATION
) O
due O
to O
nicergoline O
( O
Sermion O
) O
. O

A O
50 O
- O
year O
- O
old O
patient O
admitted O
to O
our O
hospital O
for O
fever B_DISEASE
and O
acute B_DISEASE
renal I_DISEASE
failure I_DISEASE
. O

Before O
admission O
, O
he O
had O
been O
taking O
nicergoline O
and O
bendazac O
lysine O
due O
to O
retinal B_DISEASE
vein I_DISEASE
occlusion I_DISEASE
at O
ophthalmologic O
department O
. O

Thereafter O
, O
he O
experienced O
intermittent O
fever B_DISEASE
and O
skin B_DISEASE
rash I_DISEASE
. O

On O
admission O
, O
clinical O
symptoms O
( O
i O
. O
e O
. O
arthralgia B_DISEASE
and O
fever B_DISEASE
) O
and O
laboratory O
findings O
( O
i O
. O
e O
. O
eosinophilia B_DISEASE
and O
renal B_DISEASE/B_GENE
failure I_DISEASE/I_GENE
) O
suggested O
AIN B_DISEASE
, O
and O
which O
was O
confirmed O
by O
pathologic O
findings O
on O
renal O
biopsy O
. O

A O
lymphocyte B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
transformation I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
test I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
demonstrated O
a O
positive B_DISEASE_ADJECTIVE[DISEASE]
result I_DISEASE_ADJECTIVE[DISEASE]
against O
nicergoline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O

Treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
was O
consisted O
of O
withdrawal B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
nicergoline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
intravenous B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
methylprednisolone I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
and O
his O
renal B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
function I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
completely O
recovered O
. O

To O
our O
knowledge O
, O
this O
is O
the O
first O
report O
of O
nicergoline O
- O
associated O
AIN B_DISEASE/B_GENE
. O

Neuroleptic B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
malignant I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
syndrome I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
complicated O
by O
massive O
intestinal O
bleeding B_DISEASE
in O
a O
patient O
with O
chronic B_DISEASE
renal I_DISEASE
failure I_DISEASE
. O

A O
patient O
with O
chronic B_DISEASE
renal I_DISEASE
failure I_DISEASE
( O
CRF B_LOCATION
) O
developed O
neuroleptic B_DISEASE
malignant I_DISEASE
syndrome I_DISEASE
( O
NMS B_LOCATION/B_ORGANIZATION
) O
after O
administration O
of O
risperidone O
and O
levomepromazine O
. O

In O
addition O
to O
the O
typical O
symptoms O
of O
NMS B_DISEASE/B_GENE
, O
massive O
intestinal O
bleeding B_DISEASE
was O
observed O
during O
the O
episode O
. O

This O
report O
suggests O
that O
NMS B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
in O
a O
patient O
with O
CRF B_DISEASE
may O
be O
complicated O
by O
intestinal O
bleeding B_DISEASE
and O
needs O
special O
caution O
for O
this O
complication O
. O

Blood B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
brain B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
barrier B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
in O
right B_SEQUENCE[MEASURE]/B_BODY_PART_OR_ORGAN_COMPONENT
- O
and O
left B_BODY_PART_OR_ORGAN_COMPONENT/B_SEQUENCE[MEASURE]
- O
pawed O
female B_BIO/B_BODY_PART_OR_ORGAN_COMPONENT
rats B_BIO/I_BODY_PART_OR_ORGAN_COMPONENT
assessed O
by O
a O
new B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
staining I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
method I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
asymmetrical B_DISEASE_ADJECTIVE[DISEASE]
breakdown I_DISEASE_ADJECTIVE[DISEASE]
of O
the O
blood B_BODY_PART_OR_ORGAN_COMPONENT
- O
brain B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
barrier B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
( O
BBB B_LOCATION/B_ORGANIZATION
) O
was O
studied O
in O
female B_SPECIES[BIO]/B_DISEASE
rats I_SPECIES[BIO]/I_DISEASE
. O

Paw B_PERSON/B_DISEASE
preference I_PERSON/I_DISEASE
was O
assessed O
by O
a O
food B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
reaching O
test B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O

adrenaline O
- O
induced O
hypertension B_DISEASE
was O
used O
to O
destroy O
the O
BBB O
, O
which O
was O
evaluated O
using O
triphenyltetrazolium O
( O
TTC O
) O
staining O
of O
the O
brain O
slices O
just O
after O
giving O
adrenaline O
for O
30 O
s O
. O

In O
normal B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
rats I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
, O
the O
whole B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
brain I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
sections I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
exhibited O
complete B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
staining I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
with O
TTC B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
. O

After O
adrenaline B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
infusion I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANISM_FUNCTION
for O
30 B_TIME[MEASURE]/B_BIO
s B_TIME[MEASURE]/I_BIO
, O
there O
were O
large B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
unstained I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
areas I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
left B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
brain I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
in O
right O
- O
pawed O
animals B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
vice B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
versa O
in O
left O
- O
pawed O
animals B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Similar O
results O
were O
obtained O
in O
seizure B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
induced O
breakdown O
of O
BBB O
. O

These O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
explained O
by O
an O
asymmetric B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cerebral I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
blood I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
flow I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
depending O
upon O
the O
paw B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
preference I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
in O
rats B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

It O
was O
suggested O
that O
this O
new B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
method I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
the O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
consistent B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
with O
contralateral B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
motor I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
control I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
that O
may O
be O
important B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O
determining O
the O
dominant B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
cerebral I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
hemisphere I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
in O
animals B_BIO/B_DISEASE
. O

Carvedilol O
protects O
against O
doxorubicin O
- O
induced O
mitochondrial O
cardiomyopathy B_DISEASE
. O

Several O
cytopathic O
mechanisms O
have O
been O
suggested O
to O
mediate O
the O
dose O
- O
limiting O
cumulative O
and O
irreversible O
cardiomyopathy B_DISEASE
caused O
by O
doxorubicin O
. O

Recent O
evidence O
indicates O
that O
oxidative O
stress O
and O
mitochondrial B_DISEASE/B_GENE
dysfunction I_DISEASE/I_GENE
are O
key O
factors O
in O
the O
pathogenic O
process O
. O

The O
objective O
of O
this O
investigation O
was O
to O
test O
the O
hypothesis O
that O
carvedilol O
, O
a O
nonselective O
beta O
- O
adrenergic O
receptor O
antagonist O
with O
potent O
antioxidant O
properties O
, O
protects O
against O
the O
cardiac O
and O
hepatic O
mitochondrial O
bioenergetic O
dysfunction O
associated O
with O
subchronic O
doxorubicin O
toxicity B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Heart B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
and O
liver B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
mitochondria I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
were O
isolated O
from O
rats B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treated O
for O
7 B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
weeks I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
doxorubicin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
2 B_MEASURE
mg I_MEASURE
/ O
kg B_MEASURE/B_PERSON
Sc I_MEASURE/I_PERSON
/ O
week B_TIME[MEASURE]
) O
, O
carvedilol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
1 B_MEASURE
mg I_MEASURE
/ O
kg B_MEASURE
IP I_MEASURE
/ O
week B_TIME[MEASURE]
) O
, O
or O
the O
combination B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
of O
the O
two B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
drugs I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Heart B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
mitochondria I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
isolated O
from O
doxorubicin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
treated O
rats B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
exhibited O
depressed B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
rates I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
for O
state B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
3 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
respiration I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
336 B_MEASURE
+ I_MEASURE
/ O
- O
26 B_MEASURE
versus I_MEASURE
425 I_MEASURE
+ I_MEASURE
/ O
- O
53 B_MEASURE/B_PERSON
natom I_MEASURE/I_PERSON
O I_MEASURE/I_PERSON
/ O
min B_PERSON/B_MEASURE
/ O
mg B_MEASURE
protein I_MEASURE
) O
and O
a O
lower B_MEASURE/B_DISEASE
respiratory I_MEASURE/I_DISEASE
control I_MEASURE/I_DISEASE
ratio I_MEASURE/I_DISEASE
( O
RCR B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
( O
4 B_MEASURE
. O
3 B_MEASURE
+ I_MEASURE
/ O
- O
0 B_MEASURE
. O
6 B_MEASURE
versus I_MEASURE
5 I_MEASURE
. O
8 B_MEASURE
+ I_MEASURE
/ O
- O
0 B_MEASURE
. O
4 B_MEASURE
) O
compared O
with O
cardiac B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
mitochondria I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
isolated O
from O
saline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
treated O
rats B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Mitochondrial B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
calcium I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
- O
loading B_MEASURE/B_DISEASE
capacity I_MEASURE/I_DISEASE
and O
the O
activity B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
NADH B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
dehydrogenase B_ENZYME[GENE]
were O
also O
suppressed O
in O
cardiac B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
mitochondria I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
from O
doxorubicin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- O
treated O
rats B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

doxorubicin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
treatment I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
also O
caused O
a O
decrease B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
RCR B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
for O
liver B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
mitochondria B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
( O
3 B_MEASURE
. O
9 B_MEASURE
+ I_MEASURE
/ O
- O
0 B_MEASURE
. O
9 B_MEASURE
versus I_MEASURE
5 I_MEASURE
. O
6 B_MEASURE
+ I_MEASURE
/ O
- O
0 B_MEASURE
. O
7 B_MEASURE
for O
control B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
rats I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
and O
inhibition B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
hepatic B_GENE
cytochrome I_GENE
oxidase I_GENE
activity I_GENE
. O

Coadministration B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
of O
carvedilol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
decreased O
the O
extent B_MEASURE
of O
cellular B_DISEASE
vacuolization I_DISEASE
in O
cardiac B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
myocytes I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
and O
prevented O
the O
inhibitory B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
effect I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
of O
doxorubicin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
mitochondrial B_DISEASE
respiration I_DISEASE
in O
both O
heart B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
and O
liver B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
. O

Carvedilol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
also O
prevented O
the O
decrease B_DISEASE_ADJECTIVE[DISEASE]
in O
mitochondrial B_LOCATION
Ca I_LOCATION
( O
2 B_MEASURE/B_PROTEIN[GENE]
+ I_MEASURE/I_PROTEIN[GENE]
) O
loading B_MEASURE/B_BIO
capacity I_MEASURE/I_BIO
and O
the O
inhibition B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
the O
respiratory B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
complexes B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
heart B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
mitochondria I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
caused O
by O
doxorubicin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O

Carvedilol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
by O
itself O
did O
not O
affect O
any O
of O
the O
parameters B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
measured O
for O
heart B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
or O
liver B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
mitochondria I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O

It O
is O
concluded O
that O
this O
protection O
by O
carvedilol O
against O
both O
the O
structural O
and O
functional O
cardiac O
tissue O
damage O
may O
afford O
significant O
clinical O
advantage O
in O
minimizing O
the O
dose O
- O
limiting O
mitochondrial B_DISEASE
dysfunction I_DISEASE
and O
cardiomyopathy B_DISEASE
that O
accompanies O
long O
- O
term O
doxorubicin O
therapy O
in O
cancer B_DISEASE
patients O
. O

cocaine O
- O
induced O
hyperactivity B_DISEASE
is O
more O
influenced O
by O
adenosine O
receptor O
agonists O
than O
amphetamine O
- O
induced O
hyperactivity B_DISEASE
. O

The O
influence O
of O
adenosine O
receptor O
agonists O
and O
antagonists O
on O
cocaine O
- O
and O
amphetamine O
- O
induced O
hyperactivity B_DISEASE
was O
examined O
in O
mice O
. O

All O
adenosine O
receptor O
agonists O
significantly O
decreased B_DISEASE_ADJECTIVE[DISEASE]
the I_DISEASE_ADJECTIVE[DISEASE]
locomotor I_DISEASE_ADJECTIVE[DISEASE]
activity I_DISEASE_ADJECTIVE[DISEASE]
in O
mice O
, O
and O
the O
effects O
were O
dose O
- O
dependent O
. O

It O
seems O
that O
adenosine B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
A1 I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
A2 B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
receptors I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
might O
be O
involved O
in O
this O
reaction B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Moreover O
, O
all O
adenosine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
receptor I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
agonists I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
: O
2 B_NUMBER[MEASURE]
- O
p B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
( O
2 B_MEASURE
- O
carboxyethyl B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
phenethylamino B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
5 B_NUMBER[MEASURE]
' O
- O
N B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
ethylcarboxamidoadenosine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
CGS B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
21680 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
) O
, O
A2A B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
receptor B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
agonist B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
, O
N6 B_PROTEIN[GENE]/B_MEASURE
- O
cyclopentyladenosine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
CPA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
) O
, O
A1 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
receptor I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
agonist I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O
and O
5 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
' I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
N B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
ethylcarboxamidoadenosine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
NECA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
) O
, O
A2 B_PROTEIN[GENE]
/ O
A1 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptor I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
agonist I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
significantly O
and O
dose B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
dependently O
decreased O
cocaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
induced O
locomotor B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activity I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

CPA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
reduced O
cocaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
action B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
at O
the O
doses B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
which O
, O
given O
alone O
, O
did O
not O
influence O
motility B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O
while O
CGS B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
21680 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
NECA B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
decreased O
the O
action B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O
cocaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
at O
the O
doses B_MEASURE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
which O
, O
given O
alone O
, O
decreased O
locomotor B_DISEASE/B_ORGANISM_FUNCTION
activity B_DISEASE/I_ORGANISM_FUNCTION
in O
animals B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

These O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggest O
the O
involvement B_PERSON/B_DISEASE
of O
both O
adenosine B_LOCATION/B_BIO
receptors B_LOCATION/I_BIO
in O
the O
action B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O
cocaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
although O
agonists B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
A1 B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors B_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
seem O
to O
have O
stronger B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
influence I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
it O
. O

The O
selective B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
blockade I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
of O
A2 B_GENE
adenosine I_GENE
receptor I_GENE
by O
DMPX B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
( O
3 B_NUMBER[MEASURE]
, O
7 B_NUMBER[MEASURE]
- O
dimethyl B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
1 B_MEASURE
- O
propargylxanthine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
significantly O
enhanced O
cocaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
induced O
locomotor B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activity I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
animals B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

caffeine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
had O
similar B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
action I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
but O
the O
effect B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
was O
not O
significant B_DISEASE_ADJECTIVE[DISEASE]
. O

CPT B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O
8 B_MEASURE
- O
cyclopentyltheophylline B_MEASURE
) O
- O
- O
A1 B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
receptor B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
antagonist B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
, O
did O
not O
show O
any O
influence B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
this O
test B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O

Similarly O
, O
all O
adenosine O
receptor O
agonists O
decreased O
amphetamine O
- O
induced O
hyperactivity B_DISEASE
, O
but O
at O
the O
higher O
doses O
than O
those O
which O
were O
active O
in O
cocaine O
- O
induced O
hyperactivity B_DISEASE
. O

The O
selective B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
blockade I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
A2 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
adenosine I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptors I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
DMPX B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
and O
non B_DISEASE
- O
selective B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
blockade I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
adenosine B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
receptors I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
caffeine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O
significantly O
increased O
the O
action B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
amphetamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
in O
the O
locomotor B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activity I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
test I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Our O
results O
have O
shown O
that O
all O
adenosine O
receptor O
agonists O
( O
A1 O
and O
A2 O
) O
reduce O
cocaine O
- O
and O
amphetamine O
- O
induced O
locomotor O
activity O
and O
indicate O
that O
cocaine O
- O
induced O
hyperactivity B_DISEASE
is O
more O
influenced O
by O
adenosine O
receptor O
agonists O
( O
particularly O
A1 O
receptors O
) O
than O
amphetamine O
- O
induced O
hyperactivity B_DISEASE
. O

Amiodarone O
and O
the O
risk O
of O
bradyarrhythmia B_DISEASE
requiring O
permanent O
pacemaker O
in O
elderly O
patients O
with O
atrial B_DISEASE/B_GENE
fibrillation I_DISEASE/I_GENE
and O
prior O
myocardial B_DISEASE
infarction I_DISEASE
. O

objectives O
: O
The O
aim O
of O
this O
study O
was O
to O
determine O
whether O
the O
use O
of O
amiodarone O
in O
patients O
with O
atrial B_DISEASE
fibrillation I_DISEASE
( O
AF B_LOCATION/B_ORGANIZATION
) O
increases O
the O
risk O
of O
bradyarrhythmia B_DISEASE
requiring O
a O
permanent O
pacemaker O
. O

Background O
: O
Reports O
of O
severe O
bradyarrhythmia B_DISEASE
during O
amiodarone O
therapy O
are O
infrequent O
and O
limited O
to O
studies O
assessing O
the O
therapy O
' O
s O
use O
in O
the O
management O
of O
patients O
with O
ventricular B_DISEASE
arrhythmias I_DISEASE
. O

methods O
: O
A O
study O
cohort O
of O
8 O
, O
770 O
patients O
age O
> O
or O
= O
65 O
years O
with O
a O
new O
diagnosis O
of O
AF B_DISEASE
was O
identified O
from O
a O
provincewide O
database O
of O
Quebec O
residents O
with O
a O
myocardial B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
infarction I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O
MI B_LOCATION
) O
between O
1991 O
and O
1999 O
. O

Using O
a O
nested O
case O
- O
control O
design O
, O
477 O
cases O
of O
bradyarrhythmia B_DISEASE
requiring O
a O
permanent O
pacemaker O
were O
matched O
( O
1 O
: O
4 O
) O
to O
1 O
, O
908 O
controls O
. O

Multivariable B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
logistic I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
regression I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
was O
used O
to O
estimate O
the O
odds B_MEASURE
ratio I_MEASURE
( O
OR O
) O
of O
pacemaker B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
insertion I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
associated O
with O
amiodarone B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
use I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
controlling O
for O
baseline B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
risk I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
factors I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
and O
exposure B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O
sotalol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O
Class B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
I O
antiarrhythmic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
agents I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
beta B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
blockers B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
calcium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
channel I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
blockers I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
and O
digoxin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O

RESULTS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
amiodarone B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
use I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
associated O
with O
an O
increased O
risk B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O
pacemaker B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
insertion I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O
OR O
: O
2 B_MEASURE
. O
14 B_MEASURE
, O
95 B_LOCATION
% I_LOCATION
confidence I_LOCATION
interval I_LOCATION
[ O
CI B_LOCATION/B_MEASURE
] O
: O
1 B_MEASURE
. O
30 B_MEASURE
to O
3 B_MEASURE
. O
54 B_MEASURE
) O
. O

This O
effect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
was O
modified O
by O
gender B_PERSON/B_DISEASE
, O
with O
a O
greater B_MEASURE
risk I_MEASURE
in O
women B_PERSON/B_BIO
versus O
men B_PERSON
( O
OR O
: O
3 B_MEASURE
. O
86 B_MEASURE
, O
95 B_LOCATION
% I_LOCATION
CI I_LOCATION
: O
1 B_MEASURE
. O
70 B_MEASURE
to O
8 B_NUMBER[MEASURE]
. O
75 B_MEASURE/B_SPORT[ENT]
vs I_MEASURE/I_SPORT[ENT]
. O
OR O
: O
1 B_MEASURE
. O
52 B_MEASURE
, O
95 B_LOCATION
% I_LOCATION
CI I_LOCATION
: O
0 B_MEASURE
. O
80 B_MEASURE
to O
2 B_MEASURE
. O
89 B_MEASURE
) O
. O

digoxin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
was O
the O
only B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
other B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
medication B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
associated O
with O
an O
increased O
risk B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O
pacemaker B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
insertion I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O
OR O
: O
1 B_MEASURE
. O
78 B_MEASURE
, O
95 B_LOCATION
% I_LOCATION
CI I_LOCATION
: O
1 B_NUMBER[MEASURE]
. O
37 B_MEASURE
to O
2 B_NUMBER[MEASURE]
. O
31 B_MEASURE
) O
. O

conclusions O
: O
This O
study O
suggests O
that O
the O
use O
of O
amiodarone O
in O
elderly O
patients O
with O
AF B_DISEASE
and O
a O
previous O
MI B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
increases O
the O
risk O
of O
bradyarrhythmia B_DISEASE
requiring O
a O
permanent O
pacemaker O
. O

The O
finding B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
an O
augmented B_DISEASE_ADJECTIVE[DISEASE]
risk I_DISEASE_ADJECTIVE[DISEASE]
of O
pacemaker B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
insertion I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
elderly B_PERSON/B_BIO
women I_PERSON/I_BIO
receiving O
amiodarone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
requires O
further B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
investigation I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

indomethacin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
induced O
morphologic B_DISEASE/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
changes I_DISEASE/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
rat B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
urinary I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
bladder I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
epithelium I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O

objectives B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
To O
evaluate O
the O
morphologic B_DISEASE/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
changes I_DISEASE/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
rat B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
urothelium I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
induced O
by O
indomethacin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O

Nonsteroidal O
anti O
- O
inflammatory O
drug O
- O
induced O
cystitis B_DISEASE
is O
a O
poorly O
recognized O
and O
under O
- O
reported O
condition O
. O

In O
addition B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
to O
tiaprofenic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
acid I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
, O
indomethacin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
has O
been O
reported O
to O
be O
associated O
with O
this O
condition B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O

METHODS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O
Three B_NUMBER[MEASURE]/B_PERSON
groups I_NUMBER[MEASURE]/I_PERSON
were O
established O
: O
a O
control B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
group I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
n B_MEASURE/B_LOCATION
= O
10 B_MEASURE
) O
, O
a O
high B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
- O
dose B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
group I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O
n B_LOCATION
= O
10 B_MEASURE
) O
, O
treated O
with O
one B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BODY_PART_OR_ORGAN_COMPONENT
intraperitoneal I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_BODY_PART_OR_ORGAN_COMPONENT
injection I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_BODY_PART_OR_ORGAN_COMPONENT
of O
indomethacin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
20 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mg I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
kg B_MEASURE
, O
and O
a O
therapeutic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dose I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
group I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
n B_MEASURE/B_LOCATION
= O
10 B_MEASURE
) O
in O
which O
oral B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
indomethacin I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
was O
administered O
3 B_MEASURE/B_LOCATION
. O
25 B_MEASURE
mg I_MEASURE
/ O
kg B_MEASURE
body I_MEASURE
weight I_MEASURE
daily O
for O
3 B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
weeks I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

The O
animals B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
then O
killed O
and O
the O
bladders B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
removed O
for O
light B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
electron B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
microscopic I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
studies I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

RESULTS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O
The O
light B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
microscopic I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
findings I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
showed O
some O
focal B_DISEASE
epithelial I_DISEASE
degeneration I_DISEASE
that O
was O
more O
prominent B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
high B_MEASURE/B_PERSON
- O
dose B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
group B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

When O
compared O
with O
the O
control B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
group I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
, O
both O
indomethacin B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
groups I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
revealed O
statistically O
increased O
numbers B_MEASURE
of O
mast B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
in O
the O
mucosa B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
( O
P B_PROTEIN[GENE]/B_LOCATION
< O
0 B_MEASURE/B_LOCATION
. O
0001 B_MEASURE
) O
and O
penetration B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
of O
lanthanum B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
nitrate I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
through O
intercellular B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
areas I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
epithelium B_BODY_PART_OR_ORGAN_COMPONENT
. O

Furthermore O
, O
the O
difference B_MEASURE
in O
mast B_MEASURE/B_DISEASE
cell B_MEASURE/I_DISEASE
counts B_MEASURE/I_DISEASE
between O
the O
high B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O
therapeutic B_MEASURE
dose I_MEASURE
groups I_MEASURE
was O
also O
statistically O
significant B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
( O
P B_PROTEIN[GENE]/B_LOCATION
< O
0 B_MEASURE
. O
0001 B_MEASURE
) O
. O

conclusions O
: O
Indomethacin O
resulted O
in O
histopathologic O
findings O
typical O
of O
interstitial B_DISEASE/B_LOCATION
cystitis I_DISEASE/I_LOCATION
, O
such O
as O
leaky O
bladder O
epithelium O
and O
mucosal O
mastocytosis B_DISEASE
. O

The O
true O
incidence O
of O
nonsteroidal O
anti O
- O
inflammatory O
drug O
- O
induced O
cystitis B_DISEASE
in O
humans O
must O
be O
clarified O
by O
prospective O
clinical O
trials O
. O

An O
open O
- O
label O
phase O
II O
study O
of O
low O
- O
dose O
thalidomide O
in O
androgen O
- O
independent O
prostate B_DISEASE/B_PERSON
cancer I_DISEASE/I_PERSON
. O

The O
antiangiogenic O
effects O
of O
thalidomide O
have O
been O
assessed O
in O
clinical O
trials O
in O
patients O
with O
various O
solid O
and O
haematological B_DISEASE
malignancies I_DISEASE
. O

thalidomide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
blocks O
the O
activity B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
angiogenic B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
agents I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
including O
bFGF B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
VEGF B_GENE
and O
IL B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
6 B_MEASURE
. O

We O
undertook O
an O
open O
- O
label O
study O
using O
thalidomide O
100 O
mg O
once O
daily O
for O
up O
to O
6 O
months O
in O
20 O
men O
with O
androgen O
- O
independent O
prostate B_DISEASE
cancer I_DISEASE
. O

The O
mean B_TIME[MEASURE]/B_LOCATION
time I_TIME[MEASURE]/I_LOCATION
of O
study B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
was O
109 B_MEASURE/B_ENT
days I_MEASURE/I_ENT
( O
median B_TIME[MEASURE]/B_LOCATION
107 I_TIME[MEASURE]/I_LOCATION
, O
range B_MEASURE/B_LOCATION
4 I_MEASURE/I_LOCATION
- O
184 B_TIME[MEASURE]
days I_TIME[MEASURE]
) O
. O

patients B_PERSON
underwent O
regular B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
measurement I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
prostate B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
- O
specific B_PROTEIN[GENE]/B_DISEASE
antigen I_PROTEIN[GENE]/I_DISEASE
( O
PSA B_GENE/B_LOCATION
) O
, O
urea B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
electrolytes B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
serum O
bFGF B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
VEGF B_GENE
. O

Three B_NUMBER[MEASURE]/B_PERSON
men I_NUMBER[MEASURE]/I_PERSON
( O
15 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
showed O
a O
decline B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O
serum B_DISEASE
PSA I_DISEASE
of O
at O
least O
50 B_NUMBER[MEASURE]/B_PERSON
% I_NUMBER[MEASURE]/I_PERSON
, O
sustained O
throughout O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O

Of O
16 B_PERSON/B_BIO
men I_PERSON/I_BIO
treated O
for O
at O
least O
2 B_TIME[MEASURE]/B_DISEASE
months I_TIME[MEASURE]/I_DISEASE
, O
six B_NUMBER[MEASURE]
( O
37 B_MEASURE
. O
5 B_MEASURE
% I_MEASURE
) O
showed O
a O
fall B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
absolute B_MEASURE/B_DISEASE
PSA I_MEASURE/I_DISEASE
by O
a O
median B_MEASURE/B_LOCATION
of O
48 B_NUMBER[MEASURE]/B_PERSON
% I_NUMBER[MEASURE]/I_PERSON
. O

increasing O
levels B_MEASURE/B_GENE
of O
serum B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
bFGF I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O
VEGF B_GENE/B_DISEASE
were O
associated O
with O
progressive B_DISEASE_ADJECTIVE[DISEASE]
disease I_DISEASE_ADJECTIVE[DISEASE]
; O
five B_NUMBER[MEASURE]/B_PERSON
of O
six B_NUMBER[MEASURE]/B_PERSON
men I_NUMBER[MEASURE]/I_PERSON
who O
demonstrated O
a O
fall B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O
PSA B_GENE
also O
showed O
a O
decline B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O
bFGF B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
VEGF B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
levels I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
three B_NUMBER[MEASURE]/B_PERSON
of O
four B_NUMBER[MEASURE]/B_ENT
men I_NUMBER[MEASURE]/I_ENT
with O
a O
rising O
PSA B_MEASURE/B_DISEASE
showed O
an O
increase B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
both O
growth B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
factors I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

adverse O
effects O
included O
constipation B_DISEASE
, O
morning O
drowsiness B_DISEASE
, O
dizziness B_DISEASE
and O
rash B_DISEASE
, O
and O
resulted O
in O
withdrawal O
from O
the O
study O
by O
three O
men O
. O

Evidence O
of O
peripheral B_DISEASE
sensory I_DISEASE
neuropathy I_DISEASE
was O
found O
in O
nine O
of O
13 O
men O
before O
treatment O
. O

In O
the O
seven O
men O
who O
completed O
six O
months O
on O
thalidomide O
, O
subclinical O
evidence O
of O
peripheral B_DISEASE
neuropathy I_DISEASE
was O
found O
in O
four O
before O
treatment O
, O
but O
in O
all O
seven O
at O
repeat O
testing O
. O

The O
findings O
indicate O
that O
thalidomide O
may O
be O
an O
option O
for O
patients O
who O
have O
failed O
other O
forms O
of O
therapy O
, O
provided O
close O
follow O
- O
up O
is O
maintained O
for O
development O
of O
peripheral B_DISEASE_ADJECTIVE[DISEASE]
neuropathy I_DISEASE_ADJECTIVE[DISEASE]
. O

Central B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
nervous I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
system I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
toxicity I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
following O
the O
administration O
of O
levobupivacaine O
for O
lumbar O
plexus O
block O
: O
A O
report O
of O
two O
cases O
. O

Background O
AND O
objectives O
: O
Central B_DISEASE
nervous I_DISEASE
system I_DISEASE
and I_DISEASE
cardiac I_DISEASE
toxicity I_DISEASE
following O
the O
administration O
of O
local O
anesthetics O
is O
a O
recognized O
complication O
of O
regional O
anesthesia O
. O

Levobupivacaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
, O
the O
pure B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
S I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
( O
- O
) O
enantiomer B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
bupivacaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
was O
developed O
to O
improve O
the O
cardiac B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
safety I_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
profile I_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
of O
bupivacaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

We O
describe O
2 O
cases O
of O
grand B_DISEASE
mal I_DISEASE
seizures I_DISEASE
following O
accidental O
intravascular O
injection O
of O
levobupivacaine O
. O

Case B_MEASURE
Report I_MEASURE
: O
Two B_PERSON
patients I_PERSON
presenting O
for O
elective B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
orthopedic I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
surgery I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
of O
the O
lower B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
limb I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
underwent O
blockade B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O
the O
lumbar B_BODY_PART_OR_ORGAN_COMPONENT
plexus I_BODY_PART_OR_ORGAN_COMPONENT
via O
the O
posterior B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
approach I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Immediately O
after O
the O
administration O
of O
levobupivacaine O
0 O
. O
5 O
% O
with O
epinephrine O
2 O
. O
5 O
microgram O
/ O
mL O
, O
the O
patients O
developed O
grand B_DISEASE
mal I_DISEASE
seizures I_DISEASE
, O
despite O
negative O
aspiration O
for O
blood O
and O
no O
clinical O
signs O
of O
intravenous O
epinephrine O
administration O
. O

The O
seizures B_DISEASE/B_PERSON
were O
successfully O
treated O
with O
sodium O
thiopental O
in O
addition O
to O
succinylcholine O
in O
1 O
patient O
. O

Neither O
patient O
developed O
signs O
of O
cardiovascular B_DISEASE
toxicity I_DISEASE
. O

Both O
patients B_PERSON
were O
treated O
preoperatively O
with O
beta B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
adrenergic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antagonist I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
medications I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
which O
may O
have O
masked O
the O
cardiovascular B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
signs B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
unintentional B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
intravascular B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
administration B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
levobupivacaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
epinephrine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

conclusions O
: O
Although O
levobupivacaine O
may O
have O
a O
safer O
cardiac B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
toxicity I_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
profile O
than O
racemic O
bupivacaine O
, O
if O
adequate O
amounts O
of O
levobupivacaine O
reach O
the O
circulation O
, O
it O
will O
result O
in O
convulsions B_DISEASE
. O

plasma O
concentrations O
sufficient O
to O
result O
in O
central B_DISEASE
nervous I_DISEASE
system I_DISEASE
toxicity I_DISEASE
did O
not O
produce O
manifestations O
of O
cardiac B_DISEASE
toxicity I_DISEASE
in O
these O
2 O
patients O
. O

Amiodarone O
- O
induced O
torsade B_DISEASE
de I_DISEASE
pointes I_DISEASE
during O
bladder O
irrigation O
: O
an O
unusual O
presentation O
- O
- O
a O
case O
report O
. O

The O
authors O
present O
a O
case O
of O
early O
( O
within O
4 O
days O
) O
development O
of O
torsade B_DISEASE
de I_DISEASE
pointes I_DISEASE
( O
TdP B_PROTEIN[GENE]/B_LOCATION
) O
associated O
with O
oral O
amiodarone O
therapy O
. O

consistent O
with O
other O
reports O
this O
case O
of O
TdP B_DISEASE/B_GENE
occurred O
in O
the O
context O
of O
multiple O
exacerbating O
factors O
including O
hypokalemia B_DISEASE
and O
digoxin O
excess O
. O

Transient O
prolongation O
of O
the O
QT O
during O
bladder O
irrigation O
prompted O
the O
episode O
of O
TdP B_DISEASE/B_GENE
. O

It O
is O
well O
known O
that O
bradycardia B_DISEASE
exacerbates O
acquired O
TdP B_DISEASE/B_GENE
. O

The O
authors O
speculate O
that O
the O
increased O
vagal O
tone O
during O
bladder O
irrigation O
, O
a O
vagal O
maneuver O
, O
in O
the O
context O
of O
amiodarone O
therapy O
resulted O
in O
amiodarone O
- O
induced O
proarrhythmia B_DISEASE
. O

In O
the O
absence O
of O
amiodarone O
therapy O
, O
a O
second O
bladder O
irrigation O
did O
not O
induce O
TdP B_DISEASE/B_GENE
despite O
hypokalemia B_DISEASE
and O
hypomagnesemia B_DISEASE
. O

Anaesthetic O
complications O
associated O
with O
myotonia B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
congenita B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
case O
study O
and O
comparison O
with O
other O
myotonic B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
disorders I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Myotonia B_DISEASE/B_LOCATION
congenita I_DISEASE/I_LOCATION
( O
MC B_LOCATION
) O
is O
caused O
by O
a O
defect O
in O
the O
skeletal O
muscle O
chloride O
channel O
function O
, O
which O
may O
cause O
sustained B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
membrane I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
depolarisation I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

We O
describe O
a O
previously O
healthy O
32 O
- O
year O
- O
old O
woman O
who O
developed O
a O
life O
- O
threatening O
muscle B_DISEASE
spasm I_DISEASE
and O
secondary O
ventilation O
difficulties O
following O
a O
preoperative O
injection O
of O
suxamethonium O
. O

The O
muscle B_DISEASE
spasms I_DISEASE
disappeared O
spontaneously O
and O
the O
surgery O
proceeded O
without O
further O
problems O
. O

When O
subsequently O
questioned O
, O
she O
reported O
minor O
symptoms O
suggesting O
a O
myotonic B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
condition I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Myotonia B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
was O
found O
on O
clinical O
examination O
and O
EMG O
. O

The O
diagnosis O
MC B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
was O
confirmed O
genetically O
. O

Neither O
the O
patient B_PERSON
nor O
the O
anaesthetist B_PERSON/B_LOCATION
were O
aware B_PERSON
of O
the O
diagnosis B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
before O
this O
potentially O
lethal B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
complication I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
occurred O
. O

We O
give O
a O
brief O
overview O
of O
ion B_DISEASE_ADJECTIVE[DISEASE]
channel I_DISEASE_ADJECTIVE[DISEASE]
disorders I_DISEASE_ADJECTIVE[DISEASE]
including O
malignant B_DISEASE/B_PERSON
hyperthermia I_DISEASE/I_PERSON
and O
their O
anaesthetic O
considerations O
. O

respiratory O
pattern O
in O
a O
rat O
model O
of O
epilepsy B_DISEASE/B_LOCATION
. O

purpose O
: O
Apnea B_DISEASE
is O
known O
to O
occur O
during O
seizures B_DISEASE/B_LOCATION
, O
but O
systematic O
studies O
of O
ictal O
respiratory O
changes O
in O
adults O
are O
few O
. O

Data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
regarding O
respiratory B_DISEASE_ADJECTIVE[DISEASE]
pattern I_DISEASE_ADJECTIVE[DISEASE]
defects I_DISEASE_ADJECTIVE[DISEASE]
during O
interictal B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
periods I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
also O
are O
scarce B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O

Here O
we O
sought O
to O
generate O
information O
with O
regard O
to O
the O
interictal O
period O
in O
animals O
with O
pilocarpine O
- O
induced O
epilepsy B_DISEASE
. O

methods O
: O
Twelve O
rats O
( O
six O
chronically O
epileptic B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
animals O
and O
six O
controls O
) O
were O
anesthetized O
, O
given O
tracheotomies O
, O
and O
subjected O
to O
hyperventilation B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
or O
hypoventilation O
conditions O
. O

breathing B_PERSON/B_LOCATION
movements I_PERSON/I_LOCATION
caused O
changes B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O
thoracic B_MEASURE/B_LOCATION
volume I_MEASURE/I_LOCATION
and O
forced O
air B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
to O
flow O
tidally O
through O
a O
pneumotachograph B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BODY_PART_OR_ORGAN_COMPONENT
. O

This O
flow B_MEASURE/B_SPORT[ENT]
was O
measured O
by O
using O
a O
differential B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
pressure I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
transducer I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O
passed O
through O
a O
polygraph B_MEDICAL_DEVICE[OBJECT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
from O
this O
to O
a O
computer B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEDICAL_DEVICE[OBJECT]
with O
custom B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
software I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
derived O
ventilation B_MEASURE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O
ve B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
, O
tidal B_MEASURE/B_LOCATION
volume I_MEASURE/I_LOCATION
( O
VT B_PROTEIN[GENE]/B_DISEASE
) O
, O
inspiratory B_MEASURE/B_LOCATION
time I_MEASURE/I_LOCATION
( O
TI B_PROTEIN[GENE]/B_DISEASE
) O
, O
expiratory B_MEASURE/B_LOCATION
time I_MEASURE/I_LOCATION
( O
TE B_PROTEIN[GENE]/B_DISEASE
) O
, O
breathing B_MEASURE/B_LOCATION
frequency I_MEASURE/I_LOCATION
( O
f B_PROTEIN[GENE]/B_LOCATION
) O
, O
and O
mean B_MEASURE/B_LOCATION
inspiratory I_MEASURE/I_LOCATION
flow I_MEASURE/I_LOCATION
( O
VT B_PROTEIN[GENE]/B_DISEASE
/ O
TI B_PROTEIN[GENE]/B_DISEASE
) O
on O
a O
breath B_BODY_PART_OR_ORGAN_COMPONENT
- O
by O
- O
breath B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
basis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
. O

Results O
: O
The O
hyperventilation B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
maneuver O
caused O
a O
decrease O
in O
spontaneous O
ventilation O
in O
pilocarpine O
- O
treated O
and O
control O
rats O
. O

Although O
ve O
had O
a O
similar O
decrease O
in O
both O
groups O
, O
in O
the O
epileptic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
group O
, O
the O
decrease O
in O
ve O
was O
due O
to O
a O
significant O
( O
p O
< O
0 O
. O
05 O
) O
increase O
in O
te O
peak O
in O
relation O
to O
that O
of O
the O
control O
animals O
. O

The O
hypoventilation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
maneuver I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
led O
to O
an O
increase B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
the O
arterial B_PROTEIN[GENE]/B_BODY_PART_OR_ORGAN_COMPONENT
Paco2 I_PROTEIN[GENE]/I_BODY_PART_OR_ORGAN_COMPONENT
, O
followed O
by O
an O
increase B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
VE B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
. O

In O
the O
epileptic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
group O
, O
the O
increase O
in O
ve O
was O
mediated O
by O
a O
significant O
( O
p O
< O
0 O
. O
05 O
) O
decrease O
in O
te O
peak O
compared O
with O
the O
control O
group O
. O

Systemic B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
application I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
of O
KCN B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
to O
evaluate O
the O
effects B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
peripheral B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
chemoreception B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activation B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
ventilation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PROTEIN[GENE]
, O
led O
to O
a O
similar B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
increase I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O
VE B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
for O
both O
groups B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
. O

CONCLUSIONS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O
The O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
indicate O
that O
pilocarpine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
treated O
animals B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
have O
an O
altered O
ability B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O
react O
to O
( O
or O
compensate O
for O
) O
blood B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
gas I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
changes I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O
changes B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O
ventilation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
and O
suggest O
that O
it O
is O
centrally O
determined O
. O

We O
speculate O
on O
the O
possible O
relation O
of O
the O
current O
findings O
on O
treating O
different O
epilepsy B_DISEASE
- O
associated O
conditions O
. O

fatal O
myeloencephalopathy B_DISEASE_ADJECTIVE[DISEASE]
due O
to O
intrathecal O
vincristine O
administration O
. O

Vincristine O
was O
accidentally O
given O
intrathecally O
to O
a O
child O
with O
leukaemia B_DISEASE/B_GENE
, O
producing O
sensory B_DISEASE
and I_DISEASE
motor I_DISEASE
dysfunction I_DISEASE
followed O
by O
encephalopathy B_DISEASE
and O
death O
. O

separate B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
times I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
for O
administering O
vincristine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
and O
intrathecal B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
recommended O
. O

progesterone B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
potentiation I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
bupivacaine B_DISEASE
arrhythmogenicity I_DISEASE
in O
pentobarbital B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
anesthetized B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
rats I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
beating O
rat B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
heart I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
cell I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
cultures I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
effects B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
progesterone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treatment I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
bupivacaine B_DISEASE
arrhythmogenicity I_DISEASE
in O
beating O
rat B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
heart B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
myocyte B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
cultures B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
and O
on O
anesthetized B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
rats B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
were O
determined O
. O

After O
determining O
the O
bupivacaine O
AD50 O
( O
the O
concentration O
of O
bupivacaine O
that O
caused O
50 O
% O
of O
all O
beating O
rat O
heart O
myocyte O
cultures O
to O
become O
arrhythmic B_DISEASE_ADJECTIVE[DISEASE]
) O
, O
we O
determined O
the O
effect O
of O
1 O
- O
hour O
progesterone O
HCl O
exposure O
on O
myocyte O
contractile O
rhythm O
. O

Each O
concentration B_MEASURE
of O
progesterone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
6 B_MEASURE
. O
25 B_MEASURE
, O
12 B_MEASURE
. O
5 B_MEASURE
, O
25 B_MEASURE
, O
and O
50 B_MEASURE
micrograms I_MEASURE
/ O
ml B_MEASURE/B_PERSON
) O
caused O
a O
significant B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
and O
concentration B_MEASURE
- O
dependent B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reduction I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
AD50 B_MEASURE
for O
bupivacaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O

estradiol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
treatment B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
also O
increased O
the O
arrhythmogenicity B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
bupivacaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
myocyte B_SPECIES[BIO]/B_PERSON
cultures I_SPECIES[BIO]/I_PERSON
, O
but O
was O
only O
one B_MEASURE/B_LOCATION
fourth I_MEASURE/I_LOCATION
as O
potent B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O
progesterone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Neither O
progesterone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
nor O
estradiol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
bupivacaine B_DISEASE/B_GENE
arrhythmogenicity B_DISEASE/I_GENE
were O
potentiated O
by O
epinephrine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Chronic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
progesterone I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
pretreatment I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O
5 B_MEASURE
mg I_MEASURE
/ O
kg B_MEASURE
/ O
day B_TIME[MEASURE]
for O
21 B_TIME[MEASURE]
days I_TIME[MEASURE]
) O
caused O
a O
significant B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
increase I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
bupivacaine B_DISEASE/B_GENE
arrhythmogenicity I_DISEASE/I_GENE
in O
intact B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pentobarbital I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
anesthetized O
rats B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

There O
was O
a O
significant O
decrease O
in O
the O
time O
to O
onset O
of O
arrhythmia B_DISEASE
as O
compared O
with O
control O
nonprogesterone O
- O
treated O
rats O
( O
6 O
. O
2 O
+ O
/ O
- O
1 O
. O
3 O
vs O
. O
30 O
. O
8 O
+ O
/ O
- O
2 O
. O
5 O
min O
, O
mean O
+ O
/ O
- O
SE O
) O
. O

The O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
this O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
indicate O
that O
progesterone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
can O
potentiate O
bupivacaine B_DISEASE/B_ORGANISM_FUNCTION
arrhythmogenicity I_DISEASE/I_ORGANISM_FUNCTION
both O
in O
vivo B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
in O
vitro B_SPECIES[BIO]/B_LOCATION
. O

Potentiation O
of O
bupivacaine O
arrhythmia B_DISEASE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
myocyte O
cultures O
suggests O
that O
this O
effect O
is O
at O
least O
partly O
mediated O
at O
the O
myocyte O
level O
. O

increased O
serum O
soluble O
Fas O
in O
patients O
with O
acute B_DISEASE
liver I_DISEASE
failure I_DISEASE
due O
to O
paracetamol O
overdose B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Background O
/ O
aims O
: O
Experimental O
studies O
have O
suggested O
that O
apoptosis O
via O
the O
Fas O
/ O
Fas O
Ligand O
signaling O
system O
may O
play O
an O
important O
role O
in O
the O
development O
of O
acute B_DISEASE
liver I_DISEASE
failure I_DISEASE
. O

The O
aim O
of O
the O
study O
was O
to O
investigate O
the O
soluble O
form O
of O
Fas O
in O
patients O
with O
acute B_DISEASE/B_LOCATION
liver I_DISEASE/I_LOCATION
failure I_DISEASE/I_LOCATION
. O

methodology O
: O
serum O
levels O
of O
sFas O
( O
soluble O
Fas O
) O
were O
measured O
by O
ELISA O
in O
24 O
patients O
with O
acute B_DISEASE/B_LOCATION
liver I_DISEASE/I_LOCATION
failure I_DISEASE/I_LOCATION
and O
10 O
normal O
control O
subjects O
. O

serum O
levels O
of O
tumor B_DISEASE_ADJECTIVE[DISEASE]
necrosis I_DISEASE_ADJECTIVE[DISEASE]
factor O
- O
alpha O
and O
interferon O
- O
gamma O
were O
also O
determined O
by O
ELISA O
. O

Results O
: O
serum O
sFas O
was O
significantly O
increased O
in O
patients O
with O
acute B_DISEASE/B_LOCATION
liver I_DISEASE/I_LOCATION
failure I_DISEASE/I_LOCATION
( O
median O
, O
26 O
. O
8 O
U O
/ O
mL O
; O
range O
, O
6 O
. O
9 O
- O
52 O
. O
7 O
U O
/ O
mL O
) O
compared O
to O
the O
normal O
controls O
( O
median O
, O
8 O
. O
6 O
U O
/ O
mL O
; O
range O
, O
6 O
. O
5 O
- O
12 O
. O
0 O
U O
/ O
mL O
, O
P O
< O
0 O
. O
0001 O
) O
. O

levels O
were O
significantly O
greater O
in O
patients O
with O
acute B_DISEASE
liver I_DISEASE
failure I_DISEASE
due O
to O
paracetamol O
overdose B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O
median O
, O
28 O
. O
7 O
U O
/ O
mL O
; O
range O
, O
12 O
. O
8 O
- O
52 O
. O
7 O
U O
/ O
mL O
, O
n O
= O
17 O
) O
than O
those O
due O
to O
non O
- O
A O
to O
E O
hepatitis B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O
median O
, O
12 O
. O
5 O
U O
/ O
mL O
; O
range O
, O
6 O
. O
9 O
- O
46 O
. O
0 O
U O
/ O
mL O
, O
n O
= O
7 O
, O
P O
< O
0 O
. O
01 O
) O
. O

There O
was O
no O
relationship B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
sFas B_GENE/B_DISEASE
to O
eventual B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
outcome I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
patients B_PERSON/B_LOCATION
. O

A O
significant B_DISEASE_ADJECTIVE[DISEASE]
correlation I_DISEASE_ADJECTIVE[DISEASE]
was O
observed O
between O
serum B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
sFas I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
levels I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O
aspartate B_GENE/B_DISEASE
aminotransferase B_GENE/I_DISEASE
( O
r B_OTHER/B_LOCATION
= O
0 B_MEASURE
. O
613 B_MEASURE
, O
P B_PROTEIN[GENE]/B_LOCATION
< O
0 B_MEASURE
. O
01 B_MEASURE
) O
. O

conclusions O
: O
The O
increased O
concentration O
of O
sFas O
in O
serum O
of O
patients O
with O
acute B_DISEASE/B_LOCATION
liver I_DISEASE/I_LOCATION
failure I_DISEASE/I_LOCATION
may O
reflect O
activation O
of O
Fas O
- O
mediated O
apoptosis O
in O
the O
liver O
and O
this O
together O
with O
increased O
tumor B_DISEASE_ADJECTIVE[DISEASE]
necrosis I_DISEASE_ADJECTIVE[DISEASE]
factor O
- O
alpha O
may O
be O
an O
important O
factor O
in O
liver O
cell O
loss O
. O

bilateral O
subthalamic O
nucleus O
stimulation O
for O
Parkinson B_DISEASE
' I_DISEASE
s I_DISEASE
disease I_DISEASE
. O

High O
frequency O
stimulation O
of O
the O
subthalamic O
nucleus O
( O
STN O
) O
is O
known O
to O
ameliorate O
the O
signs O
and O
symptoms O
of O
advanced O
Parkinson B_DISEASE
' I_DISEASE
s I_DISEASE
disease I_DISEASE
. O

Aim B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O
We O
studied O
the O
effect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
high B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
frequency I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
STN I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
stimulation I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
in O
23 B_PERSON/B_BIO
patients I_PERSON/I_BIO
. O

Method O
: O
Twenty O
- O
three O
patients O
suffering O
from O
severe O
Parkinson B_DISEASE
' I_DISEASE
s I_DISEASE
disease I_DISEASE
( O
stages O
III O
- O
V O
on O
Hoehn O
and O
Yahr O
scale O
) O
and O
, O
particularly O
bradykinesia B_DISEASE
, O
rigidity B_DISEASE
, O
and O
levodopa O
- O
induced O
dyskinesias B_DISEASE
underwent O
bilateral O
implantation O
of O
electrodes O
in O
the O
STN O
. O

Preoperative O
and O
postoperative O
assessments O
of O
these O
patients O
at O
1 O
, O
3 O
, O
6 O
and O
12 O
months O
follow O
- O
up O
, O
in O
' O
on O
' O
and O
' O
off O
' O
drug O
conditions O
, O
was O
carried O
out O
using O
Unified O
Parkinson B_DISEASE/B_LOCATION
' I_DISEASE/I_LOCATION
s I_DISEASE/I_LOCATION
Disease I_DISEASE/I_LOCATION
rating O
Scale O
, O
Hoehn O
and O
Yahr O
staging O
, O
England O
activities O
of O
daily O
living O
score O
and O
video O
recordings O
. O

Results O
: O
After O
one O
year O
of O
electrical O
stimulation O
of O
the O
STN O
, O
the O
patients O
' O
scores O
for O
activities O
of O
daily O
living O
and O
motor O
examination O
scores O
( O
Unified O
Parkinson B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
' I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
s I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
Disease I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
rating O
Scale O
parts O
II O
and O
III O
) O
off O
medication O
improved O
by O
62 O
% O
and O
61 O
% O
respectively O
( O
p O
< O
0 O
. O
0005 O
) O
. O

The O
subscores O
for O
the O
akinesia B_DISEASE/B_MEASURE
, O
rigidity B_DISEASE
, O
tremor B_DISEASE
and O
gait O
also O
improved O
. O

( O
p O
< O
0 B_MEASURE
. O
0005 B_MEASURE
) O
. O

The O
average B_MEASURE
levodopa I_MEASURE
dose I_MEASURE
decreased O
from O
813 B_MEASURE
mg I_MEASURE
to O
359 B_TIME[MEASURE]/B_LOCATION
mg I_TIME[MEASURE]/I_LOCATION
. O

The O
cognitive B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
functions I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
remained O
unchanged B_DISEASE_ADJECTIVE[DISEASE]
. O

Two B_PERSON
patients I_PERSON
developed O
device B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
- O
related O
complications B_DISEASE
and O
two B_NUMBER[MEASURE]/B_PERSON
patients I_NUMBER[MEASURE]/I_PERSON
experienced O
abnormal B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
weight I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
gain I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

conclusion O
: O
bilateral O
subthalamic O
nucleus O
stimulation O
is O
an O
effective O
treatment O
for O
advanced O
Parkinson B_DISEASE/B_GENE
' I_DISEASE/I_GENE
s I_DISEASE/I_GENE
disease I_DISEASE/I_GENE
. O

It O
reduces O
the O
severity B_MEASURE
of O
' O
off O
' O
phase B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
symptoms I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
improves O
the O
axial B_DISEASE
symptoms I_DISEASE
and O
reduces O
levodopa B_DISEASE
requirements I_DISEASE
. O

The O
reduction O
in O
the O
levodopa O
dose O
is O
useful O
in O
controlling O
drug B_DISEASE
- I_DISEASE
induced I_DISEASE
dyskinesias I_DISEASE
. O

Acute B_DISEASE_ADJECTIVE[DISEASE]
renal I_DISEASE_ADJECTIVE[DISEASE]
failure I_DISEASE_ADJECTIVE[DISEASE]
occurring O
during O
intravenous O
desferrioxamine O
therapy O
: O
recovery O
after O
haemodialysis O
. O

A O
patient O
with O
transfusion O
- O
dependent O
thalassemia B_DISEASE/B_GENE
was O
undergoing O
home O
intravenous O
desferrioxamine O
( O
DFX O
) O
treatment O
by O
means O
of O
a O
totally O
implanted O
system O
because O
of O
his O
poor O
compliance O
with O
the O
nightly O
subcutaneous O
therapy O
. O

Due O
to O
an O
accidental O
malfunctioning O
of O
the O
infusion O
pump O
, O
the O
patient O
was O
inadvertently O
administered O
a O
toxic O
dosage O
of O
the O
drug O
which O
caused O
renal B_DISEASE
insufficiency I_DISEASE
. O

Given O
the O
progressive O
deterioration O
of O
the O
symptoms O
and O
of O
the O
laboratory O
values O
, O
despite O
adequate O
medical O
treatment O
, O
a O
decision O
was O
made O
to O
introduce O
haemodialytical O
therapy O
in O
order O
to O
remove O
the O
drug O
and O
therapy O
reduce O
the O
nephrotoxicity B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

From O
the O
results O
obtained O
, O
haemodialysis O
can O
therefore O
be O
suggested O
as O
a O
useful O
therapy O
in O
rare O
cases O
of O
progressive O
acute B_DISEASE
renal I_DISEASE
failure I_DISEASE
caused O
by O
desferrioxamine O
. O

Ocular O
motility O
changes O
after O
subtenon O
carboplatin O
chemotherapy O
for O
retinoblastoma B_DISEASE
. O

Background O
: O
focal O
subtenon O
carboplatin O
injections O
have O
recently O
been O
used O
as O
a O
presumably O
toxicity B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
free O
adjunct O
to O
systemic O
chemotherapy O
for O
intraocular O
retinoblastoma B_DISEASE
. O

objective O
: O
To O
report O
our O
clinical O
experience O
with O
abnormal B_DISEASE
ocular I_DISEASE
motility I_DISEASE
in O
patients O
treated O
with O
subtenon O
carboplatin O
chemotherapy O
. O

methods O
: O
We O
noted O
abnormal B_DISEASE_ADJECTIVE[DISEASE]
ocular I_DISEASE_ADJECTIVE[DISEASE]
motility I_DISEASE_ADJECTIVE[DISEASE]
in O
10 O
consecutive O
patients O
with O
retinoblastoma B_DISEASE
who O
had O
received O
subtenon O
carboplatin O
. O

During O
ocular O
manipulation O
under O
general O
anesthesia O
, O
we O
assessed O
their O
eyes O
by O
forced O
duction O
testing O
, O
comparing O
ocular O
motility O
after O
tumor B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
control O
with O
ocular O
motility O
at O
diagnosis O
. O

Eyes B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
subsequently O
enucleated O
because O
of O
treatment B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
failure I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O
n B_PROTEIN[GENE]/B_LOCATION
= I_PROTEIN[GENE]/I_LOCATION
4 I_PROTEIN[GENE]/I_LOCATION
) O
were O
examined O
histologically O
. O

Results O
: O
limitation O
of O
ocular O
motility O
was O
detected O
in O
all O
12 O
eyes O
of O
10 O
patients O
treated O
for O
intraocular O
retinoblastoma B_DISEASE
with O
1 O
to O
6 O
injections O
of O
subtenon O
carboplatin O
as O
part O
of O
multimodality O
therapy O
. O

Histopathological O
examination O
revealed O
many O
lipophages O
in O
the O
periorbital O
fat O
surrounding O
the O
optic O
nerve O
in O
1 O
eye O
, O
indicative O
of O
phagocytosis O
of O
previously O
existing O
fat O
cells O
and O
suggesting O
prior O
fat O
necrosis B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

The O
enucleations O
were O
technically O
difficult O
and O
hazardous O
for O
globe O
rupture B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
because O
of O
extensive O
orbital O
soft O
tissue O
adhesions O
. O

conclusions O
: O
Subtenon O
carboplatin O
chemotherapy O
is O
associated O
with O
significant O
fibrosis B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
orbital O
soft O
tissues O
, O
leading O
to O
mechanical O
restriction O
of O
eye O
movements O
and O
making O
subsequent O
enucleation O
difficult O
. O

Subtenon O
carboplatin O
is O
not O
free O
of O
toxicity B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
its O
use O
is O
best O
restricted O
to O
specific O
indications O
. O

Ethambutol O
and O
optic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
neuropathy I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O

purpose O
: O
To O
demonstrate O
the O
association O
between O
ethambutol O
and O
optic B_DISEASE/B_LOCATION
neuropathy I_DISEASE/I_LOCATION
. O

Method O
: O
Thirteen O
patients O
who O
developed O
optic B_DISEASE
neuropathy I_DISEASE
after O
being O
treated O
with O
ethambutol O
for O
tuberculosis B_DISEASE/B_LOCATION
of I_DISEASE/I_LOCATION
the I_DISEASE/I_LOCATION
lung I_DISEASE/I_LOCATION
or I_DISEASE/I_LOCATION
lymph I_DISEASE/I_LOCATION
node I_DISEASE/I_LOCATION
at O
Siriraj O
Hospital O
between O
1997 O
and O
2001 O
were O
retrospectively O
reviewed O
. O

The O
clinical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
characteristics I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
and O
initial B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
final B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
visual B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acuity B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
analyzed O
to O
determine O
visual B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
outcome B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Results O
: O
All O
patients O
had O
optic B_DISEASE
neuropathy I_DISEASE
between O
1 O
to O
6 O
months O
( O
mean O
= O
2 O
. O
9 O
months O
) O
after O
starting O
ethambutol O
therapy O
at O
a O
dosage O
ranging O
from O
13 O
to O
20 O
mg O
/ O
kg O
/ O
day O
( O
mean O
= O
17 O
mg O
/ O
kg O
/ O
day O
) O
. O

Seven B_NUMBER[MEASURE]
( O
54 B_NUMBER[MEASURE]/B_PERSON
% I_NUMBER[MEASURE]/I_PERSON
) O
of O
the O
13 B_PERSON
patients I_PERSON
experienced O
visual B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
recovery I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
after O
stopping O
the O
drug B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Of O
6 O
patients O
with O
irreversible O
visual B_DISEASE
impairment I_DISEASE
, O
4 O
patients O
had O
diabetes B_DISEASE
mellitus I_DISEASE
, O
glaucoma B_DISEASE
and O
a O
history O
of O
heavy O
smoking O
. O

conclusion O
: O
Early O
recognition O
of O
optic B_DISEASE
neuropathy I_DISEASE
should O
be O
considered O
in O
patients O
with O
ethambutol O
therapy O
. O

A O
low O
dose O
and O
prompt O
discontinuation O
of O
the O
drug O
is O
recommended O
particularly O
in O
individuals O
with O
diabetes B_DISEASE
mellitus I_DISEASE
, O
glaucoma B_DISEASE
or O
who O
are O
heavy O
smokers O
. O

Treatment O
of O
compensatory O
gustatory B_DISEASE
hyperhidrosis I_DISEASE
with O
topical O
glycopyrrolate O
. O

Gustatory B_DISEASE
hyperhidrosis I_DISEASE
is O
facial O
sweating B_DISEASE
usually O
associated O
with O
the O
eating O
of O
hot O
spicy O
food O
or O
even O
smelling O
this O
food O
. O

Current B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
options I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
include O
oral B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
anticholinergic I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
drugs I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
the O
topical B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
application I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
of O
anticholinergics B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
or O
aluminum B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
chloride I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
the O
injection B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
botulinum B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
toxin I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Thirteen B_MEASURE/B_PERSON
patients I_MEASURE/I_PERSON
have O
been O
treated O
to O
date B_DISEASE
with O
1 B_MEASURE
. O
5 B_MEASURE
% I_MEASURE
or O
2 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
% B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
topical B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
glycopyrrolate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

All O
patients O
had O
gustatory B_DISEASE
hyperhidrosis I_DISEASE
, O
which O
interfered O
with O
their O
social O
activities O
, O
after O
transthroacic O
endoscopic O
sympathectomy O
, O
and O
which O
was O
associated O
with O
compensatory O
focal O
hyperhidrosis B_DISEASE
. O

After O
applying O
topical O
glycopyrrolate O
, O
the O
subjective O
effect O
was O
excellent O
( O
no O
sweating B_DISEASE
after O
eating O
hot O
spicy O
food O
) O
in O
10 O
patients O
( O
77 O
% O
) O
, O
and O
fair O
( O
clearly O
reduced O
sweating B_DISEASE/B_MEASURE
) O
in O
3 O
patients O
( O
23 O
% O
) O
. O

All O
had O
reported O
incidents B_PERSON/B_DISEASE
of O
being O
very O
embarrassed B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
whilst B_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
eating O
hot B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
spicy I_LOCATION/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
foods I_LOCATION/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

adverse O
effects O
included O
a O
mildly O
dry B_DISEASE
mouth I_DISEASE
and O
a O
sore B_DISEASE
throat I_DISEASE
in O
2 O
patients O
( O
2 O
% O
glycopyrrolate O
) O
, O
a O
light O
headache B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
in O
1 O
patient O
( O
1 O
. O
5 O
% O
glycopyrrolate O
) O
. O

The O
topical O
application O
of O
a O
glycopyrrolate O
pad O
appeared O
to O
be O
safe O
, O
efficacious O
, O
well O
tolerated O
, O
and O
a O
convenient O
method O
of O
treatment O
for O
moderate O
to O
severe O
symptoms O
of O
gustatory B_DISEASE
hyperhidrosis I_DISEASE
in O
post O
transthoracic O
endoscopic O
sympathectomy O
or O
sympathicotomy O
patients O
, O
with O
few O
side O
effects O
. O

Neuroleptic O
- O
associated O
hyperprolactinemia B_DISEASE
. O

Can O
it O
be O
treated O
with O
bromocriptine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Six O
stable O
psychiatric O
outpatients O
with O
hyperprolactinemia B_DISEASE
and O
amenorrhea B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
/ O
oligomenorrhea B_DISEASE
associated O
with O
their O
neuroleptic O
medications O
were O
treated O
with O
bromocriptine O
. O

Daily O
dosages O
of O
5 O
- O
10 O
mg O
corrected O
the O
hyperprolactinemia B_DISEASE_ADJECTIVE[DISEASE]
and O
restored O
menstruation O
in O
four O
of O
the O
six O
patients O
. O

One O
woman O
, O
however O
, O
developed O
worsened O
psychiatric B_DISEASE
symptoms I_DISEASE
while O
taking O
bromocriptine O
, O
and O
it O
was O
discontinued O
. O

Thus O
, O
three B_NUMBER[MEASURE]/B_PERSON
of O
six B_NUMBER[MEASURE]/B_PERSON
patients B_NUMBER[MEASURE]/I_PERSON
had O
their O
menstrual B_DISEASE
irregularity I_DISEASE
successfully O
corrected O
with O
bromocriptine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O

This O
suggests O
that O
bromocriptine O
should O
be O
further O
evaluated O
as O
potential O
therapy O
for O
neuroleptic O
- O
associated O
hyperprolactinemia B_DISEASE
and O
amenorrhea B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
/ O
galactorrhea B_DISEASE/B_BACTERIUM[BIO]
. O

Ethacrynic O
acid O
- O
induced O
convulsions B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
and O
brain O
neurotransmitters O
in O
mice O
. O

Intracerebroventricular O
injection O
of O
ethacrynic O
acid O
( O
50 O
% O
convulsive B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
dose O
; O
50 O
micrograms O
/ O
mouse O
) O
accelerated O
the O
synthesis O
/ O
turnover O
of O
5 O
- O
hydroxytryptamine O
( O
5 O
- O
HT O
) O
but O
suppressed O
the O
synthesis O
of O
gamma O
- O
aminobutyric O
acid O
and O
acetylcholine O
in O
mouse O
brain O
. O

These O
effects B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
completely O
antagonized O
by O
pretreatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O
a O
glutamate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
/ O
N B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
methyl B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
D B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O
aspartate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
antagonist I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O
aminophosphonovaleric B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acid I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

In O
ethacrynic O
acid O
- O
induced O
convulsions B_DISEASE
, O
these O
neurotransmitter O
systems O
may O
be O
differentially O
modulated O
, O
probably O
through O
activation O
of O
glutaminergic O
neurons O
in O
the O
brain O
. O

pharmacology B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
gamma B_PROTEIN[GENE]
- O
aminobutyric B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
acidA I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
receptor I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
complex I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
after O
the O
in O
vivo B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
administration I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
of O
the O
anxioselective B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O
anticonvulsant B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
beta B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
- O
carboline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
derivative I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
abecarnil I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

In O
rodents B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
the O
effect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
of O
the O
beta B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
carboline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
derivative I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
isopropyl I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
6 B_MEASURE
- O
benzyloxy B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O
4 B_MEASURE
- O
methoxymethyl B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
- O
beta B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
carboline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O
3 B_MEASURE
- O
carboxylate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
abecarrnil B_LOCATION/B_PROTEIN[GENE]
) O
, O
a O
new B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ligand I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
benzodiazepine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
receptors I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
possessing O
anxiolytic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
anticonvulsant B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
properties I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
was O
evaluated O
on O
the O
function B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
central B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
gamma I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
- O
aminobutyric B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acid I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
GABA B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
A B_PROTEIN[GENE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
receptor B_PROTEIN[GENE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
complex B_PROTEIN[GENE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O
both O
in O
vitro B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
and O
in O
vivo B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPECIES[BIO]
. O

added O
in O
vitro B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O
rat B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cortical I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
membrane I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
preparation I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O
abecarnil B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
increased O
[ B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
3H I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
] I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
GABA I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
binding I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O
enhanced B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
muscimol I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
stimulated O
36Cl B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- O
uptake B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
reduced O
the O
binding B_GENE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
t B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
[ B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
35S I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
] I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
butylbicyclophosphorothionate I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O
[ B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
35S I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
] O
TBPS B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
) O
. O

These O
effects B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
similar B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
those O
induced O
by O
diazepam B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
whereas O
the O
partial B_LOCATION/B_PERSON
agonist I_LOCATION/I_PERSON
Ro I_LOCATION/I_PERSON
16 I_LOCATION/I_PERSON
- O
6028 B_MEASURE
( O
tert B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
- O
butyl B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
( O
S B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
) O
- O
8 B_MEASURE
- O
bromo B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
11 B_NUMBER[MEASURE]
, O
12 B_SEQUENCE[MEASURE]
, O
13 B_NUMBER[MEASURE]
, O
13a B_MEASURE
- O
tetrahydro B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
9 B_MEASURE
- O
oxo B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENZYME[GENE]
- O
9H B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
- O
imidazo B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
[ B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
1 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O
5 B_NUMBER[MEASURE]
- O
a O
] B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
pyrrolo B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
- O
[ B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
2 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
, O
1 B_MEASURE
- O
c B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
] I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
[ O
1 B_MEASURE
, O
4 B_MEASURE
] I_MEASURE
benzodiazepine I_MEASURE
- O
1 B_MEASURE
- O
carboxylate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
showed O
very O
weak B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
efficacy B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
these O
biochemical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
tests I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

After O
i O
. O
p B_MEASURE/B_LOCATION
. O
injection B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O
rats B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
abecarnil B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
diazepam B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
decreased O
in O
a O
time B_MEASURE/B_DISEASE
- O
dependent B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
and O
dose B_MEASURE/B_DISEASE
- O
related O
( O
0 B_MEASURE/B_LOCATION
. O
25 B_MEASURE
- O
20 B_MEASURE
mg I_MEASURE
/ O
kg B_TIME[MEASURE]
i O
. O
p B_MEASURE/B_LOCATION
. O
) O
manner B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O
35S B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
] I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
TBPS I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
binding I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
measured O
ex B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
vivo I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
cerebral B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
cortex I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O

Moreover O
, O
both O
drugs B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O
the O
dose B_MEASURE/B_LOCATION
of O
0 B_MEASURE
. O
5 B_MEASURE
mg I_MEASURE
/ O
kg B_MEASURE
antagonized O
completely O
the O
convulsant B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
activity I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
the O
increase B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
[ B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
35S B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
] B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
TBPS B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
binding B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
induced O
by O
isoniazide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
( O
350 B_MEASURE
mg I_MEASURE
/ O
kg B_MEASURE/B_LOCATION
s I_MEASURE/I_LOCATION
. O
c O
. O
) O
as O
well O
as O
the O
increase B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
[ B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
35S B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
] B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
TBPS B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
binding B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
induced O
by O
foot B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
shock B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
stress I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

To O
better O
correlate O
the O
biochemical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
the O
pharmacological B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
we O
studied O
the O
action B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
abecarnil B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
[ O
35S B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
] B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
TBPS B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
binding B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O
exploratory B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
motility B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
and O
on O
isoniazid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
induced O
biochemical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
pharmacological B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
effects B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
in O
mice B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

In O
these O
animals B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
abecarnil B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
produced O
a O
paralleled O
dose B_MEASURE
- O
dependent B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
( O
0 B_MEASURE/B_LOCATION
. O
05 B_MEASURE
- O
1 B_MEASURE
mg I_MEASURE
/ O
kg B_MEASURE
i O
. O
p B_MEASURE/B_LOCATION
. O
) O
reduction B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
both O
motor B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
behavior I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
and O
cortical B_BODY_PART_OR_ORGAN_COMPONENT
[ O
35S B_MEASURE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] I_MEASURE/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
TBPS I_MEASURE/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
binding I_MEASURE/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Moreover O
, O
0 O
. O
05 O
mg O
/ O
kg O
of O
this O
beta O
- O
carboline O
reduced O
markedly O
the O
increase O
of O
[ O
35S O
] O
TBPS O
binding O
and O
the O
convulsions B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
induced O
by O
isoniazid O
( O
200 O
mg O
/ O
kg O
s O
. O
c O
. O
) O
. O
( O
abstract O
TRUNCATED O
AT O
250 O
Words O
) O
. O

Recurrent O
myocardial B_DISEASE
infarction I_DISEASE
in O
a O
postpartum O
patient O
receiving O
bromocriptine O
. O

Myocardial B_DISEASE
infarction I_DISEASE
in O
puerperium O
is O
infrequently O
reported O
. O

Spasm B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
coronary O
dissection O
, O
or O
atheromatous O
etiology O
has O
been O
described O
. O

Bromocriptine O
has O
been O
implicated O
in O
several O
previous O
case O
reports O
of O
myocardial B_DISEASE
infarction I_DISEASE
in O
the O
puerperium O
. O

Our O
case B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
including O
an O
inadvertent B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
rechallenge I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
) O
suggests O
such O
a O
relationship B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Although O
generally O
regarded O
as O
' O
safe B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
' O
possible B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
serious I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
cardiac I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
effects I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
of O
bromocriptine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
should O
be O
acknowledged O
. O

Asterixis B_DISEASE/B_BIO
induced O
by O
carbamazepine O
therapy O
. O

There O
are O
very O
few O
reports O
about O
asterixis B_DISEASE/B_BIO
as O
a O
side O
effect O
of O
treatment O
with O
psychopharmacologic O
agents O
. O

In O
this O
report O
we O
present O
four O
patients O
treated O
with O
a O
combination O
of O
different O
psychotropic O
drugs O
, O
in O
whom O
asterixis B_DISEASE/B_BIO
was O
triggered O
either O
by O
adding O
carbamazepine O
( O
CBZ O
) O
to O
a O
treatment O
regimen O
, O
or O
by O
increasing O
its O
dosage O
. O

Neither O
dosage B_BODY_PART_OR_ORGAN_COMPONENT/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
nor O
serum B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
levels I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
of O
CBZ B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
in O
a O
higher B_MEASURE
range I_MEASURE
. O

We O
consider O
asterixis B_DISEASE/B_BIO
to O
be O
an O
easily O
overlooked O
sign O
of O
neurotoxicity B_DISEASE
, O
which O
may O
occur O
even O
at O
low O
or O
moderate O
dosage O
levels O
, O
if O
certain O
drugs O
as O
lithium O
or O
clozapine O
are O
used O
in O
combination O
with O
CBZ O
. O

Pharmacodynamics O
of O
the O
hypotensive B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effect O
of O
levodopa O
in O
parkinsonian B_DISEASE
patients O
. O

Blood O
pressure O
effects O
of O
i O
. O
v O
. O
levodopa O
were O
examined O
in O
parkinsonian B_NUMBER[MEASURE]/B_PERSON
patients O
with O
stable O
and O
fluctuating O
responses O
to O
levodopa O
. O

The O
magnitude O
of O
the O
hypotensive B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effect O
of O
levodopa O
was O
concentration O
dependent O
and O
was O
fit O
to O
an O
Emax O
model O
in O
fluctuating O
responders O
. O

stable O
responders O
demonstrated O
a O
small O
hypotensive B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
response O
. O

Baseline O
blood O
pressures O
were O
higher O
in O
fluctuating O
patients O
; O
a O
higher O
baseline O
blood O
pressure O
correlated O
with O
greater O
hypotensive B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects O
. O

Antiparkinsonian B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
effects I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
of O
levodopa B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
temporally O
correlated O
with O
blood B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
pressure I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
changes I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

Phenylalanine O
, O
a O
large O
neutral O
amino O
acid O
( O
LNAA O
) O
competing O
with O
levodopa O
for O
transport O
across O
the O
blood O
- O
brain O
barrier O
, O
reduced O
the O
hypotensive B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O
antiparkinsonian O
effects O
of O
levodopa O
. O

We O
conclude O
that O
levodopa O
has O
a O
central O
hypotensive B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
action O
that O
parallels O
the O
motor O
effects O
in O
fluctuating O
patients O
. O

The O
hypotensive B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
effect O
appears O
to O
be O
related O
to O
the O
higher O
baseline O
blood O
pressure O
we O
observed O
in O
fluctuating O
patients O
relative O
to O
stable O
patients O
. O

Syndrome B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
of B_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
inappropriate B_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
secretion B_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
of B_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
antidiuretic B_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
hormone B_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
after O
infusional O
vincristine O
. O

A O
77 O
- O
year O
- O
old O
woman O
with O
refractory O
multiple B_DISEASE/B_GENE
myeloma I_DISEASE/I_GENE
was O
treated O
with O
a O
4 O
- O
day O
continuous O
intravenous O
infusion O
of O
vincristine O
and O
doxorubicin O
and O
4 O
days O
of O
oral O
dexamethasone O
. O

Nine O
days O
after O
her O
second O
cycle O
she O
presented O
with O
lethargy B_DISEASE
and O
weakness B_DISEASE
associated O
with O
hyponatremia B_DISEASE
. O

Evaluation O
revealed O
the O
syndrome B_DISEASE
of I_DISEASE
inappropriate I_DISEASE
secretion I_DISEASE
of I_DISEASE
antidiuretic I_DISEASE
hormone I_DISEASE
, O
which O
was O
attributed O
to O
the O
vincristine O
infusion O
. O

After O
normal B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
serum I_PERSON/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sodium I_PERSON/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
levels I_PERSON/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
returned O
, O
further B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
doxorubicin I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
dexamethasone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
chemotherapy I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
without O
vincristine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
did O
not O
produce O
this O
complication B_DISEASE
. O

Heart B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
failure B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
to O
digitalise O
or O
not O
. O

The O
view B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
against O
. O

Despite O
extensive B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
clinical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
experience B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
the O
role B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O
digoxin B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
is O
still O
not O
well O
defined O
. O

In O
patients O
with O
atrial B_DISEASE
fibrillation I_DISEASE
digoxin O
is O
beneficial O
for O
ventricular O
rate O
control O
. O

For O
patients O
in O
sinus O
rhythm O
and O
heart B_DISEASE
failure I_DISEASE
the O
situation O
is O
less O
clear O
. O

digoxin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
has O
a O
narrow B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
therapeutic B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
: O
toxic B_MEASURE/B_LOCATION
ratio I_MEASURE/I_LOCATION
and O
concentrations B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
affected O
by O
a O
number B_MEASURE
of O
drugs B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O

Also O
, O
digoxin O
has O
undesirable O
effects O
such O
as O
increasing O
peripheral O
resistance O
and O
myocardial O
demands O
, O
and O
causing O
arrhythmias B_DISEASE
. O

There O
is O
a O
paucity B_DISEASE/B_MEASURE
of O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
from O
well O
- O
designed O
trials B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
trials B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
are O
available B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
generally O
small B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
with O
limitations B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
in O
design B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
and O
these O
show B_MEASURE
variation I_MEASURE
in O
patient B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
benefit I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

More O
convincing B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
evidence I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
required O
showing O
that O
digoxin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
improves O
symptoms B_DISEASE
or O
exercise B_DISEASE_ADJECTIVE[DISEASE]
capacity I_DISEASE_ADJECTIVE[DISEASE]
. O

Furthermore O
, O
no O
trial B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
has O
had O
sufficient B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
power I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
evaluate O
mortality B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Pooled O
analysis O
of O
the O
effects O
of O
other O
inotropic O
drugs O
shows O
an O
excess O
mortality O
and O
there O
is O
a O
possibility O
that O
digoxin O
may O
increase O
mortality O
after O
myocardial B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
infarction I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O
MI B_DISEASE/B_LOCATION
) O
. O

Angiotensin B_GENE
- O
converting O
enzyme B_ENZYME[GENE]
( O
ace B_PERSON/B_PROTEIN[GENE]
) O
inhibitors B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
should O
be O
used O
first O
as O
they O
are O
safer B_DISEASE_ADJECTIVE[DISEASE]
, O
do O
not O
require O
blood B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
level I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
monitoring I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
modify O
progression B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O
disease B_DISEASE
, O
relieve O
symptoms B_DISEASE
, O
improve O
exercise B_DISEASE_ADJECTIVE[DISEASE]
tolerance I_DISEASE_ADJECTIVE[DISEASE]
and O
reduce O
mortality B_DISEASE/B_MEASURE
. O

caution B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
should O
be O
exercised O
in O
using O
digoxin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
until O
large B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mortality I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
trials I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
completed O
showing O
either O
benefit B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
or O
harm B_DISEASE
. O

Until O
then O
digoxin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
should O
be O
considered O
a O
third B_SEQUENCE[MEASURE]/B_LOCATION
- O
line B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
therapy I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_PERSON
. O

Isradipine O
treatment O
for O
hypertension B_DISEASE/B_LOCATION
in O
general O
practice O
in O
Hong O
Kong O
. O

A O
6 B_NUMBER[MEASURE]
- O
week B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
open B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
of O
the O
introduction B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
isradipine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
treatment I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
was O
conducted O
in O
general B_MEASURE
practice I_MEASURE
in O
Hong B_LOCATION
Kong I_LOCATION
. O

303 O
Chinese O
patients O
with O
mild O
to O
moderate O
hypertension B_DISEASE/B_LOCATION
entered O
the O
study O
. O

Side B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
effects B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
were O
reported O
in O
21 B_NUMBER[MEASURE]/B_PERSON
% I_NUMBER[MEASURE]/I_PERSON
of O
patients B_PERSON
and O
caused O
withdrawal B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
from O
the O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
3 B_TIME[MEASURE]/B_PERSON
patients I_TIME[MEASURE]/I_PERSON
. O

The O
main O
side O
- O
effects O
were O
headache B_DISEASE
, O
dizziness B_DISEASE
, O
palpitation B_DISEASE
and O
flushing B_DISEASE
and O
these O
were O
not O
more O
frequent O
than O
reported O
in O
other O
studies O
with O
isradipine O
or O
with O
placebo O
. O

supine B_DISEASE/B_GENE
blood I_DISEASE/I_GENE
pressure I_DISEASE/I_GENE
was O
reduced O
( O
P B_MEASURE
less I_MEASURE
than O
0 B_MEASURE
. O
01 B_MEASURE
) O
from O
170 B_MEASURE
+ I_MEASURE
/ O
- O
20 B_MEASURE
/ O
102 B_MEASURE
+ I_MEASURE
/ O
- O
6 B_MEASURE
mmHg I_MEASURE
to O
153 B_MEASURE
+ I_MEASURE
/ O
- O
19 B_MEASURE
/ O
92 B_MEASURE
+ O
/ O
- O
8 B_MEASURE
, O
147 B_MEASURE
+ I_MEASURE
/ O
- O
18 B_MEASURE
/ O
88 B_MEASURE
+ O
/ O
- O
7 B_MEASURE
and O
144 B_MEASURE
+ I_MEASURE
/ O
- O
14 B_MEASURE
/ O
87 B_MEASURE
+ O
/ O
- O
6 B_MEASURE
mmHg I_MEASURE
at O
2 B_NUMBER[MEASURE]
, O
4 B_MEASURE
and O
6 B_MEASURE/B_ENT
weeks I_MEASURE/I_ENT
respectively O
in O
evaluable B_PERSON/B_TIME[MEASURE]
patients I_PERSON/I_TIME[MEASURE]
. O

Similar O
reductions O
occurred O
in O
standing O
blood O
pressure O
and O
there O
was O
no O
evidence O
of O
postural B_DISEASE
hypotension I_DISEASE
. O

normalization B_DISEASE/B_PERSON
and O
responder B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
rates I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O
6 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENT
weeks I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENT
were O
86 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
and O
69 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
respectively O
. O

dosage B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
increased O
from O
2 B_MEASURE
. O
5 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
mg B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
b B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
. O
d B_TIME[MEASURE]/B_DISEASE
. O
to O
5 B_MEASURE
mg I_MEASURE
b O
. O
d B_TIME[MEASURE]/B_DISEASE
. O
at O
4 B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
weeks I_TIME[MEASURE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
patients B_PERSON/B_BIO
with O
diastolic B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
blood B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
pressure B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
greater B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
than O
90 B_MEASURE/B_LOCATION
mmHg I_MEASURE/I_LOCATION
and O
their O
further B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
response I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
was O
greater B_MEASURE
than O
those O
remaining O
on O
2 B_NUMBER[MEASURE]
. O
5 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
mg B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
b B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
. O
d B_TIME[MEASURE]/B_DISEASE
. O

Pharmacological B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
characteristics I_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
and O
side B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
effects I_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
of O
a O
new B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
galenic I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
formulation I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
propofol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
without O
soyabean B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
oil I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
. O

We O
compared O
the O
pharmacokinetics B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
pharmacodynamics B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O
safety B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
profile I_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
of O
a O
new B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
galenic I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
formulation I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
propofol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
AM149 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
1 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
% I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
) O
, O
which O
does O
not O
contain O
soyabean B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
oil I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
, O
with O
a O
standard B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
formulation I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
of O
propofol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
Disoprivan B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
1 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
% I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
) O
. O

In O
a O
randomised B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O
double B_MEASURE/B_COLOR
- O
blind B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
cross O
- O
over O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
30 B_PERSON/B_BIO
healthy I_PERSON/I_BIO
volunteers I_PERSON/I_BIO
received O
a O
single B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
intravenous I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
bolus I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
injection I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
of O
2 B_MEASURE
. O
5 B_MEASURE
mg I_MEASURE
. O
kg B_MEASURE
- O
1 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
propofol I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

Plasma B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
propofol I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
levels I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
were O
measured O
for O
48 B_MEASURE
h O
following O
drug B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
administration I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
evaluated O
according O
to O
a O
three B_NUMBER[MEASURE]/B_LOCATION
- O
compartment B_MEASURE/B_DISEASE
model I_MEASURE/I_DISEASE
. O

The O
pharmacodynamic O
parameters O
assessed O
included O
induction O
and O
emergence O
times O
, O
respiratory O
and O
cardiovascular O
effects O
, O
and O
pain B_DISEASE/B_MEASURE
on O
injection O
. O

patients B_PERSON/B_BIO
were O
monitored O
for O
side B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
effects B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
over O
48 B_MEASURE
h O
. O

owing O
to O
a O
high O
incidence O
of O
thrombophlebitis B_DISEASE
, O
the O
study O
was O
terminated O
prematurely O
and O
only O
the O
data O
of O
the O
two O
parallel O
treatment O
groups O
( O
15 O
patients O
in O
each O
group O
) O
were O
analysed O
. O

Plasma B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
concentrations I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
did O
not O
differ O
significantly O
between O
the O
two B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
formulations I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

anaesthesia B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_TIME[MEASURE]
induction I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_TIME[MEASURE]
and O
emergence B_MEASURE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
times B_MEASURE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
respiratory B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
cardiovascular B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
variables I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
showed O
no O
significant B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
differences I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O
the O
two B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treatment I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
groups I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Pain B_DISEASE
on O
injection O
( O
80 O
vs O
. O
20 O
% O
, O
p O
< O
0 O
. O
01 O
) O
and O
thrombophlebitis B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O
93 O
. O
3 O
vs O
. O
6 O
. O
6 O
% O
, O
p O
< O
0 O
. O
001 O
) O
occurred O
more O
frequently O
with O
AM149 O
than O
with O
Disoprivan O
. O

Although O
both O
formulations O
had O
similar O
pharmacokinetic O
and O
pharmacodynamic O
profiles O
the O
new O
formulation O
is O
not O
suitable O
for O
clinical O
use O
due O
to O
the O
high O
incidence O
of O
thrombophlebitis B_DISEASE
produced O
. O

Pure B_DISEASE
red I_DISEASE
cell I_DISEASE
aplasia I_DISEASE
, O
toxic B_DISEASE
dermatitis I_DISEASE
and O
lymphadenopathy B_DISEASE
in O
a O
patient O
taking O
diphenylhydantoin O
. O

A O
patient O
taking O
diphenylhydantoin O
for O
3 O
weeks O
developed O
a O
generalized O
skin B_DISEASE
rash I_DISEASE
, O
lymphadenopathy B_DISEASE
and O
pure B_DISEASE
red I_DISEASE
cell I_DISEASE
aplasia I_DISEASE
. O

After O
withdrawal B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O
the O
pharmacon B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
all O
symptoms B_DISEASE
disappeared O
spontaneously O
. O

Skin B_DISEASE
rash I_DISEASE
is O
a O
well O
- O
known O
complication O
of O
diphenylhydantoin O
treatment O
as O
is O
benign O
and O
malignant O
lymphadenopathy B_DISEASE
. O

Pure B_DISEASE
red I_DISEASE
cell I_DISEASE
aplasia I_DISEASE
associated O
with O
diphenylhydantoin O
medication O
has O
been O
reported O
in O
3 O
patients O
. O

The O
exact B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
mechanism B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
by O
which O
diphenylhydantoin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
exerts O
its O
toxic B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
effects I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
is O
not O
known O
. O

In O
this O
patient O
the O
time O
relation O
between O
the O
ingestion O
of O
diphenylhydantoin O
and O
the O
occurrence O
of O
the O
skin B_DISEASE
rash I_DISEASE
, O
lymphadenopathy B_DISEASE
and O
pure B_DISEASE
red I_DISEASE
cell I_DISEASE
aplasia I_DISEASE
is O
very O
suggestive O
of O
a O
direct O
connection O
. O

Vinorelbine B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
- O
related O
cardiac B_DISEASE_ADJECTIVE[DISEASE]
events I_DISEASE_ADJECTIVE[DISEASE]
: O
a O
meta B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
analysis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
randomized B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
clinical I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
trials I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O

Several B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cases I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
cardiac B_DISEASE
adverse I_DISEASE
reactions I_DISEASE
related O
to O
vinorelbine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
VNR B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
) O
have O
been O
reported O
in O
the O
literature B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

In O
order O
to O
quantify O
the O
incidence O
of O
these O
cardiac O
events O
, O
we O
performed O
a O
meta O
- O
analysis O
of O
clinical O
trials O
comparing O
VNR O
with O
other O
chemotherapeutic O
agents O
in O
the O
treatment O
of O
various O
malignancies B_DISEASE
. O

Randomized O
clinical O
trials O
comparing O
VNR O
with O
other O
drugs O
in O
the O
treatment O
of O
cancer B_DISEASE/B_LOCATION
were O
searched O
in O
Medline O
, O
Embase O
, O
Evidence O
- O
based O
Medicine O
Reviews O
databases O
and O
the O
Cochrane O
library O
from O
1987 O
to O
2002 O
. O

outcomes B_PERSON/B_LOCATION
of O
interest B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
severe B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
cardiac I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
events I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
, O
toxic B_DISEASE
deaths I_DISEASE
and O
cardiac B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
event B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
related O
deaths B_DISEASE
reported O
in O
each O
publication B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
. O

We O
found O
19 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_NUMBER[MEASURE]
trials I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_NUMBER[MEASURE]
, O
involving O
2441 B_PERSON/B_TIME[MEASURE]
patients I_PERSON/I_TIME[MEASURE]
treated O
by O
VNR B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
and O
2050 B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
control I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
patients I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
. O

The O
incidence B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O
cardiac B_DISEASE
events I_DISEASE
with O
VNR B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
was O
1 B_MEASURE
. O
19 B_MEASURE
% I_MEASURE
[ I_MEASURE
95 I_MEASURE
% I_MEASURE
confidence I_MEASURE
interval I_MEASURE
( O
CI B_MEASURE/B_LOCATION
) O
( O
0 B_MEASURE
. O
75 B_MEASURE
; O
1 B_MEASURE
. O
67 B_MEASURE
) O
] O
. O

There O
was O
no O
difference B_MEASURE
in O
the O
risk B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O
cardiac B_DISEASE
events I_DISEASE
between O
VNR B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
and O
other B_MEASURE/B_LOCATION
drugs B_MEASURE/I_LOCATION
[ B_MEASURE/I_LOCATION
odds B_MEASURE/I_LOCATION
ratio B_MEASURE/I_LOCATION
: O
0 B_MEASURE
. O
92 B_MEASURE
, O
95 B_MEASURE
% I_MEASURE
CI I_MEASURE
( O
0 B_MEASURE
. O
54 B_MEASURE
; O
1 B_MEASURE
. O
55 B_MEASURE
) O
] O
. O

The O
risk O
of O
VNR O
cardiac O
events O
was O
similar O
to O
vindesine O
( O
VDS O
) O
and O
other O
cardiotoxic B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
drugs O
[ O
fluorouracil O
, O
anthracyclines O
, O
gemcitabine O
( O
GEM O
) O
em O
leader O
] O
. O

Even O
if O
it O
did O
not O
reach O
statistical O
significance O
because O
of O
a O
few O
number O
of O
cases O
, O
the O
risk O
was O
lower O
in O
trials O
excluding O
patients O
with O
cardiac O
history O
, O
and O
seemed O
to O
be O
higher O
in O
trials O
including O
patients O
with O
pre O
- O
existing O
cardiac B_DISEASE
diseases I_DISEASE
. O

Vinorelbine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
related O
cardiac B_DISEASE
events I_DISEASE
concern O
about O
1 B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
% B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
treated O
patients B_PERSON/B_BIO
in O
clinical B_LOCATION/B_ORGANIZATION
trials I_LOCATION/I_ORGANIZATION
. O

However O
, O
the O
risk B_DISEASE
associated O
with O
VNR B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
seems O
to O
be O
similar B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O
that O
of O
other B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
chemotherapeutic I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
agents I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
in O
the O
same B_LOCATION/B_PERSON
indications I_LOCATION/I_PERSON
. O

MRI O
findings O
of O
hypoxic O
cortical O
laminar O
necrosis B_DISEASE/B_MEASURE
in O
a O
child O
with O
hemolytic B_DISEASE_ADJECTIVE[DISEASE]
anemia I_DISEASE_ADJECTIVE[DISEASE]
crisis O
. O

We O
present O
magnetic O
resonance O
imaging O
findings O
of O
a O
5 O
- O
year O
- O
old O
girl O
who O
had O
a O
rapidly O
installing O
hemolytic B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
anemia I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
crisis O
induced O
by O
trimethoprim O
- O
sulfomethoxazole O
, O
resulting O
in O
cerebral B_DISEASE
anoxia I_DISEASE
leading O
to O
permanent O
damage O
. O

magnetic O
resonance O
imaging O
revealed O
cortical O
laminar O
necrosis B_DISEASE
in O
arterial O
border O
zones O
in O
both O
cerebral O
hemispheres O
, O
ischemic O
changes O
in O
subcortical O
white O
matter O
of O
left O
cerebral O
hemisphere O
, O
and O
in O
the O
left O
putamen O
. O

Although O
cortical O
laminar O
necrosis B_DISEASE
is O
a O
classic O
entity O
in O
adulthood O
related O
to O
conditions O
of O
energy O
depletions O
, O
there O
are O
few O
reports O
available O
in O
children O
. O

A O
wide B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
review I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O
the O
literature B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
also O
presented O
. O

The O
natural O
history O
of O
Vigabatrin O
associated O
visual B_DISEASE
field I_DISEASE
defects I_DISEASE
in O
patients O
electing O
to O
continue O
their O
medication O
. O

purpose O
: O
To O
determine O
the O
natural O
history O
of O
visual B_DISEASE
field I_DISEASE
defects I_DISEASE
in O
a O
group O
of O
patients O
known O
to O
have O
Vigabatrin O
- O
associated O
changes O
who O
elected O
to O
continue O
the O
medication O
because O
of O
good O
seizure B_DISEASE
control O
. O

METHODS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O
All O
patients B_PERSON
taking O
Vigabatrin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alone O
or O
in O
combination B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANIZATION
with O
other B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
antiepileptic I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
drugs I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
for O
at O
least O
5 B_TIME[MEASURE]
years I_TIME[MEASURE]
( O
range B_NUMBER[MEASURE]/B_LOCATION
5 I_NUMBER[MEASURE]/I_LOCATION
- O
12 B_TIME[MEASURE]
years I_TIME[MEASURE]
) O
were O
entered O
into O
a O
visual B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
surveillance I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
programme I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

patients B_PERSON
were O
followed O
up O
at O
6 B_NUMBER[MEASURE]/B_LOCATION
- O
monthly B_TIME[MEASURE]
intervals I_TIME[MEASURE]
for O
not O
less B_TIME[MEASURE]
than O
18 B_TIME[MEASURE]
months I_TIME[MEASURE]
( O
range B_MEASURE/B_LOCATION
18 I_MEASURE/I_LOCATION
- O
43 B_TIME[MEASURE]
months I_TIME[MEASURE]
) O
. O

In O
all O
, O
16 B_PERSON
patients I_PERSON
with O
unequivocal B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
defects I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
continued O
the O
medication B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Following O
already O
published O
methodology O
( O
Eye O
2002 O
; O
16 O
; O
567 O
- O
571 O
) O
monocular O
mean O
radial O
degrees O
( O
MRDs O
) O
to O
the O
I O
/ O
4e O
isopter O
on O
Goldmann O
perimetry O
was O
calculated O
for O
the O
right O
eye O
at O
the O
time O
of O
discovery O
of O
a O
visual B_DISEASE
field I_DISEASE
defect I_DISEASE
and O
again O
after O
not O
less O
than O
18 O
months O
follow O
- O
up O
. O

RESULTS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O
Mean O
right B_DISEASE/B_MEASURE
eye I_DISEASE/I_MEASURE
MRD I_DISEASE/I_MEASURE
at O
presentation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
was O
36 B_MEASURE
. O
98 B_MEASURE
degrees I_MEASURE
( O
range B_MEASURE/B_LOCATION
22 I_MEASURE/I_LOCATION
. O
25 B_MEASURE
- O
51 B_MEASURE
. O
0 B_MEASURE
) O
, O
compared O
to O
38 B_MEASURE
. O
40 B_MEASURE
degrees I_MEASURE
( O
range B_MEASURE/B_LOCATION
22 I_MEASURE/I_LOCATION
. O
5 B_MEASURE
- O
49 B_MEASURE
. O
75 B_MEASURE
) O
after O
follow B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
up B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
; O
P B_PROTEIN[GENE]/B_LOCATION
= O
0 B_MEASURE
. O
338 B_MEASURE
unpaired I_MEASURE
t I_MEASURE
- O
test B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O

Only O
one O
patient O
demonstrated O
a O
deterioration B_DISEASE_ADJECTIVE[DISEASE]
in I_DISEASE_ADJECTIVE[DISEASE]
visual I_DISEASE_ADJECTIVE[DISEASE]
field I_DISEASE_ADJECTIVE[DISEASE]
during O
the O
study O
period O
and O
discontinued O
treatment O
. O

conclusion O
: O
Established O
visual B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
field B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
defects B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
presumed O
to O
be O
due O
to O
Vigabatrin O
therapy O
did O
not O
usually O
progress O
in O
spite O
of O
continuing O
use O
of O
the O
medication O
. O

These O
data O
give O
support O
to O
the O
hypothesis O
that O
the O
pathogenesis O
of O
Vigabatrin O
- O
associated O
visual B_DISEASE
field I_DISEASE
defects I_DISEASE
may O
be O
an O
idiosyncratic O
adverse O
drug O
reaction O
rather O
than O
dose O
- O
dependent O
toxicity B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

induction O
of O
rosaceiform O
dermatitis B_DISEASE
during O
treatment O
of O
facial B_DISEASE/B_GENE
inflammatory I_DISEASE/I_GENE
dermatoses I_DISEASE/I_GENE
with O
tacrolimus O
ointment O
. O

Background O
: O
Tacrolimus O
ointment O
is O
increasingly O
used O
for O
anti O
- O
inflammatory O
treatment O
of O
sensitive O
areas O
such O
as O
the O
face O
, O
and O
recent O
observations O
indicate O
that O
the O
treatment O
is O
effective O
in O
steroid O
- O
aggravated O
rosacea B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
and O
perioral B_DISEASE
dermatitis I_DISEASE
. O

We O
report O
on O
rosaceiform O
dermatitis B_DISEASE
as O
a O
complication O
of O
treatment O
with O
tacrolimus O
ointment O
. O

observations O
: O
Six O
adult O
patients O
with O
inflammatory B_DISEASE/B_PROTEIN[GENE]
facial B_DISEASE/I_PROTEIN[GENE]
dermatoses B_DISEASE/I_PROTEIN[GENE]
were O
treated O
with O
tacrolimus O
ointment O
because O
of O
the O
ineffectiveness O
of O
standard O
treatments O
. O

Within O
2 O
to O
3 O
weeks O
of O
initially O
effective O
and O
well O
- O
tolerated O
treatment O
, O
3 O
patients O
with O
a O
history O
of O
rosacea B_DISEASE
and O
1 O
with O
a O
history O
of O
acne B_DISEASE
experienced O
sudden O
worsening O
with O
pustular O
rosaceiform O
lesions O
. O

Biopsy B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
revealed O
an O
abundance B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
Demodex B_DISEASE
mites I_DISEASE
in O
2 B_NUMBER[MEASURE]
of O
these O
patients B_PERSON/B_LOCATION
. O

In O
1 O
patient O
with O
eyelid O
eczema B_DISEASE
, O
rosaceiform O
periocular B_DISEASE
dermatitis I_DISEASE
gradually O
appeared O
after O
3 O
weeks O
of O
treatment O
. O

In O
1 O
patient O
with O
atopic B_DISEASE/B_LOCATION
dermatitis I_DISEASE/I_LOCATION
, O
telangiectatic O
and O
papular B_DISEASE
rosacea I_DISEASE
insidiously O
appeared O
after O
5 O
months O
of O
treatment O
. O

conclusions O
: O
Our O
observations O
suggest O
that O
the O
spectrum O
of O
rosaceiform O
dermatitis B_DISEASE
as O
a O
complication O
of O
treatment O
with O
tacrolimus O
ointment O
is O
heterogeneous O
. O

A O
variety B_ENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
factors B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
such B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
as O
vasoactive B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
properties I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
of O
tacrolimus B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
, O
proliferation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
of O
Demodex B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
due O
to O
local B_DISEASE
immunosuppression I_DISEASE
, O
and O
the O
occlusive B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
properties I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
the O
ointment B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
, O
may O
be O
involved O
in O
the O
observed O
phenomena B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O

Future B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
studies I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
are O
needed O
to O
identify O
individual B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
risk I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
factors I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O

Intravascular O
hemolysis B_DISEASE
and O
acute B_DISEASE
renal I_DISEASE
failure I_DISEASE
following O
intermittent O
rifampin O
therapy O
. O

Renal B_DISEASE
failure I_DISEASE
is O
a O
rare O
complication O
associated O
with O
the O
use O
of O
rifampin O
. O

Intravascular O
hemolysis B_DISEASE
leading O
to O
acute B_DISEASE
renal I_DISEASE
failure I_DISEASE
following O
rifampin O
therapy O
is O
extremely O
rare O
. O

Two O
patients O
with O
leprosy B_DISEASE
who O
developed O
hemolysis B_DISEASE
and O
acute B_DISEASE
renal I_DISEASE
failure I_DISEASE
following O
rifampin O
are O
reported O
. O

Structural B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
abnormalities B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
brains B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
human B_PERSON/B_BIO
subjects I_PERSON/I_BIO
who O
use O
methamphetamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O

We O
visualize O
, O
for O
the O
first O
time O
, O
the O
profile O
of O
structural B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
deficits B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
the B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
human B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
brain B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
associated O
with O
chronic O
methamphetamine O
( O
MA O
) O
abuse O
. O

Studies O
of O
human O
subjects O
who O
have O
used O
MA O
chronically O
have O
revealed O
deficits O
in O
dopaminergic O
and O
serotonergic O
systems O
and O
cerebral O
metabolic B_DISEASE_ADJECTIVE[DISEASE]/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
abnormalities B_DISEASE_ADJECTIVE[DISEASE]/I_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
. O

Using O
magnetic O
resonance O
imaging O
( O
MRI O
) O
and O
new O
computational O
brain O
- O
mapping O
techniques O
, O
we O
determined O
the O
pattern O
of O
structural O
brain O
alterations O
associated O
with O
chronic O
MA O
abuse O
in O
human O
subjects O
and O
related O
these O
deficits O
to O
cognitive B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
impairment I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

We O
used O
high O
- O
resolution O
MRI O
and O
surface O
- O
based O
computational O
image O
analyses O
to O
map O
regional O
abnormalities B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
the B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cortex B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hippocampus B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
white B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
matter B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ventricles B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
22 O
human O
subjects O
who O
used O
MA O
and O
21 O
age O
- O
matched O
, O
healthy O
controls O
. O

cortical B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
maps I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
revealed O
severe B_COLOR/B_PERSON
gray I_COLOR/I_PERSON
- O
matter B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
deficits B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
in O
the O
cingulate B_BODY_PART_OR_ORGAN_COMPONENT
, O
limbic B_BODY_PART_OR_ORGAN_COMPONENT
, O
and O
paralimbic B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
cortices I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
of O
MA B_DISEASE/B_PERSON
abusers I_DISEASE/I_PERSON
( O
averaging O
11 B_MEASURE
. O
3 B_MEASURE
% I_MEASURE
below O
control B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
; O
p O
< O
0 B_MEASURE
. O
05 B_MEASURE
) O
. O

On O
average O
, O
MA O
abusers O
had O
7 O
. O
8 O
% O
smaller O
hippocampal O
volumes O
than O
control O
subjects O
( O
p O
< O
0 O
. O
01 O
; O
left O
, O
p O
= O
0 O
. O
01 O
; O
right O
, O
p O
< O
0 O
. O
05 O
) O
and O
significant O
white O
- O
matter O
hypertrophy B_DISEASE
( O
7 O
. O
0 O
% O
; O
p O
< O
0 O
. O
01 O
) O
. O

hippocampal B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
deficits I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
were O
mapped O
and O
correlated O
with O
memory B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
performance I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
a O
word B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
recall B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
test I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O
p B_PROTEIN[GENE]/B_DISEASE
< O
0 B_MEASURE
. O
05 B_MEASURE
) O
. O

MRI O
- O
based O
maps O
suggest O
that O
chronic O
methamphetamine O
abuse O
causes O
a O
selective O
pattern O
of O
cerebral O
deterioration O
that O
contributes O
to O
impaired B_DISEASE
memory I_DISEASE
performance I_DISEASE
. O

MA B_LOCATION/B_DISEASE
may O
selectively O
damage O
the O
medial B_BODY_PART_OR_ORGAN_COMPONENT
temporal I_BODY_PART_OR_ORGAN_COMPONENT
lobe I_BODY_PART_OR_ORGAN_COMPONENT
and O
, O
consistent B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
with O
metabolic B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
studies I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
the O
cingulate B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
- O
limbic B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
cortex I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
, O
inducing O
neuroadaptation B_DISEASE
, O
neuropil B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reduction I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
or O
cell B_DISEASE
death I_DISEASE
. O

prominent O
white O
- O
matter O
hypertrophy B_DISEASE
may O
result O
from O
altered O
myelination O
and O
adaptive O
glial O
changes O
, O
including O
gliosis B_DISEASE_ADJECTIVE[DISEASE]
secondary O
to O
neuronal B_DISEASE
damage I_DISEASE
. O

These O
brain O
substrates O
may O
help O
account O
for O
the O
symptoms O
of O
MA O
abuse O
, O
providing O
therapeutic O
targets O
for O
drug O
- O
induced O
brain B_DISEASE_ADJECTIVE[DISEASE]
injury I_DISEASE_ADJECTIVE[DISEASE]
. O

disruption B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
hepatic B_DISEASE/B_GENE
lipid I_DISEASE/I_GENE
homeostasis I_DISEASE/I_GENE
in O
mice B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
after O
amiodarone B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
is O
associated O
with O
peroxisome B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
proliferator I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- O
activated O
receptor B_GENE
- O
alpha B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
target I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
gene I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
activation I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Amiodarone O
, O
an O
efficacious O
and O
widely O
used O
antiarrhythmic O
agent O
, O
has O
been O
reported O
to O
cause O
hepatotoxicity B_DISEASE
in O
some O
patients O
. O

To O
gain O
insight B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
into O
the O
mechanism B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
of O
this O
unwanted B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
effect I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
, O
mice B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
administered O
various B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
doses I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
of O
amiodarone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
examined O
for O
changes B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
hepatic B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
histology I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O
gene B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
regulation I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Amiodarone O
induced O
hepatomegaly B_DISEASE
, O
hepatocyte O
microvesicular O
lipid O
accumulation O
, O
and O
a O
significant O
decrease O
in O
serum O
triglycerides O
and O
glucose O
. O

Northern B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
blot I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
hepatic B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
RNA I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
revealed O
a O
dose B_MEASURE
- O
dependent B_DISEASE_ADJECTIVE[DISEASE]
increase I_DISEASE_ADJECTIVE[DISEASE]
in O
the O
expression B_GENE
of O
a O
number B_MEASURE/B_LOCATION
of O
genes B_GENE/B_LOCATION
critical I_GENE/I_LOCATION
for O
fatty B_DISEASE_ADJECTIVE[DISEASE]/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
acid B_DISEASE_ADJECTIVE[DISEASE]/I_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
oxidation B_DISEASE_ADJECTIVE[DISEASE]/I_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
, O
lipoprotein B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]/B_DISEASE_ADJECTIVE[DISEASE]
assembly I_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]/I_DISEASE_ADJECTIVE[DISEASE]
, O
and O
lipid B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]/B_DISEASE_ADJECTIVE[DISEASE]
transport I_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Many B_NUMBER[MEASURE]/B_PERSON
of O
these O
genes B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
are O
regulated O
by O
the O
peroxisome B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
proliferator I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- O
activated O
receptor B_GENE
- O
alpha B_PROTEIN[GENE]
( O
PPARalpha B_GENE
) O
, O
a O
ligand B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
activated O
nuclear B_GENE
hormone I_GENE
receptor I_GENE
transcription I_GENE
factor I_GENE
. O

The O
absence O
of O
induction O
of O
these O
genes O
as O
well O
as O
hepatomegaly B_DISEASE/B_GENE
in O
PPARalpha O
knockout O
[ O
PPARalpha O
- O
/ O
- O
] O
mice O
indicated O
that O
the O
effects O
of O
amiodarone O
were O
dependent O
upon O
the O
presence O
of O
a O
functional O
PPARalpha O
gene O
. O

Compared O
to O
wild O
- O
type O
mice O
, O
treatment O
of O
PPARalpha O
- O
/ O
- O
mice O
with O
amiodarone O
resulted O
in O
an O
increased O
rate O
and O
extent O
of O
total O
body O
weight B_DISEASE
loss I_DISEASE
. O

The O
inability O
of O
amiodarone O
to O
directly O
activate O
either O
human O
or O
mouse O
PPARalpha O
transiently O
expressed O
in O
human O
HepG2 O
hepatoma B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
cells O
indicates O
that O
the O
effects O
of O
amiodarone O
on O
the O
function O
of O
this O
receptor O
were O
indirect O
. O

Based O
upon O
these O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
we O
conclude O
that O
amiodarone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
disrupts O
hepatic B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
lipid B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
homeostasis B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
and O
that O
the O
increased O
expression B_GENE
of O
PPARalpha B_GENE
target I_GENE
genes I_GENE
is O
secondary B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
this O
toxic B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effect I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

These O
results O
provide O
important O
new O
mechanistic O
information O
regarding O
the O
hepatotoxic B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects O
of O
amiodarone O
and O
indicate O
that O
PPARalpha O
protects O
against O
amiodarone O
- O
induced O
hepatotoxicity B_DISEASE
. O

Safety B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O
compliance B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
with O
once O
- O
daily B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
niacin I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
extended I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
- O
release B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
/ O
lovastatin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
as O
initial B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
Impact B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
Medical B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
Subspecialty I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
on O
Patient B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
compliance I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
to O
Treatment B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
( O
Impact B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
) O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Niacin O
extended O
- O
release O
/ O
lovastatin O
is O
a O
new O
combination O
product O
approved O
for O
treatment O
of O
primary O
hypercholesterolemia B_DISEASE
and O
mixed O
dyslipidemia B_DISEASE
. O

This O
open B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
labeled O
, O
multicenter B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
evaluated O
the O
safety B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O
bedtime B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
niacin I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
extended O
- O
release B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
/ O
lovastatin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
when O
dosed O
as O
initial B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
therapy I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
patient B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
compliance I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
to O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
in O
various B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
clinical I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
practice I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
settings I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
. O

A O
total O
of O
4 O
, O
499 O
patients O
with O
dyslipidemia B_DISEASE
requiring O
drug O
intervention O
was O
enrolled O
at O
1 O
, O
081 O
sites O
. O

patients B_PERSON
were O
treated O
with O
1 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tablet I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
500 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
mg B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
niacin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
extended O
- O
release B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
20 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mg I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
lovastatin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
once O
nightly O
for O
4 B_TIME[MEASURE]/B_ENT
weeks I_TIME[MEASURE]/I_ENT
and O
then O
2 B_TIME[MEASURE]/B_LOCATION
tablets I_TIME[MEASURE]/I_LOCATION
for O
8 B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_TIME[MEASURE]
weeks I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_TIME[MEASURE]
. O

patients O
also O
received O
dietary O
counseling O
, O
educational O
materials O
, O
and O
reminders O
to O
call O
a O
toll O
- O
free O
number O
that O
provided O
further O
education O
about O
dyslipidemia B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
niacin O
extended O
- O
release O
/ O
lovastatin O
. O

Primary O
end O
points O
were O
study O
compliance O
, O
increases O
in O
liver O
transaminases O
to O
> O
3 O
times O
the O
upper O
limit O
of O
normal O
, O
and O
clinical O
myopathy B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Final B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
status I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
available B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
for O
4 B_MEASURE
, O
217 B_MEASURE
patients I_MEASURE
( O
94 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
. O

compliance B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
niacin O
extended O
- O
release B_ENT/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
lovastatin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
was O
77 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
% I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
with O
3 B_MEASURE
, O
245 B_MEASURE
patients I_MEASURE
completing O
the O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

patients B_PERSON/B_LOCATION
in O
the O
southeast B_LOCATION/B_ORGANIZATION
and O
those O
enrolled O
by O
endocrinologists B_LOCATION/B_ORGANIZATION
had O
the O
lowest B_MEASURE
compliance I_MEASURE
and O
highest B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
adverse B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
event B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
rates B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Flushing B_DISEASE
was O
the O
most O
common O
adverse O
event O
, O
reported O
by O
18 O
% O
of O
patients O
and O
leading O
to O
discontinuation O
by O
6 O
% O
. O

incidence B_MEASURE/B_LOCATION
of O
increased O
aspartate B_ENZYME[GENE]
aminotransferase I_ENZYME[GENE]
and O
/ O
or O
alanine B_ENZYME[GENE]
aminotransferase I_ENZYME[GENE]
> O
3 B_TIME[MEASURE]/B_LOCATION
times B_TIME[MEASURE]/I_LOCATION
the O
upper B_MEASURE
limit I_MEASURE
of O
normal B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
< B_MEASURE
0 I_MEASURE
. O
3 B_MEASURE
% I_MEASURE
. O

An O
increase O
of O
creatine O
phosphokinase O
to O
> O
5 O
times O
the O
upper O
limit O
of O
normal O
occurred O
in O
0 O
. O
24 O
% O
of O
patients O
, O
and O
no O
cases O
of O
drug O
- O
induced O
myopathy B_DISEASE
were O
observed O
. O

Niacin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
extended O
- O
release B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
/ O
lovastatin B_MEASURE
1 I_MEASURE
, O
000 B_MEASURE
/ O
40 B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mg I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
dosed O
as O
initial B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
therapy I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
was O
associated O
with O
good B_DISEASE_ADJECTIVE[DISEASE]
compliance I_DISEASE_ADJECTIVE[DISEASE]
and O
safety B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
and O
had O
very O
low B_DISEASE_ADJECTIVE[DISEASE]
incidences I_DISEASE_ADJECTIVE[DISEASE]
of O
increased O
liver B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
and O
muscle B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
enzymes I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
. O

protective O
effect O
of O
Terminalia O
chebula O
against O
experimental O
myocardial B_DISEASE
injury I_DISEASE
induced O
by O
isoproterenol O
. O

Cardioprotective O
effect O
of O
ethanolic O
extract O
of O
Terminalia O
chebula O
fruits O
( O
500 O
mg O
/ O
kg O
body O
wt O
) O
was O
examined O
in O
isoproterenol O
( O
200 O
mg O
/ O
kg O
body O
wt O
) O
induced O
myocardial B_DISEASE
damage I_DISEASE
in O
rats O
. O

In O
isoproterenol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
administered O
rats B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
the O
level B_MEASURE
of O
lipid B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
peroxides I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
increased O
significantly O
in O
the O
serum B_BODY_PART_OR_ORGAN_COMPONENT/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
heart B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
. O

A O
significant B_MEASURE
decrease I_MEASURE
was O
observed O
in O
the O
activity B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
the O
myocardial B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
marker I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
enzymes I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
with O
a O
concomitant B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
increase I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
their O
activity B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
in O
serum B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
. O

Histopathological O
examination O
was O
carried O
out O
to O
confirm O
the O
myocardial O
necrosis B_DISEASE
. O

T B_OTHER/B_PROTEIN[GENE]
. O
chebula B_DISEASE_ADJECTIVE[DISEASE]/B_SPECIES[BIO]
extract B_DISEASE_ADJECTIVE[DISEASE]/I_SPECIES[BIO]
pretreatment B_DISEASE_ADJECTIVE[DISEASE]/I_SPECIES[BIO]
was O
found O
to O
ameliorate O
the O
effect B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O
isoproterenol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
on O
lipid B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
peroxide B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
formation B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O
retained O
the O
activities B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
the O
diagnostic B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
marker I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
enzymes I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

A O
case O
of O
postoperative O
anxiety B_DISEASE
due O
to O
low O
dose O
droperidol O
used O
with O
patient O
- O
controlled O
analgesia O
. O

A O
multiparous B_PERSON
woman I_PERSON
in O
good B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
psychological I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
health I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
underwent I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
urgent I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
caesarean I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
section I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
in O
labour B_PERSON/B_LOCATION
. O

Postoperatively O
, O
she O
was O
given O
a O
patient B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
controlled O
analgesia B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
device I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
delivering O
boluses B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O
diamorphine B_MEASURE
0 I_MEASURE
. O
5 B_MEASURE
mg I_MEASURE
and O
droperidol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
0 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O
025 B_MEASURE
mg I_MEASURE
. O

whilst B_NUMBER[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
using O
the O
device B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
she O
gradually O
became O
anxious B_DISEASE_ADJECTIVE[DISEASE]
, O
the O
feeling B_PERSON/B_DISEASE
worsening O
after O
each O
bolus B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
. O

The O
diagnosis O
of O
droperidol O
- O
induced O
psychological B_DISEASE
disturbance I_DISEASE
was O
not O
made O
straight O
away O
although O
on O
subsequent O
close O
questioning O
the O
patient O
gave O
a O
very O
clear O
history O
. O

After O
she O
had O
received O
a O
total B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
only O
0 B_MEASURE
. O
9 B_MEASURE
mg I_MEASURE
droperidol I_MEASURE
, O
a O
syringe B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
containing O
diamorphine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
only O
was O
substituted O
and O
her O
unease B_DISEASE
resolved O
completely O
. O

We O
feel O
that O
, O
although O
the O
dramatic B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
extrapyramidal I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
side I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
effects I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
dopaminergic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antiemetics I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
well O
known O
, O
more O
subtle B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
manifestations I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
may O
easily O
be O
overlooked O
. O

accurate O
patient O
history O
contributes O
to O
differentiating O
diabetes B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
insipidus B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
a O
case O
study O
. O

This O
case B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
highlights O
the O
important B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
contribution I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
nursing B_PERSON
in O
obtaining O
an O
accurate B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
health I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
history I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O

The O
case O
discussed O
herein O
initially O
appeared O
to O
be O
neurogenic B_DISEASE
diabetes I_DISEASE
insipidus I_DISEASE
( O
DI B_DISEASE/B_PROTEIN[GENE]
) O
secondary O
to O
a O
traumatic B_DISEASE
brain I_DISEASE
injury I_DISEASE
. O

The O
nursing O
staff O
, O
by O
reviewing O
the O
patient O
' O
s O
health O
history O
with O
his O
family O
, O
discovered O
a O
history O
of O
polydipsia B_DISEASE_ADJECTIVE[DISEASE]
and O
long O
- O
standing O
lithium O
use O
. O

Lithium O
is O
implicated O
in O
drug O
- O
induced O
nephrogenic B_DISEASE
DI I_DISEASE
, O
and O
because O
the O
patient O
had O
not O
received O
lithium O
since O
being O
admitted O
to O
the O
hospital O
, O
his O
treatment O
changed O
to O
focus O
on O
nephrogenic B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
DI B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

By O
combining O
information O
from O
the O
patient O
history O
, O
the O
physical O
examination O
, O
and O
radiologic O
and O
laboratory O
studies O
, O
the O
critical O
care O
team O
demonstrated O
that O
the O
patient O
had O
been O
self O
- O
treating O
his O
lithium O
- O
induced O
nephrogenic B_DISEASE
DI I_DISEASE
and O
developed O
neurogenic B_DISEASE
DI I_DISEASE
secondary O
to O
brain B_DISEASE
trauma I_DISEASE
. O

Thus O
successful O
treatment O
required O
that O
nephrogenic O
and O
neurogenic B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
DI I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
be O
treated O
concomitantly O
. O

factors O
contributing O
to O
ribavirin O
- O
induced O
anemia B_DISEASE
. O

Background O
AND O
aim O
: O
Interferon O
and O
ribavirin O
combination O
therapy O
for O
chronic B_DISEASE
hepatitis I_DISEASE
C I_DISEASE
produces O
hemolytic B_DISEASE_ADJECTIVE[DISEASE]
anemia I_DISEASE_ADJECTIVE[DISEASE]
. O

This O
study O
was O
conducted O
to O
identify O
the O
factors O
contributing O
to O
ribavirin O
- O
induced O
anemia B_DISEASE
. O

methods O
: O
eighty O
- O
eight O
patients O
with O
chronic B_DISEASE/B_LOCATION
hepatitis I_DISEASE/I_LOCATION
C I_DISEASE/I_LOCATION
who O
received O
interferon O
- O
alpha O
- O
2b O
at O
a O
dose O
of O
6 O
Mu O
administered O
intramuscularly O
for O
24 O
weeks O
in O
combination O
with O
ribavirin O
administered O
orally O
at O
a O
dose O
of O
600 O
mg O
or O
800 O
mg O
participated O
in O
the O
study O
. O

A O
hemoglobin O
concentration O
of O
< O
10 O
g O
/ O
DL O
was O
defined O
as O
ribavirin O
- O
induced O
anemia B_DISEASE
. O

Results O
: O
Ribavirin O
- O
induced O
anemia B_DISEASE
occurred O
in O
18 O
( O
20 O
. O
5 O
% O
) O
patients O
during O
treatment O
. O

A O
2 O
g O
/ O
DL O
decrease O
in O
hemoglobin O
concentrations O
in O
patients O
with O
anemia B_DISEASE
was O
observed O
at O
week O
2 O
after O
the O
start O
of O
treatment O
. O

The O
hemoglobin B_MEASURE
concentration I_MEASURE
in O
patients B_PERSON/B_BIO
with O
> B_MEASURE
or O
= O
2 B_MEASURE/B_PROTEIN[GENE]
g I_MEASURE/I_PROTEIN[GENE]
/ O
dL B_MEASURE
decrease I_MEASURE
at O
week B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
2 I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
was O
observed O
to O
be O
significantly O
lower B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
even O
after O
week B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
2 I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
than O
in O
patients B_PERSON
with O
< B_MEASURE/B_LOCATION
2 I_MEASURE/I_LOCATION
g I_MEASURE/I_LOCATION
/ O
DL B_MEASURE/B_LOCATION
decrease B_MEASURE/I_LOCATION
( O
P B_MEASURE/B_PROTEIN[GENE]
< O
0 B_MEASURE
. O
01 B_MEASURE
) O
. O

A O
significant O
relationship O
was O
observed O
between O
the O
rate O
of O
reduction O
of O
hemoglobin O
concentrations O
at O
week O
2 O
and O
the O
severity O
of O
anemia B_DISEASE
( O
P O
< O
0 O
. O
01 O
) O
. O

Such B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
factors I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
as O
sex B_PERSON/B_MEASURE
( O
female B_PERSON/B_MEASURE
) O
, O
age B_TIME[MEASURE]/B_PERSON
( O
> B_OTHER/B_MEASURE
or O
= O
60 B_MEASURE/B_ENT
years I_MEASURE/I_ENT
old I_MEASURE/I_ENT
) O
, O
and O
the O
ribavirin B_MEASURE/B_PERSON
dose I_MEASURE/I_PERSON
by O
body B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
weight I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
12 B_MEASURE
mg I_MEASURE
/ O
kg B_MEASURE
or O
more B_MEASURE
) O
were O
significant B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O
univariate B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

CONCLUSIONS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O
Careful B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
administration I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
is O
necessary B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
patients B_PERSON
> I_PERSON
or O
= O
60 B_MEASURE/B_ENT
years I_MEASURE/I_ENT
old I_MEASURE/I_ENT
, O
in O
female B_PERSON/B_BIO
patients I_PERSON/I_BIO
, O
and O
in O
patients B_PERSON/B_BIO
receiving O
a O
ribavirin B_MEASURE
dose I_MEASURE
of O
12 B_MEASURE
mg I_MEASURE
/ O
kg B_MEASURE
or O
more B_MEASURE
. O

patients B_PERSON
who O
experience O
a O
fall B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O
hemoglobin B_MEASURE/B_DISEASE
concentrations I_MEASURE/I_DISEASE
of O
2 B_MEASURE/B_PROTEIN[GENE]
g I_MEASURE/I_PROTEIN[GENE]
/ O
dL B_TIME[MEASURE]/B_PROTEIN[GENE]
or O
more B_MEASURE
at O
week B_TIME[MEASURE]/B_LOCATION
2 I_TIME[MEASURE]/I_LOCATION
after O
the O
start B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
should O
be O
monitored O
with O
particular B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
care I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_PERSON
. O

Zidovudine O
- O
induced O
hepatitis B_DISEASE
. O

A O
case O
of O
acute O
hepatitis B_DISEASE
induced O
by O
zidovudine O
in O
a O
38 O
- O
year O
- O
old O
patient O
with O
AIDS B_DISEASE
is O
presented O
. O

The O
mechanism O
whereby O
the O
hepatitis B_DISEASE
was O
induced O
is O
not O
known O
. O

However O
, O
the O
patient B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tolerated O
well O
an O
alternative B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
reverse I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
transcriptase I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
inhibitor I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
2 B_NUMBER[MEASURE]
' O
3 B_MEASURE
' O
dideoxyinosine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O

Physicians O
caring O
for O
patients O
with O
AIDS B_DISEASE
should O
be O
aware O
of O
this O
hitherto O
rarely O
reported O
complication O
. O

Oxidative O
damage O
precedes O
nitrative O
damage O
in O
adriamycin O
- O
induced O
cardiac O
mitochondrial B_DISEASE
injury I_DISEASE
. O

The O
purpose O
of O
the O
present O
study O
was O
to O
determine O
if O
elevated O
reactive O
oxygen O
( O
ROS O
) O
/ O
nitrogen O
species O
( O
RNS O
) O
reported O
to O
be O
present O
in O
adriamycin O
( O
ADR O
) O
- O
induced O
cardiotoxicity B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
actually O
resulted O
in O
cardiomyocyte O
oxidative O
/ O
nitrative O
damage O
, O
and O
to O
quantitatively O
determine O
the O
time O
course O
and O
subcellular O
localization O
of O
these O
postulated O
damage O
products O
using O
an O
in O
vivo O
approach O
. O

B6C3 B_PERSON
mice I_PERSON
were O
treated O
with O
a O
single B_MEASURE
dose I_MEASURE
of O
20 B_MEASURE
mg I_MEASURE
/ O
kg B_MEASURE
ADR I_MEASURE
. O

ultrastructural B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
damage I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
levels B_LOCATION/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
4 B_NUMBER[MEASURE]
- O
hydroxy B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
2 B_MEASURE
- O
nonenal B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
4HNE B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
- O
protein B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
adducts B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
3 B_MEASURE
- O
nitrotyrosine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
3NT B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O
were O
analyzed O
. O

Quantitative B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
ultrastructural I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
damage I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
using O
computerized B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
image I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
techniques I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
showed O
cardiomyocyte B_DISEASE_ADJECTIVE[DISEASE]
injury I_DISEASE_ADJECTIVE[DISEASE]
as O
early O
as O
3 B_MEASURE/B_ENT
hours I_MEASURE/I_ENT
, O
with O
mitochondria B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
being O
the O
most O
extensively O
and O
progressively O
injured B_DISEASE_ADJECTIVE[DISEASE]
subcellular I_DISEASE_ADJECTIVE[DISEASE]
organelle I_DISEASE_ADJECTIVE[DISEASE]
. O

Analysis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
4HNE B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
protein I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
adducts I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O
immunogold B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
electron I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
microscopy I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
showed O
appearance B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O
4HNE B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
protein I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
adducts I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
mitochondria B_BODY_PART_OR_ORGAN_COMPONENT
as O
early O
as O
3 B_MEASURE/B_ENT
hours I_MEASURE/I_ENT
, O
with O
a O
peak B_MEASURE
at O
6 B_TIME[MEASURE]/B_SPORT[ENT]
hours I_TIME[MEASURE]/I_SPORT[ENT]
and O
subsequent B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
decline I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
at O
24 B_TIME[MEASURE]/B_SPORT[ENT]
hours I_TIME[MEASURE]/I_SPORT[ENT]
. O

3NT B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
levels I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
were O
significantly O
increased O
in O
all O
subcellular B_PERSON/B_BIO
compartments I_PERSON/I_BIO
at O
6 B_TIME[MEASURE]/B_SPORT[ENT]
hours I_TIME[MEASURE]/I_SPORT[ENT]
and O
subsequently O
declined O
at O
24 B_TIME[MEASURE]/B_SPORT[ENT]
hours I_TIME[MEASURE]/I_SPORT[ENT]
. O

Our O
data O
showed O
ADR O
induced O
4HNE O
- O
protein O
adducts O
in O
mitochondria O
at O
the O
same O
time O
point O
as O
when O
mitochondrial B_DISEASE
injury I_DISEASE
initially O
appeared O
. O

These O
results O
document O
for O
the O
first O
time O
in O
vivo O
that O
mitochondrial B_DISEASE/B_GENE
oxidative I_DISEASE/I_GENE
damage I_DISEASE/I_GENE
precedes O
nitrative O
damage O
. O

The O
progressive O
nature O
of O
mitochondrial B_DISEASE_ADJECTIVE[DISEASE]
injury I_DISEASE_ADJECTIVE[DISEASE]
suggests O
that O
mitochondria O
, O
not O
other O
subcellular O
organelles O
, O
are O
the O
major O
site O
of O
intracellular O
injury O
. O

Sotalol O
- O
induced O
coronary B_DISEASE
spasm I_DISEASE
in O
a O
patient O
with O
dilated B_DISEASE/B_GENE
cardiomyopathy I_DISEASE/I_GENE
associated O
with O
sustained O
ventricular B_DISEASE
tachycardia I_DISEASE
. O

A O
54 O
- O
year O
- O
old O
man O
with O
severe O
left O
ventricular B_DISEASE/B_LOCATION
dysfunction I_DISEASE/I_LOCATION
due O
to O
dilated B_DISEASE
cardiomyopathy I_DISEASE
was O
referred O
to O
our O
hospital O
for O
symptomatic O
incessant O
sustained O
ventricular B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
tachycardia I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O
VT B_DISEASE/B_PROTEIN[GENE]
) O
. O

After O
the O
administration O
of O
nifekalant O
hydrochloride O
, O
sustained O
VT B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O
terminated O
. O

An O
alternate O
class O
III O
agent O
, O
sotalol O
, O
was O
also O
effective O
for O
the O
prevention O
of O
VT B_DISEASE
. O

However O
, O
one B_TIME[MEASURE]/B_LOCATION
month I_TIME[MEASURE]/I_LOCATION
after O
switching O
over O
nifekalant B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
sotalol O
, O
a O
short B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
duration B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
ST B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
elevation B_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O
documented O
in O
ECG B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
monitoring I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
at O
almost O
the O
same B_TIME[MEASURE]/B_LOCATION
time B_TIME[MEASURE]/I_LOCATION
for O
three B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
consecutive I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
days I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
. O

ST B_DISEASE/B_LOCATION
elevation I_DISEASE/I_LOCATION
with O
chest B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
discomfort B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
disappeared O
since O
he O
began O
taking O
long O
- O
acting O
diltiazem B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Coronary B_DISEASE_ADJECTIVE[DISEASE]
vasospasm I_DISEASE_ADJECTIVE[DISEASE]
may O
be O
induced O
by O
the O
non O
- O
selective O
beta O
- O
blocking O
properties O
of O
sotalol O
. O

Effects B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
antidepressant B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
trazodone I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
a O
5 B_NUMBER[MEASURE]
- O
HT B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
2A I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
/ O
2C B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
receptor I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
antagonist I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
on O
dopamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
dependent B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL_FUNCTION[ORGANISM_FUNCTION]
behaviors B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL_FUNCTION[ORGANISM_FUNCTION]
in O
rats B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

rationale B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
: O
5 B_MEASURE
- O
hydroxytryptamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
, O
via O
stimulation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
5 B_NUMBER[MEASURE]
- O
HT B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
2C I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
receptors I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
exerts O
a O
tonic B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
inhibitory I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
influence I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
on O
dopaminergic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
neurotransmission I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
whereas O
activation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
of O
5 B_NUMBER[MEASURE]
- O
HT B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
2A I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
receptors I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
enhances O
stimulated O
DAergic B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
neurotransmission B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

The O
antidepressant B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
trazodone I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
is O
a O
5 B_NUMBER[MEASURE]
- O
HT B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
2A I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
/ O
2C B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
receptor I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
antagonist I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

objectives B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
To O
evaluate O
the O
effect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
trazodone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treatment I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
behaviors B_PERSON/B_DISEASE
dependent B_PERSON/I_DISEASE
on O
the O
functional B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
status I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
nigrostriatal B_PERSON/B_BIO
DAergic I_PERSON/I_BIO
system I_PERSON/I_BIO
. O

methods O
: O
The O
effect O
of O
pretreatment O
with O
trazodone O
on O
dexamphetamine O
- O
and O
apomorphine O
- O
induced O
oral B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stereotypies I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
on O
catalepsy B_DISEASE
induced O
by O
haloperidol O
and O
apomorphine O
( O
0 O
. O
05 O
mg O
/ O
kg O
, O
i O
. O
p O
. O
) O
, O
on O
ergometrine O
- O
induced O
wet O
dog O
shake O
( O
WDS O
) O
behavior O
and O
fluoxetine O
- O
induced O
penile O
erections O
was O
studied O
in O
rats O
. O

We O
also O
investigated O
whether O
trazodone O
induces O
catalepsy B_DISEASE
in O
rats O
. O

Results O
: O
Trazodone O
at O
2 O
. O
5 O
- O
20 O
mg O
/ O
kg O
i O
. O
p O
. O
did O
not O
induce O
catalepsy B_DISEASE
, O
and O
did O
not O
antagonize O
apomorphine O
( O
1 O
. O
5 O
and O
3 O
mg O
/ O
kg O
) O
stereotypy O
and O
apomorphine O
( O
0 O
. O
05 O
mg O
/ O
kg O
) O
- O
induced O
catalepsy B_DISEASE
. O

However O
, O
pretreatment O
with O
5 O
, O
10 O
and O
20 O
mg O
/ O
kg O
i O
. O
p O
. O
trazodone O
enhanced O
dexamphetamine O
stereotypy O
, O
and O
antagonized O
haloperidol O
catalepsy B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
ergometrine O
- O
induced O
WDS O
behavior O
and O
fluoxetine O
- O
induced O
penile O
erections O
. O

Trazodone O
at O
30 O
, O
40 O
and O
50 O
mg O
/ O
kg O
i O
. O
p O
. O
induced O
catalepsy B_DISEASE
and O
antagonized O
apomorphine O
and O
dexamphetamine O
stereotypies O
. O

CONCLUSIONS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O
Our O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
indicate O
that O
trazodone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O
2 B_MEASURE
. O
5 B_MEASURE
- O
20 B_MEASURE
mg I_MEASURE
/ O
kg B_MEASURE
does O
not O
block O
pre B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
and O
postsynaptic B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
striatal I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
D2 I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
DA I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
receptors I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
, O
while O
at O
30 B_MEASURE
, O
40 B_MEASURE
and O
50 B_MEASURE
mg I_MEASURE
/ O
kg B_MEASURE
it O
blocks O
postsynaptic B_DISEASE/B_BIO
striatal I_DISEASE/I_BIO
D2 I_DISEASE/I_BIO
DA I_DISEASE/I_BIO
receptors I_DISEASE/I_BIO
. O

Furthermore O
, O
at O
5 B_TIME[MEASURE]
, O
10 B_MEASURE
and O
20 B_MEASURE
mg I_MEASURE
/ O
kg B_TIME[MEASURE]
, O
trazodone B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
blocks I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
5 I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
HT B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
2A I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
5 B_MEASURE
- O
HT B_LOCATION/B_PERSON
2C I_LOCATION/I_PERSON
receptors I_LOCATION/I_PERSON
. O

We O
suggest O
that O
trazodone O
( O
5 O
, O
10 O
and O
20 O
mg O
/ O
kg O
) O
, O
by O
blocking O
the O
5 O
- O
HT O
2C O
receptors O
, O
releases O
the O
nigrostriatal O
DAergic O
neurons O
from O
tonic O
inhibition O
caused O
by O
5 O
- O
HT O
, O
and O
thereby O
potentiates O
dexamphetamine O
stereotypy O
and O
antagonizes O
haloperidol O
catalepsy B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Swallowing B_DISEASE
abnormalities I_DISEASE
and O
dyskinesia B_DISEASE
in O
Parkinson B_DISEASE/B_PERSON
' B_DISEASE/I_PERSON
s B_DISEASE/I_PERSON
disease B_DISEASE/I_PERSON
. O

Gastrointestinal B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
abnormalities I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
in O
Parkinson B_DISEASE
' I_DISEASE
s I_DISEASE
disease I_DISEASE
( O
PD B_DISEASE/B_PROTEIN[GENE]
) O
have O
been O
known O
for O
almost O
two O
centuries O
, O
but O
many O
aspects O
concerning O
their O
pathophysiology O
have O
not O
been O
completely O
clarified O
. O

The O
aim O
of O
this O
study O
was O
to O
characterize O
the O
oropharyngeal O
dynamics O
in O
PD B_DISEASE/B_LOCATION
patients O
with O
and O
without O
levodopa O
- O
induced O
dyskinesia B_DISEASE
. O

Fifteen O
dyskinetic B_PERSON
, O
12 O
nondyskinetic O
patients O
, O
and O
a O
control O
group O
were O
included O
. O

patients O
were O
asked O
about O
dysphagia B_DISEASE
and O
evaluated O
with O
the O
Unified O
Parkinson B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
' I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
s I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
Disease I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
rating O
Scale O
Parts O
II O
and O
III O
and O
the O
Hoehn O
and O
Yahr O
scale O
. O

Deglutition B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
assessed O
using O
modified O
barium B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
swallow I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
with O
videofluoroscopy B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O

Nondyskinetic O
patients O
, O
but O
not O
the O
dyskinetic B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
ones O
, O
showed O
less O
oropharyngeal O
swallowing O
efficiency O
( O
OPSE O
) O
for O
liquid O
food O
than O
controls O
( O
Dunnett O
, O
P O
= O
0 O
. O
02 O
) O
. O

Dyskinetic B_MEASURE/B_PERSON
patients O
tended O
to O
have O
a O
greater O
OPSE O
than O
nondyskinetic O
( O
Dunnett O
, O
P O
= O
0 O
. O
06 O
) O
. O

patients B_PERSON
who O
were O
using O
a O
higher B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
dose I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
levodopa B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
had O
a O
greater B_MEASURE
OPSE I_MEASURE
and O
a O
trend B_MEASURE/B_LOCATION
toward O
a O
smaller B_MEASURE
oral I_MEASURE
transit I_MEASURE
time I_MEASURE
( O
Pearson B_LOCATION/B_PERSON
' B_LOCATION/I_PERSON
s O
correlation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
P B_PROTEIN[GENE]/B_DISEASE
= O
0 B_MEASURE
. O
01 B_MEASURE
and O
0 B_MEASURE
. O
08 B_MEASURE
, O
respectively O
) O
. O

Neither O
the O
report O
of O
dysphagia B_DISEASE
nor O
any O
of O
the O
PD B_DISEASE
severity O
parameters O
correlated O
to O
the O
videofluoroscopic O
variables O
. O

In O
the O
current O
study O
, O
dyskinetic B_NUMBER[MEASURE]/B_PERSON
patients O
performed O
better O
in O
swallowing O
function O
, O
which O
could O
be O
explained O
on O
the O
basis O
of O
a O
greater O
levodopa O
dose O
. O

Our O
results O
suggest O
a O
role O
for O
levodopa O
in O
the O
oral O
phase O
of O
deglutition O
and O
confirm O
that O
dysphagia B_DISEASE
is O
not O
a O
good O
predictor O
of O
deglutition O
alterations O
in O
PD B_DISEASE/B_LOCATION
. O

Inhibition O
of O
nuclear O
factor O
- O
kappaB O
activation O
attenuates O
tubulointerstitial B_DISEASE/B_GENE
nephritis I_DISEASE/I_GENE
induced O
by O
gentamicin O
. O

Background O
: O
Animals O
treated O
with O
gentamicin O
can O
show O
residual O
areas O
of O
interstitial O
fibrosis B_DISEASE
in O
the O
renal O
cortex O
. O

This O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
investigated O
the O
expression B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
of O
nuclear B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
factor I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- O
kappaB B_PROTEIN[GENE]/B_MEASURE
( O
NF B_DISEASE/B_PROTEIN[GENE]
- O
kappaB B_GENE
) O
, O
mitogen B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
activated O
protein B_GENE/B_BACTERIUM[BIO]
( O
MAP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
) O
kinases B_GENE/B_LOCATION
and O
macrophages B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
in O
the O
renal B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
cortex I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
and O
structural B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
and O
functional B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
renal I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
changes I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
rats B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treated O
with O
gentamicin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O
gentamicin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
+ I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pyrrolidine I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dithiocarbamate I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
PDTC B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
, O
an O
NF B_DISEASE/B_PROTEIN[GENE]
- O
kappaB B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
inhibitor I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

METHODS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O
38 B_MEASURE
female I_MEASURE
Wistar I_MEASURE
rats I_MEASURE
were O
injected O
with O
gentamicin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
40 B_MEASURE
mg I_MEASURE
/ O
kg B_MEASURE
, O
twice O
a O
day B_TIME[MEASURE]
for O
9 B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
days B_TIME[MEASURE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
38 B_MEASURE
with O
gentamicin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
+ O
PDTC B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
28 B_MEASURE
with O
0 B_MEASURE
. O
15 B_MEASURE
M I_MEASURE
NaCl I_MEASURE
solution I_MEASURE
. O

The O
animals B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
killed O
5 B_MEASURE
and O
30 B_MEASURE/B_ENT
days I_MEASURE/I_ENT
after O
these O
injections B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
and O
the O
kidneys B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
were O
removed O
for O
histological B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
immunohistochemical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
studies I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
the O
immunohistochemical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
studies I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
scored O
according O
to O
the O
extent B_MEASURE
of O
staining O
. O

The O
fractional B_MEASURE/B_LOCATION
interstitial B_MEASURE/I_LOCATION
area B_MEASURE/I_LOCATION
was O
determined O
by O
morphometry B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

RESULTS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O
gentamicin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
treated O
rats B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
presented O
a O
transitory B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
increase I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O
plasma B_DISEASE/B_MEASURE
creatinine I_DISEASE/I_MEASURE
levels I_DISEASE/I_MEASURE
. O

increased O
ED B_GENE/B_DISEASE
- O
1 B_MEASURE/B_LOCATION
, O
MAP B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
kinases I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O
NF B_DISEASE/B_GENE
- O
kappaB B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
staining I_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
also O
observed O
in O
the O
renal B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
cortex I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
from O
all O
gentamicin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- O
treated O
rats B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
compared O
to O
control O
( O
p B_PROTEIN[GENE]/B_LOCATION
< O
0 B_MEASURE
. O
05 B_MEASURE
) O
. O

The O
animals O
killed O
on O
day O
30 O
also O
presented O
fibrosis B_DISEASE
in O
the O
renal O
cortex O
despite O
the O
recovery O
of O
renal O
function O
. O

Treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O
PDTC B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
reduced O
the O
functional B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O
structural B_DISEASE
changes I_DISEASE
induced O
by O
gentamicin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O

conclusions O
: O
These O
data O
show O
that O
inhibition O
of O
NF O
- O
kappaB O
activation O
attenuates O
tubulointerstitial B_DISEASE
nephritis I_DISEASE
induced O
by O
gentamicin O
. O

glucose O
metabolism O
in O
patients O
with O
schizophrenia B_DISEASE
treated O
with O
atypical O
antipsychotic O
agents O
: O
a O
frequently O
sampled O
intravenous O
glucose O
tolerance O
test O
and O
minimal O
model O
analysis O
. O

Background O
: O
While O
the O
incidence O
of O
new O
- O
onset O
diabetes B_DISEASE
mellitus I_DISEASE
may O
be O
increasing O
in O
patients O
with O
schizophrenia B_DISEASE/B_LOCATION
treated O
with O
certain O
atypical O
antipsychotic O
agents O
, O
it O
remains O
unclear O
whether O
atypical O
agents O
are O
directly O
affecting O
glucose O
metabolism O
or O
simply O
increasing O
known O
risk O
factors O
for O
diabetes B_DISEASE
. O

Objective B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
: O
To O
study O
the O
2 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
drugs I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
most O
clearly O
implicated O
( O
clozapine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
olanzapine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
and O
risperidone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
using O
a O
frequently O
sampled O
intravenous B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
glucose I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
tolerance I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
test I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

Design O
: O
A O
cross O
- O
sectional O
design O
in O
stable O
, O
treated O
patients O
with O
schizophrenia B_DISEASE/B_GENE
evaluated O
using O
a O
frequently O
sampled O
intravenous O
glucose O
tolerance O
test O
and O
the O
Bergman O
minimal O
model O
analysis O
. O

setting B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
: O
subjects B_PERSON
were O
recruited O
from O
an O
urban B_LOCATION/B_ORGANIZATION
community B_LOCATION/I_ORGANIZATION
mental B_LOCATION/I_ORGANIZATION
health B_LOCATION/I_ORGANIZATION
clinic B_LOCATION/I_ORGANIZATION
and O
were O
studied O
at O
a O
general B_LOCATION/B_MEASURE
clinical I_LOCATION/I_MEASURE
research I_LOCATION/I_MEASURE
center I_LOCATION/I_MEASURE
. O

patients B_PERSON
Fifty I_PERSON
subjects I_PERSON
signed O
informed B_MEASURE/B_LOCATION
consent I_MEASURE/I_LOCATION
and O
41 B_TIME[MEASURE]/B_LOCATION
underwent O
the O
frequently O
sampled O
intravenous B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
glucose I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tolerance I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
test I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Thirty O
- O
six O
nonobese O
subjects O
with O
schizophrenia B_DISEASE
or O
schizoaffective B_DISEASE
disorder I_DISEASE
, O
matched O
by O
body O
mass O
index O
and O
treated O
with O
either O
clozapine O
, O
olanzapine O
, O
or O
risperidone O
, O
were O
included O
in O
the O
analysis O
. O

Main O
outcome O
measures O
: O
Fasting O
plasma O
glucose O
and O
fasting O
serum O
insulin O
levels O
, O
insulin B_DISEASE/B_MEASURE
sensitivity I_DISEASE/I_MEASURE
index O
, O
homeostasis O
model O
assessment O
of O
insulin B_DISEASE/B_ORGANISM_FUNCTION
resistance I_DISEASE/I_ORGANISM_FUNCTION
, O
and O
glucose O
effectiveness O
. O

RESULTS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O
The O
mean B_MEASURE/B_LOCATION
+ I_MEASURE/I_LOCATION
/ O
- O
SD B_MEASURE
duration I_MEASURE
of O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O
the O
identified O
atypical B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antipsychotic I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
agent I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
68 B_MEASURE
. O
3 B_MEASURE
+ I_MEASURE
/ O
- O
28 B_MEASURE
. O
9 B_TIME[MEASURE]
months I_TIME[MEASURE]
( O
clozapine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
, O
29 B_MEASURE
. O
5 B_MEASURE
+ I_MEASURE
/ O
- O
17 B_MEASURE
. O
5 B_TIME[MEASURE]
months I_TIME[MEASURE]
( O
olanzapine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
, O
and O
40 B_MEASURE
. O
9 B_MEASURE
+ I_MEASURE
/ O
- O
33 B_MEASURE
. O
7 B_MEASURE
( O
risperidone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
. O

Fasting O
serum B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
insulin I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
concentrations I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
differed O
among O
groups B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
( O
F B_MEASURE/B_PROTEIN[GENE]
( O
33 B_MEASURE
) O
= O
3 B_MEASURE
. O
35 B_MEASURE
; O
P B_PROTEIN[GENE]/B_LOCATION
= O
. O
047 B_MEASURE
) O
( O
clozapine B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
> I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
olanzapine I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
> I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
risperidone I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
with O
significant B_MEASURE
differences I_MEASURE
between O
clozapine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
risperidone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
t B_PROTEIN[GENE]/B_DISEASE
( O
33 B_MEASURE
) O
= O
2 B_MEASURE
. O
32 B_MEASURE
; O
P B_PROTEIN[GENE]/B_LOCATION
= O
. O
03 B_MEASURE
) O
and O
olanzapine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
risperidone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
t B_PROTEIN[GENE]/B_DISEASE
( O
33 B_MEASURE
) O
= O
2 B_MEASURE
. O
15 B_MEASURE
; O
P B_PROTEIN[GENE]/B_LOCATION
= O
. O
04 B_MEASURE
) O
. O

There O
was O
a O
significant O
difference O
in O
insulin B_DISEASE/B_GENE
sensitivity I_DISEASE/I_GENE
index O
among O
groups O
( O
F O
( O
33 O
) O
= O
10 O
. O
66 O
; O
P O
< O
. O
001 O
) O
( O
clozapine O
< O
olanzapine O
< O
risperidone O
) O
, O
with O
subjects O
who O
received O
clozapine O
and O
olanzapine O
exhibiting O
significant O
insulin B_DISEASE_ADJECTIVE[DISEASE]
resistance I_DISEASE_ADJECTIVE[DISEASE]
compared O
with O
subjects O
who O
were O
treated O
with O
risperidone O
( O
clozapine O
vs O
risperidone O
, O
t O
( O
33 O
) O
= O
- O
4 O
. O
29 O
; O
P O
< O
. O
001 O
; O
olanzapine O
vs O
risperidone O
, O
t O
( O
33 O
) O
= O
- O
3 O
. O
62 O
; O
P O
= O
. O
001 O
[ O
P O
< O
. O
001 O
] O
) O
. O

The O
homeostasis O
model O
assessment O
of O
insulin B_DISEASE/B_GENE
resistance I_DISEASE/I_GENE
also O
differed O
significantly O
among O
groups O
( O
F O
( O
33 O
) O
= O
4 O
. O
92 O
; O
P O
= O
. O
01 O
) O
( O
clozapine O
> O
olanzapine O
> O
risperidone O
) O
( O
clozapine O
vs O
risperidone O
, O
t O
( O
33 O
) O
= O
2 O
. O
94 O
; O
P O
= O
. O
006 O
; O
olanzapine O
vs O
risperidone O
, O
t O
( O
33 O
) O
= O
2 O
. O
42 O
; O
P O
= O
. O
02 O
) O
. O

There O
was O
a O
significant B_MEASURE
difference I_MEASURE
among O
groups B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
in O
glucose B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
effectiveness I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
( O
F B_MEASURE/B_PROTEIN[GENE]
( O
30 B_MEASURE
) O
= O
4 B_MEASURE
. O
18 B_MEASURE
; O
P B_PROTEIN[GENE]/B_LOCATION
= O
. O
02 B_MEASURE
) O
( O
clozapine B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
< I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
olanzapine I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
< I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
risperidone I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
with O
significant B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
differences I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O
clozapine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
risperidone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
t O
( O
30 B_MEASURE
) O
= O
- O
2 B_MEASURE
. O
59 B_MEASURE
; O
P B_PROTEIN[GENE]/B_LOCATION
= O
. O
02 B_MEASURE
) O
and O
olanzapine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
risperidone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
t O
( O
30 B_MEASURE
) O
= O
- O
2 B_MEASURE
. O
34 B_MEASURE
, O
P B_PROTEIN[GENE]/B_LOCATION
= O
. O
03 B_MEASURE
) O
. O

conclusions O
: O
Both O
nonobese O
clozapine O
- O
and O
olanzapine O
- O
treated O
groups O
displayed O
significant O
insulin B_DISEASE_ADJECTIVE[DISEASE]
resistance I_DISEASE_ADJECTIVE[DISEASE]
and O
impairment O
of O
glucose O
effectiveness O
compared O
with O
risperidone O
- O
treated O
subjects O
. O

patients O
taking O
clozapine O
and O
olanzapine O
must O
be O
examined O
for O
insulin B_DISEASE
resistance I_DISEASE
and O
its O
consequences O
. O

Thoracic B_DISEASE
hematomyelia I_DISEASE
secondary O
to O
coumadin O
anticoagulant O
therapy O
: O
a O
case O
report O
. O

A O
case O
of O
thoracic B_DISEASE
hematomyelia I_DISEASE
secondary O
to O
anticoagulant O
therapy O
is O
presented O
. O

Clinical B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
features I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
, O
similar B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
2 B_NUMBER[MEASURE]/B_PERSON
other I_NUMBER[MEASURE]/I_PERSON
previously O
reported O
cases B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
are O
discussed O
. O

A O
high B_MEASURE/B_DISEASE
index I_MEASURE/I_DISEASE
of O
suspicion B_DISEASE/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
may O
lead O
to O
a O
quick B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
diagnostic I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
procedure I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
successful B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
decompressive I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
surgery I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Mania B_DISEASE
associated O
with O
fluoxetine O
treatment O
in O
adolescents O
. O

Fluoxetine O
, O
a O
selective O
serotonin O
reuptake O
inhibitor O
, O
is O
gaining O
increased O
acceptance O
in O
the O
treatment O
of O
adolescent O
depression B_DISEASE
. O

Generally O
safe O
and O
well O
tolerated O
by O
adults O
, O
fluoxetine O
has O
been O
reported O
to O
induce O
mania B_DISEASE
. O

The O
cases O
of O
five O
depressed B_TIME[MEASURE]/B_DISEASE
adolescents O
, O
14 O
- O
16 O
years O
of O
age O
, O
who O
developed O
mania B_DISEASE
during O
pharmacotherapy O
with O
fluoxetine O
, O
are O
reported O
here O
. O

apparent O
risk O
factors O
for O
the O
development O
of O
mania B_DISEASE
or O
hypomania B_DISEASE
during O
fluoxetine O
pharmacotherapy O
in O
this O
population O
were O
the O
combination O
of O
attention B_DISEASE
- I_DISEASE
deficit I_DISEASE
hyperactivity I_DISEASE
disorder I_DISEASE
and O
affective O
instability O
; O
major O
depression B_DISEASE
with O
psychotic B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
features O
; O
a O
family O
history O
of O
affective B_DISEASE
disorder I_DISEASE
, O
especially O
bipolar B_DISEASE/B_PERSON
disorder I_DISEASE/I_PERSON
; O
and O
a O
diagnosis O
of O
bipolar B_DISEASE
disorder I_DISEASE
. O

Further O
study O
is O
needed O
to O
determine O
the O
optimal O
dosage O
and O
to O
identify O
risk O
factors O
that O
increase O
individual O
vulnerability O
to O
fluoxetine O
induced O
mania B_DISEASE
in O
adolescents O
. O

Acute B_DISEASE_ADJECTIVE[DISEASE]
renal I_DISEASE_ADJECTIVE[DISEASE]
insufficiency I_DISEASE_ADJECTIVE[DISEASE]
after O
high O
- O
dose O
melphalan O
in O
patients O
with O
primary B_DISEASE
systemic I_DISEASE
amyloidosis I_DISEASE
during O
stem O
cell O
transplantation O
. O

Background O
: O
patients O
with O
primary B_DISEASE
systemic I_DISEASE
amyloidosis I_DISEASE
( O
AL B_LOCATION/B_PERSON
) O
have O
a O
poor O
prognosis O
. O

median B_TIME[MEASURE]/B_PERSON
survival I_TIME[MEASURE]/I_PERSON
time I_TIME[MEASURE]/I_PERSON
from O
standard B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
treatments I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
is O
only O
17 B_TIME[MEASURE]
months I_TIME[MEASURE]
. O

High B_MEASURE/B_PERSON
- O
dose B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
intravenous B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
melphalan B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
followed O
by O
peripheral B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
blood I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
stem O
cell B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
transplant I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O
PBSCT B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
appears O
to O
be O
the O
most O
promising B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
therapy B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
, O
but O
treatment B_DISEASE_ADJECTIVE[DISEASE]
mortality I_DISEASE_ADJECTIVE[DISEASE]
can O
be O
high B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
. O

The O
authors O
have O
noted O
the O
development O
of O
acute B_DISEASE
renal I_DISEASE
insufficiency I_DISEASE
immediately O
after O
melphalan O
conditioning O
. O

This O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
undertaken O
to O
further O
examine O
its O
risk B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factors I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
impact B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
posttransplant B_DISEASE
mortality I_DISEASE
. O

methods O
: O
consecutive O
AL B_DISEASE/B_LOCATION
patients O
who O
underwent O
PBSCT O
were O
studied O
retrospectively O
. O

Acute B_DISEASE_ADJECTIVE[DISEASE]
renal I_DISEASE_ADJECTIVE[DISEASE]
insufficiency I_DISEASE_ADJECTIVE[DISEASE]
( O
ARI B_PERSON/B_LOCATION
) O
after O
high O
- O
dose O
melphalan O
was O
defined O
by O
a O
minimum O
increase O
of O
0 O
. O
5 O
mg O
/ O
DL O
( O
44 O
micromol O
/ O
L O
) O
in O
the O
serum O
creatinine O
level O
that O
is O
greater O
than O
50 O
% O
of O
baseline O
immediately O
after O
conditioning O
. O

urine B_MEASURE/B_PERSON
sediment B_MEASURE/I_PERSON
score B_MEASURE/I_PERSON
was O
the O
sum B_MEASURE/B_PERSON
of O
the O
individual B_MEASURE
types I_MEASURE
of O
sediment B_BIO/B_DISEASE
identified O
on O
urine B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
microscopy I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Results O
: O
Of O
the O
80 O
patients O
studied O
, O
ARI B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
developed O
in O
18 O
. O
8 O
% O
of O
the O
patients O
after O
high O
- O
dose O
melphalan O
. O

Univariate O
analysis O
identified O
age O
, O
hypoalbuminemia B_DISEASE/B_PERSON
, O
heavy O
proteinuria B_DISEASE
, O
diuretic O
use O
, O
and O
urine O
sediment O
score O
( O
> O
3 O
) O
as O
risk O
factors O
. O

Age B_DISEASE/B_GENE
and O
urine B_DISEASE/B_MEASURE
sediment I_DISEASE/I_MEASURE
score I_DISEASE/I_MEASURE
remained O
independently O
significant B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
risk I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
factors I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O
the O
multivariate B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O

patients O
who O
had O
ARI B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
after O
high O
- O
dose O
melphalan O
underwent O
dialysis O
more O
often O
( O
P O
= O
0 O
. O
007 O
) O
, O
and O
had O
a O
worse O
1 O
- O
year O
survival O
( O
P O
= O
0 O
. O
03 O
) O
. O

conclusion O
: O
The O
timing O
of O
renal B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
injury B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
strongly O
suggests O
melphalan O
as O
the O
causative O
agent O
. O

ongoing O
tubular B_DISEASE
injury I_DISEASE
may O
be O
a O
prerequisite O
for O
renal B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
injury I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
by O
melphalan O
as O
evidenced O
by O
the O
active O
urinary O
sediment O
. O

Development O
of O
ARI B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
adversely O
affected O
the O
outcome O
after O
PBSCT O
. O

effective O
preventive O
measures O
may O
help O
decrease O
the O
treatment O
mortality O
of O
PBSCT O
in O
AL B_LOCATION/B_DISEASE
patients O
. O

focal O
cerebral B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
ischemia I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
rats O
: O
effect O
of O
phenylephrine O
- O
induced O
hypertension B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
during O
reperfusion O
. O

After O
180 O
min O
of O
temporary O
middle B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
cerebral B_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
artery B_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
occlusion B_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
spontaneously O
hypertensive B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
rats O
, O
the O
effect O
of O
phenylephrine O
- O
induced O
hypertension B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
on O
ischemic B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
brain B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
injury B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
and O
blood O
- O
brain O
barrier O
permeability O
was O
determined O
. O

Blood O
pressure O
was O
manipulated O
by O
one O
of O
the O
following O
schedules O
during O
120 O
min O
of O
reperfusion O
: O
Control O
, O
normotensive O
reperfusion O
; O
90 O
/ O
hypertension B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O
90 O
/ O
HTN B_LOCATION
) O
, O
blood O
pressure O
was O
increased O
by O
35 O
mm O
Hg O
during O
the O
initial O
90 O
min O
of O
reperfusion O
only O
; O
15 O
/ O
hypertension B_DISEASE/B_MEASURE
( O
15 O
/ O
HTN B_DISEASE/B_LOCATION
) O
, O
normotensive O
reperfusion O
for O
30 O
min O
followed O
by O
15 O
min O
of O
hypertension B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
75 O
min O
of O
normotension O
. O

Part O
A O
, O
for O
eight O
rats O
in O
each O
group O
brain B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
injury I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
was O
evaluated O
by O
staining O
tissue O
using O
2 O
, O
3 O
, O
5 O
- O
triphenyltetrazolium O
chloride O
and O
edema B_DISEASE
was O
evaluated O
by O
microgravimetry O
. O

Part B_MEASURE/B_LOCATION
B I_MEASURE/I_LOCATION
, O
for O
eight B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
different I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
rats I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
in O
each O
group B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
blood I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
brain B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
barrier I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
permeability I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O
evaluated O
by O
measuring O
the O
amount B_MEASURE/B_LOCATION
and O
extent B_MEASURE/B_LOCATION
of O
extravasation B_DISEASE/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
of O
Evans B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Blue I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dye I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Brain B_DISEASE/B_PERSON
injury I_DISEASE/I_PERSON
( O
percentage O
of O
the O
ischemic B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
hemisphere I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
) O
was O
less O
in O
the O
15 O
/ O
HTN B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
group O
( O
16 O
+ O
/ O
- O
6 O
, O
mean O
+ O
/ O
- O
SD O
) O
versus O
the O
90 O
/ O
HTN B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
group O
( O
30 O
+ O
/ O
- O
6 O
) O
, O
which O
was O
in O
turn O
less O
than O
the O
control O
group O
( O
42 O
+ O
/ O
- O
5 O
) O
. O

specific O
gravity O
was O
greater O
in O
the O
15 O
/ O
HTN B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
group O
( O
1 O
. O
043 O
+ O
/ O
- O
0 O
. O
002 O
) O
versus O
the O
90 O
/ O
HTN B_MEASURE
( O
1 O
. O
036 O
+ O
/ O
- O
0 O
. O
003 O
) O
and O
control O
( O
1 O
. O
037 O
+ O
/ O
- O
0 O
. O
003 O
) O
groups O
. O

Evans O
Blue O
( O
mug O
g O
- O
1 O
of O
brain O
tissue O
) O
was O
greater O
in O
the O
90 O
/ O
HTN B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
group O
( O
24 O
. O
4 O
+ O
/ O
- O
6 O
. O
0 O
) O
versus O
the O
control O
group O
( O
12 O
. O
3 O
+ O
/ O
- O
4 O
. O
1 O
) O
, O
which O
was O
in O
turn O
greater O
than O
the O
15 O
/ O
HTN B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
group O
( O
7 O
. O
3 O
+ O
/ O
- O
3 O
. O
2 O
) O
. O

This O
study O
supports O
a O
hypothesis O
that O
during O
reperfusion O
, O
a O
short O
interval O
of O
hypertension B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
decreases O
brain B_DISEASE/B_GENE
injury I_DISEASE/I_GENE
and O
edema B_DISEASE
; O
and O
that O
sustained O
hypertension B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
increases O
the O
risk O
of O
vasogenic B_DISEASE
edema I_DISEASE
. O

People O
aged O
over O
75 O
in O
atrial B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fibrillation I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
warfarin O
: O
the O
rate O
of O
major O
hemorrhage B_DISEASE
and O
stroke B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
more O
than O
500 O
patient O
- O
years O
of O
follow O
- O
up O
. O

objectives O
: O
To O
determine O
the O
incidence O
of O
major O
hemorrhage B_DISEASE
and O
stroke B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
people O
aged O
76 O
and O
older O
with O
atrial B_DISEASE
fibrillation I_DISEASE
on O
adjusted O
- O
dose O
warfarin O
who O
had O
been O
recently O
been O
admitted O
to O
hospital O
. O

Design B_PERSON/B_MEASURE
: O
A O
retrospective B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
observational I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cohort I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

setting B_LOCATION
: O
A O
major B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
healthcare I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
network I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
involving O
four B_PERSON/B_LOCATION
tertiary I_PERSON/I_LOCATION
hospitals I_PERSON/I_LOCATION
. O

participants O
: O
Two O
hundred O
thirty O
- O
five O
patients O
aged O
76 O
and O
older O
admitted O
to O
a O
major O
healthcare O
network O
between O
July O
1 O
, O
2001 O
, O
and O
June O
30 O
, O
2002 O
, O
with O
atrial B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fibrillation I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
warfarin O
were O
enrolled O
. O

measurements O
: O
Information O
regarding O
major O
bleeding B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
episodes O
, O
strokes B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
and O
warfarin O
use O
was O
obtained O
from O
patients O
, O
relatives O
, O
primary O
physicians O
, O
and O
medical O
records O
. O

RESULTS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O
Two B_NUMBER[MEASURE]
hundred I_NUMBER[MEASURE]
twenty I_NUMBER[MEASURE]
- O
eight B_NUMBER[MEASURE]/B_PERSON
patients I_NUMBER[MEASURE]/I_PERSON
( O
42 B_PERSON/B_MEASURE
% I_PERSON/I_MEASURE
men I_PERSON/I_MEASURE
) O
with O
a O
mean B_MEASURE/B_DISEASE
age I_MEASURE/I_DISEASE
of O
81 B_MEASURE
. O
1 B_MEASURE
( O
range B_MEASURE/B_LOCATION
76 I_MEASURE/I_LOCATION
- O
94 B_MEASURE
) O
were O
included O
in O
the O
analysis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Total B_MEASURE/B_PERSON
follow B_MEASURE/I_PERSON
- O
up B_LOCATION/B_LANGUAGE
on O
warfarin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
was O
530 B_TIME[MEASURE]
years I_TIME[MEASURE]
( O
mean B_TIME[MEASURE]
28 I_TIME[MEASURE]
months I_TIME[MEASURE]
) O
. O

There O
were O
53 O
major O
hemorrhages B_DISEASE
, O
for O
an O
annual O
rate O
of O
10 O
. O
0 O
% O
, O
including O
24 O
( O
45 O
. O
3 O
% O
) O
life O
- O
threatening O
and O
five O
( O
9 O
. O
4 O
% O
) O
fatal O
bleeds O
. O

The O
annual O
stroke B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
rate O
after O
initiation O
of O
warfarin O
was O
2 O
. O
6 O
% O
. O

conclusion O
: O
The O
rate O
of O
major O
hemorrhage B_DISEASE
was O
high O
in O
this O
old O
, O
frail O
group O
, O
but O
excluding O
fatalities O
, O
resulted O
in O
no O
long O
- O
term O
sequelae O
, O
and O
the O
stroke B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
rate O
on O
warfarin O
was O
low O
, O
demonstrating O
how O
effective O
warfarin O
treatment O
is O
. O

Safety O
of O
celecoxib O
in O
patients O
with O
adverse O
skin B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reactions B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
acetaminophen O
( O
paracetamol O
) O
and O
nimesulide O
associated O
or O
not O
with O
common O
non O
- O
steroidal O
anti O
- O
inflammatory O
drugs O
. O

Background B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
: O
acetaminophen B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
paracetamol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- O
- O
P B_OTHER/B_PROTEIN[GENE]
) O
and O
Nimesulide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
N B_OTHER/B_LOCATION
) O
are O
widely O
used O
analgesic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
antipyretic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
/ O
anti B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
inflammatory B_DISEASE
drugs I_DISEASE
. O

The O
rate O
of O
adverse O
hypersensitivity B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
reactions O
to O
these O
agents O
is O
generally O
low O
. O

On O
the O
contrary B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_NUMBER[MEASURE]
non B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_NUMBER[MEASURE]
- O
steroidal B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
anti I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
- O
inflammatory B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
drugs I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
NSAIDs B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
) O
are O
commonly O
involved O
in O
such B_DISEASE/B_LOCATION
reactions I_DISEASE/I_LOCATION
. O

celecoxib B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O
CE B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
is O
a O
novel B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
drug I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O
with O
high B_LOCATION/B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
selectivity B_LOCATION/I_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
affinity B_GENE/B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
COX B_GENE
- O
2 B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
enzyme I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

objective O
: O
We O
evaluated O
the O
tolerability O
of O
CE O
in O
a O
group O
of O
patients O
with O
documented O
history O
of O
adverse O
cutaneous B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reactions B_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
P O
and O
N O
associated O
or O
not O
to O
classic O
NSAIDs O
. O

methods O
: O
We O
studied O
9 O
patients O
with O
hypersensitivity B_DISEASE
to O
P O
and O
N O
with O
or O
without O
associated O
reactions O
to O
classic O
NSAIDs O
. O

The O
diagnosis O
of O
P O
and O
N O
- O
induced O
skin B_DISEASE
reactions I_DISEASE
was O
based O
in O
vivo O
challenge O
. O

The O
placebo B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
was O
blindly O
administered O
at O
the O
beginning B_TIME[MEASURE]/B_LOCATION
of O
each O
challenge B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
. O

After O
three B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
days I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
a O
cumulative B_MEASURE
dosage I_MEASURE
of O
200 B_MEASURE/B_LOCATION
mg I_MEASURE/I_LOCATION
of O
CE B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
refracted B_MEASURE/B_BIO
doses B_MEASURE/I_BIO
were O
given O
. O

After O
2 B_NUMBER[MEASURE]/B_LOCATION
- O
3 B_TIME[MEASURE]/B_ENT
days I_TIME[MEASURE]/I_ENT
, O
a O
single B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
dose I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
200 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mg I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
administered O
. O

All O
patients B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
observed O
for O
6 B_TIME[MEASURE]/B_SPORT[ENT]
hours I_TIME[MEASURE]/I_SPORT[ENT]
after O
each O
challenge B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
, O
and O
controlled O
again O
after O
24 B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
hours I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
to O
exclude O
delayed O
reactions B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

The O
challenge O
was O
considered O
positive O
if O
one O
or O
more O
of O
the O
following O
appeared O
: O
erythema B_DISEASE
, O
rush O
or O
urticaria B_DISEASE
- O
angioedema B_DISEASE_ADJECTIVE[DISEASE]
. O

RESULTS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
: O
No O
reaction B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
observed O
with O
placebo B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
and O
eight B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
patients B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
( O
88 B_MEASURE
. O
8 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
tolerated O
CE B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Only O
one O
patient O
developed O
a O
moderate O
angioedema B_DISEASE
of O
the O
lips O
. O

conclusion O
: O
Only O
one O
hypersensitivity B_DISEASE_ADJECTIVE[DISEASE]
reaction O
to O
CE O
was O
documented O
among O
9 O
P O
and O
N O
- O
highly O
NSAIDs O
intolerant O
patients O
. O

Thus O
, O
we O
conclude O
that O
CE B_LOCATION/B_PERSON
is O
a O
reasonably O
safe B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alternative I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
be O
used O
in O
subjects B_PERSON/B_LOCATION
who O
do O
not O
tolerate O
P B_OTHER/B_LOCATION
and O
N B_OTHER/B_LOCATION
. O

Case O
- O
control O
study O
of O
regular O
analgesic O
and O
nonsteroidal O
anti O
- O
inflammatory O
use O
and O
end B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stage B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
renal B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
disease B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Background O
: O
Studies O
on O
the O
association O
between O
the O
long O
- O
term O
use O
of O
aspirin O
and O
other O
analgesic O
and O
nonsteroidal O
anti O
- O
inflammatory O
drugs O
( O
NSAIDs O
) O
and O
end B_DISEASE
- I_DISEASE
stage I_DISEASE
renal I_DISEASE
disease I_DISEASE
( O
ESRD B_DISEASE
) O
have O
given O
conflicting O
results O
. O

In O
order O
to O
examine O
this O
association O
, O
a O
case O
- O
control O
study O
with O
incident O
cases O
of O
ESRD B_DISEASE/B_LOCATION
was O
carried O
out O
. O

methods O
: O
The O
cases O
were O
all O
patients O
entering O
the O
local O
dialysis O
program O
because O
of O
ESRD B_DISEASE
in O
the O
study O
area O
between O
June O
1 O
, O
1995 O
and O
November O
30 O
, O
1997 O
. O

They O
were O
classified O
according O
to O
the O
underlying O
disease O
, O
which O
had O
presumably O
led O
them O
to O
ESRD B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

controls B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_NUMBER[MEASURE]
were O
patients B_PERSON/B_TIME[MEASURE]
admitted O
to O
the O
same B_LOCATION/B_ORGANIZATION
hospitals I_LOCATION/I_ORGANIZATION
from O
where O
the O
cases B_PERSON/B_DISEASE
arose O
, O
also O
matched O
by O
age B_TIME[MEASURE]/B_DISEASE
and O
sex B_PERSON/B_LOCATION
. O

odds B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ratios I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
calculated O
using O
a O
conditional B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
logistic I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
model I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O
including O
potential B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
confounding I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factors I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
both O
for O
the O
whole B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
population I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
and O
for O
the O
various B_NUMBER[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
underlying O
diseases B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

RESULTS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O
Five B_NUMBER[MEASURE]/B_LOCATION
hundred I_NUMBER[MEASURE]/I_LOCATION
and O
eighty B_NUMBER[MEASURE]
- O
three B_NUMBER[MEASURE]
cases I_NUMBER[MEASURE]
and O
1190 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
controls I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
were O
included O
in O
the O
analysis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Long B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O
term B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
use I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
any O
analgesic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
associated O
with O
an O
overall B_MEASURE
odds I_MEASURE
ratio I_MEASURE
of O
1 B_MEASURE
. O
22 B_MEASURE
( O
95 B_MEASURE
% I_MEASURE
CI I_MEASURE
, O
0 B_MEASURE
. O
89 B_MEASURE
- O
1 B_MEASURE
. O
66 B_MEASURE
) O
. O

For O
specific B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
groups I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
drugs B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
, O
the O
risks B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
were O
1 B_NUMBER[MEASURE]
. O
56 B_MEASURE
( O
1 B_MEASURE
. O
05 B_MEASURE
- O
2 B_NUMBER[MEASURE]
. O
30 B_MEASURE
) O
for O
aspirin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
1 B_NUMBER[MEASURE]
. O
03 B_MEASURE
( O
0 B_NUMBER[MEASURE]
. O
60 B_MEASURE
- O
1 B_NUMBER[MEASURE]
. O
76 B_MEASURE
) O
for O
pyrazolones B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
, O
0 B_NUMBER[MEASURE]
. O
80 B_MEASURE
( O
0 B_NUMBER[MEASURE]/B_LOCATION
. O
39 B_MEASURE
- O
1 B_NUMBER[MEASURE]
. O
63 B_MEASURE
) O
for O
paracetamol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
0 B_NUMBER[MEASURE]
. O
94 B_MEASURE
( O
0 B_NUMBER[MEASURE]
. O
57 B_MEASURE
- O
1 B_NUMBER[MEASURE]
. O
56 B_MEASURE
) O
for O
nonaspirin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
NSAIDs I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
risk O
of O
ESRD B_DISEASE
associated O
with O
aspirin O
was O
related O
to O
the O
cumulated O
dose O
and O
duration O
of O
use O
, O
and O
it O
was O
particularly O
high O
among O
the O
subset O
of O
patients O
with O
vascular O
nephropathy B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
as O
underlying O
disease O
[ O
2 O
. O
35 O
( O
1 O
. O
17 O
- O
4 O
. O
72 O
) O
] O
. O

conclusion O
: O
Our O
data O
indicate O
that O
long O
- O
term O
use O
of O
nonaspirin O
analgesic O
drugs O
and O
NSAIDs O
is O
not O
associated O
with O
an O
increased O
risk O
of O
ESRD B_DISEASE
. O

However O
, O
the O
chronic O
use O
of O
aspirin O
may O
increase O
the O
risk O
of O
ESRD B_DISEASE
. O

Two O
cases O
of O
amisulpride O
overdose B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
: O
a O
cause O
for O
prolonged B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
QT I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
syndrome I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Two O
cases O
of O
deliberate O
self O
- O
poisoning B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O
5 O
g O
and O
3 O
. O
6 O
g O
of O
amisulpride O
, O
respectively O
, O
are O
reported O
. O

In O
both O
cases O
, O
QT B_DISEASE
prolongation I_DISEASE
and O
hypocalcaemia B_DISEASE
were O
noted O
. O

The O
QT B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
prolongation I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
appeared O
to O
respond O
to O
administration O
of O
i O
. O
v O
. O
calcium O
gluconate O
. O

Growth O
- O
associated O
protein O
43 O
expression O
in O
hippocampal O
molecular O
layer O
of O
chronic O
epileptic B_DISEASE
rats O
treated O
with O
cycloheximide O
. O

purpose O
: O
GAP43 O
has O
been O
thought O
to O
be O
linked O
with O
mossy O
fiber O
sprouting O
( O
MFS O
) O
in O
various O
experimental O
models O
of O
epilepsy B_DISEASE
. O

To O
investigate O
how O
GAP43 O
expression O
( O
GAP43 O
- O
ir O
) O
correlates O
with O
MFS O
, O
we O
assessed O
the O
intensity O
( O
densitometry O
) O
and O
extension O
( O
width O
) O
of O
GAP43 O
- O
ir O
in O
the O
inner O
molecular O
layer O
of O
the O
dentate O
gyrus O
( O
IML O
) O
of O
rats O
subject O
to O
status B_DISEASE
epilepticus I_DISEASE
induced O
by O
pilocarpine O
( O
Pilo O
) O
, O
previously O
injected O
or O
not O
with O
cycloheximide O
( O
CHX O
) O
, O
which O
has O
been O
shown O
to O
inhibit O
MFS O
. O

METHODS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
CHX B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
was O
injected O
before O
the O
Pilo B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
injection I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
in O
adult B_LOCATION/B_PERSON
Wistar I_LOCATION/I_PERSON
rats I_LOCATION/I_PERSON
. O

The O
Pilo B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
group I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
was O
injected O
with O
the O
same B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
drugs I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
except O
for O
CHX B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O

Animals B_BIO/B_PERSON
were O
killed O
between O
30 B_MEASURE
and O
60 B_TIME[MEASURE]/B_ENT
days I_TIME[MEASURE]/I_ENT
later O
, O
and O
brain B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
sections I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
were O
processed O
for O
GAP43 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
immunohistochemistry I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

RESULTS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O
Densitometry B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
showed O
no O
significant B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
difference B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
regarding O
GAP43 B_GENE
- O
ir B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O
the O
IML B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
between O
Pilo B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
CHX B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
+ I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
Pilo I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
, O
and O
control B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
groups I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

However O
, O
the O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
the O
width B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
GAP43 B_GENE/B_LOCATION
- O
ir B_LOCATION/B_PROTEIN[GENE]
band B_LOCATION/I_PROTEIN[GENE]
in O
the O
IML B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
showed O
that O
CHX B_DISEASE
+ O
Pilo B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
and O
control B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
animals B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
had O
a O
significantly O
larger B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
band B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
( O
p B_MEASURE/B_PROTEIN[GENE]
= O
0 B_MEASURE
. O
03 B_MEASURE
) O
as O
compared O
with O
that O
in O
the O
Pilo B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
group I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

CONCLUSIONS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O
Our O
current B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
finding I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
animals B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
CHX B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
+ I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
Pilo I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
group I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
have O
a O
GAP43 B_GENE
- O
ir B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
band B_LOCATION/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
IML B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
, O
similar B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
that O
of O
controls B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
reinforces O
prior B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
data I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
on O
the O
blockade B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
of O
MFS B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
in O
these O
animals B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
change B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
in O
GAP43 B_GENE
- O
ir B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
present I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
in O
Pilo B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
treated O
animals B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
a O
thinning B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
the O
band B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
to O
a O
very O
narrow B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
layer B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
just O
above O
the O
granule B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
cell I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
layer I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
that O
is O
likely B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O
be O
associated O
with O
the O
loss B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
hilar B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cell I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
projections I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
that O
express O
Gap B_LOCATION/B_GENE
- O
43 B_MEASURE/B_LOCATION
. O

nicotine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
antagonizes I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
caffeine I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
- O
but O
not O
pentylenetetrazole B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
induced O
anxiogenic B_DISEASE
effect I_DISEASE
in O
mice B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

rationale B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
: O
nicotine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
caffeine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
widely O
consumed O
licit B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
psychoactive I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
drugs I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
worldwide O
. O

Epidemiological B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
studies I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
showed O
that O
they O
were O
generally O
used O
concurrently O
. O

Although O
some O
studies O
in O
experimental O
animals O
indicate O
clear O
pharmacological O
interactions O
between O
them O
, O
no O
studies O
have O
shown O
a O
specific O
interaction O
on O
anxiety B_DISEASE_ADJECTIVE[DISEASE]
responses O
. O

objectives O
: O
The O
present O
study O
investigates O
the O
effects O
of O
nicotine O
on O
anxiety B_DISEASE
induced O
by O
caffeine O
and O
another O
anxiogenic O
drug O
, O
pentylenetetrazole O
, O
in O
mice O
. O

The O
elevated O
plus O
- O
maze O
( O
EPM O
) O
test O
was O
used O
to O
evaluate O
the O
effects O
of O
drugs O
on O
anxiety B_DISEASE
. O

METHODS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
: O
Adult B_PERSON
male I_PERSON
Swiss I_PERSON
Webster I_PERSON
mice I_PERSON
( O
25 B_MEASURE
- O
32 B_MEASURE
g I_MEASURE
) O
were O
given O
nicotine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
0 B_MEASURE/B_LOCATION
. O
05 B_MEASURE
- O
0 B_MEASURE
. O
25 B_MEASURE
mg I_MEASURE
/ O
kg B_MEASURE/B_LOCATION
s I_MEASURE/I_LOCATION
. O
c B_DISEASE/B_LOCATION
. O
) O
or O
saline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
10 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
min I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
before O
caffeine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
70 B_MEASURE
mg I_MEASURE
/ O
kg B_MEASURE/B_PERSON
i O
. O
p B_MEASURE/B_LOCATION
. O
) O
or O
pentylenetetrazole B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
15 B_MEASURE
and O
30 B_MEASURE
mg I_MEASURE
/ O
kg B_MEASURE
i O
. O
p B_MEASURE/B_LOCATION
. O
) O
injections B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O

After O
15 B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
min I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_LOCATION
, O
mice B_BIO/B_PERSON
were O
evaluated O
for O
their O
open B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O
and O
closed B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
arm B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
time I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
and O
entries B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
the O
EPM B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
for O
a O
10 B_MEASURE
- O
min B_TIME[MEASURE]/B_LOCATION
session I_TIME[MEASURE]/I_LOCATION
. O

locomotor B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
activity I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
was O
recorded O
for O
individual B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
groups I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O
using O
the O
same B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treatment I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
protocol I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
the O
EPM B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
test I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
. O

RESULTS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O
nicotine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
0 B_MEASURE
. O
05 B_MEASURE
- O
0 B_MEASURE
. O
25 B_MEASURE
mg I_MEASURE
/ O
kg B_MEASURE
) O
itself O
did O
not O
produce O
any O
significant B_DISEASE_ADJECTIVE[DISEASE]
effect I_DISEASE_ADJECTIVE[DISEASE]
in O
the O
EPM B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
test I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
whereas O
caffeine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
70 B_MEASURE
mg I_MEASURE
/ O
kg B_MEASURE
) O
and O
pentylenetetrazole B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
30 B_MEASURE
mg I_MEASURE
/ O
kg B_MEASURE
) O
produced O
an O
anxiogenic B_DISEASE_ADJECTIVE[DISEASE]
effect I_DISEASE_ADJECTIVE[DISEASE]
, O
apparent B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
decreases B_DISEASE_ADJECTIVE[DISEASE]
in O
open B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
arm B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
time B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
and O
entry B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O

Nicotine O
( O
0 O
. O
25 O
mg O
/ O
kg O
) O
pretreatment O
blocked O
the O
caffeine O
- O
but O
not O
pentylenetetrazole O
- O
induced O
anxiety B_DISEASE
. O

Administration B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
of O
each O
drug B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O
their O
combinations B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
did O
not O
produce O
any O
effect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
locomotor B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activity I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

conclusions O
: O
Our O
results O
suggest O
that O
the O
antagonistic O
effect O
of O
nicotine O
on O
caffeine O
- O
induced O
anxiety B_DISEASE
is O
specific O
to O
caffeine O
, O
instead O
of O
a O
non O
- O
specific O
anxiolytic O
effect O
. O

Thus O
, O
it O
may O
extend O
the O
current B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
findings I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
on O
the O
interaction B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
between O
nicotine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
caffeine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O

Long B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
term I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hormone I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
perimenopausal B_PERSON
and O
postmenopausal B_PERSON/B_DISEASE
women I_PERSON/I_DISEASE
. O

Background O
: O
hormone O
therapy O
( O
HT O
) O
is O
widely O
used O
for O
controlling O
menopausal B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
symptoms I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

It O
has O
also O
been O
used O
for O
the O
management O
and O
prevention O
of O
cardiovascular B_DISEASE
disease I_DISEASE
, O
osteoporosis B_DISEASE
and O
dementia B_DISEASE
in O
older O
women O
but O
the O
evidence O
supporting O
its O
use O
for O
these O
indications O
is O
largely O
observational O
. O

objectives O
: O
To O
assess O
the O
effect O
of O
long O
- O
term O
HT O
on O
mortality O
, O
heart B_DISEASE
disease I_DISEASE
, O
venous B_DISEASE
thromboembolism I_DISEASE
, O
stroke B_DISEASE
, O
transient B_DISEASE
ischaemic I_DISEASE
attacks I_DISEASE
, O
breast B_DISEASE
cancer I_DISEASE
, O
colorectal B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
cancer I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
, O
ovarian B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
cancer I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
, O
endometrial B_DISEASE
cancer I_DISEASE
, O
gallbladder B_DISEASE
disease I_DISEASE
, O
cognitive O
function O
, O
dementia B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
, O
fractures B_DISEASE
and O
quality O
of O
life O
. O

search B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
strategy I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
: O
We O
searched O
the O
following B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
databases I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
up O
to O
November B_TIME[MEASURE]
2004 I_TIME[MEASURE]
: O
the O
Cochrane B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
menstrual B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
Disorders B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
and O
Subfertility B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
Group B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
Trials B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
Register B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
, O
Cochrane B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
Central I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
Register I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
of O
Controlled B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
Trials I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O
central B_LOCATION/B_TIME[MEASURE]
) O
, O
MEDLINE B_ORGANIZATION/B_PERSON
, O
EMBASE B_ORGANIZATION/B_LOCATION
, O
Biological B_ORGANIZATION/B_LOCATION
Abstracts I_ORGANIZATION/I_LOCATION
. O

relevant B_DISEASE_ADJECTIVE[DISEASE]/B_NUMBER[MEASURE]
non O
- O
indexed O
journals B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
conference B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
abstracts I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
were O
also O
searched O
. O

Selection B_MEASURE
criteria I_MEASURE
: O
Randomised O
double B_MEASURE/B_COLOR
- O
blind B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
trials I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
HT B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
oestrogens B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
with O
or O
without O
progestogens B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
) O
versus B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
placebo I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
taken O
for O
at O
least O
one B_TIME[MEASURE]
year I_TIME[MEASURE]
by O
perimenopausal B_PERSON
or O
postmenopausal B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
women B_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
collection I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
AND O
Analysis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
Fifteen B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
RCTs I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
were O
included O
. O

Trials B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
were O
assessed O
for O
quality B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
two B_PERSON/B_LOCATION
review I_PERSON/I_LOCATION
authors I_PERSON/I_LOCATION
extracted O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
independently O
. O

They O
calculated O
risk B_MEASURE
ratios I_MEASURE
for O
dichotomous B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
outcomes I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
weighted B_MEASURE
mean O
differences B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
continuous B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
outcomes I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Clinical B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
heterogeneity I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
precluded O
meta B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
analysis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
most B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
outcomes I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Main B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
RESULTS I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
All O
the O
statistically O
significant B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
results I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
were O
derived O
from O
the O
two B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_NUMBER[MEASURE]
biggest I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_NUMBER[MEASURE]
trials I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_NUMBER[MEASURE]
. O

In O
relatively O
healthy O
women O
, O
combined O
continuous O
HT O
significantly O
increased O
the O
risk O
of O
venous B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
thromboembolism I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
or O
coronary O
event O
( O
after O
one O
year O
' O
s O
use O
) O
, O
stroke B_DISEASE
( O
after O
3 O
years O
) O
, O
breast B_DISEASE
cancer I_DISEASE
( O
after O
5 O
years O
) O
and O
gallbladder B_DISEASE
disease I_DISEASE
. O

Long O
- O
term O
oestrogen O
- O
only O
HT O
also O
significantly O
increased O
the O
risk O
of O
stroke B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
and O
gallbladder B_DISEASE/B_LOCATION
disease I_DISEASE/I_LOCATION
. O

Overall O
, O
the O
only O
statistically O
significant O
benefits O
of O
HT O
were O
a O
decreased O
incidence O
of O
fractures B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
and O
colon B_DISEASE
cancer I_DISEASE
with O
long O
- O
term O
use O
. O

Among O
relatively O
healthy O
women O
over O
65 O
years O
taking O
continuous O
combined O
HT O
, O
there O
was O
a O
statistically O
significant O
increase O
in O
the O
incidence O
of O
dementia B_DISEASE
. O

Among O
women O
with O
cardiovascular B_DISEASE
disease I_DISEASE
, O
long O
- O
term O
use O
of O
combined O
continuous O
HT O
significantly O
increased O
the O
risk O
of O
venous B_DISEASE/B_LOCATION
thromboembolism I_DISEASE/I_LOCATION
. O

No O
trials B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
focussed O
specifically O
on O
younger B_PERSON/B_ENT
women I_PERSON/I_ENT
. O

However O
, O
one B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
trial I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
analysed O
subgroups B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O
2839 B_NUMBER[MEASURE]
relatively O
healthy B_MEASURE
50 I_MEASURE
to O
59 B_TIME[MEASURE]
year I_TIME[MEASURE]
- O
old B_PERSON/B_ENT
women I_PERSON/I_ENT
taking O
combined B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
continuous I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
HT I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
1637 B_NUMBER[MEASURE]/B_PERSON
taking O
oestrogen B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
only O
HT B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
versus B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
similar B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
- O
sized B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
placebo I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
groups I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O

The O
only O
significantly O
increased O
risk O
reported O
was O
for O
venous B_DISEASE
thromboembolism I_DISEASE
in O
women O
taking O
combined O
continuous O
HT O
; O
their O
absolute O
risk O
remained O
very O
low O
. O

authors O
' O
conclusions O
: O
HT O
is O
not O
indicated O
for O
the O
routine O
management O
of O
chronic B_DISEASE/B_PROTEIN[GENE]
disease B_DISEASE/I_PROTEIN[GENE]
. O

We O
need O
more B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
evidence I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
on O
the O
safety B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
HT B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
for O
menopausal B_PERSON/B_DISEASE
symptom I_PERSON/I_DISEASE
control I_PERSON/I_DISEASE
, O
though O
short B_MEASURE
- O
term B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
use I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
appears O
to O
be O
relatively O
safe B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
for O
healthy B_PERSON
younger I_PERSON
women I_PERSON
. O

Drug B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
induced B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
liver B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
injury B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
an O
analysis O
of O
461 O
incidences O
submitted O
to O
the O
Spanish O
registry O
over O
a O
10 O
- O
year O
period O
. O

Background O
& O
aims O
: O
Progress O
in O
the O
understanding O
of O
susceptibility O
factors O
to O
drug B_DISEASE
- I_DISEASE
induced I_DISEASE
liver I_DISEASE
injury I_DISEASE
( O
DILI B_DISEASE
) O
and O
outcome O
predictability O
are O
hampered O
by O
the O
lack O
of O
systematic O
programs O
to O
detect O
bona O
fide O
cases O
. O

methods O
: O
A O
cooperative O
network O
was O
created O
in O
1994 O
in O
Spain O
to O
identify O
all O
suspicions O
of O
DILI B_DISEASE
following O
a O
prospective O
structured O
report O
form O
. O

The O
liver B_DISEASE
damage I_DISEASE
was O
characterized O
according O
to O
hepatocellular O
, O
cholestatic B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
, O
and O
mixed O
laboratory O
criteria O
and O
to O
histologic O
criteria O
when O
available O
. O

Further B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
evaluation I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
causality B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
assessment I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
was O
centrally O
performed O
. O

Results O
: O
Since O
April O
1994 O
to O
August O
2004 O
, O
461 O
out O
of O
570 O
submitted O
cases O
, O
involving O
505 O
drugs O
, O
were O
deemed O
to O
be O
related O
to O
DILI B_DISEASE
. O

The O
antiinfective B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
group B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
drugs B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
was O
the O
more O
frequently O
incriminated B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O
amoxicillin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
clavulanate B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
accounting B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
the O
12 B_MEASURE
. O
8 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
of O
the O
whole B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
series I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

The O
hepatocellular B_DISEASE/B_MEASURE
pattern B_DISEASE/I_MEASURE
of O
damage B_DISEASE
was O
the O
most O
common B_DISEASE_ADJECTIVE[DISEASE]
( O
58 B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
% I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
) O
, O
was O
inversely O
correlated O
with O
age B_DISEASE/B_MEASURE
( O
P B_MEASURE/B_LOCATION
< I_MEASURE/I_LOCATION
. O
0001 B_MEASURE
) O
, O
and O
had O
the O
worst B_MEASURE/B_LOCATION
outcome I_MEASURE/I_LOCATION
( O
Cox B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
regression I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
P B_MEASURE/B_LOCATION
< I_MEASURE/I_LOCATION
. O
034 B_MEASURE
) O
. O

Indeed O
, O
the O
incidence O
of O
liver O
transplantation O
and O
death O
in O
this O
group O
was O
11 O
. O
7 O
% O
if O
patients O
had O
jaundice B_DISEASE
at O
presentation O
, O
whereas O
the O
corresponding O
figure O
was O
3 O
. O
8 O
% O
in O
nonjaundiced O
patients O
( O
P O
< O
. O
04 O
) O
. O

factors O
associated O
with O
the O
development O
of O
fulminant B_DISEASE
hepatic I_DISEASE
failure I_DISEASE
were O
female O
sex O
( O
OR O
= O
25 O
; O
95 O
% O
CI O
: O
4 O
. O
1 O
- O
151 O
; O
P O
< O
. O
0001 O
) O
, O
hepatocellular O
damage O
( O
OR O
= O
7 O
. O
9 O
; O
95 O
% O
CI O
: O
1 O
. O
6 O
- O
37 O
; O
P O
< O
. O
009 O
) O
, O
and O
higher O
baseline O
plasma O
bilirubin O
value O
( O
OR O
= O
1 O
. O
15 O
; O
95 O
% O
CI O
: O
1 O
. O
09 O
- O
1 O
. O
22 O
; O
P O
< O
. O
0001 O
) O
. O

conclusions O
: O
patients O
with O
drug O
- O
induced O
hepatocellular O
jaundice B_DISEASE
have O
11 O
. O
7 O
% O
chance O
of O
progressing O
to O
death O
or O
transplantation O
. O

Amoxicillin O
- O
clavulanate O
stands O
out O
as O
the O
most O
common O
drug O
related O
to O
DILI B_DISEASE
. O

Morphological O
evaluation O
of O
the O
effect O
of O
d O
- O
ribose O
on O
adriamycin O
- O
evoked O
cardiotoxicity B_DISEASE
in O
rats O
. O

The O
influence O
of O
d O
- O
ribose O
on O
adriamycin O
- O
induced O
myocardiopathy B_DISEASE
in O
rats O
was O
studied O
. O

Adriamycin O
in O
the O
cumulative O
dose O
of O
25 O
mg O
/ O
kg O
evoked O
fully O
developed O
cardiac B_DISEASE
toxicity I_DISEASE
. O

D O
- O
ribose O
in O
the O
multiple O
doses O
of O
200 O
mg O
/ O
kg O
did O
not O
influence O
ADR O
cardiotoxicity B_DISEASE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

In O
vivo O
evidences O
suggesting O
the O
role O
of O
oxidative O
stress O
in O
pathogenesis O
of O
vancomycin O
- O
induced O
nephrotoxicity B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
protection O
by O
erdosteine O
. O

The O
aims O
of O
this O
study O
were O
to O
examine O
vancomycin O
( O
VCM O
) O
- O
induced O
oxidative O
stress O
that O
promotes O
production O
of O
reactive O
oxygen O
species O
( O
ROS O
) O
and O
to O
investigate O
the O
role O
of O
erdosteine O
, O
an O
expectorant O
agent O
, O
which O
has O
also O
antioxidant O
properties O
, O
on O
kidney O
tissue O
against O
the O
possible O
VCM O
- O
induced O
renal B_DISEASE
impairment I_DISEASE
in O
rats O
. O

rats B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
divided O
into O
three B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_NUMBER[MEASURE]
groups B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_NUMBER[MEASURE]
: O
sham B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O
VCM B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
and O
VCM B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
plus O
erdosteine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

VCM B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
was O
administrated O
intraperitoneally O
( O
i B_DISEASE/B_TIME[MEASURE]
. O
p B_MEASURE/B_LOCATION
. O
) O
with O
200mgkg B_MEASURE
( O
- O
1 B_MEASURE/B_LOCATION
) O
twice O
daily O
for O
7 B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
days B_TIME[MEASURE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Erdosteine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
administered O
orally O
. O

VCM O
administration O
to O
control O
rats O
significantly O
increased O
renal O
malondialdehyde O
( O
MDA O
) O
and O
urinary O
N O
- O
acetyl O
- O
beta O
- O
d O
- O
glucosaminidase O
( O
NAG O
, O
a O
marker O
of O
renal B_DISEASE_ADJECTIVE[DISEASE]
tubular I_DISEASE_ADJECTIVE[DISEASE]
injury I_DISEASE_ADJECTIVE[DISEASE]
) O
excretion O
but O
decreased O
superoxide O
dismutase O
( O
SOD O
) O
and O
catalase O
( O
Cat O
) O
activities O
. O

Erdosteine B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
administration I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
with O
VCM B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
injections B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
caused O
significantly O
decreased O
renal B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
MDA B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
and O
urinary B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
NAG B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
excretion B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O
and O
increased O
SOD B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activity I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
but O
not O
CAT B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
activity B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
in O
renal B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
tissue I_BODY_PART_OR_ORGAN_COMPONENT/I_BIO
when O
compared O
with O
VCM B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
alone O
. O

Erdosteine O
showed O
histopathological O
protection O
against O
VCM O
- O
induced O
nephrotoxicity B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

There O
were O
a O
significant O
dilatation O
of O
tubular O
lumens O
, O
extensive O
epithelial O
cell O
vacuolization O
, O
atrophy B_DISEASE
, O
desquamation B_DISEASE
, O
and O
necrosis B_DISEASE
in O
VCM O
- O
treated O
rats O
more O
than O
those O
of O
the O
control O
and O
the O
erdosteine O
groups O
. O

Erdosteine B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
caused O
a O
marked B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
reduction B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
the O
extent B_DISEASE/B_MEASURE
of O
tubular B_DISEASE
damage I_DISEASE
. O

It O
is O
concluded O
that O
oxidative O
tubular O
damage O
plays O
an O
important O
role O
in O
the O
VCM O
- O
induced O
nephrotoxicity B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
the O
modulation O
of O
oxidative O
stress O
with O
erdosteine O
reduces O
the O
VCM O
- O
induced O
kidney B_DISEASE_ADJECTIVE[DISEASE]
damage I_DISEASE_ADJECTIVE[DISEASE]
both O
at O
the O
biochemical O
and O
histological O
levels O
. O

Gemfibrozil O
- O
lovastatin O
therapy O
for O
primary O
hyperlipoproteinemias B_DISEASE
. O

The O
specific O
aim O
of O
this O
retrospective O
, O
observational O
study O
was O
to O
assess O
safety O
and O
efficacy O
of O
long O
- O
term O
( O
21 O
months O
/ O
patient O
) O
, O
open O
- O
label O
, O
gemfibrozil O
- O
lovastatin O
treatment O
in O
80 O
patients O
with O
primary O
mixed O
hyperlipidemia B_DISEASE
( O
68 O
% O
of O
whom O
had O
atherosclerotic B_DISEASE
vascular I_DISEASE
disease I_DISEASE
) O
. O

Because O
ideal B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
lipid I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
targets I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
were O
not O
reached O
( O
low B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O
density B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
lipoprotein B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O
LDL B_PROTEIN[GENE]/B_LOCATION
) O
cholesterol B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
less I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
than O
130 B_MEASURE
mg I_MEASURE
/ O
dl B_MEASURE/B_DISEASE
, O
high B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O
density B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
lipoprotein B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O
HDL B_PROTEIN[GENE]/B_DISEASE
) O
cholesterol B_MEASURE
greater I_MEASURE
than O
35 B_MEASURE
mg I_MEASURE
/ O
dl B_MEASURE/B_DISEASE
, O
or O
total B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cholesterol I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
HDL B_MEASURE/B_PERSON
cholesterol I_MEASURE/I_PERSON
less I_MEASURE/I_PERSON
than O
4 B_MEASURE
. O
5 B_MEASURE
mg I_MEASURE
/ O
dl B_MEASURE/B_DISEASE
) O
with O
diet B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
plus O
a O
single B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
drug I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
gemfibrozil B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
( O
1 B_MEASURE
. O
2 B_MEASURE/B_LOCATION
g I_MEASURE/I_LOCATION
/ O
day B_TIME[MEASURE]/B_LOCATION
) O
- O
lovastatin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
( O
primarily O
20 B_MEASURE
or O
40 B_MEASURE/B_LOCATION
mg I_MEASURE/I_LOCATION
) O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
was O
given O
. O

Follow O
- O
up O
visits B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
scheduled O
with O
2 B_NUMBER[MEASURE]/B_LOCATION
- O
drug B_TIME[MEASURE]/B_PERSON
therapy I_TIME[MEASURE]/I_PERSON
every O
6 B_NUMBER[MEASURE]/B_LOCATION
to O
8 B_TIME[MEASURE]/B_ENT
weeks I_TIME[MEASURE]/I_ENT
, O
an O
average B_MEASURE/B_SOCIAL_CIRCUMSTANCES
of O
10 B_MEASURE
. O
3 B_TIME[MEASURE]
visits I_TIME[MEASURE]
per O
patient B_PERSON/B_TIME[MEASURE]
, O
with O
741 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
batteries I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
6 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
liver B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
function B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
tests B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O
714 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
creatine I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
phosphokinase I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
levels I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
measured O
. O

Only O
1 B_NUMBER[MEASURE]
of O
the O
4 B_MEASURE
, O
446 B_MEASURE
liver I_MEASURE
function I_MEASURE
tests I_MEASURE
( O
0 B_MEASURE
. O
02 B_MEASURE/B_LOCATION
% I_MEASURE/I_LOCATION
) O
, O
a O
gamma B_MEASURE/B_PERSON
glutamyl I_MEASURE/I_PERSON
transferase I_MEASURE/I_PERSON
, O
was O
greater B_MEASURE
than O
or O
equal B_MEASURE
to O
3 B_TIME[MEASURE]/B_LOCATION
times B_TIME[MEASURE]/I_LOCATION
the O
upper B_MEASURE
normal I_MEASURE
limit I_MEASURE
. O

Of O
the O
714 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
creatine I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
phosphokinase I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
levels I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O
9 B_NUMBER[MEASURE]/B_PERSON
% I_NUMBER[MEASURE]/I_PERSON
were O
high B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
; O
only O
1 B_NUMBER[MEASURE]/B_PERSON
( O
0 B_MEASURE
. O
1 B_MEASURE
% I_MEASURE
) O
was O
greater B_MEASURE
than O
or O
equal B_MEASURE
to O
3 B_TIME[MEASURE]/B_LOCATION
times B_TIME[MEASURE]/I_LOCATION
the O
upper B_MEASURE/B_LOCATION
normal I_MEASURE/I_LOCATION
limit I_MEASURE/I_LOCATION
. O

With O
2 B_NUMBER[MEASURE]/B_DISEASE
- O
drug B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
mean B_MEASURE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
total B_MEASURE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cholesterol B_MEASURE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
decreased O
22 B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
% I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
from O
255 B_MEASURE
to O
200 B_MEASURE
mg I_MEASURE
/ O
dl B_MEASURE/B_DISEASE
, O
triglyceride B_GENE
levels I_GENE
decreased O
35 B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
% I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
from O
236 B_MEASURE
to O
154 B_MEASURE
mg I_MEASURE
/ O
dl B_MEASURE/B_DISEASE
, O
LDL B_GENE
cholesterol I_GENE
decreased O
26 B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
% I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
from O
176 B_MEASURE
to O
131 B_MEASURE
mg I_MEASURE
/ O
dl B_MEASURE/B_DISEASE
, O
and O
the O
total B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cholesterol I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
HDL B_MEASURE/B_LOCATION
cholesterol B_MEASURE/I_LOCATION
ratio B_MEASURE/I_LOCATION
decreased O
24 B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
% I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
from O
7 B_MEASURE
. O
1 B_MEASURE
to O
5 B_MEASURE
. O
4 B_MEASURE
, O
all O
p B_MEASURE
less I_MEASURE
than O
or O
equal B_MEASURE
to O
0 B_MEASURE
. O
0001 B_MEASURE
. O

Myositis B_DISEASE_ADJECTIVE[DISEASE]
, O
attributable O
to O
the O
drug O
combination O
and O
symptomatic O
enough O
to O
discontinue O
it O
, O
occurred O
in O
3 O
% O
of O
patients O
, O
and O
in O
1 O
% O
with O
concurrent O
high O
creatine O
phosphokinase O
( O
769 O
U O
/ O
liter O
) O
; O
no O
patients O
had O
rhabdomyolysis B_DISEASE
or O
myoglobinuria B_DISEASE
. O
( O
abstract O
TRUNCATED O
AT O
250 O
Words O
) O
. O

Does O
domperidone O
potentiate O
mirtazapine O
- O
associated O
restless B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
legs I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
syndrome I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT

There O
is O
now O
evidence O
to O
suggest O
a O
central O
role O
for O
the O
dopaminergic O
system O
in O
restless B_DISEASE
legs I_DISEASE
syndrome I_DISEASE
( O
RLS B_DISEASE
) O
. O

For O
example O
, O
the O
symptoms O
of O
RLS B_DISEASE
can O
be O
dramatically O
improved O
by O
levodopa O
and O
dopamine O
agonists O
, O
whereas O
central O
dopamine O
D2 O
receptor O
antagonists O
can O
induce O
or O
aggravate O
RLS B_DISEASE/B_MEASURE
symptoms O
. O

To O
our O
knowledge O
, O
there O
is O
no O
previous O
report O
regarding O
whether O
domperidone O
, O
a O
peripheral O
dopamine O
D2 O
receptor O
antagonist O
, O
can O
also O
induce O
or O
aggravate O
symptoms O
of O
RLS B_DISEASE
. O

Mirtazapine O
, O
the O
first O
noradrenergic O
and O
specific O
serotonergic O
antidepressant O
( O
NaSSA O
) O
, O
has O
been O
associated O
with O
RLS B_DISEASE
in O
several O
recent O
publications O
. O

The O
authors O
report O
here O
a O
depressed O
patient O
comorbid O
with O
postprandial B_DISEASE
dyspepsia I_DISEASE
who O
developed O
RLS B_DISEASE
after O
mirtazapine O
had O
been O
added O
to O
his O
domperidone O
therapy O
. O

Our O
patient O
started O
to O
have O
symptoms O
of O
RLS B_DISEASE
only O
after O
he O
had O
been O
treated O
with O
mirtazapine O
, O
and O
his O
RLS B_DISEASE/B_MEASURE
symptoms O
resolved O
completely O
upon O
discontinuation O
of O
his O
mirtazapine O
. O

Such O
a O
temporal O
relationship O
between O
the O
use O
of O
mirtazapine O
and O
the O
symptoms O
of O
RLS B_DISEASE
in O
our O
patient O
did O
not O
support O
a O
potentiating O
effect O
of O
domperione O
on O
mirtazapine O
- O
associated O
RLS B_DISEASE
. O

However O
, O
physicians O
should O
be O
aware O
of O
the O
possibility O
that O
mirtazapine O
can O
be O
associated O
with O
RLS B_DISEASE
in O
some O
individuals O
, O
especially O
those O
receiving O
concomitant O
dopamine O
D2 O
receptor O
antagonists O
. O

Antiandrogenic O
therapy O
can O
cause O
coronary B_DISEASE
arterial I_DISEASE
disease I_DISEASE
. O

aim O
: O
To O
study O
the O
change O
of O
lipid O
metabolism O
by O
antiandrogen O
therapy O
in O
patients O
with O
prostate B_DISEASE/B_LOCATION
cancer I_DISEASE/I_LOCATION
. O

Materials O
AND O
methods O
: O
We O
studied O
with O
a O
2 O
. O
5 O
years O
follow O
- O
up O
the O
changes O
in O
plasma O
cholesterols O
( O
C O
) O
, O
triglycerides O
( O
TG O
) O
, O
lipoproteins O
( O
LP O
) O
, O
and O
apolipoproteins O
( O
Apo O
) O
B O
- O
100 O
, O
A O
- O
I O
, O
and O
A O
- O
II O
pro O
fi O
les O
in O
24 O
patients O
of O
mean O
age O
60 O
years O
with O
low O
risk O
prostate B_DISEASE
cancer I_DISEASE
( O
stage O
: O
T1cN0M0 O
, O
Gleason O
score O
: O
2 O
- O
5 O
) O
during O
treatment O
with O
cyproterone O
acetate O
( O
CPA O
) O
without O
surgical O
management O
or O
radiation O
therapy O
. O

RESULTS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O
Significant B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
decreases I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
HDL B_GENE
- O
C B_PROTEIN[GENE]
, O
Apo B_PROTEIN[GENE]/B_LOCATION
A I_PROTEIN[GENE]/I_LOCATION
- O
I B_OTHER/B_PROTEIN[GENE]
and O
Apo B_PROTEIN[GENE]/B_LOCATION
A I_PROTEIN[GENE]/I_LOCATION
- O
II B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
an O
increase B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
triglyceride B_PROTEIN[GENE]
levels I_PROTEIN[GENE]
in O
VLDL B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
were O
induced O
by O
CPA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O

After O
a O
period O
of O
2 O
. O
5 O
years O
on O
CPA O
treatment O
, O
four O
patients O
out O
of O
twenty O
- O
four O
were O
found O
to O
be O
affected O
by O
coronary B_DISEASE/B_LOCATION
heart I_DISEASE/I_LOCATION
disease I_DISEASE/I_LOCATION
. O

conclusions O
: O
Ischaemic O
coronary B_DISEASE
arteriosclerosis I_DISEASE
with O
an O
incidence O
rate O
of O
16 O
. O
6 O
% O
as O
caused O
by O
prolonged O
CPA O
therapy O
is O
mediated O
through O
changes O
in O
HDL O
cholesterol O
, O
Apo O
A O
- O
I O
and O
Apo O
A O
- O
II O
pro O
fi O
les O
, O
other O
than O
the O
well O
- O
known O
hyperglyceridemic B_DISEASE_ADJECTIVE[DISEASE]
effect I_DISEASE_ADJECTIVE[DISEASE]
caused O
by O
estrogen O
. O

5 O
- O
Fluorouracil O
cardiotoxicity B_DISEASE
induced O
by O
alpha O
- O
fluoro O
- O
beta O
- O
alanine O
. O

Cardiotoxicity B_DISEASE
is O
a O
rare O
complication O
occurring O
during O
5 O
- O
fluorouracil O
( O
5 O
- O
Fu O
) O
treatment O
for O
malignancies B_DISEASE
. O

We O
herein O
report O
the O
case O
of O
a O
70 O
- O
year O
- O
old O
man O
with O
5 O
- O
Fu O
- O
induced O
cardiotoxicity B_DISEASE
, O
in O
whom O
a O
high O
serum O
level O
of O
alpha O
- O
fluoro O
- O
beta O
- O
alanine O
( O
FBAL O
) O
was O
observed O
. O

The O
patient O
, O
who O
had O
unresectable O
colon B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
cancer B_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
metastases O
to O
the O
liver O
and O
lung O
, O
was O
referred O
to O
us O
for O
chemotherapy O
from O
an O
affiliated O
hospital O
; O
he O
had O
no O
cardiac O
history O
. O

After O
admission O
, O
the O
patient O
received O
a O
continuous O
intravenous O
infusion O
of O
5 O
- O
Fu O
( O
1000 O
mg O
/ O
day O
) O
, O
during O
which O
precordial B_DISEASE
pain I_DISEASE
with O
right B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
bundle I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
branch I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
block I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
occurred O
concomitantly O
with O
a O
high O
serum O
FBAL O
concentration O
of O
1955 O
ng O
/ O
ml O
. O

Both O
the O
precordial B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pain B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
the O
electrocardiographic O
changes O
disappeared O
spontaneously O
after O
the O
discontinuation O
of O
5 O
- O
Fu O
. O

As O
the O
precordial B_DISEASE
pain I_DISEASE
in O
this O
patient O
was O
considered O
to O
have O
been O
due O
to O
5 O
- O
Fu O
- O
induced O
cardiotoxicity B_DISEASE
, O
the O
administration O
of O
5 O
- O
Fu O
was O
abandoned O
. O

Instead O
, O
oral B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
administration I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
S B_OTHER/B_LOCATION
- O
1 B_NUMBER[MEASURE]
( O
a O
derivative B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
of O
5 B_NUMBER[MEASURE]
- O
FU B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
) O
, O
at O
200 B_TIME[MEASURE]
mg I_TIME[MEASURE]
/ O
day B_TIME[MEASURE]
twice O
a O
week B_TIME[MEASURE]
, O
was O
instituted O
, O
because O
S B_OTHER/B_LOCATION
- O
1 B_NUMBER[MEASURE]
has O
a O
strong B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
inhibitory B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effect B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
dihydropyrimidine B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
dehydrogenase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
which O
catalyzes O
the O
degradative B_BACTERIUM[BIO]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
5 B_NUMBER[MEASURE]/B_PERSON
- O
Fu B_PERSON/B_LOCATION
into O
FBAL B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O

The O
serum B_MEASURE
FBAL I_MEASURE
concentration I_MEASURE
subsequently O
decreased O
to O
352 B_MEASURE/B_PERSON
ng I_MEASURE/I_PERSON
/ O
ml B_MEASURE/B_PERSON
, O
the O
same B_MEASURE/B_LOCATION
as O
the O
value B_MEASURE/B_LOCATION
measured O
on O
the O
first B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
day B_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
S B_OTHER/B_DISEASE
- O
1 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
administration I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

Thereafter O
, O
no O
cardiac B_DISEASE_ADJECTIVE[DISEASE]
symptoms I_DISEASE_ADJECTIVE[DISEASE]
were O
observed O
. O

The O
patient B_PERSON/B_BIO
achieved O
a O
partial B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
response I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
6 I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
months I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
after O
the O
initiation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
the O
S B_DISEASE/B_GENE
- O
1 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treatment I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
experience O
of O
this O
case O
, O
together O
with O
a O
review O
of O
the O
literature O
, O
suggests O
that O
FBAL O
is O
related O
to O
5 O
- O
Fu O
- O
induced O
cardiotoxicity B_DISEASE
. O

S O
- O
1 O
may O
be O
administered O
safely O
to O
patients O
with O
5 O
- O
Fu O
- O
induced O
cardiotoxicity B_DISEASE/B_LOCATION
. O

Hepatocellular B_DISEASE
carcinoma I_DISEASE
in O
Fanconi B_PERSON/B_BIO
' I_PERSON/I_BIO
s I_PERSON/I_BIO
anemia I_PERSON/I_BIO
treated O
with O
androgen O
and O
corticosteroid O
. O

The O
case O
of O
an O
11 O
- O
year O
- O
old O
boy O
is O
reported O
who O
was O
known O
to O
have O
Fanconi B_DISEASE
' I_DISEASE
s I_DISEASE
anemia I_DISEASE
for O
3 O
years O
and O
was O
treated O
with O
androgens O
, O
corticosteroids O
and O
transfusions O
. O

Two O
weeks O
before O
his O
death O
he O
was O
readmitted O
because O
of O
aplastic O
crisis O
with O
septicemia B_DISEASE
and O
marked O
abnormalities O
in O
liver O
function O
and O
died O
of O
hemorrhagic B_DISEASE
bronchopneumonia I_DISEASE
. O

At O
autopsy O
peliosis B_DISEASE_ADJECTIVE[DISEASE]/B_NUMBER[MEASURE]
and O
multiple O
hepatic B_DISEASE
tumors I_DISEASE
were O
found O
which O
histologically O
proved O
to O
be O
well O
- O
differentiated O
hepatocellular B_DISEASE
carcinoma I_DISEASE
. O

This O
case O
contributes O
to O
the O
previous O
observations O
that O
non O
- O
metastasizing O
hepatic B_DISEASE
neoplasms I_DISEASE
and O
peliosis B_DISEASE
can O
develop O
in O
patients O
with O
androgen O
- O
and O
corticosteroid O
- O
treated O
Fanconi B_DISEASE/B_LOCATION
' I_DISEASE/I_LOCATION
s I_DISEASE/I_LOCATION
anemia I_DISEASE/I_LOCATION
. O

The O
influence O
of O
the O
time O
interval O
between O
monoHER O
and O
doxorubicin O
administration O
on O
the O
protection O
against O
doxorubicin O
- O
induced O
cardiotoxicity B_DISEASE
in O
mice O
. O

purpose O
: O
Despite O
its O
well O
- O
known O
cardiotoxicity B_DISEASE
, O
the O
anthracyclin O
doxorubicin O
( O
DOX O
) O
continues O
to O
be O
an O
effective O
and O
widely O
used O
chemotherapeutic O
agent O
. O

DOX O
- O
induced O
cardiac B_DISEASE/B_GENE
damage I_DISEASE/I_GENE
presumably O
results O
from O
the O
formation O
of O
free O
radicals O
by O
DOX O
. O

Reactive B_DISEASE/B_PERSON
oxygen I_DISEASE/I_PERSON
species I_DISEASE/I_PERSON
particularly O
affect O
the O
cardiac B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
myocytes I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
because O
these O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
seem O
to O
have O
a O
relatively O
poor B_DISEASE/B_MEASURE
antioxidant I_DISEASE/I_MEASURE
defense I_DISEASE/I_MEASURE
system I_DISEASE/I_MEASURE
. O

The O
semisynthetic O
flavonoid O
monohydroxyethylrutoside O
( O
monoHER O
) O
showed O
cardioprotection O
against O
DOX O
- O
induced O
cardiotoxicity B_DISEASE
through O
its O
radical O
scavenging O
and O
iron O
chelating O
properties O
. O

Because O
of O
the O
relatively O
short B_MEASURE/B_LOCATION
final B_MEASURE/I_LOCATION
half B_MEASURE/I_LOCATION
- O
life B_TIME[MEASURE]/B_LOCATION
of O
monoHER B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
( O
about O
30 B_TIME[MEASURE]
min I_TIME[MEASURE]
) O
, O
it O
is O
expected O
that O
the O
time B_MEASURE
interval I_MEASURE
between O
monoHER B_LOCATION/B_ORGANIZATION
and O
DOX B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
might O
be O
of O
influence B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
on O
the O
cardioprotective B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
effect I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
of O
monoHER B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Therefore O
, O
the O
aim B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
the O
present B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
was O
to O
investigate O
this O
possible B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
effect I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

METHODS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
: O
Six B_NUMBER[MEASURE]/B_ENT
groups I_NUMBER[MEASURE]/I_ENT
of O
6 B_MEASURE/B_GENE
BALB I_MEASURE/I_GENE
/ O
c B_MEASURE/B_PERSON
mice I_MEASURE/I_PERSON
were O
treated O
with O
saline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O
DOX B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alone O
or O
DOX B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
4 B_MEASURE
mg I_MEASURE
/ O
kg O
i O
. O
v B_LOCATION/B_GENE
. O
) O
preceded O
by O
monoHER B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
500 B_MEASURE
mg I_MEASURE
/ O
kg B_MEASURE
i O
. O
p B_MEASURE/B_LOCATION
. O
) O
with O
an O
interval B_MEASURE/B_PERSON
of O
10 B_MEASURE
, O
30 B_MEASURE
, O
60 B_MEASURE
or O
120 B_MEASURE/B_LOCATION
min I_MEASURE/I_LOCATION
. O

After O
a O
6 B_NUMBER[MEASURE]
- O
week B_TIME[MEASURE]
treatment I_TIME[MEASURE]
period I_TIME[MEASURE]
and O
additional B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
observation I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
2 B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
weeks I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
, O
the O
mice B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
sacrificed O
. O

Their O
cardiac O
tissues O
were O
processed O
for O
light O
microscopy O
, O
after O
which O
cardiomyocyte B_DISEASE
damage I_DISEASE
was O
evaluated O
according O
to O
Billingham O
( O
in O
Cancer B_DISEASE/B_GENE
treat O
Rep O
62 O
( O
6 O
) O
: O
865 O
- O
872 O
, O
1978 O
) O
. O

Microscopic O
evaluation O
revealed O
that O
treatment O
with O
DOX O
alone O
induced O
significant O
cardiac B_DISEASE_ADJECTIVE[DISEASE]
damage I_DISEASE_ADJECTIVE[DISEASE]
in O
comparison O
to O
the O
saline O
control O
group O
( O
P O
< O
0 O
. O
001 O
) O
. O

RESULTS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O
The O
number B_MEASURE/B_DISEASE
of O
damaged O
cardiomyocytes B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
was O
9 B_MEASURE
. O
6 B_MEASURE
- O
fold B_MEASURE
( O
95 B_MEASURE
% I_MEASURE
CI I_MEASURE
4 I_MEASURE
. O
4 B_MEASURE
- O
21 B_MEASURE
. O
0 B_MEASURE
) O
higher B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
in O
mice B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treated O
with O
DOX B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
alone O
than O
that O
in O
animals B_BIO/B_PERSON
of O
the O
control B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
group I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
. O

The O
ratio B_MEASURE
of O
aberrant B_DISEASE/B_GENE
cardiomyocytes I_DISEASE/I_GENE
in O
mice B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treated O
with O
DOX B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
preceded O
by O
monoHER B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O
those O
in O
mice B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treated O
with O
saline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ranged O
from O
1 B_NUMBER[MEASURE]
. O
6 B_MEASURE
to O
2 B_MEASURE
. O
8 B_MEASURE
( O
mean O
2 B_MEASURE
. O
2 B_MEASURE
, O
95 B_MEASURE
% I_MEASURE
CI I_MEASURE
1 I_MEASURE
. O
2 B_MEASURE
- O
4 B_MEASURE
. O
1 B_MEASURE
, O
P B_OTHER/B_PROTEIN[GENE]
= O
0 B_MEASURE
. O
019 B_MEASURE
) O
. O

The O
mean B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
protective I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
effect I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
by O
adding O
monoHER B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
before O
DOX B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
led O
to O
a O
significant B_MEASURE
4 I_MEASURE
. O
4 B_MEASURE
- O
fold B_MEASURE
reduction I_MEASURE
( O
P B_OTHER/B_MEASURE
< O
0 B_MEASURE
. O
001 B_MEASURE
, O
95 B_MEASURE
% I_MEASURE
CI I_MEASURE
2 I_MEASURE
. O
3 B_MEASURE
- O
8 B_MEASURE
. O
2 B_MEASURE
) O
of O
abnormal B_DISEASE/B_GENE
cardiomyocytes I_DISEASE/I_GENE
. O

This O
protective B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effect I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
did O
not O
depend O
on O
the O
time B_MEASURE
interval I_MEASURE
between O
monoHER B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
and O
DOX B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
administration I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O
P B_OTHER/B_PROTEIN[GENE]
= O
0 B_MEASURE
. O
345 B_MEASURE
) O
. O

Conclusion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O
The O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
indicate O
that O
in O
an O
outpatient B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
clinical I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
setting I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
monoHER I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
may O
be O
administered O
shortly O
before O
DOX B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O

Clinical O
evaluation O
of O
adverse O
effects O
during O
bepridil O
administration O
for O
atrial B_DISEASE
fibrillation I_DISEASE
and I_DISEASE
flutter I_DISEASE
. O

Background O
: O
Bepridil O
hydrochloride O
( O
Bpd O
) O
has O
attracted O
attention O
as O
an O
effective O
drug O
for O
atrial B_DISEASE_ADJECTIVE[DISEASE]
fibrillation I_DISEASE_ADJECTIVE[DISEASE]
( O
AF B_LOCATION/B_ORGANIZATION
) O
and O
atrial B_DISEASE
flutter I_DISEASE
( O
AFL B_ORGANIZATION/B_LOCATION
) O
. O

However O
, O
serious O
adverse O
effects O
, O
including O
torsade B_DISEASE
de I_DISEASE
pointes I_DISEASE
( O
Tdp B_PROTEIN[GENE]/B_LOCATION
) O
, O
have O
been O
reported O
. O

METHODS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
AND O
RESULTS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
Adverse B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
effects I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
of O
BPD B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
requiring O
discontinuation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
treatment B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
were O
evaluated O
. O

Bpd O
was O
administered O
to O
459 O
patients O
( O
361 O
males O
, O
63 O
+ O
/ O
- O
12 O
years O
old O
) O
comprising O
378 O
AF B_DISEASE/B_LOCATION
and O
81 O
AFL B_DISEASE
cases O
. O

Mean O
left O
ventricular B_MEASURE/B_LOCATION
ejection B_MEASURE/I_LOCATION
fraction B_MEASURE/I_LOCATION
and O
atrial B_MEASURE
dimension I_MEASURE
( O
lad B_PERSON/B_DISEASE
) O
were O
66 B_MEASURE
+ I_MEASURE
/ O
- O
11 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
and O
40 B_MEASURE
+ I_MEASURE
/ O
- O
6 B_MEASURE
mm I_MEASURE
, O
respectively O
. O

Adverse B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
observed O
in O
19 B_NUMBER[MEASURE]
patients I_NUMBER[MEASURE]
( O
4 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
during O
an O
average B_MEASURE/B_LOCATION
follow B_MEASURE/I_LOCATION
- O
up B_LOCATION/B_LANGUAGE
of O
20 B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
months B_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

There O
was O
marked O
QT B_DISEASE
prolongation I_DISEASE
greater O
than O
0 O
. O
55 O
s O
in O
13 O
patients O
, O
bradycardia B_DISEASE
less O
than O
40 O
beats O
/ O
min O
in O
6 O
patients O
, O
dizziness B_DISEASE
and O
general O
fatigue B_DISEASE
in O
1 O
patient O
each O
. O

In O
4 O
of O
13 O
patients O
with O
QT B_DISEASE
prolongation I_DISEASE
, O
Tdp B_DISEASE/B_GENE
occurred O
. O

The O
major O
triggering O
factors O
of O
Tdp B_DISEASE/B_GENE
were O
hypokalemia B_DISEASE_ADJECTIVE[DISEASE]
and O
sudden O
decrease O
in O
heart O
rate O
. O

There O
were O
no O
differences O
in O
the O
clinical O
backgrounds O
of O
the O
patients O
with O
and O
without O
Tdp B_DISEASE/B_GENE
other O
than O
lad O
and O
age O
, O
which O
were O
larger O
and O
older O
in O
the O
patients O
with O
Tdp B_DISEASE/B_GENE
. O

Conclusion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O
Careful B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
observation I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
serum B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
potassium B_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
concentration B_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
the O
ECG B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
should O
always O
be O
done O
during O
BPD B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
administration I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANISM_FUNCTION
, O
particularly O
in O
elderly B_PERSON/B_BIO
patients I_PERSON/I_BIO
. O

enhanced O
isoproterenol O
- O
induced O
cardiac B_DISEASE/B_GENE
hypertrophy I_DISEASE/I_GENE
in O
transgenic O
rats O
with O
low O
brain O
angiotensinogen O
. O

We O
have O
previously O
shown O
that O
a O
permanent B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
deficiency I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
the O
brain B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
renin B_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
- O
angiotensin B_DISEASE_ADJECTIVE[DISEASE]/B_ENZYME[GENE]
system B_DISEASE_ADJECTIVE[DISEASE]/I_ENZYME[GENE]
( O
RAS B_LOCATION/B_DISEASE
) O
may O
increase O
the O
sensitivity B_MEASURE
of O
the O
baroreflex B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
control I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
heart B_DISEASE
rate I_DISEASE
. O

In O
this O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
we O
aimed O
at O
studying O
the O
involvement B_PERSON/B_DISEASE
of O
the O
brain B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
RAS I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
in O
the O
cardiac B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reactivity B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
the O
beta B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
adrenoceptor B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
( O
beta B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
AR B_PROTEIN[GENE]/B_DISEASE
) O
agonist B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
isoproterenol I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
ISO B_ORGANIZATION/B_LOCATION
) O
. O

Transgenic B_PERSON/B_BIO
rats I_PERSON/I_BIO
with O
low B_DISEASE
brain I_DISEASE
angiotensinogen I_DISEASE
( O
TGR B_LOCATION/B_ORGANIZATION
) O
were O
used O
. O

In O
isolated B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
hearts I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
, O
Iso B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
induced O
a O
significantly O
greater B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
increase I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O
left B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
ventricular I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
( O
LV B_PROTEIN[GENE]/B_BODY_PART_OR_ORGAN_COMPONENT
) O
pressure B_DISEASE/B_MEASURE
and O
maximal B_MEASURE/B_DISEASE
contraction I_MEASURE/I_DISEASE
( O
+ B_LOCATION/B_PROTEIN[GENE]
dP I_LOCATION/I_PROTEIN[GENE]
/ O
dt B_PROTEIN[GENE]/B_MEASURE
( O
Max B_PERSON/B_MEASURE
) O
) O
in O
the O
TGR B_BODY_PART_OR_ORGAN_COMPONENT/B_PROTEIN[GENE]
than O
in O
the O
Sprague B_PERSON
- O
Dawley B_PERSON
( O
SD B_MEASURE/B_DISEASE
) O
rats B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

LV B_DISEASE
hypertrophy I_DISEASE
induced O
by O
ISO O
treatment O
was O
significantly O
higher O
in O
TGR O
than O
in O
SD O
rats O
( O
in O
g O
LV O
wt O
/ O
100 O
g O
body O
wt O
, O
0 O
. O
28 O
+ O
/ O
- O
0 O
. O
004 O
vs O
. O
0 O
. O
24 O
+ O
/ O
- O
0 O
. O
004 O
, O
respectively O
) O
. O

The O
greater O
LV B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
hypertrophy I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
TGR O
rats O
was O
associated O
with O
more O
pronounced O
downregulation O
of O
beta O
- O
AR O
and O
upregulation O
of O
LV O
beta O
- O
AR O
kinase O
- O
1 O
mRNA O
levels O
compared O
with O
those O
in O
SD O
rats O
. O

The O
decrease B_DISEASE
in O
the O
heart B_MEASURE/B_LOCATION
rate B_MEASURE/I_LOCATION
( O
HR B_PROTEIN[GENE]/B_BODY_PART_OR_ORGAN_COMPONENT
) O
induced O
by O
the O
beta B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
AR B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
antagonist I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
metoprolol I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
conscious B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
rats B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
was O
significantly O
attenuated O
in O
TGR B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
compared O
with O
SD B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
rats B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
( O
- O
9 B_MEASURE
. O
9 B_MEASURE
+ I_MEASURE
/ O
- O
1 B_MEASURE
. O
7 B_MEASURE
% I_MEASURE
vs I_MEASURE
. O
- O
18 B_MEASURE
. O
1 B_MEASURE/B_LOCATION
+ I_MEASURE/I_LOCATION
/ O
- O
1 B_MEASURE
. O
5 B_MEASURE
% I_MEASURE
) O
, O
whereas O
the O
effect B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
parasympathetic B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
blockade I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
by O
atropine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
HR B_PROTEIN[GENE]/B_BODY_PART_OR_ORGAN_COMPONENT
was O
similar B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
both O
strains B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

These O
results O
indicate O
that O
TGR O
are O
more O
sensitive O
to O
beta O
- O
AR O
agonist O
- O
induced O
cardiac B_DISEASE_ADJECTIVE[DISEASE]
inotropic I_DISEASE_ADJECTIVE[DISEASE]
response O
and O
hypertrophy B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
possibly O
due O
to O
chronically O
low O
sympathetic O
outflow O
directed O
to O
the O
heart O
. O

Drug O
- O
induced O
long B_DISEASE
QT I_DISEASE
syndrome I_DISEASE
in O
injection O
drug O
users O
receiving O
methadone O
: O
high O
frequency O
in O
hospitalized O
patients O
and O
risk O
factors O
. O

Background O
: O
Drug O
- O
induced O
long B_DISEASE
QT I_DISEASE
syndrome I_DISEASE
is O
a O
serious O
adverse O
drug O
reaction O
. O

methadone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
prolongs O
the O
QT B_DISEASE
interval I_DISEASE
in O
vitro B_SPECIES[BIO]/B_LOCATION
in O
a O
dose B_MEASURE
- O
dependent B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
manner I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
. O

In O
the O
inpatient O
setting O
, O
the O
frequency O
of O
QT B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
interval I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
prolongation I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
methadone O
treatment O
, O
its O
dose O
dependence O
, O
and O
the O
importance O
of O
cofactors O
such O
as O
drug O
- O
drug O
interactions O
remain O
unknown O
. O

METHODS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O
We O
performed O
a O
systematic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O
retrospective B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
comparing O
active B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
or O
former B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
intravenous B_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
drug B_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
users B_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
receiving O
methadone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
those O
not O
receiving O
methadone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
among O
all O
patients B_PERSON
hospitalized O
over O
a O
5 B_NUMBER[MEASURE]
- O
year B_TIME[MEASURE]
period I_TIME[MEASURE]
in O
a O
tertiary B_LOCATION
care I_LOCATION
hospital I_LOCATION
. O

A O
total B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
167 B_MEASURE/B_PERSON
patients I_MEASURE/I_PERSON
receiving O
methadone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fulfilled O
the O
inclusion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
criteria I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
were O
compared O
with O
a O
control B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
group I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
80 B_PERSON/B_ORGANIZATION
injection I_PERSON/I_ORGANIZATION
drug I_PERSON/I_ORGANIZATION
users I_PERSON/I_ORGANIZATION
not O
receiving O
methadone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

In O
addition O
to O
methadone O
dose O
, O
15 O
demographic O
, O
biological O
, O
and O
pharmacological O
variables O
were O
considered O
as O
potential O
risk O
factors O
for O
QT B_DISEASE
prolongation I_DISEASE
. O

RESULTS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O
Among O
167 B_PERSON/B_BIO
methadone I_PERSON/I_BIO
maintenance I_PERSON/I_BIO
patients I_PERSON/I_BIO
, O
the O
prevalence B_MEASURE/B_LOCATION
of O
QTc B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
prolongation B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
0 B_MEASURE
. O
50 B_MEASURE
second I_MEASURE
( O
( O
1 B_MEASURE
/ O
2 B_MEASURE
) O
) O
or O
longer B_MEASURE
was O
16 B_MEASURE
. O
2 B_MEASURE
% I_MEASURE
compared O
with O
0 B_MEASURE
% I_MEASURE
in O
80 B_PERSON/B_LOCATION
control I_PERSON/I_LOCATION
subjects I_PERSON/I_LOCATION
. O

Six O
patients O
( O
3 O
. O
6 O
% O
) O
in O
the O
methadone O
group O
presented O
torsades B_DISEASE
de I_DISEASE
pointes I_DISEASE
. O

QTc B_DISEASE/B_GENE
length I_DISEASE/I_GENE
was O
weakly O
but O
significantly O
associated O
with O
methadone B_MEASURE/B_LOCATION
daily I_MEASURE/I_LOCATION
dose I_MEASURE/I_LOCATION
( O
Spearman B_LOCATION/B_MEASURE
rank I_LOCATION/I_MEASURE
correlation I_LOCATION/I_MEASURE
coefficient I_LOCATION/I_MEASURE
, O
0 B_MEASURE/B_LOCATION
. O
20 B_MEASURE
; O
P B_MEASURE
< I_MEASURE
. O
01 B_MEASURE
) O
. O

Multivariate O
regression O
analysis O
allowed O
attribution O
of O
31 O
. O
8 O
% O
of O
QTc O
variability O
to O
methadone O
dose O
, O
cytochrome O
P O
- O
450 O
3A4 O
drug O
- O
drug O
interactions O
, O
hypokalemia B_DISEASE/B_PERSON
, O
and O
altered O
liver O
function O
. O

conclusions O
: O
QT B_DISEASE
interval I_DISEASE
prolongation I_DISEASE
in O
methadone O
maintenance O
patients O
hospitalized O
in O
a O
tertiary O
care O
center O
is O
a O
frequent O
finding O
. O

Methadone O
dose O
, O
presence O
of O
cytochrome O
P O
- O
450 O
3A4 O
inhibitors O
, O
potassium O
level O
, O
and O
liver O
function O
contribute O
to O
QT B_DISEASE
prolongation I_DISEASE
. O

Long B_DISEASE
QT I_DISEASE
syndrome I_DISEASE
can O
occur O
with O
low O
doses O
of O
methadone O
. O

mechanisms O
of O
hypertension B_DISEASE
induced O
by O
nitric O
oxide O
( O
NO O
) O
deficiency O
: O
focus O
on O
venous O
function O
. O

Loss O
of O
endothelial O
cell O
- O
derived O
nitric O
oxide O
( O
NO O
) O
in O
hypertension B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
is O
a O
hallmark O
of O
arterial B_DISEASE
dysfunction I_DISEASE
. O

Experimental O
hypertension B_DISEASE
created O
by O
the O
removal O
of O
NO O
, O
however O
, O
involves O
mechanisms O
in O
addition O
to O
decreased O
arterial O
vasodilator O
activity O
. O

These O
include O
augmented O
endothelin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
1 B_TIME[MEASURE]
( O
ET B_PROTEIN[GENE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
- O
1 B_NUMBER[MEASURE]
) O
release B_ENT/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
increased O
sympathetic B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
nervous I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
system I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activity I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
elevated O
tissue B_DISEASE
oxidative I_DISEASE
stress I_DISEASE
. O

We O
hypothesized O
that O
increased O
venous O
smooth O
muscle O
( O
venomotor O
) O
tone O
plays O
a O
role O
in O
Nomega O
- O
nitro O
- O
L O
- O
arginine O
( O
LNNA O
) O
hypertension B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
through O
these O
mechanisms O
. O

rats B_BIO/B_PERSON
were O
treated O
with O
the O
NO B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
synthase I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
inhibitor I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
LNNA I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
0 B_MEASURE
. O
5 B_MEASURE
g I_MEASURE
/ O
L B_OTHER/B_TIME[MEASURE]
in O
drinking B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
water I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
for O
2 B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
weeks B_TIME[MEASURE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Mean B_DISEASE/B_GENE
arterial B_DISEASE/I_GENE
pressure B_DISEASE/I_GENE
of O
conscious B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
rats B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
was O
119 B_MEASURE
+ I_MEASURE
/ O
- O
2 B_MEASURE
mm I_MEASURE
Hg I_MEASURE
in O
control B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
and O
194 B_MEASURE
+ I_MEASURE
/ O
- O
5 B_MEASURE
mm I_MEASURE
Hg I_MEASURE
in O
LNNA B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
rats I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
( O
P B_PROTEIN[GENE]/B_LOCATION
< O
0 B_MEASURE
. O
05 B_MEASURE
) O
. O

carotid B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
arteries I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
and O
vena B_BODY_PART_OR_ORGAN_COMPONENT
cava I_BODY_PART_OR_ORGAN_COMPONENT
were O
removed O
for O
measurement B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
isometric B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
contraction B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

Maximal B_TIME[MEASURE]/B_PERSON
contraction I_TIME[MEASURE]/I_PERSON
to O
norepinephrine B_LOCATION
was O
modestly O
reduced O
in O
arteries B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
from O
LNNA B_DISEASE/B_GENE
compared O
with O
control B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
rats B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
whereas O
the O
maximum B_MEASURE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
contraction I_MEASURE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O
ET B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
1 B_NUMBER[MEASURE]
was O
significantly O
reduced O
( O
54 B_PERSON/B_MEASURE
% B_PERSON/I_MEASURE
control B_PERSON/I_MEASURE
) O
. O

Maximum B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
contraction B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
vena B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
cava I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
to O
norepinephrine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
37 B_PROTEIN[GENE]/B_LOCATION
% I_PROTEIN[GENE]/I_LOCATION
control I_PROTEIN[GENE]/I_LOCATION
) O
also O
was O
reduced O
but O
no O
change B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O
response B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
to O
ET B_LOCATION
- O
1 B_NUMBER[MEASURE]
was O
observed O
. O

Mean O
circulatory O
filling O
pressure O
, O
an O
in O
vivo O
measure O
of O
venomotor O
tone O
, O
was O
not O
elevated O
in O
LNNA O
hypertension B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O
1 O
or O
2 O
weeks O
after O
LNNA O
. O

The O
superoxide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
scavenger I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
tempol I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O
30 B_MEASURE
, O
100 B_MEASURE
, O
and O
300 B_MEASURE
micromol I_MEASURE
kg I_MEASURE
( O
- O
1 B_MEASURE
) O
, O
IV B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
did O
not O
change O
arterial B_DISEASE/B_GENE
pressure B_DISEASE/I_GENE
in O
control B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
rats B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
but O
caused O
a O
dose B_MEASURE
- O
dependent B_DISEASE_ADJECTIVE[DISEASE]
decrease I_DISEASE_ADJECTIVE[DISEASE]
in O
LNNA B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
rats B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
( O
- O
18 B_MEASURE
+ I_MEASURE
/ O
- O
8 B_MEASURE
, O
- O
26 B_MEASURE
+ I_MEASURE
/ O
- O
15 B_MEASURE
, O
and O
- O
54 B_MEASURE
+ I_MEASURE
/ O
- O
11 B_MEASURE
mm I_MEASURE
Hg I_MEASURE
) O
. O

Similarly O
, O
ganglionic O
blockade O
with O
hexamethonium O
caused O
a O
significantly O
greater O
fall O
in O
LNNA O
hypertensive B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
rats O
( O
76 O
+ O
/ O
- O
9 O
mm O
Hg O
) O
compared O
with O
control O
rats O
( O
35 O
+ O
/ O
- O
10 O
mm O
Hg O
) O
. O

carotid B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
arteries I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
, O
vena B_BODY_PART_OR_ORGAN_COMPONENT
cava I_BODY_PART_OR_ORGAN_COMPONENT
, O
and O
sympathetic B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
ganglia I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
from O
LNNA B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
rats I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
had O
higher B_DISEASE_ADJECTIVE[DISEASE]
basal I_DISEASE_ADJECTIVE[DISEASE]
levels I_DISEASE_ADJECTIVE[DISEASE]
of O
superoxide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
compared O
with O
those O
from O
control B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
rats I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

These O
data O
suggest O
that O
while O
NO O
deficiency O
increases O
oxidative O
stress O
and O
sympathetic O
activity O
in O
both O
arterial O
and O
venous O
vessels O
, O
the O
impact O
on O
veins O
does O
not O
make O
a O
major O
contribution O
to O
this O
form O
of O
hypertension B_DISEASE
. O

Association O
of O
DRD2 O
polymorphisms O
and O
chlorpromazine O
- O
induced O
extrapyramidal B_DISEASE
syndrome I_DISEASE
in O
Chinese O
schizophrenic B_DISEASE/B_PERSON
patients O
. O

aim O
: O
Extrapyramidal B_DISEASE
syndrome I_DISEASE
( O
EPS B_DISEASE
) O
is O
most O
commonly O
affected O
by O
typical O
antipsychotic O
drugs O
that O
have O
a O
high O
affinity O
with O
the O
D2 O
receptor O
. O

Recently O
, O
many O
research O
groups O
have O
reported O
on O
the O
positive O
relationship O
between O
the O
genetic O
variations O
in O
the O
DRD2 O
gene O
and O
the O
therapeutic O
response O
in O
schizophrenia B_DISEASE/B_LOCATION
patients O
as O
a O
result O
of O
the O
role O
of O
variations O
in O
the O
receptor O
in O
modulating O
receptor O
expression O
. O

In O
this O
study O
, O
we O
evaluate O
the O
role O
DRD2 O
plays O
in O
chlorpromazine O
- O
induced O
EPS B_DISEASE
in O
schizophrenic B_DISEASE/B_LOCATION
patients O
. O

methods O
: O
We O
identified O
seven O
SNP O
( O
single O
nucleotide O
polymorphism O
) O
( O
- O
141Cins O
> O
del O
, O
TaqIB O
, O
TaqID O
, O
Ser311Cys O
, O
rs6275 O
, O
rs6277 O
and O
TaqIA O
) O
in O
the O
DRD2 O
gene O
in O
146 O
schizophrenic B_DISEASE/B_PERSON
inpatients O
( O
59 O
with O
EPS B_DISEASE
and O
87 O
without O
EPS B_LOCATION
according O
to O
the O
Simpson O
- O
Angus O
Scale O
) O
treated O
with O
chlorpromazine O
after O
8 O
weeks O
. O

The O
alleles B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
all O
loci B_BIO/B_PERSON
were O
determined O
by O
PCR B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O
polymerase B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
chain I_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reaction I_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
. O

RESULTS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
: O
Polymorphisms B_MEASURE/B_GENE
TaqID I_MEASURE/I_GENE
, O
Ser311Cys B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and O
rs6277 B_GENE/B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]
were O
not O
polymorphic B_DISEASE_ADJECTIVE[DISEASE]
in O
the O
population B_PERSON/B_LOCATION
recruited O
in O
the O
present B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

No O
statistical B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
significance I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
found O
in O
the O
allele B_MEASURE
distribution I_MEASURE
of O
- O
141Cins B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
> I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
del I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
TaqIB B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O
rs6275 B_GENE/B_DISEASE
and O
TaqIA B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O
in O
the O
estimated O
haplotypes B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
( O
constituted O
by O
TaqIB B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O
rs6275 B_GENE/B_LOCATION
and O
TaqIA B_GENE/B_LOCATION
) O
in O
linkage B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
disequilibrium I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
between O
the O
two B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
groups I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O

conclusion O
: O
Our O
results O
did O
not O
lend O
strong O
support O
to O
the O
view O
that O
the O
genetic O
variation O
of O
the O
DRD2 O
gene O
plays O
a O
major O
role O
in O
the O
individually O
variable O
adverse O
effect O
induced O
by O
chlorpromazine O
, O
at O
least O
in O
Chinese O
patients O
with O
schizophrenia B_DISEASE/B_LOCATION
. O

Our O
results O
confirmed O
a O
previous O
study O
on O
the O
relationship O
between O
DRD2 O
and O
EPS B_DISEASE/B_LOCATION
in O
Caucasians O
. O

Physical O
training O
decreases O
susceptibility O
to O
subsequent O
pilocarpine O
- O
induced O
seizures B_DISEASE
in O
the O
rat O
. O

Regular O
motor O
activity O
has O
many O
benefits O
for O
mental O
and O
physical O
condition O
but O
its O
implications O
for O
epilepsy B_DISEASE
are O
still O
controversial O
. O

In O
order O
to O
elucidate O
this O
problem O
, O
we O
have O
studied O
the O
effect O
of O
long O
- O
term O
physical O
activity O
on O
susceptibility O
to O
subsequent O
seizures B_DISEASE
. O

Male B_PERSON
Wistar I_PERSON
rats I_PERSON
were O
subjected O
to O
repeated O
training B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sessions I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
a O
treadmill B_LOCATION/B_ORGANIZATION
and O
swimming B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pool I_LOCATION/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Thereafter O
, O
seizures B_DISEASE
were O
induced O
by O
pilocarpine O
injections O
in O
trained O
and O
non O
- O
trained O
control O
groups O
. O

During O
the O
acute O
period O
of O
status B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
epilepticus B_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
we O
measured O
: O
( O
1 O
) O
the O
latency O
of O
the O
first O
motor O
sign O
, O
( O
2 O
) O
the O
intensity O
of O
seizures B_DISEASE
, O
( O
3 O
) O
the O
time O
when O
it O
occurred O
within O
the O
6 O
- O
h O
observation O
period O
, O
and O
( O
4 O
) O
the O
time O
when O
the O
acute O
period O
ended O
. O

All O
these O
behavioral O
parameters O
showed O
statistically O
significant O
changes O
suggesting O
that O
regular O
physical O
exercises O
decrease O
susceptibility O
to O
subsequently O
induced O
seizures B_DISEASE
and O
ameliorate O
the O
course O
of O
experimentally O
induced O
status B_DISEASE
epilepticus I_DISEASE
. O

Tonic O
dopaminergic O
stimulation O
impairs B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
associative I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
learning I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
in O
healthy O
subjects O
. O

endogenous B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dopamine I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
plays O
a O
central B_LOCATION/B_PERSON
role I_LOCATION/I_PERSON
in O
salience B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
coding B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
during O
associative B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
learning B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O

Administration O
of O
the O
dopamine O
precursor O
levodopa O
enhances O
learning O
in O
healthy O
subjects O
and O
stroke B_DISEASE
patients O
. O

Because O
levodopa B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
increases O
both O
phasic B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
and O
tonic B_DISEASE_ADJECTIVE[DISEASE]
dopaminergic I_DISEASE_ADJECTIVE[DISEASE]
neurotransmission I_DISEASE_ADJECTIVE[DISEASE]
, O
the O
critical B_LOCATION
mechanism I_LOCATION
mediating O
the O
enhancement B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
learning B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
unresolved B_DISEASE_ADJECTIVE[DISEASE]
. O

We O
here O
probed O
how O
selective B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
tonic I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
dopaminergic I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
stimulation I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
affects O
associative B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
learning B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O

Forty B_PERSON
healthy I_PERSON
subjects I_PERSON
were O
trained O
in O
a O
novel B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
vocabulary B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
45 B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
concrete I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
nouns I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
over O
the O
course B_LOCATION/B_TIME[MEASURE]
of O
5 B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
consecutive B_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
training B_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
days B_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
a O
prospective B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O
randomized O
, O
double B_MEASURE/B_COLOR
- O
blind B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
placebo B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- O
controlled O
design B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O

subjects B_PERSON
received O
the O
tonically O
stimulating B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dopamine I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
receptor B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
agonist I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pergolide I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
0 B_MEASURE
. O
1 B_MEASURE
mg I_MEASURE
) O
vs B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
placebo B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
120 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
min B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
before O
training B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
on O
each O
training B_TIME[MEASURE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
day B_TIME[MEASURE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
dopamine O
agonist O
significantly O
impaired B_DISEASE_ADJECTIVE[DISEASE]
novel I_DISEASE_ADJECTIVE[DISEASE]
word I_DISEASE_ADJECTIVE[DISEASE]
learning I_DISEASE_ADJECTIVE[DISEASE]
compared O
to O
placebo O
. O

This O
learning B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
decrement I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
persisted O
up O
to O
the O
last B_MEASURE/B_PERSON
follow O
- O
up O
4 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
weeks B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
post B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
- O
training B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O

subjects B_PERSON/B_BIO
treated O
with O
pergolide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
also O
showed O
restricted O
emotional B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
responses I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
compared O
to O
the O
Placebo B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
group I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O

The O
extent B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O
' O
flattened B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
' O
affect B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
with O
pergolide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
was O
related O
to O
the O
degree B_MEASURE
of O
learning O
inhibition B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O

These O
findings B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggest O
that O
tonic B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
occupation I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
dopamine B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
impairs B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
learning O
by O
competition B_SPORT[ENT]/B_PERSON
with O
phasic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
dopamine I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
signals I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Thus O
, O
phasic O
signaling O
seems O
to O
be O
the O
critical O
mechanism O
by O
which O
dopamine O
enhances O
associative O
learning O
in O
healthy O
subjects O
and O
stroke B_DISEASE
patients O
. O

Minocycline O
- O
induced O
vasculitis B_DISEASE
fulfilling O
the O
criteria O
of O
polyarteritis B_DISEASE
nodosa I_DISEASE
. O

A O
47 O
- O
year O
- O
old O
man O
who O
had O
been O
taking O
minocycline O
for O
palmoplantar B_DISEASE
pustulosis I_DISEASE
developed O
fever B_DISEASE
, O
myalgias B_DISEASE
, O
polyneuropathy B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
, O
and O
testicular B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pain I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
with O
elevated O
C O
- O
reactive O
protein O
( O
CRP O
) O
. O

Neither O
myeloperoxidase B_GENE
- O
nor O
proteinase B_GENE
- O
3 B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O
antineutrophil B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
cytoplasmic I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
antibody I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
was O
positive B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

These O
manifestations O
met O
the O
American O
College O
of O
Rheumatology O
1990 O
criteria O
for O
the O
classification O
of O
polyarteritis B_DISEASE/B_LOCATION
nodosa I_DISEASE/I_LOCATION
. O

stopping O
minocycline B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
led O
to O
amelioration B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
symptoms B_DISEASE
and O
normalization B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
CRP B_DISEASE
level I_DISEASE
. O

To O
our O
knowledge O
, O
this O
is O
the O
second O
case O
of O
minocycline O
- O
induced O
vasculitis B_DISEASE
satisfying O
the O
criteria O
. O

differential O
diagnosis O
for O
drug O
- O
induced O
disease O
is O
invaluable O
even O
for O
patients O
with O
classical O
polyarteritis B_DISEASE
nodosa I_DISEASE
. O

Intramuscular O
hepatitis B_DISEASE_ADJECTIVE[DISEASE]
B I_DISEASE_ADJECTIVE[DISEASE]
immune O
globulin O
combined O
with O
lamivudine O
in O
prevention O
of O
hepatitis B_DISEASE
B I_DISEASE
recurrence O
after O
liver O
transplantation O
. O

Background O
: O
Combined O
hepatitis B_DISEASE_ADJECTIVE[DISEASE]/B_SPECIES[BIO]
B B_DISEASE_ADJECTIVE[DISEASE]/I_SPECIES[BIO]
immune O
globulin O
( O
HBIg O
) O
and O
lamivudine O
in O
prophylaxis O
of O
the O
recurrence O
of O
hepatitis B_DISEASE
B I_DISEASE
after O
liver O
transplantation O
has O
significantly O
improved O
the O
survival O
of O
HBsAg O
positive O
patients O
. O

This O
study O
was O
undertaken O
to O
evaluate O
the O
outcomes O
of O
liver O
transplantation O
for O
patients O
with O
hepatitis B_DISEASE
B I_DISEASE
virus O
( O
HBV O
) O
. O

methods O
: O
A O
retrospective O
chart O
analysis O
and O
a O
review O
of O
the O
organ O
transplant O
database O
identified O
51 O
patients O
( O
43 O
men O
and O
8 O
women O
) O
transplanted O
for O
benign O
HBV O
- O
related O
cirrhotic B_DISEASE
diseases I_DISEASE
between O
June O
2002 O
and O
December O
2004 O
who O
had O
survived O
more O
than O
3 O
months O
. O

HBIg B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
was O
administered O
intravenously O
during O
the O
first B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
week I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
intramuscularly O
thereafter O
. O

RESULTS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
At O
a O
median B_MEASURE/B_LOCATION
follow B_MEASURE/I_LOCATION
- O
up B_LOCATION/B_LANGUAGE
of O
14 B_MEASURE
. O
1 B_TIME[MEASURE]
months I_TIME[MEASURE]
, O
the O
overall B_DISEASE
recurrence I_DISEASE
rate I_DISEASE
in O
the O
51 B_PERSON/B_DISEASE
patients I_PERSON/I_DISEASE
was O
3 B_MEASURE
. O
9 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
( O
2 B_MEASURE
/ O
51 B_MEASURE
) O
. O

The O
overall B_DISEASE
patient I_DISEASE
survival I_DISEASE
was O
88 B_MEASURE
. O
3 B_MEASURE
% I_MEASURE
, O
and O
82 B_MEASURE
. O
4 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
after O
1 B_SEQUENCE[MEASURE]
and O
2 B_NUMBER[MEASURE]/B_ENT
years I_NUMBER[MEASURE]/I_ENT
, O
respectively O
. O

A O
daily B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
oral B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dose B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
100 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
mg I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
lamivudine I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
for O
2 B_TIME[MEASURE]
weeks I_TIME[MEASURE]
before O
transplantation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
for O
10 B_PERSON/B_DISEASE
patients B_PERSON/I_DISEASE
enabled O
57 B_MEASURE
. O
1 B_MEASURE
% I_MEASURE
( O
4 B_MEASURE
/ O
7 B_MEASURE
) O
and O
62 B_MEASURE
. O
5 B_MEASURE
% I_MEASURE
( O
5 B_MEASURE
/ O
8 B_MEASURE
) O
of O
HBV B_DISEASE/B_GENE
- O
DNA B_GENE/B_DISEASE
and O
HBeAg B_DISEASE/B_GENE
positive B_DISEASE/I_GENE
patients B_DISEASE/I_GENE
respectively O
to O
convert O
to O
be O
negative B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

intramuscular B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
HBIg I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_LOCATION
was O
well O
tolerated O
in O
all O
patients B_PERSON/B_LOCATION
. O

Conclusion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O
lamivudine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
combined O
with O
intramuscular B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
HBIg I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
can O
effectively O
prevent O
allograft B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
from O
the O
recurrence B_DISEASE_ADJECTIVE[DISEASE]
of O
HBV B_DISEASE
after O
liver B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
transplantation I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Anticonvulsant O
effect O
of O
eslicarbazepine O
acetate O
( O
BIA O
2 O
- O
093 O
) O
on O
seizures B_DISEASE
induced O
by O
microperfusion O
of O
picrotoxin O
in O
the O
hippocampus O
of O
freely O
moving O
rats O
. O

Eslicarbazepine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
acetate I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
BIA B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
2 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
- O
093 B_MEASURE
, O
S B_OTHER/B_MEASURE
- O
( O
- O
) O
- O
10 B_MEASURE
- O
acetoxy B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
10 B_NUMBER[MEASURE]
, O
11 B_MEASURE
- O
dihydro B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
5H B_MEASURE
- O
dibenzo B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
/ O
b B_PROTEIN[GENE]/B_DISEASE
, O
f O
/ O
azepine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
5 B_MEASURE
- O
carboxamide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
is O
a O
novel B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
antiepileptic I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
drug I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
, O
now O
in O
Phase B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
III B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
clinical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
trials B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
, O
designed O
with O
the O
aim B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O
improving O
efficacy B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O
safety B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
in O
comparison B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
with O
the O
structurally O
related O
drugs B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
carbamazepine I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
CBZ B_LOCATION/B_ORGANIZATION
) O
and O
oxcarbazepine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
OXC B_LOCATION/B_ORGANIZATION
) O
. O

We O
have O
studied O
the O
effects O
of O
oral O
treatment O
with O
eslicarbazepine O
acetate O
on O
a O
whole O
- O
animal O
model O
in O
which O
partial O
seizures B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
can O
be O
elicited O
repeatedly O
on O
different O
days O
without O
changes O
in O
threshold O
or O
seizure B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
patterns O
. O

In O
the O
animals O
treated O
with O
threshold O
doses O
of O
picrotoxin O
, O
the O
average O
number O
of O
seizures B_DISEASE
was O
2 O
. O
3 O
+ O
/ O
- O
1 O
. O
2 O
, O
and O
average O
seizure B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
duration O
was O
39 O
. O
5 O
+ O
/ O
- O
8 O
. O
4s O
. O

Pre O
- O
treatment O
with O
a O
dose O
of O
30 O
mg O
/ O
kg O
2h O
before O
picrotoxin O
microperfusion O
prevented O
seizures B_DISEASE
in O
the O
75 O
% O
of O
the O
rats O
. O

Lower O
doses O
( O
3 O
and O
10mg O
/ O
kg O
) O
did O
not O
suppress O
seizures B_DISEASE
, O
however O
, O
after O
administration O
of O
10mg O
/ O
kg O
, O
significant O
reductions O
in O
seizures B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
duration O
( O
24 O
. O
3 O
+ O
/ O
- O
6 O
. O
8s O
) O
and O
seizure B_DISEASE/B_MEASURE
number O
( O
1 O
. O
6 O
+ O
/ O
- O
0 O
. O
34 O
) O
were O
found O
. O

No O
adverse B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
eslicarbazepine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
acetate I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
were O
observed O
in O
the O
behavioral B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
/ O
EEG B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
patterns I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
studied O
, O
including O
sleep B_DISEASE
/ O
wakefulness B_DISEASE
cycle I_DISEASE
, O
at O
the O
doses B_MEASURE/B_LOCATION
studied O
. O

Acute B_DISEASE_ADJECTIVE[DISEASE]
renal I_DISEASE_ADJECTIVE[DISEASE]
failure I_DISEASE_ADJECTIVE[DISEASE]
associated O
with O
prolonged O
intake O
of O
slimming O
pills O
containing O
anthraquinones O
. O

Chinese B_PERSON
herbal I_PERSON
medicine I_PERSON
preparations I_PERSON
are O
widely O
available B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
often O
regarded O
by O
the O
public B_ORGANIZATION/B_PERSON
as O
natural B_DISEASE_ADJECTIVE[DISEASE]
and O
safe B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
remedies I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
for O
a O
variety B_ENT/B_MEASURE
of O
medical B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
conditions I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Nephropathy B_DISEASE
caused O
by O
Chinese O
herbs O
has O
previously O
been O
reported O
, O
usually O
involving O
the O
use O
of O
aristolochic O
acids O
. O

We O
report O
a O
23 O
- O
year O
- O
old O
woman O
who O
developed O
acute B_DISEASE
renal I_DISEASE
failure I_DISEASE
following O
prolonged O
use O
of O
a O
proprietary O
Chinese O
herbal O
slimming O
pill O
that O
contained O
anthraquinone O
derivatives O
, O
extracted O
from O
Rhizoma O
Rhei O
( O
rhubarb O
) O
. O

The O
renal B_DISEASE_ADJECTIVE[DISEASE]
injury I_DISEASE_ADJECTIVE[DISEASE]
was O
probably O
aggravated O
by O
the O
concomitant O
intake O
of O
a O
non O
- O
steroidal O
anti O
- O
inflammatory O
drug O
, O
diclofenac O
. O

Renal O
pathology O
was O
that O
of O
hypocellular O
interstitial O
fibrosis B_DISEASE
. O

spontaneous O
renal O
recovery O
occurred O
upon O
cessation O
of O
the O
slimming O
pills O
, O
but O
mild O
interstitial O
fibrosis B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
and O
tubular O
atrophy B_DISEASE
was O
still O
evident O
histologically O
4 O
months O
later O
. O

Although O
a O
causal O
relationship O
between O
the O
use O
of O
an O
anthraquinone O
- O
containing O
herbal O
agent O
and O
renal B_DISEASE
injury I_DISEASE
remains O
to O
be O
proven O
, O
phytotherapy O
- O
associated O
interstitial O
nephropathy B_DISEASE
should O
be O
considered O
in O
patients O
who O
present O
with O
unexplained O
renal B_DISEASE
failure I_DISEASE
. O

Chloroacetaldehyde O
as O
a O
sulfhydryl O
reagent O
: O
the O
role O
of O
critical O
thiol O
groups O
in O
ifosfamide O
nephropathy B_DISEASE/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
. O

Chloroacetaldehyde O
( O
CAA O
) O
is O
a O
metabolite O
of O
the O
alkylating O
agent O
ifosfamide O
( O
IFO O
) O
and O
putatively O
responsible O
for O
renal B_DISEASE_ADJECTIVE[DISEASE]
damage I_DISEASE_ADJECTIVE[DISEASE]
following O
anti O
- O
tumor B_DISEASE/B_GENE
therapy O
with O
IFO O
. O

depletion B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
sulfhydryl B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
SH B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O
groups B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
has O
been O
reported O
from O
cell B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
culture I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
, O
animal B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
and O
clinical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
studies I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
. O

In O
this O
work B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
the O
effect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
CAA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
on O
human B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
proximal I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
tubule I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
in O
primary B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
culture I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
hRPTEC B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O
was O
investigated O
. O

Toxicity B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
CAA O
was O
determined O
by O
protein O
content O
, O
cell O
number O
, O
LDH O
release O
, O
trypan O
blue O
exclusion O
assay O
and O
caspase O
- O
3 O
activity O
. O

Free B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
thiols I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
were O
measured O
by O
the O
method B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
Ellman B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

CAA O
reduced O
hRPTEC O
cell O
number O
and O
protein O
, O
induced O
a O
loss O
in O
free O
intracellular O
thiols O
and O
an O
increase O
in O
necrosis B_DISEASE/B_GENE
markers O
. O

CAA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
but O
not O
acrolein B_TIME[MEASURE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
inhibited O
the O
cysteine B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
proteases I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
caspase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- O
3 B_NUMBER[MEASURE]
, O
caspase B_GENE
- O
8 B_NUMBER[MEASURE]
and O
cathepsin B_GENE
B I_GENE
. O

Caspase B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
activation I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
by O
cisplatin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
was O
inhibited O
by O
CAA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O

In O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
stained O
with O
fluorescent B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
dyes I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
targeting O
lysosomes B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
, O
CAA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
induced O
an O
increase B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
lysosomal B_MEASURE/B_DISEASE
size B_MEASURE/I_DISEASE
and O
lysosomal B_MEASURE
leakage I_MEASURE
. O

The O
effects B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
CAA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
on O
cysteine B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
protease B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activities B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
thiols B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
could O
be O
reproduced O
in O
cell B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
lysate I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Acidification O
, O
which O
slowed O
the O
reaction O
of O
CAA O
with O
thiol O
donors O
, O
could O
also O
attenuate O
effects O
of O
CAA O
on O
necrosis B_DISEASE
markers O
, O
thiol O
depletion O
and O
cysteine O
protease O
inhibition O
in O
living O
cells O
. O

Thus O
, O
CAA O
directly O
reacts O
with O
cellular O
protein O
and O
non O
- O
protein O
thiols O
, O
mediating O
its O
toxicity B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
hRPTEC O
. O

This O
effect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
can O
be O
reduced O
by O
acidification B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O

Therefore O
, O
urinary O
acidification O
could O
be O
an O
option O
to O
prevent O
IFO O
nephropathy B_DISEASE
in O
patients O
. O

Stereological O
methods O
reveal O
the O
robust O
size O
and O
stability O
of O
ectopic O
hilar O
granule O
cells O
after O
pilocarpine O
- O
induced O
status B_DISEASE
epilepticus I_DISEASE
in O
the O
adult O
rat O
. O

Following O
status B_DISEASE
epilepticus I_DISEASE
in O
the O
rat O
, O
dentate O
granule O
cell O
neurogenesis O
increases O
greatly O
, O
and O
many O
of O
the O
new O
neurons O
appear O
to O
develop O
ectopically O
, O
in O
the O
hilar O
region O
of O
the O
hippocampal O
formation O
. O

It O
has O
been O
suggested O
that O
the O
ectopic O
hilar O
granule O
cells O
could O
contribute O
to O
the O
spontaneous O
seizures B_DISEASE
that O
ultimately O
develop O
after O
status B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
epilepticus I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

However O
, O
the O
population B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
has O
never O
been O
quantified O
, O
so O
it O
is O
unclear B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
whether O
it O
is O
substantial B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
enough O
to O
have O
a O
strong B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
influence B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
epileptogenesis B_PERSON/B_ORGANIZATION
. O

To O
quantify O
this O
population O
, O
the O
total O
number O
of O
ectopic O
hilar O
granule O
cells O
was O
estimated O
using O
unbiased O
stereology O
at O
different O
times O
after O
pilocarpine O
- O
induced O
status B_DISEASE
epilepticus I_DISEASE
. O

The O
number B_MEASURE
of O
hilar B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
neurons I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
immunoreactive I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
Prox B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
1 B_NUMBER[MEASURE]
, O
a O
granule B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- O
cell B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
- O
specific B_PROTEIN[GENE]/B_MEASURE
marker I_PROTEIN[GENE]/I_MEASURE
, O
was O
estimated O
using O
the O
optical B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
fractionator I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
method I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

The O
results O
indicate O
that O
the O
size O
of O
the O
hilar O
ectopic O
granule O
cell O
population O
after O
status B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
epilepticus I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
is O
substantial O
, O
and O
stable O
over O
time O
. O

Interestingly O
, O
the O
size O
of O
the O
population O
appears O
to O
be O
correlated O
with O
the O
frequency O
of O
behavioral O
seizures B_DISEASE
, O
because O
animals O
with O
more O
ectopic O
granule O
cells O
in O
the O
hilus O
have O
more O
frequent O
behavioral O
seizures B_DISEASE
. O

The O
hilar B_MEASURE
ectopic I_MEASURE
granule I_MEASURE
cell I_MEASURE
population I_MEASURE
does O
not O
appear O
to O
vary O
systematically O
across O
the O
septotemporal B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
axis I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
, O
although O
it O
is O
associated O
with O
an O
increase B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
volume B_MEASURE
of O
the O
hilus B_BODY_PART_OR_ORGAN_COMPONENT/B_BACTERIUM[BIO]
. O

The O
results O
provide O
new O
insight O
into O
the O
potential O
role O
of O
ectopic O
hilar O
granule O
cells O
in O
the O
pilocarpine O
model O
of O
temporal B_DISEASE
lobe I_DISEASE
epilepsy I_DISEASE
. O

A O
prospective O
, O
open O
- O
label O
trial O
of O
galantamine O
in O
autistic B_DISEASE/B_LOCATION
disorder I_DISEASE/I_LOCATION
. O

objective O
: O
Post O
- O
mortem O
studies O
have O
reported O
abnormalities O
of O
the O
cholinergic O
system O
in O
autism B_DISEASE/B_SPECIES[BIO]
. O

The O
purpose O
of O
this O
study O
was O
to O
assess O
the O
use O
of O
galantamine O
, O
an O
acetylcholinesterase O
inhibitor O
and O
nicotinic O
receptor O
modulator O
, O
in O
the O
treatment O
of O
interfering O
behaviors O
in O
children O
with O
autism B_DISEASE/B_LOCATION
. O

methods O
: O
Thirteen O
medication O
- O
free O
children O
with O
autism B_DISEASE
( O
mean O
age O
, O
8 O
. O
8 O
+ O
/ O
- O
3 O
. O
5 O
years O
) O
participated O
in O
a O
12 O
- O
week O
, O
open O
- O
label O
trial O
of O
galantamine O
. O

patients B_PERSON/B_BIO
were O
rated O
monthly O
by O
parents B_PERSON
on O
the O
Aberrant B_LOCATION/B_PERSON
behavior B_LOCATION/I_PERSON
Checklist B_LOCATION/I_PERSON
( O
ABC B_ORGANIZATION/B_DISEASE
) O
and O
the O
Conners B_TIME[MEASURE]/B_ORGANIZATION
' I_TIME[MEASURE]/I_ORGANIZATION
parent I_TIME[MEASURE]/I_ORGANIZATION
rating I_TIME[MEASURE]/I_ORGANIZATION
Scale I_TIME[MEASURE]/I_ORGANIZATION
- O
revised O
, O
and O
by O
a O
physician B_PERSON/B_ORGANIZATION
using O
the O
Children B_ORGANIZATION/B_LOCATION
' I_ORGANIZATION/I_LOCATION
s I_ORGANIZATION/I_LOCATION
psychiatric I_ORGANIZATION/I_LOCATION
rating I_ORGANIZATION/I_LOCATION
Scale I_ORGANIZATION/I_LOCATION
and O
the O
Clinical B_ORGANIZATION/B_MEASURE
Global I_ORGANIZATION/I_MEASURE
impressions I_ORGANIZATION/I_MEASURE
scale I_ORGANIZATION/I_MEASURE
. O

Results O
: O
patients O
showed O
a O
significant O
reduction O
in O
parent O
- O
rated O
irritability B_DISEASE_ADJECTIVE[DISEASE]
and O
social O
withdrawal O
on O
the O
ABC O
as O
well O
as O
significant O
improvements O
in O
emotional O
lability O
and O
inattention O
on O
the O
Conners O
' O
parent O
rating O
Scale O
- O
- O
revised O
. O

Similarly O
, O
clinician B_PERSON
ratings I_PERSON
showed O
reductions B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
the O
anger B_MEASURE/B_ENT
subscale I_MEASURE/I_ENT
of O
the O
Children B_DISEASE
' I_DISEASE
s I_DISEASE
Psychiatric I_DISEASE
Rating I_DISEASE
Scale I_DISEASE
. O

Eight B_NUMBER[MEASURE]
of O
13 B_NUMBER[MEASURE]/B_PERSON
participants B_NUMBER[MEASURE]/I_PERSON
were O
rated O
as O
responders B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
on O
the O
basis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
their O
improvement B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
scores I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
on O
the O
Clinical B_MEASURE/B_DISEASE
Global B_MEASURE/I_DISEASE
Impressions B_MEASURE/I_DISEASE
scale B_MEASURE/I_DISEASE
. O

Overall O
, O
galantamine O
was O
well O
- O
tolerated O
, O
with O
no O
significant O
adverse O
effects O
apart O
from O
headaches B_DISEASE
in O
one O
patient O
. O

conclusion O
: O
In O
this O
open O
trial O
, O
galantamine O
was O
well O
- O
tolerated O
and O
appeared O
to O
be O
beneficial O
for O
the O
treatment O
of O
interfering O
behaviors O
in O
children O
with O
autism B_DISEASE
, O
particularly O
aggression B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
behavioral B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
dyscontrol I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
and O
inattention B_DISEASE
. O

Further B_NUMBER[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
controlled O
trials B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
warranted O
. O

Randomized O
comparison O
of O
olanzapine O
versus O
risperidone O
for O
the O
treatment O
of O
first O
- O
episode O
schizophrenia B_DISEASE/B_LOCATION
: O
4 O
- O
month O
outcomes O
. O

objective O
: O
The O
authors O
compared O
4 O
- O
month O
treatment O
outcomes O
for O
olanzapine O
versus O
risperidone O
in O
patients O
with O
first O
- O
episode O
schizophrenia B_DISEASE
spectrum O
disorders O
. O

Method O
: O
One O
hundred O
twelve O
subjects O
( O
70 O
% O
male O
; O
mean O
age O
= O
23 O
. O
3 O
years O
[ O
SD O
= O
5 O
. O
1 O
] O
) O
with O
first O
- O
episode O
schizophrenia B_DISEASE
( O
75 O
% O
) O
, O
schizophreniform B_DISEASE
disorder I_DISEASE
( O
17 O
% O
) O
, O
or O
schizoaffective B_DISEASE/B_PERSON
disorder I_DISEASE/I_PERSON
( O
8 O
% O
) O
were O
randomly O
assigned O
to O
treatment O
with O
olanzapine O
( O
2 O
. O
5 O
- O
20 O
mg O
/ O
day O
) O
or O
risperidone O
( O
1 O
- O
6 O
mg O
/ O
day O
) O
. O

RESULTS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
: O
Response B_DISEASE
rates I_DISEASE
did O
not O
significantly O
differ O
between O
olanzapine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
43 B_MEASURE
. O
7 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
, O
95 B_LOCATION
% I_LOCATION
CI I_LOCATION
= O
28 B_MEASURE
. O
8 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
- O
58 B_MEASURE
. O
6 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
and O
risperidone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
54 B_MEASURE
. O
3 B_MEASURE
% I_MEASURE
, O
95 B_LOCATION
% I_LOCATION
CI I_LOCATION
= O
39 B_MEASURE
. O
9 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
- O
68 B_MEASURE
. O
7 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
. O

Among O
those O
responding O
to O
treatment B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
more B_PERSON/B_MEASURE
subjects I_PERSON/I_MEASURE
in O
the O
olanzapine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
group I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
40 B_MEASURE
. O
9 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
, O
95 B_LOCATION
% I_LOCATION
CI I_LOCATION
= O
16 B_MEASURE
. O
8 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
- O
65 B_MEASURE
. O
0 B_MEASURE
% I_MEASURE
) O
than O
in O
the O
risperidone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
group I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O
18 B_MEASURE
. O
9 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
, O
95 B_LOCATION
% I_LOCATION
CI I_LOCATION
= O
0 B_MEASURE
% I_MEASURE
- O
39 B_MEASURE
. O
2 B_MEASURE
% I_MEASURE
) O
had O
subsequent B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
ratings I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
not O
meeting O
response B_MEASURE/B_DISEASE
criteria I_MEASURE/I_DISEASE
. O

negative O
symptom O
outcomes O
and O
measures O
of O
parkinsonism B_DISEASE
and O
akathisia B_DISEASE
did O
not O
differ O
between O
medications O
. O

Extrapyramidal B_DISEASE/B_MEASURE
symptom I_DISEASE/I_MEASURE
severity O
scores O
were O
1 O
. O
4 O
( O
95 O
% O
CI O
= O
1 O
. O
2 O
- O
1 O
. O
6 O
) O
with O
risperidone O
and O
1 O
. O
2 O
( O
95 O
% O
CI O
= O
1 O
. O
0 O
- O
1 O
. O
4 O
) O
with O
olanzapine O
. O

significantly O
more O
weight B_DISEASE
gain I_DISEASE
occurred O
with O
olanzapine O
than O
with O
risperidone O
: O
the O
increase O
in O
weight O
at O
4 O
months O
relative O
to O
baseline O
weight O
was O
17 O
. O
3 O
% O
( O
95 O
% O
CI O
= O
14 O
. O
2 O
% O
- O
20 O
. O
5 O
% O
) O
with O
olanzapine O
and O
11 O
. O
3 O
% O
( O
95 O
% O
CI O
= O
8 O
. O
4 O
% O
- O
14 O
. O
3 O
% O
) O
with O
risperidone O
. O

Body B_DISEASE/B_LOCATION
mass I_DISEASE/I_LOCATION
index I_DISEASE/I_LOCATION
at O
baseline B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O
at O
4 B_MEASURE/B_LOCATION
months I_MEASURE/I_LOCATION
was O
24 B_MEASURE
. O
3 B_MEASURE
( O
95 B_LOCATION
% I_LOCATION
CI I_LOCATION
= O
22 B_MEASURE
. O
8 B_MEASURE
- O
25 B_MEASURE
. O
7 B_MEASURE
) O
versus B_MEASURE
28 I_MEASURE
. O
2 B_MEASURE
( O
95 B_LOCATION
% I_LOCATION
CI I_LOCATION
= O
26 B_MEASURE
. O
7 B_MEASURE
- O
29 B_MEASURE
. O
7 B_MEASURE
) O
with O
olanzapine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
23 B_MEASURE
. O
9 B_MEASURE
( O
95 B_LOCATION
% I_LOCATION
CI I_LOCATION
= O
22 B_MEASURE
. O
5 B_MEASURE
- O
25 B_MEASURE
. O
3 B_MEASURE
) O
versus B_MEASURE
26 I_MEASURE
. O
7 B_MEASURE
( O
95 B_LOCATION
% I_LOCATION
CI I_LOCATION
= O
25 B_MEASURE
. O
2 B_MEASURE
- O
28 B_MEASURE
. O
2 B_MEASURE
) O
with O
risperidone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

CONCLUSIONS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O
Clinical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
outcomes I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
with O
risperidone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
equal B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
to O
those O
with O
olanzapine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
response B_TIME[MEASURE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
may O
be O
more O
stable B_DISEASE_ADJECTIVE[DISEASE]
. O

olanzapine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
may O
have O
an O
advantage B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
motor B_DISEASE/B_PERSON
side I_DISEASE/I_PERSON
effects I_DISEASE/I_PERSON
. O

Both O
medications O
caused O
substantial O
rapid O
weight B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
gain I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
but O
weight B_DISEASE_ADJECTIVE[DISEASE]
gain I_DISEASE_ADJECTIVE[DISEASE]
was O
greater O
with O
olanzapine O
. O

Early O
paracentral O
visual B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
field I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
loss I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
patients O
taking O
hydroxychloroquine O
. O

Objective B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
To O
review O
the O
natural B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
history I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
ocular B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
and O
systemic B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
adverse B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
patients B_PERSON
taking O
hydroxychloroquine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
sulfate I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
who O
attended O
an O
ophthalmic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
screening B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
program B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

Design B_PERSON/B_NUMBER[MEASURE]
: O
Retrospective B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

Results B_MEASURE
: O
Records B_ENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
262 B_PERSON
patients I_PERSON
who O
were O
taking O
hydroxychloroquine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
and O
screened O
in O
the O
Department B_ORGANIZATION/B_LOCATION
of O
Ophthalmology B_DISEASE/B_ORGANIZATION
were O
reviewed O
. O

Of O
the O
262 B_PERSON/B_DISEASE
patients I_PERSON/I_DISEASE
, O
14 B_MEASURE
( O
18 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
of O
76 B_NUMBER[MEASURE]/B_PERSON
who O
had O
stopped O
treatment B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O
the O
time B_TIME[MEASURE]/B_LOCATION
of O
the O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
experienced O
documented O
adverse B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Systemic B_DISEASE
adverse I_DISEASE
effects I_DISEASE
occurred O
in O
8 B_NUMBER[MEASURE]
patients I_NUMBER[MEASURE]
( O
10 B_MEASURE
. O
5 B_MEASURE
% I_MEASURE
) O
and O
ocular B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
adverse I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
effects I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
, O
in O
5 B_NUMBER[MEASURE]
( O
6 B_MEASURE
. O
5 B_MEASURE
% I_MEASURE
) O
. O

Thirty O
- O
five O
patients O
( O
13 O
. O
4 O
% O
) O
had O
visual B_DISEASE
field I_DISEASE
abnormalities I_DISEASE
, O
which O
were O
attributed O
to O
hydroxychloroquine O
treatment O
in O
4 O
patients O
( O
1 O
. O
5 O
% O
) O
. O

Three B_NUMBER[MEASURE]/B_PERSON
of O
the O
4 B_PERSON
patients I_PERSON
were O
taking O
less B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
than O
6 B_MEASURE
. O
5 B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mg I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
kg B_MEASURE
per O
day B_TIME[MEASURE]/B_PERSON
and O
all O
patients B_PERSON/B_NUMBER[MEASURE]
had O
normal B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
renal I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
and O
liver B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
function I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
test I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
results I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
. O

conclusions O
: O
The O
current O
study O
used O
a O
protocol O
of O
visual O
acuity O
and O
color O
vision O
assessment O
, O
funduscopy O
, O
and O
Humphrey O
10 O
- O
2 O
visual O
field O
testing O
and O
shows O
that O
visual B_DISEASE_ADJECTIVE[DISEASE]
field I_DISEASE_ADJECTIVE[DISEASE]
defects I_DISEASE_ADJECTIVE[DISEASE]
appeared O
before O
any O
corresponding O
changes O
in O
any O
other O
tested O
clinical O
parameters O
; O
the O
defects O
were O
reproducible O
and O
the O
test O
parameters O
were O
reliable O
. O

patients B_PERSON/B_BIO
taking O
hydroxychloroquine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
can O
demonstrate O
a O
toxic B_DISEASE_ADJECTIVE[DISEASE]
reaction I_DISEASE_ADJECTIVE[DISEASE]
in O
the O
retina B_BODY_PART_OR_ORGAN_COMPONENT
despite O
the O
absence B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O
known O
risk B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factors I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Screening B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
including O
Humphrey B_MEASURE/B_LOCATION
10 B_MEASURE/I_LOCATION
- O
2 B_MEASURE
visual I_MEASURE
field I_MEASURE
assessment I_MEASURE
, O
is O
recommended O
2 B_TIME[MEASURE]/B_ENT
years I_TIME[MEASURE]/I_ENT
after O
the O
initial B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
baseline I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
and O
yearly O
thereafter O
. O

Peri O
- O
operative O
atrioventricular B_DISEASE
block I_DISEASE
as O
a O
result O
of O
chemotherapy O
with O
epirubicin O
and O
paclitaxel O
. O

A O
47 O
- O
year O
- O
old O
woman O
presented O
for O
mastectomy O
and O
immediate O
latissimus O
dorsi O
flap O
reconstruction O
having O
been O
diagnosed O
with O
carcinoma B_DISEASE
of I_DISEASE
the I_DISEASE
breast I_DISEASE
6 O
months O
previously O
. O

In O
the O
preceding O
months B_TIME[MEASURE]
she O
had O
received O
neo B_DISEASE
- O
adjuvant B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
chemotherapy I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O
epirubicin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
paclitaxel B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
Taxol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
) O
and O
cyclophosphamide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

This O
had O
been O
apparently O
uncomplicated B_DISEASE_ADJECTIVE[DISEASE]
and O
she O
had O
maintained O
a O
remarkably O
high B_MEASURE/B_LOCATION
level I_MEASURE/I_LOCATION
of O
physical B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
activity I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O

She O
was O
found O
to O
be O
bradycardic B_DISEASE_ADJECTIVE[DISEASE]
at O
pre O
- O
operative O
assessment O
but O
had O
no O
cardiac O
symptoms O
. O

Second O
degree O
Mobitz O
type O
II O
atrioventricular B_DISEASE/B_LOCATION
block I_DISEASE/I_LOCATION
was O
diagnosed O
on O
electrocardiogram O
, O
and O
temporary O
transvenous O
ventricular O
pacing O
instituted O
in O
the O
peri O
- O
operative O
period O
. O

We O
discuss O
how O
evidence O
- O
based O
guidelines O
would O
not O
have O
been O
helpful O
in O
this O
case O
, O
and O
how O
chemotherapy O
can O
exhibit O
substantial O
cardiotoxicity B_DISEASE
that O
may O
develop O
over O
many O
years O
. O

We O
suggest O
that O
patients B_PERSON
who O
have O
received O
chemotherapy B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
at O
any O
time B_MEASURE/B_LOCATION
should O
have O
a O
pre B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
operative B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
electrocardiogram I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
even O
if O
they O
are O
asymptomatic B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
. O

risks B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O
benefits B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O
COX B_GENE
- O
2 B_PROTEIN[GENE]/B_MEASURE
inhibitors I_PROTEIN[GENE]/I_MEASURE
vs I_PROTEIN[GENE]/I_MEASURE
non I_PROTEIN[GENE]
- O
selective B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
NSAIDs I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
: O
does O
their O
cardiovascular B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
risk B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
exceed O
their O
gastrointestinal B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
benefit B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

A O
retrospective B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
cohort I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

objectives O
: O
The O
risk O
of O
acute B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
myocardial I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
infarction I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
( O
AMI B_LOCATION/B_ORGANIZATION
) O
with O
Cox O
- O
2 O
inhibitors O
may O
offset O
their O
gastrointestinal O
( O
GI O
) O
benefit O
compared O
with O
non O
- O
selective O
( O
NS O
) O
non O
- O
steroidal O
anti O
- O
inflammatory O
drugs O
( O
NSAIDs O
) O
. O

We O
aimed O
to O
compare O
the O
risks O
of O
hospitalization O
for O
AMI B_DISEASE
and O
GI B_DISEASE
bleeding I_DISEASE
among O
elderly O
patients O
using O
Cox O
- O
2 O
inhibitors O
, O
NS O
- O
NSAIDs O
and O
acetaminophen O
. O

METHODS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O
We O
conducted O
a O
retrospective B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cohort I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
using O
administrative B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
data I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
patients B_PERSON/B_TIME[MEASURE]
> B_PERSON/I_TIME[MEASURE]
or O
= O
65 B_TIME[MEASURE]/B_ENT
years I_TIME[MEASURE]/I_ENT
of O
age B_TIME[MEASURE]/B_PERSON
who O
filled O
a O
prescription B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
for O
NSAID B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O
acetaminophen B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
during O
1999 B_MEASURE
- O
2002 B_MEASURE
. O

outcomes B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
compared O
using O
Cox B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
regression I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
models I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
with O
time B_MEASURE/B_LOCATION
- O
dependent B_MEASURE
exposures I_MEASURE
. O

Results B_MEASURE/B_PERSON
: O
Person B_PERSON/B_NUMBER[MEASURE]
- O
years B_MEASURE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
exposure B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
among O
non B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
- O
users B_PERSON
of O
aspirin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
were O
: O
75 B_MEASURE
, O
761 B_MEASURE
to O
acetaminophen O
, O
42 B_MEASURE
, O
671 B_MEASURE
to O
rofecoxib O
65 B_NUMBER[MEASURE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
860 B_MEASURE
to O
celecoxib O
, O
and O
37 B_MEASURE
, O
495 B_MEASURE
to O
NS B_DISEASE
- O
NSAIDs B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O

Among O
users B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
aspirin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
they O
were O
: O
14 B_MEASURE
, O
671 B_MEASURE
to O
rofecoxib O
, O
22 B_MEASURE
, O
875 B_MEASURE
to O
celecoxib O
, O
9 B_MEASURE
, O
832 B_MEASURE
to O
NS B_DISEASE/B_PROTEIN[GENE]
- O
NSAIDs B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O
38 B_MEASURE
, O
048 B_MEASURE
to O
acetaminophen O
. O

Among O
non O
- O
users O
of O
aspirin O
, O
the O
adjusted O
hazard O
ratios O
( O
95 O
% O
confidence O
interval O
) O
of O
hospitalization O
for O
AMI B_LOCATION/B_ORGANIZATION
/ O
GI O
vs O
the O
acetaminophen O
( O
with O
no O
aspirin O
) O
group O
were O
: O
rofecoxib O
1 O
. O
27 O
( O
1 O
. O
13 O
, O
1 O
. O
42 O
) O
, O
celecoxib O
0 O
. O
93 O
( O
0 O
. O
83 O
, O
1 O
. O
03 O
) O
, O
naproxen O
1 O
. O
59 O
( O
1 O
. O
31 O
, O
1 O
. O
93 O
) O
, O
diclofenac O
1 O
. O
17 O
( O
0 O
. O
99 O
, O
1 O
. O
38 O
) O
and O
ibuprofen O
1 O
. O
05 O
( O
0 O
. O
74 O
, O
1 O
. O
51 O
) O
. O

Among O
users B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
aspirin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
they O
were O
: O
rofecoxib B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_NUMBER[MEASURE]
1 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_NUMBER[MEASURE]
. O
73 B_MEASURE
( O
1 B_NUMBER[MEASURE]
. O
52 B_MEASURE
, O
1 B_NUMBER[MEASURE]
. O
98 B_MEASURE
) O
, O
celecoxib B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
1 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
. O
34 B_MEASURE
( O
1 B_NUMBER[MEASURE]
. O
19 B_MEASURE
, O
1 B_NUMBER[MEASURE]
. O
52 B_MEASURE
) O
, O
ibuprofen B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
1 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
. O
51 B_MEASURE
( O
0 B_NUMBER[MEASURE]
. O
95 B_MEASURE
, O
2 B_NUMBER[MEASURE]
. O
41 B_MEASURE
) O
, O
diclofenac B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
1 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O
69 B_MEASURE
( O
1 B_NUMBER[MEASURE]
. O
35 B_MEASURE
, O
2 B_NUMBER[MEASURE]/B_LOCATION
. O
10 B_MEASURE
) O
, O
naproxen B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O
35 B_MEASURE
( O
0 B_NUMBER[MEASURE]
. O
97 B_MEASURE
, O
1 B_NUMBER[MEASURE]
. O
88 B_MEASURE
) O
and O
acetaminophen B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
1 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
. O
29 B_MEASURE
( O
1 B_NUMBER[MEASURE]
. O
17 B_MEASURE
, O
1 B_NUMBER[MEASURE]
. O
42 B_MEASURE
) O
. O

conclusion O
: O
Among O
non O
- O
users O
of O
aspirin O
, O
naproxen O
seemed O
to O
carry O
the O
highest O
risk O
for O
AMI B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
/ O
GI B_DISEASE/B_LOCATION
bleeding I_DISEASE/I_LOCATION
. O

The O
AMI B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
/ O
GI O
toxicity B_DISEASE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
celecoxib O
was O
similar O
to O
that O
of O
acetaminophen O
and O
seemed O
to O
be O
better O
than O
those O
of O
rofecoxib O
and O
NS O
- O
NSAIDs O
. O

Among O
users B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
aspirin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
both O
celecoxib B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
naproxen B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
seemed O
to O
be O
the O
least O
toxic B_DISEASE_ADJECTIVE[DISEASE]
. O

Quinine O
- O
induced O
arrhythmia B_DISEASE
in O
a O
patient O
with O
severe B_DISEASE/B_GENE
malaria I_DISEASE/I_GENE
. O

It O
was O
reported O
that O
there O
was O
a O
case O
of O
severe B_PERSON
malaria I_PERSON
patient O
with O
jaundice B_DISEASE
who O
presented O
with O
arrhythmia B_DISEASE
( O
premature B_DISEASE/B_PROTEIN[GENE]
ventricular B_DISEASE/I_PROTEIN[GENE]
contraction B_DISEASE/I_PROTEIN[GENE]
) O
while O
getting O
quinine O
infusion O
was O
reported O
. O

A O
man O
, O
25 O
years O
old O
, O
was O
admitted O
to O
hospital O
with O
high O
fever B_DISEASE/B_MEASURE
, O
chill B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
, O
vomiting B_DISEASE
, O
jaundice B_DISEASE
. O

The O
patient B_PERSON
was O
fully O
conscious B_PERSON
, O
blood B_MEASURE
pressure I_MEASURE
120 I_MEASURE
/ O
80 B_MEASURE
mmHg I_MEASURE
, O
pulse B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
rate I_MEASURE/I_BODY_PART_OR_ORGAN_COMPONENT
100 I_MEASURE/I_BODY_PART_OR_ORGAN_COMPONENT
x I_MEASURE/I_BODY_PART_OR_ORGAN_COMPONENT
/ O
minute B_MEASURE
, O
regular B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O

On O
admission O
, O
laboratory O
examination O
showed O
Plasmodium O
falciparum O
( O
+ O
+ O
+ O
+ O
) O
, O
total O
bilirubin O
8 O
. O
25 O
mg O
/ O
DL O
, O
conjugated O
bilirubin O
4 O
. O
36 O
mg O
/ O
DL O
, O
unconjugated O
bilirubin O
3 O
. O
89 O
mg O
/ O
DL O
, O
potassium O
3 O
. O
52 O
meq O
/ O
L O
patient O
was O
diagnosed O
as O
severe B_DISEASE_ADJECTIVE[DISEASE]
malaria I_DISEASE_ADJECTIVE[DISEASE]
with O
jaundice B_DISEASE
and O
got O
quinine O
infusion O
in O
dextrose O
5 O
% O
500 O
mg O
/ O
8 O
hour O
. O

On O
the O
second O
day O
the O
patient O
had O
vomitus B_DISEASE
, O
diarrhea B_DISEASE
, O
tinnitus B_DISEASE
, O
loss B_DISEASE
of I_DISEASE
hearing I_DISEASE
. O

After O
30 O
hours O
of O
quinine O
infusion O
the O
patient O
felt O
palpitation B_DISEASE_ADJECTIVE[DISEASE]
and O
electrocardiography O
( O
ECG O
) O
recording O
showed O
premature B_DISEASE
ventricular I_DISEASE
contraction I_DISEASE
( O
PVC B_LOCATION/B_DISEASE
) O
> O
5 O
x O
/ O
minute O
, O
trigemini O
, O
constant O
type O
- O
- O
sinoatrial B_DISEASE_ADJECTIVE[DISEASE]/B_PROTEIN[GENE]
block B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
, O
positive O
U O
wave O
. O

He O
was O
treated O
with O
lidocaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
50 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mg I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
intravenously O
followed O
by O
infusion B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1500 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mg I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
dextrose B_MEASURE
5 I_MEASURE
% I_MEASURE
/ O
24 B_TIME[MEASURE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hour I_TIME[MEASURE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
potassium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
aspartate I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tablet I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Quinine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
infusion I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
was O
discontinued O
and O
changed O
with O
sulfate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
quinine I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
tablets I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O

Three O
hours O
later O
the O
patient O
felt O
better O
, O
the O
frequency O
of O
PVC B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
reduced O
to O
4 O
- O
5 O
x O
/ O
minute O
and O
on O
the O
third O
day O
ECG O
was O
normal O
, O
potassium O
level O
was O
3 O
. O
34 O
meq O
/ O
L O
. O

He O
was O
discharged O
on O
7th B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
day I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_LOCATION
in O
good B_TIME[MEASURE]/B_PERSON
condition I_TIME[MEASURE]/I_PERSON
. O

Quinine O
, O
like O
quinidine O
, O
is O
a O
chincona O
alkaloid O
that O
has O
anti O
- O
arrhythmic B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
property O
, O
although O
it O
also O
pro O
- O
arrhythmic B_DISEASE_ADJECTIVE[DISEASE]
that O
can O
cause O
various O
arrhythmias B_DISEASE
, O
including O
severe O
arrhythmia B_DISEASE
such O
as O
multiple O
PVC B_DISEASE
. O

Administration O
of O
parenteral O
quinine O
must O
be O
done O
carefully O
and O
with O
good O
observation O
because O
of O
its O
pro O
- O
arrhythmic B_DISEASE_ADJECTIVE[DISEASE]
effect O
, O
especially O
in O
older O
patients O
who O
have O
heart B_DISEASE
diseases I_DISEASE
or O
patients O
with O
electrolyte B_DISEASE
disorder I_DISEASE
( O
hypokalemia B_LOCATION/B_ORGANIZATION
) O
which O
frequently O
occurs O
due O
to O
vomiting B_DISEASE
and O
or O
diarrhea B_DISEASE
in O
malaria B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
cases O
. O

Penicillamine O
- O
related O
lichenoid B_DISEASE
dermatitis I_DISEASE
and O
utility O
of O
zinc O
acetate O
in O
a O
Wilson B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
disease B_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
patient O
with O
hepatic O
presentation O
, O
anxiety B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O
SPECT O
abnormalities O
. O

Wilson B_DISEASE/B_GENE
' I_DISEASE/I_GENE
s I_DISEASE/I_GENE
disease I_DISEASE/I_GENE
is O
an O
autosomal O
recessive O
disorder O
of O
hepatic O
copper O
metabolism O
with O
consequent O
copper O
accumulation O
and O
toxicity B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
in O
many O
tissues O
and O
consequent O
hepatic B_DISEASE
, I_DISEASE
neurologic I_DISEASE
and I_DISEASE
psychiatric I_DISEASE
disorders I_DISEASE
. O

We O
report O
a O
case O
of O
Wilson B_PERSON
' I_PERSON
s I_PERSON
disease I_PERSON
with O
chronic B_DISEASE
liver I_DISEASE
disease I_DISEASE
; O
Moreover O
, O
in O
our O
patient O
, O
presenting O
also O
with O
high O
levels O
of O
state O
anxiety B_DISEASE
without O
depression B_DISEASE
, O
99mTc O
- O
ECD O
- O
SPECT O
showed O
cortical O
hypoperfusion O
in O
frontal O
lobes O
, O
more O
marked O
on O
the O
left O
frontal O
lobe O
. O

During O
the O
follow O
- O
up O
of O
our O
patient O
, O
penicillamine O
was O
interrupted O
after O
the O
appearance O
of O
a O
lichenoid B_DISEASE
dermatitis I_DISEASE
, O
and O
zinc O
acetate O
permitted O
to O
continue O
the O
successful O
treatment O
of O
the O
patient O
without O
side O
- O
effects O
. O

In O
our O
case O
the O
therapy O
with O
zinc O
acetate O
represented O
an O
effective O
treatment O
for O
a O
Wilson B_DISEASE/B_PERSON
' I_DISEASE/I_PERSON
s I_DISEASE/I_PERSON
disease I_DISEASE/I_PERSON
patient O
in O
which O
penicillamine O
- O
related O
side O
effects O
appeared O
. O

The O
safety O
of O
the O
zinc O
acetate O
allowed O
us O
to O
avoid O
other O
potentially O
toxic O
chelating O
drugs O
; O
this O
observation O
is O
in O
line O
with O
the O
growing O
evidence O
on O
the O
efficacy O
of O
the O
drug O
in O
the O
treatment O
of O
Wilson B_DISEASE
' I_DISEASE
s I_DISEASE
disease I_DISEASE
. O

Since O
most O
of O
Wilson B_PERSON
' I_PERSON
s I_PERSON
disease I_PERSON
penicillamine O
- O
treated O
patients O
do O
not O
seem O
to O
develop O
this O
skin B_DISEASE_ADJECTIVE[DISEASE]
lesion I_DISEASE_ADJECTIVE[DISEASE]
, O
it O
could O
be O
conceivable O
that O
a O
specific O
genetic O
factor O
is O
involved O
in O
drug O
response O
. O

Further O
studies O
are O
needed O
for O
a O
better O
clarification O
of O
Wilson B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
' B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
s B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
disease B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
therapy O
, O
and O
in O
particular O
to O
differentiate O
specific O
therapies O
for O
different O
Wilson B_DISEASE_ADJECTIVE[DISEASE]
' I_DISEASE_ADJECTIVE[DISEASE]
s I_DISEASE_ADJECTIVE[DISEASE]
disease I_DISEASE_ADJECTIVE[DISEASE]
phenotypes O
. O

A O
dramatic O
drop B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
blood I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pressure I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
following O
prehospital O
GTN O
administration O
. O

A O
male O
in O
his O
sixties O
with O
no O
history O
of O
cardiac O
chest B_DISEASE_ADJECTIVE[DISEASE]
pain I_DISEASE_ADJECTIVE[DISEASE]
awoke O
with O
chest B_DISEASE
pain I_DISEASE
following O
an O
afternoon O
sleep O
. O

The O
patient B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
did O
not O
self B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
medicate I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
patient B_PERSON
' O
s B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
observations I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
were O
within O
normal B_TIME[MEASURE]/B_LOCATION
limits I_TIME[MEASURE]/I_LOCATION
, O
he O
was O
administered O
oxygen B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
via O
a O
face B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEDICAL_DEVICE[OBJECT]
mask B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEDICAL_DEVICE[OBJECT]
and O
glyceryl B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BODY_PART_OR_ORGAN_COMPONENT
trinitrate B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_BODY_PART_OR_ORGAN_COMPONENT
( O
GTN B_DISEASE/B_LOCATION
) O
. O

Several O
minutes O
after O
the O
GTN O
the O
patient O
experienced O
a O
sudden O
drop B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
blood I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pressure I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
heart O
rate O
, O
this O
was O
rectified O
by O
atropine O
sulphate O
and O
a O
fluid O
challenge O
. O

There O
was O
no O
further B_DISEASE_ADJECTIVE[DISEASE]
deterioration I_DISEASE_ADJECTIVE[DISEASE]
in O
the O
patient B_PERSON
' O
s B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
condition I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
during O
transport B_ORGANIZATION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O
hospital B_LOCATION
. O

There O
are O
very O
few B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
documented I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
case I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
like O
this O
in O
the O
prehospital B_LOCATION
scientific I_LOCATION
literature I_LOCATION
. O

The O
cause B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
appears O
to O
be O
the O
Bezold B_PERSON/B_LOCATION
- O
Jarish B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
reflex B_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
stimulation B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
the O
ventricular B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
walls I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
which O
in O
turn B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
decreases O
sympathetic B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
outflow B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O
the O
vasomotor B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
centre I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Prehospital O
care O
providers O
who O
are O
managing O
any O
patient O
with O
a O
syncopal B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
episode I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
that O
fails O
to O
recover O
within O
a O
reasonable O
time O
frame O
should O
consider O
the O
Bezold O
- O
Jarisch O
reflex O
as O
the O
cause O
and O
manage O
the O
patient O
accordingly O
. O

chronic O
lesion O
of O
rostral O
ventrolateral O
medulla O
in O
spontaneously O
hypertensive B_DISEASE/B_ORGANISM_FUNCTION
rats O
. O

We O
studied O
the O
effects O
of O
chronic O
selective O
neuronal O
lesion O
of O
rostral O
ventrolateral O
medulla O
on O
mean O
arterial O
pressure O
, O
heart O
rate O
, O
and O
neurogenic O
tone O
in O
conscious O
, O
unrestrained O
spontaneously O
hypertensive B_DISEASE_ADJECTIVE[DISEASE]
rats O
. O

The O
lesions B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
were O
placed O
via O
bilateral B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
microinjections I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
of O
30 B_MEASURE/B_PERSON
nmol I_MEASURE/I_PERSON
/ O
200 B_MEASURE
NL I_MEASURE
N I_MEASURE
- O
methyl B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
D B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O
aspartic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acid I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
restimulation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
of O
this O
area B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
N B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
methyl B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
D B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O
aspartic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acid I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
15 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
days I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
postlesion I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
failed O
to O
produce O
a O
pressor B_DISEASE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
response I_DISEASE/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

One B_MEASURE/B_ENT
day I_MEASURE/I_ENT
postlesion I_MEASURE/I_ENT
, O
the O
resting B_DISEASE/B_GENE
mean B_DISEASE/I_GENE
arterial B_DISEASE/I_GENE
pressure B_DISEASE/I_GENE
was O
significantly O
decreased O
in O
lesioned B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
rats B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
when O
compared O
with O
sham B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
rats I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
( O
100 B_MEASURE
+ I_MEASURE
/ O
- O
7 B_MEASURE
versus I_MEASURE
173 I_MEASURE
+ I_MEASURE
/ O
- O
4 B_MEASURE
mm I_MEASURE
Hg I_MEASURE
, O
p B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
less B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
than O
0 B_MEASURE
. O
05 B_MEASURE
) O
. O

Fifteen B_TIME[MEASURE]/B_ENT
days I_TIME[MEASURE]/I_ENT
later O
, O
the O
lesioned B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
group I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
still O
showed O
values B_MEASURE/B_DISEASE
significantly O
lower B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
than O
the O
sham B_PERSON/B_MEASURE
group B_PERSON/I_MEASURE
( O
150 B_MEASURE
+ I_MEASURE
/ O
- O
6 B_MEASURE
versus I_MEASURE
167 I_MEASURE
+ I_MEASURE
/ O
- O
5 B_MEASURE
mm I_MEASURE
Hg I_MEASURE
, O
p B_MEASURE
less I_MEASURE
than O
0 B_MEASURE
. O
05 B_MEASURE
) O
. O

No O
significant B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
heart B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
rate B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
differences B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
observed O
between O
the O
sham B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
and O
lesioned B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
groups I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

The O
ganglionic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
blocker I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
trimethaphan I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O
5 B_MEASURE
mg I_MEASURE
/ O
kg B_TIME[MEASURE]
i O
. O
v B_PROTEIN[GENE]/B_MEASURE
. O
) O
caused O
similar B_DISEASE_ADJECTIVE[DISEASE]
reductions I_DISEASE_ADJECTIVE[DISEASE]
in O
mean B_DISEASE/B_GENE
arterial I_DISEASE/I_GENE
pressure I_DISEASE/I_GENE
in O
both O
lesioned B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
sham B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
groups I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
. O

The O
trimethaphan O
- O
induced O
hypotension B_DISEASE
was O
accompanied O
by O
a O
significant O
bradycardia B_DISEASE
in O
lesioned O
rats O
( O
- O
32 O
+ O
/ O
- O
13 O
beats O
per O
minute O
) O
but O
a O
tachycardia B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
sham O
rats O
( O
+ O
33 O
+ O
/ O
- O
12 O
beats O
per O
minute O
) O
1 O
day O
postlesion O
. O

Therefore O
, O
rostral O
ventrolateral O
medulla O
neurons O
appear O
to O
play O
a O
significant O
role O
in O
maintaining O
hypertension B_DISEASE/B_GENE
in O
conscious O
spontaneously O
hypertensive B_DISEASE/B_ORGANISM_FUNCTION
rats O
. O

spinal O
or O
suprabulbar O
structures O
could O
be O
responsible O
for O
the O
gradual O
recovery O
of O
the O
hypertension B_DISEASE
in O
the O
lesioned O
rats O
. O

Acute B_DISEASE
encephalopathy I_DISEASE
and O
cerebral B_DISEASE
vasospasm I_DISEASE
after O
multiagent O
chemotherapy O
including O
PEG O
- O
asparaginase O
and O
intrathecal O
cytarabine O
for O
the O
treatment O
of O
acute B_DISEASE
lymphoblastic I_DISEASE
leukemia I_DISEASE
. O

A O
7 O
- O
year O
- O
old O
girl O
with O
an O
unusual O
reaction O
to O
induction O
chemotherapy O
for O
precursor O
B O
- O
cell O
acute B_DISEASE
lymphoblastic I_DISEASE
leukemia I_DISEASE
( O
ALL B_DISEASE
) O
is O
described O
. O

The O
patient O
developed O
acute B_DISEASE
encephalopathy I_DISEASE
evidenced O
by O
behavioral O
changes O
, O
aphasia B_DISEASE
, O
incontinence B_DISEASE
, O
visual B_DISEASE
hallucinations I_DISEASE
, O
and O
right O
- O
sided O
weakness B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O
diffuse O
cerebral B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
vasospasm I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
on O
magnetic O
resonance O
angiography O
after O
the O
administration O
of O
intrathecal O
cytarabine O
. O

vincristine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
dexamethasone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
polyethylene B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
glycol I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
- O
asparaginase B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
were O
also O
administered O
before O
the O
episode B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
as O
part B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
induction B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
therapy I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
. O

neurologic B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
status I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
returned O
to O
baseline B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
within O
10 B_TIME[MEASURE]/B_ENT
days I_TIME[MEASURE]/I_ENT
of O
the O
acute B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
event B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
and O
magnetic B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
resonance I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
angiography I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
findings I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
returned O
to O
normal B_TIME[MEASURE]
4 I_TIME[MEASURE]
months I_TIME[MEASURE]
later O
. O

comparison O
of O
valsartan O
/ O
hydrochlorothiazide O
combination O
therapy O
at O
doses O
up O
to O
320 O
/ O
25 O
mg O
versus O
monotherapy O
: O
a O
double O
- O
blind O
, O
placebo O
- O
controlled O
study O
followed O
by O
long O
- O
term O
combination O
therapy O
in O
hypertensive B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
adults O
. O

Background O
: O
One O
third O
of O
patients O
treated O
for O
hypertension B_DISEASE
attain O
adequate O
blood O
pressure O
( O
BP O
) O
control O
, O
and O
multidrug O
regimens O
are O
often O
required O
. O

Given O
the O
lifelong O
nature O
of O
hypertension B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
there O
is O
a O
need O
to O
evaluate O
the O
long O
- O
term O
efficacy O
and O
tolerability O
of O
higher O
doses O
of O
combination O
anti O
- O
hypertensive B_DISEASE/B_GENE
therapies O
. O

objective O
: O
This O
study O
investigated O
the O
efficacy O
and O
tolerability O
of O
valsartan O
( O
Val O
) O
or O
hydrochlorothiazide O
( O
HCTZ O
) O
- O
monotherapy O
and O
higher O
- O
dose O
combinations O
in O
patients O
with O
essential B_DISEASE
hypertension I_DISEASE
. O

METHODS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O
The O
first B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENT
part I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENT
of O
this O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
an O
8 B_NUMBER[MEASURE]
- O
week B_TIME[MEASURE]/B_PERSON
, O
multicenter B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
randomized B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
double B_MEASURE/B_COLOR
- O
blind B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
placebo B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
controlled O
, O
parallel B_NUMBER[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
group B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
trial I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

patients O
with O
essential B_DISEASE
hypertension I_DISEASE
( O
mean O
sitting O
diastolic O
BP O
[ O
MSDBP O
] O
, O
> O
or O
= O
95 O
mm O
Hg O
and O
< O
110 O
mm O
Hg O
) O
were O
randomized O
to O
1 O
of O
8 O
treatment O
groups O
: O
Val O
160 O
or O
320 O
mg O
; O
HCTZ O
12 O
. O
5 O
or O
25 O
mg O
; O
Val O
/ O
HCTZ O
160 O
/ O
12 O
. O
5 O
, O
320 O
/ O
12 O
. O
5 O
, O
or O
320 O
/ O
25 O
mg O
; O
or O
placebo O
. O

Mean B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
changes B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
MSDBP B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
and O
mean O
sitting O
systolic B_MEASURE/B_LOCATION
BP I_MEASURE/I_LOCATION
( O
MSSBP B_DISEASE/B_LOCATION
) O
were O
analyzed O
at O
the O
8 B_NUMBER[MEASURE]
- O
week B_TIME[MEASURE]/B_LOCATION
core I_TIME[MEASURE]/I_LOCATION
study I_TIME[MEASURE]/I_LOCATION
end I_TIME[MEASURE]/I_LOCATION
point I_TIME[MEASURE]/I_LOCATION
. O

Val B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
HCTZ B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
320 I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
12 B_MEASURE
. O
5 B_MEASURE
and O
320 B_MEASURE
/ O
25 B_MEASURE
mg I_MEASURE
were O
further O
investigated O
in O
a O
54 B_NUMBER[MEASURE]
- O
week B_TIME[MEASURE]/B_LOCATION
, O
open B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
label B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
extension I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

Response B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
defined O
as O
MSDBP B_DISEASE/B_LOCATION
< O
90 B_MEASURE/B_LOCATION
mm I_MEASURE/I_LOCATION
Hg I_MEASURE/I_LOCATION
or O
a O
> B_MEASURE
or O
= O
10 B_MEASURE
mm I_MEASURE
Hg I_MEASURE
decrease I_MEASURE
compared O
to O
baseline B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O

Control B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
was O
defined O
as O
MSDBP B_DISEASE/B_MEASURE
< O
90 B_MEASURE
mm I_MEASURE
Hg I_MEASURE
compared O
with O
baseline B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O

Tolerability B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
was O
assessed O
by O
monitoring O
adverse B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
events I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
at O
randomization B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O
all O
subsequent B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
visits I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
regular B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
evaluation I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
hematology B_BODY_PART_OR_ORGAN_COMPONENT/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
blood B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
chemistry I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

RESULTS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O
A O
total B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
1346 B_TIME[MEASURE]
patients I_TIME[MEASURE]
were O
randomized O
into O
the O
8 B_NUMBER[MEASURE]
- O
week B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
core I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
( O
734 B_MEASURE/B_PERSON
men I_MEASURE/I_PERSON
, O
612 B_MEASURE/B_PERSON
women I_MEASURE/I_PERSON
; O
924 B_MEASURE/B_PERSON
white I_MEASURE/I_PERSON
, O
291 B_PERSON/B_COLOR
black I_PERSON/I_COLOR
, O
23 B_MEASURE/B_PERSON
Asian I_MEASURE/I_PERSON
, O
108 B_MEASURE/B_PERSON
other I_MEASURE/I_PERSON
; O
mean O
age B_TIME[MEASURE]/B_PERSON
, O
52 B_MEASURE
. O
7 B_MEASURE/B_ENT
years I_MEASURE/I_ENT
; O
mean B_MEASURE/B_PERSON
weight I_MEASURE/I_PERSON
, O
92 B_MEASURE
. O
6 B_MEASURE
kg I_MEASURE
) O
. O

All O
active B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treatments I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
associated O
with O
significantly O
reduced O
MSSBP B_DISEASE
and O
MSDBP B_DISEASE/B_GENE
during O
the O
core B_NUMBER[MEASURE]
8 I_NUMBER[MEASURE]
- O
week B_TIME[MEASURE]/B_LOCATION
study I_TIME[MEASURE]/I_LOCATION
, O
with O
each O
monotherapy B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
significantly O
contributing O
to O
the O
overall B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effect I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
combination B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
therapy I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
( O
Val B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
and O
HCTZ B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
P B_PROTEIN[GENE]/B_LOCATION
< O
0 B_MEASURE
. O
001 B_MEASURE
) O
. O

Each O
combination B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
was O
associated O
with O
significantly O
greater B_DISEASE_ADJECTIVE[DISEASE]
reductions I_DISEASE_ADJECTIVE[DISEASE]
in O
MSSBP B_DISEASE/B_GENE
and O
MSDBP B_DISEASE/B_GENE
compared O
with O
the O
monotherapies B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O
placebo B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
( O
all O
, O
P B_MEASURE/B_PROTEIN[GENE]
< O
0 B_MEASURE
. O
001 B_MEASURE
) O
. O

The O
mean B_MEASURE
reduction I_MEASURE
in O
MSSBP B_DISEASE/B_GENE
/ O
MSDBP B_DISEASE
with O
Val B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
/ O
HCTZ B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
320 I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
25 B_MEASURE
mg I_MEASURE
was O
24 B_MEASURE
. O
7 B_MEASURE
/ O
16 B_MEASURE
. O
6 B_MEASURE
mm I_MEASURE
Hg I_MEASURE
, O
compared O
with O
5 B_MEASURE
. O
9 B_MEASURE
/ O
7 B_MEASURE
. O
0 B_MEASURE
mm I_MEASURE
Hg I_MEASURE
with O
placebo B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
reduction B_DISEASE_ADJECTIVE[DISEASE]
in O
MSSBP B_DISEASE/B_GENE
was O
significantly O
greater B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
with O
Val B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
HCTZ B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
320 I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
25 B_MEASURE
mg I_MEASURE
compared O
with O
Val B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
HCTZ B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
160 I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
12 B_MEASURE
. O
5 B_MEASURE
mg I_MEASURE
( O
P B_PROTEIN[GENE]/B_LOCATION
< O
0 B_MEASURE
. O
002 B_MEASURE
) O
. O

rates B_MEASURE
of O
response B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
BP B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
control I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
significantly O
higher B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
in O
the O
groups B_ORGANIZATION/B_PERSON
that O
received O
combination B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
treatment I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
compared O
with O
those O
that O
received O
monotherapy B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
. O

The O
incidence O
of O
hypokalemia B_DISEASE
was O
lower O
with O
Val O
/ O
HCTZ O
combinations O
( O
1 O
. O
8 O
% O
- O
6 O
. O
1 O
% O
) O
than O
with O
HCTZ O
monotherapies O
( O
7 O
. O
1 O
% O
- O
13 O
. O
3 O
% O
) O
. O

The O
majority B_MEASURE
of O
adverse B_DISEASE_ADJECTIVE[DISEASE]
events I_DISEASE_ADJECTIVE[DISEASE]
in O
the O
core B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
were O
of O
mild B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
to O
moderate B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
severity I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
. O

The O
efficacy B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O
tolerability B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O
Val B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
/ O
HCTZ B_DISEASE/B_LOCATION
combinations B_DISEASE/I_LOCATION
were O
maintained O
during O
the O
extension B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
( O
797 B_TIME[MEASURE]
patients I_TIME[MEASURE]
) O
. O

conclusions O
: O
In O
this O
study O
population O
, O
combination O
therapies O
with O
Val O
/ O
HCTZ O
were O
associated O
with O
significantly O
greater O
BP O
reductions O
compared O
with O
either O
monotherapy O
, O
were O
well O
tolerated O
, O
and O
were O
associated O
with O
less O
hypokalemia B_DISEASE_ADJECTIVE[DISEASE]
than O
HCTZ O
alone O
. O

Succimer O
chelation O
improves O
learning O
, O
attention O
, O
and O
arousal O
regulation O
in O
lead O
- O
exposed O
rats O
but O
produces O
lasting O
cognitive B_DISEASE_ADJECTIVE[DISEASE]
impairment I_DISEASE_ADJECTIVE[DISEASE]
in O
the O
absence O
of O
lead O
exposure O
. O

Background B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
There O
is O
growing O
pressure B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
for O
clinicians B_PERSON/B_ORGANIZATION
to O
prescribe O
chelation B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O
only O
slightly O
elevated B_MEASURE
blood I_MEASURE
lead I_MEASURE
levels I_MEASURE
. O

However O
, O
very O
few B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
studies I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
have O
evaluated O
whether O
chelation B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
improves O
cognitive B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
outcomes B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
in O
Pb B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- O
exposed O
children B_PERSON/B_BIO
, O
or O
whether O
these O
agents B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
have O
adverse B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
effects I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
that O
may O
affect O
brain B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
development B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
absence B_DISEASE/B_LOCATION
of O
Pb B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
exposure B_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

objectives O
: O
The O
present O
study O
was O
designed O
to O
answer O
these O
questions O
, O
using O
a O
rodent O
model O
of O
early O
childhood O
Pb O
exposure O
and O
treatment O
with O
succimer O
, O
a O
widely O
used O
chelating O
agent O
for O
the O
treatment O
of O
Pb B_DISEASE
poisoning I_DISEASE
. O

Results O
: O
Pb O
exposure O
produced O
lasting O
impairments B_DISEASE_ADJECTIVE[DISEASE]
in I_DISEASE_ADJECTIVE[DISEASE]
learning I_DISEASE_ADJECTIVE[DISEASE]
, I_DISEASE_ADJECTIVE[DISEASE]
attention I_DISEASE_ADJECTIVE[DISEASE]
, I_DISEASE_ADJECTIVE[DISEASE]
inhibitory I_DISEASE_ADJECTIVE[DISEASE]
control I_DISEASE_ADJECTIVE[DISEASE]
, I_DISEASE_ADJECTIVE[DISEASE]
and I_DISEASE_ADJECTIVE[DISEASE]
arousal I_DISEASE_ADJECTIVE[DISEASE]
regulation I_DISEASE_ADJECTIVE[DISEASE]
, O
paralleling O
the O
areas O
of O
dysfunction O
seen O
in O
Pb O
- O
exposed O
children O
. O

Succimer B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
treatment I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
the O
Pb B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- O
exposed O
rats B_BIO/B_PERSON
significantly O
improved O
learning B_DISEASE
, O
attention B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O
and O
arousal B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
regulation I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
, O
although O
the O
efficacy B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
the O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
varied O
as O
a O
function B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
Pb B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
exposure B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
level B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
the O
specific B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
functional B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
deficit B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

In O
contrast O
, O
succimer O
treatment O
of O
rats O
not O
previously O
exposed O
to O
Pb O
produced O
lasting O
and O
pervasive O
cognitive B_DISEASE
and I_DISEASE
affective I_DISEASE
dysfunction I_DISEASE
comparable O
in O
magnitude O
to O
that O
produced O
by O
the O
higher O
Pb O
exposure O
regimen O
. O

conclusions O
: O
These O
are O
the O
first O
data O
, O
to O
our O
knowledge O
, O
to O
show O
that O
treatment O
with O
any O
chelating O
agent O
can O
alleviate O
cognitive B_DISEASE
deficits I_DISEASE
due O
to O
Pb O
exposure O
. O

These O
findings B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggest O
that O
it O
may O
be O
possible B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
identify O
a O
succimer B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
treatment I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
protocol I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
that O
improves O
cognitive B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
outcomes B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
in O
Pb B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
exposed O
children B_PERSON/B_BIO
. O

However O
, O
they O
also O
suggest O
that O
succimer B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
treatment I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
should O
be O
strongly O
discouraged O
for O
children B_PERSON/B_BIO
who O
do O
not O
have O
elevated O
tissue B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
levels I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
Pb B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O
other B_LOCATION
heavy I_LOCATION
metals I_LOCATION
. O

Caffeine O
challenge O
test O
in O
panic B_DISEASE/B_PERSON
disorder I_DISEASE/I_PERSON
and O
depression B_TIME[MEASURE]/B_PERSON
with O
panic B_DISEASE
attacks I_DISEASE
. O

Our O
aim O
was O
to O
observe O
if O
patients O
with O
panic B_DISEASE
disorder I_DISEASE
( O
PD B_LOCATION
) O
and O
patients O
with O
major B_DISEASE/B_PERSON
depression I_DISEASE/I_PERSON
with O
panic B_DISEASE
attacks I_DISEASE
( O
MDP B_DISEASE/B_PROTEIN[GENE]
) O
( O
diagnostic O
and O
Statistical O
Manual O
of O
Mental B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Disorders I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
Fourth O
Edition O
criteria O
) O
respond O
in O
a O
similar O
way O
to O
the O
induction O
of O
panic B_DISEASE
attacks I_DISEASE
by O
an O
oral O
caffeine O
challenge O
test O
. O

We O
randomly O
selected O
29 O
patients O
with O
PD B_DISEASE
, O
27 O
with O
MDP B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
25 O
with O
major B_DISEASE
depression I_DISEASE
without O
panic B_DISEASE
attacks I_DISEASE
( O
MD B_DISEASE
) O
, O
and O
28 O
healthy O
volunteers O
. O

The O
patients B_PERSON/B_LOCATION
had O
no O
psychotropic B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
drug I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
for O
at O
least O
a O
4 B_NUMBER[MEASURE]
- O
week B_TIME[MEASURE]
period I_TIME[MEASURE]
. O

In O
a O
randomized O
double O
- O
blind O
experiment O
performed O
in O
2 O
occasions O
7 O
days O
apart O
, O
480 O
mg O
caffeine O
and O
a O
caffeine O
- O
free O
( O
placebo O
) O
solution O
were O
administered O
in O
a O
coffee O
form O
and O
anxiety B_DISEASE/B_MEASURE
scales O
were O
applied O
before O
and O
after O
each O
test O
. O

A O
total O
of O
58 O
. O
6 O
% O
( O
n O
= O
17 O
) O
of O
patients O
with O
PD B_DISEASE
, O
44 O
. O
4 O
% O
( O
n O
= O
12 O
) O
of O
patients O
with O
MDP B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
12 O
. O
0 O
% O
( O
n O
= O
3 O
) O
of O
patients O
with O
MD B_DISEASE/B_LOCATION
, O
and O
7 O
. O
1 O
% O
( O
n O
= O
2 O
) O
of O
control O
subjects O
had O
a O
panic B_DISEASE
attack I_DISEASE
after O
the O
480 O
- O
mg O
caffeine O
challenge O
test O
( O
Chi O
( O
2 O
) O
( O
3 O
) O
= O
16 O
. O
22 O
, O
P O
= O
. O
001 O
) O
. O

The O
patients O
with O
PD B_LOCATION
and O
MDP B_DISEASE/B_PROTEIN[GENE]
were O
more O
sensitive O
to O
caffeine O
than O
were O
patients O
with O
MD B_DISEASE
and O
healthy O
volunteers O
. O

No O
panic B_DISEASE
attack I_DISEASE
was O
observed O
after O
the O
caffeine O
- O
free O
solution O
intake O
. O

The O
patients O
with O
MD B_DISEASE/B_LOCATION
had O
a O
lower O
heart O
rate O
response O
to O
the O
test O
than O
all O
the O
other O
groups O
( O
2 O
- O
way O
analysis O
of O
variance O
, O
group O
by O
time O
interaction O
with O
greenhouse O
- O
Geisser O
correction O
: O
F O
( O
3 O
, O
762 O
) O
= O
2 O
. O
85 O
, O
P O
= O
. O
026 O
) O
. O

Our O
data O
suggest O
that O
there O
is O
an O
association O
between O
panic B_DISEASE
attacks I_DISEASE
, O
no O
matter O
if O
associated O
with O
PD B_DISEASE
or O
MDP B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
hyperreactivity O
to O
an O
oral O
caffeine O
challenge O
test O
. O

Mitral O
annuloplasty O
as O
a O
ventricular O
restoration O
method O
for O
the O
failing B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
left I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
ventricle I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
: O
a O
pilot O
study O
. O

Background O
AND O
aim O
OF O
THE O
Study O
: O
Undersized O
mitral O
annuloplasty O
( O
Map O
) O
is O
effective O
in O
patients O
with O
dilated B_DISEASE_ADJECTIVE[DISEASE]
cardiomyopathy I_DISEASE_ADJECTIVE[DISEASE]
and O
functional O
mitral B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
regurgitation I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
( O
MR B_LOCATION
) O
since O
, O
as O
well O
as O
addressing O
the O
MR B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O
the O
Map O
may O
also O
reshape O
the O
dilated O
left O
ventricular O
( O
LV O
) O
base O
. O

However O
, O
the O
direct O
benefits O
of O
this O
possible O
reshaping O
on O
LV O
function O
in O
the O
absence O
of O
underlying O
MR B_DISEASE/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
remain O
incompletely O
understood O
. O

The O
study O
aim O
was O
to O
identify O
these O
benefits O
in O
a O
canine O
model O
of O
acute O
heart B_DISEASE/B_LOCATION
failure I_DISEASE/I_LOCATION
. O

methods B_MEASURE
: O
Six B_ENT/B_PERSON
dogs B_ENT/I_PERSON
underwent O
MAP B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O
a O
prosthetic B_MEDICAL_DEVICE[OBJECT]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
band I_MEDICAL_DEVICE[OBJECT]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
on O
the O
posterior B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
mitral I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
annulus I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
, O
using O
four B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
mattress I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
sutures I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
sutures B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEDICAL_DEVICE[OBJECT]
were O
passed O
individually O
through O
four B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_SPORT[ENT]
tourniquets I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_SPORT[ENT]
and O
exteriorized O
untied O
via O
the O
left B_BODY_PART_OR_ORGAN_COMPONENT/B_PRODUCT[OBJECT]
atriotomy I_BODY_PART_OR_ORGAN_COMPONENT/I_PRODUCT[OBJECT]
. O

Sonomicrometry B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
crystals I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
were O
implanted O
around O
the O
mitral B_BODY_PART_OR_ORGAN_COMPONENT
annulus I_BODY_PART_OR_ORGAN_COMPONENT
and O
left O
ventricle B_BODY_PART_OR_ORGAN_COMPONENT
to O
measure B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
geometry I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
and O
regional B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
function B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

acute O
heart B_DISEASE
failure I_DISEASE
was O
induced O
by O
propranolol O
and O
volume O
loading O
after O
weaning O
from O
cardiopulmonary O
bypass O
; O
an O
absence O
of O
MR B_DISEASE/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
confirmed O
by O
echocardiography O
. O

MAP B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
was O
accomplished O
by O
cinching O
the O
tourniquets B_LOCATION
. O

Data O
were O
acquired O
at O
baseline O
, O
after O
induction O
of O
acute O
heart B_DISEASE
failure I_DISEASE
, O
and O
after O
Map O
. O

RESULTS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
MAP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
decreased O
mitral B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
annular I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
dimensions I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O
both O
commissure B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
commissure B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
and O
septal B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
- O
lateral B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
directions I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
. O

Concomitantly O
, O
the O
diastolic B_MEASURE/B_LOCATION
diameter I_MEASURE/I_LOCATION
of O
the O
LV B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
base I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
and O
LV B_BODY_PART_OR_ORGAN_COMPONENT/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sphericity I_BODY_PART_OR_ORGAN_COMPONENT/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
decreased O
( O
i O
. O
e B_DISEASE/B_PROTEIN[GENE]
. O
, O
improved O
) O
from O
37 B_MEASURE
. O
4 B_MEASURE
+ I_MEASURE
/ O
- O
9 B_MEASURE
. O
3 B_MEASURE
to O
35 B_MEASURE
. O
9 B_MEASURE
+ I_MEASURE
/ O
- O
10 B_MEASURE
mm I_MEASURE
( O
p B_MEASURE/B_PROTEIN[GENE]
= O
0 B_MEASURE
. O
063 B_MEASURE
) O
, O
and O
from O
67 B_MEASURE
. O
9 B_MEASURE
+ I_MEASURE
/ O
- O
18 B_MEASURE
. O
6 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
to O
65 B_MEASURE
. O
3 B_MEASURE
+ I_MEASURE
/ O
- O
18 B_MEASURE
. O
9 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
( O
p B_PROTEIN[GENE]/B_LOCATION
= O
0 B_MEASURE
. O
016 B_MEASURE
) O
, O
respectively O
. O

decreases B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
were O
evident B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
both O
LV B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
end I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
diastolic B_MEASURE/B_LOCATION
pressure B_MEASURE/I_LOCATION
( O
from O
17 B_MEASURE
+ I_MEASURE
/ O
- O
7 B_MEASURE
to O
15 B_MEASURE
+ I_MEASURE
/ O
- O
6 B_MEASURE
mmHg I_MEASURE
, O
p O
= O
0 B_NUMBER[MEASURE]
. O
0480 B_MEASURE
and O
Tau B_PROTEIN[GENE]/B_DISEASE
( O
from O
48 B_MEASURE
+ I_MEASURE
/ O
- O
8 B_MEASURE
to O
45 B_MEASURE
+ I_MEASURE
/ O
- O
8 B_MEASURE
MS I_MEASURE
, O
p B_PROTEIN[GENE]/B_LOCATION
< O
0 B_MEASURE
. O
01 B_MEASURE
) O
, O
while O
fractional B_MEASURE/B_GENE
shortening B_MEASURE/I_GENE
at O
the O
LV B_MEASURE/B_PROTEIN[GENE]
base B_MEASURE/I_PROTEIN[GENE]
increased O
from O
7 B_MEASURE
. O
7 B_MEASURE
+ I_MEASURE
/ O
- O
4 B_MEASURE
. O
5 B_MEASURE
% I_MEASURE
to O
9 B_MEASURE
. O
4 B_MEASURE
+ I_MEASURE
/ O
- O
4 B_MEASURE
. O
5 B_MEASURE
% I_MEASURE
( O
p B_PROTEIN[GENE]/B_LOCATION
= O
0 B_NUMBER[MEASURE]
. O
045 B_MEASURE
) O
. O

After O
MAP B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
, O
increases B_DISEASE_ADJECTIVE[DISEASE]
were O
identified O
in O
both O
cardiac B_MEASURE/B_ORGANIZATION
output B_MEASURE/I_ORGANIZATION
( O
from O
1 B_MEASURE
. O
54 B_MEASURE
+ I_MEASURE
/ O
- O
0 B_NUMBER[MEASURE]
. O
57 B_MEASURE
to O
1 B_MEASURE
. O
65 B_MEASURE
+ I_MEASURE
/ O
- O
0 B_MEASURE
. O
57 B_MEASURE/B_PERSON
1 I_MEASURE/I_PERSON
/ O
min B_MEASURE/B_PERSON
) O
and O
Emax B_DISEASE/B_GENE
( O
from O
1 B_MEASURE
. O
86 B_MEASURE
+ I_MEASURE
/ O
- O
0 B_MEASURE
. O
9 B_MEASURE
to O
2 B_MEASURE
. O
41 B_MEASURE
+ I_MEASURE
/ O
- O
1 B_MEASURE
. O
31 B_MEASURE
mmHg I_MEASURE
/ O
ml B_MEASURE/B_PERSON
) O
. O

conclusion O
: O
The O
data O
acquired O
suggest O
that O
isolated O
Map O
may O
have O
certain O
benefits O
on O
LV O
dimension O
/ O
function O
in O
acute O
heart B_DISEASE
failure I_DISEASE
, O
even O
in O
the O
absence O
of O
MR B_DISEASE/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

However O
, O
further O
investigations O
are O
warranted O
in O
a O
model O
of O
chronic O
heart B_DISEASE
failure I_DISEASE
. O

Piperacillin O
/ O
tazobactam O
- O
induced O
seizure B_DISEASE
rapidly O
reversed O
by O
high O
flux O
hemodialysis O
in O
a O
patient O
on O
peritoneal O
dialysis O
. O

Despite O
popular O
use O
of O
piperacillin O
, O
the O
dire O
neurotoxicity B_DISEASE
associated O
with O
piperacillin O
still O
goes O
unrecognized O
, O
leading O
to O
a O
delay O
in O
appropriate O
management O
. O

We O
report O
a O
57 O
- O
year O
- O
old O
woman O
with O
end B_DISEASE/B_GENE
- I_DISEASE/I_GENE
stage I_DISEASE/I_GENE
renal I_DISEASE/I_GENE
disease I_DISEASE/I_GENE
receiving O
continuous O
ambulatory O
peritoneal O
dialysis O
( O
CAPD O
) O
, O
who O
developed O
slurred O
speech O
, O
tremor B_DISEASE
, O
bizarre O
behavior O
, O
progressive O
mental O
confusion B_DISEASE
, O
and O
2 O
episodes O
of O
generalized O
tonic B_DISEASE
- I_DISEASE
clonic I_DISEASE
seizure I_DISEASE
( O
GTCS B_LOCATION
) O
after O
5 O
doses O
of O
piperacillin O
/ O
tazobactam O
( O
2 O
g O
/ O
250 O
mg O
) O
were O
given O
for O
bronchiectasis B_PERSON
with O
secondary B_DISEASE
infection I_DISEASE
. O

The O
laboratory O
data O
revealed O
normal O
plasma O
electrolyte O
and O
ammonia O
levels O
but O
leukocytosis B_DISEASE_ADJECTIVE[DISEASE]
. O

Neurologic O
examinations O
showed O
dysarthria B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
and O
bilateral O
Babinski O
sign O
. O

Computed B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tomography I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
brain B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
and O
electroencephalogram B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
were O
unremarkable B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Despite O
the O
use O
of O
antiepileptic O
agents O
, O
another O
GTCS B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
episode O
recurred O
after O
the O
sixth O
dose O
of O
piperacillin O
/ O
tazobactam O
. O

Brain O
magnetic O
resonance O
imaging O
did O
not O
demonstrate O
acute O
infarction B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
organic B_DISEASE
brain I_DISEASE
lesions I_DISEASE
. O

initiation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
high B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O
flux B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
hemodialysis I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
rapidly O
reversed O
the O
neurologic B_DISEASE
symptoms I_DISEASE
within O
4 B_TIME[MEASURE]
hours I_TIME[MEASURE]
. O

Piperacillin O
- O
induced O
encephalopathy B_DISEASE
should O
be O
considered O
in O
any O
uremic B_DISEASE/B_PERSON
patients O
with O
unexplained O
neurological O
manifestations O
. O

CAPD O
is O
inefficient O
in O
removing O
piperacillin O
, O
whereas O
hemodialysis O
can O
rapidly O
terminate O
the O
piperacillin O
- O
induced O
encephalopathy B_DISEASE
. O

frequency O
of O
transient O
ipsilateral O
vocal B_DISEASE
cord I_DISEASE
paralysis I_DISEASE
in O
patients O
undergoing O
carotid O
endarterectomy O
under O
local O
anesthesia O
. O

Background B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
Especially O
because O
of O
improvements B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
clinical B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANIZATION
neurologic I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANIZATION
monitoring I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANIZATION
, O
carotid B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
endarterectomy I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
done O
under O
local B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
anesthesia I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
has O
become O
the O
technique B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
choice B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
in O
several B_LOCATION/B_NUMBER[MEASURE]
centers I_LOCATION/I_NUMBER[MEASURE]
. O

temporary O
ipsilateral O
vocal B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
nerve I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
palsies I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
due O
to O
local O
anesthetics O
have O
been O
described O
, O
however O
. O

Such O
complications O
are O
most O
important O
in O
situations O
where O
there O
is O
a O
pre O
- O
existing O
contralateral O
paralysis B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
. O

We O
therefore O
examined O
the O
effect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
local B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
anesthesia I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
vocal B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cord I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
function I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
better O
understand O
its O
possible B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
consequences B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

METHODS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O
This O
prospective B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
included O
28 B_PERSON
patients I_PERSON
undergoing O
carotid B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
endarterectomy I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_GENE
under O
local B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
anesthesia I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

vocal B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
cord B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
function B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
was O
evaluated O
before O
, O
during O
, O
and O
after O
surgery B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O
postoperative B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
day I_TIME[MEASURE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
1 I_TIME[MEASURE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
) O
using O
flexible B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
laryngoscopy I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O

anesthesia B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
was O
performed O
by O
injecting O
20 B_MEASURE/B_LOCATION
to O
40 B_MEASURE
mL I_MEASURE
of O
a O
mixture B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
long O
- O
acting O
( O
ropivacaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
and O
short O
- O
acting O
( O
prilocaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
anesthetic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

RESULTS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
All O
patients B_PERSON/B_BIO
had O
normal B_DISEASE
vocal I_DISEASE
cord I_DISEASE
function I_DISEASE
preoperatively O
. O

Twelve O
patients O
( O
43 O
% O
) O
were O
found O
to O
have O
intraoperative O
ipsilateral O
vocal B_DISEASE
cord I_DISEASE
paralysis I_DISEASE
. O

It O
resolved O
in O
all O
cases B_TIME[MEASURE]/B_LOCATION
< I_TIME[MEASURE]/I_LOCATION
or O
= O
24 B_MEASURE/B_SPORT[ENT]
hours I_MEASURE/I_SPORT[ENT]
. O

There O
were O
no O
significant O
differences O
in O
operating O
time O
or O
volume O
or O
frequency O
of O
anesthetic O
administration O
in O
patients O
with O
temporary O
vocal B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
cord B_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
paralysis B_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
compared O
with O
those O
without O
. O

conclusion O
: O
Local O
anesthesia O
led O
to O
temporary O
ipsilateral O
vocal B_DISEASE
cord I_DISEASE
paralysis I_DISEASE
in O
almost O
half O
of O
these O
patients O
. O

Because O
pre O
- O
existing O
paralysis B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
is O
of O
a O
relevant O
frequency O
( O
up O
to O
3 O
% O
) O
, O
a O
preoperative O
evaluation O
of O
vocal O
cord O
function O
before O
carotid O
endarterectomy O
under O
local O
anesthesia O
is O
recommended O
to O
avoid O
intraoperative O
bilateral O
paralysis B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

In O
patients O
with O
preoperative O
contralateral O
vocal B_DISEASE
cord I_DISEASE
paralysis I_DISEASE
, O
surgery O
under O
general O
anesthesia O
should O
be O
considered O
. O

Impaired B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fear B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
recognition B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
regular O
recreational O
cocaine O
users O
. O

Introduction B_TIME[MEASURE]/B_PERSON
: O
The O
ability B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O
read O
facial B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
expressions I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
is O
essential B_TIME[MEASURE]/B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
normal B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
human I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
social I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
interaction I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O

The O
aim B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
the O
present B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
was O
to O
conduct O
the O
first B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
investigation I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
facial B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expression I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
recognition I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
performance I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
recreational B_LOCATION/B_PERSON
cocaine I_LOCATION/I_PERSON
users I_LOCATION/I_PERSON
. O

materials B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
AND O
METHODS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O
Three B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
groups B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
, O
comprised O
of O
21 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
cocaine B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
naive B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
participants B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
CN B_LOCATION
) O
, O
30 B_NUMBER[MEASURE]/B_PERSON
occasional I_NUMBER[MEASURE]/I_PERSON
cocaine I_NUMBER[MEASURE]/I_PERSON
( O
OC B_LOCATION/B_PERSON
) O
, O
and O
48 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
regular B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
recreational B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
cocaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
RC B_LOCATION/B_PERSON
) O
users B_PERSON
, O
were O
compared O
. O

An O
emotional B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
facial B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expression B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
EFE B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O
task B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
consisting O
of O
a O
male B_PERSON/B_COLOR
and O
female B_PERSON
face I_PERSON
expressing O
six B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
basic I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
emotions I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
happiness B_DISEASE/B_PERSON
, O
surprise B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
sadness B_DISEASE/B_PERSON
, O
anger B_DISEASE/B_PERSON
, O
fear B_DISEASE/B_PERSON
, O
and O
disgust B_DISEASE/B_PERSON
) O
was O
administered O
. O

Mean B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
percent B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
accuracy B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
latencies B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
for O
correct B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
responses I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
across O
eight B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
presentations I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
each O
basic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
emotion I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
were O
derived O
. O

participants B_PERSON/B_BIO
were O
also O
assessed O
with O
the O
' O
eyes B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
task B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
' O
to O
investigate O
their O
ability B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O
recognize O
more O
complex B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
emotional I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
states I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
the O
Symptom B_MEASURE/B_PROTEIN[GENE]
Checklist B_MEASURE/I_PROTEIN[GENE]
- O
90 B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
revised O
to O
measure O
psychopathology B_DISEASE
. O

Results O
: O
There O
were O
no O
group O
differences O
in O
psychopathology O
or O
' O
eyes O
task O
' O
performance O
, O
but O
the O
RC O
group O
, O
who O
otherwise O
had O
similar O
illicit O
substance O
use O
histories O
to O
the O
OC O
group O
, O
exhibited O
impaired B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
fear I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
recognition I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
accuracy O
compared O
to O
the O
OC O
and O
CN O
groups O
. O

The O
RC B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
group B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
also O
correctly O
identified O
anger B_DISEASE/B_PERSON
, O
fear B_DISEASE/B_PERSON
, O
happiness B_DISEASE/B_PERSON
, O
and O
surprise B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
more O
slowly O
than O
CN B_DISEASE/B_LOCATION
, O
but O
not O
OC B_PERSON/B_LOCATION
participants B_PERSON/I_LOCATION
. O

The O
OC B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
group B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
was O
slower B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
than O
CN B_DISEASE/B_MEASURE
when O
correctly O
identifying O
disgust B_DISEASE/B_PERSON
. O

The O
selective O
deficit B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fear I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
recognition I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
accuracy O
manifested O
by O
the O
RC O
group O
cannot O
be O
explained O
by O
the O
subacute O
effects O
of O
cocaine O
, O
or O
ecstasy O
, O
because O
recent O
and O
less O
recent O
users O
of O
these O
drugs O
within O
this O
group O
were O
similarly O
impaired O
. O

possible O
parallels O
between O
RC O
users O
and O
psychopaths B_PERSON/B_DISEASE
with O
respect O
to O
impaired B_DISEASE
fear I_DISEASE
recognition I_DISEASE
, O
amygdala B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dysfunction B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
etiology O
are O
discussed O
. O

Damage B_DISEASE_ADJECTIVE[DISEASE]
of I_DISEASE_ADJECTIVE[DISEASE]
substantia I_DISEASE_ADJECTIVE[DISEASE]
nigra I_DISEASE_ADJECTIVE[DISEASE]
pars I_DISEASE_ADJECTIVE[DISEASE]
reticulata I_DISEASE_ADJECTIVE[DISEASE]
during O
pilocarpine O
- O
induced O
status B_DISEASE
epilepticus I_DISEASE
in O
the O
rat O
: O
immunohistochemical O
study O
of O
neurons O
, O
astrocytes O
and O
serum O
- O
protein O
extravasation O
. O

The O
substantia O
nigra O
has O
a O
gating O
function O
controlling O
the O
spread O
of O
epileptic B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
seizure B_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
activity O
. O

Additionally O
, O
in O
models O
of O
prolonged B_DISEASE
status I_DISEASE
epilepticus I_DISEASE
the O
pars O
reticulata O
of O
substantia O
nigra O
( O
SNR O
) O
suffers O
from O
a O
massive O
lesion O
which O
may O
arise O
from O
a O
massive O
metabolic B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
derangement I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
hyperexcitation O
developing O
in O
the O
activated O
SNR O
. O

In O
this O
study O
, O
status B_DISEASE
epilepticus I_DISEASE
was O
induced O
by O
systemic O
injection O
of O
pilocarpine O
in O
rats O
. O

The O
neuropathology B_DISEASE_ADJECTIVE[DISEASE]
of O
SNR B_DISEASE
was O
investigated O
using O
immunohistochemical B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
techniques I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
with O
the O
major B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
emphasis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
on O
the O
time B_TIME[MEASURE]/B_LOCATION
- O
course B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
changes B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
in O
neurons B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O
astrocytes B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

Animals O
surviving O
20 O
, O
30 O
, O
40 O
, O
60 O
min O
, O
2 O
, O
3 O
, O
6 O
hours O
, O
1 O
, O
2 O
, O
and O
3 O
days O
after O
induction O
of O
status B_DISEASE
epilepticus I_DISEASE
were O
perfusion O
- O
fixed O
, O
and O
brains O
processed O
for O
immunohistochemical O
staining O
of O
SNR O
. O

Nissl O
- O
staining O
and O
antibodies O
against O
the O
neuron O
- O
specific O
calcium O
- O
binding O
protein O
, O
parvalbumin O
, O
served O
to O
detect O
neuronal B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
damage B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
in O
SNR O
. O

Antibodies B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
against O
the O
astroglia B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
- O
specific B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
cytoskeletal B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
protein B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
, O
glial B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
fibrillary I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
acidic I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
GFAP B_GENE/B_LOCATION
) O
, O
and O
against O
the O
glial B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
calcium B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
- O
binding O
protein B_PROTEIN[GENE]/B_BACTERIUM[BIO]
, O
S B_OTHER/B_LOCATION
- O
100 B_GENE/B_MEASURE
protein I_GENE/I_MEASURE
, O
were O
used O
to O
assess O
the O
status B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
astrocytes B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
. O

Immunohistochemical O
staining O
for O
serum O
- O
albumin O
and O
immunoglobulins O
in O
brain O
tissue O
was O
taken O
as O
indicator O
of O
blood O
- O
brain O
barrier O
disturbances O
and O
vasogenic B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
edema I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
formation O
. O

Immunohistochemical O
staining O
indicated O
loss O
of O
GFAP O
- O
staining O
already O
at O
30 O
min O
after O
induction O
of O
seizures B_DISEASE/B_GENE
in O
an O
oval O
focus O
situated O
in O
the O
center O
of O
SNR O
while O
sparing O
medial O
and O
lateral O
aspects O
. O

At O
1 B_MEASURE
h O
there O
was O
additional B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
vacuolation I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
S B_PROTEIN[GENE]/B_DISEASE
- O
100 B_MEASURE/B_LOCATION
protein I_MEASURE/I_LOCATION
staining I_MEASURE/I_LOCATION
. O

By O
2 O
hours O
, O
parvalbumin O
- O
staining O
changed O
in O
the O
central O
SNR O
indicating O
neuronal B_DISEASE
damage I_DISEASE
, O
and O
Nissl O
- O
staining O
visualized O
some O
neuronal O
distortion O
. O

Staining O
for O
serum B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
proteins B_GENE/B_DISEASE
occurred O
in O
a O
patchy B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
manner I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
throughout O
the O
forebrain B_BODY_PART_OR_ORGAN_COMPONENT
during O
the O
first B_TIME[MEASURE]/B_ENT
hours I_TIME[MEASURE]/I_ENT
. O

By O
6 O
h O
, O
vasogenic B_PERSON
edema I_PERSON
covered O
the O
lesioned B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
SNR I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
. O

By O
24 B_TIME[MEASURE]/B_LOCATION
h O
, O
glial B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O
neuronal B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
markers I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
indicated O
a O
massive B_DISEASE/B_MEASURE
lesion I_DISEASE/I_MEASURE
in O
the O
center B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
of O
SNR B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

By O
48 B_MEASURE
- O
72 B_TIME[MEASURE]
h I_TIME[MEASURE]
, O
astrocytes B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
surrounding O
the O
lesion B_DISEASE
increased O
in O
size B_MEASURE
, O
and O
polymorphic B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
phagocytotic B_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
cells B_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
invaded O
the O
damaged O
area B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
. O

In O
a O
further O
group O
of O
animals O
surviving O
1 O
to O
5 O
days O
, O
conventional O
paraffin O
- O
sections O
confirmed O
the O
neuronal O
and O
glial O
damage B_DISEASE
of I_DISEASE
SNR I_DISEASE
. O

Additional B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
pathology I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
of O
similar B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
quality I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
found O
in O
the O
globus B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
pallidus I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
. O

Since O
astrocytes B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
were O
always O
damaged O
in O
parallel B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
with O
neurons B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
in O
SNR B_DISEASE/B_PROTEIN[GENE]
it O
is O
proposed O
that O
the O
anatomical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
functional B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
interrelationship B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
between O
neurons B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O
astrocytes B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
is O
particularly O
tight B_DISEASE_ADJECTIVE[DISEASE]
in O
SNR B_DISEASE/B_PROTEIN[GENE]
. O

Both O
cell O
elements O
may O
suffer O
in O
common O
from O
metabolic O
disturbance O
and O
neurotransmitter B_DISEASE
dysfunction I_DISEASE
as O
occur O
during O
massive O
status B_DISEASE
epilepticus I_DISEASE
. O

Neuroprotective O
effects O
of O
melatonin O
upon O
the O
offspring O
cerebellar O
cortex O
in O
the O
rat O
model O
of O
BCNU O
- O
induced O
cortical B_DISEASE
dysplasia I_DISEASE
. O

Cortical B_DISEASE/B_GENE
dysplasia I_DISEASE/I_GENE
is O
a O
malformation O
characterized O
by O
defects O
in O
proliferation O
, O
migration O
and O
maturation O
. O

This O
study O
was O
designed O
to O
evaluate O
the O
alterations O
in O
offspring O
rat O
cerebellum O
induced O
by O
maternal O
exposure O
to O
carmustine O
- O
[ O
1 O
, O
3 O
- O
bis O
( O
2 O
- O
chloroethyl O
) O
- O
1 O
- O
nitrosoure O
] O
( O
BCNU O
) O
and O
to O
investigate O
the O
effects O
of O
exogenous O
melatonin O
upon O
cerebellar O
BCNU O
- O
induced O
cortical B_DISEASE
dysplasia I_DISEASE
, O
using O
histological O
and O
biochemical O
analyses O
. O

pregnant B_PERSON/B_BIO
Wistar I_PERSON/I_BIO
rats I_PERSON/I_BIO
were O
assigned O
to O
five B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
groups I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
intact B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- O
control B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
saline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
control B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
melatonin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
treated O
, O
BCNU B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O
exposed O
and O
BCNU B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O
exposed O
plus B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
melatonin I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
. O

rats B_BIO/B_PERSON
were O
exposed O
to O
BCNU B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
on O
embryonic B_ORGANISM_FUNCTION
day I_ORGANISM_FUNCTION
15 I_ORGANISM_FUNCTION
and O
melatonin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
given O
until O
delivery B_PERSON/B_TIME[MEASURE]
. O

Immuno B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
/ O
histochemistry B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
and O
electron B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
microscopy I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
were O
carried O
out O
on O
the O
offspring O
cerebellum B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
, O
and O
levels B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
of O
malondialdehyde B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O
superoxide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
dismutase I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
were O
determined O
. O

Histopathologically O
, O
typical O
findings O
were O
observed O
in O
the O
cerebella O
from O
the O
control O
groups O
, O
but O
the O
findings O
consistent O
with O
early O
embryonic O
development O
were O
noted O
in O
BCNU O
- O
exposed O
cortical B_DISEASE/B_PERSON
dysplasia I_DISEASE/I_PERSON
group O
. O

There O
was O
a O
marked B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
increase I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O
the O
number B_MEASURE
of O
TUNEL B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
positive I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
cells I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O
nestin B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
positive I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
BCNU B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- O
exposed O
group B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
but O
a O
decreased O
immunoreactivity B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O
glial O
fibrillary B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
acidic I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
synaptophysin B_GENE
and O
transforming O
growth B_GENE/B_MEASURE
factor B_GENE/I_MEASURE
beta1 B_GENE/I_MEASURE
was O
observed O
, O
indicating O
a O
delayed B_DISEASE_ADJECTIVE[DISEASE]
maturation I_DISEASE_ADJECTIVE[DISEASE]
, O
and O
melatonin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
significantly O
reversed O
these O
changes B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

malondialdehyde B_GENE/B_DISEASE
level I_GENE/I_DISEASE
in O
BCNU B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O
exposed O
group B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
higher B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
than O
those O
in O
control B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
groups I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
and O
melatonin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
decreased O
malondialdehyde B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
levels I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
in O
BCNU B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
group B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
( O
P B_MEASURE/B_PROTEIN[GENE]
< O
0 B_MEASURE
. O
01 B_MEASURE
) O
, O
while O
there O
were O
no O
significant B_DISEASE_ADJECTIVE[DISEASE]
differences I_DISEASE_ADJECTIVE[DISEASE]
in O
the O
superoxide B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dismutase I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
levels I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O
these O
groups B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
. O

These O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggest O
that O
exposure B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O
animals B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
BCNU B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
during O
pregnancy B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
leads I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
to O
delayed O
maturation B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
of O
offspring O
cerebellum B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
and O
melatonin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
protects O
the O
cerebellum B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
against O
the O
effects B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O
BCNU B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O

reduced O
cardiotoxicity B_DISEASE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
doxorubicin O
given O
in O
the O
form O
of O
N O
- O
( O
2 O
- O
hydroxypropyl O
) O
methacrylamide O
conjugates O
: O
and O
experimental O
study O
in O
the O
rat O
. O

A O
rat O
model O
was O
used O
to O
evaluate O
the O
general O
acute O
toxicity B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
the O
late O
cardiotoxicity B_DISEASE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
4 O
mg O
/ O
kg O
doxorubicin O
( O
DOX O
) O
given O
either O
as O
free O
drug O
or O
in O
the O
form O
of O
three O
N O
- O
( O
2 O
- O
hydroxypropyl O
) O
methacrylamide O
( O
HPMA O
) O
copolymer O
conjugates O
. O

In O
these O
HPMA B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
copolymers I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
DOX B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
was O
covalently O
bound O
via O
peptide B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
linkages I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
that O
were O
either O
non O
- O
biodegradable B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
Gly B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
Gly B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
or O
degradable B_DISEASE_ADJECTIVE[DISEASE]/B_BACTERIUM[BIO]
by O
lysosomal B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
proteinases I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
Gly B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
Phe B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]
- O
Leu B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
Gly B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
. O

In O
addition B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
one B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
biodegradable I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
conjugate I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
containing O
galactosamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPECIES[BIO]
was O
used O
; O
this O
residue B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
was O
targeted O
to O
the O
liver B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
. O

Over O
the O
first B_TIME[MEASURE]/B_ENT
3 I_TIME[MEASURE]/I_ENT
weeks I_TIME[MEASURE]/I_ENT
after O
the O
i O
. O
v B_PROTEIN[GENE]/B_LOCATION
. O
administration B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
free B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
and O
polymer B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
bound O
DOX B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
all O
animals B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
showed O
a O
transient B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
reduction I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O
body B_DISEASE
weight I_DISEASE
. O

However O
, O
the O
maximal B_MEASURE
reduction I_MEASURE
in O
body B_DISEASE
weight I_DISEASE
seen O
in O
animals B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
received O
polymer B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
bound O
DOX B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
4 B_MEASURE/B_LOCATION
mg I_MEASURE/I_LOCATION
/ O
kg B_MEASURE
) O
was O
significantly O
lower B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
than O
that O
observed O
in O
those O
that O
received O
free B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
DOX I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
4 B_MEASURE
mg I_MEASURE
/ O
kg B_MEASURE/B_PERSON
) O
or O
a O
mixture B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
the O
unmodified B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
parent I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
HPMA I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
copolymer I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
and O
free B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
DOX I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
4 B_MEASURE
mg I_MEASURE
/ O
kg B_MEASURE
; O
P B_MEASURE/B_LOCATION
less I_MEASURE/I_LOCATION
than O
0 B_MEASURE
. O
01 B_MEASURE
) O
. O

Throughout O
the O
study O
( O
20 O
weeks O
) O
, O
deaths O
related O
to O
cardiotoxicity B_DISEASE
were O
observed O
only O
in O
animals O
that O
received O
either O
free O
DOX O
or O
the O
mixture O
of O
HPMA O
copolymer O
and O
free O
DOX O
; O
in O
these O
cases O
, O
histological O
investigations O
revealed O
marked O
changes O
in O
the O
heart O
that O
were O
consistent O
with O
DOX O
- O
induced O
cardiotoxicity B_DISEASE
. O

Sequential B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
measurements I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
cardiac B_DISEASE
output I_DISEASE
in O
surviving O
animals B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
received O
either O
free B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
DOX I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
or O
the O
mixture B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
HPMA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
copolymer I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
free B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
DOX I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
showed O
a O
reduction B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
approximately O
30 B_MEASURE/B_LOCATION
% I_MEASURE/I_LOCATION
in O
function B_DISEASE/B_MEASURE
beginning O
at O
the O
4th B_TIME[MEASURE]/B_LOCATION
week I_TIME[MEASURE]/I_LOCATION
after O
drug B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
administration I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
. O

The O
heart B_MEASURE/B_DISEASE
rate I_MEASURE/I_DISEASE
in O
these O
animals B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
approximately O
12 B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
% B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
lower B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
than O
that O
measured O
in O
age B_MEASURE/B_LOCATION
- O
matched O
control B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
rats I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
P B_MEASURE
less I_MEASURE
than O
0 B_MEASURE
. O
05 B_MEASURE
) O
. O

Animals B_BIO/B_PERSON
that O
were O
given O
the O
HPMA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
copolymer I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
conjugates I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
containing O
DOX B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
exhibited O
no O
significant B_MEASURE
change I_MEASURE
in O
cardiac B_MEASURE
output I_MEASURE
throughout O
the O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
P B_MEASURE
less I_MEASURE
than O
0 B_MEASURE
. O
05 B_MEASURE
) O
. O

In O
addition B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O
no O
significant B_DISEASE/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
histological I_DISEASE/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
change I_DISEASE/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
observed O
in O
the O
heart B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
of O
animals B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
received O
DOX B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
in O
the O
form B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
HPMA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
copolymer I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
conjugates I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
and O
were O
killed O
at O
the O
end B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
of O
the O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

However O
, O
these O
animals B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
had O
shown O
a O
significant B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
increase I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O
heart B_DISEASE
rate I_DISEASE
beginning O
at O
8 B_TIME[MEASURE]/B_ENT
weeks I_TIME[MEASURE]/I_ENT
after O
drug B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
administration I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
( O
P B_MEASURE
less I_MEASURE
than O
0 B_MEASURE
. O
01 B_MEASURE
) O
. O
( O
abstract B_TIME[MEASURE]/B_LOCATION
TRUNCATED I_TIME[MEASURE]/I_LOCATION
AT O
400 B_LOCATION/B_PERSON
Words I_LOCATION/I_PERSON
) O
. O

Corneal B_DISEASE
ulcers I_DISEASE
associated O
with O
aerosolized O
crack O
cocaine O
use O
. O

purpose O
: O
We O
report O
4 O
cases O
of O
corneal B_DISEASE
ulcers I_DISEASE
associated O
with O
drug B_DISEASE
abuse I_DISEASE
. O

The O
pathogenesis O
of O
these O
ulcers B_DISEASE/B_BIO
and O
management O
of O
these O
patients O
are O
also O
reviewed O
. O

methods O
: O
Review O
of O
all O
cases O
of O
corneal B_DISEASE/B_LOCATION
ulcers I_DISEASE/I_LOCATION
associated O
with O
drug B_DISEASE
abuse I_DISEASE
seen O
at O
our O
institution O
from O
July O
2006 O
to O
December O
2006 O
. O

Results O
: O
Four O
patients O
with O
corneal B_DISEASE
ulcers I_DISEASE
associated O
with O
crack O
cocaine O
use O
were O
reviewed O
. O

All O
corneal B_DISEASE/B_BIO
ulcers I_DISEASE/I_BIO
were O
cultured O
, O
and O
the O
patients O
were O
admitted O
to O
the O
hospital O
for O
intensive O
topical O
antibiotic O
treatment O
. O

Each O
patient O
received O
comprehensive O
health O
care O
, O
including O
medical O
and O
substance B_PERSON/B_ORGANIZATION
abuse I_PERSON/I_ORGANIZATION
consultations O
. O

streptococcal B_BACTERIUM[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
organisms I_BACTERIUM[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
were O
found O
in O
3 B_MEASURE
cases I_MEASURE
and O
Capnocytophaga B_BACTERIUM[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
Brevibacterium B_BACTERIUM[BIO]
casei I_BACTERIUM[BIO]
in O
1 B_NUMBER[MEASURE]/B_PERSON
patient I_NUMBER[MEASURE]/I_PERSON
. O

The O
infections B_DISEASE/B_PERSON
responded O
to O
antibiotic O
treatment O
. O

Two O
patients O
needed O
a O
lateral O
tarsorrhaphy O
for O
persistent O
epithelial B_DISEASE
defects I_DISEASE
. O

conclusions O
: O
Aerosolized O
crack O
cocaine O
use O
can O
be O
associated O
with O
the O
development O
of O
corneal B_DISEASE/B_LOCATION
ulcers I_DISEASE/I_LOCATION
. O

Drug B_DISEASE_ADJECTIVE[DISEASE]/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
abuse B_DISEASE_ADJECTIVE[DISEASE]/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
provides O
additional O
challenges O
for O
management O
. O

Not O
only O
treatment O
of O
their O
infections B_DISEASE
but O
also O
the O
overall O
poor O
health O
of O
the O
patients O
and O
increased O
risk O
of O
noncompliance O
need O
to O
be O
addressed O
. O

Comprehensive O
care O
may O
provide O
the O
patient O
the O
opportunity O
to O
discontinue O
their O
substance B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
abuse I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
, O
improve O
their O
overall O
health O
, O
and O
prevent O
future O
corneal O
complications O
. O

Topical O
0 O
. O
025 O
% O
capsaicin O
in O
chronic O
post B_DISEASE
- I_DISEASE
herpetic I_DISEASE
neuralgia I_DISEASE
: O
efficacy O
, O
predictors O
of O
response O
and O
long O
- O
term O
course O
. O

In O
order O
to O
evaluate O
the O
efficacy O
, O
time O
- O
course O
of O
action O
and O
predictors O
of O
response O
to O
topical O
capsaicin O
, O
39 O
patients O
with O
chronic O
post B_DISEASE
- I_DISEASE
herpetic I_DISEASE
neuralgia I_DISEASE
( O
PHN B_DISEASE/B_LOCATION
) O
, O
median O
duration O
24 O
months O
, O
were O
treated O
with O
0 O
. O
025 O
% O
capsaicin O
cream O
for O
8 O
weeks O
. O

During O
therapy O
the O
patients O
rated O
their O
pain B_DISEASE
on O
a O
visual O
analogue O
scale O
( O
VAS O
) O
and O
a O
verbal O
outcome O
scale O
. O

A O
follow O
- O
up O
investigation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
performed O
10 B_NUMBER[MEASURE]
- O
12 B_TIME[MEASURE]
months I_TIME[MEASURE]
after O
study B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
onset I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
on O
the O
patients B_PERSON
who O
had O
improved O
. O

nineteen O
patients O
( O
48 O
. O
7 O
% O
) O
substantially O
improved O
after O
the O
8 O
- O
week O
trial O
; O
5 O
( O
12 O
. O
8 O
% O
) O
discontinued O
therapy O
due O
to O
side O
- O
effects O
such O
as O
intolerable O
capsaicin O
- O
induced O
burning O
sensations O
( O
4 O
) O
or O
mastitis B_DISEASE
( O
1 O
) O
; O
15 O
( O
38 O
. O
5 O
% O
) O
reported O
no O
benefit O
. O

The O
decrease B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O
VAS B_MEASURE
ratings I_MEASURE
was O
significant B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
after O
2 B_TIME[MEASURE]/B_ENT
weeks I_TIME[MEASURE]/I_ENT
of O
continuous B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
application I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
. O

Of O
the O
responders B_MEASURE
72 I_MEASURE
. O
2 B_MEASURE
% I_MEASURE
were O
still O
improved O
at O
the O
follow B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
- O
up B_LOCATION/B_TIME[MEASURE]
; O
only O
one B_NUMBER[MEASURE]
- O
third B_SEQUENCE[MEASURE]
of O
them O
had O
continued O
application B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
irregularly O
. O

Treatment O
effect O
was O
not O
dependent O
on O
patient O
' O
s O
age O
, O
duration O
or O
localization O
of O
PHN B_DISEASE
( O
trigeminal O
involvement O
was O
excluded O
) O
, O
sensory B_DISEASE
disturbance I_DISEASE
or O
pain B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
character O
. O

Treatment B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
response I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
not O
correlated O
with O
the O
incidence B_MEASURE/B_LOCATION
, O
time B_MEASURE/B_LOCATION
- O
course B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
or O
severity B_MEASURE
of O
capsaicin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
induced O
burning B_DISEASE
. O

If O
confirmed O
in O
controlled O
trials O
, O
the O
long O
- O
term O
results O
of O
this O
open O
, O
non O
- O
randomized O
study O
might O
indicate O
that O
the O
analgesic O
effect O
of O
capsaicin O
in O
PHN B_DISEASE/B_SPECIES[BIO]
is O
mediated O
by O
both O
interference O
with O
neuropeptide O
metabolism O
and O
morphological O
changes O
( O
perhaps O
degeneration O
) O
of O
nociceptive O
afferents O
. O

Myo B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
inositol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
1 B_NUMBER[MEASURE]
- O
phosphate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
MIP B_GENE
) O
synthase B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
inhibition I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
in O
- O
vivo B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
in O
rats B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

lithium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O
valproate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
the O
prototypic B_MEASURE/B_ORGANIZATION
mood I_MEASURE/I_ORGANIZATION
stabilizers I_MEASURE/I_ORGANIZATION
and O
have O
diverse B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
structures B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
targets B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O

Both O
drugs B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
influence O
inositol B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
metabolism I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
. O

lithium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
inhibits I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
IMPase I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
valproate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
inhibits O
MIP B_GENE/B_DISEASE
synthase I_GENE/I_DISEASE
. O

This O
study O
shows O
that O
MIP O
synthase O
inhibition O
does O
not O
replicate O
or O
augment O
the O
effects O
of O
lithium O
in O
the O
inositol O
sensitive O
pilocarpine O
- O
induced O
seizures B_DISEASE
model O
. O

This O
lack B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
of O
effects B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
may O
stem O
from O
the O
low B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
contribution B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
de B_DISEASE
- O
novo B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
synthesis B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
to O
cellular B_DISEASE
inositol I_DISEASE
supply I_DISEASE
or O
to O
the O
inhibition B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O
the O
de B_DISEASE
- O
novo B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
synthesis B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
by O
lithium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
itself O
. O

Non O
- O
steroidal O
anti O
- O
inflammatory O
drugs O
- O
associated O
acute O
interstitial B_DISEASE
nephritis I_DISEASE
with O
granular O
tubular O
basement O
membrane O
deposits O
. O

Acute B_DISEASE_ADJECTIVE[DISEASE]
tubulo I_DISEASE_ADJECTIVE[DISEASE]
- I_DISEASE_ADJECTIVE[DISEASE]
interstitial I_DISEASE_ADJECTIVE[DISEASE]
nephritis I_DISEASE_ADJECTIVE[DISEASE]
( O
ATIN B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
is O
an O
important O
cause O
of O
acute B_DISEASE
renal I_DISEASE
failure I_DISEASE
resulting O
from O
a O
variety O
of O
insults O
, O
including O
immune O
complex O
- O
mediated O
tubulo B_DISEASE
- I_DISEASE
interstitial I_DISEASE
injury I_DISEASE
, O
but O
drugs O
such O
as O
non O
- O
steroidal O
anti O
- O
inflammatory O
drugs O
( O
NSAIDs O
) O
are O
a O
far O
more O
frequent O
cause O
. O

Overall O
, O
as O
an O
entity O
, O
ATIN B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
remains O
under O
- O
diagnosed O
, O
as O
symptoms O
resolve O
spontaneously O
if O
the O
medication O
is O
stopped O
. O

We O
report O
on O
a O
14 O
- O
year O
- O
old O
boy O
who O
developed O
acute B_DISEASE
renal I_DISEASE
failure I_DISEASE
2 O
weeks O
after O
aortic O
valve O
surgery O
. O

He O
was O
put O
on O
aspirin O
following O
surgery O
and O
took O
ibuprofen O
for O
fever B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
for O
nearly O
a O
week O
prior O
to O
presentation O
. O

He O
then O
presented O
to O
the O
emergency B_PERSON/B_LOCATION
department I_PERSON/I_LOCATION
feeling I_PERSON/I_LOCATION
quite O
ill B_DISEASE
and O
was O
found O
to O
have O
a O
blood B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
urea I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
nitrogen I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O
BUN B_PROTEIN[GENE]/B_BODY_PART_OR_ORGAN_COMPONENT
) O
concentration B_MEASURE
of O
of O
147 B_MEASURE
mg I_MEASURE
/ O
DL B_PROTEIN[GENE]/B_TIME[MEASURE]
, O
creatinine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
of O
15 B_MEASURE
. O
3 B_MEASURE
mg I_MEASURE
/ O
dl B_TIME[MEASURE]/B_PROTEIN[GENE]
and O
serum O
potassium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
8 B_MEASURE
. O
7 B_MEASURE
mEq I_MEASURE
/ O
l B_MEASURE/B_DISEASE
. O

dialysis B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
was O
immediately O
initiated O
. O

A O
kidney O
biopsy O
showed O
inflammatory O
infiltrate O
consistent O
with O
ATIN B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

However O
, O
in O
the O
tubular B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
basement I_TIME[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
membrane I_TIME[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
TBM B_DISEASE/B_PROTEIN[GENE]
) O
, O
very O
intense B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
granular B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
deposits B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O
polyclonal B_PROTEIN[GENE]
IgG I_PROTEIN[GENE]
and O
C3 B_GENE
were O
noted O
. O

He O
needed O
dialysis B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
2 B_TIME[MEASURE]/B_DISEASE
weeks B_TIME[MEASURE]/I_DISEASE
and O
was O
treated O
successfully O
with O
steroids B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
6 B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
months I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

His O
renal O
recovery O
and O
disappearance O
of O
proteinuria B_DISEASE
took O
a O
year O
. O

In O
conclusion O
, O
this O
is O
a O
first O
report O
of O
NSAIDs O
- O
associated O
ATIN B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
showing O
deposits O
of O
granular O
immune O
complex O
present O
only O
in O
the O
TBM O
and O
not O
in O
the O
glomeruli O
. O

Rifampicin O
- O
associated O
segmental O
necrotizing O
glomerulonephritis B_DISEASE
in O
staphylococcal B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
endocarditis I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
. O

Segmental O
necrotising O
glomerulonephritis B_DISEASE
has O
been O
reported O
as O
complication O
of O
rifampicin O
therapy O
in O
patients O
receiving O
treatment O
for O
tuberculosis B_DISEASE/B_GENE
. O

Changing O
epidemiology O
of O
infections B_DISEASE/B_BIO
such O
as O
infective B_DISEASE
endocarditis I_DISEASE
( O
IE B_DISEASE/B_LOCATION
) O
has O
led O
to O
an O
increase O
in O
the O
use O
of O
rifampicin O
for O
Staphylococcal B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
infections I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

We O
describe O
a O
case O
of O
a O
patient O
with O
Staphylococcal B_DISEASE/B_GENE
IE I_DISEASE/I_GENE
who O
developed O
acute B_DISEASE
renal I_DISEASE
failure I_DISEASE
secondary O
to O
a O
segmental O
necrotising O
glomerulonephritis B_DISEASE
while O
being O
treated O
with O
rifampicin O
, O
and O
review O
the O
literature O
regarding O
this O
complication O
of O
rifampicin O
therapy O
. O

Rate O
of O
YMDD O
motif O
mutants O
in O
lamivudine O
- O
untreated O
Iranian O
patients O
with O
chronic B_DISEASE/B_LOCATION
hepatitis I_DISEASE/I_LOCATION
B I_DISEASE/I_LOCATION
virus I_DISEASE/I_LOCATION
infection I_DISEASE/I_LOCATION
. O

Background O
: O
Lamivudine O
is O
used O
for O
the O
treatment O
of O
chronic B_DISEASE/B_PERSON
hepatitis I_DISEASE/I_PERSON
B I_DISEASE/I_PERSON
patients O
. O

Recent O
studies O
show O
that O
the O
YMDD O
motif O
mutants O
( O
resistant O
hepatitis B_DISEASE/B_GENE
B I_DISEASE/I_GENE
virus O
) O
occur O
as O
natural O
genome O
variability O
in O
lamivudine O
- O
untreated O
chronic B_DISEASE/B_LOCATION
hepatitis I_DISEASE/I_LOCATION
B I_DISEASE/I_LOCATION
patients O
. O

In O
this O
study O
we O
aimed O
to O
determine O
the O
rate O
of O
YMDD O
motif O
mutants O
in O
lamivudine O
- O
untreated O
chronic B_DISEASE/B_LOCATION
hepatitis I_DISEASE/I_LOCATION
B I_DISEASE/I_LOCATION
patients O
in O
Iran O
. O

patients O
AND O
methods O
: O
A O
total O
of O
77 O
chronic B_DISEASE/B_LOCATION
hepatitis I_DISEASE/I_LOCATION
B I_DISEASE/I_LOCATION
patients O
who O
had O
not O
been O
treated O
with O
lamivudine O
were O
included O
in O
the O
study O
. O

Serum B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
samples I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O
patients B_PERSON/B_LOCATION
were O
tested O
by O
polymerase B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
chain I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
reaction I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
- O
restriction B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fragment B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
length B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
polymorphism B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
PCR B_LOCATION
- O
RFLP B_PROTEIN[GENE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
for O
detection B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
YMDD B_DISEASE/B_GENE
motif B_DISEASE/I_GENE
mutants B_DISEASE/I_GENE
. O

All O
patients B_PERSON
were O
also O
tested O
for O
liver B_DISEASE/B_GENE
enzymes I_DISEASE/I_GENE
, O
anti O
- O
HCV B_DISEASE/B_GENE
, O
HBeAg B_DISEASE/B_GENE
, O
and O
anti B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
HBe B_GENE/B_DISEASE
. O

RESULTS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O
Of O
the O
77 B_PERSON
patients I_PERSON
enrolled O
in O
the O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
73 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
were O
male B_PERSON/B_COLOR
and O
27 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
were O
female B_PERSON/B_LOCATION
. O

Mean B_MEASURE/B_LOCATION
ALT I_MEASURE/I_LOCATION
and O
AST B_GENE
levels I_GENE
were O
124 B_MEASURE
. O
4 B_MEASURE
+ I_MEASURE
/ O
- O
73 B_MEASURE
. O
4 B_MEASURE
and O
103 B_MEASURE
. O
1 B_MEASURE/B_LOCATION
+ I_MEASURE/I_LOCATION
/ O
- O
81 B_MEASURE/B_LOCATION
IU I_MEASURE/I_LOCATION
/ O
l B_OTHER/B_MEASURE
, O
respectively O
. O

HBeAg B_DISEASE/B_GENE
was O
positive B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
40 B_MEASURE
% I_MEASURE
and O
anti B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
HBe B_GENE/B_DISEASE
in O
60 B_NUMBER[MEASURE]/B_LOCATION
% I_NUMBER[MEASURE]/I_LOCATION
of O
the O
patients B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Anti B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
HCV B_DISEASE
was O
negative B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
all O
of O
them O
. O

YMDD B_DISEASE/B_PERSON
motif I_DISEASE/I_PERSON
mutants I_DISEASE/I_PERSON
were O
not O
detected O
in O
any O
of O
the O
patients B_PERSON/B_BIO
despite O
the O
liver B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
enzyme I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
levels I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O
the O
presence B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
HBeAg B_DISEASE/B_GENE
or O
anti B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
HBe B_GENE/B_DISEASE
. O

conclusion O
: O
Although O
the O
natural O
occurrence O
of O
YMDD O
motif O
mutants O
in O
lamivudine O
- O
untreated O
patients O
with O
chronic B_DISEASE
hepatitis I_DISEASE
B I_DISEASE
has O
been O
reported O
, O
these O
mutants O
were O
not O
detected O
in O
Iranian O
lamivudine O
- O
untreated O
chronic B_DISEASE/B_LOCATION
hepatitis I_DISEASE/I_LOCATION
B I_DISEASE/I_LOCATION
patients O
. O

Branch O
retinal B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
vein B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
occlusion B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
fluoxetine O
. O

A O
case O
of O
branch O
retinal B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
vein I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
occlusion I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
associated O
with O
fluoxetine O
- O
induced O
secondary O
hypertension B_DISEASE
is O
described O
. O

Although O
an O
infrequent O
complication O
of O
selective O
serotonin O
reuptake O
inhibitor O
therapy O
, O
it O
is O
important O
that O
ophthalmologists O
are O
aware O
that O
these O
agents O
can O
cause O
hypertension B_DISEASE
because O
this O
class O
of O
drugs O
is O
widely O
prescribed O
. O

The O
differential O
effects O
of O
bupivacaine O
and O
lidocaine O
on O
prostaglandin O
E2 O
release O
, O
cyclooxygenase O
gene O
expression O
and O
pain B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
a O
clinical O
pain B_DISEASE
model O
. O

Background O
: O
In O
addition O
to O
blocking O
nociceptive O
input O
from O
surgical O
sites O
, O
long O
- O
acting O
local O
anesthetics O
might O
directly O
modulate O
inflammation B_DISEASE/B_BACTERIUM[BIO]
. O

In O
the O
present O
study O
, O
we O
describe O
the O
proinflammatory O
effects O
of O
bupivacaine O
on O
local O
prostaglandin O
E2 O
( O
PGE2 O
) O
production O
and O
cyclooxygenase O
( O
Cox O
) O
gene O
expression O
that O
increases O
postoperative B_DISEASE_ADJECTIVE[DISEASE]
pain I_DISEASE_ADJECTIVE[DISEASE]
in O
human O
subjects O
. O

METHODS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O
subjects B_PERSON/B_LOCATION
( O
n B_OTHER/B_MEASURE
= O
114 B_MEASURE
) O
undergoing O
extraction B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O
impacted B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
third I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
molars I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
received O
either O
2 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
% I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
lidocaine I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O
0 B_MEASURE
. O
5 B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
% I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
bupivacaine I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
before O
surgery B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
either O
rofecoxib B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
50 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mg I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O
placebo B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
orally O
90 B_TIME[MEASURE]
min I_TIME[MEASURE]
before O
surgery B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
for O
the O
following B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
48 I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
h I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Oral B_NUMBER[MEASURE]/B_PERSON
mucosal I_NUMBER[MEASURE]/I_PERSON
biopsies I_NUMBER[MEASURE]/I_PERSON
were O
taken O
before O
surgery B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
and O
48 B_TIME[MEASURE]/B_LOCATION
h B_TIME[MEASURE]/I_LOCATION
after O
surgery B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O

After O
extraction B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
a O
microdialysis B_PRODUCT[OBJECT]/B_PERSON
probe B_PRODUCT[OBJECT]/I_PERSON
was O
placed O
at O
the O
surgical B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
site I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
PGE2 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O
thromboxane B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
B2 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O
TXB2 B_GENE
) O
measurements B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Results O
: O
The O
bupivacaine O
/ O
rofecoxib O
group O
reported O
significantly O
less O
pain B_DISEASE
, O
as O
assessed O
by O
a O
visual O
analog O
scale O
, O
compared O
with O
the O
other O
three O
treatment O
groups O
over O
the O
first O
4 O
h O
. O

However O
, O
the O
bupivacaine O
/ O
placebo O
group O
reported O
significantly O
more O
pain B_DISEASE
at O
24 O
h O
and O
PGE2 O
levels O
during O
the O
first O
4 O
h O
were O
significantly O
higher O
than O
the O
other O
three O
treatment O
groups O
. O

Moreover O
, O
bupivacaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
significantly O
increased O
COX B_GENE
- O
2 B_PROTEIN[GENE]
gene I_PROTEIN[GENE]
expression I_PROTEIN[GENE]
at O
48 B_MEASURE
h O
as O
compared O
with O
the O
lidocaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
placebo B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
group I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Thromboxane B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
levels I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
not O
significantly O
affected O
by O
any O
of O
the O
treatments B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
indicating O
that O
the O
effects B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
seen O
were O
attributable B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
to O
inhibition B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
COX B_GENE
- O
2 B_NUMBER[MEASURE]
, O
but O
not O
Cox B_PERSON/B_GENE
- O
1 B_NUMBER[MEASURE]
. O

conclusions O
: O
These O
results O
suggest O
that O
bupivacaine O
stimulates O
Cox O
- O
2 O
gene O
expression O
after O
tissue B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
injury B_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
which O
is O
associated O
with O
higher O
PGE2 O
production O
and O
pain B_DISEASE
after O
the O
local O
anesthetic O
effect O
dissipates O
. O

p75NTR O
expression O
in O
rat O
urinary O
bladder O
sensory O
neurons O
and O
spinal O
cord O
with O
cyclophosphamide O
- O
induced O
cystitis B_DISEASE
. O

A O
role B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
nerve B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
growth I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
NGF B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
in O
contributing O
to O
increased O
voiding B_MEASURE/B_DISEASE
frequency B_MEASURE/I_DISEASE
and O
altered B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
sensation I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
from O
the O
urinary B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
bladder I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
has O
been O
suggested O
. O

Previous O
studies O
have O
examined O
the O
expression O
and O
regulation O
of O
tyrosine O
kinase O
receptors O
( O
Trks O
) O
in O
micturition O
reflexes O
with O
urinary B_DISEASE
bladder I_DISEASE
inflammation I_DISEASE
. O

The O
present O
studies O
examine O
the O
expression O
and O
regulation O
of O
another O
receptor O
known O
to O
bind O
NGF O
, O
p75 O
( O
NTR O
) O
, O
after O
various O
durations O
of O
bladder B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
inflammation I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
induced O
by O
cyclophosphamide O
( O
CYP O
) O
. O

CYP O
- O
induced O
cystitis B_DISEASE
increased O
( O
P O
< O
or O
= O
0 O
. O
001 O
) O
p75 O
( O
NTR O
) O
expression O
in O
the O
superficial O
lateral O
and O
medial O
dorsal O
horn O
in O
L1 O
- O
L2 O
and O
L6 O
- O
S1 O
spinal O
segments O
. O

The O
number O
of O
p75 O
( O
NTR O
) O
- O
immunoreactive O
( O
- O
IR O
) O
cells O
in O
the O
lumbosacral O
dorsal O
root O
ganglia O
( O
DRG O
) O
also O
increased O
( O
P O
< O
or O
= O
0 O
. O
05 O
) O
with O
CYP O
- O
induced O
cystitis B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O
acute O
, O
intermediate O
, O
and O
chronic O
) O
. O

quantitative O
, O
real O
- O
time O
polymerase O
chain O
reaction O
also O
demonstrated O
significant O
increases O
( O
P O
< O
or O
= O
0 O
. O
01 O
) O
in O
p75 O
( O
NTR O
) O
mRNA O
in O
DRG O
with O
intermediate O
and O
chronic O
CYP O
- O
induced O
cystitis B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

retrograde B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
dye I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
- O
tracing O
techniques B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
Fastblue B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
were O
used O
to O
identify O
presumptive B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
bladder I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
afferent I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
in O
the O
lumbosacral B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
DRG B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
. O

In O
bladder O
afferent O
cells O
in O
DRG O
, O
p75 O
( O
NTR O
) O
- O
IR O
was O
also O
increased O
( O
P O
< O
or O
= O
0 O
. O
01 O
) O
with O
cystitis B_DISEASE
. O

In O
addition B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
to O
increases B_DISEASE_ADJECTIVE[DISEASE]
in O
p75 B_GENE
( O
NTR B_LOCATION
) O
- O
IR B_LOCATION/B_PROTEIN[GENE]
in O
DRG B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
cell I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
bodies I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
, O
increases B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
( O
P B_MEASURE/B_LOCATION
< I_MEASURE/I_LOCATION
or O
= O
0 B_MEASURE/B_LOCATION
. O
001 B_MEASURE
) O
in O
pericellular B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
( O
encircling O
DRG B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
cells B_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
) O
p75 B_GENE
( O
NTR B_LOCATION/B_ORGANIZATION
) O
- O
IR B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
DRG B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
also O
increased O
. O

confocal B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
analyses I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
demonstrated O
that O
pericellular B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
p75 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
NTR B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
- O
IR B_MEASURE/B_PROTEIN[GENE]
was O
not O
colocalized O
with O
the O
glial B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
marker B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O
glial B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
fibrillary I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
acidic I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
GFAP B_GENE
) O
. O

These O
studies O
demonstrate O
that O
p75 O
( O
NTR O
) O
expression O
in O
micturition O
reflexes O
is O
present O
constitutively O
and O
modified O
by O
bladder B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
inflammation I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
functional B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
significance I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O
p75 B_GENE
( O
NTR B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
expression B_GENE
in O
micturition B_DISEASE
reflexes I_DISEASE
remains O
to O
be O
determined O
. O

azathioprine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
suicidal B_DISEASE
erythrocyte I_DISEASE
death I_DISEASE
. O

Background B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
: O
azathioprine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
widely O
used O
as O
an O
immunosuppressive B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
drug I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
side O
effects O
of O
azathioprine O
include O
anemia B_DISEASE
, O
which O
has O
been O
attributed O
to O
bone O
marrow O
suppression O
. O

Alternatively O
, O
anemia B_DISEASE/B_PERSON
could O
result O
from O
accelerated O
suicidal O
erythrocyte O
death O
or O
eryptosis O
, O
which O
is O
characterized O
by O
exposure O
of O
phosphatidylserine O
( O
PS O
) O
at O
the O
erythrocyte O
surface O
and O
by O
cell O
shrinkage O
. O

METHODS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
: O
The O
present B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
experiments I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
explored O
whether O
azathioprine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
influences I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
eryptosis O
. O

According O
to O
annexin B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
V I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
binding I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
erythrocytes B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
from O
patients B_PERSON/B_DISEASE
indeed O
showed O
a O
significant B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
increase I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
PS B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
exposure I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
within O
1 B_TIME[MEASURE]/B_LOCATION
week I_TIME[MEASURE]/I_LOCATION
of O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O
azathioprine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O

In O
a O
second B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
series I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O
cytosolic B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Ca2 B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
+ B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activity B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
Fluo3 B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
fluorescence I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
) O
, O
cell B_MEASURE/B_LOCATION
volume B_MEASURE/I_LOCATION
( O
forward B_MEASURE/B_SPORT[ENT]
scatter I_MEASURE/I_SPORT[ENT]
) O
, O
and O
PS B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
exposure B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PROTEIN[GENE]
( O
annexin B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
V I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
binding I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
) O
were O
determined O
by O
FACS B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
erythrocytes B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
from O
healthy B_PERSON/B_BIO
volunteers I_PERSON/I_BIO
. O

RESULTS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O
Exposure B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
to O
azathioprine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O
> B_MEASURE
or O
= O
2 B_MEASURE
microg I_MEASURE
/ O
mL B_MEASURE/B_LOCATION
) O
for O
48 B_TIME[MEASURE]/B_SPORT[ENT]
hours I_TIME[MEASURE]/I_SPORT[ENT]
increased O
cytosolic B_GENE
Ca2 I_GENE
+ I_GENE
activity I_GENE
and O
annexin B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
V I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
binding I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
and O
decreased O
forward O
scatter B_MEASURE
. O

The O
effect B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O
azathioprine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
both O
annexin B_LOCATION/B_MEASURE
V I_LOCATION/I_MEASURE
binding I_LOCATION/I_MEASURE
and O
forward B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
scatter I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
significantly O
blunted O
in O
the O
nominal B_PERSON/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
absence B_PERSON/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
extracellular B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
Ca2 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
+ I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

conclusions O
: O
Azathioprine O
triggers O
suicidal O
erythrocyte O
death O
, O
an O
effect O
presumably O
contributing O
to O
azathioprine O
- O
induced O
anemia B_DISEASE
. O

Levetiracetam O
as O
an O
adjunct O
to O
phenobarbital O
treatment O
in O
cats O
with O
suspected O
idiopathic B_DISEASE
epilepsy I_DISEASE
. O

objective O
: O
To O
assess O
pharmacokinetics O
, O
efficacy O
, O
and O
tolerability O
of O
oral O
levetiracetam O
administered O
as O
an O
adjunct O
to O
phenobarbital O
treatment O
in O
cats O
with O
poorly O
controlled O
suspected O
idiopathic B_DISEASE
epilepsy I_DISEASE
. O

Design B_PERSON/B_MEASURE
- O
Open B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
label B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
noncomparative B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
clinical I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
trial I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Animals O
: O
12 O
cats O
suspected O
to O
have O
idiopathic B_DISEASE
epilepsy I_DISEASE
that O
was O
poorly O
controlled O
with O
phenobarbital O
or O
that O
had O
unacceptable O
adverse O
effects O
when O
treated O
with O
phenobarbital O
. O

procedures B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
cats B_PERSON/B_BIO
were O
treated O
with O
levetiracetam B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
20 B_MEASURE
mg I_MEASURE
/ O
kg B_MEASURE
[ O
9 B_MEASURE
. O
1 B_MEASURE
mg I_MEASURE
/ O
lb B_MEASURE
] I_MEASURE
, O
PO B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
, O
q B_LOCATION/B_TIME[MEASURE]
8 I_LOCATION/I_TIME[MEASURE]
h I_LOCATION/I_TIME[MEASURE]
) O
. O

After O
a O
minimum B_MEASURE/B_LOCATION
of O
1 B_TIME[MEASURE]/B_LOCATION
week I_TIME[MEASURE]/I_LOCATION
of O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
, O
serum B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
levetiracetam I_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
concentrations I_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
measured O
before O
and O
2 B_SEQUENCE[MEASURE]/B_LOCATION
, O
4 B_SEQUENCE[MEASURE]
, O
and O
6 B_SEQUENCE[MEASURE]/B_SPORT[ENT]
hours I_SEQUENCE[MEASURE]/I_SPORT[ENT]
after O
drug B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
administration I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
, O
and O
maximum B_MEASURE
and O
minimum B_MEASURE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
serum B_MEASURE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
concentrations B_MEASURE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
elimination B_MEASURE/B_LOCATION
half I_MEASURE/I_LOCATION
- O
life B_MEASURE/B_LOCATION
were O
calculated O
. O

Seizure B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
frequencies O
before O
and O
after O
initiation O
of O
levetiracetam O
treatment O
were O
compared O
, O
and O
adverse O
effects O
were O
recorded O
. O

RESULTS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O
median B_MEASURE
maximum I_MEASURE
serum I_MEASURE
levetiracetam I_MEASURE
concentration I_MEASURE
was O
25 B_MEASURE
. O
5 B_MEASURE/B_PERSON
microg I_MEASURE/I_PERSON
/ O
mL B_MEASURE/B_LOCATION
, O
median B_MEASURE/B_DISEASE
minimum I_MEASURE/I_DISEASE
serum I_MEASURE/I_DISEASE
levetiracetam I_MEASURE/I_DISEASE
concentration I_MEASURE/I_DISEASE
was O
8 B_MEASURE
. O
3 B_MEASURE
microg I_MEASURE
/ O
mL B_MEASURE/B_LOCATION
, O
and O
median B_MEASURE/B_LOCATION
elimination B_MEASURE/I_LOCATION
half B_MEASURE/I_LOCATION
- O
life B_TIME[MEASURE]/B_LOCATION
was O
2 B_MEASURE
. O
9 B_MEASURE/B_ENT
hours I_MEASURE/I_ENT
. O

median O
seizure B_DISEASE
frequency O
prior O
to O
treatment O
with O
levetiracetam O
( O
2 O
. O
1 O
seizures B_DISEASE
/ O
Mo O
) O
was O
significantly O
higher O
than O
median O
seizure B_DISEASE/B_MEASURE
frequency O
after O
initiation O
of O
levetiracetam O
treatment O
( O
0 O
. O
42 O
seizures B_DISEASE
/ O
Mo O
) O
, O
and O
7 O
of O
10 O
cats O
were O
classified O
as O
having O
responded O
to O
levetiracetam O
treatment O
( O
ie O
, O
reduction O
in O
seizure B_DISEASE
frequency O
of O
> O
or O
= O
50 O
% O
) O
. O

Two O
cats O
had O
transient O
lethargy B_DISEASE
and O
inappetence B_DISEASE
. O

conclusions O
AND O
Clinical O
relevance O
: O
Results O
suggested O
that O
levetiracetam O
is O
well O
tolerated O
in O
cats O
and O
may O
be O
useful O
as O
an O
adjunct O
to O
phenobarbital O
treatment O
in O
cats O
with O
idiopathic B_DISEASE
epilepsy I_DISEASE
. O

Serotonin O
reuptake O
inhibitors O
, O
paranoia B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O
and O
the O
ventral O
basal O
ganglia O
. O

Antidepressants O
have O
previously O
been O
associated O
with O
paranoid B_DISEASE_ADJECTIVE[DISEASE]/B_BACTERIUM[BIO]
reactions O
in O
psychiatric O
patients O
. O

Five O
cases O
of O
paranoid B_DISEASE_ADJECTIVE[DISEASE]/B_BACTERIUM[BIO]
exacerbation O
with O
the O
serotonin O
reuptake O
inhibitors O
fluoxetine O
and O
amitriptyline O
are O
reported O
here O
. O

Elements O
common O
to O
these O
cases O
included O
a O
history O
of O
paranoid B_DISEASE_ADJECTIVE[DISEASE]/B_BACTERIUM[BIO]
symptomatology O
and O
the O
concomitant O
occurrence O
of O
depressive B_DISEASE
and I_DISEASE
psychotic I_DISEASE
symptoms I_DISEASE
. O

complicated O
depressive B_DISEASE_ADJECTIVE[DISEASE]
disorders I_DISEASE_ADJECTIVE[DISEASE]
( O
including O
atypicality O
of O
course O
and O
symptomatology O
, O
chronicity O
, O
psychosis B_DISEASE
, O
bipolarity O
, O
and O
secondary O
onset O
in O
the O
course O
of O
a O
primary O
psychosis B_DISEASE
) O
may O
present O
particular O
vulnerability O
to O
paranoid B_DISEASE_ADJECTIVE[DISEASE]/B_BACTERIUM[BIO]
exacerbations O
associated O
with O
serotonin O
reuptake O
inhibitors O
. O

Although O
the O
pharmacology O
and O
neurobiology O
of O
paranoia B_DISEASE
remain O
cryptic O
, O
several O
mechanisms O
, O
including O
5HT3 O
receptor O
- O
mediated O
dopamine O
release O
, O
beta O
- O
noradrenergic O
receptor O
downregulation O
, O
or O
GABAB O
receptor O
upregulation O
acting O
in O
the O
vicinity O
of O
the O
ventral O
basal O
ganglia O
( O
possibly O
in O
lateral O
orbitofrontal O
or O
anterior O
cingulate O
circuits O
) O
, O
might O
apply O
to O
this O
phenomenon O
. O

These O
cases O
call O
attention O
to O
possible O
paranoid B_DISEASE_ADJECTIVE[DISEASE]/B_BACTERIUM[BIO]
exacerbations O
with O
serotonin O
reuptake O
blockers O
in O
select O
patients O
and O
raise O
neurobiological O
considerations O
regarding O
paranoia B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Clinical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
comparison I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
cardiorespiratory B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
effects I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
during O
unilateral B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
conventional B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
spinal B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
anaesthesia B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
. O

Background O
: O
spinal O
anaesthesia O
is O
widely O
employed O
in O
clinical O
practice O
but O
has O
the O
main O
drawback O
of O
post O
- O
spinal O
block O
hypotension B_DISEASE
. O

Efforts B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
must O
therefore O
continue O
to O
be O
made O
to O
obviate O
this O
setback B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Objective I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
To O
evaluate O
the O
cardiovascular B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
and O
respiratory B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
changes B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
during O
unilateral B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
conventional B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
spinal I_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
anaesthesia I_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
. O

METHODS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O
With O
ethical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
approval I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
, O
we O
studied O
74 B_ORGANIZATION/B_PERSON
American I_ORGANIZATION/I_PERSON
Society I_ORGANIZATION/I_PERSON
of O
Anesthesiologists B_PERSON/B_DISEASE
( O
ASA B_ORGANIZATION/B_LOCATION
) O
, O
physical B_MEASURE/B_PERSON
status I_MEASURE/I_PERSON
class I_MEASURE/I_PERSON
1 I_MEASURE/I_PERSON
and O
2 B_NUMBER[MEASURE]/B_PERSON
patients I_NUMBER[MEASURE]/I_PERSON
scheduled O
for O
elective B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
unilateral I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
lower I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
limb I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
surgery I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

patients B_PERSON
were O
randomly O
allocated O
into O
one B_NUMBER[MEASURE]/B_LOCATION
of O
two B_NUMBER[MEASURE]/B_PERSON
groups I_NUMBER[MEASURE]/I_PERSON
: O
lateral B_BODY_PART_OR_ORGAN_COMPONENT/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
conventional B_BODY_PART_OR_ORGAN_COMPONENT/B_MEASURE
spinal I_BODY_PART_OR_ORGAN_COMPONENT/I_MEASURE
anaesthesia I_BODY_PART_OR_ORGAN_COMPONENT/I_MEASURE
groups I_BODY_PART_OR_ORGAN_COMPONENT/I_MEASURE
. O

In O
the O
lateral B_LOCATION/B_MEASURE
position I_LOCATION/I_MEASURE
with O
operative B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BODY_PART_OR_ORGAN_COMPONENT
side B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_BODY_PART_OR_ORGAN_COMPONENT
down O
, O
patients B_PERSON
recived O
10 B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
mg I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
( O
2mls B_MEASURE
) O
of O
0 B_MEASURE
. O
5 B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
% I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hyperbaric I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
bupivacaine I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
through O
a O
25 B_NUMBER[MEASURE]
- O
gauge B_MEASURE/B_LOCATION
spinal I_MEASURE/I_LOCATION
needle I_MEASURE/I_LOCATION
. O

patients B_PERSON
in O
the O
unilateral B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
group I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
were O
maintained O
in O
the O
lateral B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
position B_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
for O
15 B_TIME[MEASURE]/B_ENT
minutes I_TIME[MEASURE]/I_ENT
following O
spinal B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
injection I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
while O
those O
in O
the O
conventional B_LOCATION/B_ORGANIZATION
group I_LOCATION/I_ORGANIZATION
were O
turned O
supine B_LOCATION/B_PERSON
immediately O
after O
injection B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O

Blood B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
pressure I_MEASURE/I_BODY_PART_OR_ORGAN_COMPONENT
, O
heart B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
rate I_MEASURE/I_BODY_PART_OR_ORGAN_COMPONENT
, O
respiratory B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
rate I_MEASURE/I_BODY_PART_OR_ORGAN_COMPONENT
and O
oxygen B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
saturation B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
monitored O
over O
1 B_TIME[MEASURE]/B_ENT
hour I_TIME[MEASURE]/I_ENT
. O

Results O
: O
Three O
patients O
( O
8 O
. O
1 O
% O
) O
in O
the O
unilateral O
group O
and O
5 O
( O
13 O
. O
5 O
% O
) O
in O
the O
conventional O
group O
developed O
hypotension B_DISEASE
, O
P O
= O
0 O
. O
71 O
. O

Four O
( O
10 O
. O
8 O
% O
) O
patients O
in O
the O
conventional O
group O
and O
1 O
( O
2 O
. O
7 O
% O
) O
in O
the O
unilateral O
group O
, O
P O
= O
0 O
. O
17 O
required O
epinephrine O
infusion O
to O
treat O
hypotension B_DISEASE/B_GENE
. O

patients B_PERSON
in O
the O
conventional B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
group I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
had O
statistically O
significant B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
greater I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
fall I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O
the O
systolic B_DISEASE/B_GENE
blood I_DISEASE/I_GENE
pressures I_DISEASE/I_GENE
at O
15 B_MEASURE
, O
30 B_MEASURE
and O
45 B_MEASURE/B_ENT
minutes I_MEASURE/I_ENT
when O
compared O
to O
the O
baseline B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
( O
P B_PROTEIN[GENE]/B_LOCATION
= O
0 B_MEASURE
. O
003 B_MEASURE
, O
0 B_MEASURE/B_LOCATION
. O
001 B_MEASURE
and O
0 B_MEASURE
. O
004 B_MEASURE
) O
. O

The O
mean B_MEASURE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
respiratory B_MEASURE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
rate B_MEASURE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
oxygen B_MEASURE/B_DISEASE
saturations I_MEASURE/I_DISEASE
in O
the O
two B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
groups I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
were O
similar B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Conclusion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O
Compared O
to O
conventional B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
spinal I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
anaesthesia I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
unilateral B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
spinal I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
anaesthesia I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
was O
associated O
with O
fewer B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cardiovascular I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
perturbations I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Also O
, O
the O
type B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
spinal B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
block I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
instituted O
affected O
neither O
the O
respiratory B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
rate B_MEASURE/I_BODY_PART_OR_ORGAN_COMPONENT
nor O
the O
arterial B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
oxygen B_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
saturation B_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Spectrum O
of O
adverse O
events O
after O
generic O
HAART O
in O
southern O
Indian O
HIV B_DISEASE/B_LOCATION
- I_DISEASE/I_LOCATION
infected I_DISEASE/I_LOCATION
patients O
. O

To O
determine O
the O
incidence O
of O
clinically O
significant O
adverse O
events O
after O
long O
- O
term O
, O
fixed O
- O
dose O
, O
generic O
highly O
active O
antiretroviral O
therapy O
( O
HAART O
) O
use O
among O
HIV B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
- I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
infected I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
individuals O
in O
South O
India O
, O
we O
examined O
the O
experiences O
of O
3154 O
HIV B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
- I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
infected I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
individuals O
who O
received O
a O
minimum O
of O
3 O
months O
of O
generic O
HAART O
between O
February O
1996 O
and O
December O
2006 O
at O
a O
tertiary O
HIV O
care O
referral O
center O
in O
South O
India O
. O

The O
most O
common B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
regimens I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
were O
3TC B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
+ I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
d4T I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
+ I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
nevirapine I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
NVP B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
) O
( O
54 B_MEASURE
. O
8 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
, O
zidovudine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
( O
AZT B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
+ B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
3TC I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
+ I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
NVP I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O
14 B_MEASURE
. O
5 B_MEASURE
% I_MEASURE
) O
, O
3TC B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
+ O
d4T B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
+ I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
efavirenz I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O
EFV B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
( O
20 B_MEASURE
. O
1 B_MEASURE
% I_MEASURE
) O
, O
and O
AZT B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
+ I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
3TC I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
+ I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
EFV I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
( O
5 B_MEASURE
. O
4 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
. O

The O
most O
common O
adverse O
events O
and O
median O
CD4 O
at O
time O
of O
event O
were O
rash B_DISEASE
( O
15 O
. O
2 O
% O
; O
CD4 O
, O
285 O
cells O
/ O
microL O
) O
and O
peripheral B_DISEASE
neuropathy I_DISEASE
( O
9 O
. O
0 O
% O
and O
348 O
cells O
/ O
microL O
) O
. O

Clinically O
significant O
anemia B_DISEASE
( O
hemoglobin O
< O
7 O
g O
/ O
DL O
) O
was O
observed O
in O
5 O
. O
4 O
% O
of O
patients O
( O
CD4 O
, O
165 O
cells O
/ O
microL O
) O
and O
hepatitis B_DISEASE
( O
clinical O
jaundice B_DISEASE
with O
alanine O
aminotransferase O
> O
5 O
times O
upper O
limits O
of O
normal O
) O
in O
3 O
. O
5 O
% O
of O
patients O
( O
CD4 O
, O
260 O
cells O
/ O
microL O
) O
. O

Women O
were O
significantly O
more O
likely O
to O
experience O
lactic B_DISEASE
acidosis I_DISEASE
, O
while O
men O
were O
significantly O
more O
likely O
to O
experience O
immune B_DISEASE
reconstitution I_DISEASE
syndrome I_DISEASE
( O
p O
< O
0 O
. O
05 O
) O
. O

Among O
the O
patients O
with O
1 O
year O
of O
follow O
- O
up O
, O
NVP O
therapy O
was O
significantly O
associated O
with O
developing O
rash B_DISEASE
and O
d4T O
therapy O
with O
developing O
peripheral B_DISEASE
neuropathy I_DISEASE
( O
p O
< O
0 O
. O
05 O
) O
. O

Anemia B_DISEASE
and O
hepatitis B_DISEASE
often O
occur O
within O
12 O
weeks O
of O
initiating O
generic O
HAART O
. O

frequent O
and O
early O
monitoring O
for O
these O
toxicities B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
warranted O
in O
developing O
countries O
where O
generic O
HAART O
is O
increasingly O
available O
. O

Thalidomide O
and O
sensory B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
neurotoxicity I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
: O
a O
neurophysiological O
study O
. O

Background O
: O
Recent O
studies O
confirmed O
a O
high O
incidence O
of O
sensory B_DISEASE
axonal I_DISEASE
neuropathy I_DISEASE
in O
patients O
treated O
with O
different O
doses O
of O
thalidomide O
. O

The O
study O
' O
s O
aims O
were O
to O
measure O
variations O
in O
sural O
nerve O
sensory O
action O
potential O
( O
SAP O
) O
amplitude O
in O
patients O
with O
refractory O
cutaneous B_DISEASE/B_LOCATION
lupus I_DISEASE/I_LOCATION
erythematosus I_DISEASE/I_LOCATION
( O
CLE B_DISEASE
) O
treated O
with O
thalidomide O
and O
use O
these O
findings O
to O
identify O
the O
neurotoxic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
potential O
of O
thalidomide O
and O
the O
recovery O
capacity O
of O
sensory O
fibres O
after O
discontinuation O
of O
treatment O
. O

patients O
AND O
methods O
: O
Clinical O
and O
electrophysiological O
data O
in O
12 O
female O
patients O
with O
CLE B_DISEASE/B_PROTEIN[GENE]
during O
treatment O
with O
thalidomide O
and O
up O
to O
47 O
months O
after O
discontinuation O
of O
treatment O
were O
analysed O
. O

Sural B_MEASURE/B_PERSON
nerve I_MEASURE/I_PERSON
SAP I_MEASURE/I_PERSON
amplitude I_MEASURE/I_PERSON
reduction I_MEASURE/I_PERSON
> I_MEASURE/I_PERSON
or O
= O
40 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
was O
the O
criteria B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
for O
discontinuing O
therapy B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O

RESULTS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O
During O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
11 B_MEASURE/B_PERSON
patients I_MEASURE/I_PERSON
showed O
a O
reduction B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
sural B_DISEASE/B_GENE
nerve I_DISEASE/I_GENE
SAP I_DISEASE/I_GENE
amplitude I_DISEASE/I_GENE
compared O
to O
baseline B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
values I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
9 B_NUMBER[MEASURE]/B_PERSON
with O
a O
reduction B_MEASURE
> I_MEASURE
or O
= O
50 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
and O
2 B_MEASURE
< I_MEASURE
50 I_MEASURE
% I_MEASURE
) O
. O

One B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
patient B_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
showed O
no O
changes B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
SAP B_MEASURE/B_DISEASE
amplitude B_MEASURE/I_DISEASE
. O

Five O
patients O
complained O
of O
paresthesias B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
and O
leg O
cramps B_DISEASE
. O

After O
thalidomide B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
treatment I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
, O
sural B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
SAP I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
amplitude I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
recovered O
in O
3 B_TIME[MEASURE]/B_PERSON
patients I_TIME[MEASURE]/I_PERSON
. O

At O
detection B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
reduction B_DISEASE_ADJECTIVE[DISEASE]
in O
sural B_DISEASE/B_MEASURE
nerve I_DISEASE/I_MEASURE
SAP I_DISEASE/I_MEASURE
amplitude I_DISEASE/I_MEASURE
, O
the O
median B_MEASURE
thalidomide I_MEASURE
cumulative I_MEASURE
dose I_MEASURE
was O
21 B_MEASURE
. O
4 B_MEASURE
g I_MEASURE
. O

The O
threshold O
neurotoxic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dosage O
is O
lower O
than O
previously O
reported O
. O

CONCLUSIONS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O
Sural B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
nerve B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
SAP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
amplitude B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
reduction B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
is O
a O
reliable B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
sensitive B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
marker B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
degeneration B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
recovery B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
sensory B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
fibres I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
. O

This O
electrophysiological O
parameter O
provides O
information O
about O
subclinical O
neurotoxic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
potential O
of O
thalidomide O
but O
is O
not O
helpful O
in O
predicting O
the O
appearance O
of O
sensory O
symptoms O
. O

Five O
cases O
of O
encephalitis B_DISEASE
during O
treatment O
of O
loiasis B_DISEASE/B_PERSON
with O
diethylcarbamazine O
. O

Five O
cases O
of O
encephalitis B_DISEASE
following O
treatment O
with O
diethylcarbamazine O
( O
Dec O
) O
were O
observed O
in O
Congolese O
patients O
with O
Loa O
loa O
filariasis B_DISEASE
. O

Two B_NUMBER[MEASURE]/B_PERSON
cases I_NUMBER[MEASURE]/I_PERSON
had O
a O
fatal B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
outcome B_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
one B_NUMBER[MEASURE]/B_PERSON
resulted O
in O
severe B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
sequelae I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

The O
notable B_PERSON/B_MEASURE
fact I_PERSON/I_MEASURE
was O
that O
this O
complication B_DISEASE
occurred O
in O
three B_PERSON
patients I_PERSON
hospitalized O
before O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
began O
, O
with O
whom O
particularly O
strict B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
therapeutic I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
precautions I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
were O
taken O
, O
i O
. O
e O
. O
, O
initial B_MEASURE
dose I_MEASURE
less I_MEASURE
than O
10 B_SEQUENCE[MEASURE]/B_LOCATION
mg I_SEQUENCE[MEASURE]/I_LOCATION
of O
Dec B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
very O
gradual B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dose I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
increases I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
associated O
anti B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
allergic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
treatment I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O

This O
type B_MEASURE/B_DISEASE
of O
drug B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
complication B_DISEASE
may O
not O
be O
that O
uncommon B_DISEASE_ADJECTIVE[DISEASE]
in O
highly O
endemic B_PERSON/B_NUMBER[MEASURE]
regions I_PERSON/I_NUMBER[MEASURE]
. O

It O
occurs O
primarily O
, O
but O
not O
exclusively O
, O
in O
subjects B_PERSON/B_BIO
presenting O
with O
a O
high B_DISEASE/B_PERSON
microfilarial I_DISEASE/I_PERSON
load I_DISEASE/I_PERSON
. O

The O
relationship O
between O
the O
occurrence O
of O
encephalitis B_DISEASE
and O
the O
decrease O
in O
microfilaremia B_DISEASE/B_GENE
is O
evident O
. O

The O
pathophysiological B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
mechanisms I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
are O
discussed O
in O
the O
light B_COLOR/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
these O
observations B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
and O
the O
few B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
other I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
comments I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
on O
this O
subject B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
published O
in O
the O
literature B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Amiodarone O
- O
related O
pulmonary B_DISEASE
mass I_DISEASE
and O
unique O
membranous B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
glomerulonephritis B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
a O
patient O
with O
valvular B_DISEASE/B_GENE
heart I_DISEASE/I_GENE
disease I_DISEASE/I_GENE
: O
diagnostic O
pitfall O
and O
new O
findings O
. O

Amiodarone O
is O
an O
anti O
- O
arrhythmic B_DISEASE_ADJECTIVE[DISEASE]
drug O
for O
life O
- O
threatening O
tachycardia B_DISEASE
, O
but O
various O
adverse O
effects O
have O
been O
reported O
. O

reported O
herein O
is O
an O
autopsy O
case O
of O
valvular B_DISEASE
heart I_DISEASE
disease I_DISEASE
, O
in O
a O
patient O
who O
developed O
a O
lung B_DISEASE
mass I_DISEASE
( O
1 O
. O
5 O
cm O
in O
diameter O
) O
and O
proteinuria B_DISEASE
( O
2 O
. O
76 O
g O
/ O
day O
) O
after O
treatment O
with O
amiodarone O
for O
a O
long O
time O
. O

The O
lung B_DISEASE
mass I_DISEASE
was O
highly O
suspected O
to O
be O
lung B_DISEASE
cancer I_DISEASE
on O
CT O
and O
positron O
emission O
tomography O
, O
but O
histologically O
the O
lesion O
was O
composed O
of O
lymphoplasmacytic O
infiltrates O
in O
alveolar O
walls O
and O
intra O
- O
alveolar O
accumulation O
of O
foamy O
macrophages O
containing O
characteristic O
myelinoid O
bodies O
, O
indicating O
that O
it O
was O
an O
amiodarone O
- O
related O
lesion O
. O

In O
addition O
, O
the O
lung O
tissue O
had O
unevenly O
distributed O
hemosiderin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
deposition O
, O
and O
abnormally O
tortuous O
capillaries O
were O
seen O
in O
the O
mass O
and O
in O
heavily O
hemosiderotic B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
lung O
portions O
outside O
the O
mass O
. O

In O
the O
kidneys B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
, O
glomeruli B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
had O
membrane B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
spikes I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
, O
prominent B_DISEASE/B_LOCATION
swelling B_DISEASE/I_LOCATION
of O
podocytes B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
and O
subepithelial B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
deposits B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O
which O
were O
sometimes O
large B_BODY_PART_OR_ORGAN_COMPONENT/B_GENE
and O
hump B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
- O
like B_LOCATION/B_BIO
. O

Autoimmune B_DISEASE/B_MEASURE
diseases I_DISEASE/I_MEASURE
, O
viral B_DISEASE/B_BIO
hepatitis I_DISEASE/I_BIO
, O
malignant O
neoplasms B_DISEASE
or O
other O
diseases O
with O
a O
known O
relationship O
to O
membranous B_DISEASE
glomerulonephritis I_DISEASE
were O
not O
found O
. O

The O
present O
case O
highlights O
the O
possibility O
that O
differential O
diagnosis O
between O
an O
amiodarone O
- O
related O
pulmonary B_DISEASE
lesion I_DISEASE
and O
a O
neoplasm B_DISEASE
can O
be O
very O
difficult O
radiologically O
, O
and O
suggests O
that O
membranous B_DISEASE
glomerulonephritis I_DISEASE
might O
be O
another O
possible O
complication O
of O
amiodarone O
treatment O
. O

Risk O
of O
coronary B_DISEASE
artery I_DISEASE
disease I_DISEASE
associated O
with O
initial O
sulphonylurea O
treatment O
of O
patients O
with O
type B_DISEASE
2 I_DISEASE
diabetes I_DISEASE
: O
a O
matched O
case O
- O
control O
study O
. O

aims O
: O
This O
study O
sought O
to O
assess O
the O
risk O
of O
developing O
coronary B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
artery I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
disease I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O
CAD B_DISEASE/B_LOCATION
) O
associated O
with O
initial O
treatment O
of O
type B_PERSON
2 I_PERSON
diabetes I_PERSON
with O
different O
sulphonylureas O
. O

methods O
: O
In O
type B_DISEASE/B_MEASURE
2 I_DISEASE/I_MEASURE
diabetic I_DISEASE/I_MEASURE
patients O
, O
cases O
who O
developed O
CAD B_DISEASE
were O
compared O
retrospectively O
with O
controls O
that O
did O
not O
. O

The O
20 O
- O
year O
risk O
of O
CAD B_DISEASE
at O
diagnosis O
of O
diabetes B_DISEASE/B_LOCATION
, O
using O
the O
UKPDS O
risk O
engine O
, O
was O
used O
to O
match O
cases O
with O
controls O
. O

Results O
: O
The O
76 O
cases O
of O
CAD B_DISEASE/B_LOCATION
were O
compared O
with O
152 O
controls O
. O

The O
hazard O
of O
developing O
CAD B_DISEASE/B_GENE
( O
95 O
% O
CI O
) O
associated O
with O
initial O
treatment O
increased O
by O
2 O
. O
4 O
- O
fold O
( O
1 O
. O
3 O
- O
4 O
. O
3 O
, O
P O
= O
0 O
. O
004 O
) O
with O
glibenclamide O
; O
2 O
- O
fold O
( O
0 O
. O
9 O
- O
4 O
. O
6 O
, O
P O
= O
0 O
. O
099 O
) O
with O
glipizide O
; O
2 O
. O
9 O
- O
fold O
( O
1 O
. O
6 O
- O
5 O
. O
1 O
, O
P O
= O
0 O
. O
000 O
) O
with O
either O
, O
and O
was O
unchanged O
with O
metformin O
. O

The O
hazard B_DISEASE
decreased O
0 B_MEASURE
. O
3 B_MEASURE
- O
fold B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
( O
0 B_MEASURE/B_LOCATION
. O
7 B_MEASURE
- O
1 B_NUMBER[MEASURE]
. O
7 B_MEASURE
, O
P B_PROTEIN[GENE]/B_LOCATION
= O
0 B_MEASURE
. O
385 B_MEASURE
) O
with O
glimepiride B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
0 B_NUMBER[MEASURE]
. O
4 B_MEASURE
- O
fold B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
( O
0 B_MEASURE/B_LOCATION
. O
7 B_MEASURE
- O
1 B_NUMBER[MEASURE]
. O
3 B_MEASURE
, O
P B_PROTEIN[GENE]/B_LOCATION
= O
0 B_NUMBER[MEASURE]
. O
192 B_MEASURE
) O
with O
gliclazide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
0 B_NUMBER[MEASURE]
. O
4 B_MEASURE
- O
fold B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
( O
0 B_MEASURE/B_LOCATION
. O
7 B_MEASURE
- O
1 B_NUMBER[MEASURE]
. O
1 B_MEASURE
, O
P B_LOCATION/B_PROTEIN[GENE]
= O
0 B_MEASURE
. O
09 B_MEASURE
) O
with O
either O
. O

conclusions O
: O
Initiating O
treatment O
of O
type B_DISEASE
2 I_DISEASE
diabetes I_DISEASE
with O
glibenclamide O
or O
glipizide O
is O
associated O
with O
increased O
risk O
of O
CAD B_DISEASE
in O
comparison O
to O
gliclazide O
or O
glimepiride O
. O

If O
confirmed O
, O
this O
may O
be O
important B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
because O
most B_PERSON/B_BIO
Indian I_PERSON/I_BIO
patients I_PERSON/I_BIO
receive O
the O
cheaper B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
older I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
sulphonylureas I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
and O
present B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
guidelines I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
do O
not O
distinguish O
between O
individual B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
agents I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_PERSON
. O

reduced O
progression O
of O
adriamycin O
nephropathy B_DISEASE
in O
spontaneously O
hypertensive B_DISEASE
rats O
treated O
by O
losartan O
. O

Background O
: O
The O
aim O
of O
the O
study O
was O
to O
investigate O
the O
antihypertensive O
effects O
of O
angiotensin O
II O
type O
- O
1 O
receptor O
blocker O
, O
losartan O
, O
and O
its O
potential O
in O
slowing O
down O
renal B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
disease I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
progression O
in O
spontaneously O
hypertensive B_DISEASE
rats O
( O
SHR O
) O
with O
adriamycin O
( O
ADR O
) O
nephropathy B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

METHODS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O
Six B_NUMBER[MEASURE]
- O
month B_TIME[MEASURE]
- O
old B_PERSON
female I_PERSON
SHR I_PERSON
were O
randomly O
selected O
in O
six B_TIME[MEASURE]/B_ENT
groups I_TIME[MEASURE]/I_ENT
. O

Two B_LOCATION/B_PERSON
control I_LOCATION/I_PERSON
groups I_LOCATION/I_PERSON
( O
SH B_LOCATION
( O
6 B_MEASURE
) O
, O
SH B_LOCATION
( O
12 B_MEASURE
) O
) O
received O
vehicle B_PRODUCT[OBJECT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Groups B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ADR B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
6 B_MEASURE
) O
, O
ADR B_LOCATION/B_ORGANIZATION
+ I_LOCATION
los I_LOCATION
( O
6 B_NUMBER[MEASURE]
) O
and O
ADR B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
( O
12 B_NUMBER[MEASURE]
) O
, O
and O
ADR B_LOCATION/B_ORGANIZATION
+ I_LOCATION
los I_LOCATION
( O
12 B_MEASURE
) O
received O
ADR B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
2 B_MEASURE
mg I_MEASURE
/ O
kg B_MEASURE
/ O
b B_TIME[MEASURE]/B_DISEASE
. O
w O
. O
i O
. O
v B_TIME[MEASURE]/B_GENE
. O
) O
twice O
in O
a O
3 B_NUMBER[MEASURE]
- O
week B_TIME[MEASURE]/B_LOCATION
interval I_TIME[MEASURE]/I_LOCATION
. O

Group B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ADR I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
+ O
LOS B_DISEASE/B_LOCATION
( O
6 B_MEASURE
) O
received O
losartan B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O
10 B_MEASURE
mg I_MEASURE
/ O
kg B_MEASURE
/ O
b B_OTHER/B_TIME[MEASURE]
. O
w O
. O
/ O
day B_TIME[MEASURE]
by O
gavages B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BODY_PART_OR_ORGAN_COMPONENT
) O
for O
6 B_TIME[MEASURE]/B_ENT
weeks I_TIME[MEASURE]/I_ENT
and O
group B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
ADR I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
+ I_MEASURE
los I_MEASURE
( O
12 B_NUMBER[MEASURE]
) O
for O
12 B_TIME[MEASURE]/B_ENT
weeks I_TIME[MEASURE]/I_ENT
after O
second B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
injection I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
ADR B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O

Animals B_BIO/B_NUMBER[MEASURE]
were O
killed O
after O
6 B_NUMBER[MEASURE]
or O
12 B_NUMBER[MEASURE]/B_ENT
weeks I_NUMBER[MEASURE]/I_ENT
, O
respectively O
. O

haemodynamic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
measurements I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
were O
performed O
on O
anaesthetized B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
animals I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
, O
blood B_BODY_PART_OR_ORGAN_COMPONENT
and O
urine B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
samples I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
taken O
for O
biochemical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
the O
left B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
kidney I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
was O
processed O
for O
morphological B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
studies I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Results O
: O
Short O
- O
term O
losartan O
treatment O
, O
besides O
antihypertensive O
effect O
, O
improved O
glomerular O
filtration O
rate O
and O
ameliorated O
glomerulosclerosis B_DISEASE/B_GENE
resulting O
in O
decreased O
proteinuria B_DISEASE/B_GENE
. O

prolonged O
treatment O
with O
losartan O
showed O
further O
reduction O
of O
glomerulosclerosis B_DISEASE/B_GENE
associated O
with O
reduced O
progression O
of O
tubular O
atrophy B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
and O
interstitial B_DISEASE
fibrosis I_DISEASE
, O
thus O
preventing O
heavy O
proteinuria B_DISEASE
and O
chronic B_DISEASE
renal I_DISEASE
failure I_DISEASE
. O

Losartan O
reduced O
uraemia B_DISEASE/B_GENE
and O
increased O
urea O
clearance O
in O
advanced O
ADR O
nephropathy B_DISEASE/B_TIME[MEASURE]
in O
SHR O
. O

Histological O
examination O
showed O
that O
losartan O
could O
prevent O
tubular O
atrophy B_DISEASE
, O
interstitial O
infiltration O
and O
fibrosis B_DISEASE
in O
ADR O
nephropathy B_DISEASE/B_SPECIES[BIO]
. O

conclusion O
: O
Losartan O
reduces O
the O
rate O
of O
progression O
of O
ADR O
- O
induced O
focal B_DISEASE
segmental I_DISEASE
glomerulosclerosis I_DISEASE
to O
end B_DISEASE/B_LOCATION
- I_DISEASE/I_LOCATION
stage I_DISEASE/I_LOCATION
renal I_DISEASE/I_LOCATION
disease I_DISEASE/I_LOCATION
in O
SHR O
. O

The O
risks B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
aprotinin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O
tranexamic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
acid I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
in O
cardiac B_PERSON/B_LOCATION
surgery I_PERSON/I_LOCATION
: O
a O
one B_NUMBER[MEASURE]
- O
year B_TIME[MEASURE]/B_LOCATION
follow B_TIME[MEASURE]/I_LOCATION
- O
up B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
1188 B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
consecutive I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
patients I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
. O

Background B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
: O
Our O
aim B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
to O
investigate O
postoperative B_DISEASE_ADJECTIVE[DISEASE]
complications I_DISEASE_ADJECTIVE[DISEASE]
and O
mortality B_DISEASE
after O
administration B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
aprotinin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
compared O
to O
tranexamic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
acid I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
in O
an O
unselected B_LOCATION/B_TIME[MEASURE]
, O
consecutive B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
cohort I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O

METHODS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O
Perioperative B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
data I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O
consecutive B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
cardiac I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
surgery I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
patients I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
were O
prospectively O
collected O
between O
September B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2005 I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
June B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2006 I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
a O
university B_LOCATION/B_ORGANIZATION
- O
affiliated O
clinic B_LOCATION/B_ORGANIZATION
( O
n B_MEASURE/B_LOCATION
= O
1188 B_MEASURE
) O
. O

During O
the O
first B_LOCATION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
5 B_LOCATION/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
mo B_LOCATION/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
596 B_NUMBER[MEASURE]/B_PERSON
patients I_NUMBER[MEASURE]/I_PERSON
received O
aprotinin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
( O
Group B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
A I_LOCATION/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
; O
in O
the O
next B_SEQUENCE[MEASURE]/B_LOCATION
5 I_SEQUENCE[MEASURE]/I_LOCATION
Mo I_SEQUENCE[MEASURE]/I_LOCATION
, O
592 B_MEASURE/B_PERSON
patients I_MEASURE/I_PERSON
were O
treated O
with O
tranexamic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acid I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
Group B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
T I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
) O
. O

Except O
for O
antifibrinolytic B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
therapy I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
, O
the O
anesthetic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
surgical B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
protocols I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
remained O
unchanged B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
. O

RESULTS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
The O
pre B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
and O
intraoperative B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
variables I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
were O
comparable B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O
the O
treatment B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
groups I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

Postoperatively O
, O
a O
significantly O
higher O
incidence O
of O
seizures B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O
found O
in O
Group O
T O
( O
4 O
. O
6 O
% O
vs O
1 O
. O
2 O
% O
, O
P O
< O
0 O
. O
001 O
) O
. O

This O
difference B_MEASURE
was O
also O
significant B_DISEASE_ADJECTIVE[DISEASE]
in O
the O
primary B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
valve B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
surgery B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
and O
the O
high B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BODY_PART_OR_ORGAN_COMPONENT
risk I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_BODY_PART_OR_ORGAN_COMPONENT
surgery I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_BODY_PART_OR_ORGAN_COMPONENT
subgroups I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_BODY_PART_OR_ORGAN_COMPONENT
( O
7 B_MEASURE
. O
9 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
vs O
1 B_MEASURE
. O
2 B_MEASURE
% I_MEASURE
, O
P B_OTHER/B_LOCATION
= O
0 B_MEASURE
. O
003 B_MEASURE
; O
7 B_MEASURE
. O
3 B_MEASURE
% I_MEASURE
vs O
2 B_MEASURE
. O
4 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
, O
P B_OTHER/B_LOCATION
= O
0 B_MEASURE
. O
035 B_MEASURE
, O
respectively O
) O
. O

persistent O
atrial O
fibrillation O
( O
7 O
. O
9 O
% O
vs O
2 O
. O
3 O
% O
, O
P O
= O
0 O
. O
020 O
) O
and O
renal B_DISEASE
failure I_DISEASE
( O
9 O
. O
7 O
% O
vs O
1 O
. O
7 O
% O
, O
P O
= O
0 O
. O
002 O
) O
were O
also O
more O
common O
in O
Group O
T O
, O
in O
the O
primary O
valve O
surgery O
subgroup O
. O

On O
the O
contrary O
, O
among O
primary O
coronary O
artery O
bypass O
surgery O
patients O
, O
there O
were O
more O
acute O
myocardial B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
infarctions B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
and O
renal B_DISEASE
dysfunction I_DISEASE
in O
Group O
A O
( O
5 O
. O
8 O
% O
vs O
2 O
. O
0 O
% O
, O
P O
= O
0 O
. O
027 O
; O
22 O
. O
5 O
% O
vs O
15 O
. O
2 O
% O
, O
P O
= O
0 O
. O
036 O
, O
respectively O
) O
. O

The O
1 B_MEASURE
- O
yr B_MEASURE/B_LOCATION
mortality I_MEASURE/I_LOCATION
was O
significantly O
higher B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
after O
aprotinin B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
treatment I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_GENE
in O
the O
high B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
risk I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
surgery I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
group I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
( O
17 B_MEASURE
. O
7 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
vs O
9 B_MEASURE
. O
8 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
, O
P B_OTHER/B_PROTEIN[GENE]
= O
0 B_MEASURE
. O
034 B_MEASURE
) O
. O

Conclusion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O
Both O
antifibrinolytic B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
drugs I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
bear O
the O
risk B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
of O
adverse B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
outcome I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
depending O
on O
the O
type B_DISEASE/B_MEASURE
of O
cardiac B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
surgery I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
. O

Administration B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
aprotinin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
should O
be O
avoided O
in O
coronary B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
artery I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
bypass I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
graft I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
and O
high B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
risk I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
patients I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
, O
whereas O
administration B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O
tranexamic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acid I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
not O
recommended O
in O
valve B_PERSON/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
surgery I_PERSON/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Delirium B_DISEASE
in O
an O
elderly O
woman O
possibly O
associated O
with O
administration O
of O
misoprostol O
. O

Misoprostol O
has O
been O
associated O
with O
adverse O
reactions O
, O
including O
gastrointestinal O
symptoms O
, O
gynecologic O
problems O
, O
and O
headache B_DISEASE
. O

Changes B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O
mental B_DISEASE_ADJECTIVE[DISEASE]
status I_DISEASE_ADJECTIVE[DISEASE]
, O
however O
, O
have O
not O
been O
reported O
. O

We O
present O
a O
case B_PERSON/B_ENT
in O
which O
an O
89 B_NUMBER[MEASURE]
- O
year B_TIME[MEASURE]
- O
old B_PERSON
woman I_PERSON
in O
a O
long B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O
term B_LOCATION/B_MEASURE
care I_LOCATION/I_MEASURE
facility I_LOCATION/I_MEASURE
became O
confused O
after O
the O
initiation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O
misoprostol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
therapy I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANISM_FUNCTION
. O

The O
patient B_PERSON
' O
s B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
change B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
mental B_DISEASE
status I_DISEASE
was O
first O
reported O
nine B_TIME[MEASURE]/B_ENT
days I_TIME[MEASURE]/I_ENT
after O
the O
initiation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
therapy B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Her O
delirium B_DISEASE
significantly O
improved O
after O
misoprostol O
was O
discontinued O
and O
her O
mental O
status O
returned O
to O
normal O
within O
a O
week O
. O

Because O
no O
other O
factors O
related O
to O
this O
patient O
changed O
significantly O
, O
the O
delirium B_DISEASE
experienced O
by O
this O
patient O
possibly O
resulted O
from O
misoprostol O
therapy O
. O

The O
biological O
properties O
of O
the O
optical O
isomers O
of O
propranolol O
and O
their O
effects O
on O
cardiac B_DISEASE/B_ORGANISM_FUNCTION
arrhythmias I_DISEASE/I_ORGANISM_FUNCTION
. O

1 B_NUMBER[MEASURE]
. O

The O
optical B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
isomers I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O
propranolol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
have O
been O
compared O
for O
their O
beta B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
- O
blocking O
and O
antiarrhythmic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
activities I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O
2 B_MEASURE/B_PERSON
. O

In O
blocking O
the O
positive B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
inotropic I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
chronotropic B_DISEASE_ADJECTIVE[DISEASE]
responses I_DISEASE_ADJECTIVE[DISEASE]
to O
isoprenaline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
( O
+ O
) O
- O
propranolol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
had O
less B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
than O
one B_MEASURE/B_LOCATION
hundredth I_MEASURE/I_LOCATION
the O
potency B_MEASURE
of O
( O
- O
) O
- O
propranolol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

At O
dose B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
levels I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
of O
( O
+ B_PROTEIN[GENE]/B_DISEASE
) O
- O
propranolol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
which O
attenuated O
the O
responses B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
to O
isoprenaline O
, O
there O
was O
a O
significant B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
prolongation I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
the O
PR B_TIME[MEASURE]/B_LOCATION
interval I_TIME[MEASURE]/I_LOCATION
of O
the O
electrocardiogram B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O
3 B_MEASURE/B_PERSON
. O

The O
metabolic B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
responses I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
to O
isoprenaline O
in O
dogs B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPECIES[BIO]
( O
an O
increase B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
circulating O
glucose B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
, O
lactate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O
free B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
fatty I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
acids I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
) O
were O
all O
blocked O
by O
( O
- O
) O
- O
propranolol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O

( O
+ O
) O
- O
propranolol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
had O
no O
effect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
fatty B_DISEASE/B_GENE
acid B_DISEASE/I_GENE
mobilization B_DISEASE/I_GENE
but O
significantly O
reduced O
the O
increments B_DISEASE
in O
both O
lactate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
glucose B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
. O
4 B_MEASURE/B_LOCATION
. O

Both O
isomers B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
propranolol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
possessed O
similar B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
depressant B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
potency B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
isolated B_BODY_PART_OR_ORGAN_COMPONENT
atrial I_BODY_PART_OR_ORGAN_COMPONENT
muscle I_BODY_PART_OR_ORGAN_COMPONENT
taken O
from O
Guinea B_LOCATION/B_PERSON
- O
pigs B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O
5 B_MEASURE/B_LOCATION
. O

The O
isomers B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
propranolol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
exhibited O
similar B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
local I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
anaesthetic I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
potencies I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
on O
an O
isolated B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
frog B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
nerve B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
preparation B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
at O
a O
level B_MEASURE/B_LOCATION
approximately O
three B_MEASURE/B_LOCATION
times I_MEASURE/I_LOCATION
that O
of O
procaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
racemic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
compound I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
significantly O
less O
potent B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
than O
either O
isomer B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_NUMBER[MEASURE]
. O
6 B_MEASURE/B_LOCATION
. O

Both O
isomers O
of O
propranolol O
were O
capable O
of O
preventing O
adrenaline O
- O
induced O
cardiac B_DISEASE
arrhythmias I_DISEASE
in O
cats O
anaesthetized O
with O
halothane O
, O
but O
the O
mean O
dose O
of O
( O
- O
) O
- O
propranolol O
was O
0 O
. O
09 O
+ O
/ O
- O
0 O
. O
02 O
mg O
/ O
kg O
whereas O
that O
of O
( O
+ O
) O
- O
propranolol O
was O
4 O
. O
2 O
+ O
/ O
- O
1 O
. O
2 O
mg O
/ O
kg O
. O

At O
the O
effective B_MEASURE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
dose B_MEASURE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
level B_MEASURE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
( O
+ B_PROTEIN[GENE]/B_DISEASE
) O
- O
propranolol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
there O
was O
a O
significant B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
prolongation I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
the O
PR B_MEASURE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
interval B_MEASURE/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
electrocardiogram B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O

blockade O
of O
arrhythmias B_DISEASE
with O
both O
isomers O
was O
surmountable O
by O
increasing O
the O
dose O
of O
adrenaline O
. O
7 O
. O

Both O
isomers O
of O
propranolol O
were O
also O
capable O
of O
reversing O
ventricular B_DISEASE
tachycardia I_DISEASE
caused O
by O
ouabain O
in O
anaesthetized O
cats O
and O
dogs O
. O

The O
dose B_MEASURE/B_DISEASE
of O
( O
- O
) O
- O
propranolol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
significantly O
smaller B_MEASURE
than O
that O
of O
( O
+ B_PROTEIN[GENE]/B_DISEASE
) O
- O
propranolol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
both O
species B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
but O
much O
higher B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
than O
that O
required O
to O
produce O
evidence B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
beta B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
blockade B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O
8 B_MEASURE/B_LOCATION
. O

The O
implications B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
these O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
discussed O
. O

Topotecan O
in O
combination O
with O
radiotherapy O
in O
unresectable O
glioblastoma B_DISEASE
: O
a O
phase O
2 O
study O
. O

improving O
glioblastoma B_DISEASE
multiforme I_DISEASE
( O
GBM B_LOCATION/B_ORGANIZATION
) O
treatment O
with O
radio O
- O
chemotherapy O
remains O
a O
challenge O
. O

Topotecan O
is O
an O
attractive O
option O
as O
it O
exhibits O
growth O
inhibition O
of O
human O
glioma B_DISEASE
as O
well O
as O
brain O
penetration O
. O

The O
present O
study O
assessed O
the O
combination O
of O
radiotherapy O
( O
60 O
Gy O
/ O
30 O
fractions O
/ O
40 O
days O
) O
and O
topotecan O
( O
0 O
. O
9 O
mg O
/ O
m O
( O
2 O
) O
/ O
day O
on O
days O
1 O
- O
5 O
on O
weeks O
1 O
, O
3 O
and O
5 O
) O
in O
50 O
adults O
with O
histologically O
proven O
and O
untreated O
GBM B_DISEASE
. O

The O
incidence O
of O
non O
- O
hematological O
toxicities B_DISEASE
was O
low O
and O
grade O
3 O
- O
4 O
hematological O
toxicities B_DISEASE
were O
reported O
in O
20 O
patients O
( O
mainly O
lymphopenia B_DISEASE
and O
neutropenia B_DISEASE
) O
. O

Partial B_DISEASE_ADJECTIVE[DISEASE]
response I_DISEASE_ADJECTIVE[DISEASE]
and O
stabilization B_DISEASE
rates I_DISEASE
were O
2 B_MEASURE
% I_MEASURE
and O
32 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
, O
respectively O
, O
with O
an O
overall B_TIME[MEASURE]
time I_TIME[MEASURE]
to O
progression B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
12 B_TIME[MEASURE]
weeks I_TIME[MEASURE]
. O

One B_NUMBER[MEASURE]
- O
year B_TIME[MEASURE]/B_PERSON
overall I_TIME[MEASURE]/I_PERSON
survival I_TIME[MEASURE]/I_PERSON
( O
OS B_DISEASE
) O
rate B_MEASURE
was O
42 B_DISEASE_ADJECTIVE[DISEASE]
% I_DISEASE_ADJECTIVE[DISEASE]
, O
with O
a O
median B_MEASURE/B_LOCATION
OS I_MEASURE/I_LOCATION
of O
40 B_NUMBER[MEASURE]/B_ENT
weeks I_NUMBER[MEASURE]/I_ENT
. O

Topotecan B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O
combination B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANIZATION
with O
radiotherapy B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
well O
tolerated O
. O

However O
, O
while O
response O
and O
stabilization O
concerned O
one O
- O
third O
of O
the O
patients O
, O
the O
study O
did O
not O
show O
increased O
benefits O
in O
terms O
of O
survival O
in O
patients O
with O
unresectable O
GBM B_DISEASE
. O

Long O
- O
term O
lithium O
therapy O
leading O
to O
hyperparathyroidism B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
: O
a O
case O
report O
. O

Purpose B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
: O
This O
paper B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PRODUCT[OBJECT]
reviews O
the O
effect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
chronic B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
lithium I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
therapy I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
on O
serum B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
calcium I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
level I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
and O
parathyroid B_DISEASE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
glands B_DISEASE/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
its O
pathogenesis B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
options I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

We O
examined O
the O
case O
of O
a O
lithium O
- O
treated O
patient O
who O
had O
recurrent O
hypercalcemia B_DISEASE
to O
better O
understand O
the O
disease O
process O
. O

conclusion O
: O
Primary B_DISEASE
hyperparathyroidism I_DISEASE
is O
a O
rare O
but O
potentially O
life O
- O
threatening O
side O
effect O
of O
long O
- O
term O
lithium O
therapy O
. O

Careful B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
patient B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
selection B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
long B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O
term B_TIME[MEASURE]
follow I_TIME[MEASURE]
- O
up B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
can O
reduce O
morbidity B_DISEASE/B_MEASURE
. O

practical O
implications O
: O
As O
much O
as O
15 O
% O
of O
lithium O
- O
treated O
patients O
become O
hypercalcemic B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
. O

By O
routinely O
monitoring O
serum B_DISEASE
calcium I_DISEASE
levels I_DISEASE
, O
healthcare B_PERSON
providers I_PERSON
can O
improve O
the O
quality B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
life B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
this O
patient B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
group I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O

Comparison B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
laryngeal B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
mask I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
with O
endotracheal B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
tube I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
for O
anesthesia B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
in O
endoscopic B_PERSON/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
sinus I_PERSON/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
surgery I_PERSON/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Background O
: O
The O
purpose O
of O
this O
study O
was O
to O
compare O
surgical O
conditions O
, O
including O
the O
amount O
of O
intraoperative O
bleeding B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
as O
well O
as O
intraoperative O
blood O
pressure O
, O
during O
functional O
endoscopic O
sinus O
surgery O
( O
FESS O
) O
using O
flexible O
reinforced O
laryngeal O
mask O
airway O
( O
FRLMA O
) O
versus O
endotracheal O
tube O
( O
ETT O
) O
in O
maintaining O
controlled O
hypotension B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
anesthesia O
induced O
by O
propofol O
- O
remifentanil O
total O
i O
. O
v O
. O
anesthesia O
( O
TIVA O
) O
. O

methods O
: O
sixty O
normotensive O
American O
Society O
of O
Anesthesiologists O
I O
- O
II O
adult O
patients O
undergoing O
FESS O
under O
controlled O
hypotension B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
anesthesia O
caused O
by O
propofol O
- O
remifentanil O
- O
TIVA O
were O
randomly O
assigned O
into O
two O
groups O
: O
group O
I O
, O
FRLMA O
; O
group O
II O
, O
ETT O
. O

Hemorrhage B_DISEASE
was O
measured O
and O
the O
visibility O
of O
the O
operative O
field O
was O
evaluated O
according O
to O
a O
six O
- O
point O
scale O
. O

Results O
: O
controlled O
hypotension B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O
achieved O
within O
a O
shorter O
period O
using O
laryngeal O
mask O
using O
lower O
rates O
of O
remifentanil O
infusion O
and O
lower O
total O
dose O
of O
remifentanil O
. O

conclusion O
: O
In O
summary O
, O
our O
results O
indicate O
that O
airway O
management O
using O
FRLMA O
during O
controlled O
hypotension B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
anesthesia O
provided O
better O
surgical O
conditions O
in O
terms O
of O
quality O
of O
operative O
field O
and O
blood O
loss O
and O
allowed O
for O
convenient O
induced O
hypotension B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O
low O
doses O
of O
remifentanil O
during O
TIVA O
in O
patients O
undergoing O
FESS O
. O

Nonalcoholic B_DISEASE_ADJECTIVE[DISEASE]
fatty I_DISEASE_ADJECTIVE[DISEASE]
liver I_DISEASE_ADJECTIVE[DISEASE]
disease I_DISEASE_ADJECTIVE[DISEASE]
during O
valproate O
therapy O
. O

Valproic O
acid O
( O
VPA O
) O
is O
effective O
for O
the O
treatment O
of O
many O
types O
of O
epilepsy B_DISEASE
, O
but O
its O
use O
can O
be O
associated O
with O
an O
increase O
in O
body O
weight O
. O

We O
report O
a O
case O
of O
nonalcoholic B_DISEASE
fatty I_DISEASE
liver I_DISEASE
disease I_DISEASE
( O
NAFLD B_DISEASE/B_LOCATION
) O
arising O
in O
a O
child O
who O
developed O
obesity B_DISEASE/B_GENE
during O
VPA O
treatment O
. O

Laboratory O
data O
revealed O
hyperinsulinemia B_DISEASE/B_PERSON
with O
insulin B_DISEASE
resistance I_DISEASE
. O

After O
the O
withdrawal O
of O
VPA O
therapy O
, O
our O
patient O
showed O
a O
significant O
weight B_DISEASE_ADJECTIVE[DISEASE]
loss I_DISEASE_ADJECTIVE[DISEASE]
, O
a O
decrease O
of O
body O
mass O
index O
, O
and O
normalization O
of O
metabolic O
and O
endocrine O
parameters O
; O
Moreover O
, O
ultrasound O
measurements O
showed O
a O
complete O
normalization O
. O

The O
present O
case O
suggests O
that O
obesity B_DISEASE
, O
hyperinsulinemia B_DISEASE
, O
insulin B_DISEASE
resistance I_DISEASE
, O
and O
long O
- O
term O
treatment O
with O
VPA O
may O
be O
all O
associated O
with O
the O
development O
of O
NAFLD B_DISEASE/B_GENE
; O
this O
side O
effect O
is O
reversible O
after O
VPA O
withdrawal O
. O

Carbimazole O
induced O
ANCA B_DISEASE/B_GENE
positive I_DISEASE/I_GENE
vasculitis I_DISEASE/I_GENE
. O

Anti O
- O
thyroid O
drugs O
, O
like O
carbimazole O
and O
propylthiouracil O
( O
PTU O
) O
are O
commonly O
prescribed O
for O
the O
treatment O
of O
hyperthyroidism B_DISEASE/B_LOCATION
. O

One O
should O
be O
aware B_PERSON
of O
the O
side B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
effects I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
of O
antithyroid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
medications I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Antineutrophil B_DISEASE/B_GENE
cytoplasmic I_DISEASE/I_GENE
antibody I_DISEASE/I_GENE
( I_DISEASE/I_GENE
ANCA I_DISEASE/I_GENE
) I_DISEASE/I_GENE
- I_DISEASE/I_GENE
- I_DISEASE/I_GENE
associated I_DISEASE/I_GENE
vasculitis I_DISEASE/I_GENE
is O
a O
potentially O
life O
- O
threatening O
adverse O
effect O
of O
antithyroidmedications O
. O

We O
report O
a O
patient O
with O
Graves B_DISEASE
' I_DISEASE
disease I_DISEASE
who O
developed O
ANCA O
positive O
carbimazole O
induced O
vasculitis B_DISEASE/B_LOCATION
. O

The O
episode O
was O
characterized O
by O
a O
vasculitic B_DISEASE
skin I_DISEASE
rash I_DISEASE
associated O
with O
large O
joint O
arthritis B_DISEASE
, O
pyrexia B_DISEASE
and O
parotiditis B_DISEASE
but O
no O
renal O
or O
pulmonary O
involvement O
. O

He O
was O
referred O
to O
us O
for O
neurological O
evaluation O
because O
he O
had O
difficulty O
in O
getting O
up O
from O
squatting O
position O
and O
was O
suspected O
to O
have O
myositis B_DISEASE
. O

Carbimazole B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
methimazole B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
have O
a O
lower B_MEASURE/B_PERSON
incidence I_MEASURE/I_PERSON
of O
reported O
ANCA B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
positive I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
side I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
than O
Put B_PERSON
. O

To O
the O
best O
of O
our O
knowledge O
this O
is O
the O
first O
ANCA O
positive O
carbimazole O
induced O
vasculitis B_DISEASE
case O
reported O
from O
India O
. O

aspirin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
the O
primary B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
prevention I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
cardiovascular B_DISEASE/B_LOCATION
events I_DISEASE/I_LOCATION
: O
an O
update B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
evidence B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
for O
the O
U B_OTHER/B_LOCATION
. O
S B_OTHER/B_DISEASE
. O

preventive B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
Services I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
Task I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
Force I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
. O

Background O
: O
Coronary B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
heart I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
disease I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
and O
cerebrovascular B_DISEASE
disease I_DISEASE
are O
leading O
causes O
of O
death O
in O
the O
United O
States O
. O

In O
2002 B_MEASURE
, O
the O
U B_OTHER/B_LOCATION
. O
S B_OTHER/B_LOCATION
. O

Preventive O
Services O
Task O
Force O
( O
USPSTF O
) O
strongly O
recommended O
that O
clinicians O
discuss O
aspirin O
with O
adults O
who O
are O
at O
increased O
risk O
for O
coronary B_DISEASE
heart I_DISEASE
disease I_DISEASE
. O

purpose O
: O
To O
determine O
the O
benefits O
and O
harms O
of O
taking O
aspirin O
for O
the O
primary O
prevention O
of O
myocardial B_DISEASE
infarctions I_DISEASE
, O
strokes B_DISEASE
, O
and O
death O
. O

Data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
sources I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
: O
MEDLINE B_ORGANIZATION/B_PERSON
and O
Cochrane B_ORGANIZATION/B_LOCATION
Library I_ORGANIZATION/I_LOCATION
( O
search B_MEASURE/B_LOCATION
dates B_MEASURE/I_LOCATION
, O
1 B_TIME[MEASURE]/B_PERSON
January I_TIME[MEASURE]/I_PERSON
2001 I_TIME[MEASURE]/I_PERSON
to O
28 B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
August I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2008 I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
, O
recent B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
systematic I_ORGANIZATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reviews I_ORGANIZATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
reference B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
lists I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
of O
retrieved O
articles B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
suggestions B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
from O
experts B_PERSON/B_ORGANIZATION
. O

Study O
Selection O
: O
English O
- O
language O
randomized O
, O
controlled O
trials O
( O
RCTs O
) O
; O
case O
- O
control O
studies O
; O
meta O
- O
analyses O
; O
and O
systematic O
reviews O
of O
aspirin O
versus O
control O
for O
the O
primary O
prevention O
of O
cardiovascular B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
disease I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
( O
CVD B_DISEASE/B_LOCATION
) O
were O
selected O
to O
answer O
the O
following O
questions O
: O
Does O
aspirin O
decrease O
coronary O
heart O
events O
, O
strokes B_DISEASE
, O
death O
from O
coronary O
heart O
events O
or O
stroke B_DISEASE
, O
or O
all O
- O
cause O
mortality O
in O
adults O
without O
known O
CVD B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE

Does O
aspirin O
increase O
gastrointestinal B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
bleeding I_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
or O
hemorrhagic B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
strokes I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT

Data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
extraction I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
All O
studies B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
were O
reviewed O
, O
abstracted O
, O
and O
rated O
for O
quality B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
by O
using O
predefined O
USPSTF B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
criteria I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

Data O
synthesis O
: O
New O
evidence O
from O
1 O
good O
- O
quality O
RCT O
, O
1 O
good O
- O
quality O
meta O
- O
analysis O
, O
and O
2 O
fair O
- O
quality O
subanalyses O
of O
RCTs O
demonstrates O
that O
aspirin O
use O
reduces O
the O
number O
of O
CVD B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
events O
in O
patients O
without O
known O
CVD B_DISEASE
. O

Men O
in O
these O
studies O
experienced O
fewer O
myocardial B_DISEASE/B_LOCATION
infarctions I_DISEASE/I_LOCATION
and O
women O
experienced O
fewer O
ischemic O
strokes B_DISEASE
. O

Aspirin O
does O
not O
seem O
to O
affect O
CVD B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
mortality O
or O
all O
- O
cause O
mortality O
in O
either O
men O
or O
women O
. O

The O
use O
of O
aspirin O
for O
primary O
prevention O
increases O
the O
risk O
for O
major O
bleeding B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
events O
, O
primarily O
gastrointestinal B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
bleeding I_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
events O
, O
in O
both O
men O
and O
women O
. O

Men O
have O
an O
increased O
risk O
for O
hemorrhagic B_DISEASE
strokes I_DISEASE
with O
aspirin O
use O
. O

A O
new O
RCT O
and O
meta O
- O
analysis O
suggest O
that O
the O
risk O
for O
hemorrhagic B_DISEASE
strokes I_DISEASE
in O
women O
is O
not O
statistically O
significantly O
increased O
. O

limitations O
: O
New O
evidence O
on O
aspirin O
for O
the O
primary O
prevention O
of O
CVD B_DISEASE/B_LOCATION
is O
limited O
. O

The O
dose B_MEASURE
of O
aspirin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
used O
in O
the O
RCTs B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
varied O
, O
which O
prevented O
the O
estimation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
of O
the O
most O
appropriate B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
dose B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
for O
primary B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
prevention I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_PERSON
. O

Several B_NUMBER[MEASURE]
of O
the O
RCTs B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
conducted O
within O
populations B_LOCATION/B_ORGANIZATION
of O
health B_PERSON/B_LOCATION
professionals I_PERSON/I_LOCATION
, O
which O
potentially O
limits O
generalizability B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O

conclusion O
: O
Aspirin O
reduces O
the O
risk O
for O
myocardial B_DISEASE
infarction I_DISEASE
in O
men O
and O
strokes B_DISEASE/B_LOCATION
in O
women O
. O

Aspirin O
use O
increases O
the O
risk O
for O
serious O
bleeding B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
events O
. O

reducing O
harm O
associated O
with O
anticoagulation O
: O
practical O
considerations O
of O
argatroban O
therapy O
in O
heparin O
- O
induced O
thrombocytopenia B_DISEASE
. O

Argatroban O
is O
a O
hepatically O
metabolized O
, O
direct O
thrombin O
inhibitor O
used O
for O
prophylaxis O
or O
treatment O
of O
thrombosis B_DISEASE
in O
heparin O
- O
induced O
thrombocytopenia B_DISEASE
( O
HIT B_DISEASE
) O
and O
for O
patients O
with O
or O
at O
risk O
of O
HIT B_DISEASE/B_LOCATION
undergoing O
percutaneous O
coronary O
intervention O
( O
PCI O
) O
. O

The O
objective O
of O
this O
review O
is O
to O
summarize O
practical O
considerations O
of O
argatroban O
therapy O
in O
HIT B_DISEASE/B_GENE
. O

The O
US O
FDA O
- O
recommended O
argatroban O
dose O
in O
HIT B_GENE/B_DISEASE
is O
2 O
microg O
/ O
kg O
/ O
min O
( O
reduced O
in O
patients O
with O
hepatic B_DISEASE/B_GENE
impairment I_DISEASE/I_GENE
and O
in O
paediatric O
patients O
) O
, O
adjusted O
to O
achieve O
activated O
partial O
thromboplastin O
times O
( O
aPTTs O
) O
1 O
. O
5 O
- O
3 O
times O
baseline O
( O
not O
> O
100 O
seconds O
) O
. O

Contemporary O
experiences O
indicate O
that O
reduced O
doses O
are O
also O
needed O
in O
patients O
with O
conditions O
associated O
with O
hepatic O
hypoperfusion O
, O
e O
. O
g O
. O
heart B_DISEASE
failure I_DISEASE
, O
yet O
are O
unnecessary O
for O
renal B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
dysfunction B_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
, O
adult O
age O
, O
sex O
, O
race O
/ O
ethnicity O
or O
obesity B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Argatroban B_MEASURE/B_LOCATION
0 I_MEASURE/I_LOCATION
. O
5 B_MEASURE
- O
1 B_MEASURE
. O
2 B_MEASURE
microg I_MEASURE
/ O
kg B_MEASURE/B_LOCATION
/ O
min B_TIME[MEASURE]/B_PERSON
typically O
supports O
therapeutic B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
aPTTs I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
FDA B_ORGANIZATION/B_TIME[MEASURE]
- O
recommended O
dose B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
during O
PCI B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
is O
25 B_MEASURE
microg I_MEASURE
/ O
kg B_MEASURE
/ O
min B_PERSON/B_TIME[MEASURE]
( O
350 B_MEASURE
microg I_MEASURE
/ O
kg B_MEASURE
initial I_MEASURE
bolus I_MEASURE
) O
, O
adjusted O
to O
achieve O
activated O
clotting B_TIME[MEASURE]/B_LOCATION
times B_TIME[MEASURE]/I_LOCATION
( O
acts B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
) O
of O
300 B_MEASURE
- O
450 B_MEASURE
SEC I_MEASURE
. O

For O
PCI O
, O
argatroban O
has O
not O
been O
investigated O
in O
hepatically O
impaired O
patients O
; O
dose O
adjustment O
is O
unnecessary O
for O
adult O
age O
, O
sex O
, O
race O
/ O
ethnicity O
or O
obesity B_DISEASE/B_PERSON
, O
and O
lesser O
doses O
may O
be O
adequate O
with O
concurrent O
glycoprotein O
IIb O
/ O
IIIa O
inhibition O
. O

Argatroban B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
prolongs O
the O
International B_MEASURE/B_LOCATION
Normalized I_MEASURE
ratio I_MEASURE
, O
and O
published O
approaches B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
for O
monitoring O
the O
argatroban B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
- O
to O
- O
warfarin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
transition I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
should O
be O
followed O
. O

Major O
bleeding B_DISEASE
with O
argatroban O
is O
0 O
- O
10 O
% O
in O
the O
non O
- O
interventional O
setting O
and O
0 O
- O
5 O
. O
8 O
% O
periprocedurally O
. O

Argatroban B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
has O
no O
specific B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
antidote I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
, O
and O
if O
excessive B_DISEASE
anticoagulation I_DISEASE
occurs O
, O
argatroban B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
infusion I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
should O
be O
stopped O
or O
reduced O
. O

improved O
familiarity O
of O
healthcare O
professionals O
with O
argatroban O
therapy O
in O
HIT B_DISEASE/B_GENE
, O
including O
in O
special O
populations O
and O
during O
PCI O
, O
may O
facilitate O
reduction O
of O
harm O
associated O
with O
HIT B_DISEASE
( O
e O
. O
g O
. O
fewer O
thromboses O
) O
or O
its O
treatment O
( O
e O
. O
g O
. O
fewer O
argatroban O
medication O
errors O
) O
. O

Rhabdomyolysis B_DISEASE
and O
brain O
ischemic B_DISEASE
stroke I_DISEASE
in O
a O
heroin O
- O
dependent O
male O
under O
methadone O
maintenance O
therapy O
. O

objective O
: O
There O
are O
several O
complications O
associated O
with O
heroin B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
abuse I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
, O
some O
of O
which O
are O
life O
- O
threatening O
. O

methadone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
may O
aggravate O
this O
problem B_DISEASE
. O

Method B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
A O
clinical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
case I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
description I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Results O
: O
A O
33 O
- O
year O
- O
old O
man O
presented O
with O
rhabdomyolysis B_DISEASE
and O
cerebral O
ischemic B_DISEASE
stroke I_DISEASE
after O
intravenous O
heroin O
. O

He O
had O
used O
heroin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
since O
age B_TIME[MEASURE]
20 I_TIME[MEASURE]
, O
and O
had O
used O
150 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mg I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
methadone I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
daily O
for O
6 B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
months I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

He O
was O
found O
unconsciousness B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
at O
home O
and O
was O
sent O
to O
our O
hospital O
. O

In O
the O
ER B_LOCATION
, O
his O
opiate B_MEASURE/B_LOCATION
level I_MEASURE/I_LOCATION
was O
4497 B_MEASURE/B_PERSON
ng I_MEASURE/I_PERSON
/ O
ml B_MEASURE/B_PERSON
. O

In O
the O
ICU O
, O
we O
found O
rhabdomyolysis B_DISEASE
, O
acute B_DISEASE
renal I_DISEASE
failure I_DISEASE
and O
acute O
respiratory B_DISEASE
failure I_DISEASE
. O

After O
transfer O
to O
an O
internal O
ward O
, O
we O
noted O
aphasia B_DISEASE
and O
weakness B_DISEASE
of O
his O
left O
limbs O
. O

After O
MRI O
, O
we O
found O
cerebral B_DISEASE_ADJECTIVE[DISEASE]
ischemic I_DISEASE_ADJECTIVE[DISEASE]
infarction I_DISEASE_ADJECTIVE[DISEASE]
. O

conclusion O
: O
Those O
using O
methadone O
and O
heroin O
simultaneously O
may O
increase O
risk O
of O
rhabdomyolysis B_DISEASE
and O
ischemic B_DISEASE
stroke I_DISEASE
. O

patients B_PERSON/B_BIO
under O
methadone B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
maintenance I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
therapy I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
should O
be O
warned O
regarding O
these O
serious B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
adverse I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
events I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Hypotheses O
of O
heroin O
- O
related O
rhabdomyolysis B_DISEASE
and O
stroke B_DISEASE
in O
heroin O
abusers O
are O
discussed O
. O

increased O
vulnerability O
to O
6 O
- O
hydroxydopamine O
lesion O
and O
reduced O
development O
of O
dyskinesias B_DISEASE
in O
mice O
lacking O
CB1 O
cannabinoid O
receptors O
. O

Motor B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
impairment I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
, O
dopamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O
DA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O
neuronal B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
activity B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
and O
proenkephalin B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
( O
PENK B_LOCATION/B_GENE
) O
gene B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
expression I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
in O
the O
caudate B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
- O
putamen B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
( O
CPu B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
were O
measured O
in O
6 B_MEASURE/B_LOCATION
- O
OHDA B_TIME[MEASURE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
lesioned O
and O
treated O
( O
L B_PROTEIN[GENE]
- O
DOPA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
+ I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
benserazide I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
) O
CB1 B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
KO I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
WT B_LOCATION/B_PERSON
mice I_LOCATION/I_PERSON
. O

A O
lesion B_DISEASE/B_GENE
induced O
by O
6 B_MEASURE/B_LOCATION
- O
OHDA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
produced O
more O
severe B_DISEASE_ADJECTIVE[DISEASE]
motor I_DISEASE_ADJECTIVE[DISEASE]
deterioration I_DISEASE_ADJECTIVE[DISEASE]
in O
CB1 B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
KO I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mice I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
accompanied O
by O
more B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
loss I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
DA B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
neurons I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
and O
increased O
PENK B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
gene I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
expression I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
the O
CPu B_BODY_PART_OR_ORGAN_COMPONENT/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Oxidative B_DISEASE_ADJECTIVE[DISEASE]
/ O
nitrosative B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
and O
neuroinflammatory B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
parameters I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
were O
estimated O
in O
the O
CPu B_BODY_PART_OR_ORGAN_COMPONENT/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
cingulate B_PERSON/B_LOCATION
cortex I_PERSON/I_LOCATION
( O
cG B_DISEASE/B_LOCATION
) O
. O

CB1 B_PERSON/B_PROTEIN[GENE]
Ko I_PERSON/I_PROTEIN[GENE]
mice I_PERSON/I_PROTEIN[GENE]
exhibited O
higher B_DISEASE/B_GENE
MDA B_DISEASE/I_GENE
levels B_DISEASE/I_GENE
and O
iNOS B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
protein I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
expression I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
in O
the O
CPu B_BODY_PART_OR_ORGAN_COMPONENT/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
cG B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
compared O
to O
WT B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mice I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Treatment O
with O
L O
- O
DOPA O
+ O
benserazide O
( O
12 O
weeks O
) O
resulted O
in O
less O
severe O
dyskinesias B_DISEASE
in O
CB1 O
Ko O
than O
in O
WT O
mice O
. O

The O
results O
revealed O
that O
the O
lack O
of O
cannabinoid O
CB1 O
receptors O
increased O
the O
severity O
of O
motor O
impairment O
and O
Da O
lesion O
, O
and O
reduced O
L O
- O
DOPA O
- O
induced O
dyskinesias B_DISEASE
. O

These O
results O
suggest O
that O
activation O
of O
CB1 O
receptors O
offers O
neuroprotection O
against O
dopaminergic O
lesion O
and O
the O
development O
of O
L O
- O
DOPA O
- O
induced O
dyskinesias B_DISEASE
. O

Hepatocellular O
oxidant O
stress O
following O
intestinal O
ischemia B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
- O
reperfusion B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
injury B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Reperfusion O
of O
ischemic B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
intestine O
results O
in O
acute O
liver B_DISEASE
dysfunction I_DISEASE
characterized O
by O
hepatocellular O
enzyme O
release O
into O
plasma O
, O
reduction O
in O
bile O
flow O
rate O
, O
and O
neutrophil O
sequestration O
within O
the O
liver O
. O

The O
pathophysiology O
underlying O
this O
acute O
hepatic B_DISEASE_ADJECTIVE[DISEASE]
injury I_DISEASE_ADJECTIVE[DISEASE]
is O
unknown O
. O

This O
study O
was O
undertaken O
to O
determine O
whether O
oxidants O
are O
associated O
with O
the O
hepatic B_DISEASE_ADJECTIVE[DISEASE]
injury I_DISEASE_ADJECTIVE[DISEASE]
and O
to O
determine O
the O
relative O
value O
of O
several O
indirect O
methods O
of O
assessing O
oxidant O
exposure O
in O
vivo O
. O

rats O
were O
subjected O
to O
a O
standardized O
intestinal O
ischemia B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
- O
reperfusion B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
injury B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Hepatic B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
tissue I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
was O
assayed O
for O
lipid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
peroxidation I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
products I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
oxidized O
and O
reduced B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
glutathione I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

There O
was O
no O
change O
in O
hepatic O
tissue O
total O
glutathione O
following O
intestinal O
ischemia B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
- O
reperfusion B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
injury B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Oxidized B_TIME[MEASURE]/B_PERSON
glutathione I_TIME[MEASURE]/I_PERSON
( O
GSSG B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
) O
increased O
significantly O
following O
30 B_MEASURE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
60 B_TIME[MEASURE]
min I_TIME[MEASURE]
of O
reperfusion B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O

There O
was O
no O
increase B_DISEASE_ADJECTIVE[DISEASE]
in O
any O
of O
the O
products B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
lipid B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
peroxidation B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
associated O
with O
this O
injury B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O

An O
increase B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
GSSG B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
within O
hepatic B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
tissue I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
during O
intestinal B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
reperfusion I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
suggests O
exposure B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O
hepatocytes B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
to O
an O
oxidant B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stress B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
lack B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O
a O
significant B_DISEASE_ADJECTIVE[DISEASE]
increase I_DISEASE_ADJECTIVE[DISEASE]
in O
products B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
lipid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
peroxidation I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
suggests O
that O
the O
oxidant B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
stress B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
is O
of O
insufficient B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
magnitude I_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
result O
in O
irreversible B_DISEASE
injury I_DISEASE
to O
hepatocyte B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cell I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
membranes I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O

These O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
also O
suggest O
that O
the O
measurement B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
tissue B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
GSSG I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
may O
be O
a O
more O
sensitive B_MEASURE/B_PERSON
indicator B_MEASURE/I_PERSON
of O
oxidant B_DISEASE
stress I_DISEASE
than O
measurement B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
products B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
lipid B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
peroxidation B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Animal O
model O
of O
mania B_DISEASE
induced O
by O
ouabain O
: O
Evidence O
of O
oxidative O
stress O
in O
submitochondrial O
particles O
of O
the O
rat O
brain O
. O

The O
intracerebroventricular O
( O
ICV O
) O
administration O
of O
ouabain O
( O
a O
Na O
( O
+ O
) O
/ O
K O
( O
+ O
) O
- O
ATPase O
inhibitor O
) O
in O
rats O
has O
been O
suggested O
to O
mimic O
some O
symptoms O
of O
human O
bipolar B_DISEASE
mania I_DISEASE
. O

Clinical O
studies O
have O
shown O
that O
bipolar B_DISEASE/B_GENE
disorder I_DISEASE/I_GENE
may O
be O
related O
to O
mitochondrial B_DISEASE
dysfunction I_DISEASE
. O

Herein O
, O
we O
investigated O
the O
behavioral B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
biochemical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
induced O
by O
the O
ICV B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
administration I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
of O
ouabain B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
rats B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

To O
achieve O
this O
aim B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O
the O
effects B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
ouabain B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
injection I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
immediately O
after O
and O
7 B_TIME[MEASURE]
days I_TIME[MEASURE]
following O
a O
single B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ICV I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
administration I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
at O
concentrations B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
10 B_MEASURE
( O
- O
2 B_MEASURE
) O
and O
10 B_MEASURE
( O
- O
3 B_MEASURE
) O
M B_MEASURE/B_OTHER
) O
on O
locomotion B_DISEASE
was O
measured O
using O
the O
open B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
field B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
test B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

Additionally O
, O
thiobarbituric B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acid B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reactive B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
substances B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
TBARSs B_DISEASE
) O
and O
superoxide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
production I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
were O
measured O
in O
submitochondrial B_LOCATION/B_BIO
particles I_LOCATION/I_BIO
of O
the O
prefrontal B_BODY_PART_OR_ORGAN_COMPONENT
cortex I_BODY_PART_OR_ORGAN_COMPONENT
, O
hippocampus B_BODY_PART_OR_ORGAN_COMPONENT
, O
striatum B_BODY_PART_OR_ORGAN_COMPONENT
and O
amygdala B_BODY_PART_OR_ORGAN_COMPONENT
. O

Our O
findings O
demonstrated O
that O
ouabain O
at O
10 O
( O
- O
2 O
) O
and O
10 O
( O
- O
3 O
) O
M O
induced O
hyperlocomotion B_DISEASE
in O
rats O
, O
and O
this O
response O
remained O
up O
to O
7 O
days O
following O
a O
single O
ICV O
injection O
. O

In O
addition B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
we O
observed O
that O
the O
persistent B_DISEASE_ADJECTIVE[DISEASE]
increase I_DISEASE_ADJECTIVE[DISEASE]
in O
the O
rat B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
spontaneous B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
locomotion B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
is O
associated O
with O
increased O
TBARS B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
levels I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
superoxide B_DISEASE_ADJECTIVE[DISEASE]
generation I_DISEASE_ADJECTIVE[DISEASE]
in O
submitochondrial B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
particles I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
in O
the O
prefrontal B_BODY_PART_OR_ORGAN_COMPONENT
cortex I_BODY_PART_OR_ORGAN_COMPONENT
, O
striatum B_BODY_PART_OR_ORGAN_COMPONENT
and O
amygdala B_BODY_PART_OR_ORGAN_COMPONENT
. O

In O
conclusion O
, O
ouabain O
- O
induced O
mania B_DISEASE
- O
like O
behavior O
may O
provide O
a O
useful O
animal O
model O
to O
test O
the O
hypothesis O
of O
the O
involvement O
of O
oxidative O
stress O
in O
bipolar B_DISEASE
disorder I_DISEASE
. O

Intraoperative B_DISEASE_ADJECTIVE[DISEASE]
dialysis I_DISEASE_ADJECTIVE[DISEASE]
during O
liver B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
transplantation I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O
citrate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
dialysate I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O

liver O
transplantation O
for O
acutely O
ill O
patients O
with O
fulminant B_DISEASE
liver I_DISEASE
failure I_DISEASE
carries O
high O
intraoperative O
and O
immediate O
postoperative O
risks O
. O

These O
are O
increased O
with O
the O
presence O
of O
concomitant O
acute B_DISEASE
kidney I_DISEASE
injury I_DISEASE
( O
AKI B_DISEASE
) O
and O
intraoperative O
dialysis O
is O
sometimes O
required O
to O
allow O
the O
transplant O
to O
proceed O
. O

The O
derangements O
in O
the O
procoagulant O
and O
anticoagulant O
pathways O
during O
fulminant B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
liver B_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
failure B_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
can O
lead O
to O
difficulties O
with O
anticoagulation O
during O
dialysis O
, O
especially O
when O
continued O
in O
the O
operating O
room O
. O

systemic O
anticoagulation O
is O
unsafe O
and O
regional O
citrate O
anticoagulation O
in O
the O
absence O
of O
a O
functional O
liver O
carries O
the O
risk O
of O
citrate O
toxicity B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Citrate B_MEASURE/B_LOCATION
dialysate I_MEASURE/I_LOCATION
, O
a O
new B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
dialysate I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
with O
citric B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
acid I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
can O
be O
used O
for O
anticoagulation B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
patients B_PERSON/B_BIO
who O
cannot O
tolerate O
heparin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
or O
regional B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
citrate I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

We O
report O
a O
case O
of O
a O
40 O
- O
year O
- O
old O
female O
with O
acetaminophen O
- O
induced O
fulminant B_DISEASE
liver I_DISEASE
failure I_DISEASE
with O
associated O
AKI B_DISEASE
who O
underwent O
intraoperative O
dialytic O
support O
during O
liver O
transplantation O
anticoagulated O
with O
citrate O
dialysate O
during O
the O
entire O
procedure O
. O

The O
patient O
tolerated O
the O
procedure O
well O
without O
any O
signs O
of O
citrate O
toxicity B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
maintained O
adequate O
anticoagulation O
for O
patency O
of O
the O
dialysis O
circuit O
. O

Citrate O
dialysate O
is O
a O
safe O
alternative O
for O
intradialytic O
support O
of O
liver O
transplantation O
in O
fulminant B_DISEASE_ADJECTIVE[DISEASE]/B_SPECIES[BIO]
liver B_DISEASE_ADJECTIVE[DISEASE]/I_SPECIES[BIO]
failure B_DISEASE_ADJECTIVE[DISEASE]/I_SPECIES[BIO]
. O

Delirium B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
a O
patient O
with O
toxic O
flecainide O
plasma O
concentrations O
: O
the O
role O
of O
a O
pharmacokinetic O
drug O
interaction O
with O
paroxetine O
. O

objective O
: O
To O
describe O
a O
case O
of O
flecainide O
- O
induced O
delirium B_DISEASE
associated O
with O
a O
pharmacokinetic O
drug O
interaction O
with O
paroxetine O
. O

Case O
summary O
: O
A O
69 O
- O
year O
- O
old O
white O
female O
presented O
to O
the O
emergency O
department O
with O
a O
history O
of O
confusion B_DISEASE
and O
paranoia B_DISEASE
over O
the O
past O
several O
days O
. O

On O
admission B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
the O
patient B_PERSON/B_ORGANIZATION
was O
taking O
carvedilol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
12 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mg I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
twice O
daily O
, O
warfarin B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mg I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
day B_TIME[MEASURE]
, O
folic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
acid I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
1 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
mg I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
/ O
day B_TIME[MEASURE]
, O
levothyroxine B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
100 I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
microg I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
day B_TIME[MEASURE]
, O
pantoprazole B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
40 I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mg I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
day B_TIME[MEASURE]
, O
paroxetine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
40 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
mg I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
/ O
day B_TIME[MEASURE]
, O
and O
flecainide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
100 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mg I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
twice O
daily O
. O

Flecainide O
had O
been O
started O
2 O
weeks O
prior O
for O
atrial B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fibrillation B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Laboratory B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
test I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
findings I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
admission B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
were O
notable B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
only O
for O
a O
flecainide B_MEASURE
plasma I_MEASURE
concentration I_MEASURE
of O
1360 B_MEASURE/B_LOCATION
microg I_MEASURE/I_LOCATION
/ O
L B_OTHER/B_MEASURE
( O
reference B_MEASURE
range I_MEASURE
200 I_MEASURE
- O
1000 B_MEASURE
) O
. O

A O
metabolic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
drug I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
interaction I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
between O
flecainide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
paroxetine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
which O
the O
patient B_PERSON/B_BIO
had O
been O
taking O
for O
more B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
than O
5 B_TIME[MEASURE]
years I_TIME[MEASURE]
, O
was O
considered O
. O

Paroxetine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
discontinued O
and O
the O
dose B_MEASURE/B_DISEASE
of O
flecainide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
reduced O
to O
50 B_NUMBER[MEASURE]/B_LOCATION
mg I_NUMBER[MEASURE]/I_LOCATION
twice O
daily O
. O

Her O
delirium B_DISEASE
resolved O
3 O
days O
later O
. O

discussion O
: O
Flecainide O
and O
pharmacologically O
similar O
agents O
that O
interact O
with O
sodium O
channels O
may O
cause O
delirium B_DISEASE
in O
susceptible O
patients O
. O

A O
MEDLINE O
search O
( O
1966 O
- O
January O
2009 O
) O
revealed O
one O
in O
vivo O
pharmacokinetic O
study O
on O
the O
interaction O
between O
flecainide O
, O
a O
CYP2D6 O
substrate O
, O
and O
paroxetine O
, O
a O
CYP2D6 O
inhibitor O
, O
as O
well O
as O
3 O
case O
reports O
of O
flecainide O
- O
induced O
delirium B_DISEASE
. O

According O
to O
the O
Naranjo O
probability O
scale O
, O
flecainide O
was O
the O
probable O
cause O
of O
the O
patient O
' O
s O
delirium B_DISEASE
; O
the O
Horn O
Drug O
interaction O
probability O
Scale O
indicates O
a O
possible O
pharmacokinetic O
drug O
interaction O
between O
flecainide O
and O
paroxetine O
. O

conclusions O
: O
Supratherapeutic O
flecainide O
plasma O
concentrations O
may O
cause O
delirium B_DISEASE
. O

Because O
toxicity B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
may O
occur O
when O
flecainide O
is O
prescribed O
with O
paroxetine O
and O
other O
potent O
CYP2D6 O
inhibitors O
, O
flecainide O
plasma O
concentrations O
should O
be O
monitored O
closely O
with O
commencement O
of O
CYP2D6 O
inhibitors O
. O

efficacy O
of O
everolimus O
( O
RAD001 O
) O
in O
patients O
with O
advanced O
NSCLC B_DISEASE/B_GENE
previously O
treated O
with O
chemotherapy O
alone O
or O
with O
chemotherapy O
and O
EGFR O
inhibitors O
. O

Background O
: O
Treatment O
options O
are O
scarce O
in O
pretreated O
advanced O
non B_DISEASE
- I_DISEASE
small I_DISEASE
- I_DISEASE
cell I_DISEASE
lung I_DISEASE
cancer I_DISEASE
( O
NSCLC B_DISEASE
) O
patients O
. O

RAD001 O
, O
an O
oral O
inhibitor O
of O
the O
mammalian O
target O
of O
rapamycin O
( O
mTOR O
) O
, O
has O
shown O
phase O
I O
efficacy O
in O
NSCLC B_DISEASE
. O

methods O
: O
Stage O
IIIb O
or O
IV O
NSCLC B_DISEASE/B_LOCATION
patients O
, O
with O
two O
or O
fewer O
prior O
chemotherapy O
regimens O
, O
one O
platinum O
based O
( O
stratum O
1 O
) O
or O
both O
chemotherapy O
and O
epidermal O
growth O
factor O
receptor O
tyrosine O
kinase O
inhibitors O
( O
stratum O
2 O
) O
, O
received O
RAD001 O
10 O
mg O
/ O
day O
until O
progression O
or O
unacceptable O
toxicity B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Primary B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
objective I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
was O
overall B_DISEASE
response I_DISEASE
rate I_DISEASE
( O
ORR B_DISEASE/B_LOCATION
) O
. O

analyses O
of O
markers O
associated O
with O
the O
mTOR O
pathway O
were O
carried O
out O
on O
archival O
tumor B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
from O
a O
subgroup O
using O
immunohistochemistry O
( O
IHC O
) O
and O
direct O
mutation O
sequencing O
. O

Results B_MEASURE
: O
eighty B_NUMBER[MEASURE]
- O
five B_NUMBER[MEASURE]
patients I_NUMBER[MEASURE]
were O
enrolled O
, O
42 B_MEASURE
in O
stratum B_PERSON/B_LOCATION
1 B_PERSON/I_LOCATION
and O
43 B_MEASURE
in O
stratum B_LOCATION/B_PERSON
. O

ORR B_DISEASE/B_PERSON
was O
4 B_MEASURE
. O
7 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
( O
7 B_MEASURE
. O
1 B_MEASURE
% I_MEASURE
stratum I_MEASURE
1 I_MEASURE
; O
2 B_MEASURE
. O
3 B_MEASURE
% I_MEASURE
stratum I_MEASURE
2 I_MEASURE
) O
. O

Overall B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
disease I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
control I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
rate I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
was O
47 B_MEASURE
. O
1 B_MEASURE
% I_MEASURE
. O

median B_TIME[MEASURE]/B_PERSON
progression I_TIME[MEASURE]/I_PERSON
- O
free B_TIME[MEASURE]/B_ORGANIZATION
survivals I_TIME[MEASURE]/I_ORGANIZATION
( O
PFSs B_DISEASE
) O
were O
2 B_MEASURE
. O
6 B_MEASURE
( O
stratum B_TIME[MEASURE]/B_PERSON
1 I_TIME[MEASURE]/I_PERSON
) O
and O
2 B_MEASURE
. O
7 B_TIME[MEASURE]
months I_TIME[MEASURE]
( O
stratum B_PERSON
2 I_PERSON
) O
. O

Common O
> O
or O
= O
grade O
3 O
events O
were O
fatigue B_DISEASE
, O
dyspnea B_DISEASE
, O
stomatitis B_DISEASE
, O
anemia B_DISEASE
, O
and O
thrombocytopenia B_DISEASE
. O

Pneumonitis B_DISEASE
, O
probably O
or O
possibly O
related O
, O
mainly O
grade O
1 O
/ O
2 O
, O
occurred O
in O
25 O
% O
. O

Cox B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
regression I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
IHC B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
scores I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
found O
that O
only O
phospho B_GENE
AKT I_GENE
( O
pAKT B_PROTEIN[GENE]/B_LOCATION
) O
was O
a O
significant B_MEASURE
independent I_MEASURE
predictor I_MEASURE
of O
worse B_DISEASE
PFS I_DISEASE
. O

conclusions O
: O
RAD001 O
10 O
mg O
/ O
day O
was O
well O
tolerated O
, O
showing O
modest O
clinical O
activity O
in O
pretreated O
NSCLC B_DISEASE/B_LOCATION
. O

Evaluation O
of O
RAD001 O
plus O
standard O
therapy O
for O
metastatic O
NSCLC B_DISEASE/B_LOCATION
continues O
. O

Posttransplant O
anemia B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
: O
the O
role O
of O
sirolimus O
. O

Posttransplant O
anemia B_DISEASE
is O
a O
common O
problem O
that O
may O
hinder O
patients O
' O
quality O
of O
life O
. O

It O
occurs O
in O
12 B_MEASURE
to O
76 B_NUMBER[MEASURE]/B_LOCATION
% I_NUMBER[MEASURE]/I_LOCATION
of O
patients B_PERSON/B_DISEASE
, O
and O
is O
most O
common B_DISEASE_ADJECTIVE[DISEASE]
in O
the O
immediate B_TIME[MEASURE]/B_BODY_PART_OR_ORGAN_COMPONENT
posttransplant I_TIME[MEASURE]/I_BODY_PART_OR_ORGAN_COMPONENT
period I_TIME[MEASURE]/I_BODY_PART_OR_ORGAN_COMPONENT
. O

A O
variety O
of O
factors O
have O
been O
identified O
that O
increase O
the O
risk O
of O
posttransplant O
anemia B_DISEASE
, O
of O
which O
the O
level O
of O
renal O
function O
is O
most O
important O
. O

Sirolimus O
, O
a O
mammalian O
target O
of O
rapamycin O
inhibitor O
, O
has O
been O
implicated O
as O
playing O
a O
special O
role O
in O
posttransplant O
anemia B_DISEASE
. O

This O
review O
considers O
anemia B_DISEASE
associated O
with O
sirolimus O
, O
including O
its O
presentation O
, O
mechanisms O
, O
and O
management O
. O

Coronary O
computerized O
tomography O
angiography O
for O
rapid O
discharge O
of O
low O
- O
risk O
patients O
with O
cocaine O
- O
associated O
chest B_DISEASE/B_LOCATION
pain I_DISEASE/I_LOCATION
. O

Background O
: O
Most O
patients O
presenting O
to O
emergency O
departments O
( O
eds O
) O
with O
cocaine O
- O
associated O
chest B_DISEASE/B_LOCATION
pain I_DISEASE/I_LOCATION
are O
admitted O
for O
at O
least O
12 O
hours O
and O
receive O
a O
' O
rule O
out O
acute B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
coronary B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
syndrome B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
' O
protocol O
, O
often O
with O
noninvasive O
testing O
prior O
to O
discharge O
. O

In O
patients B_PERSON/B_LOCATION
without O
cocaine B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
use I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
coronary B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
computerized I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
tomography I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
angiography I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
CTA B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
) O
has O
been O
shown O
to O
be O
useful B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
identifying O
a O
group B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
patients B_PERSON
at O
low B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
risk I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
for O
cardiac B_DISEASE/B_LOCATION
events I_DISEASE/I_LOCATION
who O
can O
be O
safely O
discharged O
. O

It O
is O
unclear O
whether O
a O
coronary O
CTA O
strategy O
would O
be O
efficacious O
in O
cocaine O
- O
associated O
chest B_DISEASE/B_LOCATION
pain I_DISEASE/I_LOCATION
, O
as O
coronary B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
vasospasm B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
may O
account O
for O
some O
of O
the O
ischemia B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

We O
studied O
whether O
a O
negative O
coronary O
CTA O
in O
patients O
with O
cocaine O
- O
associated O
chest B_DISEASE/B_LOCATION
pain I_DISEASE/I_LOCATION
could O
identify O
a O
subset O
safe O
for O
discharge O
. O

methods O
: O
We O
prospectively O
evaluated O
the O
safety O
of O
coronary O
CTA O
for O
low O
- O
risk O
patients O
who O
presented O
to O
the O
Ed O
with O
cocaineassociated O
chest B_DISEASE
pain I_DISEASE
( O
self O
- O
reported O
or O
positive O
urine O
test O
) O
. O

consecutive B_PERSON
patients I_PERSON
received O
either O
immediate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
coronary I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
CTA I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
in O
the O
ED B_DISEASE/B_TIME[MEASURE]
( O
without O
serial B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
markers B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
or O
underwent O
coronary B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
CTA I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
after O
a O
brief B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
observation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
period B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
with O
serial B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
cardiac I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
marker I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
measurements I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O

patients O
with O
negative O
coronary O
CTA O
( O
maximal O
stenosis B_DISEASE/B_MEASURE
less O
than O
50 O
% O
) O
were O
discharged O
. O

The O
main O
outcome O
was O
30 O
- O
day O
cardiovascular O
death O
or O
myocardial B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
infarction B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Results O
: O
A O
total O
of O
59 O
patients O
with O
cocaine O
- O
associated O
chest B_DISEASE
pain I_DISEASE
were O
evaluated O
. O

patients B_PERSON
had O
a O
mean B_MEASURE/B_DISEASE
age I_MEASURE/I_DISEASE
of O
45 B_MEASURE
. O
6 B_MEASURE
+ I_MEASURE
/ O
- O
6 B_MEASURE
. O
6 B_TIME[MEASURE]
yrs I_TIME[MEASURE]
and O
were O
86 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
black I_MEASURE/I_PERSON
, O
66 B_PERSON/B_LOCATION
% B_PERSON/I_LOCATION
male B_PERSON/I_LOCATION
. O

seventy B_NUMBER[MEASURE]
- O
nine B_NUMBER[MEASURE]
percent I_NUMBER[MEASURE]
had O
a O
normal B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O
nonspecific B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
ECG I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
and O
85 B_NUMBER[MEASURE]/B_PERSON
% I_NUMBER[MEASURE]/I_PERSON
had O
a O
TIMI B_MEASURE/B_LOCATION
score I_MEASURE/I_LOCATION
< O
2 B_MEASURE
. O

Twenty B_NUMBER[MEASURE]/B_PERSON
patients I_NUMBER[MEASURE]/I_PERSON
received O
coronary B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
CTA I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
immediately O
in O
the O
Ed B_PERSON/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
18 B_NUMBER[MEASURE]
of O
whom O
were O
discharged O
following O
CTA B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
( O
90 B_NUMBER[MEASURE]/B_LOCATION
% I_NUMBER[MEASURE]/I_LOCATION
) O
. O

Thirty B_NUMBER[MEASURE]
- O
nine B_NUMBER[MEASURE]
received O
coronary B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
CTA I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
after O
a O
brief B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
observation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
period B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
, O
with O
37 B_NUMBER[MEASURE]
discharged O
home B_LOCATION/B_PERSON
following O
CTA B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
( O
95 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
. O

Six O
patients O
had O
coronary B_DISEASE
stenosis I_DISEASE
> O
or O
= O
50 O
% O
. O

During O
the O
30 O
- O
day O
follow O
- O
up O
period O
, O
no O
patients O
died O
of O
a O
cardiovascular O
event O
( O
0 O
% O
; O
95 O
% O
CI O
, O
0 O
- O
6 O
. O
1 O
% O
) O
and O
no O
patient O
sustained O
a O
nonfatal O
myocardial B_DISEASE
infarction I_DISEASE
( O
0 O
% O
; O
95 O
% O
CI O
, O
0 O
- O
6 O
. O
1 O
% O
) O
. O

conclusions O
: O
Although O
cocaine O
- O
associated O
myocardial B_DISEASE/B_LOCATION
ischemia I_DISEASE/I_LOCATION
can O
result O
from O
coronary O
vasoconstriction O
, O
patients O
with O
cocaine O
associated O
chest B_DISEASE/B_LOCATION
pain I_DISEASE/I_LOCATION
, O
a O
non O
- O
ischemic B_DISEASE_ADJECTIVE[DISEASE]
ECG O
, O
and O
a O
TIMI O
risk O
score O
< O
2 O
may O
be O
safely O
discharged O
from O
the O
Ed O
after O
a O
negative O
coronary O
CTA O
with O
a O
low O
risk O
of O
30 O
- O
day O
adverse O
events O
. O

bilateral O
haemorrhagic B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
infarction I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
of I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
the I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
globus I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
pallidus I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
after O
cocaine O
and O
alcohol O
intoxication O
. O

cocaine O
is O
a O
risk O
factor O
for O
both O
ischemic B_DISEASE_ADJECTIVE[DISEASE]
and I_DISEASE_ADJECTIVE[DISEASE]
haemorrhagic I_DISEASE_ADJECTIVE[DISEASE]
stroke I_DISEASE_ADJECTIVE[DISEASE]
. O

We O
present O
the O
case O
of O
a O
31 O
- O
year O
- O
old O
man O
with O
bilateral O
ischemia B_DISEASE
of I_DISEASE
the I_DISEASE
globus I_DISEASE
pallidus I_DISEASE
after O
excessive O
alcohol O
and O
intranasal O
cocaine O
use O
. O

Drug O
- O
related O
globus B_DISEASE_ADJECTIVE[DISEASE]
pallidus I_DISEASE_ADJECTIVE[DISEASE]
infarctions I_DISEASE_ADJECTIVE[DISEASE]
are O
most O
often O
associated O
with O
heroin O
. O

bilateral O
basal B_DISEASE_ADJECTIVE[DISEASE]
ganglia I_DISEASE_ADJECTIVE[DISEASE]
infarcts I_DISEASE_ADJECTIVE[DISEASE]
after O
the O
use O
of O
cocaine O
, O
without O
concurrent O
heroin O
use O
, O
have O
never O
been O
reported O
. O

In O
our O
patient O
, O
transient O
cardiac B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
arrhythmia I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
or O
respiratory B_DISEASE
dysfunction I_DISEASE
related O
to O
cocaine O
and O
/ O
or O
ethanol O
use O
were O
the O
most O
likely O
causes O
of O
cerebral B_DISEASE
hypoperfusion I_DISEASE
. O

Late O
fulminant O
posterior B_DISEASE
reversible I_DISEASE
encephalopathy I_DISEASE
syndrome I_DISEASE
after O
liver O
transplant O
. O

objectives O
: O
Posterior B_DISEASE
leukoencephalopathy I_DISEASE
due O
to O
calcineurin O
- O
inhibitor O
- O
related O
neurotoxicity B_DISEASE
is O
a O
rare O
but O
severe O
complication O
that O
results O
from O
treatment O
with O
immunosuppressive O
agents O
( O
primarily O
those O
administered O
after O
a O
liver O
or O
kidney O
transplant O
) O
. O

The O
pathophysiologic B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mechanisms B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
that O
disorder B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
remain O
unknown B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
. O

Case O
: O
We O
report O
the O
case O
of O
a O
46 O
- O
year O
- O
old O
woman O
who O
received O
a O
liver O
transplant O
in O
our O
center O
as O
treatment O
for O
alcoholic B_DISEASE/B_GENE
cirrhosis I_DISEASE/I_GENE
and O
in O
whom O
either O
a O
fulminant O
course O
of O
posterior B_DISEASE
leukoencephalopathy I_DISEASE
or O
posterior B_DISEASE
reversible I_DISEASE
encephalopathy I_DISEASE
syndrome I_DISEASE
developed O
110 O
days O
after O
transplant O
. O

After O
an O
initially O
uneventful B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_TIME[MEASURE]
course B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_TIME[MEASURE]
after O
the O
transplant B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
, O
the O
patient B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
rapidly O
fell O
into O
deep B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
coma I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

RESULTS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
: O
Cerebral B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
MRI I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
scan I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
showed O
typical B_DISEASE/B_LOCATION
signs B_DISEASE/I_LOCATION
of O
enhancement B_DISEASE
in O
the O
pontine B_BODY_PART_OR_ORGAN_COMPONENT/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
posterior B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
regions I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O

switching O
the O
immunosuppressive B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
regimen I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
from O
tacrolimus B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
cyclosporine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
did O
not O
improve O
the O
clinical B_DISEASE_ADJECTIVE[DISEASE]
situation I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
termination B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O
treatment B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
with O
any O
calcineurin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
inhibitor I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
resulted O
in O
a O
complete B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
resolution B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
that O
complication B_DISEASE
. O

conclusions O
: O
Posterior B_DISEASE
reversible I_DISEASE
encephalopathy I_DISEASE
syndrome I_DISEASE
after O
liver O
transplant O
is O
rare O
. O

We O
recommend O
a O
complete B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
cessation I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
any O
calcineurin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
inhibitor I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
rather O
than O
a O
dose B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
reduction I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O

prolonged O
hypothermia B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
as O
a O
bridge O
to O
recovery O
for O
cerebral B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
edema I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
and O
intracranial B_DISEASE
hypertension I_DISEASE
associated O
with O
fulminant B_DISEASE
hepatic I_DISEASE
failure I_DISEASE
. O

Background O
: O
To O
review O
evidence O
- O
based O
treatment O
options O
in O
patients O
with O
cerebral B_DISEASE/B_GENE
edema I_DISEASE/I_GENE
complicating O
fulminant B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
hepatic I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
failure I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O
FHF B_LOCATION/B_PROTEIN[GENE]
) O
and O
discuss O
the O
potential O
applications O
of O
hypothermia B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O

Method O
: O
Case O
- O
based O
observations O
from O
a O
medical O
intensive O
care O
unit O
( O
MICU O
) O
in O
a O
tertiary O
care O
facility O
in O
a O
27 O
- O
year O
- O
old O
female O
with O
FHF B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
from O
acetaminophen O
and O
resultant O
cerebral B_DISEASE_ADJECTIVE[DISEASE]
edema I_DISEASE_ADJECTIVE[DISEASE]
. O

Results O
: O
Our O
patient O
was O
admitted O
to O
the O
MICU O
after O
being O
found O
unresponsive O
with O
presumed O
toxicity B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O
acetaminophen O
which O
was O
ingested O
over O
a O
2 O
- O
day O
period O
. O

The O
patient B_PERSON
had O
depressed O
of O
mental B_DISEASE
status I_DISEASE
lasting O
at O
least O
24 B_TIME[MEASURE]/B_PERSON
h I_TIME[MEASURE]/I_PERSON
prior I_TIME[MEASURE]/I_PERSON
to O
admission B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O

Initial O
evaluation O
confirmed O
FHF B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
from O
acetaminophen O
and O
cerebral B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
edema I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
patient O
was O
treated O
with O
hyperosmolar O
therapy O
, O
hyperventilation B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O
sedation O
, O
and O
chemical O
paralysis B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Her O
intracranial B_GENE
pressure I_GENE
remained O
elevated O
despite O
maximal B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
medical I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
therapy I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

We O
then O
initiated O
therapeutic O
hypothermia B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
which O
was O
continued O
for O
5 O
days O
. O

At O
re O
- O
warming O
, O
patient O
had O
resolution O
of O
her O
cerebral B_DISEASE
edema I_DISEASE
and O
intracranial B_DISEASE
hypertension I_DISEASE
. O

At O
discharge B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
she O
had O
complete B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
recovery I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
neurological B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
and O
hepatic B_DISEASE_ADJECTIVE[DISEASE]/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
functions B_DISEASE_ADJECTIVE[DISEASE]/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

conclusion O
: O
In O
patients O
with O
FHF B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
and O
cerebral B_DISEASE
edema I_DISEASE
from O
acetaminophen O
overdose B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
prolonged O
therapeutic O
hypothermia B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
could O
potentially O
be O
used O
as O
a O
life O
saving O
therapy O
and O
a O
bridge O
to O
hepatic O
and O
neurological O
recovery O
. O

A O
clinical O
trial O
of O
hypothermia B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
patients O
with O
this O
condition O
is O
warranted O
. O

Binasal B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
visual I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
field I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
defects I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
are O
not O
specific O
to O
vigabatrin O
. O

This O
study O
investigated O
the O
visual B_DISEASE_ADJECTIVE[DISEASE]
defects I_DISEASE_ADJECTIVE[DISEASE]
associated O
with O
the O
antiepileptic O
drug O
vigabatrin O
( O
VGB O
) O
. O

Two O
hundred O
four O
people O
with O
epilepsy B_DISEASE
were O
grouped O
on O
the O
basis O
of O
antiepileptic O
drug O
therapy O
( O
current O
, O
previous O
, O
or O
no O
exposure O
to O
VGB O
) O
. O

Groups O
were O
matched O
with O
respect O
to O
age O
, O
gender O
, O
and O
seizure B_DISEASE
frequency O
. O

All O
patients B_PERSON
underwent O
objective B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
assessment I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
electrophysiological B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
function I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
wide B_NUMBER[MEASURE]/B_LOCATION
- O
field B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
multifocal B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
electroretinography B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
) O
and O
conventional B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
visual B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
field B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
testing B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
( O
static B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
perimetry I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
) O
. O

Bilateral B_DISEASE
visual I_DISEASE
field I_DISEASE
constriction I_DISEASE
was O
observed O
in O
59 B_PERSON/B_MEASURE
% B_PERSON/I_MEASURE
of O
patients B_PERSON
currently O
taking O
VGB B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
43 B_PERSON/B_MEASURE
% B_PERSON/I_MEASURE
of O
patients B_PERSON
who O
previously O
took O
VGB B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
24 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
of O
patients B_PERSON
with O
no O
exposure B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
to O
VGB B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O

Assessment B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
retinal B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
function B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
revealed O
abnormal B_DISEASE
responses I_DISEASE
in O
48 B_NUMBER[MEASURE]/B_PERSON
% I_NUMBER[MEASURE]/I_PERSON
of O
current B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
VGB B_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
users B_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
and O
22 B_NUMBER[MEASURE]/B_PERSON
% I_NUMBER[MEASURE]/I_PERSON
of O
prior B_PERSON/B_ORGANIZATION
VGB I_PERSON/I_ORGANIZATION
users I_PERSON/I_ORGANIZATION
, O
but O
in O
none B_PERSON/B_MEASURE
of O
the O
patients B_PERSON/B_LOCATION
without O
previous B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
exposure I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
to O
VGB B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O

Bilateral B_DISEASE_ADJECTIVE[DISEASE]
visual I_DISEASE_ADJECTIVE[DISEASE]
field I_DISEASE_ADJECTIVE[DISEASE]
abnormalities I_DISEASE_ADJECTIVE[DISEASE]
are O
common O
in O
the O
treated O
epilepsy B_DISEASE/B_PERSON
population O
, O
irrespective O
of O
drug O
history O
. O

Assessment O
by O
conventional O
static O
perimetry O
may O
neither O
be O
sufficiently O
sensitive O
nor O
specific O
to O
reliably O
identify O
retinal B_DISEASE_ADJECTIVE[DISEASE]
toxicity I_DISEASE_ADJECTIVE[DISEASE]
associated O
with O
VGB O
. O

smoking O
of O
crack O
cocaine O
as O
a O
risk O
factor O
for O
HIV B_DISEASE
infection I_DISEASE
among O
people O
who O
use O
injection O
drugs O
. O

Background O
: O
Little O
is O
known O
about O
the O
possible O
role O
that O
smoking O
crack O
cocaine O
has O
on O
the O
incidence O
of O
HIV B_DISEASE
infection I_DISEASE
. O

Given O
the O
increasing O
use O
of O
crack O
cocaine O
, O
we O
sought O
to O
examine O
whether O
use O
of O
this O
illicit O
drug O
has O
become O
a O
risk O
factor O
for O
HIV B_DISEASE
infection I_DISEASE
. O

METHODS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O
We O
included O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
from O
people B_PERSON
participating O
in O
the O
Vancouver B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
Injection I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
Drug I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
users I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
Study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
who O
reported O
injecting O
illicit B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
drugs I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O
least O
once O
in O
the O
month B_TIME[MEASURE]/B_LOCATION
before O
enrolment B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O
lived O
in O
the O
greater B_LOCATION
Vancouver I_LOCATION
area I_LOCATION
, O
were O
HIV B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
negative B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O
enrolment B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
completed O
at O
least O
1 B_NUMBER[MEASURE]/B_PERSON
follow O
- O
up O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
visit I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

To O
determine O
whether O
the O
risk O
of O
HIV B_DISEASE
seroconversion I_DISEASE
among O
daily O
smokers O
of O
crack O
cocaine O
changed O
over O
time O
, O
we O
used O
Cox O
proportional O
hazards O
regression O
and O
divided O
the O
study O
into O
3 O
periods O
: O
May O
1 O
, O
1996 O
- O
Nov O
. O

30 B_MEASURE
, O
1999 B_MEASURE
( O
period B_TIME[MEASURE]/B_LOCATION
1 I_TIME[MEASURE]/I_LOCATION
) O
, O
Dec B_LOCATION/B_GENE
. O

1 B_TIME[MEASURE]
, O
1999 B_TIME[MEASURE]
- O
Nov B_LOCATION/B_TIME[MEASURE]
. O

30 B_MEASURE
, O
2002 B_TIME[MEASURE]
( O
period B_TIME[MEASURE]/B_LOCATION
2 I_TIME[MEASURE]/I_LOCATION
) O
, O
and O
Dec B_TIME[MEASURE]/B_LOCATION
. O

1 B_TIME[MEASURE]
, O
2002 B_TIME[MEASURE]
- O
Dec B_TIME[MEASURE]
. O

30 B_TIME[MEASURE]/B_LOCATION
, O
2005 B_MEASURE
( O
period B_TIME[MEASURE]
3 I_TIME[MEASURE]
) O
. O

RESULTS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O
Overall O
, O
1048 B_NUMBER[MEASURE]/B_PERSON
eligible I_NUMBER[MEASURE]/I_PERSON
injection I_NUMBER[MEASURE]/I_PERSON
drug I_NUMBER[MEASURE]/I_PERSON
users I_NUMBER[MEASURE]/I_PERSON
were O
included O
in O
our O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Of O
these O
, O
137 O
acquired O
HIV B_DISEASE/B_GENE
infection I_DISEASE/I_GENE
during O
follow O
- O
up O
. O

The O
mean B_MEASURE/B_PERSON
proportion I_MEASURE/I_PERSON
of O
participants B_PERSON
who O
reported O
daily B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
smoking I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
of O
crack B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
cocaine I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
increased O
from O
11 B_MEASURE
. O
6 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
in O
period B_TIME[MEASURE]
1 I_TIME[MEASURE]
to O
39 B_MEASURE
. O
7 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
in O
period B_TIME[MEASURE]/B_PERSON
3 I_TIME[MEASURE]/I_PERSON
. O

After O
adjusting O
for O
potential O
confounders O
, O
we O
found O
that O
the O
risk O
of O
HIV B_DISEASE/B_LOCATION
seroconversion I_DISEASE/I_LOCATION
among O
participants O
who O
were O
daily O
smokers O
of O
crack O
cocaine O
increased O
over O
time O
( O
period O
1 O
: O
hazard O
ratio O
[ O
HR O
] O
1 O
. O
03 O
, O
95 O
% O
confidence O
interval O
[ O
CI O
] O
0 O
. O
57 O
- O
1 O
. O
85 O
; O
period O
2 O
: O
HR O
1 O
. O
68 O
, O
95 O
% O
CI O
1 O
. O
01 O
- O
2 O
. O
80 O
; O
and O
period O
3 O
: O
HR O
2 O
. O
74 O
, O
95 O
% O
CI O
1 O
. O
06 O
- O
7 O
. O
11 O
) O
. O

interpretation O
: O
smoking O
of O
crack O
cocaine O
was O
found O
to O
be O
an O
independent O
risk O
factor O
for O
HIV B_DISEASE/B_LOCATION
seroconversion I_DISEASE/I_LOCATION
among O
people O
who O
were O
injection O
drug O
users O
. O

This O
finding B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
points O
to O
the O
urgent B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
need I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
for O
evidence B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
- O
based O
public B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
health I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
initiatives I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
targeted O
at O
people B_PERSON
who O
smoke O
crack B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
cocaine I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

Fluoxetine O
improves O
the O
memory B_DISEASE
deficits I_DISEASE
caused O
by O
the O
chemotherapy O
agent O
5 O
- O
fluorouracil O
. O

Cancer B_DISEASE
patients O
who O
have O
been O
treated O
with O
systemic O
adjuvant O
chemotherapy O
have O
described O
experiencing O
deteriorations O
in O
cognition O
. O

A O
widely O
used O
chemotherapeutic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
agent I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
5 B_MEASURE
- O
fluorouracil B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
5 B_MEASURE/B_PERSON
- O
FU B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O
, O
readily O
crosses O
the O
blood B_BODY_PART_OR_ORGAN_COMPONENT
- O
brain B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
barrier B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
and O
so O
could O
have O
a O
direct B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
effect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
on O
brain B_DISEASE
function I_DISEASE
. O

In O
particular B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
this O
anti B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
mitotic I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
drug I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
could O
reduce O
cell B_DISEASE
proliferation I_DISEASE
in O
the O
neurogenic B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
regions I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
of O
the O
adult B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
brain I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O

In O
contrast B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
reports I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
indicate O
that O
hippocampal B_DISEASE
dependent I_DISEASE
neurogenesis I_DISEASE
and O
cognition B_DISEASE/B_ORGANISM_FUNCTION
are O
enhanced O
by O
the O
SSRI B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
antidepressant I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
fluoxetine I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
. O

In O
this O
investigation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
the O
behavioural B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
chronic B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
( O
two B_TIME[MEASURE]
week I_TIME[MEASURE]
) O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O
5 B_NUMBER[MEASURE]
- O
FU B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
and O
( O
three B_TIME[MEASURE]/B_ENT
weeks I_TIME[MEASURE]/I_ENT
) O
with O
fluoxetine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
either O
separately O
or O
in O
combination B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
with O
5 B_NUMBER[MEASURE]
- O
FU B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
tested O
on O
adult B_PERSON/B_SPECIES[BIO]
Lister I_PERSON/I_SPECIES[BIO]
hooded I_PERSON/I_SPECIES[BIO]
rats I_PERSON/I_SPECIES[BIO]
. O

behavioural B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
effects I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
were O
tested O
using O
a O
context B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
dependent I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
conditioned O
emotional B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
response I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
test I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
CER B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
which O
showed O
that O
animals B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treated O
with O
5 B_MEASURE/B_PERSON
- O
FU B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
had O
a O
significant B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
reduction I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O
freezing O
time B_MEASURE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
compared O
to O
controls B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O

A O
separate B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
group I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
animals B_BIO/B_PERSON
was O
tested O
using O
a O
hippocampal B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
dependent I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
spatial I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
working O
memory B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
test I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
the O
object B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
location I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
recognition I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
test I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O
OLR B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
. O

Animals B_BIO/B_PERSON
treated O
only O
with O
5 B_MEASURE/B_PERSON
- O
FU B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
showed O
significant B_DISEASE_ADJECTIVE[DISEASE]
deficits I_DISEASE_ADJECTIVE[DISEASE]
in O
their O
ability B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O
carry O
out O
the O
OLR B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
task I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
but O
co B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
administration I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_LOCATION
of O
fluoxetine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
improved O
their O
performance B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O

5 B_MEASURE/B_PERSON
- O
FU B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
chemotherapy B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
caused O
a O
significant B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
reduction I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O
the O
number B_MEASURE/B_ORGANISM_FUNCTION
of O
proliferating O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
in O
the O
sub B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
granular I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
zone I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
of O
the O
dentate B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
gyrus I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
compared O
to O
controls B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O

This O
reduction B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
eliminated O
when O
fluoxetine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
co B_LOCATION/B_TIME[MEASURE]
administered O
with O
5 B_MEASURE/B_PERSON
- O
FU B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
. O

fluoxetine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
on O
its O
own B_PERSON
had O
no O
effect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
proliferating O
cell B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
number B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O
behaviour B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
. O

These O
findings B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggest O
that O
5 B_TIME[MEASURE]/B_LOCATION
- O
FU B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
can O
negatively O
affect O
both O
cell B_BODY_PART_OR_ORGAN_COMPONENT/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
proliferation I_BODY_PART_OR_ORGAN_COMPONENT/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
hippocampal O
dependent B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
working O
memory B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
and O
that O
these O
deficits B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
can O
be O
reversed O
by O
the O
simultaneous B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
administration I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
of O
the O
antidepressant B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fluoxetine I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

liver O
- O
specific O
ablation O
of O
integrin O
- O
linked O
kinase O
in O
mice O
results O
in O
enhanced O
and O
prolonged O
cell O
proliferation O
and O
hepatomegaly B_DISEASE_ADJECTIVE[DISEASE]
after O
phenobarbital O
administration O
. O

We O
have O
recently O
demonstrated O
that O
disruption B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
extracellular B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
matrix I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
( O
ECM B_PROTEIN[GENE]/B_LOCATION
) O
/ O
integrin B_GENE
signaling O
via O
elimination B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
integrin B_GENE
- O
linked O
kinase B_ENZYME[GENE]/B_LOCATION
( O
ILK B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
) O
in O
hepatocytes B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
interferes O
with O
signals B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
leading O
to O
termination B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
of O
liver B_DISEASE/B_ORGANISM_FUNCTION
regeneration B_DISEASE/I_ORGANISM_FUNCTION
. O

This O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
investigates O
the O
role B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
ILK B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
in O
liver B_DISEASE
enlargement I_DISEASE
induced O
by O
phenobarbital B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
( O
PB B_PROTEIN[GENE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
) O
. O

Wild B_PERSON/B_BIO
- O
type B_MEASURE/B_DISEASE
( O
WT B_PROTEIN[GENE]/B_LOCATION
) O
and O
ILK B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
: O
liver B_DISEASE/B_MEASURE
- O
/ B_PERSON/B_PROTEIN[GENE]
- O
mice B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
given O
PB B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
( O
0 B_MEASURE
. O
1 B_MEASURE
% I_MEASURE
in O
drinking B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
water I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
) O
for O
10 B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
days B_TIME[MEASURE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Livers B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
harvested O
on O
2 B_NUMBER[MEASURE]
, O
5 B_NUMBER[MEASURE]
, O
and O
10 B_SEQUENCE[MEASURE]/B_ENT
days I_SEQUENCE[MEASURE]/I_ENT
during O
PB B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
administration I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANISM_FUNCTION
. O

In O
the O
hepatocyte B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
- O
specific B_DISEASE_ADJECTIVE[DISEASE]
ILK I_DISEASE_ADJECTIVE[DISEASE]
/ O
liver B_GENE/B_DISEASE
- O
/ B_GENE
- O
mice B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPECIES[BIO]
, O
the O
liver B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
: O
body B_MEASURE
weight I_MEASURE
ratio I_MEASURE
was O
more B_MEASURE
than O
double O
as O
compared O
to O
0 B_MEASURE
h O
at O
day B_TIME[MEASURE]/B_PERSON
2 I_TIME[MEASURE]/I_PERSON
( O
2 B_MEASURE
. O
5 B_TIME[MEASURE]
times I_TIME[MEASURE]
) O
, O
while O
at O
days B_TIME[MEASURE]
5 I_TIME[MEASURE]
and O
10 B_NUMBER[MEASURE]
, O
it O
was O
enlarged O
three B_TIME[MEASURE]
times I_TIME[MEASURE]
. O

In O
the O
WT B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
mice I_BODY_PART_OR_ORGAN_COMPONENT/I_BIO
, O
the O
increase B_DISEASE/B_MEASURE
was O
as O
expected O
from O
previous B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
literature I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O
1 B_MEASURE
. O
8 B_TIME[MEASURE]
times I_TIME[MEASURE]
) O
and O
seems O
to O
have O
leveled O
off O
after O
day B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
2 I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANISM_FUNCTION
. O

There O
were O
slightly O
increased O
proliferating O
cell B_GENE
nuclear I_GENE
antigen I_GENE
- O
positive B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
cells I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
the O
ILK B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
/ O
liver B_GENE/B_DISEASE
- O
/ B_PERSON/B_PROTEIN[GENE]
- O
animals B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O
day B_TIME[MEASURE]/B_DISEASE
2 I_TIME[MEASURE]/I_DISEASE
as O
compared O
to O
WT B_MEASURE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
after O
PB B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
administration I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
. O

In O
the O
WT B_LOCATION/B_ORGANIZATION
animals I_LOCATION/I_ORGANIZATION
, O
the O
proliferative B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
response I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
had O
come O
back O
to O
normal B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O
days B_TIME[MEASURE]
5 I_TIME[MEASURE]
and O
10 B_NUMBER[MEASURE]
. O

hepatocytes B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
of O
the O
ILK B_DISEASE/B_PROTEIN[GENE]
/ O
liver B_GENE/B_DISEASE
- O
/ B_PERSON/B_PROTEIN[GENE]
- O
mice B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
continued O
to O
proliferate O
up O
until O
day B_DISEASE/B_ORGANISM_FUNCTION
10 I_DISEASE/I_ORGANISM_FUNCTION
. O

ILK B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
/ O
liver B_GENE/B_DISEASE
- O
/ B_DISEASE/B_GENE
- O
mice B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
also O
showed O
increased B_GENE_EXPRESSION_ADJECTIVE[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
expression I_GENE_EXPRESSION_ADJECTIVE[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
key B_GENE
genes I_GENE
involved O
in O
hepatocyte B_DISEASE
proliferation I_DISEASE
at O
different B_TIME[MEASURE]/B_LOCATION
time I_TIME[MEASURE]/I_LOCATION
points I_TIME[MEASURE]/I_LOCATION
during O
PB B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
administration I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

In O
summary B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
ECM B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
proteins I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
communicate O
with O
the O
signaling O
machinery B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
dividing O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
via O
ILK B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
to O
regulate O
hepatocyte B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
proliferation B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
termination B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
of O
the O
proliferative B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
response B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

Lack B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
of O
ILK B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
in O
the O
hepatocytes B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
imparts B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
prolonged O
proliferative B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
response I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
not O
only O
to O
stimuli O
related O
to O
liver B_DISEASE
regeneration I_DISEASE
but O
also O
to O
xenobiotic B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
chemical I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mitogens I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
such B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O
PB B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O

decreased O
expression O
of O
Na O
/ O
K O
- O
ATPase O
, O
NHE3 O
, O
NBC1 O
, O
AQP1 O
and O
OAT O
in O
Gentamicin O
- O
induced O
Nephropathy B_DISEASE/B_GENE
. O

The O
present O
study O
was O
aimed O
to O
determine O
whether O
there O
is O
an O
altered O
regulation O
of O
tubular O
transporters O
in O
gentamicin O
- O
induced O
nephropathy B_DISEASE
. O

Sprague B_PERSON
- O
Dawley B_SPECIES[BIO]/B_PERSON
male I_SPECIES[BIO]/I_PERSON
rats I_SPECIES[BIO]/I_PERSON
( O
200 B_MEASURE/B_PERSON
~ O
250 B_MEASURE
g I_MEASURE
) O
were O
subcutaneously O
injected O
with O
gentamicin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
( O
100 B_MEASURE
mg I_MEASURE
/ O
kg B_MEASURE
per O
day B_TIME[MEASURE]/B_BIO
) O
for O
7 B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
days B_TIME[MEASURE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
and O
the O
expression B_GENE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
tubular B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
transporters I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O
determined O
by O
immunoblotting O
and O
immunohistochemistry B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
mRNA B_GENE
and O
protein B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
expression B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
of O
OAT B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
also O
determined O
. O

gentamicin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
treated O
rats B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
exhibited O
significantly O
decreased O
creatinine B_MEASURE/B_DISEASE
clearance B_MEASURE/I_DISEASE
along O
with O
increased O
plasma B_DISEASE/B_GENE
creatinine I_DISEASE/I_GENE
levels I_DISEASE/I_GENE
. O

Accordingly O
, O
the O
fractional B_MEASURE/B_LOCATION
excretion I_MEASURE/I_LOCATION
of O
sodium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
increased O
. O

urine B_MEASURE/B_PERSON
volume I_MEASURE/I_PERSON
was O
increased O
, O
while O
urine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
osmolality I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
and O
free B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
water I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
reabsorption I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
were O
decreased O
. O

immunoblotting B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O
immunohistochemistry B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
revealed O
decreased B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
expression B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
Na B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O
+ B_PROTEIN[GENE]/B_DISEASE
) O
/ O
K B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O
+ O
) O
- O
ATPase B_PROTEIN[GENE]/B_LOCATION
, O
NHE3 B_GENE
, O
NBC1 B_GENE
, O
and O
AQP1 B_GENE
in O
the O
kidney B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
of O
gentamicin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
treated O
rats B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
expression B_GENE/B_MEASURE
of O
OAT1 B_GENE
and O
OAT3 B_GENE
was O
also O
decreased O
. O

Gentamicin O
- O
induced O
nephropathy B_DISEASE
may O
at O
least O
in O
part O
be O
causally O
related O
with O
a O
decreased O
expression O
of O
Na O
( O
+ O
) O
/ O
K O
( O
+ O
) O
- O
ATPase O
, O
NHE3 O
, O
NBC1 O
, O
AQP1 O
and O
OAT O
. O

Acute B_DISEASE_ADJECTIVE[DISEASE]
renal I_DISEASE_ADJECTIVE[DISEASE]
failure I_DISEASE_ADJECTIVE[DISEASE]
after O
high O
- O
dose O
methotrexate O
therapy O
in O
a O
patient O
with O
ileostomy O
. O

High O
- O
dose O
methotrexate O
( O
HD O
- O
MTX O
) O
is O
an O
important O
treatment O
for O
Burkitt B_DISEASE/B_LOCATION
lymphoma I_DISEASE/I_LOCATION
, O
but O
can O
cause O
hepatic B_DISEASE
and I_DISEASE
renal I_DISEASE
toxicity I_DISEASE
when O
its O
clearance O
is O
delayed O
. O

We O
report O
a O
case O
of O
acute B_DISEASE
renal I_DISEASE
failure I_DISEASE
after O
HD O
- O
MTX O
therapy O
in O
a O
patient O
with O
ileostomy O
, O
The O
patient O
was O
a O
3 O
- O
year O
- O
old O
boy O
who O
had O
received O
a O
living O
- O
related O
liver O
transplantation O
for O
congenital O
biliary B_DISEASE
atresia I_DISEASE
. O

At O
day O
833 O
after O
the O
transplantation O
, O
he O
was O
diagnosed O
with O
PTLD B_DISEASE
( O
post B_DISEASE/B_GENE
- I_DISEASE/I_GENE
transplantation I_DISEASE/I_GENE
lymphoproliferative I_DISEASE/I_GENE
disorder I_DISEASE/I_GENE
, O
Burkitt B_DISEASE/B_GENE
- I_DISEASE/I_GENE
type I_DISEASE/I_GENE
malignant I_DISEASE/I_GENE
lymphoma I_DISEASE/I_GENE
) O
. O

During O
induction B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
therapy I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
he O
suffered O
ileal B_DISEASE
perforation I_DISEASE
and O
ileostomy B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
was O
performed O
. O

Subsequent O
HD O
- O
MTX O
therapy O
caused O
acute B_DISEASE
renal I_DISEASE
failure I_DISEASE
that O
required O
continuous O
hemodialysis O
. O

We O
supposed O
that O
intravascular O
hypovolemia B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
due O
to O
substantial O
drainage O
from O
the O
ileostoma O
caused O
acute B_DISEASE
prerenal I_DISEASE
failure I_DISEASE
. O

After O
recovery B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
his O
renal B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
function I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
we O
could O
safely O
treat O
the O
patient B_PERSON/B_DISEASE
with O
HD B_DISEASE/B_PROTEIN[GENE]
- O
MTX B_TIME[MEASURE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy I_TIME[MEASURE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O
controlling O
drainage B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
from O
ileostoma B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
with O
total B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
parenteral I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
nutrition I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
. O

longitudinal O
association O
of O
alcohol O
use O
with O
HIV B_DISEASE
disease I_DISEASE
progression O
and O
psychological O
health O
of O
women O
with O
HIV O
. O

We O
evaluated O
the O
association O
of O
alcohol O
consumption O
and O
depression B_DISEASE
, O
and O
their O
effects O
on O
HIV B_DISEASE
disease I_DISEASE
progression O
among O
women O
with O
HIV O
. O

The O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
included O
871 B_PERSON
women I_PERSON
with O
HIV B_DISEASE/B_LOCATION
who O
were O
recruited O
from O
1993 B_MEASURE
- O
1995 B_MEASURE
in O
four B_LOCATION
US I_LOCATION
cities I_LOCATION
. O

The O
participants O
had O
physical O
examination O
, O
medical O
record O
extraction O
, O
and O
venipuncture O
, O
CD4 O
+ O
T O
- O
cell O
counts O
determination O
, O
measurement O
of O
depression B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
symptoms O
( O
using O
the O
self O
- O
report O
Center O
for O
Epidemiological O
Studies O
- O
Depression B_TIME[MEASURE]/B_DISEASE
Scale O
) O
, O
and O
alcohol O
use O
assessment O
at O
enrollment O
, O
and O
semiannually O
until O
March O
2000 O
. O

Multilevel B_TIME[MEASURE]/B_ORGANIZATION
random I_TIME[MEASURE]/I_ORGANIZATION
coefficient I_TIME[MEASURE]/I_ORGANIZATION
ordinal I_TIME[MEASURE]/I_ORGANIZATION
models I_TIME[MEASURE]/I_ORGANIZATION
as O
well O
as O
multilevel B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
models I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
with O
joint B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
responses I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
used O
in O
the O
analysis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

There O
was O
no O
significant B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
association I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
between O
level B_MEASURE
of O
alcohol B_DISEASE_ADJECTIVE[DISEASE]
use I_DISEASE_ADJECTIVE[DISEASE]
and O
CD4 B_GENE/B_MEASURE
+ I_GENE/I_MEASURE
T I_GENE/I_MEASURE
- O
cell B_MEASURE
counts I_MEASURE
. O

When O
participants B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
stratified O
by O
antiretroviral B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
therapy I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
( O
ART B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
) O
use B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
, O
the O
association B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O
alcohol B_DISEASE
and O
CD4 B_GENE
+ I_GENE
T I_GENE
- O
cell B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_MEASURE
did O
not O
reach O
statistical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
significance I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
association O
between O
alcohol O
consumption O
and O
depression B_DISEASE/B_GENE
was O
significant O
( O
p O
< O
0 O
. O
001 O
) O
. O

Depression B_TIME[MEASURE]/B_DISEASE
had O
a O
significant O
negative O
effect O
on O
CD4 O
+ O
T O
- O
cell O
counts O
over O
time O
regardless O
of O
Art O
use O
. O

Our O
findings O
suggest O
that O
alcohol O
consumption O
has O
a O
direct O
association O
with O
depression B_DISEASE/B_LOCATION
. O

Moreover O
, O
depression B_DISEASE/B_GENE
is O
associated O
with O
HIV B_DISEASE
disease I_DISEASE
progression O
. O

Our O
findings B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
have O
implications B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
for O
the O
provision B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
of O
alcohol B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_EDU[ORGANIZATION]
use I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_EDU[ORGANIZATION]
interventions I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_EDU[ORGANIZATION]
and O
psychological B_ORGANIZATION/B_DISEASE_ADJECTIVE[DISEASE]
resources I_ORGANIZATION/I_DISEASE_ADJECTIVE[DISEASE]
to O
improve O
the O
health B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
women B_PERSON/B_LOCATION
with O
HIV B_DISEASE/B_LOCATION
. O

Chemokine O
CCL2 O
and O
its O
receptor O
CCR2 O
are O
increased O
in O
the O
hippocampus O
following O
pilocarpine O
- O
induced O
status B_DISEASE
epilepticus I_DISEASE
. O

Background O
: O
Neuroinflammation B_DISEASE/B_GENE
occurs O
after O
seizures B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
is O
implicated O
in O
epileptogenesis O
. O

CCR2 O
is O
a O
chemokine O
receptor O
for O
CCL2 O
and O
their O
interaction O
mediates O
monocyte O
infiltration O
in O
the O
neuroinflammatory B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
Cascade O
triggered O
in O
different O
brain O
pathologies O
. O

In O
this O
work O
CCR2 O
and O
CCL2 O
expression O
were O
examined O
following O
status B_DISEASE
epilepticus I_DISEASE
( O
SE B_DISEASE/B_LOCATION
) O
induced O
by O
pilocarpine O
injection O
. O

methods O
: O
SE B_DISEASE/B_PROTEIN[GENE]
was O
induced O
by O
pilocarpine O
injection O
. O

Control B_PERSON
rats I_PERSON
were O
injected O
with O
saline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
instead O
of O
pilocarpine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Five O
days O
after O
SE B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
CCR2 O
staining O
in O
neurons O
and O
glial O
cells O
was O
examined O
using O
imunohistochemical O
analyses O
. O

The O
number B_MEASURE/B_LOCATION
of O
CCR2 B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
positive I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
was O
determined O
using O
stereology B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
probes I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
in O
the O
hippocampus B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
. O

CCL2 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
expression I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O
the O
hippocampus B_BODY_PART_OR_ORGAN_COMPONENT
was O
examined O
by O
molecular B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
assay I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Results O
: O
increased O
CCR2 O
was O
observed O
in O
the O
hippocampus O
after O
SE B_DISEASE
. O

Seizures B_DISEASE/B_LOCATION
also O
resulted O
in O
alterations O
to O
the O
cell O
types O
expressing O
CCR2 O
. O

increased O
numbers O
of O
neurons O
that O
expressed O
CCR2 O
was O
observed O
following O
SE B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Microglial O
cells O
were O
more O
closely O
apposed O
to O
the O
CCR2 O
- O
labeled O
cells O
in O
SE B_DISEASE/B_LOCATION
rats O
. O

In O
addition O
, O
rats O
that O
experienced O
SE B_DISEASE
exhibited O
CCR2 O
- O
labeling O
in O
populations O
of O
hypertrophied B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
astrocytes O
, O
especially O
in O
CA1 O
and O
dentate O
gyrus O
. O

These O
CCR2 B_GENE
+ O
astroctytes B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
were O
not O
observed O
in O
control B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
rats I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Examination O
of O
CCL2 O
expression O
showed O
that O
it O
was O
elevated O
in O
the O
hippocampus O
following O
SE B_DISEASE
. O

conclusion O
: O
The O
data O
show O
that O
CCR2 O
and O
CCL2 O
are O
up O
- O
regulated O
in O
the O
hippocampus O
after O
pilocarpine O
- O
induced O
SE B_DISEASE
. O

Seizures B_DISEASE/B_LOCATION
also O
result O
in O
changes O
to O
CCR2 O
receptor O
expression O
in O
neurons O
and O
astrocytes O
. O

These O
changes O
might O
be O
involved O
in O
detrimental O
neuroplasticity O
and O
neuroinflammatory B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
changes O
that O
occur O
following O
seizures B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Metallothionein B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
induction I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
reduces O
caspase B_GENE/B_LOCATION
- O
3 B_TIME[MEASURE]/B_LOCATION
activity I_TIME[MEASURE]/I_LOCATION
and O
TNFalpha B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
levels I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
with O
preservation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
of O
cognitive B_DISEASE_ADJECTIVE[DISEASE]
function I_DISEASE_ADJECTIVE[DISEASE]
and O
intact B_DISEASE_ADJECTIVE[DISEASE]
hippocampal I_DISEASE_ADJECTIVE[DISEASE]
neurons I_DISEASE_ADJECTIVE[DISEASE]
in O
carmustine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O
treated O
rats B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

hippocampal B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
integrity I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
is O
essential B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
for O
cognitive B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
functions I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

On O
the O
other B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
hand I_PERSON/I_BODY_PART_OR_ORGAN_COMPONENT
, O
induction B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
metallothionein B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O
Mt B_LOCATION/B_PROTEIN[GENE]
) O
by O
ZnSO B_LOCATION/B_ORGANIZATION
( O
4 B_MEASURE/B_LOCATION
) O
and O
its O
role B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
in O
neuroprotection B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
has O
been O
documented O
. O

The O
present O
study O
aimed O
to O
explore O
the O
effect O
of O
Mt O
induction O
on O
carmustine O
( O
BCNU O
) O
- O
induced O
hippocampal O
cognitive B_DISEASE
dysfunction I_DISEASE
in O
rats O
. O

A O
total B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
60 B_NUMBER[MEASURE]/B_PERSON
male I_NUMBER[MEASURE]/I_PERSON
Wistar I_NUMBER[MEASURE]/I_PERSON
albino I_NUMBER[MEASURE]/I_PERSON
rats I_NUMBER[MEASURE]/I_PERSON
were O
randomly O
divided O
into O
four B_NUMBER[MEASURE]/B_ORGANIZATION
groups B_NUMBER[MEASURE]/I_ORGANIZATION
( O
15 B_MEASURE/B_ORGANIZATION
/ O
group B_MEASURE/B_ORGANIZATION
) O
: O
The O
control B_PERSON/B_ORGANIZATION
group I_PERSON/I_ORGANIZATION
injected O
with O
single B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
doses I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
normal B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
saline I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O
i O
. O
c O
. O
v O
) O
followed O
24 B_NUMBER[MEASURE]
h O
later O
by O
BCNU B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
solvent I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
i O
. O
v O
) O
. O

The O
second B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
group I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
administered O
ZnSO B_LOCATION
( O
4 B_MEASURE/B_LOCATION
) O
( O
0 B_MEASURE
. O
1 B_MEASURE
micromol I_MEASURE
/ O
10 B_MEASURE
microl I_MEASURE
normal I_MEASURE
saline I_MEASURE
, O
i O
. O
c O
. O
v O
, O
once O
) O
then O
BCNU B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
solvent I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
i O
. O
v O
) O
after O
24 B_MEASURE
h O
. O

Third B_PERSON/B_ORGANIZATION
group I_PERSON/I_ORGANIZATION
received O
BCNU B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
( O
20 B_MEASURE/B_LOCATION
mg I_MEASURE/I_LOCATION
/ O
kg B_TIME[MEASURE]
, O
i O
. O
v B_MEASURE/B_GENE
, O
once O
) O
24 B_MEASURE/B_LOCATION
h O
after O
injection B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
with O
normal B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
saline I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
i B_DISEASE/B_PROTEIN[GENE]
. O
c O
. O
v O
) O
. O

Fourth B_PERSON
group I_PERSON
received O
a O
single B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dose I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
ZnSO B_LOCATION
( O
4 B_TIME[MEASURE]
) O
( O
0 B_MEASURE
. O
1 B_MEASURE
micromol I_MEASURE
/ O
10 B_MEASURE
microl I_MEASURE
normal I_MEASURE
saline I_MEASURE
, O
i O
. O
c O
. O
v O
) O
then O
BCNU B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
( O
20 B_MEASURE
mg I_MEASURE
/ O
kg B_TIME[MEASURE]
, O
i O
. O
v B_MEASURE/B_GENE
, O
once O
) O
after O
24 B_MEASURE
h O
. O

The O
obtained O
data O
revealed O
that O
BCNU O
administration O
resulted O
in O
deterioration B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
learning I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
short I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
term I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
memory I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
STM O
) O
, O
as O
measured O
by O
using O
radial O
arm O
water O
maze O
, O
accompanied O
with O
decreased O
hippocampal O
glutathione O
reductase O
( O
GR O
) O
activity O
and O
reduced O
glutathione O
( O
GSH O
) O
content O
. O

Also O
, O
BCNU O
administration O
increased O
serum O
tumor B_DISEASE_ADJECTIVE[DISEASE]
necrosis I_DISEASE_ADJECTIVE[DISEASE]
factor O
- O
alpha O
( O
TNFalpha O
) O
, O
hippocampal O
Mt O
and O
malondialdehyde O
( O
MDA O
) O
contents O
as O
well O
as O
caspase O
- O
3 O
activity O
in O
addition O
to O
histological O
alterations O
. O

ZnSO B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
4 B_NUMBER[MEASURE]/B_LOCATION
) O
pretreatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
counteracted O
BCNU B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O
induced O
inhibition B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
of O
GR B_GENE/B_DISEASE
and O
depletion B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
GSH B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
resulted O
in O
significant B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
reduction I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
the O
levels B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
of O
MDA B_GENE/B_BIO
and O
TNFalpha B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
as O
well O
as O
the O
activity B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
caspase B_LOCATION/B_GENE
- O
3 B_NUMBER[MEASURE]
. O

The O
histological B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
features B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
improved O
in O
hippocampus B_BODY_PART_OR_ORGAN_COMPONENT
of O
rats B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treated O
with O
ZnSO B_LOCATION/B_ORGANIZATION
( O
4 B_MEASURE/B_LOCATION
) O
+ O
BCNU B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
compared O
to O
only O
BCNU B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O
treated O
animals B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

In O
conclusion O
, O
Mt O
induction O
halts O
BCNU O
- O
induced O
hippocampal O
toxicity B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O
it O
prevented O
GR O
inhibition O
and O
GSH O
depletion O
and O
counteracted O
the O
increased O
levels O
of O
TNFalpha O
, O
MDA O
and O
caspase O
- O
3 O
activity O
with O
subsequent O
preservation O
of O
cognition O
. O

fatal O
carbamazepine O
induced O
fulminant B_DISEASE_ADJECTIVE[DISEASE]
eosinophilic I_DISEASE_ADJECTIVE[DISEASE]
( O
hypersensitivity B_DISEASE/B_PROTEIN[GENE]
) O
myocarditis B_DISEASE
: O
emphasis O
on O
anatomical O
and O
histological O
characteristics O
, O
mechanisms O
and O
genetics O
of O
drug B_DISEASE
hypersensitivity I_DISEASE
and O
differential O
diagnosis O
. O

The O
most O
severe B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
adverse B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reactions B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
carbamazepine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
have O
been O
observed O
in O
the O
haemopoietic B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
system I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
, O
the O
liver B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
and O
the O
cardiovascular B_BODY_PART_OR_ORGAN_COMPONENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
system I_BODY_PART_OR_ORGAN_COMPONENT/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

A O
frequently O
fatal O
, O
although O
exceptionally O
rare O
side O
effect O
of O
carbamazepine O
is O
necrotizing O
eosinophilic O
( O
hypersensitivity B_DISEASE/B_LOCATION
) O
myocarditis B_DISEASE
. O

We O
report O
a O
case O
of O
hypersensitivity B_DISEASE
myocarditis I_DISEASE
secondary O
to O
administration O
of O
carbamazepine O
. O

acute O
hypersensitivity B_DISEASE
myocarditis I_DISEASE
was O
not O
suspected O
clinically O
, O
and O
the O
diagnosis O
was O
made O
post O
- O
mortem O
. O

histology B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
revealed O
diffuse B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
infiltration I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
the O
myocardium B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
by O
eosinophils B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O
lymphocytes B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
with O
myocyte B_DISEASE
damage I_DISEASE
. O

Clinically O
, O
death O
was O
due O
to O
cardiogenic B_DISEASE
shock I_DISEASE
. O

To O
best O
of O
our O
knowledge O
this O
is O
the O
second O
case O
of O
fatal O
carbamazepine O
induced O
myocarditis B_DISEASE
reported O
in O
English O
literature O
. O

Neuropsychiatric O
behaviors O
in O
the O
MPTP O
marmoset O
model O
of O
Parkinson B_DISEASE
' I_DISEASE
s I_DISEASE
disease I_DISEASE
. O

objectives O
: O
Neuropsychiatric O
symptoms O
are O
increasingly O
recognised O
as O
a O
significant O
problem O
in O
patients O
with O
Parkinson B_DISEASE
' I_DISEASE
s I_DISEASE
disease I_DISEASE
( O
PD B_DISEASE/B_PROTEIN[GENE]
) O
. O

These O
symptoms B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
may O
be O
due B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
to O
' O
sensitisation B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
' O
following O
repeated O
levodopa B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
treatment I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
or O
a O
direct B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
effect I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
of O
dopamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
on O
the O
disease B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
state I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
. O

The O
levodopa O
- O
treated O
MPTP O
- O
lesioned O
marmoset O
was O
used O
as O
a O
model O
of O
neuropsychiatric B_DISEASE
symptoms I_DISEASE
in O
PD B_DISEASE/B_LOCATION
patients O
. O

Here O
we O
compare O
the O
time O
course O
of O
levodopa O
- O
induced O
motor O
fluctuations O
and O
neuropsychiatric B_DISEASE
- I_DISEASE
like I_DISEASE
behaviors I_DISEASE
to O
determine O
the O
relationship O
between O
duration O
of O
treatment O
and O
onset O
of O
symptoms O
. O

methods O
: O
Marmosets O
were O
administered O
1 O
- O
methyl O
- O
4 O
- O
phenyl O
- O
1 O
, O
2 O
, O
3 O
, O
6 O
- O
tetrahydropyridine O
( O
2 O
. O
0 O
mg O
/ O
kg O
s O
. O
c O
. O
) O
for O
five O
days O
, O
resulting O
in O
stable O
parkinsonism B_DISEASE
. O

levodopa B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
15 B_MEASURE
mg I_MEASURE
/ O
kg B_MEASURE
and O
benserazide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
3 B_MEASURE/B_LOCATION
. O
75 B_MEASURE
mg I_MEASURE
/ O
kg B_MEASURE
) O
p B_MEASURE
. O
o O
. O

b O
. O
i O
. O
d O
, O
was O
administered O
for O
30 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
days I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Animals O
were O
evaluated O
for O
parkinsonian B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
disability I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
, O
dyskinesia B_DISEASE/B_MEASURE
and O
on O
- O
time O
( O
motor O
fluctuations O
) O
and O
neuropsychiatric B_DISEASE
- I_DISEASE
like I_DISEASE
behaviors I_DISEASE
on O
Day O
0 O
( O
prior O
to O
levodopa O
) O
and O
on O
Days O
1 O
, O
7 O
, O
13 O
, O
27 O
and O
30 O
of O
treatment O
using O
post O
hoc O
DVD O
analysis O
by O
a O
trained O
rater O
, O
blind O
to O
the O
treatment O
day O
. O

Results O
: O
The O
neuropsychiatric B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
like B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
behavior B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
rating O
scale O
demonstrated O
high O
interrater O
reliability O
between O
three O
trained O
raters O
of O
differing O
professional O
backgrounds O
. O

As O
anticipated O
, O
animals O
exhibited O
a O
progressive O
increase O
in O
levodopa O
- O
induced O
motor O
fluctuations O
, O
dyskinesia B_DISEASE
and O
wearing O
- O
off O
, O
that O
correlated O
with O
the O
duration O
of O
levodopa O
therapy O
. O

In O
contrast O
, O
levodopa O
- O
induced O
neuropsychiatric B_DISEASE
- I_DISEASE
like I_DISEASE
behaviors I_DISEASE
were O
present O
on O
Day O
1 O
of O
levodopa O
treatment O
and O
their O
severity O
did O
not O
correlate O
with O
duration O
of O
treatment O
. O

conclusions O
: O
The O
data O
suggest O
that O
neuropsychiatric B_DISEASE_ADJECTIVE[DISEASE]
disorders I_DISEASE_ADJECTIVE[DISEASE]
in O
PD B_DISEASE/B_LOCATION
are O
more O
likely O
an O
interaction O
between O
levodopa O
and O
the O
disease O
state O
than O
a O
consequence O
of O
sensitisation O
to O
repeated O
dopaminergic O
therapy O
. O

contrast O
medium O
nephrotoxicity B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
after O
renal O
artery O
and O
coronary O
angioplasty O
. O

Background O
: O
Renal B_DISEASE/B_GENE
dysfunction I_DISEASE/I_GENE
induced O
by O
iodinated O
contrast O
medium O
( O
cm O
) O
administration O
can O
minimize O
the O
benefit O
of O
the O
interventional O
procedure O
in O
patients O
undergoing O
renal O
angioplasty O
( O
PTRA O
) O
. O

purpose O
: O
To O
compare O
the O
susceptibility O
to O
nephrotoxic B_DISEASE_ADJECTIVE[DISEASE]
effect O
of O
cm O
in O
patients O
undergoing O
PTRA O
with O
that O
of O
patients O
submitted O
to O
percutaneous O
coronary O
intervention O
( O
PCI O
) O
. O

Material B_LOCATION/B_TIME[MEASURE]
AND O
METHODS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
A O
total B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
33 B_MEASURE/B_PERSON
patients B_MEASURE/I_PERSON
successfully O
treated O
with O
PTRA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
( O
PTRA B_PERSON/B_ORGANIZATION
group I_PERSON/I_ORGANIZATION
, O
mean B_TIME[MEASURE]
age I_TIME[MEASURE]
70 I_TIME[MEASURE]
+ I_TIME[MEASURE]
/ O
- O
12 B_TIME[MEASURE]
years I_TIME[MEASURE]
, O
23 B_PERSON
female I_PERSON
, O
basal B_MEASURE
creatinine I_MEASURE
1 I_MEASURE
. O
46 B_MEASURE
+ I_MEASURE
/ O
- O
0 B_MEASURE
. O
79 B_MEASURE
, O
range B_MEASURE/B_LOCATION
0 I_MEASURE/I_LOCATION
. O
7 B_MEASURE
- O
4 B_MEASURE
. O
9 B_MEASURE
mg I_MEASURE
/ O
dl B_TIME[MEASURE]/B_DISEASE
) O
were O
compared O
with O
33 B_PERSON
patients I_PERSON
undergoing O
successful B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
PCI I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
( O
PCI B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
group I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_LOCATION
) O
, O
matched O
for O
basal B_TIME[MEASURE]/B_PERSON
creatinine I_TIME[MEASURE]/I_PERSON
( O
1 B_MEASURE
. O
44 B_MEASURE
+ I_MEASURE
/ O
- O
0 B_MEASURE
. O
6 B_MEASURE
, O
range B_MEASURE/B_LOCATION
0 I_MEASURE/I_LOCATION
. O
7 B_MEASURE
- O
3 B_MEASURE
. O
4 B_MEASURE
mg I_MEASURE
/ O
dl B_TIME[MEASURE]/B_DISEASE
) O
, O
gender B_PERSON/B_MEASURE
, O
and O
age B_DISEASE
. O

In O
both O
groups B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
postprocedural I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
( O
48 B_MEASURE
h O
) O
serum B_DISEASE
creatinine I_DISEASE
was O
measured O
. O

RESULTS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O
Postprocedural B_TIME[MEASURE]/B_PERSON
creatinine I_TIME[MEASURE]/I_PERSON
level I_TIME[MEASURE]/I_PERSON
decreased O
nonsignificantly O
in O
the O
PTRA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
group I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
( O
1 B_NUMBER[MEASURE]
. O
46 B_MEASURE
+ I_MEASURE
/ O
- O
0 B_NUMBER[MEASURE]
. O
8 B_MEASURE/B_SPORT[ENT]
vs I_MEASURE/I_SPORT[ENT]
. O
1 B_NUMBER[MEASURE]
. O
34 B_MEASURE
+ I_MEASURE
/ O
- O
0 B_MEASURE
. O
5 B_MEASURE
mg I_MEASURE
/ O
dl B_TIME[MEASURE]/B_DISEASE
, O
P B_OTHER/B_MEASURE
= O
NS B_MEASURE
) O
and O
increased O
significantly O
in O
the O
PCI B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
group I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
( O
1 B_NUMBER[MEASURE]
. O
44 B_MEASURE
+ I_MEASURE
/ O
- O
0 B_NUMBER[MEASURE]
. O
6 B_MEASURE/B_SPORT[ENT]
vs I_MEASURE/I_SPORT[ENT]
. O
1 B_NUMBER[MEASURE]
. O
57 B_MEASURE
+ I_MEASURE
/ O
- O
0 B_MEASURE
. O
7 B_MEASURE
mg I_MEASURE
/ O
dl B_TIME[MEASURE]/B_DISEASE
, O
P B_OTHER/B_LOCATION
< O
0 B_MEASURE
. O
02 B_MEASURE
) O
. O

Changes B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
serum B_DISEASE/B_GENE
creatinine I_DISEASE/I_GENE
after O
intervention B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O
after O
- O
before B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
) O
were O
significantly O
different B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O
the O
PTRA B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
PCI B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
groups I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
- O
0 B_MEASURE/B_LOCATION
. O
12 B_MEASURE
+ I_MEASURE
/ O
- O
0 B_NUMBER[MEASURE]
. O
5 B_MEASURE/B_SPORT[ENT]
vs I_MEASURE/I_SPORT[ENT]
. O
0 B_MEASURE/B_LOCATION
. O
13 B_MEASURE
+ I_MEASURE
/ O
- O
0 B_MEASURE
. O
3 B_MEASURE
, O
P B_OTHER/B_PROTEIN[GENE]
= O
0 B_MEASURE
. O
014 B_MEASURE
) O
. O

This O
difference B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
not O
related O
to O
either O
a O
different B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
clinical I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
risk I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
profile I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O
to O
the O
volume B_MEASURE
of O
CM B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
administered O
. O

conclusion O
: O
In O
this O
preliminary O
study O
patients O
submitted O
to O
PTRA O
showed O
a O
lower O
susceptibility O
to O
renal B_DISEASE
damage I_DISEASE
induced O
by O
cm O
administration O
than O
PCI O
patients O
. O

The O
effectiveness O
of O
PTRA O
on O
renal O
function O
seems O
to O
be O
barely O
influenced O
by O
cm O
toxicity B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
. O

Diphenhydramine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
prevents O
the O
haemodynamic B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
changes I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
of O
cimetidine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
in O
ICU B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
patients I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

cimetidine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
a O
histamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
H2 B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
antagonist B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
produces O
a O
decrease B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
arterial B_DISEASE/B_GENE
pressure I_DISEASE/I_GENE
due O
to O
vasodilatation B_DISEASE
, O
especially O
in O
critically O
ill B_PERSON/B_DISEASE
patients I_PERSON/I_DISEASE
. O

This O
may O
be O
because O
cimetidine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acts O
as O
a O
histamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
agonist I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

We O
, O
therefore O
, O
investigated O
the O
effects B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
histamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
H1 B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
receptor B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
antagonist I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O
diphenhydramine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
on O
the O
haemodynamic B_DISEASE
changes I_DISEASE
observed O
after O
cimetidine B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
in O
ICU B_SPECIES[BIO]/B_PERSON
patients I_SPECIES[BIO]/I_PERSON
. O

Each O
patient B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
studied O
on O
two B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
separate I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
days I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
. O

In O
a O
random B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fashion I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
they O
received O
cimetidine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
200 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mg I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
iv I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
one B_NUMBER[MEASURE]/B_LOCATION
day I_NUMBER[MEASURE]/I_LOCATION
, O
and O
on O
the O
other B_SEQUENCE[MEASURE]/B_LOCATION
, O
a O
pretreatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
diphenhydramine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
40 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
mg I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
iv I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
with O
cimetidine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
200 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mg I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
iv I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

In O
the O
non B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
pretreatment B_PERSON/B_ORGANIZATION
group I_PERSON/I_ORGANIZATION
, O
mean B_DISEASE
arterial I_DISEASE
pressure I_DISEASE
( O
Map B_LOCATION/B_ORGANIZATION
) O
decreased O
from O
107 B_MEASURE
. O
4 B_MEASURE
+ I_MEASURE
/ O
- O
8 B_MEASURE
. O
4 B_MEASURE
mmHg I_MEASURE
to O
86 B_MEASURE
. O
7 B_MEASURE
+ O
/ O
- O
11 B_MEASURE
. O
4 B_MEASURE
mmHg I_MEASURE
( O
P B_MEASURE
less I_MEASURE
than O
0 B_MEASURE
. O
01 B_MEASURE
) O
two B_TIME[MEASURE]/B_ENT
minutes I_TIME[MEASURE]/I_ENT
after O
cimetidine B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Also O
, O
systemic B_DISEASE
vascular I_DISEASE
resistance I_DISEASE
( O
SVR B_DISEASE/B_PROTEIN[GENE]
) O
decreased O
during O
the O
eight B_NUMBER[MEASURE]
- O
minute B_TIME[MEASURE]/B_LOCATION
observation I_TIME[MEASURE]/I_LOCATION
period I_TIME[MEASURE]/I_LOCATION
( O
P B_MEASURE/B_PERSON
less I_MEASURE/I_PERSON
than O
0 B_MEASURE
. O
01 B_MEASURE
) O
. O

In O
contrast B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
in O
the O
pretreatment B_TIME[MEASURE]/B_LOCATION
group B_TIME[MEASURE]/I_LOCATION
, O
little B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
haemodynamic I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
change I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O
seen O
. O

We O
conclude O
that O
an O
H1 O
antagonist O
may O
be O
useful O
in O
preventing O
hypotension B_DISEASE
caused O
by O
IV O
cimetidine O
, O
since O
the O
vasodilating O
activity O
of O
cimetidine O
is O
mediated O
, O
in O
part O
, O
through O
the O
H1 O
receptor O
. O

Medical O
and O
psychiatric O
outcomes O
for O
patients O
transplanted O
for O
acetaminophen O
- O
induced O
acute B_DISEASE
liver I_DISEASE
failure I_DISEASE
: O
a O
case O
- O
control O
study O
. O

Background O
: O
Acetaminophen O
- O
induced O
hepatotoxicity B_DISEASE
is O
the O
most O
common O
cause O
of O
acute B_DISEASE
liver I_DISEASE
failure I_DISEASE
( O
ALF B_DISEASE/B_PROTEIN[GENE]
) O
in O
the O
UK O
. O

patients B_PERSON
often O
consume O
the O
drug B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
suicidal B_DISEASE
intent I_DISEASE
or O
with O
a O
background B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
substance B_DISEASE
dependence I_DISEASE
. O

aims O
AND O
methods O
: O
We O
compared O
the O
severity O
of O
pretransplant O
illness O
, O
psychiatric O
co O
- O
morbidity O
, O
medical O
and O
psychosocial O
outcomes O
of O
all O
patients O
who O
had O
undergone O
liver O
transplantation O
( O
Lt O
) O
emergently O
between O
1999 O
- O
2004 O
for O
acetaminophen O
- O
induced O
ALF B_DISEASE
( O
n O
= O
36 O
) O
with O
age O
- O
and O
sex O
- O
matched O
patients O
undergoing O
emergent O
Lt O
for O
non O
- O
acetaminophen O
- O
induced O
ALF B_DISEASE
( O
n O
= O
35 O
) O
and O
elective O
Lt O
for O
chronic B_DISEASE
liver I_DISEASE
disease I_DISEASE
( O
CLD B_DISEASE/B_MEASURE
, O
n O
= O
34 O
) O
. O

Results O
: O
Acetaminophen O
- O
induced O
ALF B_DISEASE
patients O
undergoing O
Lt O
had O
a O
greater O
severity O
of O
pre O
- O
Lt O
illness O
reflected O
by O
higher O
acute O
physiology O
and O
chronic O
Health O
Evaluation O
II O
scores O
and O
requirement O
for O
organ O
support O
compared O
with O
the O
other O
two O
groups O
. O

Twenty O
( O
56 O
% O
) O
acetaminophen O
- O
induced O
ALF B_DISEASE
patients O
had O
a O
formal O
psychiatric O
diagnosis O
before O
Lt O
( O
non O
- O
acetaminophen O
- O
induced O
ALF B_LOCATION/B_DISEASE
= O
0 O
/ O
35 O
, O
CLD B_LOCATION
= O
2 O
/ O
34 O
; O
P O
< O
0 O
. O
01 O
for O
all O
) O
and O
nine O
( O
25 O
% O
) O
had O
a O
previous O
suicide O
attempt O
. O

During O
follow O
- O
up O
( O
median O
5 O
years O
) O
, O
there O
were O
no O
significant O
differences O
in O
rejection O
( O
acute O
and O
chronic O
) O
, O
graft O
failure O
or O
survival O
between O
the O
groups O
( O
acetaminophen O
- O
induced O
ALF B_DISEASE/B_LOCATION
1 O
year O
87 O
% O
, O
5 O
years O
75 O
% O
; O
non O
- O
acetaminophen O
- O
induced O
ALF B_DISEASE
88 O
% O
, O
78 O
% O
; O
CLD B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
93 O
% O
, O
82 O
% O
: O
P O
> O
0 O
. O
6 O
log O
rank O
) O
. O

Two O
acetaminophen O
- O
induced O
ALF B_DISEASE
patients O
reattempted O
suicide O
post O
- O
Lt O
( O
one O
died O
8 O
years O
post O
- O
Lt O
) O
. O

conclusions O
: O
Despite O
a O
high O
prevalence O
of O
psychiatric O
disturbance O
, O
outcomes O
for O
patients O
transplanted O
emergently O
for O
acetaminophen O
- O
induced O
ALF B_DISEASE
were O
comparable O
to O
those O
transplanted O
for O
non O
- O
acetaminophen O
- O
induced O
ALF B_DISEASE
and O
electively O
for O
CLD B_DISEASE
. O

multidisciplinary B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
approaches I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_PERSON
with O
long B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O
term B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
psychiatric I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
follow I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
up B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
may O
contribute O
to O
low B_DISEASE/B_MEASURE
post I_DISEASE/I_MEASURE
- O
transplant B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
suicide I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
rates I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
seen O
and O
low B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
rates I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O
graft B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
loss I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
because O
of O
non B_DISEASE
- O
compliance B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Antithrombotic O
drug O
use O
, O
cerebral B_DISEASE
microbleeds I_DISEASE
, O
and O
intracerebral B_DISEASE
hemorrhage I_DISEASE
: O
a O
systematic O
review O
of O
published O
and O
unpublished O
studies O
. O

Background O
AND O
purpose O
: O
Cerebral B_DISEASE
microbleeds I_DISEASE
( O
MB B_LOCATION/B_PERSON
) O
are O
potential O
risk O
factors O
for O
intracerebral B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
hemorrhage I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
( O
ICH B_DISEASE/B_LOCATION
) O
, O
but O
it O
is O
unclear O
if O
they O
are O
a O
contraindication O
to O
using O
antithrombotic O
drugs O
. O

insights O
could O
be O
gained O
by O
pooling O
data O
on O
MB B_DISEASE/B_GENE
frequency O
stratified O
by O
antithrombotic O
use O
in O
cohorts O
with O
ICH B_DISEASE/B_LOCATION
and O
ischemic B_DISEASE_ADJECTIVE[DISEASE]
stroke I_DISEASE_ADJECTIVE[DISEASE]
( O
IS B_LOCATION
) O
/ O
transient B_DISEASE_ADJECTIVE[DISEASE]
ischemic I_DISEASE_ADJECTIVE[DISEASE]
attack I_DISEASE_ADJECTIVE[DISEASE]
( O
TIA B_LOCATION/B_ORGANIZATION
) O
. O

methods O
: O
We O
performed O
a O
systematic O
review O
of O
published O
and O
unpublished O
data O
from O
cohorts O
with O
stroke B_DISEASE/B_LOCATION
or O
TIA B_DISEASE/B_LOCATION
to O
compare O
the O
presence O
of O
MB B_DISEASE/B_GENE
in O
: O
( O
1 O
) O
antithrombotic O
users O
vs O
nonantithrombotic O
users O
with O
ICH B_DISEASE/B_LOCATION
; O
( O
2 O
) O
antithrombotic O
users O
vs O
nonusers O
with O
IS B_DISEASE/B_LOCATION
/ O
TIA B_LOCATION/B_ORGANIZATION
; O
and O
( O
3 O
) O
ICH B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
vs O
ischemic B_DISEASE/B_LOCATION
events O
stratified O
by O
antithrombotic O
use O
. O

We O
also O
analyzed O
published O
and O
unpublished O
follow O
- O
up O
data O
to O
determine O
the O
risk O
of O
ICH B_DISEASE
in O
antithrombotic O
users O
with O
MB B_DISEASE/B_GENE
. O

Results O
: O
In O
a O
pooled O
analysis O
of O
1460 O
ICH B_LOCATION/B_PERSON
and O
3817 O
IS B_LOCATION/B_ORGANIZATION
/ O
TIA B_LOCATION/B_ORGANIZATION
, O
MB B_DISEASE/B_GENE
were O
more O
frequent O
in O
ICH B_LOCATION/B_PERSON
vs O
IS B_LOCATION/B_ORGANIZATION
/ O
TIA B_LOCATION/B_ORGANIZATION
in O
all O
treatment O
groups O
, O
but O
the O
excess O
increased O
from O
2 O
. O
8 O
( O
odds O
ratio O
; O
range O
, O
2 O
. O
3 O
- O
3 O
. O
5 O
) O
in O
nonantithrombotic O
users O
to O
5 O
. O
7 O
( O
range O
, O
3 O
. O
4 O
- O
9 O
. O
7 O
) O
in O
antiplatelet O
users O
and O
8 O
. O
0 O
( O
range O
, O
3 O
. O
5 O
- O
17 O
. O
8 O
) O
in O
warfarin O
users O
( O
P O
difference O
= O
0 O
. O
01 O
) O
. O

There O
was O
also O
an O
excess O
of O
MB B_DISEASE/B_GENE
in O
warfarin O
users O
vs O
nonusers O
with O
ICH B_LOCATION/B_PERSON
( O
OR O
, O
2 O
. O
7 O
; O
95 O
% O
CI O
, O
1 O
. O
6 O
- O
4 O
. O
4 O
; O
P O
< O
0 O
. O
001 O
) O
but O
none O
in O
warfarin O
users O
with O
IS B_LOCATION
/ O
TIA B_DISEASE/B_LOCATION
( O
OR O
, O
1 O
. O
3 O
; O
95 O
% O
CI O
, O
0 O
. O
9 O
- O
1 O
. O
7 O
; O
P O
= O
0 O
. O
33 O
; O
P O
difference O
= O
0 O
. O
01 O
) O
. O

There O
was O
a O
smaller O
excess O
of O
MB B_DISEASE/B_GENE
in O
antiplatelet O
users O
vs O
nonusers O
with O
ICH B_LOCATION/B_PERSON
( O
OR O
, O
1 O
. O
7 O
; O
95 O
% O
CI O
, O
1 O
. O
3 O
- O
2 O
. O
3 O
; O
P O
< O
0 O
. O
001 O
) O
, O
but O
findings O
were O
similar O
for O
antiplatelet O
users O
with O
IS B_LOCATION
/ O
TIA B_LOCATION/B_ORGANIZATION
( O
OR O
, O
1 O
. O
4 O
; O
95 O
% O
CI O
, O
1 O
. O
2 O
- O
1 O
. O
7 O
; O
P O
< O
0 O
. O
001 O
; O
P O
difference O
= O
0 O
. O
25 O
) O
. O

In O
pooled O
follow O
- O
up O
data O
for O
768 O
antithrombotic O
users O
, O
presence O
of O
MB B_DISEASE/B_GENE
at O
baseline O
was O
associated O
with O
a O
substantially O
increased O
risk O
of O
subsequent O
ICH B_DISEASE
( O
OR O
, O
12 O
. O
1 O
; O
95 O
% O
CI O
, O
3 O
. O
4 O
- O
42 O
. O
5 O
; O
P O
< O
0 O
. O
001 O
) O
. O

conclusions O
: O
The O
excess O
of O
MB B_PROTEIN[GENE]/B_LOCATION
in O
warfarin O
users O
with O
ICH B_DISEASE
compared O
to O
other O
groups O
suggests O
that O
MB B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
increase O
the O
risk O
of O
warfarin O
- O
associated O
ICH B_DISEASE
. O

Limited B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
prospective I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
data I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
corroborate O
these O
findings B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
, O
but O
larger B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
prospective I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
studies I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
urgently O
required O
. O

Studies O
of O
synergy O
between O
morphine O
and O
a O
novel O
sodium O
channel O
blocker O
, O
CNSB002 O
, O
in O
rat O
models O
of O
inflammatory O
and O
neuropathic B_DISEASE
pain I_DISEASE
. O

objective O
: O
This O
study O
determined O
the O
antihyperalgesic O
effect O
of O
CNSB002 O
, O
a O
sodium O
channel O
blocker O
with O
antioxidant O
properties O
given O
alone O
and O
in O
combinations O
with O
morphine O
in O
rat O
models O
of O
inflammatory O
and O
neuropathic B_DISEASE
pain I_DISEASE
. O

Design O
: O
dose O
response O
curves O
for O
nonsedating O
doses O
of O
morphine O
and O
CNSB002 O
given O
intraperitoneally O
alone O
and O
together O
in O
combinations O
were O
constructed O
for O
antihyperalgesic O
effect O
using O
paw O
withdrawal O
from O
noxious O
heat O
in O
two O
rat O
pain B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
models O
: O
carrageenan O
- O
induced O
paw O
inflammation B_DISEASE/B_BACTERIUM[BIO]
and O
streptozotocin O
( O
STZ O
) O
- O
induced O
diabetic B_DISEASE
neuropathy I_DISEASE
. O

RESULTS B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O
The O
maximum B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
nonsedating I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
doses I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
were O
: O
morphine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
3 B_MEASURE
. O
2 B_MEASURE
mg I_MEASURE
/ O
kg B_MEASURE/B_PERSON
; O
CNSB002 B_MEASURE
10 I_MEASURE
. O
0 B_MEASURE
mg I_MEASURE
/ O
kg B_MEASURE/B_PERSON
; O
5 B_MEASURE
. O
0 B_MEASURE
mg I_MEASURE
/ O
kg B_MEASURE/B_PERSON
CNSB002 I_MEASURE/I_PERSON
with O
morphine B_MEASURE
3 I_MEASURE
. O
2 B_MEASURE
mg I_MEASURE
/ O
kg B_MEASURE
in O
combination B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
. O

The O
doses O
calculated O
to O
cause O
50 O
% O
reversal O
of O
hyperalgesia B_DISEASE
( O
ED50 O
) O
were O
7 O
. O
54 O
( O
1 O
. O
81 O
) O
and O
4 O
. O
83 O
( O
1 O
. O
54 O
) O
in O
the O
carrageenan O
model O
and O
44 O
. O
18 O
( O
1 O
. O
37 O
) O
and O
9 O
. O
14 O
( O
1 O
. O
24 O
) O
in O
the O
STZ O
- O
induced O
neuropathy B_DISEASE
model O
for O
CNSB002 O
and O
morphine O
, O
respectively O
( O
mg O
/ O
kg O
; O
mean O
, O
SEM O
) O
. O

These O
values B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
greater B_MEASURE
than O
the O
maximum B_MEASURE/B_PERSON
nonsedating I_MEASURE/I_PERSON
doses I_MEASURE/I_PERSON
. O

The O
ED50 O
values O
for O
morphine O
when O
given O
in O
combination O
with O
CNSB002 O
( O
5 O
mg O
/ O
kg O
) O
were O
less O
than O
the O
maximum O
nonsedating O
dose O
: O
0 O
. O
56 O
( O
1 O
. O
55 O
) O
in O
the O
carrageenan O
model O
and O
1 O
. O
37 O
( O
1 O
. O
23 O
) O
in O
the O
neuropathy B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
model O
( O
mg O
/ O
kg O
; O
mean O
, O
SEM O
) O
. O

The O
antinociception O
after O
morphine O
( O
3 O
. O
2 O
mg O
/ O
kg O
) O
was O
increased O
by O
co O
- O
administration O
with O
CNSB002 O
from O
28 O
. O
0 O
and O
31 O
. O
7 O
% O
to O
114 O
. O
6 O
and O
56 O
. O
9 O
% O
reversal O
of O
hyperalgesia B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
inflammatory O
and O
neuropathic B_DISEASE
models O
, O
respectively O
( O
P O
< O
0 O
. O
01 O
; O
one O
- O
way O
analysis O
of O
variance O
- O
significantly O
greater O
than O
either O
drug O
given O
alone O
) O
. O

CONCLUSIONS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O
The O
maximum B_MEASURE
antihyperalgesic I_MEASURE
effect I_MEASURE
achievable I_MEASURE
with O
nonsedating O
doses B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
of O
morphine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
may O
be O
increased O
significantly O
when O
the O
drug B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
is O
used O
in O
combination B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANIZATION
with O
CNSB002 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Heparin O
- O
induced O
thrombocytopenia B_DISEASE
: O
a O
practical O
review O
. O

Heparin O
- O
induced O
thrombocytopenia B_DISEASE
( O
HIT B_DISEASE/B_GENE
) O
remains O
under O
- O
recognized O
despite O
its O
potentially O
devastating O
outcomes O
. O

It O
begins O
when O
heparin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
exposure I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
stimulates O
the O
formation B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
of O
heparin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
platelet B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
factor I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
4 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
antibodies I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
which O
in O
turn B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
triggers O
the O
release B_ENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
procoagulant B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
platelet I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
particles I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Thrombosis B_DISEASE
and O
thrombocytopenia B_DISEASE
that O
follow O
comprise O
the O
2 O
hallmark O
traits O
of O
HIT B_DISEASE
, O
with O
the O
former O
largely O
responsible O
for O
significant O
vascular O
complications O
. O

The O
prevalence O
of O
HIT B_DISEASE
varies O
among O
several O
subgroups O
, O
with O
greater O
incidence O
in O
surgical O
as O
compared O
with O
medical O
populations O
. O

HIT B_DISEASE/B_GENE
must O
be O
acknowledged O
for O
its O
intense O
predilection O
for O
thrombosis B_DISEASE/B_PERSON
and O
suspected O
whenever O
thrombosis B_DISEASE/B_PERSON
occurs O
after O
heparin O
exposure O
. O

Early B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
recognition I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
that O
incorporates O
the O
clinical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
serologic B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
clues I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
is O
paramount B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
to O
timely B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
institution I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_LOCATION
of O
treatment B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
as O
its O
delay B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
may O
result O
in O
catastrophic B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
outcomes I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
treatment O
of O
HIT B_DISEASE
mandates O
an O
immediate O
cessation O
of O
all O
heparin O
exposure O
and O
the O
institution O
of O
an O
antithrombotic O
therapy O
, O
most O
commonly O
using O
a O
direct O
thrombin O
inhibitor O
. O

Current O
' O
diagnostic O
' O
tests O
, O
which O
primarily O
include O
functional O
and O
antigenic O
assays O
, O
have O
more O
of O
a O
confirmatory O
than O
diagnostic O
role O
in O
the O
management O
of O
HIT B_DISEASE/B_LOCATION
. O

Special B_PERSON
attention I_PERSON
must O
be O
paid O
to O
cardiac B_PERSON
patients I_PERSON
who O
are O
often O
exposed O
to O
heparin O
multiple B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
times I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
during O
their O
course B_LOCATION/B_TIME[MEASURE]
of O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O

Direct O
thrombin O
inhibitors O
are O
appropriate O
, O
evidence O
- O
based O
alternatives O
to O
heparin O
in O
patients O
with O
a O
history O
of O
HIT B_DISEASE/B_LOCATION
, O
who O
need O
to O
undergo O
percutaneous O
coronary O
intervention O
. O

As O
heparin O
remains O
one O
of O
the O
most O
frequently O
used O
medications O
today O
with O
potential O
for O
HIT B_DISEASE/B_PROTEIN[GENE]
with O
every O
heparin O
exposure O
, O
a O
close O
vigilance O
of O
platelet O
counts O
must O
be O
practiced O
whenever O
heparin O
is O
initiated O
. O

Abductor O
paralysis B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
after O
botox O
injection O
for O
adductor B_DISEASE/B_ORGANISM_FUNCTION
spasmodic I_DISEASE/I_ORGANISM_FUNCTION
dysphonia I_DISEASE/I_ORGANISM_FUNCTION
. O

objectives O
/ O
hypothesis O
: O
Botulinum O
toxin O
( O
Botox O
) O
injections O
into O
the O
thyroarytenoid O
muscles O
are O
the O
current O
standard O
of O
care O
for O
adductor B_DISEASE
spasmodic I_DISEASE
dysphonia I_DISEASE
( O
ADSD B_DISEASE
) O
. O

reported O
adverse O
effects O
include O
a O
period O
of O
breathiness O
, O
throat B_DISEASE
pain I_DISEASE
, O
and O
difficulty O
with O
swallowing O
liquids O
. O

Here O
we O
report O
multiple O
cases O
of O
bilateral O
abductor O
paralysis B_DISEASE
following O
Botox O
injections O
for O
ADSD B_DISEASE
, O
a O
complication O
previously O
unreported O
. O

Study B_LOCATION/B_MEASURE
Design I_LOCATION/I_MEASURE
: O
Retrospective B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
case I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
series I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O

methods O
: O
patients O
that O
received O
Botox O
injections O
for O
spasmodic B_DISEASE/B_PROTEIN[GENE]
dysphonia B_DISEASE/I_PROTEIN[GENE]
between O
January O
2000 O
and O
October O
2009 O
were O
evaluated O
. O

patients O
with O
ADSD B_DISEASE/B_LOCATION
were O
identified O
. O

The O
number B_MEASURE
of O
treatments B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
received O
and O
adverse B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
noted O
. O

For O
patients O
with O
bilateral O
abductor O
paralysis B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
, O
age O
, O
sex O
, O
paralytic O
Botox O
dose O
, O
prior O
Botox O
dose O
, O
and O
course O
following O
paralysis B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
were O
noted O
. O

Results O
: O
From O
a O
database O
of O
452 O
patients O
receiving O
Botox O
, O
352 O
patients O
had O
been O
diagnosed O
with O
ADSD B_DISEASE
. O

Of O
these O
352 O
patients O
, O
eight O
patients O
suffered O
bilateral O
abductor O
paralysis B_DISEASE
, O
and O
two O
suffered O
this O
complication O
twice O
. O

All O
affected O
patients B_PERSON
were O
females B_PERSON/B_LOCATION
over O
the O
age B_TIME[MEASURE]/B_LOCATION
of O
50 B_NUMBER[MEASURE]/B_ENT
years I_NUMBER[MEASURE]/I_ENT
. O

Most O
patients O
had O
received O
treatments O
prior O
to O
abductor O
paralysis B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
continued O
receiving O
after O
paralysis B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O

Seven B_NUMBER[MEASURE]/B_PERSON
patients I_NUMBER[MEASURE]/I_PERSON
recovered O
after O
a O
brief B_TIME[MEASURE]
period I_TIME[MEASURE]
of O
activity B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
restrictions I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
, O
and O
one B_NUMBER[MEASURE]/B_PERSON
underwent O
a O
tracheotomy B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
. O

The O
incidence O
of O
abductor O
paralysis B_DISEASE
after O
Botox O
injection O
for O
ADSD B_DISEASE
was O
0 O
. O
34 O
% O
. O

conclusions O
: O
bilateral O
abductor O
paralysis B_DISEASE
is O
a O
rare O
complication O
of O
Botox O
injections O
for O
ADSD B_DISEASE
, O
causing O
difficulty O
with O
breathing O
upon O
exertion O
. O

The O
likely O
mechanism O
of O
paralysis B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
is O
diffusion O
of O
Botox O
around O
the O
muscular O
process O
of O
the O
arytenoid O
to O
the O
posterior O
cricoarytenoid O
muscles O
. O

The O
paralysis B_DISEASE
is O
temporary O
, O
and O
watchful O
waiting O
with O
restriction O
of O
activity O
is O
the O
recommended O
management O
. O

Mitochondrial B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
impairment I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
contributes O
to O
cocaine O
- O
induced O
cardiac B_DISEASE
dysfunction I_DISEASE
: O
Prevention O
by O
the O
targeted O
antioxidant O
MitoQ O
. O

The O
goal O
of O
this O
study O
was O
to O
assess O
mitochondrial O
function O
and O
ROS O
production O
in O
an O
experimental O
model O
of O
cocaine O
- O
induced O
cardiac B_DISEASE
dysfunction I_DISEASE
. O

We O
hypothesized O
that O
cocaine B_DISEASE
abuse I_DISEASE
may O
lead O
to O
altered O
mitochondrial O
function O
that O
in O
turn O
may O
cause O
left B_DISEASE
ventricular I_DISEASE
dysfunction I_DISEASE
. O

Seven B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
days B_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
cocaine B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
administration I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
to O
rats B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
led O
to O
an O
increased O
oxygen B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
consumption B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
detected O
in O
cardiac B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
fibers I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
, O
specifically O
through O
complex B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
I O
and O
complex B_PROTEIN[GENE]
III I_PROTEIN[GENE]
. O

ROS B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
levels I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
increased O
, O
specifically O
in O
interfibrillar B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
mitochondria I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O

In O
parallel B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
there O
was O
a O
decrease B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O
ATP B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
synthesis I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
, O
whereas O
no O
difference B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
was O
observed O
in O
subsarcolemmal B_DISEASE_ADJECTIVE[DISEASE]/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
mitochondria B_DISEASE_ADJECTIVE[DISEASE]/I_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
. O

This O
uncoupling O
effect O
on O
oxidative O
phosphorylation O
was O
not O
detectable O
after O
short O
- O
term O
exposure O
to O
cocaine O
, O
suggesting O
that O
these O
mitochondrial B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
abnormalities B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
a O
late O
rather O
than O
a O
primary O
event O
in O
the O
pathological O
response O
to O
cocaine O
. O

MitoQ O
, O
a O
mitochondrial O
- O
targeted O
antioxidant O
, O
was O
shown O
to O
completely O
prevent O
these O
mitochondrial B_DISEASE_ADJECTIVE[DISEASE]
abnormalities I_DISEASE_ADJECTIVE[DISEASE]
as O
well O
as O
cardiac B_DISEASE/B_LOCATION
dysfunction I_DISEASE/I_LOCATION
characterized O
here O
by O
a O
diastolic B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dysfunction B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
studied O
with O
a O
conductance O
catheter O
to O
obtain O
pressure O
- O
volume O
data O
. O

taken O
together O
, O
these O
results O
extend O
previous O
studies O
and O
demonstrate O
that O
cocaine O
- O
induced O
cardiac B_DISEASE
dysfunction I_DISEASE
may O
be O
due O
to O
a O
mitochondrial B_DISEASE
defect I_DISEASE
. O

Trimethoprim O
- O
induced O
immune O
hemolytic B_DISEASE_ADJECTIVE[DISEASE]
anemia I_DISEASE_ADJECTIVE[DISEASE]
in O
a O
pediatric O
oncology O
patient O
presenting O
as O
an O
acute O
hemolytic O
transfusion O
reaction O
. O

A O
10 O
- O
year O
- O
old O
male O
with O
acute B_DISEASE
leukemia I_DISEASE
presented O
with O
post O
- O
chemotherapy O
anemia B_DISEASE
. O

During O
red O
cell O
transfusion O
, O
he O
developed O
hemoglobinuria B_DISEASE
. O

transfusion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reaction I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
workup I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
negative B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Drug O
- O
induced O
immune O
hemolytic B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
anemia I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O
suspected O
because O
of O
positive O
direct O
antiglobulin O
test O
, O
negative O
eluate O
, O
and O
microspherocytes O
on O
smear O
pre O
- O
and O
post O
- O
transfusion O
. O

Drug B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
studies I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
using O
the O
indirect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antiglobulin I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
test I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
strongly O
positive B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
trimethoprim B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
trimethoprim B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
sulfamethoxazole B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
but O
negative B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
sulfamethoxazole B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
. O

The O
patient B_PERSON/B_DISEASE
recovered O
after O
discontinuing O
the O
drug B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
with O
no O
recurrence B_DISEASE
in O
2 B_TIME[MEASURE]/B_ENT
years I_TIME[MEASURE]/I_ENT
. O

Other O
causes O
of O
anemia B_DISEASE
should O
be O
considered O
in O
patients O
with O
worse O
- O
than O
- O
expected O
anemia B_DISEASE
after O
chemotherapy O
. O

Furthermore O
, O
hemolysis B_DISEASE
during O
transfusion O
is O
not O
always O
a O
transfusion O
reaction O
. O

Verapamil O
stimulation O
test O
in O
hyperprolactinemia B_PERSON/B_DISEASE
: O
loss O
of O
prolactin O
response O
in O
anatomic O
or O
functional O
stalk O
effect O
. O

aim O
: O
Verapamil O
stimulation O
test O
was O
previously O
investigated O
as O
a O
tool O
for O
differential O
diagnosis O
of O
hyperprolactinemia B_DISEASE/B_LOCATION
, O
but O
with O
conflicting O
results O
. O

Macroprolactinemia B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
was O
never O
considered O
in O
those O
previous O
studies O
. O

Here O
, O
we O
aimed O
to O
re O
- O
investigate O
the O
diagnostic O
value O
of O
verapamil O
in O
a O
population O
who O
were O
all O
screened O
for O
macroprolactinemia B_DISEASE
. O

Prolactin O
responses O
to O
verapamil O
in O
65 O
female O
patients O
( O
age O
: O
29 O
. O
9 O
+ O
/ O
- O
8 O
. O
1 O
years O
) O
with O
hyperprolactinemia B_DISEASE/B_LOCATION
were O
tested O
in O
a O
descriptive O
, O
matched O
case O
- O
control O
study O
. O

METHODS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O
verapamil B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
80 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
mg I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O
p B_MEASURE/B_LOCATION
. O
o O
. O
was O
administered O
, O
and O
then O
PRL B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
levels I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
measured O
at O
8th B_SEQUENCE[MEASURE]
and O
16th B_SEQUENCE[MEASURE]/B_ENT
hours I_SEQUENCE[MEASURE]/I_ENT
, O
by O
immunometric B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
chemiluminescence I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

verapamil B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
responsiveness I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
determined O
by O
peak B_MEASURE
percent I_MEASURE
change I_MEASURE
in O
basal B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
prolactin I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
levels I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O
PRL B_MEASURE/B_GENE
) O
. O

Results O
: O
Verapamil O
significantly O
increased O
PRL O
levels O
in O
healthy O
controls O
( O
N O
. O
8 O
, O
PRL O
: O
183 O
% O
) O
, O
macroprolactinoma B_DISEASE
( O
N O
. O
8 O
, O
PRL O
: O
7 O
% O
) O
, O
microprolactinoma B_DISEASE
( O
N O
. O
19 O
, O
PRL O
: O
21 O
% O
) O
, O
macroprolactinemia B_DISEASE
( O
N O
. O
23 O
, O
PRL O
: O
126 O
% O
) O
, O
but O
not O
in O
pseudoprolactinoma B_DISEASE/B_BIO
( O
N O
. O
8 O
, O
PRL O
: O
0 O
. O
8 O
% O
) O
, O
and O
risperidone O
- O
induced O
hyperprolactinemia B_DISEASE
( O
N O
. O
7 O
, O
PRL O
: O
3 O
% O
) O
. O

ROC O
curve O
analysis O
revealed O
that O
unresponsiveness O
to O
verapamil O
defined O
as O
PRL O
< O
7 O
% O
, O
discriminated O
anatomical O
or O
functional O
stalk O
effect O
( O
sensitivity O
: O
74 O
% O
, O
specificity O
: O
73 O
% O
, O
AUC O
: O
0 O
. O
855 O
+ O
/ O
- O
0 O
. O
04 O
, O
P O
< O
0 O
. O
001 O
, O
CI O
: O
0 O
. O
768 O
- O
0 O
. O
942 O
) O
associated O
with O
pseudoprolactinoma B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O
risperidone O
- O
induced O
hyperprolactinemia B_DISEASE
, O
respectively O
. O

conclusion O
: O
Verapamil O
responsiveness O
is O
not O
a O
reliable O
finding O
for O
the O
differential O
diagnosis O
of O
hyperprolactinemia B_DISEASE
. O

However O
, O
verapamil O
unresponsiveness O
discriminates O
stalk O
effect O
( O
i O
. O
e O
. O
, O
anatomically O
or O
functionally O
inhibited O
dopaminergic O
tonus O
) O
from O
other O
causes O
of O
hyperprolactinemia B_DISEASE
with O
varying O
degrees O
of O
responsiveness O
. O

blockade O
of O
endothelial O
- O
mesenchymal O
transition O
by O
a O
Smad3 O
inhibitor O
delays O
the O
early O
development O
of O
streptozotocin O
- O
induced O
diabetic B_DISEASE
nephropathy I_DISEASE
. O

objective O
: O
A O
multicenter O
, O
controlled O
trial O
showed O
that O
early O
blockade O
of O
the O
renin O
- O
angiotensin O
system O
in O
patients O
with O
type B_DISEASE
1 I_DISEASE
diabetes I_DISEASE
and O
normoalbuminuria O
did O
not O
retard O
the O
progression O
of O
nephropathy B_DISEASE
, O
suggesting O
that O
other O
mechanism O
( O
s O
) O
are O
involved O
in O
the O
pathogenesis O
of O
early O
diabetic B_DISEASE
nephropathy I_DISEASE
( O
diabetic B_DISEASE/B_PROTEIN[GENE]
nephropathy B_DISEASE/I_PROTEIN[GENE]
) O
. O

We O
have O
previously O
demonstrated O
that O
endothelial O
- O
mesenchymal O
- O
transition O
( O
EndoMT O
) O
contributes O
to O
the O
early O
development O
of O
renal O
interstitial O
fibrosis B_DISEASE
independently O
of O
microalbuminuria O
in O
mice O
with O
streptozotocin O
( O
STZ O
) O
- O
induced O
diabetes B_DISEASE
. O

In O
the O
present O
study O
, O
we O
hypothesized O
that O
blocking O
EndoMT O
reduces O
the O
early O
development O
of O
diabetic B_DISEASE/B_GENE
nephropathy I_DISEASE/I_GENE
. O

Research B_NUMBER[MEASURE]/B_ORGANIZATION
Design I_NUMBER[MEASURE]/I_ORGANIZATION
AND O
METHODS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
EndoMT B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
induced O
in O
a O
mouse B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
pancreatic I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
microvascular I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
endothelial I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
cell I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
line I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
( O
MMEC B_DISEASE/B_TIME[MEASURE]
) O
in O
the O
presence B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O
advanced B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
glycation I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
end I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
products I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
AGEs B_DISEASE/B_BACTERIUM[BIO]
) O
and O
in O
the O
endothelial B_DISEASE/B_GENE
lineage I_DISEASE/I_GENE
- O
traceble B_GENE/B_DISEASE
mouse I_GENE/I_DISEASE
line I_GENE/I_DISEASE
Tie2 I_GENE/I_DISEASE
- O
Cre B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
; O
Loxp B_GENE/B_MEASURE
- O
EGFP B_GENE/B_MEASURE
by O
administration B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
AGEs B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
, O
with O
nonglycated B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
mouse I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
albumin I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
serving O
as O
a O
control B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O

Phosphorylated B_PERSON/B_DISEASE
Smad3 I_PERSON/I_DISEASE
was O
detected O
by O
immunoprecipitation B_LOCATION/B_PERSON
/ O
Western B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
blotting I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
confocal B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
microscopy I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

blocking O
studies O
using O
receptor O
for O
Age O
siRNA O
and O
a O
specific O
inhibitor O
of O
Smad3 O
( O
SIS3 O
) O
were O
performed O
in O
MMECs O
and O
in O
STZ O
- O
induced O
diabetic B_DISEASE
nephropathy I_DISEASE
in O
Tie2 O
- O
Cre O
; O
Loxp O
- O
EGFP O
mice O
. O

RESULTS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O
confocal B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
microscopy I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O
real B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
time B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
PCR I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
demonstrated O
that O
AGEs B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
induced O
EndoMT O
in O
MMECs B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
and O
in O
Tie2 B_GENE
- O
Cre B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
; O
Loxp B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
EGFP B_GENE
mice I_GENE
. O

Immunoprecipitation O
/ O
Western O
blotting O
showed O
that O
Smad3 O
was O
activated O
by O
Ages O
but O
was O
inhibited O
by O
SIS3 O
in O
MMECs O
and O
in O
STZ O
- O
induced O
diabetic B_DISEASE
nephropathy I_DISEASE
. O

Confocal O
microscopy O
and O
real O
- O
time O
PCR O
further O
demonstrated O
that O
SIS3 O
abrogated O
EndoMT O
, O
reduced O
renal O
fibrosis B_DISEASE/B_GENE
, O
and O
retarded O
progression O
of O
nephropathy B_DISEASE
. O

conclusions O
: O
EndoMT O
is O
a O
novel O
pathway O
leading O
to O
early O
development O
of O
diabetic B_DISEASE
nephropathy I_DISEASE
. O

blockade O
of O
EndoMT O
by O
SIS3 O
may O
provide O
a O
new O
strategy O
to O
retard O
the O
progression O
of O
diabetic B_DISEASE
nephropathy I_DISEASE
and O
other O
diabetes B_DISEASE
complications I_DISEASE
. O

Cytostatic O
and O
anti O
- O
angiogenic O
effects O
of O
temsirolimus O
in O
refractory O
mantle B_DISEASE/B_LOCATION
cell I_DISEASE/I_LOCATION
lymphoma I_DISEASE/I_LOCATION
. O

Mantle B_DISEASE
cell I_DISEASE
lymphoma I_DISEASE
( O
MCL B_DISEASE
) O
is O
a O
rare O
and O
aggressive O
type O
of O
B B_DISEASE
- I_DISEASE
cell I_DISEASE
non I_DISEASE
- I_DISEASE
Hodgkin I_DISEASE
' I_DISEASE
s I_DISEASE
lymphoma I_DISEASE
. O

patients B_PERSON/B_DISEASE
become O
progressively O
refractory B_DISEASE_ADJECTIVE[DISEASE]
to O
conventional B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
chemotherapy I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
their O
prognosis B_DISEASE
is O
poor B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

However O
, O
a O
38 O
% O
remission O
rate O
has O
been O
recently O
reported O
in O
refractory O
MCL B_DISEASE/B_PERSON
treated O
with O
temsirolimus O
, O
a O
mTOR O
inhibitor O
. O
Here O
we O
had O
the O
opportunity O
to O
study O
a O
case O
of O
refractory O
MCL B_DISEASE
who O
had O
tumor B_DISEASE
regression O
two O
months O
after O
temsirolimus O
treatment O
, O
and O
a O
progression O
- O
free O
survival O
of O
10 O
months O
. O

In O
this O
case B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
lymph B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
node I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
biopsies I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
were O
performed O
before O
and O
six B_TIME[MEASURE]/B_LOCATION
months I_TIME[MEASURE]/I_LOCATION
after O
temsirolimus B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
therapy I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

comparison O
of O
the O
two O
biopsies O
showed O
that O
temsirolimus O
inhibited O
tumor B_DISEASE
cell O
proliferation O
through O
cell O
cycle O
arrest O
, O
but O
did O
not O
induce O
any O
change O
in O
the O
number O
of O
apoptotic O
tumor B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
cells O
. O

Apart O
from O
this O
cytostatic O
effect O
, O
temsirolimus O
had O
an O
antiangiogenic O
effect O
with O
decrease O
of O
tumor B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
microvessel O
density O
and O
of O
VEGF O
expression O
. O

Moreover O
, O
numerous O
patchy O
, O
well O
- O
limited O
fibrotic O
areas O
, O
compatible O
with O
post O
- O
necrotic B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
tissue O
repair O
, O
were O
found O
after O
6 O
- O
month O
temsirolimus O
therapy O
. O

Thus O
, O
temsirolimus O
reduced O
tumor B_DISEASE
burden O
through O
associated O
cytostatic O
and O
anti O
- O
angiogenic O
effects O
. O
This O
dual O
effect O
of O
temsirolimus O
on O
tumor B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
tissue O
could O
contribute O
to O
its O
recently O
reported O
efficiency O
in O
refractory O
MCL B_DISEASE/B_MEASURE
resistant O
to O
conventional O
chemotherapy O
. O

Acute B_DISEASE
renal I_DISEASE
failure I_DISEASE
due O
to O
rifampicin O
. O

A O
23 O
- O
year O
- O
old O
male O
patient O
with O
bacteriologically O
proven O
pulmonary B_DISEASE
tuberculosis I_DISEASE
was O
treated O
with O
the O
various O
regimens O
of O
antituberculosis O
drugs O
for O
nearly O
15 O
months O
. O

Rifampicin O
was O
administered O
thrice O
as O
one O
of O
the O
3 O
- O
4 O
drug O
regimen O
and O
each O
time O
he O
developed O
untoward O
side O
effects O
like O
nausea B_DISEASE
, O
vomiting B_DISEASE
and O
fever B_DISEASE
with O
chills O
and O
rigors O
. O

The O
last B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
such I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
episode I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
of O
acute B_DISEASE/B_LOCATION
renal I_DISEASE/I_LOCATION
failure I_DISEASE/I_LOCATION
at O
which O
stage B_TIME[MEASURE]/B_ENT
the O
patient B_PERSON/B_DISEASE
was O
seen O
by O
the O
authors B_PERSON
of O
this O
report B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O

The O
patient B_PERSON/B_ORGANIZATION
, O
however O
, O
made O
a O
full B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
recovery I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Syncope B_DISEASE
caused O
by O
hyperkalemia B_DISEASE
during O
use O
of O
a O
combined O
therapy O
with O
the O
angiotensin O
- O
converting O
enzyme O
inhibitor O
and O
spironolactone O
. O

A O
76 O
year O
- O
old O
woman O
with O
a O
history O
of O
coronary O
artery O
bypass O
grafting O
and O
prior O
myocardial B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
infarction B_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O
transferred O
to O
the O
emergency O
room O
with O
loss B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of B_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
consciousness B_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
due O
to O
marked O
bradycardia B_DISEASE
caused O
by O
hyperkalemia B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
concentration B_MEASURE/B_LOCATION
of O
serum B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
potassium I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
was O
high B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
, O
and O
normal B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sinus B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
rhythm B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
restored O
after O
correction B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
the O
serum B_DISEASE
potassium I_DISEASE
level I_DISEASE
. O

The O
cause O
of O
hyperkalemia B_DISEASE
was O
considered O
to O
be O
several O
doses O
of O
spiranolactone O
, O
an O
aldosterone O
antagonist O
, O
in O
addition O
to O
the O
long O
- O
term O
intake O
of O
ramipril O
, O
an O
ace O
inhibitor O
. O

This O
case B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
a O
good B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
example I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
electrolyte B_DISEASE
imbalance I_DISEASE
causing O
acute B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
life I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
- O
threatening O
cardiac B_DISEASE
events I_DISEASE
. O

Clinicians O
should O
be O
alert O
to O
the O
possibility O
of O
hyperkalemia B_DISEASE
, O
especially O
in O
elderly O
patients O
using O
ace O
/ O
ARB O
in O
combination O
with O
potassium O
sparing O
agents O
and O
who O
have O
mild O
renal B_DISEASE/B_GENE
disturbance I_DISEASE/I_GENE
. O

Diffuse O
skeletal O
pain B_DISEASE
after O
administration O
of O
alendronate O
. O

Background O
: O
Osteoporosis B_DISEASE
is O
caused O
by O
bone O
resorption O
in O
excess O
of O
bone O
formation O
, O
and O
bisphosphonates O
, O
are O
used O
to O
inhibit O
bone O
resorption O
. O

Alendronate O
, O
a O
biphosphonate O
, O
is O
effective O
for O
both O
the O
treatment O
and O
prevention O
of O
osteoporosis B_DISEASE/B_GENE
in O
postmenopausal O
women O
. O

Side B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
effects I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
are O
relatively O
few B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
prominently O
gastrointestinal B_DISEASE_ADJECTIVE[DISEASE]
. O

Musculoskeletal B_DISEASE
pain I_DISEASE
may O
be O
an O
important O
side O
effect O
in O
these O
patients O
. O

We O
presented O
a O
patient O
admitted O
to O
our O
out O
- O
patient O
clinic O
with O
diffuse O
skeletal O
pain B_DISEASE
after O
three O
consecutive O
administration O
of O
alendronate O
. O

conclusion O
: O
We O
conclude O
that O
patients O
with O
osteoporosis B_DISEASE
can O
report O
pain B_DISEASE
, O
and O
bisphosphonate O
- O
related O
pain B_DISEASE
should O
also O
be O
considered O
before O
ascribing O
this O
complaint O
to O
osteoporosis B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Cerebrospinal O
fluid O
penetration O
of O
high O
- O
dose O
daptomycin O
in O
suspected O
Staphylococcus O
aureus O
meningitis B_DISEASE/B_PERSON
. O

objective O
: O
To O
report O
a O
case O
of O
methicillin O
- O
sensitive O
Staphylococcus O
aureus O
( O
MSSA O
) O
bacteremia B_DISEASE/B_PERSON
with O
suspected O
MSSA O
meningitis B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
treated O
with O
high O
- O
dose O
daptomycin O
assessed O
with O
concurrent O
serum O
and O
cerebrospinal O
fluid O
( O
CSF O
) O
concentrations O
. O

Case O
summary O
: O
A O
54 O
- O
year O
- O
old O
male O
presented O
to O
the O
emergency O
department O
with O
generalized O
weakness B_DISEASE
and O
presumed O
health O
- O
care O
- O
associated O
pneumonia B_DISEASE
shown O
on O
chest O
radiograph O
. O

Treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
was O
empirically O
initiated O
with O
vancomycin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
levofloxacin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O
and O
piperacillin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
/ O
tazobactam B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Blood B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
cultures I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
revealed O
S B_LOCATION/B_DISEASE
. O
aureus B_BACTERIUM[BIO]/B_DISEASE
susceptible I_BACTERIUM[BIO]/I_DISEASE
to O
oxacillin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O

Empiric B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
antibiotic I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
treatment I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
was O
narrowed O
to O
nafcillin O
on O
day B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
4 I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

On O
day O
8 O
, O
the O
patient O
developed O
acute B_DISEASE
renal I_DISEASE
failure I_DISEASE
( O
serum O
creatinine O
1 O
. O
9 O
mg O
/ O
DL O
, O
increased O
from O
1 O
. O
2 O
mg O
/ O
DL O
the O
previous O
day O
and O
0 O
. O
8 O
mg O
/ O
DL O
on O
admission O
) O
. O

The O
patient O
' O
s O
Glasgow O
coma O
Score O
was O
3 O
, O
with O
normal O
findings O
shown O
on O
computed O
tomography O
scan O
of O
the O
head O
72 O
hours O
following O
an O
episode O
of O
cardiac B_DISEASE
arrest I_DISEASE
on O
day O
10 O
. O

The O
patient O
experienced O
relapsing O
MSSA O
bacteremia B_DISEASE
on O
day O
9 O
, O
increasing O
the O
suspicion O
for O
a O
central O
nervous O
system O
( O
CNS O
) O
infection B_DISEASE/B_LOCATION
. O

Nafcillin O
was O
discontinued O
and O
daptomycin O
9 O
mg O
/ O
kg O
daily O
was O
initiated O
for O
suspected O
meningitis B_DISEASE
and O
was O
continued O
until O
the O
patient O
' O
s O
death O
on O
day O
16 O
. O

Daptomycin B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
serum I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
CSF B_MEASURE
trough I_MEASURE
concentrations I_MEASURE
were O
11 B_MEASURE
. O
21 B_MEASURE
ug I_MEASURE
/ O
mL B_MEASURE/B_LOCATION
and O
0 B_MEASURE
. O
52 B_MEASURE/B_PERSON
ug I_MEASURE/I_PERSON
/ O
mL B_MEASURE/B_LOCATION
, O
respectively O
, O
prior B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
to O
the O
third B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
dose I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
. O

lumbar B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
puncture I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
results I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
were O
inconclusive B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
no O
further B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
blood I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
cultures I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
were O
positive B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
MSSA B_DISEASE/B_BACTERIUM[BIO]
. O

creatine B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
kinase I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
levels I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
were O
normal B_DISEASE_ADJECTIVE[DISEASE]/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
prior I_DISEASE_ADJECTIVE[DISEASE]/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
daptomycin B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
therapy I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
were O
not O
reassessed O
. O

discussion O
: O
Daptomycin O
was O
initiated O
in O
our O
patient O
secondary O
to O
possible O
nafcillin O
- O
induced O
acute O
interstitial B_DISEASE
nephritis I_DISEASE
and O
relapsing O
bacteremia B_DISEASE
. O

At O
a O
dose B_MEASURE/B_LOCATION
of O
9 B_MEASURE
mg I_MEASURE
/ O
kg B_MEASURE
, O
resultant B_DISEASE_ADJECTIVE[DISEASE]
penetration I_DISEASE_ADJECTIVE[DISEASE]
of O
5 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
% I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
higher B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
than O
in O
previous B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
reports I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
, O
more O
consistent B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
with O
inflamed B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
meninges B_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

conclusions O
: O
High O
- O
dose O
daptomycin O
may O
be O
an O
alternative O
option O
for O
MSSA O
bacteremia B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
or O
without O
a O
CNS O
source O
in O
patients O
who O
have O
failed O
or O
cannot O
tolerate O
standard O
therapy O
. O

Further O
clinical O
evaluation O
in O
patients O
with O
confirmed O
meningitis B_DISEASE
is O
warranted O
. O

The O
role O
of O
nitric O
oxide O
in O
convulsions B_DISEASE
induced O
by O
lindane O
in O
rats O
. O

Lindane B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
an O
organochloride B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
pesticide I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
scabicide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O

It O
evokes O
convulsions B_DISEASE
mainly O
trough O
the O
blockage O
of O
GABA O
( O
A O
) O
receptors O
. O

Nitric O
oxide O
( O
NO O
) O
, O
gaseous O
neurotransmitter O
, O
has O
contradictor O
role O
in O
epileptogenesis O
due O
to O
opposite O
effects O
of O
L O
- O
arginine O
, O
precursor O
of O
NO O
syntheses O
( O
NOS O
) O
, O
and O
L O
- O
Name O
( O
NOS O
inhibitor O
) O
observed O
in O
different O
epilepsy B_DISEASE
models O
. O

The O
aim O
of O
the O
current O
study O
was O
to O
determine O
the O
effects O
of O
NO O
on O
the O
behavioral O
and O
EEG O
characteristics O
of O
lindane O
- O
induced O
epilepsy B_DISEASE
in O
male O
Wistar O
albino O
rats O
. O

The O
administration O
of O
L O
- O
arginine O
( O
600 O
, O
800 O
and O
1000 O
mg O
/ O
kg O
, O
i O
. O
p O
. O
) O
in O
dose O
- O
dependent O
manner O
significantly O
increased O
convulsion B_DISEASE
incidence O
and O
severity O
and O
shortened O
latency O
time O
to O
first O
convulsion B_DISEASE_ADJECTIVE[DISEASE]
elicited O
by O
lower O
lindane O
dose O
( O
4 O
mg O
/ O
kg O
, O
i O
. O
p O
. O
) O
. O

On O
the O
contrary O
, O
pretreatment O
with O
L O
- O
Name O
( O
500 O
, O
700 O
and O
900 O
mg O
/ O
kg O
, O
i O
. O
p O
. O
) O
decreased O
convulsion B_DISEASE
incidence O
and O
severity O
and O
prolonged O
latency O
time O
to O
convulsion B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
following O
injection O
with O
a O
convulsive B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
dose O
of O
lindane O
( O
8 O
mg O
/ O
kg O
, O
i O
. O
p O
. O
) O
. O

EEG B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
analyses I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
showed O
increase B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
number B_MEASURE
and O
duration B_MEASURE
of O
ictal B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
periods B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
EEG B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
of O
rats B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receiving O
l B_PROTEIN[GENE]/B_DISEASE
- O
arginine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
prior I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
to O
lindane B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
decrease B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
this O
number B_MEASURE
in O
rats B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pretreated O
with O
L B_OTHER/B_LOCATION
- O
NAME B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

These O
results O
support O
the O
conclusion O
that O
NO O
plays O
a O
role O
of O
endogenous O
convulsant O
in O
rat O
model O
of O
lindane O
seizures B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

severe O
polyneuropathy B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
and O
motor O
loss O
after O
intrathecal O
thiotepa O
combination O
chemotherapy O
: O
description O
of O
two O
cases O
. O

Two O
cases O
of O
severe O
delayed O
neurologic B_DISEASE
toxicity I_DISEASE
related O
to O
the O
administration O
of O
intrathecal O
( O
IT O
) O
combination O
chemotherapy O
including O
thiotepa O
( O
TSPA O
) O
are O
presented O
. O

Both O
cases O
developed O
axonal B_DISEASE/B_LOCATION
neuropathy I_DISEASE/I_LOCATION
with O
motor O
predominance O
in O
the O
lower O
extremities O
1 O
and O
6 O
months O
after O
IT O
chemotherapy O
was O
administered O
. O

Neurologic B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
toxicities I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
have O
been O
described O
with O
IT O
- O
methotrexate O
, O
IT O
- O
cytosine O
arabinoside O
and O
IT O
- O
TSPA O
. O

To O
our O
knowledge O
, O
however O
, O
axonal B_DISEASE
neuropathy I_DISEASE
following O
administration O
of O
these O
three O
agents O
has O
not O
been O
previously O
described O
. O

In O
spite O
of O
the O
fact O
that O
TSPA O
is O
a O
useful O
IT O
agent O
, O
its O
combination O
with O
MTX O
, O
Ara O
- O
C O
and O
radiotherapy O
could O
cause O
severe O
neurotoxicity B_DISEASE
. O

This O
unexpected B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
complication B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
indicates O
the O
need B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
for O
further B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
toxicology I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
research I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
IT O
- O
TSPA B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
. O

Effects B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
cromakalim B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
pinacidil B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
large B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
epicardial I_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
and O
small B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
coronary I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
arteries I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
in O
conscious B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
dogs I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
effects B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
i O
. O
v B_PROTEIN[GENE]/B_LOCATION
. O
bolus B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
administration I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
cromakalim B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
1 B_NUMBER[MEASURE]
- O
10 B_MEASURE
micrograms I_MEASURE
/ O
kg B_MEASURE/B_PERSON
) O
and O
pinacidil B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
3 B_MEASURE
- O
100 B_MEASURE
micrograms I_MEASURE
/ O
kg B_MEASURE/B_PERSON
) O
on O
large B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
( O
circumflex B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
artery B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
) O
and O
small B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
coronary B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
arteries B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
and O
on O
systemic B_DISEASE
hemodynamics I_DISEASE
were O
investigated O
in O
chronically O
instrumented O
conscious B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
dogs I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
and O
compared O
to O
those O
of O
nitroglycerin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
0 B_MEASURE
. O
03 B_MEASURE
- O
10 B_MEASURE
micrograms I_MEASURE
/ O
kg B_MEASURE
) O
. O

nitroglycerin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
up O
to O
0 B_MEASURE
. O
3 B_MEASURE
micrograms I_MEASURE
/ O
kg B_MEASURE
, O
selectively O
increased O
circumflex B_MEASURE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
artery B_MEASURE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
diameter B_MEASURE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
CxAD B_DISEASE/B_LOCATION
) O
without O
simultaneously O
affecting O
any O
other B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
cardiac I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
or O
systemic B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
hemodynamic B_MEASURE/I_BODY_PART_OR_ORGAN_COMPONENT
parameter B_MEASURE/I_BODY_PART_OR_ORGAN_COMPONENT
. O

In O
contrast B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPECIES[BIO]
, O
cromakalim B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
pinacidil B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O
all O
doses B_MEASURE/B_LOCATION
and O
nitroglycerin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O
doses B_MEASURE
higher I_MEASURE
than O
0 B_MEASURE
. O
3 B_MEASURE
micrograms I_MEASURE
/ O
kg B_MEASURE
simultaneously O
and O
dose B_MEASURE
- O
dependently O
increased O
CxAD B_DISEASE/B_GENE
, O
coronary B_DISEASE/B_GENE
blood B_DISEASE/I_GENE
flow B_DISEASE/I_GENE
and O
heart B_MEASURE/B_DISEASE
rate I_MEASURE/I_DISEASE
and O
decreased O
coronary B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
vascular I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
resistance I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
and O
aortic B_MEASURE/B_DISEASE
pressure B_MEASURE/I_DISEASE
. O

Cromakalim B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
was O
approximately O
8 B_NUMBER[MEASURE]
- O
to O
9 B_MEASURE
. O
5 B_MEASURE
- O
fold B_LOCATION/B_MEASURE
more O
potent B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
than O
pinacidil B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
increasing O
CxAD B_DISEASE
. O

Vasodilation O
of O
large O
and O
small O
coronary O
vessels O
and O
hypotension B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
induced O
by O
cromakalim O
and O
pinacidil O
were O
not O
affected O
by O
prior O
combined O
beta O
adrenergic O
and O
muscarinic O
receptors O
blockade O
but O
drug O
- O
induced O
tachycardia B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O
abolished O
. O

When O
circumflex B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
artery B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
blood B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
flow B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
maintained O
constant B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
, O
the O
increases B_DISEASE_ADJECTIVE[DISEASE]
in O
CxAD B_DISEASE/B_GENE
induced O
by O
cromakalim B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
10 B_MEASURE
micrograms I_MEASURE
/ O
kg B_MEASURE/B_PERSON
) O
, O
pinacidil B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
30 B_MEASURE
micrograms I_MEASURE
/ O
kg B_MEASURE/B_PERSON
) O
and O
nitroglycerin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
10 B_MEASURE
micrograms I_MEASURE
/ O
kg B_MEASURE/B_PERSON
) O
were O
reduced O
by O
68 B_MEASURE
+ I_MEASURE
/ O
- O
7 B_MEASURE
, O
54 B_MEASURE
+ I_MEASURE
/ O
- O
9 B_MEASURE
and O
1 B_MEASURE/B_LOCATION
+ I_MEASURE/I_LOCATION
/ O
- O
1 B_MEASURE
% I_MEASURE
, O
respectively O
. O

Thus O
, O
whereas O
nitroglycerin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
preferentially O
and O
flow B_MEASURE/B_SPORT[ENT]
- O
independently O
dilates B_DISEASE_ADJECTIVE[DISEASE]
large I_DISEASE_ADJECTIVE[DISEASE]
coronary I_DISEASE_ADJECTIVE[DISEASE]
arteries I_DISEASE_ADJECTIVE[DISEASE]
, O
cromakalim B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
pinacidil B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
dilate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
both O
large B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
and O
small B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
coronary I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
arteries I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
and O
this O
effect B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
is O
not O
dependent B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
upon O
the O
simultaneous B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
beta B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
adrenoceptors B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
mediated O
rise B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
in O
myocardial B_DISEASE/B_MEASURE
metabolic B_DISEASE/I_MEASURE
demand B_DISEASE/I_MEASURE
. O

Finally O
, O
two B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
mechanisms I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
at O
least O
, O
direct B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
vasodilation B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
and O
flow B_DISEASE
dependency I_DISEASE
, O
are O
involved O
in O
the O
cromakalim B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
and O
pinacidil B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
induced O
increase B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
CxAD B_DISEASE/B_GENE
. O

Mefenamic O
acid O
- O
induced O
neutropenia B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
and O
renal B_DISEASE
failure I_DISEASE
in O
elderly O
females O
with O
hypothyroidism B_DISEASE
. O

We O
report O
mefenamic O
acid O
- O
induced O
non O
- O
oliguric O
renal B_DISEASE
failure I_DISEASE
and O
severe O
neutropenia B_DISEASE
occurring O
simultaneously O
in O
two O
elderly O
females O
. O

The O
neutropenia B_DISEASE
was O
due O
to O
maturation O
arrest O
of O
the O
myeloid O
series O
in O
one O
patient O
. O

Both O
patients O
were O
also O
hypothyroid B_DISEASE_ADJECTIVE[DISEASE]
, O
but O
it O
is O
not O
clear O
whether O
this O
was O
a O
predisposing O
factor O
to O
the O
development O
of O
these O
adverse O
reactions O
. O

However O
, O
it O
would O
seem O
prudent O
not O
to O
use O
mefenamic O
acid O
in O
hypothyroid B_DISEASE/B_PERSON
patients O
until O
the O
hypothyroidism B_DISEASE/B_MEASURE
has O
been O
corrected O
. O

Etiology O
of O
hypercalcemia B_DISEASE
in O
hemodialysis O
patients O
on O
calcium O
carbonate O
therapy O
. O

Fourteen O
of O
39 O
dialysis O
patients O
( O
36 O
% O
) O
became O
hypercalcemic B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
after O
switching O
to O
calcium O
carbonate O
as O
their O
principal O
phosphate O
binder O
. O

In O
order O
to O
identify O
risk O
factors O
associated O
with O
the O
development O
of O
hypercalcemia B_DISEASE
, O
indirect O
parameters O
of O
intestinal O
calcium O
reabsorption O
and O
bone O
turnover O
rate O
in O
these O
14 O
patients O
were O
compared O
with O
results O
in O
14 O
eucalcemic O
patients O
matched O
for O
age O
, O
sex O
, O
length O
of O
time O
on O
dialysis O
, O
and O
etiology O
of O
renal B_DISEASE
disease I_DISEASE
. O

In O
addition O
to O
experiencing O
hypercalcemic B_DISEASE_ADJECTIVE[DISEASE]
episodes O
with O
peak O
calcium O
values O
of O
2 O
. O
7 O
to O
3 O
. O
8 O
mmol O
/ O
L O
( O
10 O
. O
7 O
to O
15 O
. O
0 O
mg O
/ O
DL O
) O
, O
patients O
in O
the O
hypercalcemic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
group O
exhibited O
a O
significant O
increase O
in O
the O
mean O
calcium O
concentration O
obtained O
during O
6 O
months O
before O
the O
switch O
, O
compared O
with O
the O
mean O
value O
obtained O
during O
the O
7 O
months O
of O
observation O
after O
the O
switch O
( O
2 O
. O
4 O
+ O
/ O
- O
0 O
. O
03 O
to O
2 O
. O
5 O
+ O
/ O
- O
0 O
. O
03 O
mmol O
/ O
L O
[ O
9 O
. O
7 O
+ O
/ O
- O
0 O
. O
2 O
to O
10 O
. O
2 O
+ O
/ O
- O
0 O
. O
1 O
mg O
/ O
DL O
] O
, O
P O
= O
0 O
. O
006 O
) O
. O

In O
contrast B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
eucalcemic B_PERSON/B_BIO
patients I_PERSON/I_BIO
exhibited O
no O
change B_MEASURE
in O
mean B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
calcium I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
values I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
over O
the O
same B_TIME[MEASURE]/B_LOCATION
time I_TIME[MEASURE]/I_LOCATION
period I_TIME[MEASURE]/I_LOCATION
( O
2 B_MEASURE
. O
3 B_MEASURE
+ I_MEASURE
/ O
- O
0 B_MEASURE
. O
05 B_MEASURE
to O
2 B_MEASURE
. O
3 B_MEASURE
+ I_MEASURE
/ O
- O
0 B_MEASURE
. O
05 B_MEASURE/B_LOCATION
mmol I_MEASURE/I_LOCATION
/ O
L B_OTHER/B_TIME[MEASURE]
[ O
9 B_MEASURE
. O
2 B_MEASURE/B_LOCATION
+ I_MEASURE/I_LOCATION
/ O
- O
0 B_MEASURE
. O
2 B_MEASURE
to O
9 B_MEASURE
. O
2 B_MEASURE/B_LOCATION
+ I_MEASURE/I_LOCATION
/ O
- O
0 B_MEASURE
. O
2 B_MEASURE
mg I_MEASURE
/ O
DL B_MEASURE/B_LOCATION
] I_MEASURE/I_LOCATION
) O
. O

CaCO3 B_MEASURE/B_PERSON
dosage I_MEASURE/I_PERSON
, O
calculated O
dietary B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
calcium I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
intake I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O
and O
circulating O
levels B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
of O
vitamin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
D I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
metabolites I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
were O
similar B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O
both O
groups B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
. O

Physical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activity I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
index I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
predialysis B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
serum O
bicarbonate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
levels I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
also O
were O
similar B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
both O
groups B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
. O

However O
, O
there O
was O
a O
significant B_MEASURE
difference I_MEASURE
in O
parameters B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
reflecting O
bone B_DISEASE/B_GENE
turnover I_DISEASE/I_GENE
rates I_DISEASE/I_GENE
between O
groups B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O
( O
abstract B_TIME[MEASURE]/B_ORGANIZATION
TRUNCATED I_TIME[MEASURE]/I_ORGANIZATION
AT O
250 B_LOCATION/B_ENT
Words I_LOCATION/I_ENT
) O
. O

Late O
- O
onset O
scleroderma B_DISEASE
renal I_DISEASE
crisis I_DISEASE
induced O
by O
tacrolimus O
and O
prednisolone O
: O
a O
case O
report O
. O

Scleroderma B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
renal I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
crisis I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
( O
SRC B_LOCATION
) O
is O
a O
rare O
complication O
of O
systemic B_DISEASE
sclerosis I_DISEASE
( O
SSc B_LOCATION/B_ORGANIZATION
) O
but O
can O
be O
severe O
enough O
to O
require O
temporary O
or O
permanent O
renal O
replacement O
therapy O
. O

moderate O
to O
high O
dose O
corticosteroid O
use O
is O
recognized O
as O
a O
major O
risk O
factor O
for O
SRC B_DISEASE/B_GENE
. O

Furthermore O
, O
there O
have O
been O
reports O
of O
thrombotic B_DISEASE
microangiopathy I_DISEASE
precipitated O
by O
cyclosporine O
in O
patients O
with O
SSc B_DISEASE/B_LOCATION
. O

In O
this O
article O
, O
we O
report O
a O
patient O
with O
SRC B_GENE/B_DISEASE
induced O
by O
tacrolimus O
and O
corticosteroids O
. O

The O
aim O
of O
this O
work O
is O
to O
call O
attention O
to O
the O
risk O
of O
tacrolimus O
use O
in O
patients O
with O
SSc B_DISEASE/B_GENE
. O

Methyldopa O
- O
induced O
hemolytic B_DISEASE/B_LOCATION
anemia I_DISEASE/I_LOCATION
in O
a O
15 O
year O
old O
presenting O
as O
near O
- O
syncope B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
. O

Methyldopa B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
is O
an O
antihypertensive B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
medication I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
which O
is O
available B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
generically O
and O
under O
the O
trade B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
name I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
Aldomet I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
that O
is O
widely O
prescribed O
in O
the O
adult B_MEASURE/B_LOCATION
population B_MEASURE/I_LOCATION
and O
infrequently O
used O
in O
children B_PERSON/B_LOCATION
. O

Methyldopa O
causes O
an O
autoimmune B_DISEASE
hemolytic I_DISEASE
anemia I_DISEASE
in O
a O
small O
percentage O
of O
patients O
who O
take O
the O
drug O
. O

We O
report O
a O
case O
of O
methyldopa O
- O
induced O
hemolytic B_DISEASE
anemia I_DISEASE
in O
a O
15 O
- O
year O
- O
old O
boy O
who O
presented O
to O
the O
emergency B_LOCATION/B_PERSON
department B_LOCATION/I_PERSON
with O
near O
- O
syncope B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
. O

The O
boy O
had O
been O
treated O
with O
intravenous O
methyldopa O
during O
a O
trauma B_DISEASE_ADJECTIVE[DISEASE]/B_SEQUENCE[MEASURE]
admission O
seven O
weeks O
prior O
to O
presentation O
. O

Evaluation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
revealed O
a O
hemoglobin B_MEASURE
of O
three B_MEASURE
grams I_MEASURE
, O
3 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
+ I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Coombs I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
' I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
test I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
polyspecific B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
anti I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
human B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
globulin I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
monospecific B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
IgG I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
reagents I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
and O
a O
warm B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reacting B_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
autoantibody B_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

transfusion B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BODY_PART_OR_ORGAN_COMPONENT
and O
corticosteroid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
resulted O
in O
a O
complete B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
recovery I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
patient B_PERSON/B_DISEASE
. O

Emergency B_PERSON
physicians I_PERSON
treating O
children B_PERSON/B_DISEASE
must O
be O
aware B_PERSON
of O
this O
syndrome B_DISEASE
in O
order B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
diagnose O
and O
treat O
it O
correctly O
. O

A O
brief O
review O
of O
autoimmune O
and O
drug O
- O
induced O
hemolytic B_DISEASE
anemias I_DISEASE
is O
provided O
. O

The O
risk O
and O
associated O
factors O
of O
methamphetamine O
psychosis B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
methamphetamine O
- O
dependent O
patients O
in O
Malaysia O
. O

objective O
: O
The O
objective O
of O
this O
study O
was O
to O
determine O
the O
risk O
of O
lifetime O
and O
current O
methamphetamine O
- O
induced O
psychosis B_DISEASE
in O
patients O
with O
methamphetamine O
dependence O
. O

The O
association O
between O
psychiatric O
co O
- O
morbidity O
and O
methamphetamine O
- O
induced O
psychosis B_DISEASE/B_LOCATION
was O
also O
studied O
. O

METHODS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O
This O
was O
a O
cross B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
sectional B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
conducted O
concurrently O
at O
a O
teaching O
hospital B_LOCATION/B_ORGANIZATION
and O
a O
drug B_LOCATION
rehabilitation I_LOCATION
center I_LOCATION
in O
Malaysia B_LOCATION
. O

patients O
with O
the O
diagnosis O
of O
methamphetamine O
based O
on O
DSM O
- O
IV O
were O
interviewed O
using O
the O
Mini O
International O
Neuropsychiatric O
Interview O
( O
M O
. O
I O
. O
N O
. O
I O
. O
) O
for O
methamphetamine O
- O
induced O
psychosis B_DISEASE
and O
other O
Axis O
I O
psychiatric B_DISEASE
disorders I_DISEASE
. O

The O
information B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
sociodemographic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
background I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
and O
drug B_DISEASE_ADJECTIVE[DISEASE]
use I_DISEASE_ADJECTIVE[DISEASE]
history I_DISEASE_ADJECTIVE[DISEASE]
was O
obtained O
from O
interview B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O
medical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
records I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Results O
: O
Of O
292 O
subjects O
, O
47 O
. O
9 O
% O
of O
the O
subjects O
had O
a O
past O
history O
of O
psychotic B_DISEASE
symptoms I_DISEASE
and O
13 O
. O
0 O
% O
of O
the O
patients O
were O
having O
current O
psychotic B_DISEASE
symptoms I_DISEASE
. O

Co O
- O
morbid O
major O
depressive B_DISEASE
disorder I_DISEASE
( O
OR O
= O
7 O
. O
18 O
, O
95 O
CI O
= O
2 O
. O
612 O
- O
19 O
. O
708 O
) O
, O
bipolar B_DISEASE
disorder I_DISEASE
( O
OR O
= O
13 O
. O
807 O
, O
95 O
CI O
= O
5 O
. O
194 O
- O
36 O
. O
706 O
) O
, O
antisocial B_DISEASE
personality I_DISEASE
disorder I_DISEASE
( O
OR O
= O
12 O
. O
619 O
, O
95 O
CI O
= O
6 O
. O
702 O
- O
23 O
. O
759 O
) O
and O
heavy O
methamphetamine O
uses O
were O
significantly O
associated O
with O
lifetime O
methamphetamine O
- O
induced O
psychosis B_DISEASE/B_LOCATION
after O
adjusted O
for O
other O
factors O
. O

Major B_DISEASE/B_PERSON
depressive I_DISEASE/I_PERSON
disorder I_DISEASE/I_PERSON
( O
OR O
= O
2 O
. O
870 O
, O
CI O
= O
1 O
. O
154 O
- O
7 O
. O
142 O
) O
and O
antisocial B_DISEASE/B_PERSON
personality I_DISEASE/I_PERSON
disorder I_DISEASE/I_PERSON
( O
OR O
= O
3 O
. O
299 O
, O
95 O
CI O
= O
1 O
. O
375 O
- O
7 O
. O
914 O
) O
were O
the O
only O
factors O
associated O
with O
current O
psychosis B_DISEASE
. O

conclusion O
: O
There O
was O
a O
high O
risk O
of O
psychosis B_DISEASE
in O
patients O
with O
methamphetamine O
dependence O
. O

It O
was O
associated O
with O
co O
- O
morbid O
affective B_DISEASE
disorder I_DISEASE
, O
antisocial B_DISEASE
personality I_DISEASE
, O
and O
heavy O
methamphetamine O
use O
. O

It O
is O
recommended O
that O
all O
cases O
of O
methamphetamine O
dependence O
should O
be O
screened O
for O
psychotic B_DISEASE/B_LOCATION
symptoms I_DISEASE/I_LOCATION
. O

Cerebellar O
sensory O
processing O
alterations O
impact O
motor O
cortical O
plasticity O
in O
Parkinson B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
' I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
s I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
disease I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
: O
clues O
from O
dyskinetic B_DISEASE_ADJECTIVE[DISEASE]/B_NUMBER[MEASURE]
patients O
. O

The O
plasticity O
of O
primary O
motor O
cortex O
( O
M1 O
) O
in O
patients O
with O
Parkinson B_DISEASE
' I_DISEASE
s I_DISEASE
disease I_DISEASE
( O
PD B_DISEASE/B_PROTEIN[GENE]
) O
and O
levodopa O
- O
induced O
dyskinesias B_DISEASE_ADJECTIVE[DISEASE]
( O
LIDs B_DISEASE/B_PROTEIN[GENE]
) O
is O
severely O
impaired O
. O

We O
recently O
reported O
in O
young B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
healthy I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
subjects I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
inhibitory O
cerebellar B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
stimulation I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
enhanced O
the O
sensorimotor B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
plasticity B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
M1 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
that O
was O
induced O
by O
paired B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
associative I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
stimulation I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
( O
PAS B_DISEASE/B_LOCATION
) O
. O

This O
study O
demonstrates O
that O
the O
deficient O
sensorimotor O
M1 O
plasticity O
in O
16 O
patients O
with O
LIDs B_DISEASE
could O
be O
reinstated O
by O
a O
single O
session O
of O
real O
inhibitory O
cerebellar O
stimulation O
but O
not O
sham O
stimulation O
. O

This O
was O
evident B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
only O
when O
a O
sensory B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
component I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
was O
involved O
in O
the O
induction B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
plasticity B_DISEASE
, O
indicating O
that O
cerebellar B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sensory B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
processing B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
function B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
involved O
in O
the O
resurgence B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
of O
M1 B_DISEASE/B_ORGANISM_FUNCTION
plasticity I_DISEASE/I_ORGANISM_FUNCTION
. O

The O
benefit O
of O
inhibitory O
cerebellar O
stimulation O
on O
LIDs B_DISEASE
is O
known O
. O

To O
explore O
whether O
this O
benefit O
is O
linked O
to O
the O
restoration O
of O
sensorimotor O
plasticity O
of O
M1 O
, O
we O
conducted O
an O
additional O
study O
looking O
at O
changes O
in O
LIDs B_DISEASE_ADJECTIVE[DISEASE]
and O
PAS O
- O
induced O
plasticity O
after O
10 O
sessions O
of O
either O
bilateral O
, O
real O
inhibitory O
cerebellar O
stimulation O
or O
sham O
stimulation O
. O

Only O
real B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
not O
sham B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
stimulation I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
had O
an O
antidyskinetic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effect I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
it O
was O
paralleled O
by O
a O
resurgence B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
the O
sensorimotor B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
plasticity B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O
M1 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
. O

These O
results O
suggest O
that O
alterations O
in O
cerebellar O
sensory O
processing O
function O
, O
occurring O
secondary O
to O
abnormal O
basal O
ganglia O
signals O
reaching O
it O
, O
may O
be O
an O
important O
element O
contributing O
to O
the O
maladaptive O
sensorimotor O
plasticity O
of O
M1 O
and O
the O
emergence O
of O
abnormal B_DISEASE
involuntary I_DISEASE
movements I_DISEASE
. O

The O
long O
- O
term O
safety O
of O
danazol O
in O
women O
with O
hereditary B_DISEASE/B_LOCATION
angioedema I_DISEASE/I_LOCATION
. O

Although O
the O
short B_PERSON/B_MEASURE
- O
term B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
safety I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
( O
less B_MEASURE
than O
or O
equal B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
to O
6 B_TIME[MEASURE]
months I_TIME[MEASURE]
) O
of O
danazol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
has O
been O
established O
in O
a O
variety B_ENT/B_MEASURE
of O
settings B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
no O
information B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
exists O
as O
to O
its O
long B_TIME[MEASURE]/B_LOCATION
- O
term B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
safety I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

We O
therefore O
investigated O
the O
long O
- O
term O
safety O
of O
danazol O
by O
performing O
a O
retrospective O
chart O
review O
of O
60 O
female O
patients O
with O
hereditary B_DISEASE/B_LOCATION
angioedema I_DISEASE/I_LOCATION
treated O
with O
danazol O
for O
a O
continuous O
period O
of O
6 O
months O
or O
longer O
. O

The O
mean B_TIME[MEASURE]/B_LOCATION
age I_TIME[MEASURE]/I_LOCATION
of O
the O
patients B_PERSON
was O
35 B_MEASURE
. O
2 B_MEASURE/B_ENT
years I_MEASURE/I_ENT
and O
the O
mean B_TIME[MEASURE]/B_LOCATION
duration I_TIME[MEASURE]/I_LOCATION
of O
therapy B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
was O
59 B_MEASURE
. O
7 B_TIME[MEASURE]
months I_TIME[MEASURE]
. O

virtually O
all O
patients B_PERSON
experienced O
one B_NUMBER[MEASURE]
or O
more B_NUMBER[MEASURE]/B_PERSON
adverse I_NUMBER[MEASURE]/I_PERSON
reactions I_NUMBER[MEASURE]/I_PERSON
. O

Menstrual B_DISEASE
abnormalities I_DISEASE
( O
79 O
% O
) O
, O
weight B_DISEASE
gain I_DISEASE
( O
60 O
% O
) O
, O
muscle B_DISEASE
cramps I_DISEASE
/ O
myalgias B_DISEASE
( O
40 O
% O
) O
, O
and O
transaminase O
elevations O
( O
40 O
% O
) O
were O
the O
most O
common O
adverse O
reactions O
. O

The O
drug B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O
discontinued O
due O
to O
adverse B_DISEASE
reactions I_DISEASE
in O
8 B_PERSON/B_TIME[MEASURE]
patients I_PERSON/I_TIME[MEASURE]
. O

No O
patient B_PERSON
has O
died O
or O
suffered O
any O
apparent B_TIME[MEASURE]/B_PERSON
long I_TIME[MEASURE]/I_PERSON
- O
term B_DISEASE_ADJECTIVE[DISEASE]
sequelae I_DISEASE_ADJECTIVE[DISEASE]
that O
were O
directly O
attributable B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
to O
the O
drug B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O

We O
conclude O
that O
, O
despite O
a O
relatively O
high B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
incidence I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O
adverse B_DISEASE
reactions I_DISEASE
, O
danazol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
has O
proven O
to O
be O
remarkably O
safe B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
over O
the O
long B_TIME[MEASURE]/B_LOCATION
- O
term B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
this O
group B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
patients B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
function O
of O
P2X3 O
receptor O
and O
NK1 O
receptor O
antagonists O
on O
cyclophosphamide O
- O
induced O
cystitis B_DISEASE
in O
rats O
. O

purpose O
: O
The O
purpose O
of O
the O
study O
is O
to O
explore O
the O
function O
of O
P2X3 O
and O
NK1 O
receptors O
antagonists O
on O
cyclophosphamide O
( O
CYP O
) O
- O
induced O
cystitis B_DISEASE
in O
rats O
. O

METHODS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O
sixty B_PERSON
female I_PERSON
Sprague I_PERSON
- O
Dawley B_PERSON/B_MEASURE
( O
SD B_MEASURE/B_DISEASE
) O
rats B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
randomly O
divided O
into O
three B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_NUMBER[MEASURE]
groups B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_NUMBER[MEASURE]
. O

The O
rats B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
control B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
group I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
were O
intraperitoneally O
( O
i O
. O
p B_MEASURE/B_LOCATION
. O
) O
injected O
with O
0 B_MEASURE
. O
9 B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
% I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
saline I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
4 B_MEASURE
ml I_MEASURE
/ O
kg B_MEASURE
) O
; O
the O
rats B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
model B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
group I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
were O
i O
. O
p B_MEASURE/B_LOCATION
. O
injected O
with O
CYP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
( O
150 B_MEASURE
mg I_MEASURE
/ O
kg B_MEASURE
) O
; O
and O
the O
rats B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
intervention B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
group I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
i O
. O
p B_MEASURE/B_LOCATION
. O
injected O
with O
CYP B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
subsequently O
perfusion B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BODY_PART_OR_ORGAN_COMPONENT
of O
bladder B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
with O
P2X3 B_GENE
and O
NK1 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
receptors I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
' I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
antagonists I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
Suramin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
GR B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
82334 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

spontaneous O
pain B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
behaviors O
following O
the O
administration O
of O
CYP O
were O
observed O
. O

Urodynamic B_TIME[MEASURE]/B_LOCATION
parameters I_TIME[MEASURE]/I_LOCATION
, O
bladder B_MEASURE/B_LOCATION
pressure I_MEASURE/I_LOCATION
- O
volume B_MEASURE/B_LOCATION
curve I_MEASURE/I_LOCATION
, O
maximum B_MEASURE/B_LOCATION
voiding I_MEASURE/I_LOCATION
pressure I_MEASURE/I_LOCATION
( O
MVP B_PERSON/B_DISEASE
) O
, O
and O
maximum B_MEASURE/B_LOCATION
cystometric I_MEASURE/I_LOCATION
capacity I_MEASURE/I_LOCATION
( O
MCC B_DISEASE/B_GENE
) O
, O
were O
recorded O
. O

Pathological B_DISEASE_ADJECTIVE[DISEASE]
changes I_DISEASE_ADJECTIVE[DISEASE]
in O
bladder B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
tissue I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
were O
observed O
. O

immunofluorescence B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
was O
used O
to O
detect O
the O
expression B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
of O
P2X3 B_GENE
and O
NK1 B_GENE
receptors I_GENE
in O
bladder B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
. O

Results O
: O
Cyclophosphamide O
treatment O
increased O
the O
spontaneous O
pain B_DISEASE/B_ORGANISM_FUNCTION
behaviors O
scores O
. O

The O
incidence B_MEASURE
of O
bladder B_DISEASE
instability I_DISEASE
during O
urine B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
storage I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
period I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
of O
model B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
group I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
was O
significantly O
higher B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
than O
intervention B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
group I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
( O
X B_OTHER/B_PROTEIN[GENE]
( O
2 B_NUMBER[MEASURE]
) O
= O
7 B_MEASURE
. O
619 B_MEASURE
, O
P B_PROTEIN[GENE]/B_LOCATION
= O
0 B_MEASURE
. O
007 B_MEASURE
) O
and O
control B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
group I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
( O
X B_OTHER/B_PROTEIN[GENE]
( O
2 B_NUMBER[MEASURE]
) O
= O
13 B_MEASURE
. O
755 B_MEASURE
, O
P B_PROTEIN[GENE]/B_LOCATION
= O
0 B_MEASURE
. O
000 B_MEASURE
) O
. O

MCC B_DISEASE/B_MEASURE
in O
the O
model B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
group I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
was O
lower B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
than O
the O
control B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
and O
intervention B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
groups I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O
P B_PROTEIN[GENE]/B_LOCATION
< O
0 B_MEASURE
. O
01 B_MEASURE
) O
. O

Histological O
changes O
evident O
in O
model O
and O
intervention O
groups O
rats O
' O
bladder O
included O
edema B_DISEASE
, O
vasodilation O
, O
and O
infiltration O
of O
inflammatory O
cells O
. O

In O
model B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
group I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
, O
the O
expression B_GENE/B_MEASURE
of O
P2X3 B_GENE
receptor I_GENE
increased O
in O
urothelium B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
and O
suburothelium B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
, O
and O
NK1 B_GENE
receptor I_GENE
increased O
in O
suburothelium B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
, O
while O
the O
expression B_GENE/B_MEASURE
of O
them O
in O
intervention B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
group I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
lower B_DISEASE_ADJECTIVE[DISEASE]
. O

conclusions O
: O
In O
CYP O
- O
induced O
cystitis B_DISEASE
, O
the O
expression O
of O
P2X3 O
and O
NK1 O
receptors O
increased O
in O
urothelium O
and O
/ O
or O
suburothelium O
. O

perfusion B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BODY_PART_OR_ORGAN_COMPONENT
of O
bladder B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
with O
P2X3 B_GENE
and O
NK1 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
receptors B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
antagonists B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
ameliorated O
the O
bladder B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
function I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

patient O
tolerance O
study O
of O
topical O
chlorhexidine O
diphosphanilate O
: O
a O
new O
topical O
agent O
for O
burns B_DISEASE
. O

effective O
topical O
antimicrobial O
agents O
decrease O
infection B_DISEASE
and O
mortality O
in O
burn B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
patients O
. O

Chlorhexidine O
phosphanilate O
( O
CHP O
) O
, O
a O
new O
broad O
- O
spectrum O
antimicrobial O
agent O
, O
has O
been O
evaluated O
as O
a O
topical O
burn B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
wound O
dressing O
in O
cream O
form O
, O
but O
preliminary O
clinical O
trials O
reported O
that O
it O
was O
painful O
upon O
application O
. O

This O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
compared O
various B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
concentrations I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
CHP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O
determine O
if O
a O
tolerable B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
concentration B_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
could O
be O
identified O
with O
retention B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
antimicrobial B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
efficacy I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O

Twenty O
- O
nine O
burn B_DISEASE/B_PERSON
patients O
, O
each O
with O
two O
similar O
burns B_PERSON/B_DISEASE
which O
could O
be O
separately O
treated O
, O
were O
given O
pairs O
of O
treatments O
at O
successive O
12 O
- O
h O
intervals O
over O
a O
3 O
- O
day O
period O
. O

One O
burn B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
site O
was O
treated O
with O
each O
of O
four O
different O
CHP O
concentrations O
, O
from O
0 O
. O
25 O
per O
cent O
to O
2 O
per O
cent O
, O
their O
vehicle O
, O
and O
1 O
per O
cent O
silver O
sulphadiazine O
( O
AgSD O
) O
cream O
, O
an O
antimicrobial O
agent O
frequently O
used O
for O
topical O
treatment O
of O
burn B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
wounds O
. O

The O
other B_LOCATION/B_PERSON
site I_LOCATION/I_PERSON
was O
always O
treated O
with O
AgSD B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
cream I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

There O
was O
a O
direct O
relationship O
between O
CHP O
concentration O
and O
patients O
' O
ratings O
of O
pain B_DISEASE
on O
an O
analogue O
scale O
. O

The O
0 O
. O
25 O
per O
cent O
CHP O
cream O
was O
closest O
to O
AgSD O
in O
pain B_DISEASE
tolerance O
; O
however O
, O
none O
of O
the O
treatments O
differed O
statistically O
from O
AgSD O
or O
from O
each O
other O
. O

In O
addition B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
ease B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
application B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
CHP B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
creams B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
was O
less O
satisfactory B_DISEASE_ADJECTIVE[DISEASE]
than O
that O
of O
AgSD B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O

It O
was O
concluded O
that O
formulations B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
at O
or O
below O
0 B_MEASURE
. O
5 B_MEASURE
per O
cent B_MEASURE
CHP I_MEASURE
may O
prove O
acceptable B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
wound B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
care I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_PERSON
, O
but O
the O
vehicle B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
system I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
needs O
pharmaceutical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
improvement I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
render O
it O
more O
tolerable B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
and O
easier B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O
use O
. O

acute O
hepatitis B_DISEASE
associated O
with O
clopidogrel O
: O
a O
case O
report O
and O
review O
of O
the O
literature O
. O

Drug O
- O
induced O
hepatotoxicity B_DISEASE
is O
a O
common O
cause O
of O
acute O
hepatitis B_DISEASE
, O
and O
the O
recognition O
of O
the O
responsible O
drug O
may O
be O
difficult O
. O

We O
describe O
a O
case O
of O
clopidogrel O
- O
related O
acute O
hepatitis B_DISEASE
. O

The O
diagnosis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
is O
strongly O
suggested O
by O
an O
accurate B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
medical I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
history I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
and O
liver B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
biopsy I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Reports O
about O
cases O
of O
hepatotoxicity B_DISEASE
due O
to O
clopidogrel O
are O
increasing O
in O
the O
last O
few O
years O
, O
after O
the O
increased O
use O
of O
this O
drug O
. O

In O
conclusion O
, O
we O
believe O
that O
physicians O
should O
carefully O
consider O
the O
risk O
of O
drug O
- O
induced O
hepatic B_DISEASE
injury I_DISEASE
when O
clopidogrel O
is O
prescribed O
. O

Bortezomib O
and O
dexamethasone O
as O
salvage O
therapy O
in O
patients O
with O
relapsed O
/ O
refractory O
multiple B_DISEASE
myeloma I_DISEASE
: O
analysis O
of O
long O
- O
term O
clinical O
outcomes O
. O

Bortezomib O
( O
bort O
) O
- O
dexamethasone O
( O
Dex O
) O
is O
an O
effective O
therapy O
for O
relapsed O
/ O
refractory O
( O
R O
/ O
R O
) O
multiple B_DISEASE
myeloma I_DISEASE
( O
MM B_TIME[MEASURE]/B_LOCATION
) O
. O

This O
retrospective O
study O
investigated O
the O
combination O
of O
bort O
( O
1 O
. O
3 O
mg O
/ O
m O
( O
2 O
) O
on O
days O
1 O
, O
4 O
, O
8 O
, O
and O
11 O
every O
3 O
weeks O
) O
and O
Dex O
( O
20 O
mg O
on O
the O
day O
of O
and O
the O
day O
after O
bort O
) O
as O
salvage O
treatment O
in O
85 O
patients O
with O
R O
/ O
R O
MM B_DISEASE
after O
prior O
autologous O
stem O
cell O
transplantation O
or O
conventional O
chemotherapy O
. O

The O
median B_MEASURE
number I_MEASURE
of O
prior B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_TIME[MEASURE]
lines I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_TIME[MEASURE]
of O
therapy B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O
2 B_NUMBER[MEASURE]
. O

eighty B_NUMBER[MEASURE]
- O
seven B_NUMBER[MEASURE]
percent I_NUMBER[MEASURE]
of O
the O
patients B_PERSON/B_LOCATION
had O
received O
immunomodulatory B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
drugs I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
included O
in O
some O
line B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
therapy B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
before O
bort B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
dex B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O

The O
median B_MEASURE/B_LOCATION
number I_MEASURE/I_LOCATION
of O
bort B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O
Dex B_PERSON/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
cycles I_PERSON/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O
6 B_NUMBER[MEASURE]
, O
up O
to O
a O
maximum B_MEASURE/B_LOCATION
of O
12 B_NUMBER[MEASURE]/B_LOCATION
cycles I_NUMBER[MEASURE]/I_LOCATION
. O

On O
an O
intention B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
to O
- O
treat B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
basis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
55 B_NUMBER[MEASURE]/B_PERSON
% I_NUMBER[MEASURE]/I_PERSON
of O
the O
patients B_PERSON
achieved O
at O
least O
partial B_DISEASE/B_LOCATION
response I_DISEASE/I_LOCATION
, O
including O
19 B_DISEASE/B_LOCATION
% I_DISEASE/I_LOCATION
CR I_DISEASE/I_LOCATION
and O
35 B_PERSON
% I_PERSON
achieved O
at O
least O
very O
good B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
partial I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
response I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
. O

median B_TIME[MEASURE]/B_PERSON
durations I_TIME[MEASURE]/I_PERSON
of O
response B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
, O
time B_TIME[MEASURE]/B_PERSON
to O
next B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
therapy B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
and O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
- O
free B_TIME[MEASURE]/B_LOCATION
interval I_TIME[MEASURE]/I_LOCATION
were O
8 B_MEASURE
, O
11 B_MEASURE
. O
2 B_MEASURE
, O
and O
5 B_MEASURE
. O
1 B_TIME[MEASURE]
months I_TIME[MEASURE]
, O
respectively O
. O

The O
most O
relevant O
adverse O
event O
was O
peripheral B_DISEASE
neuropathy I_DISEASE
, O
which O
occurred O
in O
78 O
% O
of O
the O
patients O
( O
grade O
II O
, O
38 O
% O
; O
grade O
III O
, O
21 O
% O
) O
and O
led O
to O
treatment O
discontinuation O
in O
6 O
% O
. O

With O
a O
median B_MEASURE
follow O
up O
of O
22 B_TIME[MEASURE]/B_DISEASE
months B_TIME[MEASURE]/I_DISEASE
, O
median B_MEASURE/B_PERSON
time I_MEASURE/I_PERSON
to O
progression B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
progression B_DISEASE_ADJECTIVE[DISEASE]
- O
free B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
survival I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O
PFS B_LOCATION
) O
and O
overall B_DISEASE_ADJECTIVE[DISEASE]
survival I_DISEASE_ADJECTIVE[DISEASE]
( O
OS B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
) O
were O
8 B_MEASURE
. O
9 B_MEASURE
, O
8 B_MEASURE
. O
7 B_MEASURE
, O
and O
22 B_TIME[MEASURE]
months I_TIME[MEASURE]
, O
respectively O
. O

Prolonged B_DISEASE
PFS B_LOCATION/B_DISEASE
and O
OS B_TIME[MEASURE]/B_DISEASE
were O
observed O
in O
patients B_PERSON
achieving O
CR B_DISEASE
and O
receiving O
bort B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O
Dex B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
a O
single B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
line B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
of O
prior B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
therapy I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Bort O
- O
Dex O
was O
an O
effective O
salvage O
treatment O
for O
MM B_TIME[MEASURE]/B_DISEASE
patients O
, O
particularly O
for O
those O
in O
first O
relapse O
. O

Pubertal O
exposure O
to O
Bisphenol O
A O
increases O
anxiety B_DISEASE
- O
like O
behavior O
and O
decreases O
acetylcholinesterase O
activity O
of O
hippocampus O
in O
adult O
male O
mice O
. O

The O
negative B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
effects I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O
Bisphenol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
A I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
BPA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
) O
on O
neurodevelopment B_DISEASE_ADJECTIVE[DISEASE]
and O
behaviors B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
have O
been O
well O
established O
. O

Acetylcholinesterase O
( O
ache O
) O
is O
a O
regulatory O
enzyme O
which O
is O
involved O
in O
anxiety B_DISEASE
- O
like O
behavior O
. O

This O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
investigated O
behavioral B_DISEASE/B_GENE
phenotypes B_DISEASE/I_GENE
and O
AChE B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
activity I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
male B_PERSON/B_BIO
mice I_PERSON/I_BIO
following O
BPA B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
exposure B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
during O
puberty B_ORGANISM_FUNCTION/B_PERSON
. O

On O
postnatal B_TIME[MEASURE]
day I_TIME[MEASURE]
( O
PND B_TIME[MEASURE]/B_PROTEIN[GENE]
) O
35 B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
male B_PERSON/B_BIO
mice I_PERSON/I_BIO
were O
exposed O
to O
50mg B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
BPA I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
kg B_MEASURE/B_LOCATION
diet I_MEASURE/I_LOCATION
per O
day B_TIME[MEASURE]/B_PERSON
for O
a O
period B_MEASURE/B_LOCATION
of O
35 B_TIME[MEASURE]/B_ENT
days I_TIME[MEASURE]/I_ENT
. O

On O
PND71 B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_TIME[MEASURE]
, O
a O
behavioral B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
assay I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
performed O
using O
the O
elevated O
plus B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
maze I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O
EPM B_DISEASE/B_PROTEIN[GENE]
) O
and O
the O
light B_COLOR
/ O
dark B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENT
test I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENT
. O

In O
addition B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
AChE B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
activity B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
was O
measured O
in O
the O
prefrontal B_BODY_PART_OR_ORGAN_COMPONENT
cortex I_BODY_PART_OR_ORGAN_COMPONENT
, O
hypothalamus B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
, O
cerebellum B_BODY_PART_OR_ORGAN_COMPONENT
and O
hippocampus B_BODY_PART_OR_ORGAN_COMPONENT
. O

Results O
from O
our O
behavioral O
phenotyping O
indicated O
that O
anxiety B_DISEASE
- O
like O
behavior O
was O
increased O
in O
mice O
exposed O
to O
BPA O
. O

AChE B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
activity I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O
significantly O
decreased O
in O
the O
hippocampus B_BODY_PART_OR_ORGAN_COMPONENT
of O
mice B_BIO/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O
BPA B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
compared O
to O
control O
mice B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
whereas O
no O
difference B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
found O
in O
the O
prefrontal B_BODY_PART_OR_ORGAN_COMPONENT
cortex I_BODY_PART_OR_ORGAN_COMPONENT
, O
hypothalamus B_BODY_PART_OR_ORGAN_COMPONENT
and O
cerebellum B_BODY_PART_OR_ORGAN_COMPONENT
. O

Our O
findings O
showed O
that O
pubertal O
BPA O
exposure O
increased O
anxiety B_DISEASE
- O
like O
behavior O
, O
which O
may O
be O
associated O
with O
decreased O
ache O
activity O
of O
the O
hippocampus O
in O
adult O
male O
mice O
. O

Further O
studies O
are O
necessary O
to O
investigate O
the O
cholinergic O
signaling O
of O
the O
hippocampus O
in O
PBE O
induced O
anxiety B_DISEASE
- O
like O
behaviors O
. O

Biochemical O
effects O
of O
Solidago O
virgaurea O
extract O
on O
experimental O
cardiotoxicity B_DISEASE
. O

Cardiovascular B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
diseases I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
( O
CVDs B_DISEASE/B_LOCATION
) O
are O
the O
major O
health O
problem O
of O
advanced O
as O
well O
as O
developing O
countries O
of O
the O
world O
. O

The O
aim O
of O
the O
present O
study O
was O
to O
investigate O
the O
protective O
effect O
of O
the O
Solidago O
virgaurea O
extract O
on O
isoproterenol O
- O
induced O
cardiotoxicity B_DISEASE
in O
rats O
. O

The O
subcutaneous B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
injection I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
isoproterenol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O
30 B_MEASURE/B_LOCATION
mg I_MEASURE/I_LOCATION
/ O
kg B_MEASURE
) O
into O
rats B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
twice O
at O
an O
interval B_MEASURE/B_LOCATION
of O
24 B_MEASURE
h O
, O
for O
two B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
consecutive B_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
days B_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
led O
to O
a O
significant B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
increase I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
serum B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
lactate I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
dehydrogenase I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
creatine B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
phosphokinase I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
alanine B_ENZYME[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
transaminase B_ENZYME[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
aspartate B_ENZYME[GENE]
transaminase I_ENZYME[GENE]
, O
and O
angiotensin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
converting O
enzyme B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
activities I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
total B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
cholesterol I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O
triglycerides B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
free B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
serum I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
fatty I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
acid I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O
cardiac B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
tissue I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
malondialdehyde I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
MDA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
) O
, O
and O
nitric B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
oxide I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
levels I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
a O
significant B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
decrease I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
levels B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
of O
glutathione B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O
superoxide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
dismutase I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
cardiac B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
tissue I_BODY_PART_OR_ORGAN_COMPONENT/I_BIO
as O
compared O
to O
the O
normal B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
control I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
group I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
P B_PROTEIN[GENE]/B_LOCATION
< O
0 B_MEASURE
. O
05 B_MEASURE
) O
. O

Pretreatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
with O
S B_OTHER/B_LOCATION
. O
virgaurea B_BACTERIUM[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
extract I_BACTERIUM[BIO]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
5 B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
weeks I_TIME[MEASURE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
at O
a O
dose B_MEASURE/B_LOCATION
of O
250 B_MEASURE
mg I_MEASURE
/ O
kg B_MEASURE
followed O
by O
isoproterenol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
injection I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
significantly O
prevented O
the O
observed B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alterations I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

captopril B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
50 B_MEASURE
mg I_MEASURE
/ O
kg B_MEASURE
/ O
day B_MEASURE/B_LOCATION
, O
given O
orally O
) O
, O
an O
inhibitor B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
angiotensin B_GENE
- O
converting O
enzyme B_ENZYME[GENE]/B_LOCATION
used O
as O
a O
standard B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
cardioprotective I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
drug I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O
was O
used O
as O
a O
positive B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
control I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
in O
this O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
present B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggest O
that O
S B_OTHER/B_LOCATION
. O
virgaurea B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
extract O
exerts O
its O
protective B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
effect I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
by O
decreasing O
MDA B_MEASURE/B_DISEASE
level B_MEASURE/I_DISEASE
and O
increasing O
the O
antioxidant B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
status B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
in O
isoproterenol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
treated O
rats B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
emphasizes O
the O
beneficial B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
action I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
S B_OTHER/B_LOCATION
. O
virgaurea B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
extract B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BACTERIUM[BIO]
as O
a O
cardioprotective B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
agent I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

' O
Real O
- O
world O
' O
data O
on O
the O
efficacy O
and O
safety O
of O
lenalidomide O
and O
dexamethasone O
in O
patients O
with O
relapsed O
/ O
refractory O
multiple B_DISEASE/B_LOCATION
myeloma I_DISEASE/I_LOCATION
who O
were O
treated O
according O
to O
the O
standard O
clinical O
practice O
: O
a O
study O
of O
the O
Greek O
Myeloma B_DISEASE
Study O
Group O
. O

Lenalidomide O
and O
dexamethasone O
( O
Rd O
) O
is O
a O
standard O
of O
care O
for O
relapsed O
/ O
refractory O
multiple B_DISEASE/B_LOCATION
myeloma I_DISEASE/I_LOCATION
( O
RRMM B_DISEASE/B_LOCATION
) O
, O
but O
there O
is O
limited O
published O
data O
on O
its O
efficacy O
and O
safety O
in O
the O
' O
real O
world O
' O
( O
RW O
) O
, O
according O
to O
the O
International O
Society O
of O
Pharmacoeconomics O
and O
outcomes O
Research O
definition O
. O

We O
studied O
212 O
RRMM B_DISEASE/B_MEASURE
patients O
who O
received O
Rd O
in O
RW O
. O

objective B_LOCATION/B_PERSON
response I_LOCATION/I_PERSON
( O
> B_LOCATION
PR I_LOCATION
( O
partial B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
response I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
) O
) O
rate B_MEASURE/B_LOCATION
was O
77 B_MEASURE
. O
4 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
( O
complete B_LOCATION
response I_LOCATION
( O
CR B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
) O
, O
20 B_MEASURE
. O
2 B_MEASURE
% I_MEASURE
) O
. O

median B_TIME[MEASURE]/B_PERSON
time I_TIME[MEASURE]/I_PERSON
to O
first B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
best B_SEQUENCE[MEASURE]/B_DISEASE
response I_SEQUENCE[MEASURE]/I_DISEASE
was O
2 B_MEASURE
and O
5 B_TIME[MEASURE]
months I_TIME[MEASURE]
, O
respectively O
. O

median B_TIME[MEASURE]/B_PERSON
time I_TIME[MEASURE]/I_PERSON
to O
CR B_DISEASE
when O
RD B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
was O
given O
as O
2nd B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
or O
> O
2 B_SEQUENCE[MEASURE]
( O
nd B_SEQUENCE[MEASURE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
- O
line B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treatment I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O
4 B_NUMBER[MEASURE]
and O
11 B_TIME[MEASURE]
months I_TIME[MEASURE]
, O
respectively O
. O

Quality B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
response B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
independent B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
previous B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
lines B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
therapies B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
or O
previous B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
exposure I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
to O
thalidomide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O
bortezomib B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

median B_TIME[MEASURE]/B_PERSON
duration I_TIME[MEASURE]/I_PERSON
of O
response B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
was O
34 B_MEASURE
. O
4 B_TIME[MEASURE]
months I_TIME[MEASURE]
, O
and O
it O
was O
higher B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
in O
patients B_PERSON
who O
received O
RD B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
until O
progression B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
( O
not O
reached O
versus O
19 B_TIME[MEASURE]
months I_TIME[MEASURE]
, O
p O
< O
0 B_MEASURE
. O
001 B_MEASURE
) O
. O

Improvement B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O
humoral B_DISEASE
immunity I_DISEASE
occurred O
in O
60 B_MEASURE/B_LOCATION
% I_MEASURE/I_LOCATION
of O
responders B_PERSON/B_BIO
( O
p B_MEASURE/B_PROTEIN[GENE]
< O
0 B_MEASURE
. O
001 B_MEASURE
) O
and O
in O
the O
majority B_PERSON/B_MEASURE
of O
patients B_PERSON/B_BIO
who O
achieved O
stable B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
disease I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

adverse O
events O
were O
reported O
in O
68 O
. O
9 O
% O
of O
patients O
( O
myelosuppression B_DISEASE_ADJECTIVE[DISEASE]
in O
49 O
. O
4 O
% O
) O
and O
12 O
. O
7 O
% O
of O
patients O
needed O
hospitalization O
. O

Peripheral B_DISEASE
neuropathy I_DISEASE
was O
observed O
only O
in O
2 O
. O
5 O
% O
of O
patients O
and O
deep B_DISEASE
vein I_DISEASE
thrombosis I_DISEASE
in O
5 O
. O
7 O
% O
. O

Dose B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
reductions B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
were O
needed O
in O
31 B_MEASURE
% I_MEASURE
of O
patients B_PERSON/B_LOCATION
and O
permanent B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
discontinuation I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
38 B_MEASURE
. O
9 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
. O

median B_TIME[MEASURE]/B_PERSON
time I_TIME[MEASURE]/I_PERSON
to O
treatment B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
discontinuation I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O
16 B_MEASURE
. O
8 B_TIME[MEASURE]
months I_TIME[MEASURE]
. O

Performance B_MEASURE/B_LOCATION
status B_MEASURE/I_LOCATION
( O
PS B_PROTEIN[GENE]/B_LOCATION
) O
and O
initial B_MEASURE
lenalidomide I_MEASURE
dose I_MEASURE
predicted O
for O
treatment B_DISEASE_ADJECTIVE[DISEASE]
discontinuation I_DISEASE_ADJECTIVE[DISEASE]
. O

extra B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
medullary B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
relapses I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
occurred O
in O
3 B_MEASURE
. O
8 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
of O
patients B_PERSON/B_LOCATION
. O

Our O
study O
confirms O
that O
Rd O
is O
effective O
and O
safe O
in O
RRMM B_DISEASE/B_PERSON
in O
the O
RW O
; O
it O
produces O
durable O
responses O
especially O
in O
patients O
who O
continue O
on O
treatment O
till O
progression O
and O
improves O
humoral O
immunity O
even O
in O
patients O
with O
stable O
disease O
. O

The O
cytogenetic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
action I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
of O
ifosfamide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
mesna B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O
and O
their O
combination B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
on O
peripheral B_DISEASE
rabbit I_DISEASE
lymphocytes I_DISEASE
: O
an O
in O
vivo B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
/ O
in O
vitro B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cytogenetic I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Ifosfamide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O
IFO B_LOCATION/B_DISEASE
) O
is O
an O
alkylating B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
nitrogen I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mustard I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
administrated O
as O
an O
antineoplasmic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
agent I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

It O
is O
characterized O
by O
its O
intense O
urotoxic O
action O
, O
leading O
to O
hemorrhagic B_DISEASE
cystitis I_DISEASE
. O

This O
side B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effect I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
IFO B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
raises O
the O
requirement B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
for O
the O
co B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
administration B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O
sodium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
sulfanylethanesulfonate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O
Mesna B_DISEASE
) O
aiming O
to O
avoid O
or O
minimize O
this O
effect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

IFO B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
Mesna B_LOCATION/B_PERSON
were O
administrated O
separately O
on O
rabbit B_BIO/B_PERSON
' O
s B_BODY_PART_OR_ORGAN_COMPONENT
lymphocytes I_BODY_PART_OR_ORGAN_COMPONENT
in O
vivo B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
, O
which O
were O
later O
developed O
in O
vitro B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

cytogenetic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
markers I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
for O
sister B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
chromatid B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
exchanges B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
( O
SCEs B_LOCATION/B_ORGANIZATION
) O
, O
proliferation B_MEASURE/B_LOCATION
rate B_MEASURE/I_LOCATION
index B_MEASURE/I_LOCATION
( O
PRI B_LOCATION/B_ORGANIZATION
) O
and O
Mitotic B_MEASURE/B_DISEASE
Index B_MEASURE/I_DISEASE
were O
recorded O
. O

Mesna B_PERSON/B_COLOR
' O
s B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
action I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O
in O
conjunction B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
IFO B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
reduces O
the O
frequency B_MEASURE
of O
SCEs B_DISEASE
, O
in O
comparison B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
with O
the O
SCEs B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
recordings I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
obtained O
when O
IFO B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
is O
administered O
alone O
. O

In O
addition B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
to O
this O
, O
when O
high B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
concentrations I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
of O
Mesna B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
were O
administered O
alone O
significant B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
reductions I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
the O
pri B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
were O
noted O
, O
than O
with O
IFO B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
acting O
at O
the O
same B_MEASURE
concentration I_MEASURE
on O
the O
lymphocytes B_BODY_PART_OR_ORGAN_COMPONENT
. O

Mesna O
significantly O
reduces O
IFO O
' O
s O
genotoxicity B_DISEASE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
while O
when O
administered O
in O
high O
concentrations O
it O
acts O
in O
an O
inhibitory O
fashion O
on O
the O
cytostatic O
action O
of O
the O
drug O
. O

Risk O
factors O
and O
predictors O
of O
levodopa O
- O
induced O
dyskinesia B_DISEASE
among O
multiethnic O
Malaysians O
with O
Parkinson B_DISEASE
' I_DISEASE
s I_DISEASE
disease I_DISEASE
. O

chronic O
pulsatile O
levodopa O
therapy O
for O
Parkinson B_DISEASE
' I_DISEASE
s I_DISEASE
disease I_DISEASE
( O
PD B_DISEASE/B_PROTEIN[GENE]
) O
leads O
to O
the O
development O
of O
motor O
fluctuations O
and O
dyskinesia B_DISEASE
. O

We O
studied O
the O
prevalence O
and O
predictors O
of O
levodopa O
- O
induced O
dyskinesia B_DISEASE
among O
multiethnic O
Malaysian O
patients O
with O
PD B_DISEASE
. O

methods O
: O
This O
is O
a O
cross O
- O
sectional O
study O
involving O
95 O
patients O
with O
PD B_DISEASE
on O
uninterrupted O
levodopa O
therapy O
for O
at O
least O
6 O
months O
. O

The O
instrument B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
used O
was O
the O
UPDRS B_ENT/B_ORGANIZATION
questionnaires I_ENT/I_ORGANIZATION
. O

The O
predictors O
of O
dyskinesia B_DISEASE
were O
determined O
using O
multivariate O
logistic O
regression O
analysis O
. O

RESULTS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O
The O
mean B_MEASURE/B_PERSON
age I_MEASURE/I_PERSON
was O
65 B_MEASURE
. O
6 B_MEASURE
+ I_MEASURE
8 I_MEASURE
. O
5 B_TIME[MEASURE]
years I_TIME[MEASURE]
. O

The O
mean B_MEASURE/B_PERSON
onset I_MEASURE/I_PERSON
age I_MEASURE/I_PERSON
was O
58 B_MEASURE
. O
5 B_MEASURE
+ I_MEASURE
9 I_MEASURE
. O
8 B_TIME[MEASURE]
years I_TIME[MEASURE]
. O

The O
median B_TIME[MEASURE]/B_PERSON
disease I_TIME[MEASURE]/I_PERSON
duration I_TIME[MEASURE]/I_PERSON
was O
6 B_NUMBER[MEASURE]
( O
7 B_MEASURE
) O
years B_TIME[MEASURE]/B_ORGANIZATION
. O

Dyskinesia B_DISEASE
was O
present O
in O
44 O
% O
( O
n O
= O
42 O
) O
with O
median O
levodopa O
therapy O
of O
3 O
years O
. O

There O
were O
64 B_MEASURE
. O
3 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
Chinese I_MEASURE/I_PERSON
, O
31 B_PERSON/B_LOCATION
% I_PERSON/I_LOCATION
Malays I_PERSON/I_LOCATION
, O
and O
3 B_MEASURE
. O
7 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
Indians I_MEASURE/I_PERSON
and O
other B_PERSON/B_LOCATION
ethnic I_PERSON/I_LOCATION
groups I_PERSON/I_LOCATION
. O

eighty O
- O
one O
percent O
of O
patients O
with O
dyskinesia B_DISEASE
had O
clinical O
fluctuations O
. O

patients O
with O
dyskinesia B_DISEASE
had O
lower O
onset O
age O
( O
p O
< O
0 O
. O
001 O
) O
, O
longer O
duration O
of O
levodopa O
therapy O
( O
p O
< O
0 O
. O
001 O
) O
, O
longer O
disease O
duration O
( O
p O
< O
0 O
. O
001 O
) O
, O
higher O
total O
daily O
levodopa O
dose O
( O
p O
< O
0 O
. O
001 O
) O
, O
and O
higher O
total O
UPDRS O
scores O
( O
p O
= O
0 O
. O
005 O
) O
than O
patients O
without O
dyskinesia B_DISEASE
. O

The O
three O
significant O
predictors O
of O
dyskinesia B_DISEASE
were O
duration O
of O
levodopa O
therapy O
, O
onset O
age O
, O
and O
total O
daily O
levodopa O
dose O
. O

conclusions O
: O
The O
prevalence O
of O
levodopa O
- O
induced O
dyskinesia B_DISEASE
in O
our O
patients O
was O
44 O
% O
. O

The O
most O
significant B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
predictors I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
were O
duration B_MEASURE
of O
levodopa B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
therapy I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
, O
total B_TIME[MEASURE]/B_DISEASE
daily I_TIME[MEASURE]/I_DISEASE
levodopa I_TIME[MEASURE]/I_DISEASE
dose I_TIME[MEASURE]/I_DISEASE
, O
and O
onset B_MEASURE/B_DISEASE
age I_MEASURE/I_DISEASE
. O

dose O
- O
dependent O
neurotoxicity B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
high O
- O
dose O
busulfan O
in O
children O
: O
a O
clinical O
and O
pharmacological O
study O
. O

Busulfan O
is O
known O
to O
be O
neurotoxic B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
animals O
and O
humans O
, O
but O
its O
acute O
neurotoxicity B_DISEASE
remains O
poorly O
characterized O
in O
children O
. O

We O
report O
here O
a O
retrospective O
study O
of O
123 O
children O
( O
median O
age O
, O
6 O
. O
5 O
years O
) O
receiving O
high O
- O
dose O
busulfan O
in O
combined O
chemotherapy O
before O
bone O
marrow O
transplantation O
for O
malignant O
solid O
tumors B_DISEASE
, O
brain B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
tumors B_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
excluded O
. O

Busulfan B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
given O
p B_MEASURE/B_DISEASE
. O
o O
. O
, O
every O
6 B_TIME[MEASURE]/B_SPORT[ENT]
hours I_TIME[MEASURE]/I_SPORT[ENT]
for O
16 B_TIME[MEASURE]/B_PERSON
doses B_TIME[MEASURE]/I_PERSON
over O
4 B_TIME[MEASURE]/B_ENT
days I_TIME[MEASURE]/I_ENT
. O

Two B_NUMBER[MEASURE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
total I_NUMBER[MEASURE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
doses I_NUMBER[MEASURE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
consecutively O
used O
: O
16 B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mg I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
kg B_MEASURE
, O
then O
600 B_MEASURE
mg I_MEASURE
/ O
m2 B_MEASURE
. O

The O
dose B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
calculation I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
on O
the O
basis B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
body B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
surface I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
area I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
results O
in O
higher B_MEASURE
doses I_MEASURE
in O
young B_PERSON/B_ORGANIZATION
children I_PERSON/I_ORGANIZATION
than O
in O
older B_PERSON
patients I_PERSON
( O
16 B_MEASURE
to O
28 B_MEASURE
mg I_MEASURE
/ O
kg B_MEASURE
) O
. O

ninety O
- O
six O
patients O
were O
not O
given O
anticonvulsive O
prophylaxis O
; O
7 O
( O
7 O
. O
5 O
% O
) O
developed O
seizures B_DISEASE
during O
the O
4 O
days O
of O
the O
busulfan O
course O
or O
within O
24 O
h O
after O
the O
last O
dosing O
. O

When O
the O
total O
busulfan O
dose O
was O
taken O
into O
account O
, O
there O
was O
a O
significant O
difference O
in O
terms O
of O
neurotoxicity B_DISEASE
incidence O
among O
patients O
under O
16 O
mg O
/ O
kg O
( O
1 O
of O
57 O
, O
1 O
. O
7 O
% O
) O
and O
patients O
under O
600 O
mg O
/ O
m2 O
( O
6 O
of O
39 O
, O
15 O
. O
4 O
% O
) O
( O
P O
less O
than O
0 O
. O
02 O
) O
. O

Twenty O
- O
seven O
patients O
were O
given O
a O
600 O
- O
mg O
/ O
m2 O
busulfan O
total O
dose O
with O
continuous O
i O
. O
v O
. O
infusion O
of O
clonazepam O
; O
none O
had O
any O
neurological B_DISEASE
symptoms I_DISEASE
. O

Busulfan O
levels O
were O
measured O
by O
a O
gas O
chromatographic O
- O
mass O
spectrometry O
assay O
in O
the O
plasma O
and O
cerebrospinal O
fluid O
of O
9 O
children O
without O
central B_DISEASE
nervous I_DISEASE
system I_DISEASE
disease I_DISEASE
under O
600 O
mg O
/ O
m2 O
busulfan O
with O
clonazepam O
: O
busulfan O
cerebrospinal O
fluid O
: O
plasma O
ratio O
was O
1 O
. O
39 O
. O

This O
was O
significantly O
different B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
P B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
less B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
than O
0 B_MEASURE
. O
02 B_MEASURE
) O
from O
the O
cerebrospinal B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fluid I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
plasma B_MEASURE/B_LOCATION
ratio B_MEASURE/I_LOCATION
previously O
defined O
in O
children B_PERSON/B_SPECIES[BIO]
receiving O
a O
16 B_MEASURE
- O
mg B_MEASURE/B_LOCATION
/ O
kg B_MEASURE
total I_MEASURE
dose I_MEASURE
of O
busulfan B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
. O

This O
study O
shows O
that O
busulfan O
neurotoxicity B_DISEASE
is O
dose O
- O
dependent O
in O
children O
and O
efficiently O
prevented O
by O
clonazepam O
. O

A O
busulfan O
dose O
calculated O
on O
the O
basis O
of O
body O
surface O
area O
, O
resulting O
in O
higher O
doses O
in O
young O
children O
, O
was O
followed O
by O
increased O
neurotoxicity B_DISEASE
, O
close O
to O
neurotoxicity B_DISEASE/B_MEASURE
incidence O
observed O
in O
adults O
. O

Since O
plasma B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
pharmacokinetic I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
studies I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
showed O
a O
faster B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
busulfan B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
clearance B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
in O
children B_PERSON/B_BIO
than O
in O
adults B_PERSON/B_BIO
, O
this O
new B_MEASURE
dose I_MEASURE
may O
approximate O
more O
closely O
the O
adult B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
systemic I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
exposure I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
obtained O
after O
the O
usual B_MEASURE
16 I_MEASURE
- O
mg B_MEASURE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
kg B_TIME[MEASURE]
total I_TIME[MEASURE]
dose I_TIME[MEASURE]
, O
with O
potential B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
inferences I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
terms B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O
anticancer B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O
myeloablative B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
effects I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

The O
busulfan B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
dose I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
in O
children B_PERSON/B_BIO
and O
infants B_PERSON/B_BIO
undergoing O
bone B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
marrow I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
transplantation I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
should O
be O
reconsidered O
on O
the O
basis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
pharmacokinetic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
studies I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O

An O
unexpected O
diagnosis O
in O
a O
renal O
- O
transplant O
patient O
with O
proteinuria B_DISEASE
treated O
with O
everolimus O
: O
AL B_DISEASE_ADJECTIVE[DISEASE]
amyloidosis I_DISEASE_ADJECTIVE[DISEASE]
. O

Proteinuria B_DISEASE
is O
an O
expected O
complication O
in O
transplant O
patients O
treated O
with O
mammalian O
target O
of O
rapamycin O
inhibitors O
( O
mTOR O
- O
i O
) O
. O

However O
, O
clinical O
suspicion O
should O
always O
be O
supported O
by O
histological O
evidence O
in O
order O
to O
investigate O
potential O
alternate O
diagnoses O
such O
as O
acute O
or O
chronic O
rejection O
, O
interstitial O
fibrosis B_DISEASE
and O
tubular O
atrophy B_DISEASE
, O
or O
recurrent O
or O
de O
novo O
glomerulopathy B_DISEASE
. O

In O
this O
case O
we O
report O
the O
unexpected O
diagnosis O
of O
amyloidosis B_DISEASE
in O
a O
renal O
- O
transplant O
patient O
with O
pre O
- O
transplant O
monoclonal O
gammapathy O
of O
undetermined O
significance O
who O
developed O
proteinuria B_DISEASE
after O
conversion O
from O
tacrolimus O
to O
everolimus O
. O

Long O
- O
term O
oral O
galactose O
treatment O
prevents O
cognitive B_DISEASE
deficits I_DISEASE
in O
male O
Wistar O
rats O
treated O
intracerebroventricularly O
with O
streptozotocin O
. O

Basic O
and O
clinical O
research O
has O
demonstrated O
that O
dementia B_DISEASE
of O
sporadic O
Alzheimer B_DISEASE/B_MEASURE
' I_DISEASE/I_MEASURE
s I_DISEASE/I_MEASURE
disease I_DISEASE/I_MEASURE
( O
Sad O
) O
type O
is O
associated O
with O
dysfunction O
of O
the O
insulin O
- O
receptor O
( O
IR O
) O
system O
followed O
by O
decreased O
glucose O
transport O
via O
glucose O
transporter O
GLUT4 O
and O
decreased O
glucose O
metabolism O
in O
brain O
cells O
. O

An O
alternative B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
source I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
energy B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
d B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
galactose B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
the O
C B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
4 B_MEASURE/B_LOCATION
- O
epimer B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
d B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
glucose B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
) O
which O
is O
transported O
into O
the O
brain B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
by O
insulin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
independent B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
GLUT3 B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
transporter B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
where O
it O
might O
be O
metabolized O
to O
glucose O
via O
the O
Leloir B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
pathway B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
. O

exclusively O
parenteral O
daily O
injections O
of O
galactose O
induce O
memory B_DISEASE
deterioration I_DISEASE
in O
rodents O
and O
are O
used O
to O
generate O
animal O
aging O
model O
, O
but O
the O
effects O
of O
oral O
galactose O
treatment O
on O
cognitive O
functions O
have O
never O
been O
tested O
. O

We O
have O
investigated O
the O
effects O
of O
continuous O
daily O
oral O
galactose O
( O
200 O
mg O
/ O
kg O
/ O
day O
) O
treatment O
on O
cognitive B_DISEASE_ADJECTIVE[DISEASE]
deficits I_DISEASE_ADJECTIVE[DISEASE]
in O
streptozotocin O
- O
induced O
( O
STZ O
- O
icv O
) O
rat O
model O
of O
Sad O
, O
tested O
by O
Morris O
Water O
maze O
and O
passive O
Avoidance O
test O
, O
respectively O
. O

One O
month O
of O
oral O
galactose O
treatment O
initiated O
immediately O
after O
the O
STZ O
- O
icv O
administration O
, O
successfully O
prevented O
development O
of O
the O
STZ O
- O
icv O
- O
induced O
cognitive B_DISEASE
deficits I_DISEASE
. O

beneficial B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
effect I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
of O
oral B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
galactose I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
was O
independent B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O
the O
rat B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
age I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
and O
of O
the O
galactose B_MEASURE
dose I_MEASURE
ranging O
from O
100 B_MEASURE
to O
300 B_MEASURE
mg I_MEASURE
/ O
kg B_MEASURE
/ O
day B_MEASURE
. O

Additionally O
, O
oral B_DISEASE/B_PERSON
galactose I_DISEASE/I_PERSON
administration I_DISEASE/I_PERSON
led O
to O
the O
appearance B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O
galactose B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
in O
the O
blood B_BODY_PART_OR_ORGAN_COMPONENT
. O

The O
increase B_MEASURE
of O
galactose B_MEASURE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
concentration B_MEASURE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
cerebrospinal B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fluid I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
several B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
times B_TIME[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
lower B_TIME[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
after O
oral B_BODY_PART_OR_ORGAN_COMPONENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
than O
after O
parenteral B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
administration I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANISM_FUNCTION
of O
the O
same B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
galactose I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dose I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Oral O
galactose O
exposure O
might O
have O
beneficial O
effects O
on O
learning O
and O
memory O
ability O
and O
could O
be O
worth O
investigating O
for O
improvement O
of O
cognitive B_DISEASE_ADJECTIVE[DISEASE]
deficits I_DISEASE_ADJECTIVE[DISEASE]
associated O
with O
glucose B_DISEASE/B_LOCATION
hypometabolism I_DISEASE/I_LOCATION
in O
AD B_DISEASE/B_LOCATION
. O

An O
investigation O
of O
the O
pattern O
of O
kidney B_DISEASE
injury I_DISEASE
in O
HIV O
- O
positive O
persons O
exposed O
to O
tenofovir O
disoproxil O
fumarate O
: O
an O
examination O
of O
a O
large O
population O
database O
( O
MHRA O
database O
) O
. O

The O
potential B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
for O
tenofovir B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O
cause O
a O
range B_LOCATION/B_MEASURE
of O
kidney B_DISEASE_ADJECTIVE[DISEASE]
syndromes I_DISEASE_ADJECTIVE[DISEASE]
has O
been O
established O
from O
mechanistic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
randomised O
clinical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
trials I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

However O
, O
the O
exact B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
pattern I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O
kidney B_DISEASE_ADJECTIVE[DISEASE]
involvement I_DISEASE_ADJECTIVE[DISEASE]
is O
still O
uncertain B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

We O
undertook O
a O
descriptive B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
yellow B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
card I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
records I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
407 B_DISEASE
HIV I_DISEASE
- O
positive B_PERSON/B_DISEASE
persons I_PERSON/I_DISEASE
taking O
tenofovir B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
disoproxil I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fumarate I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
TDF B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O
as O
part B_MEASURE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
their O
antiretroviral B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
therapy I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
regimen I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
submitted O
to O
the O
medicines B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
and O
Healthcare B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
products I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
regulatory I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
Agency I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O
MHRA B_DISEASE/B_ORGANIZATION
) O
with O
suspected O
kidney B_DISEASE_ADJECTIVE[DISEASE]
adverse I_DISEASE_ADJECTIVE[DISEASE]
effects I_DISEASE_ADJECTIVE[DISEASE]
. O

Reports O
that O
satisfy O
defined O
criteria O
were O
classified O
as O
acute B_DISEASE
kidney I_DISEASE
injury I_DISEASE
, O
kidney B_DISEASE
tubular I_DISEASE
dysfunction I_DISEASE
and O
Fanconi B_DISEASE/B_PERSON
syndrome I_DISEASE/I_PERSON
. O

Of O
the O
407 O
Yellow O
Card O
records O
analysed O
, O
106 O
satisfied O
criteria O
for O
TDF O
- O
related O
kidney B_DISEASE_ADJECTIVE[DISEASE]
disease I_DISEASE_ADJECTIVE[DISEASE]
, O
of O
which O
53 O
( O
50 O
% O
) O
had O
features O
of O
kidney B_DISEASE
tubular I_DISEASE
dysfunction I_DISEASE
, O
35 O
( O
33 O
% O
) O
were O
found O
to O
have O
features O
of O
glomerular B_DISEASE
dysfunction I_DISEASE
and O
18 O
( O
17 O
% O
) O
had O
Fanconi B_DISEASE/B_LOCATION
syndrome I_DISEASE/I_LOCATION
. O

The O
median B_TIME[MEASURE]/B_LOCATION
TDF I_TIME[MEASURE]/I_LOCATION
exposure I_TIME[MEASURE]/I_LOCATION
was O
316 B_MEASURE/B_PERSON
days I_MEASURE/I_PERSON
( O
interquartile B_MEASURE
range I_MEASURE
120 I_MEASURE
- O
740 B_MEASURE
) O
. O

The O
incidence O
of O
hospitalisation O
for O
TDF O
kidney O
adverse O
effects O
was O
high O
, O
particularly O
amongst O
patients O
with O
features O
of O
Fanconi B_DISEASE/B_GENE
syndrome I_DISEASE/I_GENE
. O

The O
pattern B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O
kidney B_DISEASE_ADJECTIVE[DISEASE]
syndromes I_DISEASE_ADJECTIVE[DISEASE]
in O
this O
population B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
series I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
mirrors I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
that O
reported O
in O
randomised B_MEASURE/B_LOCATION
clinical I_MEASURE/I_LOCATION
trials I_MEASURE/I_LOCATION
. O

cessation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
TDF B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
was O
associated O
with O
complete B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
restoration I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
kidney B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
function I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
up O
half B_MEASURE
of O
the O
patients B_PERSON
in O
this O
report B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O

incidence O
of O
postoperative B_DISEASE/B_LOCATION
delirium I_DISEASE/I_LOCATION
is O
high O
even O
in O
a O
population O
without O
known O
risk O
factors O
. O

purpose O
: O
Postoperative B_DISEASE/B_GENE
delirium I_DISEASE/I_GENE
is O
a O
recognized O
complication O
in O
populations O
at O
risk O
. O

The O
aim O
of O
this O
study O
is O
to O
assess O
the O
prevalence O
of O
early O
postoperative B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
delirium I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
a O
population O
without O
known O
risk O
factors O
admitted O
to O
the O
ICU O
for O
postoperative O
monitoring O
after O
elective O
major O
surgery O
. O

The O
secondary B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
outcome I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
investigated O
is O
to O
identify O
eventual B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
independent I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
risk I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factors I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
among O
demographic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
data I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
anesthetic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
drugs I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
used O
. O

METHODS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O
An O
observational B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
prospective B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
conducted O
on O
a O
consecutive B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
cohort I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
patients B_PERSON
admitted O
to O
our O
ICU B_LOCATION/B_ORGANIZATION
within O
and O
for O
at O
least O
24 B_MEASURE
h O
after O
major B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
surgical I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
procedures I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
. O

exclusion O
criteria O
were O
any O
preexisting O
predisposing O
factor O
for O
delirium B_DISEASE
or O
other O
potentially O
confounding O
neurological B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dysfunctions B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

patients O
were O
assessed O
daily O
using O
the O
confusion B_DISEASE/B_MEASURE
assessment O
method O
for O
the O
ICU O
scale O
for O
3 O
days O
after O
the O
surgical O
procedure O
. O

Early O
postoperative B_DISEASE/B_ORGANISM_FUNCTION
delirium I_DISEASE/I_ORGANISM_FUNCTION
incidence O
risk O
factors O
were O
then O
assessed O
through O
three O
different O
multiple O
regression O
models O
. O

Results O
: O
According O
to O
the O
confusion O
assessment O
method O
for O
the O
ICU O
scale O
, O
28 O
% O
of O
patients O
were O
diagnosed O
with O
early O
postoperative B_DISEASE
delirium I_DISEASE
. O

The O
use O
of O
thiopentone O
was O
significantly O
associated O
with O
an O
eight O
- O
fold O
- O
higher O
risk O
for O
delirium B_DISEASE
compared O
to O
propofol O
( O
57 O
. O
1 O
% O
vs O
. O
7 O
. O
1 O
% O
, O
RR O
= O
8 O
. O
0 O
, O
X2 O
= O
4 O
. O
256 O
; O
df O
= O
1 O
; O
0 O
. O
05 O
< O
p O
< O
0 O
. O
02 O
) O
. O

conclusion O
: O
In O
this O
study O
early O
postoperative B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
delirium I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O
found O
to O
be O
a O
very O
common O
complication O
after O
major O
surgery O
, O
even O
in O
a O
population O
without O
known O
risk O
factors O
. O

Thiopentone B_DISEASE/B_PERSON
was O
independently O
associated O
with O
an O
increase B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
its O
relative B_MEASURE/B_DISEASE
risk I_MEASURE/I_DISEASE
. O

A O
single O
neurotoxic B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dose O
of O
methamphetamine O
induces O
a O
long O
- O
lasting O
depressive B_DISEASE
- O
like O
behaviour O
in O
mice O
. O

Methamphetamine O
( O
METH O
) O
triggers O
a O
disruption O
of O
the O
monoaminergic O
system O
and O
METH O
abuse O
leads O
to O
negative O
emotional O
states O
including O
depressive B_DISEASE
symptoms I_DISEASE
during O
drug O
withdrawal O
. O

However O
, O
it O
is O
currently O
unknown O
if O
the O
acute O
toxic O
dosage O
of O
METH O
also O
causes O
a O
long O
- O
lasting O
depressive B_DISEASE
phenotype O
and O
persistent O
monoaminergic O
deficits O
. O

Thus O
, O
we O
now O
assessed O
the O
depressive B_DISEASE
- O
like O
behaviour O
in O
mice O
at O
early O
and O
long O
- O
term O
periods O
following O
a O
single O
high O
METH O
dose O
( O
30 O
mg O
/ O
kg O
, O
i O
. O
p O
. O
) O
. O

Meth B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
did O
not O
alter O
the O
motor B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
function I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
and O
procedural B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
memory I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANISM_FUNCTION
of O
mice B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O
assessed O
by O
swimming O
speed B_MEASURE
and O
escape B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
latency B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
to O
find O
the O
platform B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
in O
a O
cued B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
version I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
the O
water B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
maze I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
task I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

However O
, O
Meth B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
significantly O
increased O
the O
immobility B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
time I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
tail B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPECIES[BIO]
suspension B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_SPECIES[BIO]
test B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_SPECIES[BIO]
at O
3 B_MEASURE
and O
49 B_TIME[MEASURE]/B_LOCATION
days I_TIME[MEASURE]/I_LOCATION
post I_TIME[MEASURE]/I_LOCATION
- O
administration B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O

This O
depressive B_DISEASE
- O
like O
profile O
induced O
by O
METH O
was O
accompanied O
by O
a O
marked O
depletion O
of O
frontostriatal O
dopaminergic O
and O
serotonergic O
neurotransmission O
, O
indicated O
by O
a O
reduction O
in O
the O
levels O
of O
dopamine O
, O
DOPAC O
and O
HVA O
, O
tyrosine O
hydroxylase O
and O
serotonin O
, O
observed O
at O
both O
3 O
and O
49 O
days O
post O
- O
administration O
. O

In O
parallel O
, O
another O
neurochemical O
feature O
of O
depression B_DISEASE
- O
- O
astroglial O
dysfunction O
- O
- O
was O
unaffected O
in O
the O
cortex O
and O
the O
striatal O
levels O
of O
the O
astrocytic O
protein O
marker O
, O
glial O
fibrillary O
acidic O
protein O
, O
were O
only O
transiently O
increased O
at O
3 O
days O
. O

These O
findings O
demonstrate O
for O
the O
first O
time O
that O
a O
single O
high O
dose O
of O
METH O
induces O
long O
- O
lasting O
depressive B_DISEASE
- O
like O
behaviour O
in O
mice O
associated O
with O
a O
persistent O
disruption O
of O
frontostriatal O
dopaminergic O
and O
serotonergic O
homoeostasis O
. O

Linezolid O
- O
induced O
optic B_DISEASE
neuropathy I_DISEASE
. O

Many B_PERSON
systemic I_PERSON
antimicrobials I_PERSON
have O
been O
implicated O
to O
cause O
ocular B_DISEASE
adverse I_DISEASE
effects I_DISEASE
. O

This O
is O
especially O
relevant B_DISEASE_ADJECTIVE[DISEASE]
in O
multidrug B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
therapy I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
where O
more B_MEASURE/B_PERSON
than O
one B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
drug I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
can O
cause O
a O
similar B_DISEASE
ocular I_DISEASE
adverse I_DISEASE
effect I_DISEASE
. O

We O
describe O
a O
case O
of O
progressive O
loss B_DISEASE
of I_DISEASE
vision I_DISEASE
associated O
with O
linezolid O
therapy O
. O

A O
45 O
- O
year O
- O
old O
male O
patient O
who O
was O
on O
treatment O
with O
multiple O
second O
- O
line O
anti O
- O
tuberculous O
drugs O
including O
linezolid O
and O
ethambutol O
for O
extensively B_DISEASE
drug I_DISEASE
- I_DISEASE
resistant I_DISEASE
tuberculosis I_DISEASE
( O
XDR B_DISEASE
- I_DISEASE
TB I_DISEASE
) O
presented O
to O
us O
with O
painless O
progressive O
loss B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
of I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
vision I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
in O
both O
eyes O
. O

Color O
vision O
was O
defective O
and O
fundus O
examination O
revealed O
optic B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
disc I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
edema I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
in O
both O
eyes O
. O

Ethambutol O
- O
induced O
toxic B_DISEASE
optic I_DISEASE
neuropathy I_DISEASE
was O
suspected O
and O
tablet O
ethambutol O
was O
withdrawn O
. O

Deterioration B_DISEASE/B_PERSON
of I_DISEASE/I_PERSON
vision I_DISEASE/I_PERSON
occurred O
despite O
withdrawal O
of O
ethambutol O
. O

discontinuation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O
linezolid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
resulted O
in O
marked B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
improvement B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
vision B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
. O

Our O
report B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
emphasizes O
the O
need B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
monitoring B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
visual B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
function I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
patients B_PERSON/B_LOCATION
on O
long B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O
term B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
linezolid I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treatment I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Resuscitation O
with O
lipid O
, O
epinephrine O
, O
or O
both O
in O
levobupivacaine O
- O
induced O
cardiac B_DISEASE
toxicity I_DISEASE
in O
newborn O
piglets O
. O

Background O
: O
The O
optimal O
dosing O
regimens O
of O
lipid O
emulsion O
, O
epinephrine O
, O
or O
both O
are O
not O
yet O
determined O
in O
neonates O
in O
cases O
of O
local O
anaesthetic O
systemic O
toxicity B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
( O
Last O
) O
. O

methods O
: O
newborn O
piglets O
received O
levobupivacaine O
until O
cardiovascular B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
collapse I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
occurred O
. O

Standard O
cardiopulmonary O
resuscitation O
was O
started O
and O
electrocardiogram O
( O
ECG O
) O
was O
monitored O
for O
ventricular B_DISEASE
tachycardia I_DISEASE
, O
fibrillation B_DISEASE
, O
or O
QRS O
prolongation O
. O

Piglets B_PERSON
were O
then O
randomly O
allocated O
to O
four B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
groups I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
control O
( O
saline O
) O
, O
Intralipid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
) O
alone O
, O
epinephrine O
alone O
, O
or O
a O
combination B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
Intralipd B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
plus O
epinephrine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

resuscitation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
continued O
for O
30 B_TIME[MEASURE]/B_LOCATION
min I_TIME[MEASURE]/I_LOCATION
or O
until O
there O
was O
a O
return B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O
spontaneous B_DISEASE/B_MEASURE
circulation I_DISEASE/I_MEASURE
( O
ROSC B_DISEASE/B_PROTEIN[GENE]
) O
accompanied O
by O
a O
mean B_MEASURE/B_LOCATION
arterial I_MEASURE/I_LOCATION
pressure I_MEASURE/I_LOCATION
at O
or O
superior B_PERSON/B_MEASURE
to O
the O
baseline B_MEASURE/B_LOCATION
pressure B_MEASURE/I_LOCATION
and O
normal B_DISEASE_ADJECTIVE[DISEASE]
sinus I_DISEASE_ADJECTIVE[DISEASE]
rhythm I_DISEASE_ADJECTIVE[DISEASE]
for O
a O
period B_MEASURE/B_LOCATION
of O
30 B_TIME[MEASURE]
min I_TIME[MEASURE]
. O

RESULTS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
ROSC B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O
achieved O
in O
only O
one B_NUMBER[MEASURE]
of O
the O
control B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
piglets I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
compared O
with O
most B_NUMBER[MEASURE]/B_PERSON
of O
the O
treated O
piglets B_BIO/B_PERSON
. O

Mortality B_DISEASE
was O
not O
significantly O
different B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O
the O
three B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
treatment I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
groups I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
, O
but O
was O
significantly O
lower B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
in O
all O
the O
treatment B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
groups I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
compared O
with O
control B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
. O

The O
number B_MEASURE
of O
ECG B_DISEASE/B_MEASURE
abnormalities I_DISEASE/I_MEASURE
was O
zero B_MEASURE
in O
the O
Intralipid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
only I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
group I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
but O
14 B_MEASURE
and O
17 B_MEASURE
, O
respectively O
, O
in O
the O
epinephrine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
epinephrine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
plus O
lipid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
groups I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
( O
P B_MEASURE/B_PROTEIN[GENE]
< O
0 B_MEASURE
. O
05 B_MEASURE
) O
. O

CONCLUSIONS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O
Lipid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
emulsion I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
with O
or O
without O
epinephrine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
or O
epinephrine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alone O
were O
equally O
effective B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O
achieving O
a O
return B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O
spontaneous B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
circulation I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
this O
model B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
Last B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O

Epinephrine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
alone O
or O
in O
combination B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
with O
lipid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
associated O
with O
an O
increased O
number B_MEASURE/B_LOCATION
of O
ECG B_DISEASE
abnormalities I_DISEASE
compared O
with O
lipid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
emulsion I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alone O
. O

incidence O
of O
heparin O
- O
induced O
thrombocytopenia B_DISEASE
type I_DISEASE
II I_DISEASE
and O
postoperative O
recovery O
of O
platelet O
count O
in O
liver O
graft O
recipients O
: O
a O
retrospective O
cohort O
analysis O
. O

Background O
: O
Thrombocytopenia B_DISEASE
in O
patients O
with O
end B_DISEASE/B_GENE
- I_DISEASE/I_GENE
stage I_DISEASE/I_GENE
liver I_DISEASE/I_GENE
disease I_DISEASE/I_GENE
is O
a O
common O
disorder O
caused O
mainly O
by O
portal B_DISEASE
hypertension I_DISEASE
, O
low O
levels O
of O
thrombopoetin O
, O
and O
endotoxemia B_DISEASE
. O

The O
impact O
of O
immune O
- O
mediated O
heparin O
- O
induced O
thrombocytopenia B_DISEASE
type I_DISEASE
II I_DISEASE
( O
HIT B_DISEASE/B_GENE
type B_DISEASE/I_GENE
II B_DISEASE/I_GENE
) O
as O
a O
cause O
of O
thrombocytopenia B_DISEASE
after O
liver O
transplantation O
is O
not O
yet O
understood O
, O
with O
few O
literature O
citations O
reporting O
contradictory O
results O
. O

The O
aim O
of O
our O
study O
was O
to O
demonstrate O
the O
perioperative O
course O
of O
thrombocytopenia B_DISEASE
after O
liver O
transplantation O
and O
determine O
the O
occurrence O
of O
clinical O
HIT B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
type B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
II B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Method O
: O
We O
retrospectively O
evaluated O
the O
medical O
records O
of O
205 O
consecutive O
adult O
patients O
who O
underwent O
full O
- O
size O
liver O
transplantation O
between O
January O
2006 O
and O
December O
2010 O
due O
to O
end B_DISEASE
- I_DISEASE
stage I_DISEASE
or I_DISEASE
malignant I_DISEASE
liver I_DISEASE
disease I_DISEASE
. O

Preoperative O
platelet O
count O
, O
postoperative O
course O
of O
platelets O
, O
and O
clinical O
signs O
of O
HIT B_DISEASE
type I_DISEASE
II I_DISEASE
were O
analyzed O
. O

Results O
: O
A O
total O
of O
155 O
( O
75 O
. O
6 O
% O
) O
of O
205 O
patients O
had O
thrombocytopenia B_DISEASE
before O
transplantation O
, O
significantly O
influenced O
by O
Model O
of O
End B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
- I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
Stage I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
Liver I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
Disease I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
score O
and O
liver B_DISEASE_ADJECTIVE[DISEASE]
cirrhosis I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
platelet B_MEASURE/B_DISEASE
count I_MEASURE/I_DISEASE
exceeded O
100 B_MEASURE
, O
000 B_MEASURE
/ O
ul B_MEASURE
in O
most B_NUMBER[MEASURE]
of O
the O
patients B_PERSON/B_LOCATION
( O
n B_OTHER/B_MEASURE
= O
193 B_MEASURE
) O
at O
a O
medium B_MEASURE
of O
7 B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
d I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
. O

Regarding O
HIT B_DISEASE/B_PERSON
II I_DISEASE/I_PERSON
, O
there O
were O
four O
( O
1 O
. O
95 O
% O
) O
patients O
with O
a O
background O
of O
HIT B_DISEASE
type I_DISEASE
II I_DISEASE
. O

conclusions O
: O
The O
incidence O
of O
HIT B_DISEASE/B_GENE
in O
patients O
with O
end B_DISEASE/B_GENE
- I_DISEASE/I_GENE
stage I_DISEASE/I_GENE
hepatic I_DISEASE/I_GENE
failure I_DISEASE/I_GENE
is O
, O
with O
about O
1 O
. O
95 O
% O
, O
rare O
. O

For O
further O
reduction O
of O
HIT B_DISEASE_ADJECTIVE[DISEASE]
type I_DISEASE_ADJECTIVE[DISEASE]
II I_DISEASE_ADJECTIVE[DISEASE]
, O
the O
use O
of O
intravenous O
heparin O
should O
be O
avoided O
and O
the O
prophylactic O
anticoagulation O
should O
be O
performed O
with O
low O
- O
molecular O
- O
weight O
heparin O
after O
normalization O
of O
platelet O
count O
. O

Takotsubo B_DISEASE
syndrome I_DISEASE
( O
or O
apical B_DISEASE
ballooning I_DISEASE
syndrome I_DISEASE
) O
secondary O
to O
Zolmitriptan O
. O

Takotsubo B_DISEASE/B_GENE
syndrome I_DISEASE/I_GENE
( O
TS B_LOCATION
) O
, O
also O
known O
as O
broken B_LOCATION
heart I_LOCATION
syndrome I_LOCATION
, O
is O
characterized O
by O
left O
ventricle O
apical O
ballooning O
with O
elevated O
cardiac O
biomarkers O
and O
electrocardiographic O
changes O
suggestive O
of O
an O
acute B_DISEASE/B_LOCATION
coronary I_DISEASE/I_LOCATION
syndrome I_DISEASE/I_LOCATION
( O
ie O
, O
ST O
- O
segment O
elevation O
, O
T O
wave O
inversions O
, O
and O
pathologic O
Q O
waves O
) O
. O

We O
report O
a O
case O
of O
54 O
- O
year O
- O
old O
woman O
with O
medical O
history O
of O
mitral B_DISEASE
valve I_DISEASE
prolapse I_DISEASE
and O
migraines B_DISEASE/B_LOCATION
, O
who O
was O
admitted O
to O
the O
hospital O
for O
substernal O
chest B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
pain I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
electrocardiogram O
demonstrated O
1 O
/ O
2 O
mm O
ST O
- O
segment O
elevation O
in O
leads O
II O
, O
III O
, O
aVF O
, O
V5 O
, O
and O
V6 O
and O
positive O
troponin O
I O
. O

Emergent O
coronary O
angiogram O
revealed O
normal O
coronary O
arteries O
with O
moderately O
reduced O
left O
ventricular O
ejection O
fraction O
with O
wall O
motion O
abnormalities O
consistent O
with O
TS B_DISEASE
. O

detailed O
history O
obtained O
retrospectively O
revealed O
that O
the O
patient O
took O
zolmitriptan O
sparingly O
only O
when O
she O
had O
migraines B_DISEASE
. O

But O
before O
this O
event O
, O
she O
was O
taking O
zolmitriptan O
2 O
- O
3 O
times O
daily O
for O
several O
days O
because O
of O
a O
persistent O
migraine B_DISEASE
headache I_DISEASE
. O

She O
otherwise O
reported O
that O
she O
is O
quite O
active B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O
rides O
horses B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
, O
and O
does O
show O
jumping O
without O
any O
limitations B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O
her O
physical B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activity I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

There O
was O
no O
evidence O
of O
any O
recent O
stress O
or O
status B_DISEASE
migrainosus I_DISEASE
. O

extensive O
literature O
search O
revealed O
multiple O
cases O
of O
coronary B_DISEASE
artery I_DISEASE
vasospasm I_DISEASE
secondary O
to O
zolmitriptan O
, O
but O
none O
of O
the O
cases O
were O
associated O
with O
TS B_DISEASE
. O

Depression B_DISEASE
, O
impulsiveness B_DISEASE
, O
sleep O
, O
and O
memory O
in O
past O
and O
present O
polydrug O
users O
of O
3 O
, O
4 O
- O
methylenedioxymethamphetamine O
( O
MDMA O
, O
ecstasy O
) O
. O

rationale B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O
Ecstasy B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
3 B_NUMBER[MEASURE]
, O
4 B_NUMBER[MEASURE]
- O
methylenedioxymethamphetamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O
MDMA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
) O
is O
a O
worldwide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
recreational I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
drug I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
abuse B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Unfortunately O
, O
the O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O
human B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
research I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
investigating O
its O
psychological B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
have O
been O
inconsistent B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

objectives B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O
The O
present B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
aimed O
to O
be O
the O
largest B_SEQUENCE[MEASURE]
to O
date B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
sample B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
size I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
and O
5HT B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
related O
behaviors B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
; O
the O
first B_SEQUENCE[MEASURE]
to O
compare O
present B_PERSON/B_ORGANIZATION
ecstasy I_PERSON/I_ORGANIZATION
users I_PERSON/I_ORGANIZATION
with O
past B_PERSON
users I_PERSON
after O
an O
abstinence B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
4 B_NUMBER[MEASURE]
or O
more B_TIME[MEASURE]
years I_TIME[MEASURE]
, O
and O
the O
first B_SEQUENCE[MEASURE]
to O
include O
robust B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
controls I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
for O
other B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
recreational I_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
substances I_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

METHODS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O
A O
sample B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
997 B_PERSON/B_MEASURE
participants I_PERSON/I_MEASURE
( O
52 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
male I_MEASURE/I_PERSON
) O
was O
recruited O
to O
four B_NUMBER[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
control I_NUMBER[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
groups I_NUMBER[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
non B_DISEASE_ADJECTIVE[DISEASE]
- O
drug B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
( O
ND B_LOCATION
) O
, O
alcohol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
/ O
nicotine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
AN B_LOCATION/B_ORGANIZATION
) O
, O
cannabis B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
alcohol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
/ O
nicotine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
Can B_LOCATION/B_EDU[ORGANIZATION]
) O
, O
non B_DISEASE
- O
ecstasy B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
polydrug I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
( O
PD B_LOCATION
) O
) O
, O
and O
two B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
ecstasy B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
polydrug B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
groups B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
( O
present B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
( O
MDMA B_LOCATION
) O
and O
past B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
users B_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
( O
EX B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O
MDMA B_LOCATION/B_PERSON
) O
. O

participants O
completed O
a O
drug O
history O
questionnaire O
, O
Beck O
Depression B_DISEASE
inventory O
, O
Barratt O
Impulsiveness B_DISEASE_ADJECTIVE[DISEASE]
Scale O
, O
Pittsburgh O
Sleep O
Quality O
Index O
, O
and O
Wechsler O
Memory O
Scale O
- O
revised O
which O
, O
in O
total O
, O
provided O
13 O
psychometric O
measures O
. O

RESULTS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O
While O
the O
Can B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O
PD B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
groups I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
tended O
to O
record O
greater B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
deficits I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
than O
the O
non B_DISEASE/B_LOCATION
- O
drug B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
controls I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
, O
the O
MDMA B_LOCATION
and O
EX B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O
MDMA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
groups B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
recorded O
greater B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
deficits I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
than O
all O
the O
control B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
groups B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
on O
ten B_NUMBER[MEASURE]
of O
the O
13 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
psychometric I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
measures I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

Strikingly O
, O
despite O
prolonged O
abstinence B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
( O
mean B_MEASURE/B_LOCATION
, O
4 B_MEASURE
. O
98 B_MEASURE
; O
range B_MEASURE
, O
4 B_NUMBER[MEASURE]
- O
9 B_TIME[MEASURE]
years I_TIME[MEASURE]
) O
, O
past O
ecstasy B_PERSON/B_ORGANIZATION
users I_PERSON/I_ORGANIZATION
showed O
few B_DISEASE_ADJECTIVE[DISEASE]
signs I_DISEASE_ADJECTIVE[DISEASE]
of O
recovery B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Compared O
with O
present B_TIME[MEASURE]/B_ORGANIZATION
ecstasy I_TIME[MEASURE]/I_ORGANIZATION
users I_TIME[MEASURE]/I_ORGANIZATION
, O
the O
past B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
users I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
showed O
no O
change B_DISEASE_ADJECTIVE[DISEASE]
for O
ten B_TIME[MEASURE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
measures B_TIME[MEASURE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
increased O
impairment B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
two B_NUMBER[MEASURE]/B_PERSON
measures I_NUMBER[MEASURE]/I_PERSON
, O
and O
improvement B_DISEASE_ADJECTIVE[DISEASE]
on O
just O
one B_NUMBER[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
measure I_NUMBER[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

conclusions O
: O
Given O
this O
record O
of O
impaired B_DISEASE_ADJECTIVE[DISEASE]
memory I_DISEASE_ADJECTIVE[DISEASE]
and O
clinically O
significant O
levels O
of O
depression B_DISEASE
, O
impulsiveness B_DISEASE
, O
and O
sleep B_DISEASE_ADJECTIVE[DISEASE]
disturbance I_DISEASE_ADJECTIVE[DISEASE]
, O
the O
prognosis O
for O
the O
current O
generation O
of O
ecstasy O
users O
is O
a O
major O
cause O
for O
concern O
. O

Association O
of O
common O
genetic O
variants O
of O
HOMER1 O
gene O
with O
levodopa O
adverse O
effects O
in O
Parkinson B_DISEASE/B_LOCATION
' I_DISEASE/I_LOCATION
s I_DISEASE/I_LOCATION
disease I_DISEASE/I_LOCATION
patients O
. O

Levodopa O
is O
the O
most O
effective O
symptomatic O
therapy O
for O
Parkinson B_DISEASE
' I_DISEASE
s I_DISEASE
disease I_DISEASE
, O
but O
its O
chronic O
use O
could O
lead O
to O
chronic O
adverse O
outcomes O
, O
such O
as O
motor O
fluctuations O
, O
dyskinesia B_DISEASE
and O
visual B_DISEASE
hallucinations I_DISEASE
. O

HOMER1 B_GENE
is O
a O
protein B_GENE/B_BACTERIUM[BIO]
with O
pivotal B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
function I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
glutamate B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
transmission I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
which O
has O
been O
related O
to O
the O
pathogenesis B_DISEASE_ADJECTIVE[DISEASE]
of O
these O
complications B_DISEASE
. O

This O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
investigates O
whether O
polymorphisms B_GENE
in O
the O
HOMER1 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
promoter I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
region I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
are O
associated O
with O
the O
occurrence B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O
the O
chronic B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
complications B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
levodopa B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
therapy I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

A O
total O
of O
205 O
patients O
with O
idiopathic B_DISEASE/B_LOCATION
Parkinson I_DISEASE/I_LOCATION
' I_DISEASE/I_LOCATION
s I_DISEASE/I_LOCATION
disease I_DISEASE/I_LOCATION
were O
investigated O
. O

patients B_PERSON
were O
genotyped O
for O
rs4704559 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
rs10942891 B_MEASURE/B_GENE
and O
rs4704560 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O
allelic B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
discrimination I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
with O
Taqman B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
assays I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
rs4704559 O
G O
allele O
was O
associated O
with O
a O
lower O
prevalence O
of O
dyskinesia B_DISEASE
( O
prevalence O
ratio O
( O
PR O
) O
= O
0 O
. O
615 O
, O
95 O
% O
confidence O
interval O
( O
CI O
) O
0 O
. O
426 O
- O
0 O
. O
887 O
, O
P O
= O
0 O
. O
009 O
) O
and O
visual B_DISEASE
hallucinations I_DISEASE
( O
PR O
= O
0 O
. O
515 O
, O
95 O
% O
CI O
0 O
. O
295 O
- O
0 O
. O
899 O
, O
P O
= O
0 O
. O
020 O
) O
. O

Our O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
suggest O
that O
HOMER1 B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
rs4704559 I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
G I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
allele I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
has O
a O
protective B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
role I_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
the O
development B_DISEASE_ADJECTIVE[DISEASE]
of O
levodopa B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
adverse I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Crocin B_BIO/B_GENE
improves O
lipid B_DISEASE_ADJECTIVE[DISEASE]
dysregulation I_DISEASE_ADJECTIVE[DISEASE]
in O
subacute B_DISEASE/B_BIO
diazinon I_DISEASE/I_BIO
exposure I_DISEASE/I_BIO
through O
ERK1 B_GENE
/ O
2 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
pathway I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O
rat B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
liver I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Introduction B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
: O
Diazinon B_NUMBER[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Yis I_NUMBER[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
one I_NUMBER[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
most O
broadly O
used O
organophosphorus B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
insecticides I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
agriculture B_LOCATION
. O

It O
has O
been O
shown O
that O
exposure B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
to O
diazinon B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
may O
interfere O
with O
lipid B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
metabolism B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
. O

Moreover O
, O
the O
hypolipidemic B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
effect I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
crocin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
has O
been O
established O
. O

Earlier B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
studies I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
revealed O
the O
major B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENT
role I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENT
of O
Extracellular B_GENE
signal I_GENE
- O
regulated O
kinase B_ENZYME[GENE]
( O
ERK B_GENE/B_LOCATION
) O
pathways B_LOCATION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
low B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O
density B_GENE/B_MEASURE
lipoprotein I_GENE/I_MEASURE
receptor I_GENE/I_MEASURE
( O
LDLr B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
expression B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O

The O
aim B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O
this O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
to O
evaluate O
changes B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
regulation B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
lipid B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
metabolism I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
ERK B_GENE
and O
LDLr B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
expression I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O
the O
liver B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
of O
rats B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
exposed O
to O
subacute O
diazinon B_DISEASE/B_BIO
. O

Furthermore O
ameliorating B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
effect I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
crocin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
on O
diazinon B_DISEASE/B_BIO
induced O
disturbed B_DISEASE/B_GENE
cholesterol I_DISEASE/I_GENE
homeostasis I_DISEASE/I_GENE
was O
studied O
. O

METHODS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O
24 B_PERSON
rats I_PERSON
were O
divided O
into O
4 B_MEASURE/B_ORGANIZATION
groups B_MEASURE/I_ORGANIZATION
and O
received O
following O
treatments B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
for O
4 B_DISEASE/B_LOCATION
weeks I_DISEASE/I_LOCATION
; O
corn B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
oil I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
( O
control B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
, O
diazinon B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
( O
15mg B_MEASURE
/ O
kg B_MEASURE/B_PERSON
per O
day B_TIME[MEASURE]
, O
orally O
) O
and O
crocin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
( O
12 B_MEASURE
. O
5 B_MEASURE
and O
25mg B_MEASURE
/ O
kg B_MEASURE
per O
day B_TIME[MEASURE]
, O
intraperitoneally O
) O
in O
combination B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANIZATION
with O
diazinon B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
( O
15 B_MEASURE
mg I_MEASURE
/ O
kg B_MEASURE
) O
. O

The O
levels B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
of O
cholesterol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
, O
triglyceride B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
and O
LDL B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
blood B_BODY_PART_OR_ORGAN_COMPONENT/B_GENE
of O
rats B_BIO/B_PERSON
were O
analyzed O
. O

Moreover O
mRNA B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
levels I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
of O
LDLr B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
ERK1 B_GENE
/ O
2 B_NUMBER[MEASURE]
as O
well O
as O
protein B_MEASURE/B_LOCATION
levels I_MEASURE/I_LOCATION
of O
total B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
and O
activated O
forms B_DISEASE/B_GENE
of O
ERK1 B_GENE
/ O
2 B_NUMBER[MEASURE]
in O
rat B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
liver I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
were O
evaluated O
by O
Western B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
blotting I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
quantitative B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
real I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
time I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
polymerase I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
chain I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reaction I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

RESULTS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O
Our O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
showed O
that O
subacute B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
exposure I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
to O
diazinon B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
significantly O
increased O
concentrations B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
cholesterol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
triglyceride B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
LDL B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Moreover O
diazinon B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
decreased O
ERK1 B_GENE
/ O
2 B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
protein I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
phosphorylation I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
LDLr B_GENE
transcript I_GENE
. O

Crocin O
reduced O
inhibition O
of O
ERK O
activation O
and O
diazinon O
- O
induced O
hyperlipemia B_DISEASE/B_GENE
and O
increased O
levels O
of O
LDLr O
transcript O
. O

conclusions O
: O
Crocin O
may O
be O
considered O
as O
a O
novel O
protective O
agent O
in O
diazinon O
- O
induced O
hyperlipemia B_DISEASE/B_GENE
through O
modulating O
of O
ERK O
pathway O
and O
increase O
of O
LDLr O
expression O
. O

GEM O
- O
P O
chemotherapy O
is O
active O
in O
the O
treatment O
of O
relapsed O
Hodgkin B_DISEASE/B_GENE
lymphoma I_DISEASE/I_GENE
. O

Hodgkin B_DISEASE
lymphoma I_DISEASE
( O
HL B_PROTEIN[GENE]/B_DISEASE
) O
is O
a O
relatively O
chemosensitive O
malignancy B_DISEASE/B_MEASURE
. O

However O
, O
for O
those O
who O
relapse O
, O
high B_MEASURE
- O
dose B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
chemotherapy I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
with O
autologous B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stem I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cell I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
transplant I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
the O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
of O
choice B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
which O
relies O
on O
adequate B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
disease I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
control I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
with O
salvage B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
chemotherapy I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Regimens O
commonly O
used O
often O
require O
inpatient O
administration O
and O
can O
be O
difficult O
to O
deliver O
due O
to O
toxicity B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Gemcitabine O
and O
cisplatin O
have O
activity O
in O
HL B_DISEASE
, O
non O
- O
overlapping O
toxicity B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
with O
first O
- O
line O
chemotherapeutics O
, O
and O
may O
be O
delivered O
in O
an O
outpatient O
setting O
. O

In O
this O
retrospective O
single O
- O
centre O
analysis O
, O
patients O
with O
relapsed O
or O
refractory O
HL B_DISEASE/B_GENE
treated O
with O
gemcitabine O
1 O
, O
000 O
mg O
/ O
m O
( O
2 O
) O
day O
( O
D O
) O
1 O
, O
D8 O
and O
D15 O
; O
methylprednisolone O
1 O
, O
000 O
mg O
D1 O
- O
5 O
; O
and O
cisplatin O
100 O
mg O
/ O
m O
( O
2 O
) O
D15 O
, O
every O
28 O
days O
( O
GEM O
- O
P O
) O
were O
included O
. O

demographic O
, O
survival O
, O
response O
and O
toxicity B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
data O
were O
recorded O
. O

Forty B_NUMBER[MEASURE]
- O
one B_NUMBER[MEASURE]/B_PERSON
eligible I_NUMBER[MEASURE]/I_PERSON
patients I_NUMBER[MEASURE]/I_PERSON
were O
identified O
: O
median B_MEASURE/B_PERSON
age I_MEASURE/I_PERSON
27 I_MEASURE/I_PERSON
. O

One B_NUMBER[MEASURE]
hundred I_NUMBER[MEASURE]
and O
twenty B_NUMBER[MEASURE]
- O
two B_NUMBER[MEASURE]/B_LOCATION
cycles I_NUMBER[MEASURE]/I_LOCATION
of O
GEM B_LOCATION/B_ORGANIZATION
- O
P B_OTHER/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
administered O
in O
total B_MEASURE/B_PERSON
( O
median B_TIME[MEASURE]/B_LOCATION
3 I_TIME[MEASURE]/I_LOCATION
cycles I_TIME[MEASURE]/I_LOCATION
; O
range B_MEASURE
1 I_MEASURE
- O
6 B_MEASURE
) O
. O

Twenty B_NUMBER[MEASURE]
of O
41 B_NUMBER[MEASURE]/B_PERSON
( O
48 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
patients B_PERSON/B_LOCATION
received O
GEM B_LOCATION/B_ORGANIZATION
- O
P B_OTHER/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O
second B_SEQUENCE[MEASURE]/B_LOCATION
- O
line B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
treatment I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
and O
11 B_MEASURE
/ O
41 B_MEASURE
( O
27 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
as O
third B_SEQUENCE[MEASURE]/B_LOCATION
- O
line B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
therapy I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
. O

Overall B_MEASURE/B_LOCATION
response B_MEASURE/I_LOCATION
rate B_MEASURE/I_LOCATION
( O
ORR B_DISEASE/B_PROTEIN[GENE]
) O
to O
GEM B_LOCATION/B_ORGANIZATION
- O
P B_OTHER/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
entire B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
cohort I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
was O
80 B_MEASURE/B_LOCATION
% I_MEASURE/I_LOCATION
( O
complete B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
response I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
( O
CR B_LOCATION/B_MEASURE
) O
37 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
, O
partial B_DISEASE/B_LOCATION
response I_DISEASE/I_LOCATION
44 I_DISEASE/I_LOCATION
% I_DISEASE/I_LOCATION
) O
with O
14 B_MEASURE
/ O
15 B_MEASURE
CR I_MEASURE
confirmed O
as O
a O
metabolic B_DISEASE/B_LOCATION
CR I_DISEASE/I_LOCATION
on O
PET B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O
ORR B_DISEASE/B_MEASURE
of O
85 B_PERSON/B_MEASURE
% B_PERSON/I_MEASURE
in O
the O
20 B_SEQUENCE[MEASURE]/B_LOCATION
second I_SEQUENCE[MEASURE]/I_LOCATION
- O
line B_TIME[MEASURE]/B_LOCATION
patients I_TIME[MEASURE]/I_LOCATION
. O

The O
most O
common O
grade O
3 O
/ O
4 O
toxicities B_DISEASE
were O
haematological O
: O
neutropenia B_DISEASE
54 O
% O
and O
thrombocytopenia B_DISEASE
51 O
% O
. O

Median B_MEASURE/B_PERSON
follow I_MEASURE/I_PERSON
- O
up B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O
the O
start B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O
Gem B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
- O
P B_OTHER/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
4 B_MEASURE
. O
5 B_TIME[MEASURE]
years I_TIME[MEASURE]
. O

Following O
GEM B_LOCATION/B_ORGANIZATION
- O
P B_OTHER/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
5 B_NUMBER[MEASURE]
- O
year B_TIME[MEASURE]/B_LOCATION
progression I_TIME[MEASURE]/I_LOCATION
- O
free B_DISEASE/B_MEASURE
survival I_DISEASE/I_MEASURE
was O
46 B_MEASURE
% I_MEASURE
( O
95 B_MEASURE
% I_MEASURE
confidence I_MEASURE
interval I_MEASURE
( O
CI B_LOCATION/B_MEASURE
) O
, O
30 B_MEASURE
- O
62 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
and O
5 B_NUMBER[MEASURE]
- O
year B_TIME[MEASURE]
overall I_TIME[MEASURE]
survival I_TIME[MEASURE]
was O
59 B_MEASURE
% I_MEASURE
( O
95 B_MEASURE/B_LOCATION
% B_MEASURE/I_LOCATION
CI B_MEASURE/I_LOCATION
, O
43 B_MEASURE
- O
74 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
. O

Fourteen B_NUMBER[MEASURE]/B_PERSON
of O
41 B_NUMBER[MEASURE]/B_PERSON
patients B_NUMBER[MEASURE]/I_PERSON
proceeded O
directly O
to O
autologous B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
transplant I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

GEM O
- O
P O
is O
a O
salvage O
chemotherapy O
with O
relatively O
high O
response O
rates O
, O
leading O
to O
successful O
transplantation O
in O
appropriate O
patients O
, O
in O
the O
treatment O
of O
relapsed O
or O
refractory O
HL B_DISEASE/B_PERSON
. O

Basal B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
functioning O
of O
the O
hypothalamic B_BODY_PART_OR_ORGAN_COMPONENT
- O
pituitary B_BODY_PART_OR_ORGAN_COMPONENT
- O
adrenal B_BODY_PART_OR_ORGAN_COMPONENT
( O
HPA B_LOCATION/B_DISEASE
) O
axis B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
and O
psychological B_DISEASE_ADJECTIVE[DISEASE]
distress I_DISEASE_ADJECTIVE[DISEASE]
in O
recreational B_PERSON/B_ORGANIZATION
ecstasy I_PERSON/I_ORGANIZATION
polydrug I_PERSON/I_ORGANIZATION
users I_PERSON/I_ORGANIZATION
. O

RATIONALE O
: O
ecstasy O
( O
MDMA O
) O
is O
a O
psychostimulant O
drug O
which O
is O
increasingly O
associated O
with O
psychobiological B_DISEASE
dysfunction I_DISEASE
. O

While O
some O
recent B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
studies I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
suggest O
acute B_DISEASE_ADJECTIVE[DISEASE]
changes I_DISEASE_ADJECTIVE[DISEASE]
in O
neuroendocrine B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
function I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
less B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
is O
known O
about O
long B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O
term B_MEASURE/B_LOCATION
changes B_MEASURE/I_LOCATION
in O
HPA B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
functionality B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
recreational B_PERSON/B_BIO
users B_PERSON/I_BIO
. O

objectives B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O
The O
current B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
the O
first B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SEQUENCE[MEASURE]
to O
explore O
the O
effects B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENT
of O
ecstasy B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
polydrug B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
use B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_LOCATION
on O
psychological B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
distress B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
and O
basal B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
functioning B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
HPA B_BODY_PART_OR_ORGAN_COMPONENT/B_PERSON
axis I_BODY_PART_OR_ORGAN_COMPONENT/I_PERSON
through O
assessing O
the O
secretion B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
cortisol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
across O
the O
diurnal B_TIME[MEASURE]/B_BODY_PART_OR_ORGAN_COMPONENT
period I_TIME[MEASURE]/I_BODY_PART_OR_ORGAN_COMPONENT
. O

Method B_MEASURE
: O
seventy B_NUMBER[MEASURE]
- O
six B_NUMBER[MEASURE]
participants I_NUMBER[MEASURE]
( O
21 B_MEASURE/B_PERSON
nonusers I_MEASURE/I_PERSON
, O
29 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
light I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ecstasy I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
polydrug B_PERSON/B_ORGANIZATION
users I_PERSON/I_ORGANIZATION
, O
26 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
heavy I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ecstasy I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
polydrug B_PERSON/B_ORGANIZATION
users I_PERSON/I_ORGANIZATION
) O
completed O
a O
substance B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
use I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
inventory I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
and O
measures B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
psychological B_DISEASE_ADJECTIVE[DISEASE]
distress I_DISEASE_ADJECTIVE[DISEASE]
at O
baseline B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
, O
then O
two B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
consecutive B_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
days B_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
cortisol B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
sampling I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
( O
on O
awakening O
, O
30 B_TIME[MEASURE]/B_ENT
min I_TIME[MEASURE]/I_ENT
post I_TIME[MEASURE]/I_ENT
awakening I_TIME[MEASURE]/I_ENT
, O
between O
1400 B_MEASURE
and O
1600 B_TIME[MEASURE]
hours I_TIME[MEASURE]
and O
pre B_TIME[MEASURE]/B_LOCATION
bedtime I_TIME[MEASURE]/I_LOCATION
) O
. O

On O
day B_TIME[MEASURE]/B_LOCATION
2 I_TIME[MEASURE]/I_LOCATION
, O
participants B_PERSON
also O
attended O
the O
laboratory B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
to O
complete O
a O
20 B_MEASURE
- O
min B_PERSON/B_TIME[MEASURE]
multitasking O
stressor B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Results O
: O
Both O
user O
groups O
exhibited O
significantly O
greater O
levels O
of O
anxiety B_DISEASE
and O
depression B_DISEASE
than O
nonusers O
. O

On O
day B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
all O
participants B_PERSON
exhibited O
a O
typical B_DISEASE/B_MEASURE
cortisol I_DISEASE/I_MEASURE
profile I_DISEASE/I_MEASURE
, O
though O
light B_PERSON/B_ORGANIZATION
users I_PERSON/I_ORGANIZATION
had O
significantly O
elevated O
levels B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pre I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
bed B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BODY_PART_OR_ORGAN_COMPONENT
. O

On O
day B_TIME[MEASURE]/B_PERSON
2 I_TIME[MEASURE]/I_PERSON
, O
heavy B_PERSON/B_ORGANIZATION
users I_PERSON/I_ORGANIZATION
demonstrated O
elevated B_DISEASE_ADJECTIVE[DISEASE]
levels I_DISEASE_ADJECTIVE[DISEASE]
upon O
awakening O
and O
all O
ecstasy B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
polydrug B_PERSON/B_ORGANIZATION
users I_PERSON/I_ORGANIZATION
demonstrated O
elevated B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
pre I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
- O
bed B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
levels I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
compared O
to O
non B_DISEASE
- O
users B_PERSON
. O

Significant B_DISEASE_ADJECTIVE[DISEASE]
between O
group B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
differences I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
were O
also O
observed O
in O
afternoon B_MEASURE/B_PERSON
cortisol B_MEASURE/I_PERSON
levels B_MEASURE/I_PERSON
and O
in O
overall B_DISEASE
cortisol I_DISEASE
secretion I_DISEASE
across O
the O
day B_TIME[MEASURE]/B_BODY_PART_OR_ORGAN_COMPONENT
. O

conclusions O
: O
The O
increases O
in O
anxiety B_DISEASE
and O
depression B_DISEASE
are O
in O
line O
with O
previous O
observations O
in O
recreational O
ecstasy O
- O
polydrug O
users O
. O

dysregulated B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
diurnal I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
cortisol I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
may O
be O
indicative B_DISEASE/B_PERSON
of O
inappropriate B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
anticipation I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
forthcoming B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
demands I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
hypersecretion B_TIME[MEASURE]/B_LOCATION
may O
lead O
to O
the O
increased O
psychological B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
physical B_DISEASE_ADJECTIVE[DISEASE]
morbidity I_DISEASE_ADJECTIVE[DISEASE]
associated O
with O
heavy B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_TIME[MEASURE]
recreational I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_TIME[MEASURE]
use I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_TIME[MEASURE]
of O
ecstasy B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Ifosfamide O
related O
encephalopathy B_DISEASE
: O
the O
need O
for O
a O
timely O
EEG O
evaluation O
. O

Background O
: O
Ifosfamide O
is O
an O
alkylating O
agent O
useful O
in O
the O
treatment O
of O
a O
wide O
range O
of O
cancers B_DISEASE
including O
sarcomas B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
, O
lymphoma B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
, O
gynecologic B_DISEASE
and I_DISEASE
testicular I_DISEASE
cancers I_DISEASE
. O

Encephalopathy B_DISEASE
has O
been O
reported O
in O
10 O
- O
40 O
% O
of O
patients O
receiving O
high O
- O
dose O
IV O
ifosfamide O
. O

objective O
: O
To O
highlight O
the O
role O
of O
electroencephalogram O
( O
EEG O
) O
in O
the O
early O
detection O
and O
management O
of O
ifosfamide O
related O
encephalopathy B_DISEASE
. O

methods O
: O
retrospective O
chart O
review O
including O
clinical O
data O
and O
EEG O
recordings O
was O
done O
on O
five O
patients O
, O
admitted O
to O
MD O
Anderson O
Cancer B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
Center O
between O
years O
2009 O
and O
2012 O
, O
who O
developed O
ifosfamide O
related O
acute O
encephalopathy B_DISEASE
. O

Results O
: O
All O
five O
patients O
experienced O
symptoms O
of O
encephalopathy B_DISEASE
soon O
after O
( O
within O
12 O
h O
- O
2 O
days O
) O
receiving O
ifosfamide O
. O

Two O
patients O
developed O
generalized O
convulsions B_DISEASE
while O
one O
patient O
developed O
continuous O
non B_DISEASE
- I_DISEASE
convulsive I_DISEASE
status I_DISEASE
epilepticus I_DISEASE
( O
NCSE B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
that O
required O
ICU O
admission O
and O
intubation O
. O

Initial B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
EEG I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
showed O
epileptiform B_DISEASE_ADJECTIVE[DISEASE]
discharges I_DISEASE_ADJECTIVE[DISEASE]
in O
three B_NUMBER[MEASURE]/B_PERSON
patients B_NUMBER[MEASURE]/I_PERSON
; O
run O
of O
triphasic B_DISEASE/B_MEASURE
waves I_DISEASE/I_MEASURE
in O
one B_PERSON/B_NUMBER[MEASURE]
patient I_PERSON/I_NUMBER[MEASURE]
and O
moderate B_DISEASE_ADJECTIVE[DISEASE]
degree I_DISEASE_ADJECTIVE[DISEASE]
diffuse I_DISEASE_ADJECTIVE[DISEASE]
generalized O
slowing B_DISEASE
. O

Mixed B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pattern I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
the O
presence B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
both O
sharps B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
and O
triphasic B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
waves B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
were O
also O
noted O
. O

repeat O
EEGs B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
within O
24 B_MEASURE
_ I_MEASURE
h O
of O
symptom B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
onset I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
showed O
marked B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
improvement B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
that O
was O
correlated O
with O
clinical B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
improvement I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O

conclusions O
: O
severity O
of O
ifosfamide O
related O
encephalopathy B_DISEASE
correlates O
with O
EEG O
changes O
. O

We O
suggest O
a O
timely O
EEG O
evaluation O
for O
patients O
receiving O
ifosfamide O
who O
develop O
features O
of O
encephalopathy B_DISEASE
. O

incidence O
of O
contrast O
- O
induced O
nephropathy B_DISEASE
in O
hospitalised O
patients O
with O
cancer B_DISEASE
. O

objectives O
: O
To O
determine O
the O
frequency O
of O
and O
possible O
factors O
related O
to O
contrast O
- O
induced O
nephropathy B_DISEASE
( O
CIN O
) O
in O
hospitalised O
patients O
with O
cancer B_DISEASE
. O

METHODS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O
ninety B_MEASURE/B_PERSON
adult B_MEASURE/I_PERSON
patients B_MEASURE/I_PERSON
were O
enrolled O
. O

patients O
with O
risk O
factors O
for O
acute B_DISEASE
renal I_DISEASE
failure I_DISEASE
were O
excluded O
. O

Blood B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
samples I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
examined O
the O
day B_TIME[MEASURE]
before O
contrast B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
enhanced O
computed O
tomography B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
( O
CT B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
) O
and O
serially O
for O
3 B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
days B_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
thereafter O
. O

CIN B_DISEASE/B_LOCATION
was O
defined O
as O
an O
increase B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O
serum B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
creatinine I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O
Cr B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O
of O
0 B_MEASURE
. O
5 B_MEASURE
mg I_MEASURE
/ O
dl B_TIME[MEASURE]/B_PROTEIN[GENE]
or O
more B_MEASURE/B_LOCATION
, O
or O
elevation B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
CR B_LOCATION/B_MEASURE
to O
25 B_MEASURE/B_LOCATION
% I_MEASURE/I_LOCATION
over O
baseline B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
. O

relationships B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O
CIN B_DISEASE
and O
possible B_DISEASE/B_ORGANIZATION
risk I_DISEASE/I_ORGANIZATION
factors I_DISEASE/I_ORGANIZATION
were O
investigated O
. O

RESULTS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
: O
CIN B_DISEASE/B_GENE
was O
detected O
in O
18 B_MEASURE
/ O
90 B_MEASURE
( O
20 B_MEASURE/B_LOCATION
% I_MEASURE/I_LOCATION
) O
patients B_PERSON
. O

CIN B_DISEASE
developed O
in O
25 B_MEASURE
. O
5 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
patients I_MEASURE/I_PERSON
who O
underwent O
chemotherapy B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
and O
in O
11 B_PERSON
% I_PERSON
patients I_PERSON
who O
did O
not O
( O
P B_OTHER/B_MEASURE
= O
0 B_MEASURE
. O
1 B_MEASURE
) O
. O

CIN B_DISEASE
more O
frequently O
developed O
in O
patients B_PERSON
who O
had O
undergone O
CT B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
within O
45 B_TIME[MEASURE]/B_ENT
days I_TIME[MEASURE]/I_ENT
after O
the O
last B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
chemotherapy I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
( O
P B_OTHER/B_LOCATION
= O
0 B_MEASURE
. O
005 B_MEASURE
) O
; O
it O
was O
also O
an O
independent B_DISEASE_ADJECTIVE[DISEASE]
risk I_DISEASE_ADJECTIVE[DISEASE]
factor I_DISEASE_ADJECTIVE[DISEASE]
( O
P B_OTHER/B_LOCATION
= O
0 B_MEASURE
. O
017 B_MEASURE
) O
. O

CIN O
was O
significantly O
more O
after O
treatment O
with O
bevacizumab O
/ O
irinotecan O
( O
P O
= O
0 O
. O
021 O
) O
and O
in O
patients O
with O
hypertension B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
( O
P O
= O
0 O
. O
044 O
) O
. O

CONCLUSIONS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O
The O
incidence B_MEASURE/B_DISEASE
of O
CIN B_DISEASE/B_LOCATION
after O
CT B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
hospitalised B_PERSON/B_LOCATION
oncological B_PERSON/I_LOCATION
patients B_PERSON/I_LOCATION
was O
20 B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
% I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
. O

CIN O
developed O
4 O
. O
5 O
- O
times O
more O
frequently O
in O
patients O
with O
cancer B_DISEASE/B_LOCATION
who O
had O
undergone O
recent O
chemotherapy O
. O

Hypertension B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
the O
combination O
of O
bevacizumab O
/ O
irinotecan O
may O
be O
additional O
risk O
factors O
for O
CIN O
development O
. O

Key B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Points I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
. O

contrast O
- O
induced O
nephropathy B_DISEASE
( O
CIN O
) O
is O
a O
concern O
for O
oncological O
patients O
undergoing O
CT O
. O

. O
CIN B_DISEASE
occurs O
more O
often O
when O
CT B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
is O
performed O
< O
45 B_TIME[MEASURE]/B_ENT
days I_TIME[MEASURE]/I_ENT
after O
chemotherapy B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O

. O
Hypertension B_DISEASE
and O
treatment O
with O
bevacizumab O
appear O
to O
be O
additional O
risk O
factors O
. O

Syndrome B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
inappropriate I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
antidiuretic I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
hormone I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
secretion O
associated O
with O
desvenlafaxine O
. O

objective O
: O
To O
report O
a O
case O
of O
syndrome B_DISEASE
of I_DISEASE
inappropriate I_DISEASE
anti I_DISEASE
- I_DISEASE
diuretic I_DISEASE
hormone I_DISEASE
( O
SIADH B_DISEASE/B_GENE
) O
secretion O
associated O
with O
desvenlafaxine O
. O

Case O
summary O
: O
A O
57 O
- O
year O
old O
female O
with O
hyponatraemia B_DISEASE
. O

Her O
medications O
included O
desvenlafaxine O
, O
and O
symptoms O
included O
nausea B_DISEASE
, O
anxiety B_DISEASE
and O
confusion B_DISEASE
. O

The O
serum O
sodium O
at O
this O
time O
was O
120 O
mmol O
/ O
L O
, O
serum O
osmolality O
was O
263 O
mosmol O
/ O
kg O
, O
urine O
osmolality O
410 O
mosmol O
/ O
kg O
and O
urine O
sodium O
63 O
mmol O
/ O
L O
, O
consistent O
with O
a O
diagnosis O
of O
SIADH B_DISEASE
. O

Desvenlafaxine B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O
ceased O
and O
fluid B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
restriction I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
implemented O
. O

After O
4 B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
days I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
the O
sodium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
increased O
to O
128 B_MEASURE/B_PERSON
mmol I_MEASURE/I_PERSON
/ O
L B_OTHER/B_TIME[MEASURE]
and O
fluid B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
restriction I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
was O
relaxed O
. O

During O
her O
further B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
3 B_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
weeks B_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
inpatient B_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
admission B_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
the O
serum B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
sodium I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
ranged O
from O
134 B_MEASURE
to O
137 B_MEASURE/B_LOCATION
mmol I_MEASURE/I_LOCATION
/ O
L B_OTHER/B_MEASURE
during O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O
mirtazapine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

discussion O
: O
SIADH B_DISEASE
has O
been O
widely O
reported O
with O
a O
range O
of O
antidepressants O
. O

This O
case O
report O
suggests O
that O
desvenlafaxine O
might O
cause O
clinically O
significant O
hyponatremia B_DISEASE
. O

conclusions O
: O
Clinicians O
should O
be O
aware O
of O
the O
potential O
for O
antidepressants O
to O
cause O
hyponatremia B_DISEASE
, O
and O
take O
appropriate O
corrective O
action O
where O
necessary O
. O

Oxidative O
stress O
on O
cardiotoxicity B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
after O
treatment O
with O
single O
and O
multiple O
doses O
of O
doxorubicin O
. O

The O
mechanism O
of O
doxorubicin O
( O
DOX O
) O
- O
induced O
cardiotoxicity B_DISEASE/B_GENE
remains O
controversial O
. O

Wistar B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
rats I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
n B_OTHER/B_MEASURE
= O
66 B_MEASURE
) O
received O
DOX B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
injections I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
intraperitoneally O
and O
were O
randomly O
assigned O
to O
2 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
experimental I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
protocols I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
( O
1 B_NUMBER[MEASURE]
) O
rats B_BIO/B_PERSON
were O
killed O
before O
( O
- O
24 B_MEASURE
h O
, O
n O
= O
8 B_MEASURE
) O
and O
24 B_MEASURE
h O
after O
( O
+ O
24 B_MEASURE
h O
, O
n B_PROTEIN[GENE]/B_LOCATION
= O
8 B_MEASURE
) O
a O
single B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dose I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
DOX B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
( O
4 B_MEASURE
mg I_MEASURE
/ O
kg B_MEASURE
body I_MEASURE
weight I_MEASURE
) O
to O
determine O
the O
DOX B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
acute B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
effect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
and O
( O
2 B_NUMBER[MEASURE]
) O
rats B_BIO/B_PERSON
( O
n B_MEASURE/B_LOCATION
= O
58 B_MEASURE
) O
received O
4 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
injections I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
DOX B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
4 B_MEASURE
mg I_MEASURE
/ O
kg B_MEASURE
body I_MEASURE
weight I_MEASURE
/ O
week B_MEASURE
) O
and O
were O
killed O
before O
the O
first B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
injection I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O
M0 B_PROTEIN[GENE]
) O
and O
1 B_NUMBER[MEASURE]/B_LOCATION
week I_NUMBER[MEASURE]/I_LOCATION
after O
each O
injection B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
( O
M1 B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
M2 B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
M3 B_PROTEIN[GENE]
, O
and O
M4 B_PROTEIN[GENE]
) O
to O
determine O
the O
chronological B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
effects B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O

Animals B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
used O
at O
M0 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
n B_OTHER/B_MEASURE
= O
8 B_MEASURE
) O
were O
also O
used O
at O
moment B_MEASURE
- O
24 B_TIME[MEASURE]/B_LOCATION
h I_TIME[MEASURE]/I_LOCATION
of O
acute B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

Cardiac B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
total I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
antioxidant I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
performance I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O
TAP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
) O
, O
DNA B_DISEASE_ADJECTIVE[DISEASE]/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
damage B_DISEASE_ADJECTIVE[DISEASE]/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
morphology B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
analyses I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
were O
carried O
out O
at O
each O
time B_MEASURE/B_LOCATION
point B_MEASURE/I_LOCATION
. O

Single O
dose O
of O
DOX O
was O
associated O
with O
increased O
cardiac B_DISEASE/B_GENE
disarrangement I_DISEASE/I_GENE
, O
necrosis B_DISEASE/B_GENE
, O
and O
DNA O
damage O
( O
strand O
breaks O
( O
SBS O
) O
and O
oxidized O
pyrimidines O
) O
and O
decreased O
tap O
. O

The O
chronological O
study O
showed O
an O
effect O
of O
a O
cumulative O
dose O
on O
body O
weight O
( O
R O
= O
- O
0 O
. O
99 O
, O
p O
= O
0 O
. O
011 O
) O
, O
necrosis B_DISEASE/B_GENE
( O
R O
= O
1 O
. O
00 O
, O
p O
= O
0 O
. O
004 O
) O
, O
tap O
( O
R O
= O
0 O
. O
95 O
, O
p O
= O
0 O
. O
049 O
) O
, O
and O
DNA O
SBS O
( O
R O
= O
- O
0 O
. O
95 O
, O
p O
= O
0 O
. O
049 O
) O
. O

DNA O
SBS O
damage O
was O
negatively O
associated O
with O
tap O
( O
R O
= O
- O
0 O
. O
98 O
, O
p O
= O
0 O
. O
018 O
) O
, O
and O
necrosis B_DISEASE/B_GENE
( O
R O
= O
- O
0 O
. O
97 O
, O
p O
= O
0 O
. O
027 O
) O
. O

Our O
results O
suggest O
that O
oxidative O
damage O
is O
associated O
with O
acute O
cardiotoxicity B_DISEASE
induced O
by O
a O
single O
dose O
of O
DOX O
only O
. O

increased O
resistance B_DISEASE_ADJECTIVE[DISEASE]
to O
the O
oxidative B_DISEASE_ADJECTIVE[DISEASE]
stress I_DISEASE_ADJECTIVE[DISEASE]
is O
plausible B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
the O
multiple B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
dose B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
of O
DOX B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Thus O
, O
different O
mechanisms O
may O
be O
involved O
in O
acute O
toxicity B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
versus O
chronic O
toxicity B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Tacrolimus O
- O
related O
seizure B_DISEASE
after O
pediatric O
liver O
transplantation O
- O
- O
a O
single O
- O
center O
experience O
. O

To O
identify O
the O
risk O
factors O
for O
new O
- O
onset O
seizures B_DISEASE
after O
pediatric O
Lt O
and O
to O
assess O
their O
clinical O
implications O
and O
long O
- O
term O
prognosis O
. O

The O
clinical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
laboratory B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
data I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
27 B_PERSON
consecutive I_PERSON
children I_PERSON
who O
underwent O
LT B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
from O
January B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2007 I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
December B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2010 I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
our O
center B_LOCATION
were O
analyzed O
retrospectively O
. O

patients O
were O
divided O
into O
seizures B_DISEASE
group O
and O
a O
non O
- O
seizures B_DISEASE
group O
. O

Pre B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
operative B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
intra B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
operative B_PERSON/B_ORGANIZATION
, O
and O
post B_DISEASE
- O
operative B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
data I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
were O
collected O
. O

Seizures B_DISEASE
occurred O
in O
four O
children O
, O
an O
incidence O
of O
14 O
. O
8 O
% O
. O

All O
exhibited O
generalized O
tonic B_DISEASE
- I_DISEASE
clonic I_DISEASE
seizures I_DISEASE
within O
the O
first O
two O
wk O
after O
Lt O
. O

Univariate O
analysis O
showed O
that O
the O
risk O
factors O
associated O
with O
seizures B_DISEASE/B_GENE
after O
pediatric O
Lt O
included O
gender O
, O
pediatric O
end B_DISEASE_ADJECTIVE[DISEASE]
- I_DISEASE_ADJECTIVE[DISEASE]
stage I_DISEASE_ADJECTIVE[DISEASE]
liver I_DISEASE_ADJECTIVE[DISEASE]
disease I_DISEASE_ADJECTIVE[DISEASE]
score O
before O
surgery O
, O
Child O
- O
Pugh O
score O
before O
surgery O
, O
serum O
total O
bilirubin O
after O
surgery O
, O
and O
trough O
TAC O
level O
. O

Multivariate O
analysis O
showed O
that O
trough O
TAC O
level O
was O
the O
only O
independent O
risk O
factor O
associated O
with O
the O
seizures B_DISEASE
. O

All O
children O
who O
experienced O
seizures B_DISEASE
survived O
with O
good O
graft O
function O
and O
remained O
seizure B_DISEASE
- O
free O
without O
anti O
- O
epileptic B_DISEASE/B_GENE
drugs O
over O
a O
mean O
follow O
- O
up O
period O
of O
33 O
. O
7 O
+ O
14 O
. O
6 O
months O
. O

High O
trough O
TAC O
level O
was O
the O
predominant O
factor O
that O
contributed O
to O
seizures B_DISEASE
in O
the O
early O
post O
- O
operative O
period O
after O
pediatric O
Lt O
. O

High O
PELD O
and O
Child O
- O
Pugh O
scores O
before O
Lt O
and O
high O
post O
- O
operative O
serum O
Tbil O
may O
be O
contributory O
risk O
factors O
for O
TAC O
- O
related O
seizures B_DISEASE
. O

The O
flavonoid B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
apigenin I_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
delays I_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
forgetting O
of O
passive B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
avoidance I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
conditioning I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
in O
rats B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
present B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
experiments I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
performed O
to O
study O
the O
effect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
flavonoid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
apigenin I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
20 B_MEASURE
mg I_MEASURE
/ O
kg B_MEASURE
intraperitoneally O
( O
i O
. O
p B_MEASURE/B_LOCATION
. O
) O
, O
1 B_MEASURE
h O
before O
acquisition B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
) O
, O
on O
24 B_MEASURE
h O
retention B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
performance I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
and O
forgetting O
of O
a O
step B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- O
through O
passive B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
avoidance I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
task I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
, O
in O
young B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
male I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Wistar I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
rats I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

There O
were O
no O
differences B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O
saline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
and O
apigenin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
treated O
groups B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
24 B_MEASURE
h O
retention B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
trial I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

Furthermore O
, O
apigenin O
did O
not O
prevent O
the O
amnesia B_DISEASE_ADJECTIVE[DISEASE]
induced O
by O
scopolamine O
( O
1mg O
/ O
kg O
, O
i O
. O
p O
. O
, O
30 O
min O
before O
the O
acquisition O
) O
. O

The O
saline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
and O
apigenin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
treated O
rats B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
that O
did O
not O
step O
through O
into O
the O
dark B_BODY_PART_OR_ORGAN_COMPONENT
compartment I_BODY_PART_OR_ORGAN_COMPONENT
during O
the O
cut O
- O
off O
time B_TIME[MEASURE]/B_LOCATION
( O
540 B_TIME[MEASURE]/B_LOCATION
s I_TIME[MEASURE]/I_LOCATION
) O
were O
retested O
weekly O
for O
up O
to O
eight B_NUMBER[MEASURE]/B_ENT
weeks I_NUMBER[MEASURE]/I_ENT
. O

In O
the O
saline O
treated O
group O
, O
the O
first O
significant O
decline O
in O
passive O
avoidance O
response O
was O
observed O
at O
four O
weeks O
, O
and O
complete O
memory B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
loss B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O
found O
five O
weeks O
after O
the O
acquisition O
of O
the O
passive O
avoidance O
task O
. O

At O
the O
end B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
experimental B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
period I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
60 B_NUMBER[MEASURE]/B_LOCATION
% I_NUMBER[MEASURE]/I_LOCATION
of O
the O
animals B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treated O
with O
apigenin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
still O
did O
not O
step O
through O
. O

These O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggest O
that O
1 B_SEQUENCE[MEASURE]/B_PERSON
) O
apigenin B_DISEASE_ADJECTIVE[DISEASE]
delays I_DISEASE_ADJECTIVE[DISEASE]
the O
long B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O
term B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
forgetting B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
but O
did O
not O
modulate O
the O
24 B_MEASURE
h O
retention B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O
fear B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
memory I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
2 B_NUMBER[MEASURE]
) O
the O
obtained B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
beneficial I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effect I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
apigenin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
the O
passive B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
avoidance I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
conditioning I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
is O
mediated O
by O
mechanisms B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
that O
do O
not O
implicate O
its O
action B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
the O
muscarinic B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BODY_PART_OR_ORGAN_COMPONENT
cholinergic B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_BODY_PART_OR_ORGAN_COMPONENT
system B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_BODY_PART_OR_ORGAN_COMPONENT
. O

Histamine O
antagonists O
and O
d O
- O
tubocurarine O
- O
induced O
hypotension B_DISEASE
in O
cardiac O
surgical O
patients O
. O

hemodynamic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
effects I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
and O
histamine B_DISEASE
release I_DISEASE
by O
bolus B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
injection I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
0 B_MEASURE
. O
35 B_MEASURE
mg I_MEASURE
/ O
kg B_MEASURE
of O
d B_PROTEIN[GENE]/B_DISEASE
- O
tubocurarine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
studied O
in O
24 B_SPECIES[BIO]/B_TIME[MEASURE]
patients I_SPECIES[BIO]/I_TIME[MEASURE]
. O

H1 O
- O
and O
H2 B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
histamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
antagonists I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
or O
placebo B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
were O
given O
before O
dosing O
with O
d B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
tubocurarine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
a O
randomized B_MEASURE/B_COLOR
double I_MEASURE/I_COLOR
- O
blind B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
fashion I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
to O
four B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
groups I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
: O
group B_NUMBER[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 I_NUMBER[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
- O
placebo B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
; O
group B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
- O
cimetidine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
4 B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mg I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
kg B_MEASURE
, O
plus O
placebo B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
; O
group B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
3 I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
- O
chlorpheniramine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
0 B_MEASURE
. O
1 B_MEASURE
mg I_MEASURE
/ O
kg B_MEASURE
, O
plus O
placebo B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
; O
and O
group B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_NUMBER[MEASURE]
4 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_NUMBER[MEASURE]
- O
- O
cimetidine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
plus O
chlorpheniramine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

histamine B_DISEASE
release I_DISEASE
occurred O
in O
most B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
patients I_BODY_PART_OR_ORGAN_COMPONENT/I_BIO
, O
the O
highest B_TIME[MEASURE]
level I_TIME[MEASURE]
2 I_TIME[MEASURE]
minutes I_TIME[MEASURE]
after O
d B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
tubocurarine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
dosing I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Group B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
1 I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
had O
a O
moderate B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
negative B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
correlation B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O
plasma B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
histamine I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
change I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
and O
systemic B_DISEASE_ADJECTIVE[DISEASE]
vascular I_DISEASE_ADJECTIVE[DISEASE]
resistance I_DISEASE_ADJECTIVE[DISEASE]
( O
r B_OTHER/B_LOCATION
= O
0 B_MEASURE
. O
58 B_MEASURE
; O
P B_MEASURE
less I_MEASURE
than O
0 B_MEASURE
. O
05 B_MEASURE
) O
not O
present B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O
group B_PERSON/B_BIO
4 I_PERSON/I_BIO
. O

Prior B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
dosing I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O
antagonists B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
partially O
prevented O
the O
fall B_DISEASE_ADJECTIVE[DISEASE]
in O
systemic B_DISEASE/B_GENE
vascular B_DISEASE/I_GENE
resistance B_DISEASE/I_GENE
. O

These O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
demonstrate O
that O
the O
hemodynamic B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
changes I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
associated O
with O
d B_PROTEIN[GENE]/B_DISEASE
- O
tubocurarine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
dosing I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
are O
only O
partially O
explained O
by O
histamine B_DISEASE
release I_DISEASE
. O

Thus O
prior B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
dosing O
with O
H1 B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
and O
H2 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O
antagonists B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
provides O
only O
partial B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
protection I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
. O

Cholecystokinin B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- O
octapeptide B_PROTEIN[GENE]/B_DISEASE
restored O
morphine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
induced O
hippocampal B_TIME[MEASURE]/B_LOCATION
long I_TIME[MEASURE]/I_LOCATION
- O
term B_DISEASE_ADJECTIVE[DISEASE]
potentiation I_DISEASE_ADJECTIVE[DISEASE]
impairment I_DISEASE_ADJECTIVE[DISEASE]
in O
rats B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Cholecystokinin B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- O
octapeptide B_NUMBER[MEASURE]
( O
CCK B_LOCATION/B_ORGANIZATION
- O
8 B_NUMBER[MEASURE]
) O
, O
which O
is O
a O
typical B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
brain I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
- O
gut B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
peptide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O
exerts O
a O
wide B_MEASURE/B_LOCATION
range I_MEASURE/I_LOCATION
of O
biological B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activities I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
the O
central B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
nervous I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
system I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O

We O
have O
previously O
reported O
that O
CCK O
- O
8 O
significantly O
alleviated O
morphine O
- O
induced O
amnesia B_DISEASE
and O
reversed O
spine O
density O
decreases O
in O
the O
CA1 O
region O
of O
the O
hippocampus O
in O
morphine O
- O
treated O
animals O
. O

Here O
, O
we O
investigated O
the O
effects B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
CCK B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
8 B_NUMBER[MEASURE]
on O
long B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O
term B_DISEASE_ADJECTIVE[DISEASE]
potentiation I_DISEASE_ADJECTIVE[DISEASE]
( O
LTP B_DISEASE
) O
in O
the O
lateral B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
perforant I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
path I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
( O
LPP B_LOCATION/B_PROTEIN[GENE]
) O
- O
granule B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
cell B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_LOCATION
synapse B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_LOCATION
of O
rat B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
dentate I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
gyrus I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
( O
DG B_PROTEIN[GENE]/B_LOCATION
) O
in O
acute B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
saline B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O
morphine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
treated O
rats B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
. O

Population B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
spikes I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
( O
PS B_LOCATION/B_PROTEIN[GENE]
) O
, O
which O
were O
evoked O
by O
stimulation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O
the O
LPP B_DISEASE/B_PROTEIN[GENE]
, O
were O
recorded O
in O
the O
DG B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
region I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O

Acute B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
morphine B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
30mg B_MEASURE/B_LOCATION
/ O
kg B_MEASURE
, O
s O
. O
c B_DISEASE/B_LOCATION
. O
) O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
significantly O
attenuated O
hippocampal B_LOCATION/B_DISEASE
LTP I_LOCATION/I_DISEASE
and O
CCK B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
8 B_NUMBER[MEASURE]
( O
1ug B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
, O
i O
. O
c O
. O
v O
. O
) O
restored O
the O
amplitude B_MEASURE
of O
PS B_DISEASE
that O
was O
attenuated O
by O
morphine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
injection I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

Furthermore O
, O
microinjection B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
CCK B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
8 B_NUMBER[MEASURE]
( O
0 B_MEASURE/B_LOCATION
. O
1 B_MEASURE
and O
1ug B_MEASURE/B_LOCATION
, O
i O
. O
c O
. O
v O
. O
) O
also O
significantly O
augmented O
hippocampal B_DISEASE/B_GENE
LTP I_DISEASE/I_GENE
in O
saline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
treated O
( O
1ml B_MEASURE
/ O
kg B_MEASURE
, O
s O
. O
c B_DISEASE/B_PROTEIN[GENE]
. O
) O
rats B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Pre B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
the O
CCK2 B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptor I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antagonist I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
L I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
365 B_MEASURE
, O
260 B_MEASURE
( O
10ug B_MEASURE
, O
i O
. O
c O
. O
v O
) O
reversed O
the O
effects B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
CCK B_LOCATION/B_PROTEIN[GENE]
- O
8 B_NUMBER[MEASURE]
, O
but O
the O
CCK1 B_LOCATION
receptor I_LOCATION
antagonist I_LOCATION
L I_LOCATION
- O
364 B_MEASURE
, O
718 B_MEASURE
( O
10ug B_MEASURE
, O
i O
. O
c O
. O
v B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
did O
not O
. O

The O
present O
results O
demonstrate O
that O
CCK O
- O
8 O
attenuates O
the O
effect O
of O
morphine O
on O
hippocampal O
LTP O
through O
CCK2 O
receptors O
and O
suggest O
an O
ameliorative O
function O
of O
CCK O
- O
8 O
on O
morphine O
- O
induced O
memory B_DISEASE
impairment I_DISEASE
. O

Glial O
activation O
and O
post O
- O
synaptic O
neurotoxicity B_DISEASE
: O
the O
key O
events O
in O
Streptozotocin O
( O
ICV O
) O
induced O
memory B_DISEASE
impairment I_DISEASE
in O
rats O
. O

In O
the O
present O
study O
the O
role O
of O
glial O
activation O
and O
post O
synaptic O
toxicity B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
ICV O
Streptozotocin O
( O
STZ O
) O
induced O
memory B_DISEASE
impaired I_DISEASE
rats O
was O
explored O
. O

In O
experiment O
set O
up O
1 O
: O
Memory B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
deficit I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
was O
found O
in O
Morris O
water O
maze O
test O
on O
14 O
- O
16 O
days O
after O
STZ O
( O
ICV O
; O
3mg O
/ O
kg O
) O
administration O
. O

STZ O
causes O
increased O
expression O
of O
GFAP O
, O
CD11b O
and O
TNF O
- O
a O
indicating O
glial O
activation O
and O
neuroinflammation B_DISEASE
. O

STZ O
also O
significantly O
increased O
the O
level O
of O
ROS O
, O
nitrite O
, O
ca O
( O
2 O
+ O
) O
and O
reduced O
the O
mitochondrial O
activity O
in O
synaptosomal O
preparation O
illustrating O
free O
radical O
generation O
and O
excitotoxicity B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

increased O
expression B_GENE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
activity B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
Caspase B_GENE
- O
3 B_NUMBER[MEASURE]
was O
also O
observed O
in O
STZ B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
treated O
rat B_BODY_PART_OR_ORGAN_COMPONENT/B_GENE
which O
specify O
apoptotic B_DISEASE_ADJECTIVE[DISEASE]
cell I_DISEASE_ADJECTIVE[DISEASE]
death I_DISEASE_ADJECTIVE[DISEASE]
in O
hippocampus B_BODY_PART_OR_ORGAN_COMPONENT
and O
cortex B_BODY_PART_OR_ORGAN_COMPONENT
. O

STZ O
treatment O
showed O
decrease O
expression O
of O
post O
synaptic O
markers O
CaMKIIa O
and O
PSD O
- O
95 O
, O
while O
, O
expression O
of O
pre O
synaptic O
markers O
( O
synaptophysin O
and O
snap O
- O
25 O
) O
remains O
unaltered O
indicating O
selective O
post O
synaptic O
neurotoxicity B_DISEASE
. O

Oral O
treatment O
with O
Memantine O
( O
10mg O
/ O
kg O
) O
and O
Ibuprofen O
( O
50 O
mg O
/ O
kg O
) O
daily O
for O
13 O
days O
attenuated O
STZ O
induced O
glial O
activation O
, O
apoptotic O
cell O
death O
and O
post O
synaptic O
neurotoxicity B_DISEASE
in O
rat O
brain O
. O

Further O
, O
in O
experiment B_MEASURE/B_SPORT[ENT]
set O
up O
2 B_MEASURE/B_LOCATION
: O
where O
memory B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
function B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
was O
not O
affected O
i O
. O
e O
. O
7 B_NUMBER[MEASURE]
- O
9 B_TIME[MEASURE]/B_ENT
days I_TIME[MEASURE]/I_ENT
after O
STZ B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
treatment I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
. O

The O
level B_MEASURE
of O
GFAP B_GENE
, O
CD11b B_GENE
, O
TNF B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
a B_PROTEIN[GENE]/B_LOCATION
, O
ROS B_GENE
and O
nitrite B_GENE/B_LOCATION
levels I_GENE/I_LOCATION
were O
increased O
. O

On O
the O
other B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
hand I_PERSON/I_BODY_PART_OR_ORGAN_COMPONENT
, O
apoptotic B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
marker I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
, O
synaptic B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
markers I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
mitochondrial B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
activity B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O
Ca B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O
2 B_PROTEIN[GENE]/B_LOCATION
+ I_PROTEIN[GENE]/I_LOCATION
) O
levels B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
remained O
unaffected B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
. O

Collective O
data O
indicates O
that O
neuroinflammatory B_DISEASE_ADJECTIVE[DISEASE]
process O
and O
oxidative O
stress O
occurs O
earlier O
to O
apoptosis O
and O
does O
not O
affect O
memory O
function O
. O

Present O
study O
clearly O
suggests O
that O
glial O
activation O
and O
post O
synaptic O
neurotoxicity B_DISEASE
are O
the O
key O
factors O
in O
STZ O
induced O
memory B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
impairment B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O
neuronal O
cell O
death O
. O

comparison O
of O
effects O
of O
isotonic O
sodium O
chloride O
with O
diltiazem O
in O
prevention O
of O
contrast O
- O
induced O
nephropathy B_DISEASE
. O

Introduction O
AND O
objective O
: O
contrast O
- O
induced O
nephropathy B_DISEASE
( O
CIN O
) O
significantly O
increases O
the O
morbidity O
and O
mortality O
of O
patients O
. O

The O
aim B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
this O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
to O
investigate O
and O
compare O
the O
protective B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
effects I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
isotonic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
sodium I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
chloride I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
with O
sodium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
bicarbonate I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
infusion I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
isotonic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
sodium I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
chloride I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
infusion I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
with O
diltiazem B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
a O
calcium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
channel I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
blocker I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
in O
preventing O
CIN B_DISEASE
. O

materials B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
AND O
METHODS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O
Our O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
included O
patients B_PERSON
who O
were O
administered O
30 B_MEASURE
- O
60 B_MEASURE
mL I_MEASURE
of O
iodinated B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
contrast I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
agent I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
percutaneous B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
coronary I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
angiography I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
PCAG B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O
, O
all O
with O
creatinine B_MEASURE
values I_MEASURE
between O
1 B_MEASURE
. O
1 B_MEASURE
and O
3 B_MEASURE
. O
1 B_MEASURE
mg I_MEASURE
/ O
DL B_PROTEIN[GENE]/B_TIME[MEASURE]
. O

patients B_PERSON
were O
divided O
into O
three B_ORGANIZATION/B_LOCATION
groups B_ORGANIZATION/I_LOCATION
and O
each O
group B_ORGANIZATION/B_LOCATION
had O
20 B_TIME[MEASURE]/B_PERSON
patients B_TIME[MEASURE]/I_PERSON
. O

The O
first B_SEQUENCE[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
group I_SEQUENCE[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
patients B_PERSON
was O
administered O
isotonic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sodium I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
chloride I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
; O
the O
second B_SEQUENCE[MEASURE]/B_ORGANIZATION
group I_SEQUENCE[MEASURE]/I_ORGANIZATION
was O
administered O
a O
solution B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
that O
of O
5 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
% I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dextrose I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
sodium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
bicarbonate I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
while O
the O
third B_SEQUENCE[MEASURE]/B_ORGANIZATION
group I_SEQUENCE[MEASURE]/I_ORGANIZATION
was O
administered O
isotonic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sodium I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
chloride I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
before O
and O
after O
the O
contrast B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
injection I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

The O
third B_PERSON/B_ORGANIZATION
group I_PERSON/I_ORGANIZATION
received O
an O
additional B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
injection I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
of O
diltiazem B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
the O
day B_TIME[MEASURE]
before O
and O
first B_TIME[MEASURE]/B_ENT
2 I_TIME[MEASURE]/I_ENT
days I_TIME[MEASURE]/I_ENT
after O
the O
contrast B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
injection I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
. O

All O
of O
the O
patients B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
' I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
plasma I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
blood I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
urea I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
nitrogen I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
BUN B_PROTEIN[GENE]/B_BODY_PART_OR_ORGAN_COMPONENT
) O
and O
creatinine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
levels I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
were O
measured O
on O
the O
second B_SEQUENCE[MEASURE]
and O
seventh B_SEQUENCE[MEASURE]/B_LOCATION
day I_SEQUENCE[MEASURE]/I_LOCATION
after O
the O
administration B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O
intravenous B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
contrast I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
material I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

RESULTS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O
The O
basal B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
creatinine B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
levels B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
similar B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
all O
three B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
groups I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O
p B_MEASURE/B_PROTEIN[GENE]
> O
0 B_MEASURE
. O
05 B_MEASURE
) O
. O

Among O
a O
total O
of O
60 O
patients O
included O
in O
the O
study O
, O
16 O
patients O
developed O
acute B_DISEASE
renal I_DISEASE
failure I_DISEASE
( O
ARF B_DISEASE/B_GENE
) O
on O
the O
second O
day O
after O
contrast O
material O
was O
injected O
( O
26 O
. O
6 O
% O
) O
. O

The O
number O
of O
patients O
who O
developed O
ARF B_DISEASE
on O
the O
second O
day O
after O
the O
injection O
in O
the O
first O
group O
was O
five O
( O
25 O
% O
) O
, O
in O
the O
second O
group O
was O
six O
( O
30 O
% O
) O
and O
the O
third O
group O
was O
five O
( O
25 O
% O
) O
( O
p O
> O
0 O
. O
05 O
) O
. O

Conclusion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
There O
was O
no O
significant B_MEASURE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
difference B_MEASURE/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O
isotonic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sodium I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
chloride I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
sodium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
bicarbonate I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
isotonic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
sodium I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
chloride I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
with O
diltiazem B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
application I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
prevention B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
CIN B_DISEASE
. O

Neurocognitive O
and O
neuroradiologic O
central O
nervous O
system O
late O
effects O
in O
children O
treated O
on O
Pediatric O
Oncology O
Group O
( O
POG O
) O
P9605 O
( O
standard O
risk O
) O
and O
P9201 O
( O
lesser O
risk O
) O
acute B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
lymphoblastic I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
leukemia I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
protocols O
( O
ACCL0131 O
) O
: O
a O
methotrexate O
consequence O
. O

A O
report B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
from O
the O
Children B_ORGANIZATION/B_LOCATION
' I_ORGANIZATION/I_LOCATION
s I_ORGANIZATION/I_LOCATION
Oncology I_ORGANIZATION/I_LOCATION
Group I_ORGANIZATION/I_LOCATION
. O

concerns O
about O
long O
- O
term O
methotrexate O
( O
MTX O
) O
neurotoxicity B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
the O
1990s O
led O
to O
modifications O
in O
intrathecal O
( O
IT O
) O
therapy O
, O
leucovorin O
rescue O
, O
and O
frequency O
of O
systemic O
MTX O
administration O
in O
children O
with O
acute B_DISEASE
lymphoblastic I_DISEASE
leukemia I_DISEASE
. O

In O
this O
study O
, O
neurocognitive O
outcomes O
and O
neuroradiologic O
evidence O
of O
leukoencephalopathy B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
were O
compared O
in O
children O
treated O
with O
intense O
central O
nervous O
system O
( O
CNS O
) O
- O
directed O
therapy O
( O
P9605 O
) O
versus O
those O
receiving O
fewer O
CNS O
- O
directed O
treatment O
days O
during O
intensive O
consolidation O
( O
P9201 O
) O
. O

A O
total O
of O
66 O
children O
from O
16 O
Pediatric O
Oncology O
Group O
institutions O
with O
' O
standard O
- O
risk O
' O
acute B_DISEASE
lymphoblastic I_DISEASE
leukemia I_DISEASE
, O
1 O
. O
00 O
to O
9 O
. O
99 O
years O
at O
diagnosis O
, O
without O
evidence O
of O
CNS O
leukemia B_DISEASE
at O
diagnosis O
were O
enrolled O
on O
ACCL0131 O
: O
28 O
from O
P9201 O
and O
38 O
from O
P9605 O
. O

Magnetic B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
resonance I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
imaging I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
scans I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
and O
standard B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
neuropsychological I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tests I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
performed O
> B_MEASURE/B_LOCATION
2 I_MEASURE/I_LOCATION
. O
6 B_TIME[MEASURE]
years I_TIME[MEASURE]
after O
the O
end B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O

significantly O
more O
P9605 O
patients O
developed O
leukoencephalopathy B_DISEASE
compared O
with O
P9201 O
patients O
( O
68 O
% O
, O
95 O
% O
confidence O
interval O
49 O
% O
- O
83 O
% O
vs O
. O
22 O
% O
, O
95 O
% O
confidence O
interval O
5 O
% O
- O
44 O
% O
; O
P O
= O
0 O
. O
001 O
) O
identified O
as O
late O
as O
7 O
. O
7 O
years O
after O
the O
end O
of O
treatment O
. O

Overall O
, O
40 B_NUMBER[MEASURE]/B_PERSON
% I_NUMBER[MEASURE]/I_PERSON
of O
patients B_PERSON
scored O
< O
85 B_MEASURE
on O
either O
verbal B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O
Performance B_MEASURE/B_EDU[ORGANIZATION]
IQ B_MEASURE/I_EDU[ORGANIZATION]
. O

Children O
on O
both O
studies O
had O
significant O
attention B_DISEASE_ADJECTIVE[DISEASE]
problems I_DISEASE_ADJECTIVE[DISEASE]
, O
but O
P9605 O
children O
scored O
below O
average O
on O
more O
neurocognitive O
measures O
than O
those O
treated O
on O
P9201 O
( O
82 O
% O
, O
14 O
/ O
17 O
measures O
vs O
. O
24 O
% O
, O
4 O
/ O
17 O
measures O
) O
. O

This O
supports O
ongoing B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
concerns I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
about O
intensive B_DISEASE
MTX I_DISEASE
exposure I_DISEASE
as O
a O
major B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
contributor I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
to O
CNS B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
late I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Tranexamic O
acid O
overdosage O
- O
induced O
generalized O
seizure B_DISEASE
in O
renal B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
failure I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
. O

We O
report O
a O
45 O
- O
year O
- O
old O
lady O
with O
chronic B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
kidney I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
disease I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
stage O
4 O
due O
to O
chronic O
tubulointerstial B_DISEASE
disease I_DISEASE
. O

She O
was O
admitted O
to O
our O
center O
for O
severe O
anemia B_DISEASE
due O
to O
menorrhagia B_DISEASE
and O
deterioration B_DISEASE
of I_DISEASE
renal I_DISEASE
function I_DISEASE
. O

She O
was O
infused O
three B_MEASURE/B_LOCATION
units B_MEASURE/I_LOCATION
of O
packed O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
during O
a O
session B_TIME[MEASURE]
of O
hemodialysis B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Tranexamic O
acid O
( O
TNA O
) O
1 O
g O
8 O
- O
hourly O
was O
administered O
to O
her O
to O
control O
bleeding B_DISEASE
per O
vaginum O
. O

Two O
hours O
after O
the O
sixth O
dose O
of O
TNA O
, O
she O
had O
an O
episode O
of O
generalized O
tonic B_DISEASE
clonic I_DISEASE
convulsions I_DISEASE
. O

TNA B_ORGANIZATION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O
discontinued O
. O

investigations O
of O
the O
patient O
revealed O
no O
biochemical O
or O
structural O
central O
nervous B_DISEASE_ADJECTIVE[DISEASE]
system I_DISEASE_ADJECTIVE[DISEASE]
abnormalities I_DISEASE_ADJECTIVE[DISEASE]
that O
could O
have O
provoked O
the O
convulsions B_DISEASE
. O

She O
did O
not O
require O
any O
further B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
dialytic I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
support I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
. O

She O
had O
no O
further O
episodes O
of O
convulsion B_DISEASE
till O
dis O
- O
charge O
and O
during O
the O
two O
months O
of O
follow O
- O
up O
. O

Thus O
, O
the O
precipitating O
cause O
of O
convulsions B_DISEASE
was O
believed O
to O
be O
an O
overdose B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
TNA O
. O

Pre O
- O
treatment O
of O
bupivacaine O
- O
induced O
cardiovascular B_DISEASE
depression I_DISEASE
using O
different O
lipid O
formulations O
of O
propofol O
. O

Background O
: O
Pre O
- O
treatment O
with O
lipid O
emulsions O
has O
been O
shown O
to O
increase O
lethal O
doses O
of O
bupivacaine O
, O
and O
the O
lipid O
content O
of O
propofol O
may O
alleviate O
bupivacaine O
- O
induced O
cardiotoxicity B_DISEASE
. O

The O
aim O
of O
this O
study O
is O
to O
investigate O
the O
effects O
of O
propofol O
in O
intralipid O
or O
medialipid O
emulsions O
on O
bupivacaine O
- O
induced O
cardiotoxicity B_DISEASE
. O

METHODS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O
rats B_BIO/B_PERSON
were O
anaesthetised O
with O
ketamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
were O
given O
0 B_MEASURE
. O
5 B_MEASURE
mg I_MEASURE
/ O
kg B_MEASURE
/ O
min B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
propofol I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
in O
intralipid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
( O
Group B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
P I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
, O
propofol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
medialipid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
( O
Group B_LOCATION/B_PROTEIN[GENE]
L I_LOCATION/I_PROTEIN[GENE]
) O
, O
or O
saline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
( O
Group B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
C I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
over O
20 B_TIME[MEASURE]/B_BIO
min I_TIME[MEASURE]/I_BIO
. O

Thereafter O
, O
2 B_MEASURE
mg I_MEASURE
/ O
kg B_MEASURE
/ O
min B_MEASURE
bupivacaine I_MEASURE
0 I_MEASURE
. O
5 B_MEASURE
% I_MEASURE
was O
infused O
. O

We O
recorded O
time O
to O
first O
dysrhythmia B_DISEASE
occurrence O
, O
respective O
times O
to O
25 O
% O
and O
50 O
% O
reduction O
of O
the O
heart O
rate O
( O
HR O
) O
and O
mean O
arterial O
pressure O
, O
and O
time O
to O
asystole B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
total O
amount O
of O
bupivacaine O
consumption O
. O

Blood O
and O
tissue O
samples O
were O
collected O
following O
asystole B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
. O

Results O
: O
The O
time O
to O
first O
dysrhythmia B_DISEASE
occurrence O
, O
time O
to O
25 O
% O
and O
50 O
% O
reductions O
in O
HR O
, O
and O
time O
to O
asystole B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
were O
longer O
in O
Group O
P O
than O
the O
other O
groups O
. O

The O
cumulative B_MEASURE
bupivacaine I_MEASURE
dose I_MEASURE
given O
at O
those O
time B_MEASURE/B_LOCATION
points B_MEASURE/I_LOCATION
was O
higher B_MEASURE
in O
Group B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
P I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O
Plasma B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
bupivacaine I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
levels I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
were O
significantly O
lower B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
in O
Group B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
P I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
than O
in O
Group B_LOCATION
C I_LOCATION
. O
bupivacaine B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
levels I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
in O
the O
brain B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
and O
heart B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
were O
significantly O
lower B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
in O
Group B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
P I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
Group B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
L B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
than O
in O
Group B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
C I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

conclusion O
: O
We O
conclude O
that O
pre O
- O
treatment O
with O
propofol O
in O
intralipid O
, O
compared O
with O
propofol O
in O
medialipid O
or O
saline O
, O
delayed O
the O
onset O
of O
bupivacaine O
- O
induced O
cardiotoxic B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects O
as O
well O
as O
reduced O
plasma O
bupivacaine O
levels O
. O

Further B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
studies I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
are O
needed O
to O
explore O
tissue B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
bupivacaine I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
levels I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
of O
propofol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
in O
medialipid B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
adapt O
these O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O
clinical B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
practice I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_PERSON
. O

Drug B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Induced B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Acute B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Liver B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Injury B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Within O
12 O
Hours O
After O
Fluvastatin O
Therapy O
. O

Although O
statins O
are O
generally O
well O
- O
tolerated O
drugs O
, O
recent O
cases O
of O
drug B_DISEASE
- I_DISEASE
induced I_DISEASE
liver I_DISEASE
injury I_DISEASE
associated O
with O
their O
use O
have O
been O
reported O
. O

A O
52 O
- O
year O
- O
old O
Chinese O
man O
reported O
with O
liver B_DISEASE
damage I_DISEASE
, O
which O
appeared O
12 O
hours O
after O
beginning O
treatment O
with O
fluvastatin O
. O

patient O
presented O
with O
complaints O
of O
increasing O
nausea B_DISEASE/B_MEASURE
, O
anorexia B_DISEASE
, O
and O
upper O
abdominal B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
pain I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
. O

His O
laboratory B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
values I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
showed O
elevated B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
creatine B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
kinase B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
transaminases B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
. O

Testing B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
autoantibodies B_DISEASE
was O
also O
negative B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
liver B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
biochemistries I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
eventually O
normalized O
within O
3 B_TIME[MEASURE]/B_ENT
weeks I_TIME[MEASURE]/I_ENT
of O
stopping O
the O
fluvastatin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Therefore O
, O
when O
prescribing O
statins O
, O
the O
possibility O
of O
hepatic B_DISEASE
damage I_DISEASE
should O
be O
taken O
into O
account O
. O

Fluconazole O
associated O
agranulocytosis B_DISEASE
and O
thrombocytopenia B_DISEASE
. O

Case O
: O
We O
describe O
a O
second O
case O
of O
fluconazole O
associated O
agranulocytosis B_DISEASE/B_GENE
with O
thrombocytopenia B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
recovery O
upon O
discontinuation O
of O
therapy O
. O

The O
patient B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
began O
to O
have O
changes B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
white B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
blood I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
and O
platelets B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
within O
48 B_MEASURE
h O
of O
administration B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O
fluconazole B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
began O
to O
recover O
with O
48 B_TIME[MEASURE]/B_DISEASE
h I_TIME[MEASURE]/I_DISEASE
of O
discontinuation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O

This O
case O
highlights O
that O
drug O
- O
induced O
blood B_DISEASE
dyscrasias I_DISEASE
can O
occur O
unexpectedly O
as O
a O
result O
of O
treatment O
with O
a O
commonly O
used O
drug O
thought O
to O
be O
' O
safe O
' O
. O

conclusion O
: O
According O
to O
Naranjo O
' O
s O
algorithm O
the O
likelihood O
that O
our O
patient O
' O
s O
agranulocytosis B_DISEASE
and O
thrombocytopenia B_DISEASE
occurred O
as O
a O
result O
of O
therapy O
with O
fluconazole O
is O
probable O
, O
with O
a O
total O
of O
six O
points O
. O

We O
feel O
that O
the O
weight B_MEASURE
of O
the O
overall B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
evidence I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
this O
evidence B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
is O
strong B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
. O

In O
particular O
the O
temporal O
relationship O
of O
bone B_DISEASE_ADJECTIVE[DISEASE]
marrow I_DISEASE_ADJECTIVE[DISEASE]
suppression I_DISEASE_ADJECTIVE[DISEASE]
to O
the O
initiation O
of O
fluconazole O
and O
the O
abatement O
of O
symptoms O
that O
rapidly O
reversed O
immediately O
following O
discontinuation O
. O

Two O
- O
dimensional O
speckle O
tracking O
echocardiography O
combined O
with O
high O
- O
sensitive O
cardiac O
troponin O
T O
in O
early O
detection O
and O
prediction O
of O
cardiotoxicity B_DISEASE
during O
epirubicine O
- O
based O
chemotherapy O
. O

aims O
: O
To O
investigate O
whether O
alterations O
of O
myocardial B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
strain B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
and O
high O
- O
sensitive O
cardiac O
troponin O
T O
( O
cTnT O
) O
could O
predict O
future O
cardiac B_DISEASE
dysfunction I_DISEASE
in O
patients O
after O
epirubicin O
exposure O
. O

methods O
: O
seventy O
- O
five O
patients O
with O
non B_DISEASE/B_LOCATION
- I_DISEASE/I_LOCATION
Hodgkin I_DISEASE/I_LOCATION
lymphoma I_DISEASE/I_LOCATION
treated O
with O
epirubicin O
were O
studied O
. O

Blood B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
collection I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O
echocardiography B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
performed O
at O
baseline B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
, O
1 B_TIME[MEASURE]/B_LOCATION
day I_TIME[MEASURE]/I_LOCATION
after O
the O
third B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
cycle I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
and O
1 B_TIME[MEASURE]/B_LOCATION
day I_TIME[MEASURE]/I_LOCATION
after O
completion B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O
chemotherapy B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

patients B_PERSON
were O
studied O
using O
echocardiography B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
during O
follow B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
up B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Global B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
longitudinal I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O
GLS B_LOCATION/B_ORGANIZATION
) O
, O
circumferential B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
( O
GCS B_LOCATION/B_ORGANIZATION
) O
, O
and O
radial B_MEASURE/B_LOCATION
strain B_MEASURE/I_LOCATION
( O
GRS B_LOCATION
) O
were O
calculated O
using O
speckle B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
tracking I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
echocardiography I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

Left O
ventricular B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
ejection B_MEASURE/I_BODY_PART_OR_ORGAN_COMPONENT
fraction B_MEASURE/I_BODY_PART_OR_ORGAN_COMPONENT
was O
analysed O
by O
real B_NUMBER[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
time B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
3D I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
echocardiography I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Cardiotoxicity B_DISEASE/B_LOCATION
was O
defined O
as O
a O
reduction O
of O
the O
LVEF O
of O
> O
5 O
% O
to O
< O
55 O
% O
with O
symptoms O
of O
heart B_DISEASE
failure I_DISEASE
or O
an O
asymptomatic O
reduction O
of O
the O
LVEF O
of O
> O
10 O
% O
to O
< O
55 O
% O
. O

Results O
: O
Fourteen O
patients O
( O
18 O
. O
67 O
% O
) O
developed O
cardiotoxicity B_DISEASE/B_GENE
after O
treatment O
. O

GLS B_LOCATION/B_ORGANIZATION
( O
- O
18 B_MEASURE
. O
48 B_MEASURE
+ O
1 B_MEASURE
. O
72 B_MEASURE
% I_MEASURE
vs I_MEASURE
. O
- O
15 B_MEASURE
. O
96 B_MEASURE
+ O
1 B_MEASURE
. O
6 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
, O
GCS B_LOCATION
( O
- O
20 B_MEASURE
. O
93 B_MEASURE
+ I_MEASURE
2 I_MEASURE
. O
86 B_MEASURE
% I_MEASURE
vs I_MEASURE
. O
- O
19 B_MEASURE
. O
20 B_MEASURE
+ O
3 B_MEASURE
. O
21 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
, O
and O
GRS B_LOCATION/B_DISEASE
( O
39 B_MEASURE
. O
23 B_MEASURE
+ I_MEASURE
6 I_MEASURE
. O
44 B_MEASURE
% I_MEASURE
vs I_MEASURE
. O
34 B_MEASURE
. O
98 B_MEASURE
+ O
6 B_MEASURE
. O
2 B_MEASURE
% I_MEASURE
) O
were O
markedly O
reduced O
and O
cTnT B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
was O
elevated O
from O
0 B_NUMBER[MEASURE]
. O
0010 B_MEASURE
+ I_MEASURE
0 I_MEASURE
. O
0020 B_MEASURE
to O
0 B_NUMBER[MEASURE]
. O
0073 B_MEASURE
+ I_MEASURE
0 I_MEASURE
. O
0038 B_MEASURE/B_PERSON
ng I_MEASURE/I_PERSON
/ O
mL B_MEASURE/B_LOCATION
( O
P B_OTHER/B_MEASURE
all O
< O
0 B_MEASURE
. O
01 B_MEASURE
) O
at O
the O
completion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
chemotherapy B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
compared O
with O
baseline B_TIME[MEASURE]/B_LOCATION
values I_TIME[MEASURE]/I_LOCATION
. O

A O
> O
15 O
. O
9 O
% O
decrease O
in O
GLS O
[ O
sensitivity O
, O
86 O
% O
; O
specificity O
, O
75 O
% O
; O
area O
under O
the O
curve O
( O
AUC O
) O
= O
0 O
. O
815 O
; O
P O
= O
0 O
. O
001 O
] O
and O
a O
> O
0 O
. O
004 O
ng O
/ O
mL O
elevation O
in O
cTnT O
( O
sensitivity O
, O
79 O
% O
; O
specificity O
, O
64 O
% O
; O
AUC O
= O
0 O
. O
757 O
; O
P O
= O
0 O
. O
005 O
) O
from O
baseline O
to O
the O
third O
cycle O
of O
chemotherapy O
predicted O
later O
cardiotoxicity B_DISEASE
. O

The O
decrease O
in O
GLS O
remained O
the O
only O
independent O
predictor O
of O
cardiotoxicity B_DISEASE
( O
P O
= O
0 O
. O
000 O
) O
. O

conclusions O
: O
GLS O
combined O
with O
cTnT O
may O
provide O
a O
reliable O
and O
non O
- O
invasive O
method O
to O
predict O
cardiac B_DISEASE
dysfunction I_DISEASE
in O
patients O
receiving O
anthracycline O
- O
based O
chemotherapy O
. O

Prevention O
of O
etomidate O
- O
induced O
myoclonus B_DISEASE
: O
which O
is O
superior O
: O
Fentanyl O
, O
midazolam O
, O
or O
a O
combination O
. O

A O
Retrospective B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
comparative I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

Background O
: O
In O
this O
retrospective O
comparative O
study O
, O
we O
aimed O
to O
compare O
the O
effectiveness O
of O
fentanyl O
, O
midazolam O
, O
and O
a O
combination O
of O
fentanyl O
and O
midazolam O
to O
prevent O
etomidate O
- O
induced O
myoclonus B_DISEASE
. O

Material B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
AND O
METHODS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O
This O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
performed O
based O
on O
anesthesia B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
records I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O

Depending O
on O
the O
drugs B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
would O
be O
given O
before O
the O
induction B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
anesthesia B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
with O
etomidate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
the O
patients B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
separated O
into O
4 B_MEASURE/B_LOCATION
groups B_MEASURE/I_LOCATION
: O
no O
pretreatment B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
Group B_LOCATION
NP I_LOCATION
) O
, O
fentanyl B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Ug I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O
kg B_MEASURE/B_LOCATION
- O
1 B_NUMBER[MEASURE]
( O
Group B_LOCATION/B_ORGANIZATION
F I_LOCATION/I_ORGANIZATION
) O
, O
midazolam B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
0 I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O
03 B_MEASURE/B_PERSON
mg I_MEASURE/I_PERSON
. O
kg B_MEASURE/B_LOCATION
- O
1 B_NUMBER[MEASURE]
( O
Group B_LOCATION
M I_LOCATION
) O
, O
and O
midazolam B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
0 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O
015 B_MEASURE
mg I_MEASURE
. O
kg B_MEASURE/B_LOCATION
- O
1 B_MEASURE
+ I_MEASURE
fentanyl I_MEASURE
0 I_MEASURE
. O
5 B_MEASURE
ug I_MEASURE
. O
kg B_MEASURE/B_LOCATION
- O
1 B_NUMBER[MEASURE]
( O
Group B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
FM I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
. O

patients B_PERSON
who O
received O
the O
same B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
anesthetic I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
procedure I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
were O
selected O
: O
2 B_TIME[MEASURE]/B_ENT
minutes I_TIME[MEASURE]/I_ENT
after O
intravenous B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
injections I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
of O
the O
pretreatment B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
drugs I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
anesthesia B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
is O
induced O
with O
0 B_MEASURE
. O
3 B_MEASURE
mg I_MEASURE
. O
kg B_MEASURE
- O
1 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
etomidate I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
injected O
intravenously O
over O
a O
period B_MEASURE/B_LOCATION
of O
20 B_MEASURE
- O
30 B_TIME[MEASURE]/B_ENT
seconds I_TIME[MEASURE]/I_ENT
. O

Myoclonic B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
movements I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
are O
evaluated O
, O
which O
were O
observed O
and O
graded O
according O
to O
clinical O
severity O
during O
the O
2 O
minutes O
after O
etomidate O
injection O
. O

The O
severity O
of O
pain B_DISEASE
due O
to O
etomidate O
injection O
, O
mean O
arterial O
pressure O
, O
heart O
rate O
, O
and O
adverse O
effects O
were O
also O
evaluated O
. O

Results O
: O
Study O
results O
showed O
that O
myoclonus B_DISEASE/B_GENE
incidence O
was O
85 O
% O
, O
40 O
% O
, O
70 O
% O
, O
and O
25 O
% O
in O
Group O
NP O
, O
Group O
F O
, O
Group O
M O
, O
and O
Group O
FM O
, O
respectively O
, O
and O
were O
significantly O
lower O
in O
Group O
F O
and O
Group O
FM O
. O

conclusions O
: O
We O
conclude O
that O
pretreatment O
with O
fentanyl O
or O
combination O
of O
fentanyl O
and O
midazolam O
was O
effective O
in O
preventing O
etomidate O
- O
induced O
myoclonus B_DISEASE
. O

Convulsant B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effect B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
lindane B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
and O
regional B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
brain I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
concentration I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
GABA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
dopamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O

Lindane O
( O
gamma O
- O
hexachlorocyclohexane O
) O
is O
an O
organochlorine O
insecticide O
with O
known O
neurotoxic B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects O
. O

Its O
mechanism B_LOCATION
of O
action B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
is O
not O
well O
understood O
although O
it O
has O
been O
proposed O
that O
lindane B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
acts O
as O
a O
non B_DISEASE
- O
competitive B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
antagonist I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
at O
the O
gamma B_PROTEIN[GENE]
- O
aminobutyric B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acid I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
GABA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O
- O
A B_PROTEIN[GENE]/B_LOCATION
receptor I_PROTEIN[GENE]/I_LOCATION
. O

We O
studied O
the O
effect O
of O
lindane O
( O
150 O
mg O
/ O
kg O
) O
on O
the O
GABAergic O
and O
dopaminergic O
systems O
by O
measuring O
the O
concentration O
of O
GABA O
, O
dopamine O
and O
its O
metabolites O
in O
7 O
brain O
areas O
at O
the O
onset O
of O
seizures B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

All O
animals O
suffered O
tonic O
convulsions B_DISEASE
at O
18 O
. O
3 O
+ O
/ O
- O
1 O
. O
4 O
min O
after O
lindane O
administration O
. O

The O
concentration B_MEASURE
of O
GABA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
was O
only O
slightly O
but O
significantly O
decreased O
in O
the O
colliculi B_BIO/B_BODY_PART_OR_ORGAN_COMPONENT
without O
modifications B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
in O
the O
other B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
areas B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
. O

The O
concentration B_MEASURE/B_LOCATION
of O
dopamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
increased O
in O
the O
mesencephalon B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
and O
that O
of O
its O
metabolite B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
DOPAC I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
also O
increased O
in O
the O
mesencephalon B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
and O
the O
striatum B_BODY_PART_OR_ORGAN_COMPONENT
. O

Cholestatic B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
presentation O
of O
yellow O
phosphorus O
poisoning B_DISEASE
. O

Yellow O
phosphorus O
, O
a O
component O
of O
certain O
pesticide O
pastes O
and O
fireworks O
, O
is O
well O
known O
to O
cause O
hepatotoxicity B_DISEASE
. O

Poisoning B_DISEASE/B_PERSON
with O
yellow O
phosphorus O
classically O
manifests O
with O
acute B_DISEASE
hepatitis I_DISEASE
leading O
to O
acute B_DISEASE
liver I_DISEASE
failure I_DISEASE
which O
may O
need O
liver O
transplantation O
. O

We O
present O
a O
case O
of O
yellow O
phosphorus O
poisoning B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
which O
a O
patient O
presented O
with O
florid O
clinical O
features O
of O
cholestasis B_DISEASE
highlighting O
the O
fact O
that O
cholestasis B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
can O
rarely O
be O
a O
presenting O
feature O
of O
yellow O
phosphorus O
hepatotoxicity B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Vasovagal B_DISEASE_ADJECTIVE[DISEASE]
syncope I_DISEASE_ADJECTIVE[DISEASE]
and O
severe O
bradycardia B_DISEASE
following O
intranasal O
dexmedetomidine O
for O
pediatric O
procedural O
sedation O
. O

We O
report O
syncope B_DISEASE
and O
bradycardia B_DISEASE
in O
an O
11 O
- O
year O
- O
old O
girl O
following O
administration O
of O
intranasal O
dexmedetomidine O
for O
sedation O
for O
a O
voiding O
cystourethrogram O
. O

Following O
successful B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
completion I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
of O
VCUG B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
a O
60 B_MEASURE
- O
min B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
recovery B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
period B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
, O
the O
patient B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
' O
s B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
level I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
consciousness B_DISEASE
and O
vital B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
signs B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
returned O
to O
presedation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
levels I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Upon O
leaving O
the O
sedation B_LOCATION
area I_LOCATION
, O
the O
patient B_PERSON/B_LOCATION
collapsed O
, O
with O
no O
apparent B_DISEASE
inciting I_DISEASE
event I_DISEASE
. O

The O
patient B_PERSON
quickly O
regained O
consciousness B_DISEASE/B_MEASURE
and O
no O
injury B_DISEASE
occurred O
. O

The O
primary O
abnormality O
found O
was O
persistent O
bradycardia B_DISEASE
, O
and O
she O
was O
admitted O
to O
the O
hospital O
for O
telemetric O
observation O
. O

The O
bradycardia B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
lasted O
~ O
2 O
h O
, O
and O
further O
cardiac O
workup O
revealed O
no O
underlying O
abnormality O
. O

Unanticipated B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
and O
previously O
unreported B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
outcomes I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
may O
be O
witnessed O
as O
we O
expand O
the O
use B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
of O
certain B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sedatives I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
alternative B_NUMBER[MEASURE]/B_LOCATION
routes B_NUMBER[MEASURE]/I_LOCATION
of O
administration B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Paradoxical O
severe O
agitation B_DISEASE
induced O
by O
add O
- O
on O
high O
- O
doses O
quetiapine O
in O
schizo B_DISEASE/B_PERSON
- I_DISEASE/I_PERSON
affective I_DISEASE/I_PERSON
disorder I_DISEASE/I_PERSON
. O

We O
report O
the O
case O
of O
a O
35 O
- O
year O
- O
old O
patient O
suffering O
from O
schizo B_DISEASE/B_LOCATION
- I_DISEASE/I_LOCATION
affective I_DISEASE/I_LOCATION
disorder I_DISEASE/I_LOCATION
since O
the O
age O
of O
19 O
years O
, O
treated O
by O
a O
combination O
of O
first O
- O
generation O
antipsychotics O
, O
zuclopenthixol O
( O
100 O
mg O
/ O
day O
) O
and O
lithium O
( O
1200 O
mg O
/ O
day O
) O
( O
serum O
lithium O
= O
0 O
. O
85 O
mEq O
/ O
l O
) O
. O

This O
patient O
had O
no O
associated O
personality B_DISEASE_ADJECTIVE[DISEASE]
disorder I_DISEASE_ADJECTIVE[DISEASE]
( O
particularly O
no O
antisocial B_DISEASE
disorder I_DISEASE
) O
and O
no O
substance B_DISEASE
abuse I_DISEASE
disorder I_DISEASE
. O

Within O
the O
48 O
h O
following O
the O
gradual O
introduction O
of O
quetiapine O
( O
up O
to O
600 O
mg O
/ O
day O
) O
, O
the O
patient O
presented O
severe O
agitation B_DISEASE
without O
an O
environmental O
explanation O
, O
contrasting O
with O
the O
absence O
of O
a O
history O
of O
aggressiveness B_DISEASE
or O
personality B_DISEASE
disorder I_DISEASE
. O

The O
diagnoses O
of O
manic B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
shift O
and O
akathisia B_DISEASE
were O
dismissed O
. O

The O
withdrawal O
and O
the O
gradual O
reintroduction O
of O
quetiapine O
2 O
weeks O
later O
, O
which O
led O
to O
another O
severe O
agitation B_DISEASE/B_TIME[MEASURE]
, O
enabled O
us O
to O
attribute O
the O
agitation B_DISEASE/B_TIME[MEASURE]
specifically O
to O
quetiapine O
. O

Antioxidant O
effects O
of O
bovine O
lactoferrin O
on O
dexamethasone O
- O
induced O
hypertension B_DISEASE
in O
rat O
. O

Dexamethasone O
- O
( O
Dex O
- O
) O
induced O
hypertension B_DISEASE
is O
associated O
with O
enhanced O
oxidative O
stress O
. O

Lactoferrin B_DISEASE_ADJECTIVE[DISEASE]/B_PROTEIN[GENE]
( O
LF B_PROTEIN[GENE]/B_DISEASE
) O
is O
an O
iron B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O
binding O
glycoprotein B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
antihypertensive B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
properties I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O

In O
this O
study O
, O
we O
investigated O
the O
effect O
of O
chronic O
administration O
of O
LF O
on O
oxidative O
stress O
and O
hypertension B_DISEASE/B_GENE
upon O
Dex O
administration O
. O

Male B_PERSON
Wistar I_PERSON
rats I_PERSON
were O
treated O
by O
Dex B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O
30 B_MEASURE
u I_MEASURE
g I_MEASURE
/ O
kg B_MEASURE
/ O
day B_MEASURE
subcutaneously O
) O
or O
saline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
for O
14 B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
days B_TIME[MEASURE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Oral B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
bovine I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
LF I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
30 B_MEASURE
, O
100 B_MEASURE
, O
300 B_MEASURE
mg I_MEASURE
/ O
kg B_TIME[MEASURE]
) O
was O
given O
from O
day B_TIME[MEASURE]
8 I_TIME[MEASURE]
to O
14 B_MEASURE
in O
a O
reversal B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
. O

In O
a O
prevention B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
rats B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
received O
4 B_TIME[MEASURE]/B_ENT
days I_TIME[MEASURE]/I_ENT
of O
LF B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treatment I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
followed O
by O
Dex B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
and O
continued O
during O
the O
test B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
period I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Systolic B_MEASURE/B_DISEASE
blood I_MEASURE/I_DISEASE
pressure I_MEASURE/I_DISEASE
( O
SBP B_DISEASE/B_PROTEIN[GENE]
) O
was O
measured O
using O
tail B_BODY_PART_OR_ORGAN_COMPONENT/B_MEASURE
- O
cuff B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
method I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

thymus B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
weight I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
was O
used O
as O
a O
marker B_MEASURE/B_DISEASE
of O
glucocorticoid B_MEASURE/B_ORGANISM_FUNCTION
activity B_MEASURE/I_ORGANISM_FUNCTION
. O

Plasma B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
hydrogen I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
peroxide I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
H2O2 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O
concentration B_MEASURE
and O
ferric B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
reducing O
antioxidant B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
power I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O
FRAP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O
value B_MEASURE/B_LOCATION
were O
determined O
. O

dexamethasone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
significantly O
increased O
SBP B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
plasma B_DISEASE/B_PROTEIN[GENE]
H2O2 B_DISEASE/I_PROTEIN[GENE]
level B_DISEASE/I_PROTEIN[GENE]
and O
decreased O
thymus B_BODY_PART_OR_ORGAN_COMPONENT
and O
body B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
weights B_MEASURE/I_BODY_PART_OR_ORGAN_COMPONENT
. O

LF O
lowered O
( O
P O
< O
0 O
. O
01 O
) O
and O
dose O
dependently O
prevented O
( O
P O
< O
0 O
. O
001 O
) O
Dex O
- O
induced O
hypertension B_DISEASE
. O

LF O
prevented O
body O
weight B_DISEASE/B_MEASURE
loss I_DISEASE/I_MEASURE
and O
significantly O
reduced O
the O
elevated O
plasma O
H2O2 O
and O
increased O
FRAP O
values O
. O

chronic O
administration O
of O
LF O
strongly O
reduced O
the O
blood O
pressure O
and O
production O
of O
ROS O
and O
improved O
antioxidant O
capacity O
in O
Dex O
- O
induced O
hypertension B_DISEASE
, O
suggesting O
the O
role O
of O
inhibition O
of O
oxidative O
stress O
as O
another O
mechanism O
of O
antihypertensive O
action O
of O
LF O
. O

The O
association O
between O
tranexamic O
acid O
and O
convulsive B_DISEASE_ADJECTIVE[DISEASE]
seizures I_DISEASE_ADJECTIVE[DISEASE]
after O
cardiac O
surgery O
: O
a O
multivariate O
analysis O
in O
11 O
529 O
patients O
. O

Because O
of O
a O
lack O
of O
contemporary O
data O
regarding O
seizures B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
after O
cardiac O
surgery O
, O
we O
undertook O
a O
retrospective O
analysis O
of O
prospectively O
collected O
data O
from O
11 O
529 O
patients O
in O
whom O
cardiopulmonary O
bypass O
was O
used O
from O
January O
2004 O
to O
December O
2010 O
. O

A O
convulsive B_DISEASE
seizure I_DISEASE
was O
defined O
as O
a O
transient O
episode O
of O
disturbed O
brain O
function O
characterised O
by O
abnormal B_DISEASE
involuntary I_DISEASE
motor I_DISEASE
movements I_DISEASE
. O

Multivariate O
regression O
analysis O
was O
performed O
to O
identify O
independent O
predictors O
of O
postoperative O
seizures B_DISEASE
. O

A O
total O
of O
100 O
( O
0 O
. O
9 O
% O
) O
patients O
developed O
postoperative O
convulsive B_DISEASE
seizures I_DISEASE
. O

Generalised B_DISEASE/B_PERSON
and I_DISEASE/I_PERSON
focal I_DISEASE/I_PERSON
seizures I_DISEASE/I_PERSON
were O
identified O
in O
68 O
and O
32 O
patients O
, O
respectively O
. O

The O
median O
( O
IQR O
[ O
range O
] O
) O
time O
after O
surgery O
when O
the O
seizure B_DISEASE
occurred O
was O
7 O
( O
6 O
- O
12 O
[ O
1 O
- O
216 O
] O
) O
h O
and O
8 O
( O
6 O
- O
11 O
[ O
4 O
- O
18 O
] O
) O
h O
, O
respectively O
. O

Epileptiform B_DISEASE_ADJECTIVE[DISEASE]
findings I_DISEASE_ADJECTIVE[DISEASE]
on O
electroencephalography B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
were O
seen O
in O
19 B_TIME[MEASURE]/B_LOCATION
patients B_TIME[MEASURE]/I_LOCATION
. O

Independent O
predictors O
of O
postoperative O
seizures B_DISEASE
included O
age O
, O
female O
sex O
, O
redo O
cardiac O
surgery O
, O
calcification O
of O
ascending O
aorta O
, O
congestive B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
heart I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
failure I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
deep O
hypothermic B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
circulatory O
arrest O
, O
duration O
of O
aortic O
cross O
- O
clamp O
and O
tranexamic O
acid O
. O

When O
tested O
in O
a O
multivariate O
regression O
analysis O
, O
tranexamic O
acid O
was O
a O
strong O
independent O
predictor O
of O
seizures B_DISEASE
( O
OR O
14 O
. O
3 O
, O
95 O
% O
CI O
5 O
. O
5 O
- O
36 O
. O
7 O
; O
p O
< O
0 O
. O
001 O
) O
. O

patients O
with O
convulsive B_DISEASE
seizures I_DISEASE
had O
2 O
. O
5 O
times O
higher O
in O
- O
hospital O
mortality O
rates O
and O
twice O
the O
length O
of O
hospital O
stay O
compared O
with O
patients O
without O
convulsive B_DISEASE/B_PERSON
seizures I_DISEASE/I_PERSON
. O

Mean O
( O
IQR O
[ O
range O
] O
) O
length O
of O
stay O
in O
the O
intensive O
care O
unit O
was O
115 O
( O
49 O
- O
228 O
[ O
32 O
- O
481 O
] O
) O
h O
in O
patients O
with O
convulsive B_DISEASE
seizures I_DISEASE
compared O
with O
26 O
( O
22 O
- O
69 O
[ O
14 O
- O
1080 O
] O
) O
h O
in O
patients O
without O
seizures B_DISEASE/B_PERSON
( O
p O
< O
0 O
. O
001 O
) O
. O

Convulsive B_DISEASE_ADJECTIVE[DISEASE]
seizures I_DISEASE_ADJECTIVE[DISEASE]
are O
a O
serious O
postoperative B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
complication B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
after O
cardiac O
surgery O
. O

As O
tranexamic O
acid O
is O
the O
only O
modifiable O
factor O
, O
its O
administration O
, O
particularly O
in O
doses O
exceeding O
80 O
mg O
. O
kg O
( O
- O
1 O
) O
, O
should O
be O
weighed O
against O
the O
risk O
of O
postoperative O
seizures B_DISEASE
. O

Dysfunctional B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
overnight B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
memory B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
consolidation O
in O
ecstasy O
users O
. O

Sleep B_DISEASE
plays O
an O
important B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
role B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
the O
consolidation B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
integration B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
memory B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O
a O
process B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
called O
overnight B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
memory I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
consolidation I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
. O

Previous O
studies O
indicate O
that O
ecstasy O
users O
have O
marked O
and O
persistent O
neurocognitive O
and O
sleep B_DISEASE_ADJECTIVE[DISEASE]
- I_DISEASE_ADJECTIVE[DISEASE]
related I_DISEASE_ADJECTIVE[DISEASE]
impairments I_DISEASE_ADJECTIVE[DISEASE]
. O

We O
extend O
past B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
research I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
by O
examining O
overnight B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
memory I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
consolidation I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
among O
regular B_DISEASE/B_PERSON
ecstasy I_DISEASE/I_PERSON
users I_DISEASE/I_PERSON
( O
n B_MEASURE/B_LOCATION
= O
12 B_MEASURE
) O
and O
drug B_PERSON
naive I_PERSON
healthy I_PERSON
controls I_PERSON
( O
n B_OTHER/B_MEASURE
= O
26 B_MEASURE
) O
. O

Memory B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
recall I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
word B_PERSON/B_BIO
pairs I_PERSON/I_BIO
was O
evaluated O
before O
and O
after O
a O
period B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
sleep B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
, O
with O
and O
without O
interference B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
prior I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
to O
testing B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O

In O
addition B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
we O
assessed O
neurocognitive B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
performances I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
across O
tasks B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
learning B_PERSON/B_DISEASE
, O
memory B_PERSON/B_DISEASE
and O
executive B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
functioning I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

ecstasy O
users O
demonstrated O
impaired B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
overnight I_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
memory I_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
consolidation O
, O
a O
finding O
that O
was O
more O
pronounced O
following O
associative O
interference O
. O

Additionally O
, O
ecstasy B_PERSON/B_ORGANIZATION
users I_PERSON/I_ORGANIZATION
demonstrated O
impairments B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
tasks B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
recruiting O
frontostriatal B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
and O
hippocampal B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
neural I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
circuitry I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
, O
in O
the O
domains B_LOCATION
of O
proactive B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
interference I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
memory I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
, O
long B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O
term B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
memory B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
, O
encoding B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
, O
working B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
memory I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
and O
complex B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
planning I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

We O
suggest O
that O
ecstasy O
- O
associated O
dysfunction O
in O
fronto O
- O
temporal O
circuitry O
may O
underlie O
overnight O
consolidation O
memory B_DISEASE_ADJECTIVE[DISEASE]
impairments I_DISEASE_ADJECTIVE[DISEASE]
in O
regular O
ecstasy O
users O
. O

Normoammonemic O
encephalopathy B_DISEASE
: O
solely O
valproate O
induced O
or O
multiple O
mechanisms O
. O

A O
77 O
- O
year O
- O
old O
woman O
presented O
with O
subacute O
onset O
progressive O
confusion B_DISEASE
, O
aggression B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
auditory B_DISEASE
hallucinations I_DISEASE
and O
delusions B_DISEASE
. O

In O
the O
preceding O
months O
, O
the O
patient O
had O
a O
number O
of O
admissions O
with O
transient O
unilateral O
hemiparesis B_DISEASE
with O
facial O
droop O
, O
and O
had O
been O
started O
on O
valproate O
for O
presumed O
hemiplegic B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
migraine I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

valproate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
was O
withdrawn O
soon O
after O
admission B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
and O
her O
cognitive B_DISEASE_ADJECTIVE[DISEASE]
abilities I_DISEASE_ADJECTIVE[DISEASE]
have O
gradually O
improved O
over O
3 B_TIME[MEASURE]/B_LOCATION
months I_TIME[MEASURE]/I_LOCATION
of O
follow B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
- O
up B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

valproate B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
levels I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
taken O
prior B_PERSON/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O
withdrawal B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
were O
subtherapeutic B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
and O
the O
patient B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
normoammonaemic B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

EEG O
undertaken O
during O
inpatient O
stay O
showed O
changes O
consistent O
with O
encephalopathy B_DISEASE
, O
and O
low O
titre O
N O
- O
methyl O
- O
D O
- O
aspartate O
( O
NMDA O
) O
receptor O
antibodies O
were O
present O
in O
this O
patient O
. O

The O
possible O
aetiologies O
of O
valproate O
- O
induced O
encephalopathy B_DISEASE
and O
NMDA O
receptor O
- O
associated O
encephalitis B_DISEASE
present O
a O
diagnostic O
dilemma O
. O

We O
present O
a O
putative B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
combinatorial I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
hypothesis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
to O
explain O
this O
patient B_PERSON/B_BIO
' O
s B_DISEASE_ADJECTIVE[DISEASE]
symptoms I_DISEASE_ADJECTIVE[DISEASE]
. O

Cerebellar B_DISEASE
and I_DISEASE
oculomotor I_DISEASE
dysfunction I_DISEASE
induced O
by O
rapid O
infusion O
of O
pethidine O
. O

Pethidine O
is O
an O
opioid O
that O
gains O
its O
popularity O
for O
the O
effective O
pain B_DISEASE
control O
through O
acting O
on O
the O
opioid O
- O
receptors O
. O

However O
, O
rapid O
pain B_DISEASE
relief O
sometimes O
brings O
about O
unfavourable O
side O
effects O
that O
largely O
limit O
its O
clinical O
utility O
. O

Common O
side O
effects O
include O
nausea B_DISEASE
, O
vomiting B_DISEASE
and O
hypotension B_DISEASE
. O

In O
patients O
with O
impaired B_DISEASE
renal I_DISEASE
and I_DISEASE
liver I_DISEASE
function I_DISEASE
, O
and O
those O
who O
need O
long O
- O
term O
pain B_DISEASE
control O
, O
pethidine O
may O
cause O
excitatory O
central O
nervous O
system O
( O
CNS O
) O
effects O
through O
its O
neurotoxic B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
metabolite O
, O
norpethidine O
, O
resulting O
in O
irritability B_DISEASE
and O
seizure B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
attack O
. O

On O
the O
contrary B_MEASURE/B_BIO
, O
though O
not O
clinically O
apparent B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
pethidine B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
potentially O
causes O
inhibitory B_DISEASE_ADJECTIVE[DISEASE]
impacts I_DISEASE_ADJECTIVE[DISEASE]
on O
the O
CNS B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
and O
impairs O
normal B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
cerebellar B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
and O
oculomotor B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
function I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
in O
the O
short B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
term I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
. O

In O
this O
case O
report O
, O
we O
highlight O
opioid O
' O
s O
inhibitory O
side O
effects O
on O
the O
cerebellar O
structure O
that O
causes O
dysmetria B_DISEASE
, O
dysarthria B_DISEASE/B_LOCATION
, O
reduced O
smooth O
pursuit O
gain O
and O
decreased O
saccadic O
velocity O
. O

Baboon B_DISEASE
syndrome I_DISEASE
induced O
by O
ketoconazole O
. O

A O
27 O
- O
year O
- O
old O
male O
patient O
presented O
with O
a O
maculopapular B_DISEASE/B_LOCATION
eruption I_DISEASE/I_LOCATION
on O
the O
flexural O
areas O
and O
buttocks O
after O
using O
oral O
ketoconazole O
. O

The O
patient O
was O
diagnosed O
with O
drug O
- O
induced O
baboon B_DISEASE
syndrome I_DISEASE
based O
on O
his O
history O
, O
which O
included O
prior O
sensitivity O
to O
topical O
ketoconazole O
, O
a O
physical O
examination O
, O
and O
histopathological O
findings O
. O

Baboon B_DISEASE/B_PROTEIN[GENE]
syndrome B_DISEASE/I_PROTEIN[GENE]
is O
a O
drug O
- O
or O
contact O
allergen O
- O
related O
maculopapular B_DISEASE
eruption I_DISEASE
that O
typically O
involves O
the O
flexural O
and O
gluteal O
areas O
. O

To O
the O
best O
of O
our O
knowledge O
, O
this O
is O
the O
first O
reported O
case O
of O
ketoconazole O
- O
induced O
baboon B_DISEASE
syndrome I_DISEASE
in O
the O
English O
literature O
. O

A O
Case O
of O
Sudden B_DISEASE
Cardiac I_DISEASE
Death I_DISEASE
due O
to O
Pilsicainide O
- O
induced O
Torsades B_DISEASE
de I_DISEASE
Pointes I_DISEASE
. O

An O
84 O
- O
year O
- O
old O
male O
received O
oral O
pilsicainide O
, O
a O
pure O
sodium O
channel O
blocker O
with O
slow O
recovery O
kinetics O
, O
to O
convert O
his O
paroxysmal O
atrial B_DISEASE
fibrillation I_DISEASE
to O
a O
sinus O
rhythm O
; O
the O
patient O
developed O
sudden B_DISEASE
cardiac I_DISEASE
death I_DISEASE
two O
days O
later O
. O

The O
Holter O
electrocardiogram O
, O
which O
was O
worn O
by O
chance O
, O
revealed O
torsade B_DISEASE/B_LOCATION
de I_DISEASE/I_LOCATION
pointes I_DISEASE/I_LOCATION
with O
gradually O
prolonged O
QT O
intervals O
. O

This O
drug B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
rapidly O
absorbed O
from O
the O
gastrointestinal B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
tract I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
, O
and O
most B_DISEASE/B_MEASURE
of O
it O
is O
excreted O
from O
the O
kidney B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
. O

Although O
the O
patient O
' O
s O
renal O
function O
was O
not O
highly O
impaired O
and O
the O
dose O
of O
pilsicainide O
was O
low O
, O
the O
plasma O
concentration O
of O
pilsicainide O
may O
have O
been O
high O
, O
which O
can O
produce O
torsades B_DISEASE
de I_DISEASE
pointes I_DISEASE
in O
the O
octogenarian O
. O

Although O
the O
oral O
administration O
of O
class O
IC O
drugs O
, O
including O
pilsicainide O
, O
is O
effective O
to O
terminate O
atrial B_DISEASE
fibrillation I_DISEASE
, O
careful O
consideration O
must O
be O
taken O
before O
giving O
these O
drugs O
to O
octogenarians O
. O

All O
- O
trans O
retinoic O
acid O
- O
induced O
inflammatory O
myositis B_DISEASE
in O
a O
patient O
with O
acute B_DISEASE/B_LOCATION
promyelocytic I_DISEASE/I_LOCATION
leukemia I_DISEASE/I_LOCATION
. O

All O
- O
trans O
retinoic O
acid O
( O
ATRA O
) O
, O
a O
component O
of O
standard O
therapy O
for O
acute B_DISEASE
promyelocytic I_DISEASE
leukemia I_DISEASE
( O
APL B_LOCATION/B_ORGANIZATION
) O
, O
is O
associated O
with O
potentially O
serious O
but O
treatable O
adverse O
effects O
involving O
numerous O
organ O
systems O
, O
including O
rare O
skeletal O
muscle O
involvement O
. O

Only O
a O
handful O
of O
cases O
of O
ATRA O
- O
induced O
myositis B_DISEASE
in O
children O
have O
been O
reported O
, O
and O
none O
in O
the O
radiology O
literature O
. O

We O
present O
such O
a O
case O
in O
a O
15 O
- O
year O
- O
old O
boy O
with O
APL B_DISEASE/B_GENE
, O
where O
recognition O
of O
imaging O
findings O
played O
a O
crucial O
role O
in O
making O
the O
diagnosis O
and O
facilitated O
prompt O
, O
effective O
treatment O
. O

Tolerability O
of O
lomustine O
in O
combination O
with O
cyclophosphamide O
in O
dogs O
with O
lymphoma B_DISEASE
. O

This O
retrospective O
study O
describes O
toxicity B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
associated O
with O
a O
protocol O
of O
lomustine O
( O
CCNU O
) O
and O
cyclophosphamide O
( O
CTX O
) O
in O
dogs O
with O
lymphoma B_DISEASE
. O

CCNU B_LOCATION
was O
administered O
per O
os B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
( O
PO B_PROTEIN[GENE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
) O
at O
a O
targeted O
dosage B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
60 B_MEASURE
mg I_MEASURE
/ O
m B_OTHER/B_MEASURE
( O
2 B_SEQUENCE[MEASURE]
) O
body B_TIME[MEASURE]/B_ORGANIZATION
surface I_TIME[MEASURE]/I_ORGANIZATION
area I_TIME[MEASURE]/I_ORGANIZATION
on O
day B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
0 I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
CTX B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
administered O
Po B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O
a O
targeted O
dosage B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
250 B_MEASURE
mg I_MEASURE
/ O
m B_OTHER/B_MEASURE
( O
2 B_MEASURE/B_LOCATION
) O
divided O
over O
days B_TIME[MEASURE]
0 I_TIME[MEASURE]
through O
4 B_MEASURE
, O
and O
all O
dogs B_BIO/B_PERSON
received O
prophylactic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antibiotics I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Ninety B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
treatments I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
were O
given O
to O
the O
57 B_PERSON/B_BIO
dogs I_PERSON/I_BIO
included O
in O
the O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Neutropenia B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O
the O
principal O
toxic O
effect O
, O
and O
the O
overall O
frequency O
of O
grade O
4 O
neutropenia B_DISEASE
after O
the O
first O
treatment O
of O
CCNU O
/ O
CTX O
was O
30 O
% O
( O
95 O
% O
confidence O
interval O
, O
19 O
- O
43 O
% O
) O
. O

The O
mean O
body O
weight O
of O
dogs O
with O
grade O
4 O
neutropenia B_DISEASE
( O
19 O
. O
7 O
kg O
+ O
13 O
. O
4 O
kg O
) O
was O
significantly O
less O
than O
the O
mean O
body O
weight O
of O
dogs O
that O
did O
not O
develop O
grade O
4 O
neutropenia B_DISEASE
( O
31 O
. O
7 O
kg O
+ O
12 O
. O
4 O
kg O
; O
P O
= O
. O
005 O
) O
. O

One O
dog O
( O
3 O
% O
) O
developed O
hematologic O
changes O
suggestive O
of O
hepatotoxicity B_DISEASE
. O

No O
dogs O
had O
evidence O
of O
either O
renal B_DISEASE_ADJECTIVE[DISEASE]
toxicity I_DISEASE_ADJECTIVE[DISEASE]
or O
hemorrhagic B_DISEASE
cystitis I_DISEASE
. O

Adverse B_DISEASE_ADJECTIVE[DISEASE]
gastrointestinal I_DISEASE_ADJECTIVE[DISEASE]
effects I_DISEASE_ADJECTIVE[DISEASE]
were O
uncommon B_DISEASE_ADJECTIVE[DISEASE]
. O

On O
the O
basis O
of O
the O
findings O
reported O
herein O
, O
a O
dose O
of O
60 O
mg O
/ O
m O
( O
2 O
) O
of O
CCNU O
combined O
with O
250 O
mg O
/ O
m O
( O
2 O
) O
of O
CTX O
( O
divided O
over O
5 O
days O
) O
q O
4 O
wk O
is O
tolerable O
in O
tumor B_DISEASE/B_LOCATION
- O
bearing O
dogs O
. O

Nelarabine O
neurotoxicity B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O
concurrent O
intrathecal O
chemotherapy O
: O
Case O
report O
and O
review O
of O
literature O
. O

severe O
nelarabine O
neurotoxicity B_DISEASE
in O
a O
patient O
who O
received O
concurrent O
intrathecal O
( O
IT O
) O
chemotherapy O
is O
reported O
. O

A O
37 O
- O
year O
- O
old O
Caucasian O
woman O
with O
a O
history O
of O
T B_DISEASE
- I_DISEASE
cell I_DISEASE
lymphoblastic I_DISEASE
lymphoma I_DISEASE
was O
admitted O
for O
relapsed O
disease O
. O

She O
was O
originally O
treated O
with O
induction B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
chemotherapy I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
followed O
by O
an O
autologous B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
transplant I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

She O
developed O
relapsed O
disease O
10 O
months O
later O
with O
leukemic B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
involvement O
. O

She O
was O
re B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
with O
nelarabine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
1500 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
mg I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
/ O
m B_OTHER/B_MEASURE
( O
2 B_MEASURE/B_LOCATION
) O
on O
days B_TIME[MEASURE]
1 I_TIME[MEASURE]
, O
3 B_NUMBER[MEASURE]
, O
and O
5 B_NUMBER[MEASURE]/B_LOCATION
with O
1 B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
dose I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
of O
IT O
cytarabine O
100 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mg I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
day B_TIME[MEASURE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 B_TIME[MEASURE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O
central B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
nervous B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
system B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
( O
CNS B_LOCATION/B_DISEASE
) O
prophylaxis B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O

At O
the O
time O
of O
treatment O
, O
she O
was O
on O
continuous O
renal O
replacement O
therapy O
due O
to O
sequelae O
of O
tumor B_DISEASE
lysis I_DISEASE
syndrome I_DISEASE
( O
TLS B_DISEASE/B_GENE
) O
. O

She O
tolerated O
therapy B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
well O
, O
entered O
a O
complete B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
remission I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
, O
and O
recovered O
her O
renal B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
function I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

She O
received O
a O
second B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
cycle I_TIME[MEASURE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
nelarabine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
without O
additional B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
IT O
prophylaxis O
one B_TIME[MEASURE]
month I_TIME[MEASURE]
later O
. O

A O
week B_TIME[MEASURE]
after O
this O
second B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
cycle I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
, O
she O
noted O
numbness B_DISEASE
in O
her O
lower B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
extremities I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O

predominantly O
sensory O
, O
though O
also O
motor O
and O
autonomic O
, O
peripheral B_DISEASE_ADJECTIVE[DISEASE]
neuropathy I_DISEASE_ADJECTIVE[DISEASE]
started O
in O
her O
feet O
, O
ascended O
proximally O
to O
the O
mid O
- O
thoracic O
region O
, O
and O
eventually O
included O
her O
distal O
upper O
extremities O
. O

A O
magnetic B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
resonance I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
imaging I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
MRI B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
) O
of O
her O
spine B_BODY_PART_OR_ORGAN_COMPONENT
demonstrated O
changes B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O
C2 B_PROTEIN[GENE]
to O
C6 B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
consistent I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
subacute B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
combined O
degeneration B_DISEASE
. O

Nelarabine B_DISEASE/B_PERSON
was O
felt O
to O
be O
the O
cause B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
her O
symptoms B_DISEASE
. O

Her O
neuropathy B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
stabilized O
and O
showed O
slight O
improvement O
and O
ultimately O
received O
an O
unrelated O
, O
reduced O
- O
intensity O
allogeneic O
transplant O
while O
in O
complete O
remission O
, O
but O
relapsed O
disease O
10 O
weeks O
later O
. O

She O
is O
currently O
being O
treated O
with O
best B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
supportive I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
care I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

To O
our O
knowledge O
, O
this O
is O
the O
first O
published O
case O
report O
of O
severe O
neurotoxicity B_DISEASE
caused O
by O
nelarabine O
in O
a O
patient O
who O
received O
concurrent O
IT O
chemotherapy O
. O

Valproate O
- O
induced O
hyperammonemic B_DISEASE
encephalopathy I_DISEASE
in O
a O
renal O
transplanted O
patient O
. O

Neurological B_DISEASE
complications I_DISEASE
after O
renal O
transplantation O
constitute O
an O
important O
cause O
of O
morbidity O
and O
mortality O
. O

Their O
differential B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
diagnosis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
difficult B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
essential B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
subsequent B_PERSON/B_DISEASE
patient I_PERSON/I_DISEASE
' O
s B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
management I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Valproate O
- O
induced O
hyperammonemic B_DISEASE
encephalopathy I_DISEASE
is O
an O
uncommon O
but O
serious O
effect O
of O
valproate O
treatment O
. O

Here O
, O
we O
describe O
the O
case O
of O
a O
15 O
- O
year O
- O
old O
girl O
who O
was O
on O
a O
long O
- O
term O
therapy O
with O
valproate O
due O
to O
epilepsy B_DISEASE
and O
revealed O
impaired B_DISEASE_ADJECTIVE[DISEASE]
consciousness I_DISEASE_ADJECTIVE[DISEASE]
with O
hyperammonemia B_DISEASE
12 O
days O
after O
renal O
transplantation O
. O

After O
withdraw B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O
valproate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
patients B_DISEASE
' I_DISEASE
symptoms I_DISEASE
resolved O
within O
24 B_MEASURE
h O
. O

Clinicians B_PERSON
should O
increase O
their O
awareness B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
potential B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
complication I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
valproate B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
, O
especially O
in O
transplanted B_PERSON/B_BIO
patients I_PERSON/I_BIO
. O

Necrotising B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fasciitis B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
after O
bortezomib O
and O
dexamethasone O
- O
containing O
regimen O
in O
an O
elderly O
patient O
of O
Waldenstrom B_DISEASE/B_LOCATION
macroglobulinaemia I_DISEASE/I_LOCATION
. O

Bortezomib O
and O
high O
- O
dose O
dexamethasone O
- O
containing O
regimens O
are O
considered O
to O
be O
generally O
tolerable O
with O
few O
severe O
bacterial B_DISEASE
infections I_DISEASE
in O
patients O
with O
B O
- O
cell O
malignancies B_DISEASE
. O

However O
, O
information B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
is O
limited O
concerning O
the O
safety B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O
the O
regimen B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
elderly B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
patients I_PERSON/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

We O
report O
a O
case O
of O
a O
76 O
- O
year O
- O
old O
man O
with O
Waldenstrom B_DISEASE/B_LOCATION
macroglobulinaemia I_DISEASE/I_LOCATION
who O
suffered O
necrotising B_DISEASE
fasciitis I_DISEASE
without O
neutropenia B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
after O
the O
combination O
treatment O
with O
bortezomib O
, O
high O
- O
dose O
dexamethasone O
and O
rituximab O
. O

Despite O
immediate B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
intravenous I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
antimicrobial I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
therapy I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
, O
he O
succumbed O
23 B_MEASURE/B_LOCATION
h O
after O
the O
onset B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Physicians O
should O
recognise O
the O
possibility O
of O
fatal O
bacterial B_DISEASE
infections I_DISEASE
related O
to O
bortezomib O
plus O
high O
- O
dose O
dexamethasone O
in O
elderly O
patients O
, O
and O
we O
believe O
this O
case O
warrants O
further O
investigation O
. O

An O
integrated O
characterization O
of O
serological O
, O
pathological O
, O
and O
functional O
events O
in O
doxorubicin O
- O
induced O
cardiotoxicity B_DISEASE
. O

Many O
efficacious O
cancer B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treatments O
cause O
significant O
cardiac O
morbidity O
, O
yet O
biomarkers O
or O
functional O
indices O
of O
early O
damage O
, O
which O
would O
allow O
monitoring O
and O
intervention O
, O
are O
lacking O
. O

In O
this O
study O
, O
we O
have O
utilized O
a O
rat O
model O
of O
progressive O
doxorubicin O
( O
DOX O
) O
- O
induced O
cardiomyopathy B_DISEASE
, O
applying O
multiple O
approaches O
, O
including O
cardiac O
magnetic O
resonance O
imaging O
( O
MRI O
) O
, O
to O
provide O
the O
most O
comprehensive O
characterization O
to O
date O
of O
the O
timecourse O
of O
serological O
, O
pathological O
, O
and O
functional O
events O
underlying O
this O
toxicity B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Hannover B_PERSON/B_BIO
Wistar I_PERSON/I_BIO
rats I_PERSON/I_BIO
were O
dosed O
with O
1 B_MEASURE
. O
25 B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mg I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
kg B_MEASURE
DOX I_MEASURE
weekly O
for O
8 B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
weeks I_TIME[MEASURE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
followed O
by O
a O
4 B_TIME[MEASURE]
week I_TIME[MEASURE]
off O
- O
dosing B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
' O
recovery B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
' O
period B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

electron O
microscopy O
of O
the O
myocardium O
revealed O
subcellular B_DISEASE_ADJECTIVE[DISEASE]
degeneration I_DISEASE_ADJECTIVE[DISEASE]
and O
marked O
mitochondrial O
changes O
after O
a O
single O
dose O
. O

Histopathological O
analysis O
revealed O
progressive O
cardiomyocyte B_DISEASE
degeneration I_DISEASE
, O
hypertrophy B_DISEASE
/ O
cytomegaly O
, O
and O
extensive O
vacuolation O
after O
two O
doses O
. O

extensive O
replacement O
fibrosis B_DISEASE
( O
quantified O
by O
Sirius O
red O
staining O
) O
developed O
during O
the O
off O
- O
dosing O
period O
. O

functional O
indices O
assessed O
by O
cardiac O
MRI O
( O
including O
left O
ventricular O
ejection O
fraction O
( O
LVEF O
) O
, O
cardiac O
output O
, O
and O
E O
/ O
A O
ratio O
) O
declined O
progressively O
, O
reaching O
statistical O
significance O
after O
two O
doses O
and O
culminating O
in O
' O
clinical O
' O
LV B_DISEASE_ADJECTIVE[DISEASE]
dysfunction I_DISEASE_ADJECTIVE[DISEASE]
by O
12 O
weeks O
. O

Significant B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
increases I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
peak B_BODY_PART_OR_ORGAN_COMPONENT
myocardial I_BODY_PART_OR_ORGAN_COMPONENT
contrast I_BODY_PART_OR_ORGAN_COMPONENT
enhancement I_BODY_PART_OR_ORGAN_COMPONENT
and O
serological B_DISEASE
cardiac I_DISEASE
troponin I_DISEASE
I I_DISEASE
( O
cTnI B_LOCATION/B_PROTEIN[GENE]
) O
emerged O
after O
eight B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
doses I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
importantly O
preceding O
the O
LVEF B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
decline B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
to O
< O
50 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
. O

Troponin O
I O
levels O
positively O
correlated O
with O
delayed O
and O
peak O
gadolinium O
contrast O
enhancement O
, O
histopathological O
grading O
, O
and O
diastolic B_DISEASE/B_MEASURE
dysfunction I_DISEASE/I_MEASURE
. O

In O
summary O
, O
subcellular O
cardiomyocyte B_DISEASE
degeneration I_DISEASE
was O
the O
earliest O
marker O
, O
followed O
by O
progressive O
functional O
decline O
and O
histopathological O
manifestations O
. O

Myocardial B_DISEASE
contrast I_DISEASE
enhancement I_DISEASE
and O
elevations B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
cTnI B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
occurred O
later O
. O

However O
, O
all O
indices O
predated O
' O
clinical O
' O
LV B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dysfunction B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
thus O
warrant O
further O
evaluation O
as O
predictive O
biomarkers O
. O

Intradermal O
glutamate O
and O
capsaicin O
injections O
: O
intra O
- O
and O
interindividual O
variability O
of O
provoked O
hyperalgesia B_DISEASE/B_MEASURE
and O
allodynia B_DISEASE
. O

Intradermal O
injections O
of O
glutamate O
and O
capsaicin O
are O
attractive O
to O
use O
in O
human O
experimental O
pain B_DISEASE
models O
because O
hyperalgesia B_DISEASE
and O
allodynia B_DISEASE
mimic O
isolated O
aspects O
of O
clinical O
pain B_DISEASE
disorders I_DISEASE
. O

The O
aim B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
the O
present B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
was O
to O
investigate O
the O
reproducibility B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
these O
models B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O

Twenty B_PERSON
healthy I_PERSON
male I_PERSON
volunteers I_PERSON
( O
mean B_TIME[MEASURE]/B_PERSON
age B_TIME[MEASURE]/I_PERSON
24 B_TIME[MEASURE]/I_PERSON
years B_TIME[MEASURE]/I_PERSON
; O
range O
18 B_MEASURE
- O
38 B_MEASURE/B_ENT
years I_MEASURE/I_ENT
) O
received O
intradermal B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
injections I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
glutamate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O
capsaicin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
volar B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
forearm I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O

Magnitudes O
of O
secondary O
pinprick O
hyperalgesia B_DISEASE
and O
brush O
- O
evoked O
allodynia B_DISEASE
were O
investigated O
using O
von O
Frey O
filaments O
( O
gauges O
10 O
, O
15 O
, O
60 O
and O
100 O
g O
) O
and O
brush O
strokes O
. O

Areas O
of O
secondary B_DISEASE
hyperalgesia I_DISEASE
and O
allodynia B_DISEASE
were O
quantified O
immediately O
after O
injection O
and O
after O
15 O
, O
30 O
and O
60 O
min O
. O

Two B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
identical I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
experiments I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
separated O
by O
at O
least O
7 B_NUMBER[MEASURE]/B_ENT
days I_NUMBER[MEASURE]/I_ENT
were O
performed O
. O

reproducibility B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
across O
and O
within O
volunteers B_PERSON/B_LOCATION
( O
inter B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
and O
intra B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
individual B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
variation I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O
respectively O
) O
was O
assessed O
using O
intraclass B_MEASURE/B_ORGANIZATION
correlation I_MEASURE/I_ORGANIZATION
coefficient I_MEASURE/I_ORGANIZATION
( O
ICC B_ORGANIZATION/B_DISEASE
) O
and O
coefficient B_MEASURE
of O
variation B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
( O
CV B_LOCATION/B_ORGANIZATION
) O
. O

Secondary O
pinprick O
hyperalgesia B_DISEASE
was O
observed O
as O
a O
marked O
increase O
in O
the O
visual O
analogue O
scale O
( O
VAS O
) O
response O
to O
von O
Frey O
gauges O
60 O
and O
100 O
g O
( O
P O
< O
0 O
. O
001 O
) O
after O
glutamate O
injection O
. O

For O
capsaicin O
, O
secondary O
pinprick O
hyperalgesia B_DISEASE
was O
detected O
with O
all O
von O
Frey O
gauges O
( O
P O
< O
0 O
. O
001 O
) O
. O

Glutamate B_PERSON/B_LOCATION
evoked O
reproducible B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
VAS I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
response I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
all O
von B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
frey I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gauges I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
ICC B_ORGANIZATION/B_LOCATION
> O
0 B_MEASURE
. O
60 B_MEASURE
) O
and O
brush B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
strokes I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O
ICC B_ORGANIZATION/B_LOCATION
> I_MEASURE
0 B_MEASURE
. O
83 B_MEASURE
) O
. O

Capsaicin O
injection O
was O
reproducible O
for O
secondary B_DISEASE
hyperalgesia I_DISEASE
( O
ICC O
> O
0 O
. O
70 O
) O
and O
allodynia B_DISEASE
( O
ICC O
> O
0 O
. O
71 O
) O
. O

Intra O
- O
individual O
variability O
was O
generally O
lower O
for O
the O
VAS O
response O
to O
von O
Frey O
and O
brush O
compared O
with O
areas O
of O
secondary B_DISEASE
hyperalgesia I_DISEASE
and O
allodynia B_DISEASE
. O

In O
conclusion O
, O
glutamate O
and O
capsaicin O
yield O
reproducible O
hyperalgesic B_DISEASE_ADJECTIVE[DISEASE]
and O
allodynic B_DISEASE_ADJECTIVE[DISEASE]
responses O
, O
and O
the O
present O
model O
is O
well O
suited O
for O
basic O
research O
, O
as O
well O
as O
for O
assessing O
the O
modulation O
of O
central O
phenomena O
. O

Ocular O
- O
specific O
ER O
stress O
reduction O
rescues O
glaucoma B_DISEASE
in O
murine O
glucocorticoid O
- O
induced O
glaucoma B_DISEASE
. O

Administration O
of O
glucocorticoids O
induces O
ocular B_DISEASE
hypertension I_DISEASE
in O
some O
patients O
. O

If O
untreated O
, O
these O
patients O
can O
develop O
a O
secondary O
glaucoma B_DISEASE
that O
resembles O
primary B_DISEASE/B_GENE
open I_DISEASE/I_GENE
- I_DISEASE/I_GENE
angle I_DISEASE/I_GENE
glaucoma I_DISEASE/I_GENE
( O
POAG B_LOCATION
) O
. O

The O
underlying O
pathology O
of O
glucocorticoid O
- O
induced O
glaucoma B_DISEASE
is O
not O
fully O
understood O
, O
due O
in O
part O
to O
lack O
of O
an O
appropriate O
animal O
model O
. O

Here O
, O
we O
developed O
a O
murine O
model O
of O
glucocorticoid O
- O
induced O
glaucoma B_DISEASE
that O
exhibits O
glaucoma B_DISEASE
features O
that O
are O
observed O
in O
patients O
. O

Treatment O
of O
WT O
mice O
with O
topical O
ocular O
0 O
. O
1 O
% O
dexamethasone O
led O
to O
elevation O
of O
intraocular O
pressure O
( O
IOP O
) O
, O
functional O
and O
structural O
loss O
of O
retinal B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
ganglion I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
cells O
, O
and O
axonal B_DISEASE
degeneration I_DISEASE
, O
resembling O
glucocorticoid O
- O
induced O
glaucoma B_DISEASE
in O
human O
patients O
. O

Furthermore O
, O
dexamethasone O
- O
induced O
ocular B_DISEASE/B_GENE
hypertension I_DISEASE/I_GENE
was O
associated O
with O
chronic O
ER O
stress O
of O
the O
trabecular O
meshwork O
( O
TM O
) O
. O

Similar B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
patients B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
withdrawal B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O
dexamethasone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treatment I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reduced O
elevated O
IOP B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
ER B_DISEASE
stress I_DISEASE
in O
this O
animal B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
model I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

Dexamethasone O
induced O
the O
transcriptional O
factor O
CHOP O
, O
a O
marker O
for O
chronic O
ER O
stress O
, O
in O
the O
anterior O
segment O
tissues O
, O
and O
Chop O
deletion O
reduced O
ER O
stress O
in O
these O
tissues O
and O
prevented O
dexamethasone O
- O
induced O
ocular B_DISEASE/B_GENE
hypertension I_DISEASE/I_GENE
. O

Furthermore O
, O
reduction O
of O
ER O
stress O
in O
the O
TM O
with O
sodium O
4 O
- O
phenylbutyrate O
prevented O
dexamethasone O
- O
induced O
ocular B_DISEASE/B_GENE
hypertension I_DISEASE/I_GENE
in O
WT O
mice O
. O

Our O
data O
indicate O
that O
ER O
stress O
contributes O
to O
glucocorticoid O
- O
induced O
ocular B_DISEASE/B_GENE
hypertension I_DISEASE/I_GENE
and O
suggest O
that O
reducing O
ER O
stress O
has O
potential O
as O
a O
therapeutic O
strategy O
for O
treating O
glucocorticoid O
- O
induced O
glaucoma B_DISEASE
. O

Effects O
of O
ginsenosides O
on O
opioid O
- O
induced O
hyperalgesia B_DISEASE
in O
mice O
. O

Opioid O
- O
induced O
hyperalgesia B_DISEASE
( O
OIH B_DISEASE/B_LOCATION
) O
is O
characterized O
by O
nociceptive O
sensitization O
caused O
by O
the O
cessation O
of O
chronic O
opioid O
use O
. O

OIH B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
can O
limit O
the O
clinical O
use O
of O
opioid O
analgesics O
and O
complicate O
withdrawal O
from O
opioid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
addiction I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

In O
this O
study O
, O
we O
investigated O
the O
effects O
of O
Re O
, O
Rg1 O
, O
and O
Rb1 O
ginsenosides O
, O
the O
bioactive O
components O
of O
ginseng O
, O
on O
OIH B_DISEASE/B_GENE
. O

OIH B_DISEASE
was O
achieved O
in O
mice O
after O
subcutaneous O
administration O
of O
morphine O
for O
7 O
consecutive O
days O
three O
times O
per O
day O
. O

During O
withdrawal B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
( O
days B_TIME[MEASURE]
8 I_TIME[MEASURE]
and O
9 B_NUMBER[MEASURE]
) O
, O
these O
mice B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
administered O
Re B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
Rg1 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
or O
Rb1 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
intragastrically O
two B_TIME[MEASURE]
times I_TIME[MEASURE]
per O
day B_TIME[MEASURE]/B_ORGANIZATION
. O

On O
the O
test B_SEQUENCE[MEASURE]
day I_SEQUENCE[MEASURE]
( O
day B_TIME[MEASURE]
10 I_TIME[MEASURE]
) O
, O
mice B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
subjected O
to O
the O
thermal B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
sensitivity I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
test I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
and O
the O
acetic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acid I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
induced O
writhing B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
test I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Re O
( O
300 O
mg O
/ O
kg O
) O
inhibited O
OIH B_DISEASE
in O
both O
the O
thermal O
sensitivity O
test O
and O
the O
acetic O
acid O
- O
induced O
writhing O
test O
. O

However O
, O
the O
Rg1 O
and O
Rb1 O
ginsenosides O
failed O
to O
prevent O
OIH B_DISEASE
in O
either O
test O
. O

Furthermore O
, O
Rg1 O
showed O
a O
tendency O
to O
aggravate O
OIH B_DISEASE
in O
the O
acetic O
acid O
- O
induced O
writhing O
test O
. O

Our O
data O
suggested O
that O
the O
ginsenoside O
Re O
, O
but O
not O
Rg1 O
or O
Rb1 O
, O
may O
contribute O
toward O
reversal O
of O
OIH B_DISEASE/B_GENE
. O

A O
comparison B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
severe B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hemodynamic B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
disturbances B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O
dexmedetomidine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
propofol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
sedation B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
in O
neurocritical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
care I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
patients I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
. O

Objective B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O
dexmedetomidine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
and O
propofol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
commonly O
used O
sedatives B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O
neurocritical B_PERSON/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
care I_PERSON/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
as O
they O
allow O
for O
frequent B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
neurologic I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
examinations I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
. O

However O
, O
both O
agents B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
associated O
with O
significant B_DISEASE
hemodynamic I_DISEASE
side I_DISEASE
effects I_DISEASE
. O

The O
primary B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
objective I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O
this O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
to O
compare O
the O
prevalence B_MEASURE
of O
severe B_DISEASE
hemodynamic I_DISEASE
effects I_DISEASE
in O
neurocritical B_PERSON
care I_PERSON
patients I_PERSON
receiving O
dexmedetomidine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
propofol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Design B_PERSON/B_MEASURE
: O
Multicenter B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
retrospective B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
propensity B_MEASURE/B_PERSON
- O
matched O
cohort B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

setting B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
Neurocritical B_PERSON/B_ORGANIZATION
care I_PERSON/I_ORGANIZATION
units I_PERSON/I_ORGANIZATION
at O
two B_LOCATION/B_MEASURE
academic I_LOCATION/I_MEASURE
medical I_LOCATION/I_MEASURE
centers I_LOCATION/I_MEASURE
with O
dedicated O
neurocritical B_PERSON/B_ORGANIZATION
care I_PERSON/I_ORGANIZATION
teams I_PERSON/I_ORGANIZATION
and O
board B_ORGANIZATION/B_LOCATION
- O
certified O
neurointensivists B_PERSON/B_ORGANIZATION
. O

patients B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
Neurocritical B_PERSON/B_LOCATION
care I_PERSON/I_LOCATION
patients I_PERSON/I_LOCATION
admitted O
between O
July B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2009 I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
September B_TIME[MEASURE]
2012 I_TIME[MEASURE]
were O
evaluated O
and O
then O
matched O
1 B_MEASURE
: O
1 B_MEASURE
based O
on O
propensity B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
scoring O
of O
baseline B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
characteristics I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O

Interventions B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
Continuous B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
sedation I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
with O
dexmedetomidine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O
propofol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Measurements B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
AND O
Main B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
RESULTS I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
A O
total B_MEASURE
of O
342 B_MEASURE
patients I_MEASURE
( O
105 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dexmedetomidine I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
237 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
propofol I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
were O
included O
in O
the O
analysis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
with O
190 B_MEASURE/B_PERSON
matched O
( O
95 B_NUMBER[MEASURE]
in O
each O
group B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
by O
propensity B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
score I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
primary O
outcome O
of O
this O
study O
was O
a O
composite O
of O
severe O
hypotension B_DISEASE
( O
mean O
arterial O
pressure O
< O
60 O
mm O
Hg O
) O
and O
bradycardia B_DISEASE
( O
heart O
rate O
< O
50 O
beats O
/ O
min O
) O
during O
sedative O
infusion O
. O

No O
difference B_MEASURE
in O
the O
primary B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
composite I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
outcome I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
both O
the O
unmatched B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
( O
30 B_MEASURE/B_LOCATION
% I_MEASURE/I_LOCATION
vs I_MEASURE/I_LOCATION
30 I_MEASURE/I_LOCATION
% I_MEASURE/I_LOCATION
, O
p O
= O
0 B_MEASURE
. O
94 B_MEASURE
) O
or O
matched O
cohorts B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
( O
28 B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
% I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
vs I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
34 I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
% I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
, O
p O
= O
0 B_MEASURE
. O
35 B_MEASURE
) O
could O
be O
found O
. O

When O
analyzed O
separately O
, O
no O
differences O
could O
be O
found O
in O
the O
prevalence O
of O
severe O
hypotension B_DISEASE
or O
bradycardia B_DISEASE
in O
either O
the O
unmatched O
or O
matched O
cohorts O
. O

conclusions O
: O
severe O
hypotension B_DISEASE
and O
bradycardia B_DISEASE
occur O
at O
similar O
prevalence O
in O
neurocritical O
care O
patients O
who O
receive O
dexmedetomidine O
or O
propofol O
. O

providers O
should O
similarly O
consider O
the O
likelihood O
of O
hypotension B_DISEASE
or O
bradycardia B_DISEASE
before O
starting O
either O
sedative O
. O

Hydroxytyrosol O
ameliorates O
oxidative O
stress O
and O
mitochondrial B_DISEASE_ADJECTIVE[DISEASE]
dysfunction I_DISEASE_ADJECTIVE[DISEASE]
in O
doxorubicin O
- O
induced O
cardiotoxicity B_DISEASE/B_GENE
in O
rats O
with O
breast B_DISEASE
cancer I_DISEASE
. O

Oxidative O
stress O
is O
involved O
in O
several O
processes O
including O
cancer B_DISEASE/B_ORGANISM_FUNCTION
, O
aging O
and O
cardiovascular B_DISEASE
disease I_DISEASE
, O
and O
has O
been O
shown O
to O
potentiate O
the O
therapeutic O
effect O
of O
drugs O
such O
as O
doxorubicin O
. O

Doxorubicin O
causes O
significant O
cardiotoxicity B_DISEASE
characterized O
by O
marked O
increases O
in O
oxidative O
stress O
and O
mitochondrial B_DISEASE/B_GENE
dysfunction I_DISEASE/I_GENE
. O

Herein O
, O
we O
investigate O
whether O
doxorubicin O
- O
associated O
chronic O
cardiac B_DISEASE
toxicity I_DISEASE
can O
be O
ameliorated O
with O
the O
antioxidant O
hydroxytyrosol O
in O
rats O
with O
breast B_DISEASE/B_GENE
cancer I_DISEASE/I_GENE
. O

Thirty O
- O
six O
rats O
bearing O
breast B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tumors B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
induced O
chemically O
were O
divided O
into O
4 O
groups O
: O
control O
, O
hydroxytyrosol O
( O
0 O
. O
5mg O
/ O
kg O
, O
5days O
/ O
week O
) O
, O
doxorubicin O
( O
1mg O
/ O
kg O
/ O
week O
) O
, O
and O
doxorubicin O
plus O
hydroxytyrosol O
. O

Cardiac B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
disturbances B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O
the O
cellular O
and O
mitochondrial O
level O
, O
mitochondrial O
electron O
transport O
chain O
complexes O
I O
- O
IV O
and O
apoptosis O
- O
inducing O
factor O
, O
and O
oxidative O
stress O
markers O
have O
been O
analyzed O
. O

Hydroxytyrosol O
improved O
the O
cardiac B_DISEASE_ADJECTIVE[DISEASE]
disturbances I_DISEASE_ADJECTIVE[DISEASE]
enhanced O
by O
doxorubicin O
by O
significantly O
reducing O
the O
percentage O
of O
altered O
mitochondria O
and O
oxidative O
damage O
. O

These O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggest O
that O
hydroxytyrosol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
improve O
the O
mitochondrial B_DISEASE
electron I_DISEASE
transport I_DISEASE
chain I_DISEASE
. O

This O
study O
demonstrates O
that O
hydroxytyrosol O
protect O
rat O
heart B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
damage I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
provoked O
by O
doxorubicin O
decreasing O
oxidative O
damage O
and O
mitochondrial O
alterations O
. O

Amiodarone O
- O
induced O
myxoedema B_DISEASE
coma I_DISEASE
. O

A O
62 O
- O
year O
- O
old O
man O
was O
found O
to O
have O
bradycardia B_DISEASE
, O
hypothermia B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
respiratory B_DISEASE
failure I_DISEASE
3 O
weeks O
after O
initiation O
of O
amiodarone O
therapy O
for O
atrial B_DISEASE
fibrillation I_DISEASE
. O

Thyroid O
- O
stimulating O
hormone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
was O
found O
to O
be O
168 B_MEASURE
uIU I_MEASURE
/ O
mL B_MEASURE/B_LOCATION
( O
NL B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O
0 B_MEASURE
. O
3 B_MEASURE
- O
5 B_MEASURE
uIU I_MEASURE
/ O
mL B_MEASURE
) O
and O
free B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
thyroxine I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
FT4 B_GENE
) O
was O
< B_MEASURE
0 I_MEASURE
. O
2 B_MEASURE/B_PERSON
ng I_MEASURE/I_PERSON
/ O
dL B_MEASURE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
( O
NL B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O
0 B_MEASURE
. O
8 B_MEASURE
- O
1 B_MEASURE
. O
8 B_MEASURE/B_PERSON
ng I_MEASURE/I_PERSON
/ O
dL B_MEASURE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
) O
. O

He O
received O
intravenous B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
fluids I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
vasopressor B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
stress B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dose I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
steroids I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
; O
he O
was O
intubated O
and O
admitted O
to O
the O
intensive B_LOCATION
care I_LOCATION
unit I_LOCATION
. O

He O
received O
500 B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
Ug I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
intravenous B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
levothyroxine I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
first B_TIME[MEASURE]/B_LOCATION
18 B_TIME[MEASURE]/I_LOCATION
h B_TIME[MEASURE]/I_LOCATION
of O
therapy B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
, O
and O
150 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
Ug B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
intravenous B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
daily O
thereafter O
. O

haemodynamic B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
improvement I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
, O
along O
with O
complete B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
recovery I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
mental B_DISEASE
status I_DISEASE
, O
occurred O
after O
48 B_MEASURE
h O
. O

Twelve B_TIME[MEASURE]/B_LOCATION
hours I_TIME[MEASURE]/I_LOCATION
after O
the O
initiation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
therapy B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
FT4 B_GENE
was O
0 B_MEASURE
. O
96 B_MEASURE/B_PERSON
ng I_MEASURE/I_PERSON
/ O
DL B_PROTEIN[GENE]/B_MEASURE
. O

The O
patient B_PERSON/B_LOCATION
was O
maintained O
on O
levothyroxine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
175 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O
g B_MEASURE
POorally I_MEASURE
daily O
. O

A O
thyroid B_SEQUENCE[MEASURE]/B_PERSON
ultrasound I_SEQUENCE[MEASURE]/I_PERSON
showed O
diffuse B_DISEASE
heterogeneity I_DISEASE
. O

The O
24 B_MEASURE/B_DISEASE
hour I_MEASURE/I_DISEASE
excretion I_MEASURE/I_DISEASE
of O
iodine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
was O
3657 B_MEASURE
( O
mcg B_MEASURE/B_PERSON
( O
25 B_MEASURE/B_LOCATION
- O
756 B_MEASURE
( O
mcg B_MEASURE/B_PERSON
) O
. O

The O
only O
two O
cases O
of O
amiodarone O
- O
induced O
myxoedema B_DISEASE
coma I_DISEASE
in O
the O
literature O
report O
patient O
death O
despite O
supportive O
therapy O
and O
thyroid O
hormone O
replacement O
. O

This O
case O
represents O
the O
most O
thoroughly O
investigated O
case O
of O
amiodarone O
- O
induced O
myxoedema B_DISEASE
coma I_DISEASE
with O
a O
history O
significant O
for O
subclinical O
thyroid B_DISEASE
disease I_DISEASE
. O

Use O
of O
argatroban O
and O
catheter O
- O
directed O
thrombolysis B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
with O
alteplase O
in O
an O
oncology O
patient O
with O
heparin O
- O
induced O
thrombocytopenia B_DISEASE
with O
thrombosis B_DISEASE
. O

purpose O
: O
The O
case O
of O
an O
oncology O
patient O
who O
developed O
heparin O
- O
induced O
thrombocytopenia B_DISEASE
with O
thrombosis B_DISEASE
( O
HITT B_LOCATION/B_ORGANIZATION
) O
and O
was O
treated O
with O
argatroban O
plus O
catheter O
- O
directed O
thrombolysis B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
( O
CDT O
) O
with O
alteplase O
is O
presented O
. O

summary O
: O
A O
63 O
- O
year O
- O
old O
Caucasian O
man O
with O
renal O
amyloidosis B_DISEASE
undergoing O
peripheral O
blood O
stem O
cell O
collection O
for O
an O
autologous O
stem O
cell O
transplant O
developed O
extensive O
bilateral O
upper B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
- I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
extremity I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
deep I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
venous I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
thrombosis I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
( O
DVT B_DISEASE/B_LOCATION
) O
and O
pulmonary B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
embolism I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
secondary O
to O
heparin O
- O
induced O
thrombocytopenia B_DISEASE
. O

A O
continuous B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
i O
. O
v O
. O
infusion B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
of O
argatroban B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
initiated O
, O
and O
the O
patient B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
managed O
on O
the O
general B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
medical I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
floor I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

After O
one O
week O
of O
therapy O
, O
he O
was O
transferred O
to O
the O
intensive O
care O
unit O
with O
cardiopulmonary O
compromise O
related O
to O
superior B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
vena I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
cava I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
SVC I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
) I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
syndrome I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

A O
percutaneous O
mechanical O
thrombectomy O
and O
CDT O
with O
alteplase O
were O
attempted O
, O
but O
the O
procedure O
was O
aborted O
due O
to O
epistaxis B_DISEASE
. O

The O
epistaxis B_DISEASE
resolved O
the O
next O
day O
, O
and O
the O
patient O
was O
restarted O
on O
argatroban O
. O

A O
second B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
percutaneous I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
mechanical I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
thrombectomy I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O
performed O
six B_TIME[MEASURE]/B_ENT
days I_TIME[MEASURE]/I_ENT
later O
and O
resulted O
in O
partial B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
revascularization I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
of O
the O
SVC B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
and O
central B_DISEASE/B_LOCATION
veins I_DISEASE/I_LOCATION
. O

Postthrombectomy B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
continuous I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
CDT I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
with O
alteplase B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
commenced O
while O
argatroban B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
withheld O
, O
and O
complete B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
patency B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
the O
SVC B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
and O
central B_DISEASE/B_LOCATION
veins I_DISEASE/I_LOCATION
was O
achieved O
after O
three B_TIME[MEASURE]/B_ENT
days I_TIME[MEASURE]/I_ENT
of O
therapy B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O

Alteplase B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
was O
discontinued O
, O
and O
the O
patient B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
reinitiated O
on O
argatroban B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
; O
ultimately O
, O
he O
was O
transitioned O
to O
warfarin O
for O
long B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O
term B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
anticoagulation B_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
. O

Although O
the O
patient O
recovered O
, O
he O
experienced O
permanent O
vision B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hearing I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
loss I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
as O
well O
as O
end B_DISEASE
- I_DISEASE
stage I_DISEASE
renal I_DISEASE
disease I_DISEASE
. O

conclusion O
: O
A O
63 O
- O
year O
- O
old O
man O
with O
renal O
amyloidosis B_DISEASE
and O
SVC B_DISEASE
syndrome I_DISEASE
secondary O
to O
HITT B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
successfully O
treated O
with O
argatroban O
and O
CDT O
with O
alteplase O
. O

Effects O
of O
dehydroepiandrosterone O
in O
amphetamine O
- O
induced O
schizophrenia B_DISEASE
models O
in O
mice O
. O

objective O
: O
To O
examine O
the O
effects O
of O
dehydroepiandrosterone O
( O
DHEA O
) O
on O
animal O
models O
of O
schizophrenia B_DISEASE
. O

METHODS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O
Seventy B_SPECIES[BIO]/B_MEASURE
Swiss I_SPECIES[BIO]/I_MEASURE
albino I_SPECIES[BIO]/I_MEASURE
female I_SPECIES[BIO]/I_MEASURE
mice I_SPECIES[BIO]/I_MEASURE
( O
25 B_MEASURE
- O
35 B_MEASURE
g I_MEASURE
) O
were O
divided O
into O
4 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
groups I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
: O
amphetamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
- O
free B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O
control B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O
, O
amphetamine B_MEASURE
, O
50 B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
100 B_MEASURE
mg I_MEASURE
/ O
kg B_MEASURE
DHEA I_MEASURE
. O

The O
DHEA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
administered O
intraperitoneally O
( O
IP B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
for O
5 B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
days B_TIME[MEASURE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Amphetamine O
( O
3 O
mg O
/ O
kg O
IP O
) O
induced O
hyper B_DISEASE_ADJECTIVE[DISEASE]
locomotion O
, O
apomorphine O
( O
1 O
. O
5 O
mg O
/ O
kg O
subcutaneously O
[ O
Sc O
] O
) O
induced O
climbing O
, O
and O
haloperidol O
( O
1 O
. O
5 O
mg O
/ O
kg O
Sc O
) O
induced O
catalepsy B_DISEASE_ADJECTIVE[DISEASE]
tests O
were O
used O
as O
animal O
models O
of O
schizophrenia B_DISEASE
. O

The O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
conducted O
at O
the O
Animal B_LOCATION/B_PERSON
Experiment I_LOCATION/I_PERSON
Laboratories I_LOCATION/I_PERSON
, O
Department B_ORGANIZATION/B_LOCATION
of O
Pharmacology B_EDU[ORGANIZATION]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
Medical B_LOCATION/B_EDU[ORGANIZATION]
School B_LOCATION/I_EDU[ORGANIZATION]
, O
Eskisehir B_LOCATION
Osmangazi I_LOCATION
University I_LOCATION
, O
Eskisehir B_LOCATION/B_PERSON
, O
Turkey B_LOCATION
between O
March B_TIME[MEASURE]/B_LOCATION
and O
May B_TIME[MEASURE]
2012 I_TIME[MEASURE]
. O

Statistical O
analysis O
was O
carried O
out O
using O
Kruskal O
- O
Wallis O
test O
for O
hyper B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
locomotion O
, O
and O
one O
- O
way O
ANOVA O
for O
climbing O
and O
catalepsy B_SPORT[ENT]/B_LOCATION
tests O
. O

RESULTS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
In O
the O
amphetamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
induced O
locomotion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
test I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
, O
there O
were O
significant B_DISEASE_ADJECTIVE[DISEASE]
increases I_DISEASE_ADJECTIVE[DISEASE]
in O
all O
movements B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
compared O
with O
the O
amphetamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
free B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
group I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
. O

Both O
DHEA B_MEASURE/B_PERSON
50 I_MEASURE/I_PERSON
mg I_MEASURE/I_PERSON
/ O
kg B_MEASURE
( O
p B_MEASURE/B_PROTEIN[GENE]
< O
0 B_MEASURE
. O
05 B_MEASURE
) O
, O
and O
100 B_MEASURE
mg I_MEASURE
/ O
kg B_MEASURE
( O
p B_MEASURE/B_PROTEIN[GENE]
< O
0 B_MEASURE
. O
01 B_MEASURE
) O
significantly O
decreased O
all O
movements B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
compared O
with O
the O
amphetamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
locomotion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
group I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

There O
was O
a O
significant O
difference O
between O
groups O
in O
the O
haloperidol O
- O
induced O
catalepsy B_DISEASE_ADJECTIVE[DISEASE]
test O
( O
p O
< O
0 O
. O
05 O
) O
. O

There O
was O
no O
significant B_MEASURE
difference I_MEASURE
between O
groups B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
in O
terms B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O
total B_MEASURE
climbing O
time B_MEASURE
in O
the O
apomorphine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
climbing B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
test I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
p B_PROTEIN[GENE]/B_LOCATION
> O
0 B_MEASURE
. O
05 B_MEASURE
) O
. O

conclusion O
: O
We O
observed O
that O
DHEA O
reduced O
locomotor O
activity O
and O
increased O
catalepsy B_DISEASE/B_ORGANISM_FUNCTION
at O
both O
doses O
, O
while O
it O
had O
no O
effect O
on O
climbing O
behavior O
. O

We O
suggest O
that O
DHEA O
displays O
typical O
neuroleptic O
- O
like O
effects O
, O
and O
may O
be O
used O
in O
the O
treatment O
of O
schizophrenia B_DISEASE
. O

availability O
of O
human O
induced O
pluripotent O
stem O
cell O
- O
derived O
cardiomyocytes O
in O
assessment O
of O
drug O
potential O
for O
QT B_DISEASE
prolongation I_DISEASE
. O

Field B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
potential I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
duration I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
( O
FPD B_DISEASE/B_LOCATION
) O
in O
human B_PERSON/B_SPECIES[BIO]
- O
induced B_BODY_PART_OR_ORGAN_COMPONENT/B_PERSON
pluripotent I_BODY_PART_OR_ORGAN_COMPONENT/I_PERSON
stem O
cell B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
- O
derived O
cardiomyocytes B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
( O
hips B_BIO/B_LOCATION
- O
CMS B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
) O
, O
which O
can O
express O
QT B_DISEASE
interval I_DISEASE
in O
an O
electrocardiogram B_BODY_PART_OR_ORGAN_COMPONENT/B_TIME[MEASURE]
, O
is O
reported O
to O
be O
a O
useful B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
tool B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
to O
predict O
K B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
+ B_PROTEIN[GENE]/B_DISEASE
) O
channel B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O
Ca B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O
2 B_MEASURE/B_PROTEIN[GENE]
+ I_MEASURE/I_PROTEIN[GENE]
) O
channel B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
blocker I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
QT B_DISEASE
interval I_DISEASE
. O

However O
, O
there O
is O
no O
report O
showing O
that O
this O
technique O
can O
be O
used O
to O
predict O
multichannel O
blocker O
potential O
for O
QT B_DISEASE
prolongation I_DISEASE
. O

The O
aim O
of O
this O
study O
is O
to O
show O
that O
FPD O
from O
MEA O
( O
Multielectrode O
array O
) O
of O
hips O
- O
CMs O
can O
detect O
QT B_DISEASE
prolongation I_DISEASE
induced O
by O
multichannel O
blockers O
. O

hips B_LOCATION/B_DISEASE
- O
CMS B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
were O
seeded O
onto O
MEA B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
and O
FPD B_DISEASE_ADJECTIVE[DISEASE]
was O
measured O
for O
2min B_MEASURE/B_LOCATION
every O
10min B_TIME[MEASURE]
for O
30min B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
after O
drug B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
exposure I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
for O
the O
vehicle B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O
each O
drug B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
concentration I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O

IKr B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O
IKs B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
blockers O
concentration B_MEASURE
- O
dependently O
prolonged O
corrected O
FPD B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
( O
FPDc B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
) O
, O
whereas O
Ca B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O
2 B_MEASURE/B_PROTEIN[GENE]
+ I_MEASURE/I_PROTEIN[GENE]
) O
channel B_MEASURE
blockers I_MEASURE
concentration I_MEASURE
- O
dependently O
shortened O
FPDc B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O

Also O
, O
the O
multichannel B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
blockers I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
Amiodarone I_MEASURE
, O
Paroxetine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
Terfenadine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
Citalopram B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
prolonged O
FPDc B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
a O
concentration B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
dependent I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
manner I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

Finally O
, O
the O
IKr O
blockers O
, O
Terfenadine O
and O
Citalopram O
, O
which O
are O
reported O
to O
cause O
Torsade B_DISEASE
de I_DISEASE
Pointes I_DISEASE
( O
TdP B_PROTEIN[GENE]/B_DISEASE
) O
in O
clinical O
practice O
, O
produced O
early O
afterdepolarization O
( O
EAD O
) O
. O

hips B_DISEASE/B_PROTEIN[GENE]
- O
CMS B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
using O
MEA B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
system I_LOCATION/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
FPDc B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
can O
predict O
the O
effects B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
drug B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
candidates I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
on O
QT B_DISEASE/B_GENE
interval I_DISEASE/I_GENE
. O

This O
study O
also O
shows O
that O
this O
assay O
can O
help O
detect O
EAD O
for O
drugs O
with O
TdP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
potential O
. O

Dermal O
developmental O
toxicity B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O
N O
- O
phenylimide O
herbicides O
in O
rats O
. O

Background O
: O
S O
- O
53482 O
and O
S O
- O
23121 O
are O
N O
- O
phenylimide O
herbicides O
and O
produced O
embryolethality B_DISEASE/B_ORGANISM_FUNCTION
, O
teratogenicity B_DISEASE
( O
mainly O
ventricular B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
septal I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
defects I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
and O
wavy O
ribs O
) O
, O
and O
growth B_DISEASE/B_ORGANISM_FUNCTION
retardation I_DISEASE/I_ORGANISM_FUNCTION
in O
rats O
in O
conventional O
oral O
developmental O
toxicity B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
studies O
. O

Our O
objective O
in O
this O
study O
was O
to O
investigate O
whether O
the O
compounds O
induce O
developmental O
toxicity B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
via O
the O
dermal O
route O
, O
which O
is O
more O
relevant O
to O
occupational O
exposure O
, O
hence O
better O
addressing O
human O
health O
risks O
. O

METHODS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
: O
S B_PROTEIN[GENE]/B_DISEASE
- O
53482 B_MEASURE
was O
administered O
dermally O
to O
rats B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O
30 B_MEASURE
, O
100 B_MEASURE
, O
and O
300 B_MEASURE
mg I_MEASURE
/ O
kg B_MEASURE
during O
organogenesis B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
, O
and O
S B_PROTEIN[GENE]/B_DISEASE
- O
23121 B_MEASURE
was O
administered O
at O
200 B_MEASURE
, O
400 B_MEASURE
, O
and O
800 B_MEASURE
mg I_MEASURE
/ O
kg B_MEASURE
( O
the O
maximum B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
applicable B_MEASURE/I_BODY_PART_OR_ORGAN_COMPONENT
dose B_MEASURE/I_BODY_PART_OR_ORGAN_COMPONENT
level B_MEASURE/I_BODY_PART_OR_ORGAN_COMPONENT
) O
. O

Fetuses B_PERSON/B_LOCATION
were O
obtained O
by O
a O
cesarean B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
section I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_PERSON
and O
examined O
for O
external B_BODY_PART_OR_ORGAN_COMPONENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
visceral B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
, O
and O
skeletal B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alterations I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Results O
: O
Dermal O
exposure O
of O
rats O
to O
S O
- O
53482 O
at O
300 O
mg O
/ O
kg O
produced O
patterns O
of O
developmental O
toxicity B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
similar O
to O
those O
resulting O
from O
oral O
exposure O
. O

Toxicity B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
included O
embryolethality B_DISEASE
, O
teratogenicity B_DISEASE
, O
and O
growth B_DISEASE/B_ORGANISM_FUNCTION
retardation I_DISEASE/I_ORGANISM_FUNCTION
. O

Dermal O
administration O
of O
S O
- O
23121 O
at O
800 O
mg O
/ O
kg O
resulted O
in O
an O
increased O
incidence O
of O
embryonic B_DISEASE
death I_DISEASE
and O
ventricular B_DISEASE
septal I_DISEASE
defect I_DISEASE
, O
but O
retarded O
fetal O
growth O
was O
not O
observed O
as O
it O
was O
following O
oral O
exposure O
to O
S O
- O
23121 O
. O

conclusions O
: O
Based O
on O
the O
results O
, O
S O
- O
53482 O
and O
S O
- O
23121 O
were O
teratogenic B_DISEASE_ADJECTIVE[DISEASE]
when O
administered O
dermally O
to O
pregnant O
rats O
as O
were O
the O
compounds O
administered O
orally O
. O

Thus O
, O
investigation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
mechanism B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O
its O
human B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
relevancy I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
become O
more O
important B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

rates O
of O
Renal B_DISEASE
Toxicity I_DISEASE
in O
Cancer B_DISEASE/B_PERSON
patients O
receiving O
Cisplatin O
With O
and O
Without O
Mannitol O
. O

Background B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
: O
cisplatin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
a O
widely O
used O
antineoplastic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

One O
of O
the O
major O
complications O
of O
cisplatin O
use O
is O
dose O
- O
limiting O
nephrotoxicity B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

There O
are O
many O
strategies O
to O
prevent O
this O
toxicity B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
including O
the O
use O
of O
mannitol O
as O
a O
nephroprotectant O
in O
combination O
with O
hydration O
. O

objective O
: O
We O
aimed O
to O
evaluate O
the O
rates O
of O
cisplatin O
- O
induced O
nephrotoxicity B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
cancer B_DISEASE/B_PERSON
patients O
receiving O
single O
- O
agent O
cisplatin O
with O
and O
without O
mannitol O
. O

METHODS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O
This O
single B_NUMBER[MEASURE]
- O
center B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
retrospective I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
was O
a O
quasi B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
experiment I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
created O
by O
the O
national B_PERSON/B_ORGANIZATION
mannitol B_PERSON/I_ORGANIZATION
shortage B_PERSON/I_ORGANIZATION
. O

Data O
were O
collected O
on O
adult O
cancer B_DISEASE/B_LOCATION
patients O
receiving O
single O
- O
agent O
cisplatin O
as O
an O
outpatient O
from O
January O
2011 O
to O
September O
2012 O
. O

The O
primary O
outcome O
was O
acute B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
kidney I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
injury I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
( O
AKI B_DISEASE/B_GENE
) O
. O

Results O
: O
We O
evaluated O
143 O
patients O
who O
received O
single O
- O
agent O
cisplatin O
; O
97 O
. O
2 O
% O
of O
patients O
had O
head B_DISEASE
and I_DISEASE
neck I_DISEASE
cancer I_DISEASE
as O
their O
primary O
malignancy B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

patients O
who O
did O
not O
receive O
mannitol O
were O
more O
likely O
to O
develop O
nephrotoxicity B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
odds O
ratio O
[ O
OR O
] O
= O
2 O
. O
646 O
( O
95 O
% O
CI O
= O
1 O
. O
008 O
, O
6 O
. O
944 O
; O
P O
= O
0 O
. O
048 O
) O
. O

patients O
who O
received O
the O
100 O
mg O
/ O
m O
( O
2 O
) O
dosing O
and O
patients O
who O
had O
a O
history O
of O
hypertension B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
also O
had O
a O
higher O
likelihood O
of O
developing O
nephrotoxicity B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
OR O
= O
11 O
. O
494 O
( O
95 O
% O
CI O
= O
4 O
. O
149 O
, O
32 O
. O
258 O
; O
P O
< O
0 O
. O
0001 O
) O
and O
OR O
= O
3 O
. O
219 O
( O
95 O
% O
CI O
= O
1 O
. O
228 O
, O
8 O
. O
439 O
; O
P O
= O
0 O
. O
017 O
) O
, O
respectively O
. O

conclusions O
: O
When O
limited O
quantities O
of O
mannitol O
are O
available O
, O
it O
should O
preferentially O
be O
given O
to O
patients O
at O
particularly O
high O
risk O
of O
nephrotoxicity B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Our O
analysis O
suggests O
that O
those O
patients O
receiving O
the O
dosing O
schedule O
of O
100 O
mg O
/ O
m O
( O
2 O
) O
cisplatin O
every O
3 O
weeks O
and O
those O
with O
hypertension B_DISEASE
are O
at O
the O
greatest O
risk O
of O
nephrotoxicity B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
would O
benefit O
from O
the O
addition O
of O
mannitol O
. O

Metformin O
protects O
against O
seizures B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
, O
learning B_DISEASE
and I_DISEASE
memory I_DISEASE
impairments I_DISEASE
and O
oxidative O
damage O
induced O
by O
pentylenetetrazole O
- O
induced O
kindling O
in O
mice O
. O

Cognitive B_DISEASE
impairment I_DISEASE
, O
the O
most O
common O
and O
severe O
comorbidity O
of O
epilepsy B_DISEASE/B_LOCATION
, O
greatly O
diminishes O
the O
quality O
of O
life O
. O

However O
, O
current O
therapeutic O
interventions O
for O
epilepsy B_DISEASE/B_LOCATION
can O
also O
cause O
untoward O
cognitive O
effects O
. O

Thus O
, O
there O
is O
an O
urgent O
need O
for O
new O
kinds O
of O
agents O
targeting O
both O
seizures B_DISEASE
and O
cognition B_DISEASE
deficits I_DISEASE
. O

Oxidative O
stress O
is O
considered O
to O
play O
an O
important O
role O
in O
epileptogenesis O
and O
cognitive B_DISEASE/B_ORGANISM_FUNCTION
deficits I_DISEASE/I_ORGANISM_FUNCTION
, O
and O
antioxidants O
have O
a O
putative O
antiepileptic O
potential O
. O

metformin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
the O
most O
commonly O
prescribed O
antidiabetic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
oral I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
drug I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
has O
antioxidant B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
properties I_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

This O
study O
was O
designed O
to O
evaluate O
the O
ameliorative O
effects O
of O
metformin O
on O
seizures B_DISEASE
, O
cognitive B_DISEASE_ADJECTIVE[DISEASE]
impairment I_DISEASE_ADJECTIVE[DISEASE]
and O
brain O
oxidative O
stress O
markers O
observed O
in O
pentylenetetrazole O
- O
induced O
kindling O
animals O
. O

Male B_MEASURE/B_GENE
C57BL I_MEASURE/I_GENE
/ O
6 B_PERSON/B_MEASURE
mice I_PERSON/I_MEASURE
were O
administered O
with O
subconvulsive B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dose B_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
pentylenetetrazole B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
37 B_MEASURE
mg I_MEASURE
/ O
kg B_TIME[MEASURE]
, O
i O
. O
p B_MEASURE/B_LOCATION
. O
) O
every O
other B_TIME[MEASURE]
day I_TIME[MEASURE]
for O
14 B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
injections I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

metformin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
injected O
intraperitoneally O
in O
dose B_MEASURE/B_LOCATION
of O
200mg B_MEASURE
/ O
kg B_MEASURE
along O
with O
alternate B_NUMBER[MEASURE]
- O
day B_TIME[MEASURE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
PTZ B_TIME[MEASURE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

We O
found O
that O
metformin O
suppressed O
the O
progression O
of O
kindling O
, O
ameliorated O
the O
cognitive B_DISEASE
impairment I_DISEASE
and O
decreased O
brain O
oxidative O
stress O
. O

Thus O
the O
present O
study O
concluded O
that O
metformin O
may O
be O
a O
potential O
agent O
for O
the O
treatment O
of O
epilepsy B_DISEASE
as O
well O
as O
a O
protective O
medicine O
against O
cognitive B_DISEASE
impairment I_DISEASE
induced O
by O
seizures B_DISEASE
. O

P53 O
inhibition O
exacerbates O
late O
- O
stage O
anthracycline O
cardiotoxicity B_DISEASE
. O

aims O
: O
Doxorubicin O
( O
DOX O
) O
is O
an O
effective O
anti O
- O
cancer B_DISEASE
therapeutic O
, O
but O
is O
associated O
with O
both O
acute O
and O
late O
- O
stage O
cardiotoxicity B_DISEASE
. O

Children O
are O
particularly O
sensitive O
to O
DOX O
- O
induced O
heart B_DISEASE/B_GENE
failure I_DISEASE/I_GENE
. O

Here O
, O
the O
impact O
of O
p53 O
inhibition O
on O
acute O
vs O
. O
late O
- O
stage O
DOX O
cardiotoxicity B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O
examined O
in O
a O
juvenile O
model O
. O

METHODS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
AND O
RESULTS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
: O
Two B_NUMBER[MEASURE]
- O
week B_TIME[MEASURE]
- O
old B_MEASURE/B_LOCATION
MHC I_MEASURE/I_LOCATION
- O
CB7 B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mice I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
which O
express O
dominant O
- O
interfering O
p53 B_GENE
in O
cardiomyocytes B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
) O
and O
their O
non B_DISEASE/B_GENE
- O
transgenic B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
( O
Non B_GENE/B_DISEASE
- O
TXG B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
littermates B_PERSON/B_ORGANIZATION
received O
weekly B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
DOX I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
injections I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
5 B_TIME[MEASURE]/B_DISEASE
weeks B_TIME[MEASURE]/I_DISEASE
( O
25 B_MEASURE
mg I_MEASURE
/ O
kg B_MEASURE
cumulative I_MEASURE
dose I_MEASURE
) O
. O

One B_TIME[MEASURE]/B_LOCATION
week I_TIME[MEASURE]/I_LOCATION
after O
the O
last B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
DOX I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
treatment I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
( O
acute B_MEASURE
stage I_MEASURE
) O
, O
MHC B_PROTEIN[GENE]/B_DISEASE
- O
CB7 B_MEASURE/B_PROTEIN[GENE]
mice I_MEASURE/I_PROTEIN[GENE]
exhibited O
improved B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
cardiac I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
function I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
and O
lower B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
levels B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
cardiomyocyte B_DISEASE/B_GENE
apoptosis I_DISEASE/I_GENE
when O
compared O
with O
the O
Non B_GENE/B_DISEASE
- O
TXG B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
mice I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O

surprisingly O
, O
by O
13 B_TIME[MEASURE]/B_ENT
weeks I_TIME[MEASURE]/I_ENT
following O
the O
last B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
DOX I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
treatment I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
( O
late B_TIME[MEASURE]
stage I_TIME[MEASURE]
) O
, O
MHC B_PROTEIN[GENE]/B_DISEASE
- O
CB7 B_MEASURE/B_GENE
exhibited O
a O
progressive B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
decrease I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
cardiac B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
function I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
higher B_DISEASE_ADJECTIVE[DISEASE]
rates I_DISEASE_ADJECTIVE[DISEASE]
of O
cardiomyocyte B_DISEASE/B_GENE
apoptosis I_DISEASE/I_GENE
when O
compared O
with O
Non B_GENE/B_DISEASE
- O
TXG B_LOCATION/B_ORGANIZATION
mice I_LOCATION/I_ORGANIZATION
. O

p53 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
inhibition I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
blocked O
transient B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
DOX B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
induced O
STAT3 B_DISEASE/B_GENE
activation I_DISEASE/I_GENE
in O
MHC B_PROTEIN[GENE]/B_DISEASE
- O
CB7 B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mice I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
which O
was O
associated O
with O
enhanced B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
induction I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
the O
DNA B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
repair I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
proteins I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
Ku70 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O
Ku80 B_GENE
. O

Mice B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
cardiomyocyte B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
- O
restricted O
deletion B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE_EXPRESSION_ADJECTIVE[GENE]
of O
STAT3 B_GENE
exhibited O
worse B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cardiac I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
function I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
higher B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
levels B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
cardiomyocyte B_DISEASE/B_GENE
apoptosis B_DISEASE/I_GENE
, O
and O
a O
greater B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
induction B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
of O
Ku70 B_GENE
and O
Ku80 B_GENE
in O
response B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
DOX B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
treatment I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
during O
the O
acute B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stage B_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
when O
compared O
with O
control B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
animals I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O

Conclusion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O
These O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
support O
a O
model B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
wherein O
a O
p53 B_GENE
- O
dependent B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
cardioprotective B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
pathway B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
mediated O
via O
STAT3 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
activation I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
mitigates O
DOX B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
myocardial B_DISEASE/B_GENE
stress I_DISEASE/I_GENE
during O
drug B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
delivery I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Furthermore O
, O
these O
data O
suggest O
an O
explanation O
as O
to O
how O
p53 O
inhibition O
can O
result O
in O
cardioprotection O
during O
drug O
treatment O
and O
, O
paradoxically O
, O
enhanced O
cardiotoxicity B_DISEASE
long O
after O
the O
cessation O
of O
drug O
treatment O
. O

Metronidazole O
- O
induced O
encephalopathy B_DISEASE
: O
an O
uncommon O
scenario O
. O

metronidazole B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
can O
produce O
neurological B_DISEASE
complications I_DISEASE
although O
it O
is O
not O
a O
common B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
scenario I_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

We O
present O
a O
case O
where O
a O
patient O
developed O
features O
of O
encephalopathy B_DISEASE
following O
prolonged O
metronidazole O
intake O
. O

Magnetic B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
resonance I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
imaging I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
( O
MRI B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O
brain B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
showed O
abnormal B_DISEASE
signal I_DISEASE
intensity I_DISEASE
involving O
both O
dentate B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
nuclei I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
of O
cerebellum B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
and O
splenium B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
of O
corpus B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
callosum I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
diagnosis O
of O
metronidazole O
toxicity B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
made O
by O
the O
MRI O
findings O
and O
supported O
clinically O
. O

Aconitine O
- O
induced O
Ca2 O
+ O
overload O
causes O
arrhythmia B_DISEASE/B_GENE
and O
triggers O
apoptosis O
through O
p38 O
MAPK O
signaling O
pathway O
in O
rats O
. O

Aconitine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
is O
a O
major B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
bioactive I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
diterpenoid I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
alkaloid I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
with O
high B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
content I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
derived O
from O
herbal B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
aconitum I_BIO/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
plants I_BIO/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

emerging O
evidence O
indicates O
that O
voltage O
- O
dependent O
Na O
( O
+ O
) O
channels O
have O
pivotal O
roles O
in O
the O
cardiotoxicity B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
aconitine O
. O

However O
, O
no O
reports O
are O
available O
on O
the O
role O
of O
ca O
( O
2 O
+ O
) O
in O
aconitine O
poisoning B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

In O
this O
study O
, O
we O
explored O
the O
importance O
of O
pathological O
ca O
( O
2 O
+ O
) O
signaling O
in O
aconitine O
poisoning B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
vitro O
and O
in O
vivo O
. O

We O
found O
that O
ca O
( O
2 O
+ O
) O
overload O
lead O
to O
accelerated O
beating O
rhythm O
in O
adult O
rat O
ventricular O
myocytes O
and O
caused O
arrhythmia B_DISEASE
in O
conscious O
freely O
moving O
rats O
. O

To O
investigate O
effects O
of O
aconitine O
on O
myocardial B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
injury B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O
we O
performed O
cytotoxicity B_DISEASE/B_GENE
assay O
in O
neonatal O
rat O
ventricular O
myocytes O
( O
NRVMs O
) O
, O
as O
well O
as O
measured O
lactate O
dehydrogenase O
level O
in O
the O
culture O
medium O
of O
NRVMs O
and O
activities O
of O
serum O
cardiac O
enzymes O
in O
rats O
. O

The O
results O
showed O
that O
aconitine O
resulted O
in O
myocardial B_DISEASE/B_GENE
injury I_DISEASE/I_GENE
and O
reduced O
NRVMs O
viability O
dose O
- O
dependently O
. O

To O
confirm O
the O
pro B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
apoptotic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
effects B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
, O
we O
performed O
flow B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
cytometric I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
detection I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
, O
cardiac B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
histology I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O
transmission B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
electron I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
microscopy I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O
terminal B_GENE
deoxynucleotidyl I_GENE
transferase I_GENE
- O
mediated O
dUTP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
biotin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENZYME[GENE]
nick B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENZYME[GENE]
end B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENZYME[GENE]
labeling I_TIME[MEASURE]
assay B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
. O

The O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
showed O
that O
aconitine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
stimulated O
apoptosis B_TIME[MEASURE]
time I_TIME[MEASURE]
- O
dependently O
. O

The O
expression B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
Ca B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O
2 B_MEASURE/B_PROTEIN[GENE]
+ I_MEASURE/I_PROTEIN[GENE]
) O
handling O
proteins B_GENE/B_DISEASE
demonstrated O
that O
aconitine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
promoted O
Ca B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O
2 B_MEASURE/B_PROTEIN[GENE]
+ I_MEASURE/I_PROTEIN[GENE]
) O
overload B_DISEASE/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
through O
the O
expression B_DISEASE_ADJECTIVE[DISEASE]
regulation I_DISEASE_ADJECTIVE[DISEASE]
of O
Ca B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O
2 B_MEASURE/B_PROTEIN[GENE]
+ I_MEASURE/I_PROTEIN[GENE]
) O
handling O
proteins B_GENE/B_DISEASE
. O

The O
expression B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
apoptosis B_DISEASE/B_GENE
- O
related O
proteins B_GENE/B_DISEASE
revealed O
that O
pro B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
apoptotic B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
protein I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expression I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
upregulated O
, O
and O
anti B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
apoptotic B_GENE/B_DISEASE
protein I_GENE/I_DISEASE
BCL I_GENE/I_DISEASE
- O
2 B_MEASURE/B_PROTEIN[GENE]
expression I_MEASURE/I_PROTEIN[GENE]
was O
downregulated O
. O

Furthermore O
, O
increased O
phosphorylation B_GENE_EXPRESSION_ADJECTIVE[GENE]/B_MEASURE
of O
MAPK B_GENE
family I_GENE
members I_GENE
, O
especially O
the O
P B_GENE
- O
p38 B_GENE
/ O
p38 B_GENE
ratio I_GENE
was O
found O
in O
cardiac B_DISEASE
tissues I_DISEASE
. O

Hence O
, O
our O
results O
suggest O
that O
aconitine O
significantly O
aggravates O
ca O
( O
2 O
+ O
) O
overload O
and O
causes O
arrhythmia B_DISEASE/B_GENE
and O
finally O
promotes O
apoptotic O
development O
via O
phosphorylation O
of O
P38 O
mitogen O
- O
activated O
protein O
kinase O
. O

chronic O
treatment O
with O
metformin O
suppresses O
toll O
- O
like O
receptor O
4 O
signaling O
and O
attenuates O
left B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
ventricular I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
dysfunction I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
following O
myocardial B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
infarction I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

acute O
treatment O
with O
metformin O
has O
a O
protective O
effect O
in O
myocardial B_DISEASE
infarction I_DISEASE
by O
suppression O
of O
inflammatory O
responses O
due O
to O
activation O
of O
AMP O
- O
activated O
protein O
kinase O
( O
AMPK O
) O
. O

In O
the O
present O
study O
, O
the O
effect O
of O
chronic O
pre O
- O
treatment O
with O
metformin O
on O
cardiac B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
dysfunction B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
and O
toll O
- O
like O
receptor O
4 O
( O
TLR4 O
) O
activities O
following O
myocardial B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
infarction I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
their O
relation O
with O
AMPK O
were O
assessed O
. O

Male B_PERSON/B_ORGANIZATION
Wistar I_PERSON/I_ORGANIZATION
rats I_PERSON/I_ORGANIZATION
were O
randomly O
assigned O
to O
one B_NUMBER[MEASURE]/B_LOCATION
of O
5 B_NUMBER[MEASURE]/B_PERSON
groups I_NUMBER[MEASURE]/I_PERSON
( O
n B_OTHER/B_MEASURE
= O
6 B_MEASURE
) O
: O
normal B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
control I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
groups B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
were O
injected O
isoproterenol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
after O
chronic B_DISEASE/B_MEASURE
pre I_DISEASE/I_MEASURE
- O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
with O
0 B_MEASURE
, O
25 B_MEASURE
, O
50 B_MEASURE
, O
or O
100mg B_MEASURE
/ O
kg B_MEASURE
of O
metformin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
twice O
daily O
for O
14 B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
days I_TIME[MEASURE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Isoproterenol O
( O
100mg O
/ O
kg O
) O
was O
injected O
subcutaneously O
on O
the O
13th O
and O
14th O
days O
to O
induce O
acute B_DISEASE
myocardial I_DISEASE
infarction I_DISEASE
. O

isoproterenol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
alone O
decreased O
left B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
ventricular B_MEASURE/I_BODY_PART_OR_ORGAN_COMPONENT
systolic B_MEASURE/I_BODY_PART_OR_ORGAN_COMPONENT
pressure B_MEASURE/I_BODY_PART_OR_ORGAN_COMPONENT
and O
myocardial B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
contractility B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
indexed O
as O
LVdp B_GENE/B_LOCATION
/ O
dtmax B_MEASURE/B_LOCATION
and O
LVdp B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
/ O
dtmin B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
left B_DISEASE/B_MEASURE
ventricular I_DISEASE/I_MEASURE
dysfunction I_DISEASE/I_MEASURE
was O
significantly O
lower O
in O
the O
groups O
treated O
with O
25 O
and O
50mg O
/ O
kg O
of O
metformin O
. O

Metfromin O
markedly O
lowered O
isoproterenol O
- O
induced O
elevation O
in O
the O
levels O
of O
TLR4 O
mRNA O
, O
myeloid O
differentiation O
protein O
88 O
( O
MyD88 O
) O
, O
tumor B_DISEASE_ADJECTIVE[DISEASE]
necrosis I_DISEASE_ADJECTIVE[DISEASE]
factor O
- O
alpha O
( O
TNF O
- O
a O
) O
, O
and O
interleukin O
6 O
( O
IL O
- O
6 O
) O
in O
the O
heart O
tissues O
. O

Similar B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
changes I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
also O
seen O
in O
the O
serum B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
levels I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
TNF B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
a B_PROTEIN[GENE]
and O
IL B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
6 B_NUMBER[MEASURE]
. O

However O
, O
the O
lower B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
doses I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
25 B_MEASURE
and O
50mg B_MEASURE
/ O
kg B_MEASURE
were O
more O
effective B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
than O
100mg B_MEASURE
/ O
kg B_MEASURE
. O

Phosphorylated B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
AMPKa I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
( O
p O
- O
AMPK B_GENE
) O
in O
the O
myocardium B_BODY_PART_OR_ORGAN_COMPONENT
was O
significantly O
elevated O
by O
25mg B_MEASURE
/ O
kg B_MEASURE
of O
metformin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
slightly O
by O
50mg B_MEASURE
/ O
kg B_MEASURE/B_PERSON
, O
but O
not O
by O
100mg B_MEASURE
/ O
kg B_MEASURE/B_PERSON
. O

chronic O
pre O
- O
treatment O
with O
metformin O
reduces O
post O
- O
myocardial B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
infarction B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
cardiac O
dysfunction O
and O
suppresses O
inflammatory O
responses O
, O
possibly O
through O
inhibition O
of O
TLR4 O
activities O
. O

This O
mechanism B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
can O
be O
considered O
as O
a O
target B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
to O
protect O
infarcted B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
myocardium B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
. O

unusual B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
complications I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
of O
antithyroid B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
drug I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
therapy I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
: O
four B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
case I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
reports I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
and O
review B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
literature B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Two O
cases O
of O
propylthiouracil O
- O
associated O
acute O
hepatitis B_DISEASE
, O
one O
case O
of O
fatal O
methimazole O
- O
associated O
hepatocellular B_DISEASE
necrosis I_DISEASE
and O
one O
case O
of O
propylthiouracil O
- O
associated O
lupus B_DISEASE
- I_DISEASE
like I_DISEASE
syndrome I_DISEASE
are O
described O
. O

The O
literature B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
related O
to O
antithyroid B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
drug I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
side I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
the O
mechanisms B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
their O
occurrence B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
are O
reviewed O
and O
the O
efficacy B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
complications B_DISEASE
of O
thyroidectomy B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O
radioiodine B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
compared O
to O
those O
of O
antithyroid B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
drugs I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

It O
is O
concluded O
that O
in O
most O
circumstances O
131I O
is O
the O
therapy O
of O
choice O
for O
hyperthyroidism B_DISEASE/B_PERSON
. O

Neuroleptic B_DISEASE
malignant I_DISEASE
syndrome I_DISEASE
induced O
by O
combination O
therapy O
with O
tetrabenazine O
and O
tiapride O
in O
a O
Japanese O
patient O
with O
Huntington B_DISEASE
' I_DISEASE
s I_DISEASE
disease I_DISEASE
at O
the O
terminal O
stage O
of O
recurrent O
breast B_DISEASE
cancer I_DISEASE
. O

We O
herein O
describe O
the O
case O
of O
an O
81 O
- O
year O
- O
old O
Japanese O
woman O
with O
neuroleptic B_DISEASE
malignant I_DISEASE
syndrome I_DISEASE
that O
occurred O
36 O
days O
after O
the O
initiation O
of O
combination O
therapy O
with O
tiapride O
( O
75 O
mg O
/ O
day O
) O
and O
tetrabenazine O
( O
12 O
. O
5 O
mg O
/ O
day O
) O
for O
Huntington B_DISEASE
' I_DISEASE
s I_DISEASE
disease I_DISEASE
. O

The O
patient B_PERSON/B_DISEASE
had O
been O
treated O
with O
tiapride B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O
tetrabenazine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alone O
without O
any O
adverse B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
before O
the O
administration B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANIZATION
of O
the O
combination B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
therapy I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

She O
also O
had O
advanced O
breast B_DISEASE
cancer I_DISEASE
when O
the O
combination O
therapy O
was O
initiated O
. O

To O
the O
best O
of O
our O
knowledge O
, O
the O
occurrence O
of O
neuroleptic B_DISEASE
malignant I_DISEASE
syndrome I_DISEASE
due O
to O
combination O
therapy O
with O
tetrabenazine O
and O
tiapride O
has O
not O
been O
previously O
reported O
. O

Tetrabenazine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
should O
be O
administered O
very O
carefully O
in O
combination B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANIZATION
with O
other B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
neuroleptic I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
drugs I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
particularly O
in O
patients B_PERSON/B_LOCATION
with O
a O
worsening O
general B_DISEASE
condition I_DISEASE
. O

A O
metoprolol O
- O
terbinafine O
combination O
induced O
bradycardia B_DISEASE
. O

To O
report O
a O
sinus B_DISEASE/B_BIO
bradycardia I_DISEASE/I_BIO
induced O
by O
metoprolol O
and O
terbinafine O
drug O
- O
drug O
interaction O
and O
its O
management O
. O

A O
63 O
year O
- O
old O
Caucasian O
man O
on O
metoprolol O
200 O
mg O
/ O
day O
for O
stable O
coronary B_DISEASE
artery I_DISEASE
disease I_DISEASE
was O
prescribed O
a O
90 O
- O
day O
course O
of O
oral O
terbinafine O
250 O
mg O
/ O
day O
for O
onychomycosis B_DISEASE
. O

On O
the O
49th O
day O
of O
terbinafine O
therapy O
, O
he O
was O
brought O
to O
the O
emergency O
room O
for O
a O
decrease O
of O
his O
global O
health O
status O
, O
confusion B_DISEASE
and O
falls O
. O

The O
electrocardiogram O
revealed O
a O
37 O
beats O
/ O
min O
sinus B_DISEASE/B_MEASURE
bradycardia I_DISEASE/I_MEASURE
. O

A O
score O
of O
7 O
on O
the O
Naranjo O
adverse B_DISEASE_ADJECTIVE[DISEASE]
drug I_DISEASE_ADJECTIVE[DISEASE]
reaction I_DISEASE_ADJECTIVE[DISEASE]
probability O
scale O
indicates O
a O
probable O
relationship O
between O
the O
patient O
' O
s O
sinus B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
bradycardia B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
the O
drug O
interaction O
between O
metoprolol O
and O
terbinafine O
. O

The O
heart B_DISEASE
rate I_DISEASE
ameliorated O
first O
with O
a O
decrease B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
the O
dose B_MEASURE/B_LOCATION
of O
metoprolol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

It O
was O
subsequently O
changed O
to O
bisoprolol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
the O
heart B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
rate I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
remained O
normal B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

By O
inhibiting O
the O
cytochrome O
P450 O
2D6 O
, O
terbinafine O
had O
decreased O
metoprolol O
' O
s O
clearance O
, O
leading O
in O
metoprolol O
accumulation O
which O
has O
resulted O
in O
clinically O
significant O
sinus B_DISEASE
bradycardia I_DISEASE
. O

Optochiasmatic O
and O
peripheral B_DISEASE/B_LOCATION
neuropathy I_DISEASE/I_LOCATION
due O
to O
ethambutol O
overtreatment O
. O

Ethambutol O
is O
known O
to O
cause O
optic B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
neuropathy I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
and O
, O
more O
rarely O
, O
axonal O
polyneuropathy B_DISEASE
. O

We O
characterize O
the O
clinical O
, O
neurophysiological O
, O
and O
neuroimaging O
findings O
in O
a O
72 O
- O
year O
- O
old O
man O
who O
developed O
visual B_DISEASE
loss I_DISEASE
and O
paresthesias B_DISEASE
after O
11 O
weeks O
of O
exposure O
to O
a O
supratherapeutic O
dose O
of O
ethambutol O
. O

This O
case O
demonstrates O
the O
selective O
vulnerability O
of O
the O
anterior O
visual O
pathways O
and O
peripheral O
nerves O
to O
ethambutol O
toxicity B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O

Testosterone O
ameliorates O
streptozotocin O
- O
induced O
memory B_DISEASE
impairment I_DISEASE
in O
male O
rats O
. O

aim O
: O
To O
study O
the O
effects O
of O
testosterone O
on O
streptozotocin O
( O
STZ O
) O
- O
induced O
memory B_DISEASE
impairment I_DISEASE
in O
male O
rats O
. O

METHODS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O
Adult B_PERSON/B_BIO
male I_PERSON/I_BIO
Wistar I_PERSON/I_BIO
rats I_PERSON/I_BIO
were O
intracerebroventricularly O
( O
icv B_PERSON/B_PROTEIN[GENE]
) O
infused O
with O
STZ B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O
750 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Ug I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
on O
d B_MEASURE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
1 I_MEASURE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
d B_SEQUENCE[MEASURE]/B_LOCATION
3 I_SEQUENCE[MEASURE]/I_LOCATION
, O
and O
a O
passive B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
avoidance I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
task I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
was O
assessed O
2 B_TIME[MEASURE]/B_ENT
weeks I_TIME[MEASURE]/I_ENT
after O
the O
first B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
injection I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
of O
STZ B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O

castration B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
surgery I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
was O
performed O
in O
another O
group B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
rats B_BIO/B_PERSON
, O
and O
the O
passive B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
avoidance B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
task B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
was O
assessed O
4 B_TIME[MEASURE]
weeks I_TIME[MEASURE]
after O
the O
operation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O

testosterone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
( O
1 B_MEASURE
mg I_MEASURE
. O
kg B_MEASURE/B_PERSON
( O
- O
1 B_NUMBER[MEASURE]
) O
. O
d B_TIME[MEASURE]/B_DISEASE
( O
- O
1 B_NUMBER[MEASURE]
) O
, O
Sc B_LOCATION
) O
, O
the O
androgen B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
receptor I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
antagonist I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
flutamide I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O
10 B_MEASURE
mg I_MEASURE
. O
kg B_MEASURE
( O
- O
1 B_NUMBER[MEASURE]
) O
. O
d B_TIME[MEASURE]/B_DISEASE
( O
- O
1 B_NUMBER[MEASURE]
) O
, O
IP B_LOCATION
) O
, O
the O
estrogen B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptor I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antagonist I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tamoxifen I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
1 B_MEASURE
mg I_MEASURE
. O
kg B_MEASURE/B_PERSON
( O
- O
1 B_NUMBER[MEASURE]
) O
. O
d B_TIME[MEASURE]/B_DISEASE
( O
- O
1 B_NUMBER[MEASURE]
) O
, O
IP B_LOCATION
) O
or O
the O
aromatase B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
inhibitor I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
letrozole I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O
4 B_MEASURE
mg I_MEASURE
. O
kg B_MEASURE
( O
- O
1 B_NUMBER[MEASURE]
) O
. O
d B_TIME[MEASURE]/B_DISEASE
( O
- O
1 B_NUMBER[MEASURE]
) O
, O
IP B_LOCATION
) O
were O
administered O
for O
6 B_TIME[MEASURE]/B_LOCATION
d I_TIME[MEASURE]/I_LOCATION
after O
the O
first B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
injection I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
STZ B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O

RESULTS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
: O
STZ B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANIZATION
administration I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANIZATION
and O
castration B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
markedly O
decreased O
both O
STL1 B_GENE/B_DISEASE
( O
the O
short B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
memory I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
) O
and O
STL2 B_GENE
( O
the O
long B_DISEASE/B_MEASURE
memory I_DISEASE/I_MEASURE
) O
in O
passive B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
avoidance I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tests I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

testosterone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
replacement B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
almost O
restored O
the O
STL1 B_GENE/B_LOCATION
and O
STL2 B_GENE/B_DISEASE
in O
castrated B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
rats I_BODY_PART_OR_ORGAN_COMPONENT/I_BIO
, O
and O
significantly O
prolonged O
the O
STL1 B_GENE/B_LOCATION
and O
STL2 B_GENE
in O
STZ B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
treated O
rats B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Administration O
of O
flutamide O
, O
letrozole O
or O
tamoxifen O
significantly O
impaired B_DISEASE_ADJECTIVE[DISEASE]
the I_DISEASE_ADJECTIVE[DISEASE]
memory I_DISEASE_ADJECTIVE[DISEASE]
in O
intact O
rats O
, O
and O
significantly O
attenuated O
the O
testosterone O
replacement O
in O
improving O
STZ O
- O
and O
castration O
- O
induced O
memory B_DISEASE
impairment I_DISEASE
. O

conclusion O
: O
Testosterone O
administration O
ameliorates O
STZ O
- O
and O
castration O
- O
induced O
memory B_DISEASE
impairment I_DISEASE
in O
male O
Wistar O
rats O
. O

behavioral O
and O
neurochemical O
studies O
in O
mice O
pretreated O
with O
garcinielliptone O
FC O
in O
pilocarpine O
- O
induced O
seizures B_DISEASE
. O

Garcinielliptone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_NUMBER[MEASURE]
FC I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_NUMBER[MEASURE]
( O
GFC B_MEASURE
) O
isolated O
from O
hexanic B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
fraction I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
seed I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
extract I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
of O
species B_BIO/B_LOCATION
Platonia B_BIO/I_LOCATION
insignis B_BIO/I_LOCATION
mart B_BIO/I_LOCATION
. O

It O
is O
widely O
used O
in O
folk O
medicine O
to O
treat O
skin B_DISEASE
diseases I_DISEASE
in O
both O
humans O
and O
animals O
as O
well O
as O
the O
seed O
decoction O
has O
been O
used O
to O
treat O
diarrheas B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
and O
inflammatory B_DISEASE
diseases I_DISEASE
. O

However O
, O
there O
is O
no O
research B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
GFC B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
effects B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
in O
the O
central B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
nervous I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
system I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
of O
rodents B_SPECIES[BIO]/B_PERSON
. O

The O
present O
study O
aimed O
to O
evaluate O
the O
GFC O
effects O
at O
doses O
of O
25 O
, O
50 O
or O
75 O
mg O
/ O
kg O
on O
seizure B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
parameters O
to O
determine O
their O
anticonvulsant O
activity O
and O
its O
effects O
on O
amino O
acid O
( O
r O
- O
aminobutyric O
acid O
( O
GABA O
) O
, O
glutamine O
, O
aspartate O
and O
glutathione O
) O
levels O
as O
well O
as O
on O
acetylcholinesterase O
( O
ache O
) O
activity O
in O
mice O
hippocampus O
after O
seizures B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

GFC O
produced O
an O
increased O
latency O
to O
first O
seizure B_DISEASE
, O
at O
doses O
25mg O
/ O
kg O
( O
20 O
. O
12 O
+ O
2 O
. O
20 O
min O
) O
, O
50mg O
/ O
kg O
( O
20 O
. O
95 O
+ O
2 O
. O
21 O
min O
) O
or O
75 O
mg O
/ O
kg O
( O
23 O
. O
43 O
+ O
1 O
. O
99 O
min O
) O
when O
compared O
with O
seized O
mice O
. O

In O
addition B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O
GABA B_DISEASE/B_GENE
content B_DISEASE/I_GENE
of O
mice B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
hippocampus I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
treated O
with O
GFC75 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
plus O
P400 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
showed O
an O
increase B_DISEASE_ADJECTIVE[DISEASE]
of O
46 B_MEASURE
. O
90 B_MEASURE/B_LOCATION
% I_MEASURE/I_LOCATION
when O
compared O
with O
seized O
mice B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

In O
aspartate B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
, O
glutamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O
glutamate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
levels I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
detected O
a O
decrease B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O
5 B_MEASURE
. O
21 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
, O
13 B_MEASURE
. O
55 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
and O
21 B_MEASURE
. O
80 B_MEASURE/B_LOCATION
% I_MEASURE/I_LOCATION
, O
respectively O
in O
mice B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
hippocampus I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
treated O
with O
GFC75 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
plus O
P400 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
when O
compared O
with O
seized O
mice B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Hippocampus B_BIO/B_PERSON
mice I_BIO/I_PERSON
treated O
with O
GFC75 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
plus O
P400 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
showed O
an O
increase B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
AChE B_DISEASE/B_MEASURE
activity I_DISEASE/I_MEASURE
( O
63 B_MEASURE
. O
30 B_MEASURE/B_LOCATION
% I_MEASURE/I_LOCATION
) O
when O
compared O
with O
seized O
mice B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
results O
indicate O
that O
GFC O
can O
exert O
anticonvulsant O
activity O
and O
reduce O
the O
frequency O
of O
installation O
of O
pilocarpine O
- O
induced O
status B_DISEASE
epilepticus I_DISEASE
, O
as O
demonstrated O
by O
increase O
in O
latency O
to O
first O
seizure B_DISEASE
and O
decrease O
in O
mortality O
rate O
of O
animals O
. O

In O
conclusion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O
our O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggest O
that O
GFC B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
may O
influence O
in O
epileptogenesis B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
promote O
anticonvulsant B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
actions I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
pilocarpine B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
model B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
by O
modulating O
the O
GABA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
glutamate O
contents B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
of O
AChE B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
activity B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
in O
seized O
mice B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
hippocampus B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
. O

This O
compound B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
may O
be O
useful B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O
produce O
neuronal B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
protection I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
it O
can O
be O
considered O
as O
an O
anticonvulsant B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
agent I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Standard O
operating O
procedures O
for O
antibiotic O
therapy O
and O
the O
occurrence O
of O
acute B_DISEASE
kidney I_DISEASE
injury I_DISEASE
: O
a O
prospective O
, O
clinical O
, O
non O
- O
interventional O
, O
observational O
study O
. O

Introduction O
: O
Acute B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
kidney I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
injury I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
( O
AKI B_DISEASE/B_GENE
) O
occurs O
in O
7 O
% O
of O
hospitalized O
and O
66 O
% O
of O
intensive O
Care O
Unit O
( O
ICU O
) O
patients O
. O

It O
increases O
mortality B_DISEASE
, O
hospital B_MEASURE/B_PERSON
length I_MEASURE/I_PERSON
of O
stay B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
, O
and O
costs B_DISEASE
. O

The O
aim O
of O
this O
study O
was O
to O
investigate O
, O
whether O
there O
is O
an O
association O
between O
adherence O
to O
guidelines O
( O
standard O
operating O
procedures O
( O
SOP O
) O
) O
for O
potentially O
nephrotoxic B_DISEASE_ADJECTIVE[DISEASE]
antibiotics O
and O
the O
occurrence O
of O
AKI B_DISEASE
. O

METHODS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O
This O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
carried O
out O
as O
a O
prospective B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
clinical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O
non B_DISEASE
- O
interventional B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
observational B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Data B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
collection I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_GENE
was O
performed O
over O
a O
total B_MEASURE/B_LOCATION
of O
170 B_TIME[MEASURE]/B_ENT
days I_TIME[MEASURE]/I_ENT
in O
three B_MEASURE/B_LOCATION
ICUs I_MEASURE/I_LOCATION
at O
Charite B_PERSON/B_LOCATION
- O
Universitaetsmedizin B_LOCATION/B_PERSON
Berlin I_LOCATION/I_PERSON
. O

A O
total B_MEASURE
of O
675 B_TIME[MEASURE]
patients I_TIME[MEASURE]
were O
included O
; O
163 B_NUMBER[MEASURE]
of O
these O
had O
therapy B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
with O
vancomycin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
gentamicin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
or O
tobramycin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
; O
were O
> O
18 B_TIME[MEASURE]
years I_TIME[MEASURE]
; O
and O
treated O
in O
the O
ICU B_LOCATION
for O
> O
24 B_NUMBER[MEASURE]/B_SPORT[ENT]
hours I_NUMBER[MEASURE]/I_SPORT[ENT]
. O

patients B_PERSON
with O
an O
adherence B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
to O
SOP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
> O
70 B_MEASURE/B_LOCATION
% I_MEASURE/I_LOCATION
were O
classified O
into O
the O
high B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
adherence I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
group I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O
HAG B_LOCATION/B_ORGANIZATION
) O
and O
patients B_PERSON
with O
an O
adherence B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O
< O
70 B_MEASURE/B_LOCATION
% I_MEASURE/I_LOCATION
into O
the O
low B_MEASURE/B_LOCATION
adherence I_MEASURE/I_LOCATION
group I_MEASURE/I_LOCATION
( O
LAG B_LOCATION/B_ORGANIZATION
) O
. O

AKI B_DISEASE
was O
defined O
according O
to O
Rifle O
criteria O
. O

Adherence B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
SOPs B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
was O
evaluated O
by O
retrospective B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expert I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
audit I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Development O
of O
AKI B_DISEASE
was O
compared O
between O
groups O
with O
exact O
Chi2 O
- O
test O
and O
multivariate O
logistic O
regression O
analysis O
( O
two O
- O
sided O
P O
< O
0 O
. O
05 O
) O
. O

RESULTS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
lag B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
consisted O
of O
75 B_MEASURE/B_PERSON
patients I_MEASURE/I_PERSON
( O
46 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
versus O
88 B_MEASURE
HAG I_MEASURE
patients I_MEASURE
( O
54 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
. O

AKI B_DISEASE/B_GENE
occurred O
significantly O
more O
often O
in O
LAG O
with O
36 O
% O
versus O
21 O
% O
in O
HAG O
( O
P O
= O
0 O
. O
035 O
) O
. O

Basic O
characteristics O
were O
comparable O
, O
except O
an O
increased O
rate O
of O
soft O
tissue O
infections B_DISEASE
in O
LAG O
. O

Multivariate O
analysis O
revealed O
an O
odds O
ratio O
of O
2 O
. O
5 O
- O
fold O
for O
LAG O
to O
develop O
AKI B_DISEASE
compared O
with O
HAG O
( O
95 O
% O
confidence O
interval O
1 O
. O
195 O
to O
5 O
. O
124 O
, O
P O
= O
0 O
. O
039 O
) O
. O

conclusion O
: O
Low O
adherence O
to O
SOPs O
for O
potentially O
nephrotoxic B_DISEASE_ADJECTIVE[DISEASE]
antibiotics O
was O
associated O
with O
a O
higher O
occurrence O
of O
AKI B_DISEASE
. O

Trial B_LOCATION
registration I_LOCATION
: O
Current B_NUMBER[MEASURE]/B_LOCATION
Controlled I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Trials I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ISRCTN54598675 I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

registered O
17 B_PERSON
August I_PERSON
2007 I_PERSON
. O

Rhabdomyolysis B_DISEASE_ADJECTIVE[DISEASE]
in O
a O
hepatitis B_DISEASE/B_LOCATION
C I_DISEASE/I_LOCATION
virus I_DISEASE/I_LOCATION
infected I_DISEASE/I_LOCATION
patient O
treated O
with O
telaprevir O
and O
simvastatin O
. O

A O
46 O
- O
year O
old O
man O
with O
a O
chronic O
hepatitis B_DISEASE
C I_DISEASE
virus I_DISEASE
infection I_DISEASE
received O
triple O
therapy O
with O
ribavirin O
, O
pegylated O
interferon O
and O
telaprevir O
. O

The O
patient B_PERSON/B_LOCATION
also O
received O
simvastatin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

One O
month O
after O
starting O
the O
antiviral O
therapy O
, O
the O
patient O
was O
admitted O
to O
the O
hospital O
because O
he O
developed O
rhabdomyolysis B_DISEASE
. O

At O
admission O
simvastatin O
and O
all O
antiviral O
drugs O
were O
discontinued O
because O
toxicity B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
due O
to O
a O
drug O
- O
drug O
interaction O
was O
suspected O
. O

The O
creatine B_GENE
kinase I_GENE
peaked O
at O
62 B_MEASURE
, O
246 B_MEASURE/B_PERSON
IU I_MEASURE/I_PERSON
/ O
L B_OTHER/B_MEASURE
and O
the O
patient B_PERSON/B_BIO
was O
treated O
with O
intravenous B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
normal I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
saline I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
patient B_PERSON/B_BIO
' O
s O
renal B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
function I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
remained O
unaffected B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
. O

Fourteen B_TIME[MEASURE]/B_ENT
days I_TIME[MEASURE]/I_ENT
after O
hospitalization B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
, O
creatine B_PERSON/B_GENE
kinase I_PERSON/I_GENE
level I_PERSON/I_GENE
had O
returned O
to O
230 B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
IU I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
L B_OTHER/B_MEASURE
and O
the O
patient B_PERSON
was O
discharged O
. O

Telaprevir B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
considered O
the O
probable B_BACTERIUM[BIO]/B_MEASURE
causative B_BACTERIUM[BIO]/I_MEASURE
agent B_BACTERIUM[BIO]/I_MEASURE
of O
an O
interaction B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
with O
simvastatin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
according O
to O
the O
Drug B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
Interaction I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
probability I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
Scale I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

The O
interaction B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
due O
to O
inhibition B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
of O
CYP3A4 B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
- O
mediated O
simvastatin B_MEASURE/B_ENZYME[GENE]
clearance B_MEASURE/I_ENZYME[GENE]
. O

Simvastatin O
plasma O
concentration O
increased O
30 O
times O
in O
this O
patient O
and O
statin O
induced O
muscle B_DISEASE
toxicity I_DISEASE
is O
related O
to O
the O
concentration O
of O
the O
statin O
in O
blood O
. O

In O
conclusion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O
with O
this O
case B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
we O
illustrate O
that O
telaprevir B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O
well O
as O
statins B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
susceptible B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O
clinical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
relevant I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
drug I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
drug B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
interactions I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

combination O
of O
bortezomib O
, O
thalidomide O
, O
and O
dexamethasone O
( O
VTD O
) O
as O
a O
consolidation O
therapy O
after O
autologous O
stem O
cell O
transplantation O
for O
symptomatic O
multiple B_DISEASE/B_LOCATION
myeloma I_DISEASE/I_LOCATION
in O
Japanese O
patients O
. O

consolidation O
therapy O
for O
patients O
with O
multiple B_DISEASE
myeloma I_DISEASE
( O
MM B_TIME[MEASURE]/B_LOCATION
) O
has O
been O
widely O
adopted O
to O
improve O
treatment O
response O
following O
autologous O
stem O
cell O
transplantation O
. O

In O
this O
study O
, O
we O
retrospectively O
analyzed O
the O
safety O
and O
efficacy O
of O
combination O
regimen O
of O
bortezomib O
, O
thalidomide O
, O
and O
dexamethasone O
( O
VTD O
) O
as O
consolidation O
therapy O
in O
24 O
Japanese O
patients O
with O
newly O
diagnosed O
MM B_DISEASE/B_LOCATION
. O

VTD B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
consisted O
of O
bortezomib B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O
a O
dose B_MEASURE/B_DISEASE
of O
1 B_MEASURE
. O
3 B_MEASURE
mg I_MEASURE
/ O
m B_OTHER/B_MEASURE
( O
2 B_MEASURE/B_LOCATION
) O
and O
dexamethasone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O
a O
dose B_MEASURE/B_DISEASE
of O
40 B_MEASURE
mg I_MEASURE
/ O
day B_MEASURE
on O
days B_TIME[MEASURE]
1 I_TIME[MEASURE]
, O
8 B_MEASURE
, O
15 B_MEASURE
, O
and O
22 B_MEASURE
of O
a O
35 B_NUMBER[MEASURE]
- O
day B_TIME[MEASURE]/B_LOCATION
cycle I_TIME[MEASURE]/I_LOCATION
, O
with O
daily B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
oral I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
thalidomide I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O
a O
dose B_MEASURE/B_LOCATION
of O
100 B_MEASURE
mg I_MEASURE
/ O
day B_MEASURE
. O

Grade O
3 O
- O
4 O
neutropenia B_DISEASE
and O
thrombocytopenia B_DISEASE
were O
documented O
in O
four O
and O
three O
patients O
( O
17 O
and O
13 O
% O
) O
, O
respectively O
, O
but O
drug O
dose O
reduction O
due O
to O
cytopenia B_DISEASE
was O
not O
required O
in O
any O
case O
. O

Peripheral B_DISEASE
neuropathy I_DISEASE
was O
common O
( O
63 O
% O
) O
, O
but O
severe O
grade O
3 O
- O
4 O
peripheral B_DISEASE
neuropathy I_DISEASE
was O
not O
observed O
. O

Very O
good B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
partial I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
response I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
or O
better B_DISEASE_ADJECTIVE[DISEASE]
response I_DISEASE_ADJECTIVE[DISEASE]
( O
> O
VGPR B_MEASURE
) O
rates B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
before O
and O
after O
consolidation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
therapy I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
were O
54 B_MEASURE
and O
79 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
, O
respectively O
. O

patients B_PERSON
had O
a O
significant B_MEASURE
probability I_MEASURE
of O
improving O
from O
< B_PROTEIN[GENE]/B_DISEASE
VGPR I_PROTEIN[GENE]/I_DISEASE
before O
consolidation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
therapy I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
to O
> B_MEASURE
VGPR I_MEASURE
after O
consolidation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
therapy I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
( O
p B_PROTEIN[GENE]/B_MEASURE
= O
0 B_MEASURE
. O
041 B_MEASURE
) O
. O

The O
VTD B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
regimen I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
may O
be O
safe B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
effective B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
as O
a O
consolidation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
therapy I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
in O
the O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
MM B_DISEASE/B_LOCATION
in O
Japanese B_PERSON/B_LOCATION
population I_PERSON/I_LOCATION
. O

conversion O
to O
sirolimus O
ameliorates O
cyclosporine O
- O
induced O
nephropathy B_DISEASE
in O
the O
rat O
: O
focus O
on O
serum O
, O
urine O
, O
gene O
, O
and O
protein O
renal O
expression O
biomarkers O
. O

protocols O
of O
conversion O
from O
cyclosporin O
A O
( O
CsA O
) O
to O
sirolimus O
( O
SRL O
) O
have O
been O
widely O
used O
in O
immunotherapy O
after O
transplantation O
to O
prevent O
CsA O
- O
induced O
nephropathy B_DISEASE
, O
but O
the O
molecular O
mechanisms O
underlying O
these O
protocols O
remain O
nuclear O
. O

This O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
aimed O
to O
identify O
the O
molecular B_DISEASE_ADJECTIVE[DISEASE]
pathways I_DISEASE_ADJECTIVE[DISEASE]
and O
putative B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
biomarkers I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O
CsA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
to O
- O
SRL B_DISEASE
conversion I_DISEASE
in O
a O
rat B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
model I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
. O

Four B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_NUMBER[MEASURE]
animal I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_NUMBER[MEASURE]
groups I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_NUMBER[MEASURE]
( O
n B_OTHER/B_MEASURE
= O
6 B_MEASURE
) O
were O
tested O
during O
9 B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
weeks I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
: O
control B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
CsA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
SRL B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
conversion B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
CsA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
3 B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
weeks B_TIME[MEASURE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
followed O
by O
SRL B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
for O
6 B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
weeks I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
) O
. O

Classical B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
emergent B_BODY_PART_OR_ORGAN_COMPONENT/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
serum I_BODY_PART_OR_ORGAN_COMPONENT/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
urinary B_BODY_PART_OR_ORGAN_COMPONENT
, O
and O
kidney B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
tissue I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
( O
gene B_GENE
and O
protein B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expression I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
markers B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
were O
assessed O
. O

Renal B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
lesions I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
were O
analyzed O
in O
hematoxylin O
and O
eosin O
, O
periodic O
acid O
- O
Schiff O
, O
and O
Masson O
' O
s O
trichrome O
stains O
. O

SRL O
- O
treated O
rats O
presented O
proteinuria B_DISEASE/B_GENE
and O
NGAL O
( O
serum O
and O
urinary O
) O
as O
the O
best O
markers O
of O
renal B_DISEASE/B_GENE
impairment I_DISEASE/I_GENE
. O

Short O
CsA O
treatment O
presented O
slight O
or O
even O
absent O
kidney B_DISEASE_ADJECTIVE[DISEASE]
lesions I_DISEASE_ADJECTIVE[DISEASE]
and O
TGF O
- O
b O
, O
NF O
- O
kb O
, O
mTOR O
, O
PCNA O
, O
TP53 O
, O
Kim O
- O
1 O
, O
and O
CTGF O
as O
relevant O
gene O
and O
protein O
changes O
. O

prolonged O
CsA O
exposure O
aggravated O
renal B_DISEASE/B_LOCATION
damage I_DISEASE/I_LOCATION
, O
without O
clear O
changes O
on O
the O
traditional O
markers O
, O
but O
with O
changes O
in O
serums O
TGF O
- O
b O
and O
IL O
- O
7 O
, O
TBARs O
clearance O
, O
and O
kidney O
TGF O
- O
b O
and O
mTOR O
. O

conversion O
to O
SRL O
prevented O
CsA O
- O
induced O
renal B_DISEASE_ADJECTIVE[DISEASE]
damage I_DISEASE_ADJECTIVE[DISEASE]
evolution O
( O
absent O
/ O
mild O
grade O
lesions O
) O
, O
while O
NGAL O
( O
serum O
versus O
urine O
) O
seems O
to O
be O
a O
feasible O
biomarker O
of O
CsA O
replacement O
to O
SRL O
. O

Kinin O
B2 O
receptor O
deletion O
and O
blockage O
ameliorates O
cisplatin O
- O
induced O
acute B_DISEASE/B_GENE
renal I_DISEASE/I_GENE
injury I_DISEASE/I_GENE
. O

Cisplatin O
treatment O
has O
been O
adopted O
in O
some O
chemotherapies O
; O
however O
, O
this O
drug O
can O
induce O
acute B_DISEASE
kidney I_DISEASE
injury I_DISEASE
due O
its O
ability O
to O
negatively O
affect O
renal O
function O
, O
augment O
serum O
levels O
of O
creatinine O
and O
urea O
, O
increase O
the O
acute B_DISEASE_ADJECTIVE[DISEASE]
tubular I_DISEASE_ADJECTIVE[DISEASE]
necrosis I_DISEASE_ADJECTIVE[DISEASE]
score O
and O
up O
- O
regulate O
cytokines O
( O
e O
. O
g O
. O
, O
IL O
- O
1b O
and O
TNF O
- O
a O
) O
. O

The O
kinin O
B2 O
receptor O
has O
been O
associated O
with O
the O
inflammation B_DISEASE_ADJECTIVE[DISEASE]/B_BACTERIUM[BIO]
process O
, O
as O
well O
as O
the O
regulation O
of O
cytokine O
expression O
, O
and O
its O
deletion O
resulted O
in O
an O
improvement O
in O
the O
diabetic B_DISEASE_ADJECTIVE[DISEASE]
nephropathy I_DISEASE_ADJECTIVE[DISEASE]
status O
. O

To O
examine O
the O
role O
of O
the O
kinin O
B2 O
receptor O
in O
cisplatin O
- O
induced O
acute B_DISEASE
kidney I_DISEASE
injury I_DISEASE
, O
kinin O
B2 O
receptor O
knockout O
mice O
were O
challenged O
with O
cisplatin O
. O

Additionally O
, O
WT B_PERSON/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
mice I_PERSON/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
were O
treated O
with O
a O
B2 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
receptor I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
antagonist I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
after O
cisplatin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
administration B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O

B2 O
receptor O
- O
deficient O
mice O
were O
less O
sensitive O
to O
this O
drug O
than O
the O
WT O
mice O
, O
as O
shown O
by O
reduced O
weight B_DISEASE/B_GENE
loss I_DISEASE/I_GENE
, O
better O
preservation O
of O
kidney O
function O
, O
down O
regulation O
of O
inflammatory O
cytokines O
and O
less O
acute B_DISEASE
tubular I_DISEASE
necrosis I_DISEASE
. O

Moreover O
, O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
with O
the O
kinin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
B2 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
receptor I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
antagonist I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
effectively O
reduced O
the O
levels B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O
serum B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
creatinine I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O
blood B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
urea I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
after O
cisplatin B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
administration I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
. O

Thus O
, O
our O
data O
suggest O
that O
the O
kinin O
B2 O
receptor O
is O
involved O
in O
cisplatin O
- O
induced O
acute B_DISEASE
kidney I_DISEASE
injury I_DISEASE
by O
mediating O
the O
necrotic B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
process O
and O
the O
expression O
of O
inflammatory O
cytokines O
, O
thus O
resulting O
in O
declined O
renal O
function O
. O

These O
results O
highlight O
the O
kinin O
B2 O
receptor O
antagonist O
treatment O
in O
amelioration O
of O
nephrotoxicity B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
induced O
by O
cisplatin O
therapy O
. O

Safety O
and O
efficacy O
of O
fluocinolone O
acetonide O
intravitreal O
implant O
( O
0 O
. O
59 O
mg O
) O
in O
birdshot B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
retinochoroidopathy I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
. O

purpose O
: O
To O
report O
the O
treatment O
outcomes O
of O
the O
fluocinolone O
acetonide O
intravitreal O
implant O
( O
0 O
. O
59 O
mg O
) O
in O
patients O
with O
birdshot B_DISEASE/B_LOCATION
retinochoroidopathy I_DISEASE/I_LOCATION
whose O
disease O
is O
refractory O
or O
intolerant O
to O
conventional O
immunomodulatory O
therapy O
. O

methods O
: O
A O
retrospective O
case O
series O
involving O
11 O
birdshot B_DISEASE/B_PERSON
retinochoroidopathy I_DISEASE/I_PERSON
patients O
( O
11 O
eyes O
) O
. O

Eleven B_NUMBER[MEASURE]/B_PERSON
patients B_NUMBER[MEASURE]/I_PERSON
( O
11 B_MEASURE/B_ENT
eyes I_MEASURE/I_ENT
) O
underwent O
surgery B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
for O
fluocinolone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
acetonide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
implant B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
( O
0 B_MEASURE
. O
59 B_MEASURE
mg I_MEASURE
) O
. O

Treatment B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
outcomes I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
interest B_PERSON/B_DISEASE
were O
noted O
at O
baseline B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
, O
before O
fluocinolone B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
acetonide I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
implant I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
and O
then O
at O
6 B_MEASURE/B_LOCATION
months I_MEASURE/I_LOCATION
, O
1 B_TIME[MEASURE]/B_LOCATION
year I_TIME[MEASURE]/I_LOCATION
, O
2 B_MEASURE/B_ENT
years I_MEASURE/I_ENT
, O
3 B_MEASURE/B_ENT
years I_MEASURE/I_ENT
, O
and O
beyond O
3 B_TIME[MEASURE]/B_ENT
years I_TIME[MEASURE]/I_ENT
. O

Disease O
activity O
markers O
, O
including O
signs O
of O
ocular O
inflammation B_DISEASE/B_BACTERIUM[BIO]
, O
evidence O
of O
retinal B_DISEASE
vasculitis I_DISEASE
, O
Swedish O
interactive O
threshold O
algorithm O
- O
short O
wavelength O
automated O
perimetry O
Humphrey O
visual O
field O
analysis O
, O
electroretinographic O
parameters O
, O
and O
optical O
coherence O
tomography O
were O
recorded O
. O

Data O
on O
occurrence O
of O
cataract B_DISEASE
and O
raised B_DISEASE
intraocular I_DISEASE
pressure I_DISEASE
were O
collected O
in O
all O
eyes O
. O

Results O
: O
Intraocular O
inflammation B_DISEASE/B_BACTERIUM[BIO]
was O
present O
in O
54 O
. O
5 O
, O
9 O
. O
9 O
, O
11 O
. O
1 O
, O
and O
0 O
% O
of O
patients O
at O
baseline O
, O
6 O
months O
, O
1 O
year O
, O
2 O
years O
, O
3 O
years O
, O
and O
beyond O
3 O
years O
after O
receiving O
the O
implant O
, O
respectively O
. O

Active O
vasculitis B_DISEASE/B_LOCATION
was O
noted O
in O
36 O
. O
3 O
% O
patients O
at O
baseline O
and O
0 O
% O
at O
3 O
years O
of O
follow O
- O
up O
. O

More O
than O
20 O
% O
( O
47 O
. O
61 O
- O
67 O
. O
2 O
% O
) O
reduction O
in O
central O
retinal O
thickness O
was O
noted O
in O
all O
patients O
with O
cystoid B_DISEASE/B_LOCATION
macular I_DISEASE/I_LOCATION
edema I_DISEASE/I_LOCATION
at O
6 O
months O
, O
1 O
year O
, O
2 O
years O
, O
and O
3 O
years O
postimplant O
. O

At O
baseline B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
54 B_MEASURE
. O
5 B_MEASURE
% I_MEASURE
patients I_MEASURE
were O
on O
immunomodulatory B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
agents I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

This O
percentage B_MEASURE/B_PERSON
decreased O
to O
45 B_MEASURE
. O
45 B_MEASURE
, O
44 B_MEASURE
. O
4 B_MEASURE
, O
and O
14 B_MEASURE
. O
28 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
at O
1 B_TIME[MEASURE]/B_PERSON
year I_TIME[MEASURE]/I_PERSON
, O
2 B_SEQUENCE[MEASURE]/B_ENT
years I_SEQUENCE[MEASURE]/I_ENT
, O
and O
3 B_MEASURE/B_LOCATION
years I_MEASURE/I_LOCATION
postimplant I_MEASURE/I_LOCATION
, O
respectively O
. O

adverse O
events O
included O
increased B_DISEASE
intraocular I_DISEASE
pressure I_DISEASE
( O
54 O
. O
5 O
% O
) O
and O
cataract B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
formation O
( O
100 O
% O
) O
. O

conclusion O
: O
The O
data O
suggest O
that O
fluocinolone O
acetonide O
implant O
( O
0 O
. O
59 O
mg O
) O
helps O
to O
control O
inflammation B_DISEASE/B_BACTERIUM[BIO]
in O
otherwise O
treatment O
- O
refractory O
cases O
of O
birdshot B_DISEASE/B_LOCATION
retinochoroidopathy I_DISEASE/I_LOCATION
. O

It O
is O
associated O
with O
significant O
side O
effects O
of O
cataract B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
ocular B_DISEASE
hypertension I_DISEASE
requiring O
treatment O
. O

optimal O
precurarizing O
dose O
of O
rocuronium O
to O
decrease O
fasciculation B_DISEASE
and O
myalgia B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
following O
succinylcholine O
administration O
. O

Background O
: O
Succinylcholine O
commonly O
produces O
frequent O
adverse O
effects O
, O
including O
muscle B_DISEASE
fasciculation I_DISEASE
and O
myalgia B_DISEASE
. O

The O
current O
study O
identified O
the O
optimal O
dose O
of O
rocuronium O
to O
prevent O
succinylcholine O
- O
induced O
fasciculation B_DISEASE
and O
myalgia B_DISEASE
and O
evaluated O
the O
influence O
of O
rocuronium O
on O
the O
speed O
of O
onset O
produced O
by O
succinylcholine O
. O

METHODS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O
This O
randomized B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
double B_MEASURE/B_PERSON
- O
blinded B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
was O
conducted O
in O
100 B_PERSON/B_TIME[MEASURE]
patients I_PERSON/I_TIME[MEASURE]
randomly O
allocated O
into O
five B_LOCATION/B_ORGANIZATION
groups I_LOCATION/I_ORGANIZATION
of O
20 B_NUMBER[MEASURE]
patients I_NUMBER[MEASURE]
each O
. O

patients B_PERSON/B_BIO
were O
randomized O
to O
receive O
0 B_MEASURE/B_LOCATION
. O
02 B_MEASURE
, O
0 B_NUMBER[MEASURE]
. O
03 B_MEASURE
, O
0 B_NUMBER[MEASURE]
. O
04 B_MEASURE
, O
0 B_NUMBER[MEASURE]
. O
05 B_MEASURE
and O
0 B_NUMBER[MEASURE]
. O
06 B_MEASURE
mg I_MEASURE
/ O
kg B_MEASURE
rocuronium I_MEASURE
as O
a O
precurarizing O
dose B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
. O

neuromuscular B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
monitoring I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
after O
each O
precurarizing O
dose B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
was O
recorded O
from O
the O
adductor B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
pollicis I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
muscle I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
using O
acceleromyography B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
with O
train B_LOCATION/B_NUMBER[MEASURE]
- O
of O
- O
four B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stimulation B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
ulnar B_BODY_PART_OR_ORGAN_COMPONENT
nerve I_BODY_PART_OR_ORGAN_COMPONENT
. O

All O
patients O
received O
succinylcholine O
1 O
. O
5 O
mg O
/ O
kg O
at O
2 O
minutes O
after O
the O
precurarization O
, O
and O
were O
assessed O
the O
incidence O
and O
severity O
of O
fasciculations B_DISEASE
, O
while O
myalgia B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
assessed O
at O
24 O
hours O
after O
surgery O
. O

Results O
: O
The O
incidence O
and O
severity O
of O
visible O
muscle B_DISEASE_ADJECTIVE[DISEASE]
fasciculation I_DISEASE_ADJECTIVE[DISEASE]
was O
significantly O
less O
with O
increasing O
the O
amount O
of O
precurarizing O
dose O
of O
rocuronium O
( O
P O
< O
0 O
. O
001 O
) O
. O

Those O
of O
myalgia B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tend O
to O
decrease O
according O
to O
increasing O
the O
amount O
of O
precurarizing O
dose O
of O
rocuronium O
, O
but O
there O
was O
no O
significance O
( O
P O
= O
0 O
. O
072 O
) O
. O

The O
onset B_MEASURE/B_DISEASE
time I_MEASURE/I_DISEASE
of O
succinylcholine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
was O
significantly O
longer B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
with O
increasing O
the O
amount B_MEASURE
of O
precurarizing O
dose B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
of O
rocuronium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
( O
P B_PROTEIN[GENE]/B_LOCATION
< O
0 B_MEASURE
. O
001 B_MEASURE
) O
. O

conclusions O
: O
Precurarization O
with O
0 O
. O
04 O
mg O
/ O
kg O
rocuronium O
was O
the O
optimal O
dose O
considering O
the O
reduction O
in O
the O
incidence O
and O
severity O
of O
fasciculation B_DISEASE
and O
myalgia B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O
acceptable O
onset O
time O
, O
and O
the O
safe O
and O
effective O
precurarization O
. O

absence O
of O
PKC O
- O
alpha O
attenuates O
lithium O
- O
induced O
nephrogenic B_DISEASE
diabetes I_DISEASE
insipidus I_DISEASE
. O

Lithium O
, O
an O
effective O
antipsychotic O
, O
induces O
nephrogenic B_DISEASE
diabetes I_DISEASE
insipidus I_DISEASE
( O
NDI B_DISEASE/B_PROTEIN[GENE]
) O
in O
40 O
% O
of O
patients O
. O

The O
decreased O
capacity B_MEASURE
to O
concentrate O
urine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
likely O
due O
to O
lithium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
acutely O
disrupting O
the O
cAMP B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
pathway I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
and O
chronically O
reducing O
urea B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
transporter B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
UT B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
A1 B_MEASURE/B_GENE
) O
and O
water B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
channel I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
AQP2 B_LOCATION/B_ORGANIZATION
) O
expression B_GENE
in O
the O
inner B_BODY_PART_OR_ORGAN_COMPONENT
medulla I_BODY_PART_OR_ORGAN_COMPONENT
. O

targeting O
an O
alternative O
signaling O
pathway O
, O
such O
as O
PKC O
- O
mediated O
signaling O
, O
may O
be O
an O
effective O
method O
of O
treating O
lithium O
- O
induced O
polyuria B_DISEASE
. O

PKC B_GENE/B_LOCATION
- O
alpha B_DISEASE_ADJECTIVE[DISEASE]/B_GENE_EXPRESSION_ADJECTIVE[GENE]
null B_DISEASE_ADJECTIVE[DISEASE]/I_GENE_EXPRESSION_ADJECTIVE[GENE]
mice B_DISEASE_ADJECTIVE[DISEASE]/I_GENE_EXPRESSION_ADJECTIVE[GENE]
( O
PKCa B_LOCATION/B_PERSON
Ko I_LOCATION/I_PERSON
) O
and O
strain B_DISEASE/B_BIO
- O
matched O
wild B_BIO/B_GENE
type I_BIO/I_GENE
( O
WT B_PROTEIN[GENE]/B_LOCATION
) O
controls B_PERSON/B_BIO
were O
treated O
with O
lithium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
for O
0 B_NUMBER[MEASURE]/B_LOCATION
, O
3 B_NUMBER[MEASURE]
or O
5 B_MEASURE/B_ENT
days I_MEASURE/I_ENT
. O

WT B_BIO/B_PERSON
mice I_BIO/I_PERSON
had O
increased O
urine B_MEASURE/B_DISEASE
output I_MEASURE/I_DISEASE
and O
lowered O
urine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
osmolality I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
after O
3 B_NUMBER[MEASURE]
and O
5 B_TIME[MEASURE]/B_ENT
days I_TIME[MEASURE]/I_ENT
of O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
whereas O
PKCa B_BIO/B_GENE
Ko I_BIO/I_GENE
mice I_BIO/I_GENE
had O
no O
change B_MEASURE
in O
urine B_MEASURE
output I_MEASURE
or O
concentration B_MEASURE
. O

Western B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
blot I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
analysis I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
revealed O
that O
AQP2 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
expression I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O
medullary B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
tissues I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
was O
lowered O
after O
3 B_NUMBER[MEASURE]
and O
5 B_SEQUENCE[MEASURE]/B_ENT
days I_SEQUENCE[MEASURE]/I_ENT
in O
WT B_PROTEIN[GENE]/B_BIO
mice I_PROTEIN[GENE]/I_BIO
; O
however O
, O
AQP2 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
was O
unchanged B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O
PKCa B_PERSON/B_GENE
Ko I_PERSON/I_GENE
. O

Similar B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
results I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
were O
observed O
with O
UT B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
A1 B_MEASURE
expression I_MEASURE
. O

Animals B_BIO/B_PERSON
were O
also O
treated O
with O
lithium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
6 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
weeks I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O

lithium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
treated O
WT B_SPECIES[BIO]/B_PERSON
mice I_SPECIES[BIO]/I_PERSON
had O
19 B_MEASURE
- O
fold B_MEASURE/B_LOCATION
increased O
urine B_MEASURE/B_ENT
output I_MEASURE/I_ENT
whereas O
treated O
PKCa B_BIO/B_GENE
Ko I_BIO/I_GENE
animals I_BIO/I_GENE
had O
a O
4 B_MEASURE
- O
fold B_MEASURE/B_LOCATION
increase I_MEASURE/I_LOCATION
in O
output B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O

AQP2 B_GENE
and O
UT B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O
A1 B_PROTEIN[GENE]
expression I_PROTEIN[GENE]
was O
lowered O
in O
6 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
week I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
lithium I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
- O
treated O
WT B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
animals I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
whereas O
in O
treated O
PKCa B_BIO/B_GENE
Ko I_BIO/I_GENE
mice I_BIO/I_GENE
, O
AQP2 B_GENE/B_DISEASE
was O
only O
reduced O
by O
2 B_NUMBER[MEASURE]
- O
fold B_LOCATION/B_PROTEIN[GENE]
and O
UT B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
A1 B_PROTEIN[GENE]
expression I_PROTEIN[GENE]
was O
unaffected B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
. O

Urinary B_MEASURE/B_LOCATION
sodium B_MEASURE/I_LOCATION
, O
potassium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O
calcium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
were O
elevated O
in O
lithium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
fed O
WT B_BIO/B_GENE
but O
not O
in O
lithium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
fed O
PKCa B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
KO I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mice I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Our O
data O
show O
that O
ablation O
of O
PKCa O
preserves O
AQP2 O
and O
UT O
- O
A1 O
protein O
expression O
and O
localization O
in O
lithium O
- O
induced O
NDI B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
, O
and O
prevents O
the O
development O
of O
the O
severe O
polyuria B_DISEASE_ADJECTIVE[DISEASE]
associated O
with O
lithium O
therapy O
. O

Is O
Dysguesia B_LOCATION/B_PERSON
Going O
to O
be O
a O
Rare O
or O
a O
Common O
Side O
- O
effect O
of O
Amlodipine O
. O

A O
very O
rare O
side O
- O
effect O
of O
amlodipine O
is O
dysguesia B_DISEASE
. O

A O
review B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
literature B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
produced O
only O
one B_NUMBER[MEASURE]
case I_NUMBER[MEASURE]
. O

We O
report O
a O
case O
about O
a O
female O
with O
essential O
hypertension B_DISEASE
on O
drug O
treatment O
with O
amlodipine O
developed O
loss B_DISEASE/B_GENE
of I_DISEASE/I_GENE
taste I_DISEASE/I_GENE
sensation I_DISEASE/I_GENE
. O

condition B_PERSON
moderately O
improved O
on O
stoppage B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
of O
the O
drug B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
for O
25 B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
days I_TIME[MEASURE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

We O
conclude O
that O
amlodipine O
can O
cause O
dysguesia B_DISEASE
. O

Here O
, O
we O
describe O
the O
clinical O
presentation O
and O
review O
the O
relevant O
literature O
on O
amlodipine O
and O
dysguesia B_DISEASE/B_LOCATION
. O

Rhabdomyolysis B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
association O
with O
simvastatin O
and O
dosage O
increment O
in O
clarithromycin O
. O

clarithromycin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
is O
the O
most O
documented B_DISEASE_ADJECTIVE[DISEASE]
cytochrome I_DISEASE_ADJECTIVE[DISEASE]
P450 I_DISEASE_ADJECTIVE[DISEASE]
3A4 I_DISEASE_ADJECTIVE[DISEASE]
( O
CYP3A4 B_GENE
) O
inhibitor B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
to O
cause O
an O
adverse B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
interaction I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
simvastatin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

This O
particular O
case O
is O
of O
interest O
as O
rhabdomyolysis B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
only O
occurred O
after O
an O
increase O
in O
the O
dose O
of O
clarithromycin O
. O

The O
patient O
developed O
raised O
cardiac O
biomarkers O
without O
any O
obvious O
cardiac O
issues O
, O
a O
phenomenon O
that O
has O
been O
linked O
to O
rhabdomyolysis B_DISEASE
previously O
. O

To O
date O
, O
there O
has O
been O
no O
reported O
effect O
of O
rhabdomyolysis B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
the O
structure O
and O
function O
of O
cardiac O
muscle O
. O

Clinicians O
need O
to O
be O
aware O
of O
prescribing O
concomitant O
medications O
that O
increase O
the O
risk O
of O
myopathy B_DISEASE/B_GENE
or O
inhibit O
the O
CYP3A4 O
enzyme O
. O

Our O
case O
suggests O
that O
troponin O
elevation O
could O
be O
associated O
with O
statin O
induced O
rhabdomyolysis B_DISEASE
, O
which O
may O
warrant O
further O
studies O
. O

characterization O
of O
a O
novel O
BCHE O
' O
silent O
' O
allele O
: O
point O
mutation O
( O
p O
. O
Val204Asp O
) O
causes O
loss O
of O
activity O
and O
prolonged O
apnea B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O
suxamethonium O
. O

Butyrylcholinesterase B_DISEASE/B_LOCATION
deficiency I_DISEASE/I_LOCATION
is O
characterized O
by O
prolonged O
apnea B_DISEASE
after O
the O
use O
of O
muscle O
relaxants O
( O
suxamethonium O
or O
mivacurium O
) O
in O
patients O
who O
have O
mutations O
in O
the O
BCHE O
gene O
. O

Here O
, O
we O
report O
a O
case B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
prolonged B_DISEASE
neuromuscular I_DISEASE
block I_DISEASE
after O
administration B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O
suxamethonium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
leading O
to O
the O
discovery B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
of O
a O
novel B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
BCHE B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
variant B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
( O
c B_DISEASE/B_GENE
. O
695T B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
> O
A B_OTHER/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
p B_PROTEIN[GENE]/B_LOCATION
. O
Val204Asp B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
. O

Inhibition B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
studies I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
kinetic B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
molecular B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
dynamics I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
were O
undertaken O
to O
understand O
how O
this O
mutation B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]
disrupts O
the O
catalytic B_LOCATION/B_ENZYME[GENE]
triad B_LOCATION/I_ENZYME[GENE]
and O
determines O
a O
' O
silent B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
' O
phenotype B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O

Low B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
activity I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
patient B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
plasma I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
butyrylcholinesterase I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
with O
butyrylthiocholine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O
BTC B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
and O
benzoylcholine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
values B_MEASURE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
dibucaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O
fluoride B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
numbers I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fit O
with O
heterozygous B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
atypical I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
silent I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
genotype I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

electrophoretic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
plasma B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
BChE I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
of O
the O
proband B_PERSON
and O
his O
mother B_PERSON
showed O
that O
patient B_PERSON/B_BIO
has O
a O
reduced O
amount B_MEASURE/B_LOCATION
of O
tetrameric B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
enzyme I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
plasma B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
and O
that O
minor B_PERSON/B_NUMBER[MEASURE]
fast O
- O
moving O
BChE B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
components I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
: O
monomer B_GENE/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
dimer B_GENE/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
monomer B_GENE
- O
albumin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
conjugate I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
missing O
. O

Kinetic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
showed O
that O
the O
p B_PROTEIN[GENE]/B_LOCATION
. O
Val204Asp B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
p B_PROTEIN[GENE]/B_LOCATION
. O
Asp70Gly B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
- O
p B_PROTEIN[GENE]/B_LOCATION
. O
Ala539Thr B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
BChE I_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
displays O
a O
pure B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
Michaelian I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
behavior I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
with O
BTC B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
as O
the O
substrate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Both O
catalytic B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
parameters I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
km O
= O
265 B_MEASURE/B_LOCATION
um I_MEASURE/I_LOCATION
for O
BTC B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O
two B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
times B_TIME[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
higher B_TIME[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
than O
that O
of O
the O
atypical B_ENZYME[GENE]/B_MEASURE
enzyme I_ENZYME[GENE]/I_MEASURE
, O
and O
a O
low B_MEASURE
Vmax I_MEASURE
are O
consistent B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
with O
the O
absence B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O
activity B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
against O
suxamethonium B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
. O

Molecular B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
dynamic I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
( O
MD B_DISEASE/B_PROTEIN[GENE]
) O
simulations B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
showed O
that O
the O
overall B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
effect I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O
the O
mutation B_DISEASE/B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]
p B_DISEASE/I_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]
. O
Val204Asp B_MEASURE/B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]
is O
disruption B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
hydrogen B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
bonding I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
between O
Gln223 B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
Glu441 B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
leading O
Ser198 B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/B_PERSON
and O
His438 B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
move O
away O
from O
each O
other B_NUMBER[MEASURE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
subsequent B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
disruption B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
the O
catalytic B_LOCATION/B_MEASURE
triad I_LOCATION/I_MEASURE
functionality I_LOCATION/I_MEASURE
regardless O
of O
the O
type B_MEASURE/B_DISEASE
of O
substrate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O

MD B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
also O
showed O
that O
the O
enzyme B_MEASURE
volume I_MEASURE
is O
increased O
, O
suggesting O
a O
pre B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
denaturation B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
state B_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

This O
fits O
with O
the O
reduced O
concentration B_MEASURE
of O
p B_MEASURE/B_PROTEIN[GENE]
. O
Ala204Asp B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
/ O
p B_PROTEIN[GENE]/B_LOCATION
. O
Asp70Gly B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
- O
p B_PROTEIN[GENE]/B_LOCATION
. O
Ala539Thr B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
tetrameric I_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
enzyme I_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
in O
the O
plasma B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
non O
- O
detectable B_DISEASE_ADJECTIVE[DISEASE]
fast I_DISEASE_ADJECTIVE[DISEASE]
moving I_DISEASE_ADJECTIVE[DISEASE]
- O
bands B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
on O
electrophoresis B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
gels I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

delayed O
anemia B_DISEASE
after O
treatment O
with O
injectable O
artesunate O
in O
the O
Democratic O
Republic O
of O
the O
Congo O
: O
a O
manageable O
issue O
. O

cases O
of O
delayed O
hemolytic B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
anemia I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
have O
been O
described O
after O
treatment O
with O
injectable O
artesunate O
, O
the O
current O
World O
Health O
Organization O
( O
WHO O
) O
- O
recommended O
first O
- O
line O
drug O
for O
the O
treatment O
of O
severe O
malaria B_DISEASE
. O

A O
total O
of O
350 O
patients O
( O
215 O
[ O
61 O
. O
4 O
% O
] O
< O
5 O
years O
of O
age O
and O
135 O
[ O
38 O
. O
6 O
% O
] O
> O
5 O
years O
of O
age O
) O
were O
followed O
- O
up O
after O
treatment O
with O
injectable O
artesunate O
for O
severe O
malaria B_DISEASE
in O
hospitals O
and O
health O
centers O
of O
the O
Democratic O
Republic O
of O
the O
Congo O
. O

Complete B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
series I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
hemoglobin B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
( O
Hb B_PROTEIN[GENE]
) O
measurements B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
were O
available B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
201 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
patients I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O

A O
decrease B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O
Hb B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
levels B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
between O
2 B_NUMBER[MEASURE]
and O
5 B_MEASURE
g I_MEASURE
/ O
dL B_TIME[MEASURE]/B_PROTEIN[GENE]
was O
detected O
in O
23 B_NUMBER[MEASURE]
( O
11 B_MEASURE
. O
4 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
patients B_PERSON/B_BIO
during O
the O
follow O
- O
up O
period B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

For O
five B_PERSON/B_TIME[MEASURE]
patients I_PERSON/I_TIME[MEASURE]
, O
Hb B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
levels B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
decreased O
below O
5 B_MEASURE/B_PROTEIN[GENE]
g I_MEASURE/I_PROTEIN[GENE]
/ O
dL B_TIME[MEASURE]/B_PROTEIN[GENE]
during O
at O
least O
one B_NUMBER[MEASURE]/B_PERSON
follow O
- O
up O
visit B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

All O
cases O
of O
delayed O
anemia B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
were O
clinically O
manageable O
and O
resolved O
within O
one O
month O
. O

Regulation O
of O
signal O
transducer O
and O
activator O
of O
transcription O
3 O
and O
apoptotic O
pathways O
by O
betaine O
attenuates O
isoproterenol O
- O
induced O
acute O
myocardial B_DISEASE
injury I_DISEASE
in O
rats O
. O

The O
present O
study O
was O
designed O
to O
investigate O
the O
cardioprotective O
effects O
of O
betaine O
on O
acute O
myocardial B_DISEASE
ischemia I_DISEASE
induced O
experimentally O
in O
rats O
focusing O
on O
regulation O
of O
signal O
transducer O
and O
activator O
of O
transcription O
3 O
( O
STAT3 O
) O
and O
apoptotic O
pathways O
as O
the O
potential O
mechanism O
underlying O
the O
drug O
effect O
. O

Male B_PERSON/B_BIO
Sprague I_PERSON/I_BIO
Dawley I_PERSON/I_BIO
rats I_PERSON/I_BIO
were O
treated O
with O
betaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O
100 B_MEASURE
, O
200 B_MEASURE
, O
and O
400 B_MEASURE
mg I_MEASURE
/ O
kg B_MEASURE
) O
orally O
for O
40 B_TIME[MEASURE]
days I_TIME[MEASURE]
. O

acute O
myocardial B_DISEASE
ischemic I_DISEASE
injury I_DISEASE
was O
induced O
in O
rats O
by O
subcutaneous O
injection O
of O
isoproterenol O
( O
85 O
mg O
/ O
kg O
) O
, O
for O
two O
consecutive O
days O
. O

serum B_TIME[MEASURE]/B_LOCATION
cardiac I_TIME[MEASURE]/I_LOCATION
marker I_TIME[MEASURE]/I_LOCATION
enzyme I_TIME[MEASURE]/I_LOCATION
, O
histopathological B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
variables I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O
expression B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
of O
protein B_GENE
levels I_GENE
were O
analyzed O
. O

Oral O
administration O
of O
betaine O
( O
200 O
and O
400 O
mg O
/ O
kg O
) O
significantly O
reduced O
the O
level O
of O
cardiac O
marker O
enzyme O
in O
the O
serum O
and O
prevented O
left O
ventricular B_DISEASE
remodeling I_DISEASE
. O

Western B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
blot I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
showed O
that O
isoproterenol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
phosphorylation B_GENE_EXPRESSION_ADJECTIVE[GENE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
STAT3 B_GENE
was O
maintained O
or O
further O
enhanced O
by O
betaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
treatment I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
in O
myocardium B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

Furthermore O
, O
betaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O
200 B_MEASURE
and O
400 B_MEASURE
mg I_MEASURE
/ O
kg B_MEASURE
) O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
increased O
the O
ventricular B_MEASURE
expression I_MEASURE
of O
Bcl B_GENE
- O
2 B_NUMBER[MEASURE]
and O
reduced O
the O
level B_MEASURE
of O
Bax B_GENE
, O
therefore O
causing O
a O
significant B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
increase I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
the O
ratio B_MEASURE
of O
Bcl B_GENE
- O
2 B_NUMBER[MEASURE]
/ O
Bax B_GENE/B_PERSON
. O

The O
protective O
role O
of O
betaine O
on O
myocardial B_DISEASE
damage I_DISEASE
was O
further O
confirmed O
by O
histopathological O
examination O
. O

In O
summary O
, O
our O
results O
showed O
that O
betaine O
pretreatment O
attenuated O
isoproterenol O
- O
induced O
acute O
myocardial B_DISEASE
ischemia I_DISEASE
via O
the O
regulation O
of O
STAT3 O
and O
apoptotic O
pathways O
. O

Quetiapine O
- O
induced O
neutropenia B_DISEASE
in O
a O
bipolar B_DISEASE/B_MEASURE
patient O
with O
hepatocellular B_DISEASE
carcinoma I_DISEASE
. O

objective O
: O
Quetiapine O
is O
a O
dibenzothiazepine O
derivative O
, O
similar O
to O
clozapine O
, O
which O
has O
the O
highest O
risk O
of O
causing O
blood B_DISEASE
dyscrasias I_DISEASE
, O
especially O
neutropenia B_DISEASE
. O

There O
are O
some O
case B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
reports I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
about O
this O
side B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
effect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
of O
quetiapine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
but O
possible B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
risk I_PERSON/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factors I_PERSON/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
seldom O
discussed O
and O
identified O
. O

A O
case O
of O
a O
patient O
with O
hepatocellular B_DISEASE/B_LOCATION
carcinoma I_DISEASE/I_LOCATION
that O
developed O
neutropenia B_DISEASE
after O
treatment O
with O
quetiapine O
is O
described O
here O
. O

Case O
Report O
: O
A O
62 O
- O
year O
- O
old O
Taiwanese O
widow O
with O
bipolar B_DISEASE
disorder I_DISEASE
was O
diagnosed O
with O
hepatocellular B_DISEASE
carcinoma I_DISEASE
at O
age O
60 O
. O

She O
developed O
leucopenia B_DISEASE
after O
being O
treated O
with O
quetiapine O
. O

After O
quetiapine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
discontinued O
, O
her O
white B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
blood I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
cell I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
count I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
returned O
to O
normal B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

conclusions O
: O
Although O
neutropenia B_DISEASE
is O
not O
a O
common O
side O
effect O
of O
quetiapine O
, O
physicians O
should O
be O
cautious O
about O
its O
presentation O
and O
associated O
risk O
factors O
. O

Hepatic B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
dysfunction I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
may O
be O
one O
of O
the O
possible O
risk O
factors O
, O
and O
concomitant O
fever B_DISEASE
may O
be O
a O
diagnostic O
marker O
for O
adverse O
reaction O
to O
quetiapine O
. O

lateral O
antebrachial O
cutaneous O
neuropathy B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
after O
steroid O
injection O
at O
lateral O
epicondyle O
. O

Background O
AND O
objectives O
: O
This O
report O
aimed O
to O
present O
a O
case O
of O
lateral O
antebrachial O
cutaneous O
neuropathy B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O
LACNP O
) O
that O
occurred O
after O
a O
steroid O
injection O
in O
the O
lateral O
epicondyle O
to O
treat O
lateral B_DISEASE/B_LOCATION
epicondylitis I_DISEASE/I_LOCATION
in O
a O
40 O
- O
year O
- O
old O
woman O
. O

Material O
AND O
Method O
: O
A O
40 O
- O
year O
- O
old O
woman O
presented O
with O
decreased O
sensation O
and O
paresthesia B_DISEASE/B_MEASURE
over O
her O
right O
lateral O
forearm O
; O
the O
paresthesia B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
had O
occurred O
after O
a O
steroid O
injection O
in O
the O
right O
lateral O
epicondyle O
3 O
months O
before O
. O

Her O
sensation O
of O
light O
touch O
and O
pain B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O
diminished O
over O
the O
lateral O
side O
of O
the O
right O
forearm O
and O
wrist O
area O
. O

RESULTS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
The O
sensory B_MEASURE
action I_MEASURE
potential I_MEASURE
amplitude I_MEASURE
of O
the O
right B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
lateral I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
antebrachial I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
cutaneous I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
nerve I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
( O
LACN B_DISEASE/B_PROTEIN[GENE]
) O
( O
6 B_MEASURE
. O
2 B_MEASURE
UV I_MEASURE
) O
was O
lower B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
than O
that O
of O
the O
left B_BODY_PART_OR_ORGAN_COMPONENT
( O
13 B_MEASURE
. O
1 B_MEASURE/B_PERSON
UV I_MEASURE/I_PERSON
) O
. O

The O
difference B_MEASURE
of O
amplitude B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O
both O
sides B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
was O
significant B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
because O
there O
was O
more B_MEASURE
than O
a O
50 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
reduction I_MEASURE/I_PERSON
. O

She O
was O
diagnosed O
with O
right B_DISEASE/B_LOCATION
LACNP I_DISEASE/I_LOCATION
( O
mainly O
axonal B_DISEASE_ADJECTIVE[DISEASE]
involvement I_DISEASE_ADJECTIVE[DISEASE]
) O
on O
the O
basis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
the O
clinical B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
manifestation I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
the O
electrodiagnostic B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
findings I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Her O
symptoms B_DISEASE
improved O
through O
physical B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
therapy I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
but O
persisted O
to O
some O
degree B_TIME[MEASURE]/B_LOCATION
. O

conclusion O
: O
This O
report O
describes O
the O
case O
of O
a O
woman O
with O
LACNP O
that O
developed O
after O
a O
steroid O
injection O
for O
the O
treatment O
of O
lateral B_DISEASE/B_GENE
epicondylitis I_DISEASE/I_GENE
. O

An O
electrodiagnostic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
including O
a O
nerve B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
conduction I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O
the O
LACN B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
, O
was O
helpful B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
to O
diagnose O
right B_DISEASE
LACNP I_DISEASE
and O
to O
find O
the O
passage B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
of O
the O
LACN B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
on O
the O
lateral B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
epicondyle I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Curcumin O
prevents O
maleate O
- O
induced O
nephrotoxicity B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
relation O
to O
hemodynamic O
alterations O
, O
oxidative O
stress O
, O
mitochondrial O
oxygen O
consumption O
and O
activity O
of O
respiratory O
complex O
I O
. O

The O
potential O
protective O
effect O
of O
the O
dietary O
antioxidant O
curcumin O
( O
120 O
mg O
/ O
kg O
/ O
day O
for O
6 O
days O
) O
against O
the O
renal B_DISEASE
injury I_DISEASE
induced O
by O
maleate O
was O
evaluated O
. O

Tubular O
proteinuria B_DISEASE
and O
oxidative O
stress O
were O
induced O
by O
a O
single O
injection O
of O
maleate O
( O
400 O
mg O
/ O
kg O
) O
in O
rats O
. O

Maleate O
- O
induced O
renal B_DISEASE
injury I_DISEASE
included O
increase O
in O
renal O
vascular O
resistance O
and O
in O
the O
urinary O
excretion O
of O
total O
protein O
, O
glucose O
, O
sodium O
, O
neutrophil O
gelatinase O
- O
associated O
lipocalin O
( O
NGAL O
) O
and O
N O
- O
acetyl O
b O
- O
D O
- O
glucosaminidase O
( O
NAG O
) O
, O
upregulation O
of O
kidney B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
injury B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
molecule O
( O
Kim O
) O
- O
1 O
, O
decrease O
in O
renal O
blood O
flow O
and O
claudin O
- O
2 O
expression O
besides O
of O
necrosis B_DISEASE/B_GENE
and O
apoptosis O
of O
tubular O
cells O
on O
24 O
h O
. O

Oxidative B_DISEASE
stress I_DISEASE
was O
determined O
by O
measuring O
the O
oxidation B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
lipids B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O
proteins B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O
diminution B_DISEASE_ADJECTIVE[DISEASE]
in O
renal B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
Nrf2 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
levels I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Studies B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
were O
also O
conducted O
in O
renal B_DISEASE_ADJECTIVE[DISEASE]/B_PROTEIN[GENE]
epithelial B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
LLC B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
- O
PK1 B_NUMBER[MEASURE]/B_BIO
cells I_NUMBER[MEASURE]/I_BIO
and O
in O
mitochondria B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
isolated O
from O
kidneys B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
of O
all O
the O
experimental B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
groups I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
. O

Maleate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
induced O
cell B_DISEASE_ADJECTIVE[DISEASE]
damage I_DISEASE_ADJECTIVE[DISEASE]
and O
reactive B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
oxygen I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
species I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
ROS B_GENE
) O
production B_ENT/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
LLC B_DISEASE/B_PROTEIN[GENE]
- O
PK1 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
cells B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
in O
culture B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

In O
addition B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
maleate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
treatment I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
reduced O
oxygen B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
consumption B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
ADP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
stimulated O
mitochondria B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O
diminished O
respiratory B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
control I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
index I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
when O
using O
malate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
glutamate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O
substrate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
activities B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
both O
complex B_LOCATION/B_PERSON
I O
and O
aconitase B_PROTEIN[GENE]/B_TIME[MEASURE]
were O
also O
diminished O
. O

All O
the O
above O
- O
described O
alterations B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
were O
prevented O
by O
curcumin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

It O
is O
concluded O
that O
curcumin O
is O
able O
to O
attenuate O
in O
vivo O
maleate O
- O
induced O
nephropathy B_DISEASE
and O
in O
vitro O
cell O
damage O
. O

The O
in O
vivo B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
protection I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
was O
associated O
to O
the O
prevention B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
oxidative B_DISEASE_ADJECTIVE[DISEASE]
stress I_DISEASE_ADJECTIVE[DISEASE]
and O
preservation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
mitochondrial B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
oxygen B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
consumption B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
activity B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
respiratory B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
complex B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
I O
, O
and O
the O
in O
vitro B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
protection I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
was O
associated O
to O
the O
prevention B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
ROS B_DISEASE/B_GENE
production I_DISEASE/I_GENE
. O

Anticonvulsant O
actions O
of O
Mk O
- O
801 O
on O
the O
lithium O
- O
pilocarpine O
model O
of O
status B_DISEASE
epilepticus I_DISEASE
in O
rats O
. O

Mk O
- O
801 O
, O
a O
noncompetitive O
N O
- O
methyl O
- O
D O
- O
aspartate O
( O
NMDA O
) O
receptor O
antagonist O
, O
was O
tested O
for O
anticonvulsant O
effects O
in O
rats O
using O
two O
seizure B_DISEASE
models O
, O
coadministration O
of O
lithium O
and O
pilocarpine O
and O
administration O
of O
a O
high O
dose O
of O
pilocarpine O
alone O
. O

Three B_NUMBER[MEASURE]/B_PERSON
major I_NUMBER[MEASURE]/I_PERSON
results I_NUMBER[MEASURE]/I_PERSON
are O
reported O
. O

First O
, O
pretreatment O
with O
Mk O
- O
801 O
produced O
an O
effective O
and O
dose O
- O
dependent O
anticonvulsant O
action O
with O
the O
lithium O
- O
pilocarpine O
model O
but O
not O
with O
rats O
treated O
with O
pilocarpine O
alone O
, O
suggesting O
that O
different O
biochemical O
mechanisms O
control O
seizures B_DISEASE
in O
these O
two O
models O
. O

Second O
, O
the O
anticonvulsant O
effect O
of O
Mk O
- O
801 O
in O
the O
lithium O
- O
pilocarpine O
model O
only O
occurred O
after O
initial O
periods O
of O
seizure B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activity O
. O

This O
observation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
suggested O
to O
be O
an O
in O
vivo B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
demonstration I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
the O
conclusion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
derived O
from O
in O
vitro B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
experiments I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
that O
Mk B_PROTEIN[GENE]/B_LOCATION
- O
801 B_MEASURE
binding I_MEASURE
requires O
agonist B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
induced B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
opening B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
the O
channel B_LOCATION/B_ORGANIZATION
sites I_LOCATION/I_ORGANIZATION
of O
the O
NMDA B_PROTEIN[GENE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
receptor B_PROTEIN[GENE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

Third O
, O
although O
it O
is O
relatively O
easy O
to O
block O
seizures B_DISEASE
induced O
by O
lithium O
and O
pilocarpine O
by O
administration O
of O
anticonvulsants O
prior O
to O
pilocarpine O
, O
it O
is O
more O
difficult O
to O
terminate O
ongoing O
status B_DISEASE
epilepticus I_DISEASE
and O
block O
the O
lethality O
of O
the O
seizures B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Administration O
of O
Mk O
- O
801 O
30 O
or O
60 O
min O
after O
pilocarpine O
, O
i O
. O
e O
. O
, O
during O
status B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
epilepticus I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
gradually O
reduced O
electrical O
and O
behavioral O
seizure B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
activity O
and O
greatly O
enhanced O
the O
survival O
rate O
. O

These O
results O
suggest O
that O
activation O
of O
NMDA O
receptors O
plays O
an O
important O
role O
in O
status B_DISEASE
epilepticus I_DISEASE
and O
brain B_DISEASE
damage I_DISEASE
in O
the O
lithium O
- O
pilocarpine O
model O
. O

This O
was O
further O
supported O
by O
results O
showing O
that O
nonconvulsive O
doses O
of O
NMDA O
and O
pilocarpine O
were O
synergistic O
, O
resulting O
in O
status B_DISEASE
epilepticus I_DISEASE
and O
subsequent O
mortality O
. O

continuous O
infusion O
tobramycin O
combined O
with O
carbenicillin O
for O
infections B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
cancer B_DISEASE/B_PERSON
patients O
. O

The O
cure O
rate O
of O
infections B_DISEASE
in O
cancer B_DISEASE/B_PERSON
patients O
is O
adversely O
affected O
by O
neutropenia B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
( O
less O
than O
1 O
, O
000 O
/ O
mm3 O
) O
. O

In O
particular O
, O
patients O
with O
severe O
neutropenia B_DISEASE
( O
less O
than O
100 O
/ O
mm3 O
) O
have O
shown O
a O
poor O
response O
to O
antibiotics O
. O

To O
overcome O
the O
adverse O
effects O
of O
neutropenia B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O
tobramycin O
was O
given O
by O
continuous O
infusion O
and O
combined O
with O
intermittent O
carbenicillin O
. O

Tobramycin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
was O
given O
to O
a O
total B_MEASURE
daily I_MEASURE
dose I_MEASURE
of O
300 B_MEASURE
mg I_MEASURE
/ O
m2 B_MEASURE
and O
carbenicillin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
was O
given O
at O
a O
dose B_MEASURE
of O
5 B_NUMBER[MEASURE]/B_PERSON
GM I_NUMBER[MEASURE]/I_PERSON
every O
four B_TIME[MEASURE]/B_ENT
hours I_TIME[MEASURE]/I_ENT
. O

There O
were O
125 O
infectious O
episodes O
in O
116 O
cancer B_DISEASE
patients O
receiving O
myelosuppressive O
chemotherapy O
. O

The O
overall B_MEASURE/B_PERSON
cure I_MEASURE/I_PERSON
rate I_MEASURE/I_PERSON
was O
70 B_MEASURE/B_LOCATION
% I_MEASURE/I_LOCATION
. O

Pneumonia B_DISEASE
was O
the O
most O
common O
infection B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
61 O
% O
of O
59 O
episodes O
were O
cured O
. O

Gram O
- O
negative O
bacilli O
were O
the O
most O
common O
causative O
organisms O
and O
69 O
% O
of O
these O
infections B_DISEASE/B_BIO
were O
cured O
. O

The O
most O
common O
pathogen O
was O
Klebsiella O
pneumoniae B_BACTERIUM[BIO]/B_DISEASE
and O
this O
, O
together O
with O
Escherichia O
coli O
and O
Pseudomonas O
aeruginosa O
, O
accounted O
for O
74 O
% O
of O
all O
gram B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
- B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
negative B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
bacillary B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
infections B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
. O

Response O
was O
not O
influenced O
by O
the O
initial O
neutrophil O
count O
, O
with O
a O
62 O
% O
cure O
rate O
for O
39 O
episodes O
associated O
with O
severe O
neutropenia B_DISEASE
. O

However O
, O
failure B_DISEASE_ADJECTIVE[DISEASE]
of O
the O
neutrophil B_MEASURE
count I_MEASURE
to O
increase O
during O
therapy B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
adversely O
affected O
response B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O

Azotemia B_DISEASE
was O
the O
major O
side O
effect O
recognized O
, O
and O
it O
occurred O
in O
11 O
% O
of O
episodes O
. O

Major O
azotemia B_DISEASE
( O
serum O
creatinine O
greater O
than O
2 O
. O
5 O
mg O
/ O
DL O
or O
BUN O
greater O
than O
50 O
mg O
/ O
DL O
) O
occurred O
in O
only O
2 O
% O
. O

Azotemia B_DISEASE_ADJECTIVE[DISEASE]
was O
not O
related O
to O
duration O
of O
therapy O
or O
serum O
tobramycin O
concentration O
. O

This O
antibiotic O
regimen O
showed O
both O
therapeutic O
efficacy O
and O
acceptable O
renal B_DISEASE_ADJECTIVE[DISEASE]
toxicity I_DISEASE_ADJECTIVE[DISEASE]
for O
these O
patients O
. O

incidence O
of O
solid O
tumours B_DISEASE
among O
pesticide O
applicators O
exposed O
to O
the O
organophosphate O
insecticide O
diazinon O
in O
the O
Agricultural O
Health O
Study O
: O
an O
updated O
analysis O
. O

objective O
: O
Diazinon O
, O
a O
common O
organophosphate O
insecticide O
with O
genotoxic O
properties O
, O
was O
previously O
associated O
with O
lung B_DISEASE
cancer I_DISEASE
in O
the O
Agricultural O
Health O
Study O
( O
AHS O
) O
cohort O
, O
but O
few O
other O
epidemiological O
studies O
have O
examined O
diazinon O
- O
associated O
cancer B_DISEASE
risk O
. O

We O
used O
updated O
diazinon O
exposure O
and O
cancer B_DISEASE/B_MEASURE
incidence O
information O
to O
evaluate O
solid O
tumour B_DISEASE
risk O
in O
the O
AHS O
. O

methods O
: O
Male O
pesticide O
applicators O
in O
Iowa O
and O
North O
Carolina O
reported O
lifetime O
diazinon O
use O
at O
enrolment O
( O
1993 O
- O
1997 O
) O
and O
follow O
- O
up O
( O
1998 O
- O
2005 O
) O
; O
cancer B_DISEASE/B_MEASURE
incidence O
was O
assessed O
through O
2010 O
( O
North O
Carolina O
) O
/ O
2011 O
( O
Iowa O
) O
. O

Among O
applicators O
with O
usage O
information O
sufficient O
to O
evaluate O
exposure O
- O
response O
patterns O
, O
we O
used O
Poisson O
regression O
to O
estimate O
adjusted O
rate O
ratios O
( O
RRs O
) O
and O
95 O
% O
CI O
for O
cancer B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sites O
with O
> O
10 O
exposed O
cases O
for O
both O
lifetime O
( O
Lt O
) O
exposure O
days O
and O
intensity O
- O
weighted O
( O
IW O
) O
lifetime O
exposure O
days O
( O
accounting O
for O
factors O
impacting O
exposure O
) O
. O

Results O
: O
We O
observed O
elevated O
lung B_DISEASE/B_MEASURE
cancer I_DISEASE/I_MEASURE
risks O
( O
N O
= O
283 O
) O
among O
applicators O
with O
the O
greatest O
number O
of O
Lt O
( O
RR O
= O
1 O
. O
60 O
; O
95 O
% O
CI O
1 O
. O
11 O
to O
2 O
. O
31 O
; O
Ptrend O
= O
0 O
. O
02 O
) O
and O
IW O
days O
of O
diazinon O
use O
( O
RR O
= O
1 O
. O
41 O
; O
95 O
% O
CI O
0 O
. O
98 O
to O
2 O
. O
04 O
; O
Ptrend O
= O
0 O
. O
08 O
) O
. O

Kidney B_DISEASE/B_MEASURE
cancer I_DISEASE/I_MEASURE
( O
N O
= O
94 O
) O
risks O
were O
non O
- O
significantly O
elevated O
( O
RRLT O
days O
= O
1 O
. O
77 O
; O
95 O
% O
CI O
0 O
. O
90 O
to O
3 O
. O
51 O
; O
Ptrend O
= O
0 O
. O
09 O
; O
RRIW O
days O
1 O
. O
37 O
; O
95 O
% O
CI O
0 O
. O
64 O
to O
2 O
. O
92 O
; O
Ptrend O
= O
0 O
. O
50 O
) O
, O
as O
were O
risks O
for O
aggressive O
prostate B_DISEASE
cancer I_DISEASE
( O
N O
= O
656 O
) O
. O

conclusions O
: O
Our O
updated O
evaluation O
of O
diazinon O
provides O
additional O
evidence O
of O
an O
association O
with O
lung B_DISEASE
cancer I_DISEASE
risk O
. O

newly O
identified O
links O
to O
kidney B_DISEASE/B_LOCATION
cancer I_DISEASE/I_LOCATION
and O
associations O
with O
aggressive O
prostate B_DISEASE
cancer I_DISEASE
require O
further O
evaluation O
. O

associations O
of O
Ozone O
and O
PM2 O
. O
5 O
concentrations O
With O
Parkinson B_DISEASE/B_LOCATION
' I_DISEASE/I_LOCATION
s I_DISEASE/I_LOCATION
Disease I_DISEASE/I_LOCATION
Among O
participants O
in O
the O
Agricultural O
Health O
Study O
. O

objective O
: O
This O
study O
describes O
associations O
of O
ozone O
and O
fine O
particulate O
matter O
with O
Parkinson B_DISEASE
' I_DISEASE
s I_DISEASE
disease I_DISEASE
observed O
among O
farmers O
in O
North O
Carolina O
and O
Iowa O
. O

methods O
: O
We O
used O
logistic O
regression O
to O
determine O
the O
associations O
of O
these O
pollutants O
with O
self O
- O
reported O
, O
doctor O
- O
diagnosed O
Parkinson B_DISEASE
' I_DISEASE
s I_DISEASE
disease I_DISEASE
. O

Daily O
predicted O
pollutant B_MEASURE/B_LOCATION
concentrations B_MEASURE/I_LOCATION
were O
used O
to O
derive O
surrogates B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
long B_TIME[MEASURE]/B_LOCATION
- O
term B_TIME[MEASURE]/B_LOCATION
exposure I_TIME[MEASURE]/I_LOCATION
and O
link O
them O
to O
study O
participants B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
' I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
geocoded I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
addresses I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O

Results O
: O
We O
observed O
positive O
associations O
of O
Parkinson B_DISEASE
' I_DISEASE
s I_DISEASE
disease I_DISEASE
with O
ozone O
( O
odds O
ratio O
= O
1 O
. O
39 O
; O
95 O
% O
CI O
: O
0 O
. O
98 O
to O
1 O
. O
98 O
) O
and O
fine O
particulate O
matter O
( O
odds O
ratio O
= O
1 O
. O
34 O
; O
95 O
% O
CI O
: O
0 O
. O
93 O
to O
1 O
. O
93 O
) O
in O
North O
Carolina O
but O
not O
in O
Iowa O
. O

conclusions O
: O
The O
plausibility O
of O
an O
effect O
of O
ambient O
concentrations O
of O
these O
pollutants O
on O
Parkinson B_DISEASE
' I_DISEASE
s I_DISEASE
disease I_DISEASE
risk O
is O
supported O
by O
experimental O
data O
demonstrating O
damage O
to O
dopaminergic O
neurons O
at O
relevant O
concentrations O
. O

Additional B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
studies I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
are O
needed O
to O
address O
uncertainties B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
related O
to O
confounding O
and O
to O
examine O
temporal B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
aspects I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
associations B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
we O
observed O
. O

Low O
functional O
programming O
of O
renal O
AT2R O
mediates O
the O
developmental O
origin O
of O
glomerulosclerosis B_DISEASE
in O
adult O
offspring O
induced O
by O
prenatal O
caffeine O
exposure O
. O

UNASSIGNED O
: O
Our O
previous O
study O
has O
indicated O
that O
prenatal O
caffeine O
exposure O
( O
PCE O
) O
could O
induce O
intrauterine B_DISEASE/B_ORGANISM_FUNCTION
growth I_DISEASE/I_ORGANISM_FUNCTION
retardation I_DISEASE/I_ORGANISM_FUNCTION
( O
IUGR B_DISEASE/B_GENE
) O
of O
offspring O
. O

Recent O
research O
suggested O
that O
IUGR B_DISEASE
is O
a O
risk O
factor O
for O
glomerulosclerosis B_DISEASE
. O

However O
, O
whether O
PCE O
could O
induce O
glomerulosclerosis B_DISEASE/B_GENE
and O
its O
underlying O
mechanisms O
remain O
unknown O
. O

This O
study O
aimed O
to O
demonstrate O
the O
induction O
to O
glomerulosclerosis B_DISEASE/B_ORGANISM_FUNCTION
in O
adult O
offspring O
by O
PCE O
and O
its O
intrauterine O
programming O
mechanisms O
. O

A O
rat O
model O
of O
IUGR B_DISEASE
was O
established O
by O
PCE O
, O
male O
fetuses O
and O
adult O
offspring O
at O
the O
age O
of O
postnatal O
week O
24 O
were O
euthanized O
. O

The O
results O
revealed O
that O
the O
adult O
offspring O
kidneys O
in O
the O
PCE O
group O
exhibited O
glomerulosclerosis B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
as O
well O
as O
interstitial B_DISEASE
fibrosis I_DISEASE
, O
accompanied O
by O
elevated O
levels O
of O
serum O
creatinine O
and O
urine O
protein O
. O

Renal B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
angiotensin I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
II I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptor I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
type I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
2 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
AT2R B_GENE/B_LOCATION
) O
gene B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expression I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
adult B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
offspring B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
was O
reduced O
by O
PCE B_DISEASE
, O
whereas O
the O
renal B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
angiotensin I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
II I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptor I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
type I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1a I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
AT1aR B_PROTEIN[GENE]/B_LOCATION
) O
/ O
AT2R B_GENE
expression I_GENE
ratio I_GENE
was O
increased O
. O

The O
fetal B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
kidneys B_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
in O
the O
PCE B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
group I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
displayed O
an O
enlarged O
Bowman B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
' I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
s I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
space I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
and O
a O
shrunken B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
glomerular I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tuft I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
accompanied O
by O
a O
reduced O
cortex B_MEASURE/B_DISEASE
width I_MEASURE/I_DISEASE
and O
an O
increase B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
the O
nephrogenic B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
zone I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
/ O
cortical B_MEASURE/B_LOCATION
zone B_MEASURE/I_LOCATION
ratio B_MEASURE/I_LOCATION
. O

observation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O
electronic B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
microscope I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
revealed O
structural B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
damage I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
podocytes B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
; O
the O
reduced B_DISEASE_ADJECTIVE[DISEASE]/B_GENE_EXPRESSION_ADJECTIVE[GENE]
expression B_DISEASE_ADJECTIVE[DISEASE]/I_GENE_EXPRESSION_ADJECTIVE[GENE]
level B_DISEASE_ADJECTIVE[DISEASE]/I_GENE_EXPRESSION_ADJECTIVE[GENE]
of O
podocyte B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
marker I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
genes I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
nephrin B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and O
podocin B_GENE/B_BACTERIUM[BIO]
, O
was O
also O
detected O
by O
q O
- O
PCR B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O

Moreover O
, O
AT2R B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O
protein B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
expressions I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O
fetal B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
kidneys I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
were O
inhibited O
by O
PCE B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O
associated O
with O
the O
repression B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
of O
the O
gene B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
expression B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
of O
glial B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
- O
cell B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
- O
line B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- O
derived O
neurotrophic B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factor I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
GDNF B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
/ O
tyrosine B_GENE/B_DISEASE
kinase I_GENE/I_DISEASE
receptor I_GENE/I_DISEASE
( O
c B_GENE/B_DISEASE
- O
Ret B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
signaling O
pathway B_LOCATION/B_BIO
. O

These O
results O
demonstrated O
that O
PCE O
could O
induce O
dysplasia B_DISEASE/B_GENE
of I_DISEASE/I_GENE
fetal I_DISEASE/I_GENE
kidneys I_DISEASE/I_GENE
as O
well O
as O
glomerulosclerosis B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
of O
adult O
offspring O
, O
and O
the O
low O
functional O
programming O
of O
renal O
AT2R O
might O
mediate O
the O
developmental O
origin O
of O
adult O
glomerulosclerosis B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
. O

1 O
, O
3 O
- O
Butadiene O
, O
CML B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O
the O
t O
( O
9 O
: O
22 O
) O
translocation O
: O
A O
reality O
check O
. O

UNASSIGNED O
: O
Epidemiological O
studies O
of O
1 O
, O
3 O
- O
butadiene O
have O
suggest O
that O
exposures O
to O
humans O
are O
associated O
with O
chronic B_DISEASE
myeloid I_DISEASE
leukemia I_DISEASE
( O
CML B_DISEASE/B_LOCATION
) O
. O

CML B_DISEASE/B_LOCATION
has O
a O
well O
- O
documented O
association O
with O
ionizing O
radiation O
, O
but O
reports O
of O
associations O
with O
chemical O
exposures O
have O
been O
questioned O
. O

Ionizing O
radiation O
is O
capable O
of O
inducing O
the O
requisite O
CML B_DISEASE
- O
associated O
t O
( O
9 O
: O
22 O
) O
translocation O
( O
Philadelphia B_LOCATION/B_ORGANIZATION
chromosome I_LOCATION/I_ORGANIZATION
) O
in O
appropriate O
cells O
in O
vitro O
but O
, O
thus O
far O
, O
chemicals O
have O
not O
shown O
this O
capacity O
. O

We O
have O
proposed O
that O
1 B_NUMBER[MEASURE]
, O
3 B_NUMBER[MEASURE]
- O
butadiene B_DISEASE/B_PROTEIN[GENE]
metabolites B_DISEASE/I_PROTEIN[GENE]
be O
so O
tested O
as O
a O
reality B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
check I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
on O
the O
epidemiological B_LOCATION/B_PERSON
reports I_LOCATION/I_PERSON
. O

In O
order B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
conduct O
reliable B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
testing I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
this O
regard B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
it O
is O
essential B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
a O
positive B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
control I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
for O
induction B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
be O
available B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

We O
have O
used O
ionizing O
radiation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
to O
develop O
such O
a O
control B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
. O

Results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
described O
here O
demonstrate O
that O
this O
agent B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
does O
in O
fact B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
induce O
pathogenic B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
t O
( O
9 B_MEASURE
: O
22 B_MEASURE
) O
translocations B_DISEASE/B_GENE
in O
a O
human B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
myeloid I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
cell I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
line I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
in O
vitro B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
but O
does O
so O
at O
low B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
frequencies B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
. O

conditions B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
will O
be O
required O
for O
studies B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
of O
1 B_NUMBER[MEASURE]
, O
3 B_NUMBER[MEASURE]
- O
butadiene B_MEASURE/B_PROTEIN[GENE]
are O
discussed O
. O

Cancer B_DISEASE
incidence O
and O
metolachlor O
use O
in O
the O
Agricultural O
Health O
Study O
: O
An O
update O
. O

UNASSIGNED B_MEASURE/B_ORGANIZATION
: O
Metolachlor B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
, O
a O
widely O
used O
herbicide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
is O
classified O
as O
a O
Group B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
C I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
carcinogen I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
by O
the O
U B_OTHER/B_LOCATION
. O
S B_OTHER/B_DISEASE
. O

Environmental O
Protection O
Agency O
based O
on O
increased O
liver B_DISEASE/B_ORGANISM_FUNCTION
neoplasms I_DISEASE/I_ORGANISM_FUNCTION
in O
female O
rats O
. O

epidemiologic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
studies I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
health B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
effects I_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
of O
metolachlor B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
have O
been O
limited B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
agricultural B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
Health I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
Study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O
AHS B_LOCATION/B_ORGANIZATION
) O
is O
a O
prospective B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
cohort I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
including O
licensed O
private B_PERSON/B_LOCATION
and O
commercial B_ORGANIZATION/B_PERSON
pesticide B_ORGANIZATION/I_PERSON
applicators B_ORGANIZATION/I_PERSON
in O
Iowa B_LOCATION
and O
North B_LOCATION
Carolina I_LOCATION
enrolled O
1993 B_MEASURE
- O
1997 B_MEASURE
. O

We O
evaluated O
cancer B_DISEASE
incidence O
through O
2010 O
/ O
2011 O
( O
NC O
/ O
IA O
) O
for O
49 O
, O
616 O
applicators O
, O
53 O
% O
of O
whom O
reported O
ever O
using O
metolachlor O
. O

We O
used O
Poisson O
regression O
to O
evaluate O
relations O
between O
two O
metrics O
of O
metolachlor O
use O
( O
lifetime O
days O
, O
intensity O
- O
weighted O
lifetime O
days O
) O
and O
cancer B_DISEASE
incidence O
. O

We O
saw O
no O
association O
between O
metolachlor O
use O
and O
incidence O
of O
all O
cancers B_DISEASE
combined O
( O
n O
= O
5 O
, O
701 O
with O
a O
5 O
- O
year O
lag O
) O
or O
most O
site O
- O
specific O
cancers B_DISEASE
. O

For O
liver B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
cancer B_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
, O
in O
analyses O
restricted O
to O
exposed O
workers O
, O
elevations O
observed O
at O
higher O
categories O
of O
use O
were O
not O
statistically O
significant O
. O

However O
, O
trends B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
for O
both O
lifetime B_TIME[MEASURE]
and O
intensity B_MEASURE/B_DISEASE
- O
weighted O
lifetime B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
days B_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
metolachor B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
use I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
positive B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
statistically O
significant B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
with O
an O
unexposed B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
reference I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
group I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

A O
similar O
pattern O
was O
observed O
for O
follicular B_DISEASE
cell I_DISEASE
lymphoma I_DISEASE
, O
but O
no O
other O
lymphoma B_DISEASE
subtypes O
. O

An O
earlier O
suggestion O
of O
increased O
lung B_DISEASE/B_GENE
cancer I_DISEASE/I_GENE
risk O
at O
high O
levels O
of O
metolachlor O
use O
in O
this O
cohort O
was O
not O
confirmed O
in O
this O
update O
. O

This O
suggestion O
of O
an O
association O
between O
metolachlor O
and O
liver B_DISEASE
cancer I_DISEASE
among O
pesticide O
applicators O
is O
a O
novel O
finding O
and O
echoes O
observation O
of O
increased O
liver B_DISEASE_ADJECTIVE[DISEASE]
neoplasms I_DISEASE_ADJECTIVE[DISEASE]
in O
some O
animal O
studies O
. O

However O
, O
our O
findings O
for O
both O
liver B_DISEASE
cancer I_DISEASE
and O
follicular O
cell O
lymphoma B_DISEASE
warrant O
follow O
- O
up O
to O
better O
differentiate O
effects O
of O
metolachlor O
use O
from O
other O
factors O
. O

mechanisms B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
underlying O
latent B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Disease I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Risk I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Associated O
with O
Early B_MEASURE/B_LOCATION
- O
Life B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
arsenic I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
Exposure I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
: O
Current B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
Research I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
trends I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
and O
Scientific B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
gaps I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Background B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
millions B_MEASURE/B_PERSON
of O
individuals B_PERSON
worldwide O
, O
particularly O
those O
living O
in O
rural B_LOCATION
and O
developing O
areas B_LOCATION/B_ORGANIZATION
, O
are O
exposed O
to O
harmful B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
levels I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
inorganic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
arsenic I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
iAs B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O
in O
their O
drinking B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
water I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
. O

inorganic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
As O
exposure B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
during O
key B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
developmental I_TIME[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
periods I_TIME[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
is O
associated O
with O
a O
variety B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
adverse B_DISEASE_ADJECTIVE[DISEASE]
health I_DISEASE_ADJECTIVE[DISEASE]
effects I_DISEASE_ADJECTIVE[DISEASE]
including O
those O
that O
are O
evident B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
adulthood B_PERSON
. O

There O
is O
considerable O
interest O
in O
identifying O
the O
molecular O
mechanisms O
that O
relate O
early O
- O
life O
iAs O
exposure O
to O
the O
development O
of O
these O
latent O
diseases O
, O
particularly O
in O
relationship O
to O
cancer B_DISEASE
. O

objectives O
: O
This O
work O
summarizes O
research O
on O
the O
molecular O
mechanisms O
that O
underlie O
the O
increased O
risk O
of O
cancer B_DISEASE
development O
in O
adulthood O
that O
is O
associated O
with O
early O
- O
life O
iAs O
exposure O
. O

discussion O
: O
Epigenetic O
reprogramming O
that O
imparts O
functional O
changes O
in O
gene O
expression O
, O
the O
development O
of O
cancer B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
stem O
cells O
, O
and O
immunomodulation O
are O
plausible O
underlying O
mechanisms O
by O
which O
early O
- O
life O
iAs O
exposure O
elicits O
latent O
carcinogenic O
effects O
. O

conclusions O
: O
Evidence O
is O
mounting O
that O
relates O
early O
- O
life O
iAs O
exposure O
and O
cancer B_DISEASE/B_PERSON
development O
later O
in O
life O
. O

Future B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
research I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
should O
include O
animal B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
studies I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
that O
address O
mechanistic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
hypotheses B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
and O
studies B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
human B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
populations I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
that O
integrate O
early B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
- O
life B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
exposure I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
, O
molecular B_DISEASE_ADJECTIVE[DISEASE]
alterations I_DISEASE_ADJECTIVE[DISEASE]
, O
and O
latent B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
disease I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
outcomes I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O

Nifedipine O
induced O
bradycardia B_DISEASE
in O
a O
patient O
with O
autonomic B_DISEASE/B_LOCATION
neuropathy I_DISEASE/I_LOCATION
. O

An O
80 O
year O
old O
diabetic B_PERSON/B_LOCATION
male O
with O
evidence O
of O
peripheral B_DISEASE
and I_DISEASE
autonomic I_DISEASE
neuropathy I_DISEASE
was O
admitted O
with O
chest B_DISEASE
pain I_DISEASE
. O

He O
was O
found O
to O
have O
atrial B_DISEASE
flutter I_DISEASE
at O
a O
ventricular O
rate O
of O
70 O
/ O
min O
which O
slowed O
down O
to O
30 O
- O
40 O
/ O
min O
when O
nifedipine O
( O
60 O
mg O
) O
in O
3 O
divided O
doses O
, O
during O
which O
he O
was O
paced O
at O
a O
rate O
of O
70 O
/ O
min O
. O

This O
is O
inconsistent O
with O
the O
well O
- O
established O
finding O
that O
nifedipine O
induces O
tachycardia B_DISEASE
in O
normally O
innervated O
hearts O
. O

However O
, O
in O
hearts O
deprived O
of O
compensatory O
sympathetic O
drive O
, O
it O
may O
lead O
to O
bradycardia B_DISEASE
. O

The O
effect B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O
haloperidol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
cocaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O
amphetamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
intoxication I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
effectiveness B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
haloperidol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pretreatment I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
preventing O
the O
toxic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
effects B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
of O
high B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
doses I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
of O
amphetamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
cocaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
studied O
in O
rats B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

In O
this O
model B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
toxic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
effects B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
were O
induced O
by O
intraperitoneal B_BODY_PART_OR_ORGAN_COMPONENT/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
i O
. O
p B_MEASURE/B_LOCATION
. O
) O
injection B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
amphetamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
75 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mg I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
kg B_MEASURE
( O
100 B_MEASURE
% I_MEASURE
death I_MEASURE
rate I_MEASURE
) O
or O
cocaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
70 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
mg I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
/ O
kg B_MEASURE
( O
82 B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
% I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
death I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
rate I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
) O
. O

Haloperidol O
failed O
to O
prevent O
amphetamine O
- O
induced O
seizures B_DISEASE
, O
but O
did O
lower O
the O
mortality O
rate O
at O
most O
doses O
tested O
. O

Haloperidol O
decreased O
the O
incidence O
of O
cocaine O
- O
induced O
seizures B_DISEASE
at O
the O
two O
highest O
doses O
, O
but O
the O
lowering O
of O
the O
mortality O
rate O
did O
not O
reach O
statistical O
significance O
at O
any O
dose O
. O

These O
data O
suggest O
a O
protective O
role O
for O
the O
central O
dopamine O
blocker O
haloperidol O
against O
death O
from O
high O
- O
dose O
amphetamine O
exposure O
without O
reducing O
the O
incidence O
of O
seizures B_DISEASE
. O

In O
contrast O
, O
haloperidol O
demonstrated O
an O
ability O
to O
reduce O
cocaine O
- O
induced O
seizures B_DISEASE
without O
significantly O
reducing O
mortality O
. O

Autoradiographic O
evidence O
of O
estrogen O
binding O
sites O
in O
nuclei O
of O
diethylstilbesterol O
induced O
hamster O
renal B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
carcinomas I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O

Estrogen O
binding O
sites O
were O
demonstrated O
by O
autoradiography O
in O
one O
transplantable O
and O
five O
primary O
diethylstilbesterol O
induced O
renal B_DISEASE/B_LOCATION
carcinomas I_DISEASE/I_LOCATION
in O
three O
hamsters O
. O

Radiolabelling O
, O
following O
the O
in O
vivo O
injection O
of O
3H O
- O
17 O
beta O
estradiol O
, O
was O
increased O
only O
over O
the O
nuclei O
of O
tumor B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
cells O
; O
stereologic O
analysis O
revealed O
a O
4 O
. O
5 O
- O
to O
6 O
. O
7 O
- O
times O
higher O
concentration O
of O
reduced O
silver O
grains O
over O
nuclei O
than O
cytoplasm O
of O
these O
cells O
. O

Despite O
rapid B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tubular B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
excretion B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
estradiol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
which O
peaked O
in O
less B_MEASURE
than O
1 B_MEASURE
h O
, O
the O
normal B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cells I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
did O
not O
appear O
to O
bind O
the O
ligand B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

This O
is O
the O
first O
published O
report O
documenting O
the O
preferential O
in O
vivo O
binding O
of O
estrogen O
to O
nuclei O
of O
cells O
in O
estrogen O
induced O
hamster O
renal B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
carcinomas B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
. O

Bradycardia B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
due O
to O
biperiden O
. O

In O
a O
38 O
- O
year O
- O
old O
male O
patient O
suffering O
from O
a O
severe O
postzosteric B_DISEASE
trigeminal I_DISEASE
neuralgia I_DISEASE
, O
intravenous O
application O
of O
10 O
mg O
biperiden O
lactate O
led O
to O
a O
long O
- O
lasting O
paradoxical O
reaction O
characterized O
by O
considerable O
bradycardia B_DISEASE
, O
dysarthria B_DISEASE
, O
and O
dysphagia B_DISEASE
. O

The O
heart B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
rate B_MEASURE/I_BODY_PART_OR_ORGAN_COMPONENT
was O
back O
to O
normal B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
within O
12 B_TIME[MEASURE]/B_ENT
hours I_TIME[MEASURE]/I_ENT
upon O
administration B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O
orciprenaline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
under O
cardiac B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
monitoring I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_PERSON
in O
an O
intensive B_PERSON/B_LOCATION
care I_PERSON/I_LOCATION
unit I_PERSON/I_LOCATION
. O

Bradycardia B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
induced O
by O
biperiden O
is O
attributed O
to O
the O
speed O
of O
injection O
and O
to O
a O
dose O
- O
related O
dual O
effect O
of O
atropine O
- O
like O
drugs O
on O
muscarine O
receptors O
. O

deliberate O
hypotension B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
induced O
by O
labetalol O
with O
halothane O
, O
enflurane O
or O
isoflurane O
for O
middle O
- O
ear O
surgery O
. O

The O
feasibility O
of O
using O
labetalol O
, O
an O
alpha O
- O
and O
beta O
- O
adrenergic O
blocking O
agent O
, O
as O
a O
hypotensive B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
agent O
in O
combination O
with O
inhalation O
anaesthetics O
( O
halothane O
, O
enflurane O
or O
isoflurane O
) O
was O
studied O
in O
23 O
adult O
patients O
undergoing O
middle O
- O
ear O
surgery O
. O

The O
mean B_DISEASE/B_GENE
arterial I_DISEASE/I_GENE
pressure I_DISEASE/I_GENE
was O
decreased O
from O
86 B_MEASURE
+ I_MEASURE
/ O
- O
5 B_MEASURE
( O
s B_DISEASE/B_MEASURE
. O
e O
. O
mean B_MEASURE
) O
mmHg B_MEASURE/B_LOCATION
to O
52 B_MEASURE
+ I_MEASURE
/ O
- O
1 B_MEASURE
mmHg I_MEASURE
( O
11 B_MEASURE
. O
5 B_MEASURE
+ I_MEASURE
/ O
- O
0 B_NUMBER[MEASURE]
. O
7 B_MEASURE
to O
6 B_MEASURE
. O
9 B_MEASURE
+ I_MEASURE
/ O
- O
0 B_MEASURE
. O
1 B_MEASURE
kPa I_MEASURE
) O
for O
98 B_MEASURE
+ I_MEASURE
/ O
- O
10 B_TIME[MEASURE]/B_PERSON
min I_TIME[MEASURE]/I_PERSON
in O
the O
halothane B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
H B_OTHER/B_PROTEIN[GENE]
) O
group B_ORGANIZATION/B_LOCATION
, O
from O
79 B_MEASURE
+ I_MEASURE
/ O
- O
5 B_MEASURE
to O
53 B_MEASURE
+ I_MEASURE
/ O
- O
1 B_MEASURE
mmHg I_MEASURE
( O
10 B_MEASURE
. O
5 B_MEASURE
+ I_MEASURE
/ O
- O
0 B_NUMBER[MEASURE]
. O
7 B_MEASURE
to O
7 B_MEASURE
. O
1 B_MEASURE/B_LOCATION
+ I_MEASURE/I_LOCATION
/ O
- O
0 B_MEASURE
. O
1 B_MEASURE
kPa I_MEASURE
) O
for O
129 B_MEASURE
+ I_MEASURE
/ O
- O
11 B_TIME[MEASURE]/B_PERSON
min I_TIME[MEASURE]/I_PERSON
in O
the O
enflurane B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
E B_OTHER/B_PROTEIN[GENE]
) O
group B_ORGANIZATION/B_LOCATION
, O
and O
from O
80 B_MEASURE
+ I_MEASURE
/ O
- O
4 B_MEASURE
to O
49 B_MEASURE
+ I_MEASURE
/ O
- O
1 B_MEASURE
mmHg I_MEASURE
( O
10 B_MEASURE
. O
7 B_MEASURE
+ I_MEASURE
/ O
- O
0 B_NUMBER[MEASURE]
. O
5 B_MEASURE
to O
6 B_MEASURE
. O
5 B_MEASURE
+ I_MEASURE
/ O
- O
0 B_MEASURE
. O
1 B_MEASURE
kPa I_MEASURE
) O
for O
135 B_MEASURE
+ I_MEASURE
/ O
- O
15 B_TIME[MEASURE]/B_PERSON
min I_TIME[MEASURE]/I_PERSON
in O
the O
isoflurane B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
( O
I B_OTHER/B_MEASURE
) O
group B_ORGANIZATION/B_MEASURE
. O

The O
mean O
H O
concentration O
during O
hypotension B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
the O
inspiratory O
gas O
was O
0 O
. O
7 O
+ O
/ O
- O
0 O
. O
1 O
vol O
% O
, O
the O
mean O
E O
concentration O
1 O
. O
6 O
+ O
/ O
- O
0 O
. O
2 O
vol O
% O
, O
and O
the O
mean O
I O
concentration O
1 O
. O
0 O
+ O
/ O
- O
0 O
. O
1 O
vol O
% O
. O

In O
addition B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
, O
the O
patients B_PERSON/B_LOCATION
received O
fentanyl B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
d B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
tubocurarine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
initial B_MEASURE
dose I_MEASURE
of O
labetalol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
for O
lowering O
blood B_DISEASE/B_GENE
pressure I_DISEASE/I_GENE
was O
similar B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O
0 B_MEASURE/B_LOCATION
. O
52 B_MEASURE
- O
0 B_MEASURE
. O
59 B_MEASURE
mg I_MEASURE
/ O
kg B_MEASURE
, O
in O
all O
the O
groups B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
. O

During O
hypotension B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
, O
the O
heart O
rate O
was O
stable O
without O
tachy B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
- B_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
or B_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
bradycardia B_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

The O
operating O
conditions O
regarding O
bleeding B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
were O
estimated O
in O
a O
double O
- O
blind O
manner O
, O
and O
did O
not O
differ O
significantly O
between O
the O
groups O
. O

During O
hypotension B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
the O
serum O
creatinine O
concentration O
rose O
significantly O
in O
all O
groups O
from O
the O
values O
before O
hypotension B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
returned O
postoperatively O
to O
the O
initial O
level O
in O
the O
other O
groups O
, O
except O
the O
isoflurane O
group O
. O

After O
hypotension B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
there O
was O
no O
rebound O
phenomenon O
in O
either O
blood O
pressure O
or O
heart O
rate O
. O

These O
results O
indicate O
that O
labetalol O
induces O
easily O
adjustable O
hypotension B_DISEASE
without O
compensatory O
tachycardia B_DISEASE
and O
rebound O
hypertension B_DISEASE
. O

Convulsion B_DISEASE_ADJECTIVE[DISEASE]
following O
intravenous O
fluorescein O
angiography O
. O

Tonic B_DISEASE/B_PERSON
- I_DISEASE/I_PERSON
clonic I_DISEASE/I_PERSON
seizures I_DISEASE/I_PERSON
followed O
intravenous O
fluorescein O
injection O
for O
fundus O
angiography O
in O
a O
47 O
- O
year O
- O
old O
male O
. O

Despite O
precautions B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
this O
adverse B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reaction I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
recurred O
on O
re B_LOCATION/B_DISEASE
- O
exposure B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
to O
intravenous B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fluorescein I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

pharmacology B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
ACC B_DISEASE/B_PROTEIN[GENE]
- O
9653 B_NUMBER[MEASURE]
( O
phenytoin B_MEASURE
prodrug I_MEASURE
) O
. O

ACC B_ORGANIZATION/B_LOCATION
- O
9653 B_NUMBER[MEASURE]
, O
the O
disodium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
phosphate I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ester I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
3 B_NUMBER[MEASURE]
- O
hydroxymethyl B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
5 B_NUMBER[MEASURE]
, O
5 B_NUMBER[MEASURE]
- O
diphenylhydantoin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
is O
a O
prodrug B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
phenytoin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
advantageous B_DISEASE_ADJECTIVE[DISEASE]
physicochemical I_DISEASE_ADJECTIVE[DISEASE]
properties I_DISEASE_ADJECTIVE[DISEASE]
. O

ACC B_ORGANIZATION/B_LOCATION
- O
9653 B_NUMBER[MEASURE]
is O
rapidly O
converted O
enzymatically O
to O
phenytoin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
vivo B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

ACC O
- O
9653 O
and O
phenytoin O
sodium O
have O
equivalent O
anticonvulsant O
activity O
against O
seizures B_DISEASE/B_LOCATION
induced O
by O
maximal O
electroshock O
( O
MES O
) O
in O
mice O
following O
i O
. O
p O
. O
, O
oral O
, O
or O
i O
. O
v O
. O
administration O
. O

The O
ED50 B_MEASURE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
doses B_MEASURE/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
16 B_MEASURE
mg I_MEASURE
/ O
kg B_MEASURE
for O
i O
. O
v B_PROTEIN[GENE]/B_LOCATION
. O
ACC B_DISEASE/B_PROTEIN[GENE]
- O
9653 B_NUMBER[MEASURE]/B_LOCATION
and O
8 B_MEASURE
mg I_MEASURE
/ O
kg B_MEASURE
for O
i O
. O
v B_PROTEIN[GENE]/B_LOCATION
. O
phenytoin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
sodium I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

ACC O
- O
9653 O
and O
phenytoin O
sodium O
have O
similar O
antiarrhythmic O
activity O
against O
ouabain O
- O
induced O
ventricular B_DISEASE
tachycardia I_DISEASE
in O
anesthetized O
dogs O
. O

The O
total O
doses O
of O
ACC O
- O
9653 O
or O
phenytoin O
sodium O
necessary O
to O
convert O
the O
arrhythmia B_DISEASE
to O
a O
normal O
sinus O
rhythm O
were O
24 O
+ O
/ O
- O
6 O
and O
14 O
+ O
/ O
- O
3 O
mg O
/ O
kg O
, O
respectively O
. O

Only O
phenytoin O
sodium O
displayed O
in O
vitro O
antiarrhythmic O
activity O
against O
strophanthidin O
- O
induced O
arrhythmias B_DISEASE
in O
Guinea O
pig O
right O
atria O
. O

In O
anesthetized B_MEASURE
dogs I_MEASURE
, O
a O
high B_MEASURE
dose I_MEASURE
of O
ACC B_ORGANIZATION/B_LOCATION
- O
9653 B_NUMBER[MEASURE]
( O
31 B_MEASURE
mg I_MEASURE
/ O
kg B_MEASURE
) O
was O
infused O
over O
15 B_NUMBER[MEASURE]
, O
20 B_MEASURE
, O
and O
30 B_TIME[MEASURE]
min I_TIME[MEASURE]
and O
the O
responses B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
compared O
to O
an O
equimolar B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
dose I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
of O
phenytoin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sodium I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
21 B_MEASURE
mg I_MEASURE
/ O
kg B_MEASURE
) O
. O

The O
ACC B_ORGANIZATION/B_LOCATION
- O
9653 B_NUMBER[MEASURE]/B_LOCATION
and O
phenytoin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sodium I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treatments I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
produced O
similar B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
marked O
reductions B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
in O
diastolic B_MEASURE/B_DISEASE
blood B_MEASURE/I_DISEASE
pressure B_MEASURE/I_DISEASE
and O
contractile B_MEASURE/B_ORGANIZATION
force I_MEASURE/I_ORGANIZATION
( O
LVdP B_PROTEIN[GENE]/B_LOCATION
/ O
dt B_LOCATION
) O
. O

The O
maximum B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
effects I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
of O
each O
treatment B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
occurred O
at O
the O
time B_MEASURE/B_LOCATION
of O
maximum B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
phenytoin I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
sodium I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
levels I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
. O

acute O
toxicity B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
studies O
of O
ACC O
- O
9653 O
and O
phenytoin O
sodium O
were O
carried O
out O
in O
mice O
, O
rats O
, O
rabbits O
, O
and O
dogs O
by O
i O
. O
v O
. O
, O
i O
. O
m O
. O
, O
and O
i O
. O
p O
. O
routes O
of O
administration O
. O

The O
systemic B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
toxic B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
signs B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
both O
agents B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
were O
similar B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
occurred O
at O
approximately O
equivalent B_MEASURE/B_LOCATION
doses I_MEASURE/I_LOCATION
. O

importantly O
, O
the O
local B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
irritation B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
ACC B_ORGANIZATION/B_LOCATION
- O
9653 B_NUMBER[MEASURE]
was O
markedly O
less B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
than O
phenytoin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
sodium I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
following O
i O
. O
m B_DISEASE/B_LOCATION
. O
administration B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O
( O
abstract B_MEASURE/B_ORGANIZATION
TRUNCATED I_MEASURE/I_ORGANIZATION
AT O
250 B_LOCATION/B_ENT
Words I_LOCATION/I_ENT
) O
. O

Tachyphylaxis O
to O
systemic O
but O
not O
to O
airway O
responses O
during O
prolonged O
therapy O
with O
high O
dose O
inhaled O
salbutamol O
in O
asthmatics B_DISEASE/B_PERSON
. O

High O
doses O
of O
inhaled O
salbutamol O
produce O
substantial O
improvements O
in O
airway O
response O
in O
patients O
with O
asthma B_DISEASE/B_LOCATION
, O
and O
are O
associated O
with O
dose O
- O
dependent O
systemic O
beta O
- O
adrenoceptor O
responses O
. O

The O
purpose B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O
the O
present B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
was O
to O
investigate O
whether O
tachyphylaxis B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
occurs O
during O
prolonged O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O
high B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
dose B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
inhaled O
salbutamol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Twelve O
asthmatic B_DISEASE/B_PERSON
patients O
( O
FEV1 O
, O
81 O
+ O
/ O
- O
4 O
% O
predicted O
) O
, O
requiring O
only O
occasional O
inhaled O
beta O
- O
agonists O
as O
their O
sole O
therapy O
, O
were O
given O
a O
14 O
- O
day O
treatment O
with O
high O
dose O
inhaled O
salbutamol O
( O
HDS O
) O
, O
4 O
, O
000 O
micrograms O
daily O
, O
low O
dose O
inhaled O
salbutamol O
( O
LDS O
) O
, O
800 O
micrograms O
daily O
, O
or O
placebo O
( O
Pi O
) O
by O
metered O
- O
dose O
inhaler O
in O
a O
double O
- O
blind O
, O
randomized O
crossover O
design O
. O

During O
the O
14 B_NUMBER[MEASURE]
- O
day B_TIME[MEASURE]/B_LOCATION
run I_TIME[MEASURE]/I_LOCATION
- O
in B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
during O
washout B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
periods I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
, O
inhaled O
beta B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
agonists B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
were O
withheld O
and O
ipratropium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
bromide I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
substituted O
for O
rescue B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
purposes I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

At O
the O
end O
of O
each O
14 O
- O
day O
treatment O
, O
a O
dose O
- O
response O
curve O
( O
DRC O
) O
was O
performed O
, O
and O
airway O
( O
FEV1 O
, O
FEF25 O
- O
75 O
) O
chronotropic O
( O
HR O
) O
, O
tremor B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
, O
and O
metabolic O
( O
K O
, O
Glu O
) O
responses O
were O
measured O
at O
each O
step O
( O
from O
100 O
to O
4 O
, O
000 O
micrograms O
) O
. O

Treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
had O
no O
significant B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effect B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
baseline B_DISEASE
values I_DISEASE
. O

There O
were O
dose B_MEASURE
- O
dependent B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
increases I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
FEV1 B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
FEF25 B_LOCATION
- O
75 B_MEASURE
( O
p B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
less B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
than O
0 B_MEASURE/B_LOCATION
. O
001 B_MEASURE
) O
, O
and O
pretreatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
with O
HDS B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
did O
not O
displace O
the O
DRC B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
to O
the O
right B_BODY_PART_OR_ORGAN_COMPONENT/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

DRC B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
for O
HR B_LOCATION/B_PERSON
( O
p B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
less B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
than O
0 B_NUMBER[MEASURE]
. O
001 B_MEASURE
) O
, O
K B_OTHER/B_LOCATION
( O
p B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
less B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
than O
0 B_NUMBER[MEASURE]
. O
001 B_MEASURE
) O
, O
and O
Glu B_LOCATION/B_PERSON
( O
p B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
less B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
than O
0 B_MEASURE
. O
005 B_MEASURE
) O
were O
attenuated O
after O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O
HDS B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
compared O
with O
PI B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

There O
were O
also O
differences B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O
HDS B_LOCATION/B_ORGANIZATION
and O
LDS B_DISEASE/B_PROTEIN[GENE]
for O
HR B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O
p B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
less B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
than O
0 B_MEASURE
. O
001 B_MEASURE
) O
and O
Glu B_LOCATION/B_PROTEIN[GENE]
( O
p B_MEASURE
less I_MEASURE
than O
0 B_MEASURE
. O
05 B_MEASURE
) O
responses B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O

frequency O
and O
severity O
of O
subjective O
adverse O
effects O
were O
also O
reduced O
after O
HDS O
: O
tremor B_DISEASE
( O
p O
less O
than O
0 O
. O
001 O
) O
, O
palpitations B_DISEASE
( O
p O
less O
than O
0 O
. O
001 O
) O
. O
( O
abstract O
TRUNCATED O
AT O
250 O
Words O
) O
. O

Phenytoin O
induced O
fatal O
hepatic B_DISEASE
injury I_DISEASE
. O

A O
61 O
year O
old O
female O
developed O
fatal O
hepatic B_DISEASE
failure I_DISEASE
after O
phenytoin O
administration O
. O

A O
typical O
multisystem O
clinical O
pattern O
precedes O
the O
manifestations O
of O
hepatic B_DISEASE/B_LOCATION
injury I_DISEASE/I_LOCATION
. O

The O
hematologic O
, O
biochemical O
and O
pathologic O
features O
indicate O
a O
mixed O
hepatocellular B_DISEASE
damage I_DISEASE
due O
to O
drug B_DISEASE
hypersensitivity I_DISEASE
. O

In O
a O
patient B_PERSON
receiving I_PERSON
phenytoin I_PERSON
who O
presents O
a O
viral B_DISEASE
- O
like B_DISEASE
illness I_DISEASE
, O
early B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
recognition I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
and O
discontinuation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O
the O
drug B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
mandatory B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
lethal B_DISEASE/B_PERSON
pertussis I_DISEASE/I_PERSON
vaccine I_DISEASE/I_PERSON
reaction I_DISEASE/I_PERSON
with O
histamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
H1 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
antagonists I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

We O
studied O
mortality O
after O
pertussis B_DISEASE
immunization O
in O
the O
mouse O
. O

Without O
treatment O
, O
73 O
of O
92 O
animals O
( O
80 O
% O
) O
died O
after O
injection O
of O
bovine O
serum O
albumin O
( O
BSA O
) O
on O
day O
+ O
7 O
of O
pertussis B_DISEASE
immunization O
. O

After O
pretreatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
with O
3 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
mg I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
cyproheptadine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
2 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mg I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mianserin I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
or O
2 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
mg I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
chlorpheniramine I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
, O
only O
5 B_NUMBER[MEASURE]
of O
105 B_NUMBER[MEASURE]/B_PERSON
animals I_NUMBER[MEASURE]/I_PERSON
( O
5 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
died O
after O
receiving O
BSA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
day B_TIME[MEASURE]/B_LOCATION
+ O
7 B_TIME[MEASURE]
( O
p B_MEASURE
less I_MEASURE
than O
0 B_MEASURE
. O
001 B_MEASURE
) O
. O

blockade O
of O
histamine O
H1 O
receptors O
may O
reduce O
mortality O
in O
pertussis B_DISEASE/B_BIO
immunization O
- O
induced O
encephalopathy B_DISEASE
in O
mice O
. O

Support O
for O
adrenaline O
- O
hypertension B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hypothesis O
: O
18 O
hour O
pressor O
effect O
after O
6 O
hours O
adrenaline O
infusion O
. O

In O
a O
double B_MEASURE
blind I_MEASURE
, O
crossover B_MEASURE
study I_MEASURE
6 I_MEASURE
h O
infusions B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
adrenaline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
15 B_MEASURE/B_PERSON
ng I_MEASURE/I_PERSON
/ O
kg B_MEASURE
/ O
min B_TIME[MEASURE]/B_PERSON
; O
1 B_MEASURE/B_PERSON
ng I_MEASURE/I_PERSON
= O
5 B_MEASURE
. O
458 B_MEASURE/B_LOCATION
pmol I_MEASURE/I_LOCATION
) O
, O
noradrenaline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
30 B_MEASURE/B_PERSON
ng I_MEASURE/I_PERSON
/ O
kg B_MEASURE/B_PERSON
/ O
min B_PERSON/B_TIME[MEASURE]
; O
1 B_MEASURE/B_PERSON
ng I_MEASURE/I_PERSON
= O
5 B_MEASURE
. O
911 B_MEASURE/B_PERSON
pmol I_MEASURE/I_PERSON
) O
, O
and O
a O
5 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
% I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
dextrose I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
solution I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O
5 B_MEASURE
. O
4 B_MEASURE
ml I_MEASURE
/ O
h B_OTHER/B_TIME[MEASURE]
) O
, O
were O
given O
to O
ten B_PERSON/B_BIO
healthy I_PERSON/I_BIO
volunteers I_PERSON/I_BIO
in O
random B_NUMBER[MEASURE]/B_ENT
order I_NUMBER[MEASURE]/I_ENT
2 I_NUMBER[MEASURE]/I_ENT
weeks I_NUMBER[MEASURE]/I_ENT
apart O
. O

By O
means B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
intra B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
arterial B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BODY_PART_OR_ORGAN_COMPONENT
ambulatory I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_BODY_PART_OR_ORGAN_COMPONENT
monitoring I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_BODY_PART_OR_ORGAN_COMPONENT
the O
haemodynamic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
effects B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
were O
followed O
for O
18 B_MEASURE
h O
after O
the O
infusions B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
stopped O
. O

adrenaline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
but O
not O
noradrenaline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
caused O
a O
delayed B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
and O
protracted B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
pressor I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
effect I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
. O

Over O
the O
total B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
postinfusion I_MEASURE/I_BODY_PART_OR_ORGAN_COMPONENT
period I_MEASURE/I_BODY_PART_OR_ORGAN_COMPONENT
systolic I_MEASURE/I_BODY_PART_OR_ORGAN_COMPONENT
and O
diastolic B_MEASURE/B_DISEASE
arterial B_MEASURE/I_DISEASE
pressure B_MEASURE/I_DISEASE
were O
6 B_MEASURE
( O
SEM B_MEASURE
2 I_MEASURE
) O
% B_MEASURE/B_OTHER
and O
7 B_MEASURE
( O
2 B_MEASURE
) O
% B_MEASURE/B_OTHER
, O
respectively O
, O
higher B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
than O
after O
dextrose B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
infusion I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
( O
ANOVA B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O
p B_MEASURE
less I_MEASURE
than O
0 B_MEASURE/B_LOCATION
. O
001 B_MEASURE
) O
. O

Thus O
, O
' O
stress B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
' O
levels B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
of O
adrenaline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O
230 B_MEASURE/B_ORGANIZATION
pg I_MEASURE/I_ORGANIZATION
/ O
ml B_MEASURE/B_PERSON
) O
for O
6 B_MEASURE
h O
cause O
a O
delayed B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
and O
protracted B_DISEASE_ADJECTIVE[DISEASE]
pressor I_DISEASE_ADJECTIVE[DISEASE]
effect I_DISEASE_ADJECTIVE[DISEASE]
. O

These O
findings O
are O
strong O
support O
for O
the O
adrenaline O
- O
hypertension B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hypothesis O
in O
man O
. O

Effect O
of O
alkylxanthines O
on O
gentamicin O
- O
induced O
acute B_DISEASE
renal I_DISEASE
failure I_DISEASE
in O
the O
rat O
. O

Adenosine O
antagonists O
have O
been O
previously O
shown O
to O
be O
of O
benefit O
in O
some O
ischaemic B_DISEASE_ADJECTIVE[DISEASE]
and O
nephrotoxic B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
models O
of O
acute B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
renal I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
failure I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O
ARF B_DISEASE/B_GENE
) O
. O

In O
the O
present O
study O
, O
the O
effects O
of O
three O
alkylxanthines O
with O
different O
potencies O
as O
adenosine O
antagonists O
8 O
- O
phenyltheophylline O
, O
theophylline O
and O
enprofylline O
, O
were O
examined O
in O
rats O
developing O
acute B_DISEASE
renal I_DISEASE
failure I_DISEASE
after O
4 O
daily O
injections O
of O
gentamicin O
( O
200 O
mg O
kg O
- O
1 O
) O
. O

Renal O
function O
was O
assessed O
by O
biochemical O
( O
plasma O
urea O
and O
creatinine O
) O
, O
functional O
( O
urine O
analysis O
and O
[ O
3H O
] O
inulin O
and O
[ O
14C O
] O
p O
- O
aminohippuric O
acid O
clearances O
) O
and O
morphological O
( O
degree O
of O
necrosis B_DISEASE
) O
indices O
. O

The O
various B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
drug I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
treatments I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
produced O
improvements B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
some O
, O
but O
not O
all O
, O
measurements B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
renal B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
function I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

However O
, O
any O
improvement B_DISEASE_ADJECTIVE[DISEASE]
produced O
by O
drug B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treatment I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
largely O
a O
result B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
a O
beneficial B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effect I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
exerted O
by O
its O
vehicle B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
polyethylene B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
glycol I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O
NaOH B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
. O

The O
lack O
of O
any O
consistent O
protective O
effect O
noted O
with O
the O
alkylxanthines O
tested O
in O
the O
present O
study O
indicates O
that O
adenosine O
plays O
little O
, O
if O
any O
, O
pathophysiological O
role O
in O
gentamicin O
- O
induced O
ARF B_DISEASE
. O

Adverse B_DISEASE
ocular I_DISEASE
reactions I_DISEASE
possibly O
associated O
with O
isotretinoin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

A O
total O
of O
261 O
adverse O
ocular O
reactions O
occurred O
in O
237 O
patients O
who O
received O
isotretinoin O
, O
a O
commonly O
used O
drug O
in O
the O
treatment O
of O
severe O
cystic O
acne B_DISEASE
. O

Blepharoconjunctivitis B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
, O
subjective O
complaints O
of O
dry B_DISEASE
eyes I_DISEASE
, O
blurred B_DISEASE
vision I_DISEASE
, O
contact O
lens O
intolerance O
, O
and O
photodermatitis B_DISEASE
are O
reversible O
side O
effects O
. O

More O
serious O
ocular O
adverse O
reactions O
include O
papilledema B_DISEASE
, O
pseudotumor B_DISEASE
cerebri I_DISEASE
, O
and O
white O
or O
gray O
subepithelial O
corneal B_DISEASE
opacities I_DISEASE
; O
all O
of O
these O
are O
reversible O
if O
the O
drug O
is O
discontinued O
. O

reported O
cases B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
decreased B_DISEASE
dark I_DISEASE
adaptation I_DISEASE
are O
under O
investigation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Isotretinoin O
is O
contraindicated O
in O
pregnancy O
because O
of O
the O
many O
reported O
congenital B_DISEASE_ADJECTIVE[DISEASE]
abnormalities I_DISEASE_ADJECTIVE[DISEASE]
after O
maternal O
use O
( O
including O
microphthalmos B_DISEASE
, O
orbital O
hypertelorism B_DISEASE
, O
and O
optic B_DISEASE
nerve I_DISEASE
hypoplasia I_DISEASE
) O
. O

Procaterol O
and O
terbutaline O
in O
bronchial B_DISEASE/B_PERSON
asthma B_DISEASE/I_PERSON
. O

A O
double B_MEASURE/B_PERSON
- O
blind B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
placebo B_LOCATION/B_PERSON
- O
controlled O
, O
cross O
- O
over O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Procaterol O
, O
a O
new O
beta O
- O
2 O
adrenoceptor O
stimulant O
, O
was O
studied O
in O
a O
double O
- O
blind O
, O
placebo O
- O
controlled O
, O
cross O
- O
over O
trial O
in O
patients O
with O
bronchial B_DISEASE
asthma I_DISEASE
. O

Oral B_MEASURE/B_PERSON
procaterol I_MEASURE/I_PERSON
50 I_MEASURE/I_PERSON
micrograms I_MEASURE/I_PERSON
b I_MEASURE/I_PERSON
. O
d B_TIME[MEASURE]/B_DISEASE
. O
, O
procaterol B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
100 I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
micrograms I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
b I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O
d B_TIME[MEASURE]/B_DISEASE
. O
, O
and O
terbutaline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
5 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mg I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
t O
. O
i O
. O
d O
. O
, O
were O
compared O
when O
given O
randomly O
in O
1 B_NUMBER[MEASURE]
- O
week B_TIME[MEASURE]
treatment I_TIME[MEASURE]
periods I_TIME[MEASURE]
. O

The O
best B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
clinical I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effect I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
found O
with O
terbutaline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Both O
anti O
- O
asthmatic B_DISEASE
and O
tremorgenic B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects O
of O
procaterol O
were O
dose O
- O
related O
. O

Procaterol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
appeared O
effective B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
in O
the O
doses B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tested O
, O
and O
a O
twice B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
daily I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
regimen I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
would O
appear O
to O
be O
suitable B_DISEASE_ADJECTIVE[DISEASE]
with O
this O
drug B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O

Subacute O
effects O
of O
propranolol O
and O
B O
24 O
/ O
76 O
on O
isoproterenol O
- O
induced O
rat O
heart B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
hypertrophy I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
in O
correlation O
with O
blood O
pressure O
. O

We O
compared O
the O
potential B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
beta I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
receptor B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
blocker I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
B B_MEASURE
24 I_MEASURE
/ O
76 B_MEASURE
i O
. O
e B_DISEASE/B_PROTEIN[GENE]
. O
1 B_MEASURE
- O
( O
2 B_NUMBER[MEASURE]/B_LOCATION
, O
4 B_NUMBER[MEASURE]
- O
dichlorophenoxy B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
- O
3 B_MEASURE/B_LOCATION
[ O
2 B_MEASURE/B_PROTEIN[GENE]
- O
3 B_NUMBER[MEASURE]/B_LOCATION
, O
4 B_NUMBER[MEASURE]
- O
dimethoxyphenyl B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
ethanolamino B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] O
- O
prop B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
an O
- O
2 B_MEASURE
- O
ol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
which O
is O
characterized O
by O
beta B_PROTEIN[GENE]/B_DISEASE
1 I_PROTEIN[GENE]/I_DISEASE
- O
adrenoceptor B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
blocking I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
beta B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
adrenoceptor B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
stimulating I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
properties I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
with O
propranolol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
studies O
were O
performed O
using O
an O
experimental O
model O
of O
isoproterenol O
- O
induced O
heart B_DISEASE/B_LOCATION
hypertrophy I_DISEASE/I_LOCATION
in O
rats O
. O

A O
correlation O
of O
the O
blood O
pressure O
was O
neither O
found O
in O
the O
development O
nor O
in O
the O
attempt O
to O
suppress O
the O
development O
of O
heart B_DISEASE/B_GENE
hypertrophy I_DISEASE/I_GENE
with O
the O
two O
beta O
- O
receptor O
blockers O
. O

Both O
beta O
- O
blockers O
influenced O
the O
development O
of O
hypertrophy B_DISEASE
to O
a O
different O
, O
but O
not O
reproducible O
extent O
. O

It O
was O
possible O
to O
suppress O
the O
increased O
ornithine O
decarboxylase O
activity O
with O
both O
beta O
- O
blockers O
in O
hypertrophied B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
hearts I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
, O
but O
there O
was O
no O
effect O
on O
the O
heart O
mass O
. O

Neither O
propranolol O
nor O
B O
24 O
/ O
76 O
could O
stop O
the O
changes O
in O
the O
characteristic O
myosin O
isoenzyme O
pattern O
of O
the O
hypertrophied B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
rat O
heart O
. O

Thus O
, O
the O
investigations O
did O
not O
provide O
any O
evidence O
that O
the O
beta O
- O
receptor O
blockers O
propranolol O
and O
B O
24 O
/ O
76 O
have O
the O
potency O
to O
prevent O
isoproterenol O
from O
producing O
heart B_DISEASE/B_GENE
hypertrophy I_DISEASE/I_GENE
. O

increased O
anxiogenic O
effects O
of O
caffeine O
in O
panic B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
disorders I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
. O

The O
effects O
of O
oral O
administration O
of O
caffeine O
( O
10 O
mg O
/ O
kg O
) O
on O
behavioral O
ratings O
, O
somatic O
symptoms O
, O
blood O
pressure O
and O
plasma O
levels O
of O
3 O
- O
methoxy O
- O
4 O
- O
hydroxyphenethyleneglycol O
( O
MHPG O
) O
and O
cortisol O
were O
determined O
in O
17 O
healthy O
subjects O
and O
21 O
patients O
meeting O
DSM O
- O
III O
criteria O
for O
agoraphobia B_DISEASE/B_PERSON
with O
panic B_DISEASE
attacks I_DISEASE
or O
panic B_DISEASE
disorder I_DISEASE
. O

Caffeine O
produced O
significantly O
greater O
increases O
in O
subject O
- O
rated O
anxiety B_DISEASE
, O
nervousness O
, O
fear O
, O
nausea B_DISEASE
, O
palpitations B_DISEASE
, O
restlessness B_DISEASE
, O
and O
tremors B_DISEASE
in O
the O
patients O
compared O
with O
healthy O
subjects O
. O

In O
the O
patients B_PERSON/B_DISEASE
, O
but O
not O
the O
healthy B_PERSON/B_BIO
subjects I_PERSON/I_BIO
, O
these O
symptoms B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
were O
significantly O
correlated O
with O
plasma B_DISEASE/B_GENE
caffeine I_DISEASE/I_GENE
levels I_DISEASE/I_GENE
. O

seventy O
- O
one O
percent O
of O
the O
patients O
reported O
that O
the O
behavioral O
effects O
of O
caffeine O
were O
similar O
to O
those O
experienced O
during O
panic B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
attacks B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

caffeine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
did O
not O
alter O
plasma B_DISEASE
MHPG I_DISEASE
levels I_DISEASE
in O
either O
the O
healthy B_PERSON/B_BIO
subjects I_PERSON/I_BIO
or O
patients B_PERSON/B_BIO
. O

caffeine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
increased O
plasma B_DISEASE/B_GENE
cortisol I_DISEASE/I_GENE
levels I_DISEASE/I_GENE
equally O
in O
the O
patient B_PERSON/B_DISEASE
and O
healthy B_PERSON/B_BIO
groups I_PERSON/I_BIO
. O

Because O
caffeine O
is O
an O
adenosine O
receptor O
antagonist O
, O
these O
results O
suggest O
that O
some O
panic B_DISEASE/B_GENE
disorder I_DISEASE/I_GENE
patients O
may O
have O
abnormalities B_DISEASE_ADJECTIVE[DISEASE]
in I_DISEASE_ADJECTIVE[DISEASE]
neuronal I_DISEASE_ADJECTIVE[DISEASE]
systems I_DISEASE_ADJECTIVE[DISEASE]
involving O
adenosine O
. O

patients O
with O
anxiety B_DISEASE
disorders I_DISEASE
may O
benefit O
by O
avoiding O
caffeine O
- O
containing O
foods O
and O
beverages O
. O

comparison O
of O
the O
effect O
of O
oxitropium O
bromide O
and O
of O
slow O
- O
release O
theophylline O
on O
nocturnal O
asthma B_DISEASE
. O

The O
effects O
of O
a O
new O
inhaled O
antimuscarinic O
drug O
, O
oxitropium O
bromide O
, O
and O
of O
a O
slow O
- O
release O
theophylline O
preparation O
upon O
nocturnal O
asthma B_DISEASE
were O
compared O
in O
a O
placebo O
- O
controlled O
double O
- O
blind O
study O
. O

Two B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_NUMBER[MEASURE]
samples I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_NUMBER[MEASURE]
were O
studied O
: O
12 B_PERSON
patients I_PERSON
received O
oxitropium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O
600 B_MEASURE
micrograms I_MEASURE
( O
6 B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
subjects B_PERSON/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
or O
at O
400 B_MEASURE
micrograms I_MEASURE
t O
. O
i O
. O
d O
. O

( O
6 B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
subjects B_PERSON/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
whereas O
11 B_NUMBER[MEASURE]/B_PERSON
received O
theophylline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O
300 B_MEASURE
mg O
b B_DISEASE/B_PROTEIN[GENE]
. O
i O
. O
d B_TIME[MEASURE]/B_DISEASE
. O

morning B_DISEASE
dipping I_DISEASE
, O
assessed O
by O
the O
fall B_DISEASE/B_MEASURE
in O
peak B_MEASURE/B_PROTEIN[GENE]
flow B_MEASURE/I_PROTEIN[GENE]
overnight O
, O
was O
significantly O
reduced O
in O
the O
periods B_TIME[MEASURE]/B_LOCATION
when O
either O
active B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
drug I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
was O
taken O
, O
whereas O
no O
difference B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
was O
noticed O
during O
the O
placebo B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
administration I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
. O

No O
significant B_MEASURE
difference I_MEASURE
was O
noticed O
between O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
obtained O
with O
either O
active B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
drug I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O
as O
well O
as O
with O
either O
dosage B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
oxitropium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

No O
subject O
reported O
side O
effects O
of O
oxitropium O
, O
as O
compared O
to O
three O
subjects O
reporting O
nausea B_DISEASE
, O
vomiting B_DISEASE
and O
tremors B_DISEASE
after O
theophylline O
. O

Oxitropium O
proves O
to O
be O
a O
valuable O
alternative O
to O
theophylline O
in O
nocturnal O
asthma B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
since O
it O
is O
equally O
potent O
, O
safer O
and O
does O
not O
require O
the O
titration O
of O
dosage O
. O

Penicillin O
anaphylaxis B_DISEASE/B_MEASURE
. O

A O
case O
of O
oral O
penicillin O
anaphylaxis B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
is O
described O
, O
and O
the O
terminology O
, O
occurrence O
, O
clinical O
manifestations O
, O
pathogenesis O
, O
prevention O
, O
and O
treatment O
of O
anaphylaxis B_DISEASE
are O
reviewed O
. O

Emergency O
physicians O
should O
be O
aware O
of O
oral O
penicillin O
anaphylaxis B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
order O
to O
prevent O
its O
occurrence O
by O
prescribing O
the O
antibiotic O
judiciously O
and O
knowledgeably O
and O
to O
offer O
optimal O
medical O
therapy O
once O
this O
life O
- O
threatening O
reaction O
has O
begun O
. O

Reversible O
valproic O
acid O
- O
induced O
dementia B_DISEASE
: O
a O
case O
report O
. O

Reversible O
valproic O
acid O
- O
induced O
dementia B_DISEASE
was O
documented O
in O
a O
21 O
- O
year O
- O
old O
man O
with O
epilepsy B_DISEASE/B_GENE
who O
had O
a O
3 O
- O
year O
history O
of O
insidious O
progressive O
decline O
in O
global O
cognitive O
abilities O
documented O
by O
serial O
neuropsychological O
studies O
. O

repeat O
neuropsychological B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
testing I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
7 I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
weeks I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
after O
discontinuation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O
the O
drug B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
revealed O
dramatic B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
improvement I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
IQ B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
memory B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
naming B_TIME[MEASURE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
other B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
tasks I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
commensurate I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
with O
clinical B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
recovery I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
his O
intellectual B_MEASURE/B_PERSON
capacity I_MEASURE/I_PERSON
. O

possible O
pathophysiological O
mechanisms O
which O
may O
have O
been O
operative O
in O
this O
case O
include O
: O
a O
direct O
central O
nervous O
system O
( O
CNS O
) O
toxic O
effect O
of O
valproic O
acid O
; O
a O
paradoxical O
epileptogenic O
effect O
secondary O
to O
the O
drug O
; O
and O
an O
indirect O
CNS O
toxic O
effect O
mediated O
through O
valproic O
acid O
- O
induced O
hyperammonemia B_DISEASE
. O

reversal O
of O
scopolamine O
- O
induced O
amnesia B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
passive O
avoidance O
by O
pre O
- O
and O
post O
- O
training O
naloxone O
. O

In O
a O
series O
of O
five O
experiments O
, O
the O
modulating O
role O
of O
naloxone O
on O
a O
scopolamine O
- O
induced O
retention B_DISEASE
deficit I_DISEASE
in O
a O
passive O
avoidance O
paradigm O
was O
investigated O
in O
mice O
. O

Scopolamine O
, O
but O
not O
methyl O
scopolamine O
( O
1 O
and O
3 O
mg O
/ O
kg O
) O
, O
induced O
an O
amnesia B_DISEASE_ADJECTIVE[DISEASE]
as O
measured O
by O
latency O
and O
duration O
parameters O
. O

Naloxone O
( O
0 O
. O
3 O
, O
1 O
, O
3 O
, O
and O
10 O
mg O
/ O
kg O
) O
injected O
prior O
to O
training O
attenuated O
the O
retention B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
deficit I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
with O
a O
peak O
of O
activity O
at O
3 O
mg O
/ O
kg O
. O

The O
effect B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O
naloxone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
could O
be O
antagonized O
with O
morphine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
1 B_MEASURE/B_LOCATION
, O
3 B_NUMBER[MEASURE]
, O
and O
10 B_MEASURE
mg I_MEASURE
/ O
kg B_MEASURE
) O
, O
demonstrating O
the O
opioid B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
specificity I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
the O
naloxone B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effect I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Post O
- O
training O
administration O
of O
naloxone O
( O
3 O
mg O
/ O
kg O
) O
as O
a O
single O
or O
as O
a O
split O
dose O
also O
attenuated O
the O
scopolamine O
- O
induced O
amnesia B_DISEASE_ADJECTIVE[DISEASE]
. O

Control O
experiments O
indicated O
that O
neither O
an O
increase O
in O
pain B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sensitivity O
( O
pre O
- O
training O
naloxone O
) O
nor O
an O
induced O
aversive O
state O
( O
post O
- O
training O
naloxone O
) O
appear O
to O
be O
responsible O
for O
the O
influence O
of O
naloxone O
on O
the O
scopolamine O
- O
induced O
retention B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
deficit I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O

These O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
extend O
previous B_LOCATION/B_MEASURE
findings I_LOCATION/I_MEASURE
implicating O
a O
cholinergic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
opioid B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
interaction B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
in O
memory B_DISEASE
processes I_DISEASE
. O

A O
possible B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
mechanism I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
for O
this O
interaction B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
involving O
the O
septo B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
- O
hippocampal B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
cholinergic I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
pathway I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
is O
discussed O
. O

electron O
microscopic O
investigations O
of O
the O
cyclophosphamide O
- O
induced O
lesions B_DISEASE
of I_DISEASE
the I_DISEASE
urinary I_DISEASE
bladder I_DISEASE
of O
the O
rat O
and O
their O
prevention O
by O
mesna O
. O

fully O
developed O
cyclophosphamide O
- O
induced O
cystitis B_DISEASE
is O
characterized O
by O
nearly O
complete O
detachment O
of O
the O
urothelium O
, O
severe O
submucosal O
edema B_DISEASE
owing O
to O
damage O
to O
the O
microvascular O
bed O
and O
focal O
muscle O
necroses B_DISEASE
. O

The O
initial B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
response I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
to O
the O
primary B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
attack B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
by O
the O
cyclophosphamide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
metabolites B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
seems O
to O
be O
fragmentation B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
the O
luminal B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
membrane I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
. O

This O
damages O
the O
cellular B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
barrier I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
against O
the O
hypertonic B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
urine I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Subsequent O
breaks O
in O
the O
lateral O
cell O
membranes O
of O
the O
superficial O
cells O
and O
in O
all O
the O
plasma O
membranes O
of O
the O
intermediate O
and O
basal O
cells O
, O
intercellular O
and O
intracellular O
edema B_DISEASE
and O
disintegration O
of O
the O
desmosomes O
and O
hemidesmosomes O
lead O
to O
progressive O
degeneration O
and O
detachment O
of O
the O
epithelial O
cells O
with O
exposure O
and O
splitting O
of O
the O
basal O
membrane O
. O

The O
morphological B_DISEASE_ADJECTIVE[DISEASE]
changes I_DISEASE_ADJECTIVE[DISEASE]
of O
the O
endothelial B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
cells I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
, O
which O
become O
more O
pronounced O
in O
the O
later B_TIME[MEASURE]/B_LOCATION
stages I_TIME[MEASURE]/I_LOCATION
of O
the O
experiment B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
the O
involvement B_DISEASE/B_MEASURE
of O
blood B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
vessels I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
regardless O
of O
their O
diameter B_MEASURE/B_LOCATION
and O
the O
location B_MEASURE
- O
dependent B_MEASURE/B_LOCATION
extent I_MEASURE/I_LOCATION
of O
the O
damage B_DISEASE
indicate O
a O
direct B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
type B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
damage B_DISEASE
which O
is O
preceded O
by O
a O
mediator B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
increase B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
permeability B_DISEASE/B_MEASURE
, O
the O
morphological B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
correlate I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
of O
which O
is O
the O
formation B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
of O
gaps B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
interendothelial B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
cell B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
connections B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
on O
the O
venules B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

These O
changes B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
can O
be O
effectively O
prevented O
by O
mesna B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O

The O
only B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sign I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
a O
possible B_DISEASE
involvement I_DISEASE
is O
the O
increase B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O
the O
number B_MEASURE/B_LOCATION
of O
specific B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
granules I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
with O
a O
presumed B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
lysosomal B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
function B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
in O
the O
superficial B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
cells I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
. O

increase O
in O
intragastric O
pressure O
during O
suxamethonium O
- O
induced O
muscle B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
fasciculations I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
children O
: O
inhibition O
by O
alfentanil O
. O

Changes B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
intragastric B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
pressure I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
after O
the O
administration B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
suxamethonium B_MEASURE
1 I_MEASURE
. O
5 B_MEASURE
mg I_MEASURE
kg I_MEASURE
- O
1 B_NUMBER[MEASURE]
i O
. O
v B_PROTEIN[GENE]/B_LOCATION
. O
were O
studied O
in O
32 B_PERSON/B_BIO
children I_PERSON/I_BIO
( O
mean B_TIME[MEASURE]
age I_TIME[MEASURE]
6 I_TIME[MEASURE]
. O
9 B_MEASURE
yr I_MEASURE
) O
pretreated O
with O
either O
physiological B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
saline I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
or O
alfentanil B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
50 I_LOCATION/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
micrograms I_LOCATION/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
kg I_LOCATION/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
1 B_MEASURE/B_LOCATION
. O

anaesthesia B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
was O
induced O
with O
thiopentone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
5 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
mg I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
kg I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
- O
1 B_MEASURE/B_LOCATION
. O

The O
incidence O
and O
intensity O
of O
muscle B_DISEASE
fasciculations I_DISEASE
caused O
by O
suxamethonium O
were O
significantly O
greater O
in O
the O
control O
than O
in O
the O
alfentanil O
group O
. O

The O
intragastric O
pressure O
during O
muscle B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
fasciculations B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O
significantly O
higher O
in O
the O
control O
group O
( O
16 O
+ O
/ O
- O
0 O
. O
7 O
( O
SEM O
) O
cm O
H2O O
) O
than O
in O
the O
alfentanil O
group O
( O
7 O
. O
7 O
+ O
/ O
- O
1 O
. O
5 O
( O
SEM O
) O
cm O
H2O O
) O
. O

The O
increase O
in O
intragastric O
pressure O
was O
directly O
related O
to O
the O
intensity O
of O
muscle B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
fasciculations I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O
regression O
line O
: O
y O
= O
0 O
. O
5 O
+ O
4 O
. O
78x O
with O
r O
of O
0 O
. O
78 O
) O
. O

It O
is O
concluded O
that O
intragastric O
pressure O
increases O
significantly O
during O
muscle B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
fasciculations I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
caused O
by O
suxamethonium O
in O
healthy O
children O
. O

Alfentanil O
50 O
micrograms O
kg O
- O
1 O
effectively O
inhibits O
the O
incidence O
and O
intensity O
of O
suxamethonium O
- O
induced O
muscle B_DISEASE
fasciculations I_DISEASE
; O
Moreover O
, O
intragastric O
pressure O
remains O
at O
its O
control O
value O
. O

acute O
insulin O
treatment O
normalizes O
the O
resistance O
to O
the O
cardiotoxic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
effect O
of O
isoproterenol O
in O
streptozotocin O
diabetic B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
rats O
. O

A O
morphometric O
study O
of O
isoproterenol O
induced O
myocardial O
fibrosis B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
. O

The O
acute O
effect O
of O
insulin O
treatment O
on O
the O
earlier O
reported O
protective O
effect O
of O
streptozotocin O
diabetes B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
against O
the O
cardiotoxic B_DISEASE_ADJECTIVE[DISEASE]
effect O
of O
high O
doses O
of O
isoproterenol O
( O
ISO O
) O
was O
investigated O
in O
rats O
. O

Thirty O
to O
135 O
min O
after O
the O
injection O
of O
crystalline O
insulin O
, O
ISO O
was O
given O
subcutaneously O
and O
when O
ISO O
induced O
fibrosis B_DISEASE
in O
the O
myocardium O
was O
morphometrically O
analyzed O
7 O
days O
later O
, O
a O
highly O
significant O
correlation O
( O
r O
= O
0 O
. O
83 O
, O
2 O
p O
= O
0 O
. O
006 O
) O
to O
the O
slope O
of O
the O
fall O
in O
blood O
glucose O
after O
insulin O
treatment O
appeared O
. O

The O
myocardial O
content O
of O
catecholamines O
was O
estimated O
in O
these O
8 O
day O
diabetic B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
rats O
. O

The O
norepinephrine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
content I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
was O
significantly O
increased O
while O
epinephrine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
remained O
unchanged B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
. O

An O
enhanced B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
sympathetic I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
nervous I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
system I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
activity I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O
a O
consequent B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
down O
regulation B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
myocardial B_PROTEIN[GENE]/B_BODY_PART_OR_ORGAN_COMPONENT
beta I_PROTEIN[GENE]/I_BODY_PART_OR_ORGAN_COMPONENT
- O
adrenergic B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
receptors I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
could O
, O
therefore O
, O
explain O
this O
catecholamine B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
resistance B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
rapid O
reversion O
after O
insulin O
treatment O
excludes O
the O
possibility O
that O
streptozotocin O
in O
itself O
causes O
the O
ISO O
resistance O
and O
points O
towards O
a O
direct O
insulin O
effect O
on O
myocardial O
catecholamine O
sensitivity O
in O
diabetic B_DISEASE/B_PERSON
rats O
. O

The O
phenomenon O
described O
might O
elucidate O
pathogenetic O
mechanisms O
behind O
toxic O
myocardial O
cell O
degeneration O
and O
may O
possibly O
have O
relevance O
for O
acute O
cardiovascular O
complications O
in O
diabetic B_DISEASE/B_PERSON
patients O
. O

differential O
effects O
of O
non O
- O
steroidal O
anti O
- O
inflammatory O
drugs O
on O
seizures B_DISEASE
produced O
by O
pilocarpine O
in O
rats O
. O

The O
muscarinic O
cholinergic O
agonist O
pilocarpine O
induces O
in O
rats O
seizures B_DISEASE
and O
status B_DISEASE
epilepticus I_DISEASE
followed O
by O
widespread O
damage O
to O
the O
forebrain O
. O

The O
present O
study O
was O
designed O
to O
investigate O
the O
effect O
of O
5 O
non O
- O
steroidal O
anti O
- O
inflammatory O
drugs O
, O
sodium O
salicylate O
, O
phenylbutazone O
, O
indomethacin O
, O
ibuprofen O
and O
mefenamic O
acid O
, O
on O
seizures B_DISEASE
produced O
by O
pilocarpine O
. O

Pretreatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O
rats B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
sodium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
salicylate I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
ED50 B_MEASURE
103 I_MEASURE
mg I_MEASURE
/ O
kg B_MEASURE
( O
60 B_MEASURE
- O
174 B_MEASURE
) O
, O
and O
phenylbutazone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
59 B_MEASURE
mg I_MEASURE
/ O
kg B_MEASURE
( O
50 B_MEASURE
- O
70 B_MEASURE
) O
converted O
the O
non B_DISEASE/B_MEASURE
- O
convulsant B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
dose I_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
of O
pilocarpine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
200 B_MEASURE
mg I_MEASURE
/ O
kg B_MEASURE
, O
to O
a O
convulsant B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
one I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

Indomethacin O
, O
1 O
- O
10 O
mg O
/ O
kg O
, O
and O
ibuprofen O
, O
10 O
- O
100 O
mg O
/ O
kg O
, O
failed O
to O
modulate O
seizures B_DISEASE
produced O
by O
pilocarpine O
. O

Mefenamic O
acid O
, O
26 O
( O
22 O
- O
30 O
) O
mg O
/ O
kg O
, O
prevented O
seizures B_DISEASE
and O
protected O
rats O
from O
seizure B_DISEASE
- O
related O
brain B_DISEASE_ADJECTIVE[DISEASE]
damage I_DISEASE_ADJECTIVE[DISEASE]
induced O
by O
pilocarpine O
, O
380 O
mg O
/ O
kg O
. O

These O
results O
indicate O
that O
non O
- O
steroidal O
anti O
- O
inflammatory O
drugs O
differentially O
modulate O
the O
threshold O
for O
pilocarpine O
- O
induced O
seizures B_DISEASE
. O

Acute B_DISEASE_ADJECTIVE[DISEASE]
neurologic I_DISEASE_ADJECTIVE[DISEASE]
dysfunction I_DISEASE_ADJECTIVE[DISEASE]
after O
high O
- O
dose O
etoposide O
therapy O
for O
malignant B_DISEASE
glioma I_DISEASE
. O

Etoposide O
( O
VP O
- O
16 O
- O
213 O
) O
has O
been O
used O
in O
the O
treatment O
of O
many O
solid O
tumors B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
and O
hematologic B_DISEASE
malignancies I_DISEASE
. O

When O
used O
in O
high O
doses O
and O
in O
conjunction O
with O
autologous O
bone O
marrow O
transplantation O
, O
this O
agent O
has O
activity O
against O
several O
treatment O
- O
resistant O
cancers B_DISEASE
including O
malignant B_DISEASE
glioma I_DISEASE
. O

In O
six O
of O
eight O
patients O
( O
75 O
% O
) O
who O
we O
treated O
for O
recurrent O
or O
resistant O
glioma B_DISEASE
, O
sudden O
severe O
neurologic B_DISEASE
deterioration I_DISEASE
occurred O
. O

This O
developed O
a O
median B_LOCATION/B_MEASURE
of O
9 B_NUMBER[MEASURE]/B_ENT
days I_NUMBER[MEASURE]/I_ENT
after O
initiation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O
high B_MEASURE
- O
dose B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
etoposide I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
therapy I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

significant O
clinical O
manifestations O
have O
included O
confusion B_DISEASE
, O
papilledema B_DISEASE
, O
somnolence B_DISEASE
, O
exacerbation O
of O
motor B_DISEASE
deficits I_DISEASE
, O
and O
sharp O
increase O
in O
seizure B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
activity O
. O

These O
abnormalities B_DISEASE_ADJECTIVE[DISEASE]
resolved O
rapidly O
after O
initiation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O
high B_MEASURE
- O
dose B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
intravenous I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
dexamethasone I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
therapy I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

In O
all O
patients O
, O
computerized O
tomographic O
( O
CT O
) O
brain O
scans O
demonstrated O
stability O
in O
tumor B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
size O
and O
peritumor O
edema B_DISEASE/B_MEASURE
when O
compared O
with O
pretransplant O
scans O
. O

This O
complication O
appears O
to O
represent O
a O
significant O
new O
toxicity B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
high O
- O
dose O
etoposide O
therapy O
for O
malignant B_DISEASE
glioma I_DISEASE
. O

Progressive O
bile B_DISEASE
duct I_DISEASE
injury I_DISEASE
after O
thiabendazole O
administration O
. O

A O
27 O
- O
yr O
- O
old O
man O
developed O
jaundice B_DISEASE
2 O
wk O
after O
exposure O
to O
thiabendazole O
. O

Cholestasis B_DISEASE/B_PERSON
persisted O
for O
3 O
yr O
, O
at O
which O
time O
a O
liver O
transplant O
was O
performed O
. O

Two B_PERSON
liver I_PERSON
biopsy I_PERSON
specimens I_PERSON
and O
the O
hepatectomy B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
specimen I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
were O
remarkable B_DISEASE_ADJECTIVE[DISEASE]
for O
almost O
complete B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
disappearance B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
interlobular B_DISEASE
bile I_DISEASE
ducts I_DISEASE
. O

prominent O
fibrosis B_DISEASE
and O
hepatocellular O
regeneration O
were O
also O
present O
; O
however O
, O
the O
lobular O
architecture O
was O
preserved O
. O

This O
case O
represents O
an O
example O
of O
' O
idiosyncratic O
' O
drug B_DISEASE
- I_DISEASE
induced I_DISEASE
liver I_DISEASE
damage I_DISEASE
in O
which O
the O
primary O
target O
of O
injury O
is O
the O
bile O
duct O
. O

An O
autoimmune O
pathogenesis O
of O
the O
bile B_DISEASE/B_BIO
duct I_DISEASE/I_BIO
destruction I_DISEASE/I_BIO
is O
suggested O
. O

Differential B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
effects I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
of O
1 B_NUMBER[MEASURE]
, O
4 B_MEASURE
- O
dihydropyridine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
calcium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
channel B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
blockers B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
: O
therapeutic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
implications B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
. O

increasing O
recognition O
of O
the O
importance O
of O
calcium O
in O
the O
pathogenesis O
of O
cardiovascular B_DISEASE
disease I_DISEASE
has O
stimulated O
research O
into O
the O
use O
of O
calcium O
channel O
blocking O
agents O
for O
treatment O
of O
a O
variety O
of O
cardiovascular B_DISEASE_ADJECTIVE[DISEASE]
diseases I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
favorable B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
efficacy I_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
and O
tolerability B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
profiles B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
of O
these O
agents B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
make O
them O
attractive B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
therapeutic B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
modalities B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
. O

Clinical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
applications I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
of O
calcium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
channel I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
blockers I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
parallel O
their O
tissue B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
selectivity I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

In O
contrast B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
verapamil B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
diltiazem B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
which O
are O
roughly O
equipotent B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
their O
actions B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
on O
the O
heart B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
and O
vascular B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
smooth I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
muscle I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
, O
the O
dihydropyridine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
calcium I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
channel I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
blockers I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
are O
a O
group B_ORGANIZATION/B_PERSON
of O
potent B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
peripheral I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
vasodilator I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
agents I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
that O
exert O
minimal B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
electrophysiologic I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
effects I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
on O
cardiac B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
nodal I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
or O
conduction B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
tissue I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
. O

As O
the O
first O
dihydropyridine O
available O
for O
use O
in O
the O
United O
States O
, O
nifedipine O
controls O
angina B_DISEASE
and O
hypertension B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O
minimal O
depression O
of O
cardiac O
function O
. O

Additional B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
members I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
this O
group B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
calcium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
channel I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
blockers I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
have O
been O
studied O
for O
a O
variety B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
indications B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
for O
which O
they O
may O
offer O
advantages B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
over O
current B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Once O
or O
twice O
daily O
dosage O
possible O
with O
nitrendipine O
and O
nisoldipine O
offers O
a O
convenient O
administration O
schedule O
, O
which O
encourages O
patient O
compliance O
in O
long O
- O
term O
therapy O
of O
hypertension B_DISEASE
. O

The O
coronary O
vasodilating O
properties O
of O
nisoldipine O
have O
led O
to O
the O
investigation O
of O
this O
agent O
for O
use O
in O
angina B_DISEASE/B_PERSON
. O

Selectivity O
for O
the O
cerebrovascular O
bed O
makes O
nimodipine O
potentially O
useful O
in O
the O
treatment O
of O
subarachnoid B_DISEASE
hemorrhage I_DISEASE
, O
migraine B_DISEASE
headache I_DISEASE
, O
dementia B_DISEASE
, O
and O
stroke B_DISEASE
. O

In O
general O
, O
the O
dihydropyridine O
calcium O
channel O
blockers O
are O
usually O
well O
tolerated O
, O
with O
headache B_DISEASE
, O
facial O
flushing B_DISEASE
, O
palpitations B_DISEASE
, O
edema B_DISEASE
, O
nausea B_DISEASE
, O
anorexia B_DISEASE
, O
and O
dizziness B_DISEASE
being O
the O
more O
common O
adverse O
effects O
. O

The O
enhancement O
of O
aminonucleoside O
nephrosis B_DISEASE_ADJECTIVE[DISEASE]/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
by O
the O
co O
- O
administration O
of O
protamine O
. O

An O
experimental O
model O
of O
focal B_DISEASE
segmental I_DISEASE
glomerular I_DISEASE
sclerosis I_DISEASE
( O
FSGS B_LOCATION/B_DISEASE
) O
was O
developed O
in O
rats O
by O
the O
combined O
administration O
of O
puromycin O
- O
aminonucleoside O
( O
AMNS O
) O
and O
protamine O
sulfate O
( O
PS O
) O
. O

Male B_PERSON
Sprague I_PERSON
- O
Dawley B_PERSON/B_MEASURE
rats I_PERSON/I_MEASURE
, O
uninephrectomized B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
three I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
weeks I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
before O
, O
received O
daily B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
injections I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
subcutaneous B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
AMNS B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
( O
1 B_MEASURE
mg I_MEASURE
/ O
100 B_MEASURE
g I_MEASURE
body I_MEASURE
wt I_MEASURE
) O
and O
intravenous B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
PS I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O
2 B_NUMBER[MEASURE]/B_LOCATION
separated O
doses B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
of O
2 B_MEASURE
. O
5 B_MEASURE
mg I_MEASURE
/ O
100 B_MEASURE
g I_MEASURE
body I_MEASURE
wt I_MEASURE
) O
for O
four B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
days B_TIME[MEASURE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

The O
series B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
injections B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
repeated O
another O
three B_TIME[MEASURE]
times I_TIME[MEASURE]
at O
10 B_TIME[MEASURE]/B_LOCATION
day I_TIME[MEASURE]/I_LOCATION
intervals I_TIME[MEASURE]/I_LOCATION
. O

The O
animals B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
sacrificed O
on O
days B_TIME[MEASURE]
24 I_TIME[MEASURE]
, O
52 B_MEASURE
, O
and O
80 B_MEASURE
. O

They O
developed O
nephrotic B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
syndrome I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
and O
finally O
renal B_DISEASE
failure I_DISEASE
. O

The O
time B_NUMBER[MEASURE]/B_LOCATION
- O
course B_MEASURE/B_LOCATION
curve I_MEASURE/I_LOCATION
of O
creatinine B_MEASURE/B_LOCATION
clearance B_MEASURE/I_LOCATION
dropped O
and O
showed O
significant B_MEASURE
difference I_MEASURE
( O
P B_MEASURE/B_PERSON
less I_MEASURE/I_PERSON
than O
0 B_MEASURE
. O
01 B_MEASURE
) O
from O
that O
of O
each O
control B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
group I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
, O
such B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
as O
, O
AMNS B_LOCATION/B_ORGANIZATION
alone O
, O
PS B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alone O
or O
saline B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
injected O
. O

Their O
glomeruli O
showed O
changes O
of O
progressive O
FSGS B_DISEASE
. O

The O
ultrastructural B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
studies I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
initial B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
stage I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
revealed O
significant B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
lack B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
particles B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
perfused B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ruthenium I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
red I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
the O
lamina B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
rara I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
externa I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
marked B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
changes I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
epithelial B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cell I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
cytoplasm I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Therefore O
, O
it O
is O
suggested O
that O
the O
administration O
of O
PS O
enhances O
the O
toxicity B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
AMNS O
on O
the O
glomerulus O
and O
readily O
produces O
progressive O
FSGS B_DISEASE
in O
rats O
resulting O
in O
the O
end B_DISEASE
- I_DISEASE
stage I_DISEASE
renal I_DISEASE
disease I_DISEASE
. O

Theophylline O
neurotoxicity B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
pregnant O
rats O
. O

The O
purpose O
of O
this O
investigation O
was O
to O
determine O
whether O
the O
neurotoxicity B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
theophylline O
is O
altered O
in O
advanced O
pregnancy O
. O

Sprague O
- O
Dawley O
rats O
that O
were O
20 O
days O
pregnant O
and O
nonpregnant O
rats O
of O
the O
same O
age O
and O
strain O
received O
infusions O
of O
aminophylline O
until O
onset O
of O
maximal O
seizures B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
which O
occurred O
after O
28 O
and O
30 O
minutes O
respectively O
. O

theophylline B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
concentrations I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
at O
this O
endpoint B_LOCATION/B_MEASURE
in O
serum B_BODY_PART_OR_ORGAN_COMPONENT/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
total B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
) O
and O
CSF B_BODY_PART_OR_ORGAN_COMPONENT
were O
similar B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
but O
serum B_BODY_PART_OR_ORGAN_COMPONENT/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
free B_BODY_PART_OR_ORGAN_COMPONENT/B_MEASURE
) O
and O
brain B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
concentrations I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
were O
slightly O
different B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
pregnant B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
rats I_BODY_PART_OR_ORGAN_COMPONENT/I_BIO
. O

Theophylline B_TIME[MEASURE]/B_PERSON
serum I_TIME[MEASURE]/I_PERSON
protein I_TIME[MEASURE]/I_PERSON
binding I_TIME[MEASURE]/I_PERSON
determined O
by O
equilibrium B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dialysis I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
lower B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O
pregnant B_PERSON/B_BIO
rats I_PERSON/I_BIO
. O

Fetal O
serum O
concentrations O
at O
onset O
of O
seizures B_DISEASE/B_ORGANISM_FUNCTION
in O
the O
mother O
were O
similar O
to O
maternal O
brain O
and O
CSF O
concentrations O
and O
correlated O
significantly O
with O
the O
former O
. O

It O
is O
concluded O
that O
advanced O
pregnancy O
has O
a O
negligible O
effect O
on O
the O
neurotoxic B_BODY_PART_OR_ORGAN_COMPONENT/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
response O
to O
theophylline O
in O
rats O
. O

Hyperkalemia B_DISEASE/B_LOCATION
induced O
by O
indomethacin O
and O
naproxen O
and O
reversed O
by O
fludrocortisone O
. O

We O
have O
described O
a O
patient O
with O
severe O
rheumatoid B_DISEASE
arthritis I_DISEASE
and O
a O
history O
of O
mefenamic O
acid O
nephropathy B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
whom O
hyperkalemia B_DISEASE
and O
inappropriate O
hypoaldosteronism B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
caused O
by O
both O
indomethacin O
and O
naproxen O
, O
without O
major O
decline O
in O
renal O
function O
. O

It O
is O
likely O
that O
preexisting O
renal B_DISEASE
disease I_DISEASE
predisposed O
this O
patient O
to O
type B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
IV B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
renal B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
tubular B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
acidosis B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O
prostaglandin O
synthetase O
inhibitors O
. O

Because O
he O
was O
unable O
to O
discontinue O
nonsteroidal O
anti O
- O
inflammatory O
drug O
therapy O
, O
fludrocortisone O
was O
added O
, O
correcting O
the O
hyperkalemia B_DISEASE
and O
allowing O
indomethacin O
therapy O
to O
be O
continued O
safely O
. O

Hypotension B_DISEASE
as O
a O
manifestation O
of O
cardiotoxicity B_DISEASE
in O
three O
patients O
receiving O
cisplatin O
and O
5 O
- O
fluorouracil O
. O

cardiac O
symptoms O
, O
including O
hypotension B_DISEASE
, O
developed O
in O
three O
patients O
with O
advanced O
colorectal B_DISEASE/B_GENE
carcinoma I_DISEASE/I_GENE
while O
being O
treated O
with O
cisplatin O
( O
CDDP O
) O
and O
5 O
- O
fluorouracil O
( O
5 O
- O
Fu O
) O
. O

In O
two O
patients O
, O
hypotension B_DISEASE
was O
associated O
with O
severe O
left B_DISEASE
ventricular I_DISEASE
dysfunction I_DISEASE
. O

All O
three B_PERSON/B_TIME[MEASURE]
patients I_PERSON/I_TIME[MEASURE]
required O
therapy B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
discontinuation I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
. O

Cardiac B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
enzymes I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
remained O
normal B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
despite O
transient B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
electrocardiographic I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
EKG B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O
changes B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
presentation O
and O
cardiac O
evaluation O
( O
hemodynamic O
, O
echocardiographic O
, O
and O
scintigraphic O
) O
of O
these O
patients O
suggest O
new O
manifestations O
of O
5 O
- O
Fu O
cardiotoxicity B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
that O
may O
be O
influenced O
by O
CDDP O
. O

The O
possible B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
pathophysiologic I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
mechanisms I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
are O
discussed O
. O

fatal O
aplastic B_DISEASE
anemia I_DISEASE
in O
a O
patient O
treated O
with O
carbamazepine O
. O

A O
case O
of O
fatal O
aplastic B_DISEASE
anemia I_DISEASE
due O
to O
carbamazepine O
treatment O
in O
an O
epileptic B_DISEASE/B_PERSON
woman O
is O
reported O
. O

Despite O
concerns O
of O
fatal O
bone B_DISEASE
marrow I_DISEASE
toxicity I_DISEASE
due O
to O
carbamazepine O
, O
this O
is O
only O
the O
fourth O
documented O
and O
published O
report O
. O

carbamazepine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
is O
a O
safe B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
drug I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
but O
physicians B_PERSON
and O
patients B_PERSON
should O
be O
aware B_PERSON
of O
the O
exceedingly O
rare B_DISEASE_ADJECTIVE[DISEASE]
but O
potentially O
fatal B_DISEASE_ADJECTIVE[DISEASE]
side I_DISEASE_ADJECTIVE[DISEASE]
effects I_DISEASE_ADJECTIVE[DISEASE]
, O
better O
prevented O
by O
clinical B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
than O
by O
laboratory B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
monitoring I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_PERSON
. O

participation O
of O
a O
bulbospinal O
serotonergic O
pathway O
in O
the O
rat O
brain O
in O
clonidine O
- O
induced O
hypotension B_DISEASE
and O
bradycardia B_DISEASE
. O

The O
effects B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
microinjection B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
clonidine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O
1 B_NUMBER[MEASURE]
- O
10 B_MEASURE
micrograms I_MEASURE
in O
1 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
microliter B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
) O
into O
a O
region B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
adjacent O
to O
the O
ventrolateral B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
surface I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
of O
the O
medulla B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
oblongata I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
on O
cardiovascular B_DISEASE/B_ORGANISM_FUNCTION
function I_DISEASE/I_ORGANISM_FUNCTION
were O
assessed O
in O
urethane B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
- O
anesthetized O
rats B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

intramedullary B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
administration I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
clonidine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
but O
not O
saline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
vehicle I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
caused O
a O
dose B_MEASURE
- O
dependent B_DISEASE_ADJECTIVE[DISEASE]
decrease I_DISEASE_ADJECTIVE[DISEASE]
in O
both O
the O
mean B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
arterial B_MEASURE/I_BODY_PART_OR_ORGAN_COMPONENT
pressure B_MEASURE/I_BODY_PART_OR_ORGAN_COMPONENT
and O
the O
heart B_MEASURE/B_DISEASE
rate I_MEASURE/I_DISEASE
. O

The O
clonidine O
- O
induced O
hypotension B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O
antagonized O
by O
prior O
spinal O
transection O
, O
but O
not O
bilateral O
vagotomy O
. O

On O
the O
other O
hand O
, O
the O
clonidine O
- O
induced O
bradycardia B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O
antagonized O
by O
prior O
bilateral O
vagotomy O
, O
but O
not O
spinal O
transection O
. O

Furthermore O
, O
selective O
destruction O
of O
the O
spinal O
5 O
- O
HT O
nerves O
, O
produced O
by O
bilateral O
spinal O
injection O
of O
5 O
, O
7 O
- O
dihydroxytryptamine O
, O
reduced O
the O
magnitude O
of O
the O
vasodepressor O
or O
the O
bradycardiac B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
responses O
to O
clonidine O
microinjected O
into O
the O
area O
near O
the O
ventrolateral O
surface O
of O
the O
medulla O
oblongata O
in O
rats O
. O

The O
data O
indicate O
that O
a O
bulbospinal O
serotonergic O
pathway O
is O
involved O
in O
development O
of O
clonidine O
- O
induced O
hypotension B_DISEASE
and O
bradycardia B_DISEASE
. O

The O
induced O
hypotension B_DISEASE
is O
brought O
about O
by O
a O
decrease O
in O
sympathetic O
efferent O
activity O
, O
whereas O
the O
induced O
bradycardia B_DISEASE
was O
due O
to O
an O
increase O
in O
vagal O
efferent O
activity O
. O

Hypertension B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
neuroblastoma B_DISEASE/B_BIO
induced O
by O
imipramine O
. O

Hypertension B_DISEASE/B_GENE
is O
a O
well O
- O
known O
finding O
in O
some O
patients O
with O
neuroblastoma B_DISEASE/B_LOCATION
. O

However O
, O
it O
has O
not O
previously O
been O
described O
in O
association B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
the O
use B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O
Imipramine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

We O
report O
the O
occurrence O
of O
severe O
hypertension B_DISEASE
( O
blood O
pressure O
190 O
/ O
160 O
) O
in O
a O
4 O
- O
year O
- O
old O
girl O
with O
neuroblastoma B_DISEASE/B_LOCATION
who O
was O
given O
Imipramine O
to O
control O
a O
behavior B_DISEASE
disorder I_DISEASE
. O

It O
was O
determined O
later O
that O
this O
patient O
' O
s O
tumor B_DISEASE
was O
recurring O
at O
the O
time O
of O
her O
hypertensive B_DISEASE
episode O
. O

Since O
she O
had O
no O
blood O
pressure O
elevation O
at O
initial O
diagnosis O
and O
none O
following O
discontinuation O
of O
the O
Imipramine O
( O
when O
she O
was O
in O
florid O
relapse O
) O
, O
we O
believe O
that O
this O
drug O
rather O
than O
her O
underlying O
disease O
alone O
caused O
her O
hypertension B_DISEASE
. O

The O
mechanism B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
for O
this O
reaction B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
is O
believed O
to O
be O
increased O
levels B_LOCATION/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
vasoactive B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
catecholamines I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
due O
to O
interference B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O
their O
physiologic B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
inactivation B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
by O
Imipramine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O

From O
this O
experience O
, O
we O
urge O
extreme O
caution O
in O
the O
use O
of O
tricyclic O
antidepressants O
in O
children O
with O
active O
neuroblastoma B_DISEASE
. O

Rechallenge O
of O
patients O
who O
developed O
oral B_DISEASE
candidiasis I_DISEASE
or O
hoarseness B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O
beclomethasone O
dipropionate O
. O

Of O
158 O
asthmatic B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
patients O
who O
were O
placed O
on O
inhaled O
beclomethasone O
, O
15 O
( O
9 O
. O
5 O
% O
) O
developed O
either O
hoarseness B_DISEASE
( O
8 O
) O
, O
oral O
thrush B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O
6 O
) O
, O
or O
both O
( O
1 O
) O
. O

When O
their O
adverse B_DISEASE
reactions I_DISEASE
subsided O
, O
seven B_NUMBER[MEASURE]
of O
these O
15 B_PERSON/B_BIO
patients I_PERSON/I_BIO
were O
rechallenged O
with O
inhaled B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
beclomethasone I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

These O
included O
five O
cases O
who O
developed O
hoarseness B_DISEASE
and O
three O
who O
developed O
Candidiasis B_DISEASE
. O

One B_PERSON
patient I_PERSON
had O
both O
. O

Oral O
thrush B_DISEASE
did O
not O
recur O
, O
but O
60 O
% O
( O
3 O
/ O
5 O
) O
of O
patients O
with O
hoarseness B_DISEASE
had O
recurrence O
. O

We O
conclude O
that O
patients O
may O
be O
restarted O
on O
inhaled O
beclomethasone O
when O
clinically O
indicated O
; O
however O
, O
because O
of O
the O
high O
recurrence O
rate O
, O
patients O
who O
develop O
hoarseness B_DISEASE
should O
not O
be O
re O
- O
challenged O
. O

Concomitant O
use O
of O
oral O
prednisone O
and O
topical O
beclomethasone O
may O
increase O
the O
risk O
of O
developing O
hoarseness B_DISEASE
or O
candidiasis B_DISEASE
. O

Cyclophosphamide O
cardiotoxicity B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
: O
an O
analysis O
of O
dosing O
as O
a O
risk O
factor O
. O

patients B_PERSON/B_BIO
who O
undergo O
bone B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
marrow I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
transplantation I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
are O
generally O
immunosuppressed O
with O
a O
dose B_MEASURE
of O
cyclophosphamide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
CYA B_LOCATION/B_ORGANIZATION
) O
which O
is O
usually O
calculated O
based O
on O
the O
patient B_PERSON/B_BIO
' O
s B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
weight B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

At O
these O
high O
doses O
of O
CYA O
, O
serious O
cardiotoxicity B_DISEASE
may O
occur O
, O
but O
definitive O
risk O
factors O
for O
the O
development O
of O
such O
cardiotoxicity B_DISEASE
have O
not O
been O
described O
. O

Since O
chemotherapeutic O
agent O
toxicity B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
generally O
correlates O
with O
dose O
per O
body O
surface O
area O
, O
we O
retrospectively O
calculated O
the O
dose O
of O
CYA O
in O
patients O
transplanted O
at O
our O
institution O
to O
determine O
whether O
the O
incidence O
of O
CYA O
cardiotoxicity B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
correlated O
with O
the O
dose O
per O
body O
surface O
area O
. O

eighty O
patients O
who O
were O
to O
receive O
CYA O
50 O
mg O
/ O
kg O
/ O
d O
for O
four O
days O
as O
preparation O
for O
marrow O
grafting O
underwent O
a O
total O
of O
84 O
transplants O
for O
aplastic B_DISEASE
anemia I_DISEASE
, O
Wiskott B_DISEASE
- I_DISEASE
Aldrich I_DISEASE
syndrome I_DISEASE
, O
or O
severe B_DISEASE
combined I_DISEASE
immunodeficiency I_DISEASE
syndrome I_DISEASE
. O

Fourteen O
of O
84 O
( O
17 O
% O
) O
patients O
had O
symptoms O
and O
signs O
consistent O
with O
CYA O
cardiotoxicity B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
within O
ten O
days O
of O
receiving O
1 O
to O
4 O
doses O
of O
CYA O
. O

Six O
of O
the O
14 O
patients O
died O
with O
congestive B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
heart I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
failure I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

The O
dose B_MEASURE
of O
CYA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
per O
body B_TIME[MEASURE]/B_PERSON
surface I_TIME[MEASURE]/I_PERSON
area I_TIME[MEASURE]/I_PERSON
was O
calculated O
for O
all O
patients B_PERSON/B_LOCATION
and O
the O
patients B_PERSON
were O
divided O
into O
two B_ORGANIZATION/B_LOCATION
groups I_ORGANIZATION/I_LOCATION
based O
on O
daily B_MEASURE/B_DISEASE
CYA I_MEASURE/I_DISEASE
dose I_MEASURE/I_DISEASE
: O
Group B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
1 I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O
CYA B_MEASURE/B_PERSON
less I_MEASURE/I_PERSON
than O
or O
equal B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
to O
1 B_NUMBER[MEASURE]
. O
55 B_MEASURE
g I_MEASURE
/ O
m2 B_MEASURE/B_LOCATION
/ O
d B_TIME[MEASURE]/B_DISEASE
; O
Group B_SEQUENCE[MEASURE]/B_ORGANIZATION
2 I_SEQUENCE[MEASURE]/I_ORGANIZATION
, O
CYA B_MEASURE/B_LOCATION
greater I_MEASURE/I_LOCATION
than O
1 B_NUMBER[MEASURE]
. O
55 B_MEASURE
g I_MEASURE
/ O
m2 B_MEASURE/B_LOCATION
/ O
d B_TIME[MEASURE]/B_DISEASE
. O

Cardiotoxicity B_DISEASE
that O
was O
thought O
to O
be O
related O
to O
CYA O
occurred O
in O
1 O
/ O
32 O
( O
3 O
% O
) O
of O
patients O
in O
Group O
1 O
and O
in O
13 O
/ O
52 O
( O
25 O
% O
) O
patients O
in O
Group O
2 O
( O
P O
less O
than O
0 O
. O
025 O
) O
. O

Congestive B_DISEASE/B_LOCATION
heart I_DISEASE/I_LOCATION
failure I_DISEASE/I_LOCATION
caused O
or O
contributed O
to O
death O
in O
0 O
/ O
32 O
patients O
in O
Group O
1 O
v O
6 O
/ O
52 O
( O
12 O
% O
) O
of O
patients O
in O
Group O
2 O
( O
P O
less O
than O
0 O
. O
25 O
) O
. O

There O
was O
no O
difference B_MEASURE
in O
the O
rate B_MEASURE
of O
engraftment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
of O
evaluable B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_PERSON
patients I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_PERSON
in O
the O
two B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
groups I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O
P B_MEASURE/B_LOCATION
greater I_MEASURE/I_LOCATION
than O
0 B_MEASURE
. O
5 B_MEASURE
) O
. O

We O
conclude O
that O
the O
CYA O
cardiotoxicity B_DISEASE/B_MEASURE
correlates O
with O
CYA O
dosage O
as O
calculated O
by O
body O
surface O
area O
, O
and O
that O
patients O
with O
aplastic B_DISEASE
anemia I_DISEASE
and O
immunodeficiencies B_DISEASE
can O
be O
effectively O
prepared O
for O
bone O
marrow O
grafting O
at O
a O
CYA O
dose O
of O
1 O
. O
55 O
g O
/ O
m2 O
/ O
d O
for O
four O
days O
with O
a O
lower O
incidence O
of O
cardiotoxicity B_DISEASE
than O
patients O
whose O
CYA O
dosage O
is O
calculated O
based O
on O
weight O
. O

This O
study O
reaffirms O
the O
principle O
that O
drug O
toxicity B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
correlates O
with O
dose O
per O
body O
surface O
area O
. O

Studies O
of O
risk O
factors O
for O
aminoglycoside O
nephrotoxicity B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
epidemiology O
of O
aminoglycoside O
- O
induced O
nephrotoxicity B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
not O
fully O
understood O
. O

Experimental O
studies O
in O
healthy O
human O
volunteers O
indicate O
aminoglycosides O
cause O
proximal O
tubular O
damage O
in O
most O
patients O
, O
but O
rarely O
, O
if O
ever O
, O
cause O
glomerular B_DISEASE
or I_DISEASE
tubular I_DISEASE
dysfunction I_DISEASE
. O

Clinical O
trials O
of O
aminoglycosides O
in O
seriously O
ill O
patients O
indicate O
that O
the O
relative O
risk O
for O
developing O
acute B_DISEASE
renal I_DISEASE
failure I_DISEASE
during O
therapy O
ranges O
from O
8 O
to O
10 O
and O
that O
the O
attributable O
risk O
is O
70 O
% O
to O
80 O
% O
. O

Further O
analysis O
of O
these O
data O
suggests O
that O
the O
duration O
of O
therapy O
, O
plasma O
aminoglycoside O
levels O
, O
liver B_DISEASE
disease I_DISEASE
, O
advanced O
age O
, O
high O
initial O
estimated O
creatinine O
clearance O
and O
, O
possibly O
, O
female O
gender O
all O
increase O
the O
risk O
for O
nephrotoxicity B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Other O
causes O
of O
acute B_DISEASE
renal I_DISEASE
failure I_DISEASE
, O
such O
as O
shock B_DISEASE
, O
appear O
to O
have O
an O
additive O
effect O
. O

predictive B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
models I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
have O
been O
developed O
from O
these O
analyses B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
that O
should O
be O
useful B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
identifying O
patients B_PERSON/B_LOCATION
at O
high B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
risk I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

These O
models O
may O
also O
be O
useful O
in O
developing O
insights O
into O
the O
pathophysiology O
of O
aminoglycoside O
- O
induced O
nephrotoxicity B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Central B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
action I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
of O
narcotic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
analgesics I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Part B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
IV I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
. O

noradrenergic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
influences I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
on O
the O
activity B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
analgesics B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O
rats B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
effect O
of O
clonidine O
, O
naphazoline O
and O
xylometazoline O
on O
analgesia O
induced O
by O
morphine O
, O
codeine O
, O
fentanyl O
and O
pentazocine O
, O
and O
on O
cataleptic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
effect O
of O
morphine O
, O
codine O
and O
fentanyl O
was O
studied O
in O
rats O
. O

The O
biochemical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
assays O
on O
the O
influence B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O
four B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
analgesics I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
on O
the O
brain B_MEASURE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
concentration I_MEASURE/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
turnover B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
of O
noradrenaline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
NA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O
were O
also O
performed O
. O

It O
was O
found O
that O
three O
drugs O
stimulating O
central O
Na O
receptors O
failed O
to O
affect O
the O
analgesic O
ED50 O
of O
all O
antinociceptive O
agents O
and O
they O
enhanced O
catalepsy B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
induced O
by O
morphine O
and O
fentanyl O
. O

Codeine O
catalepsy B_DISEASE_ADJECTIVE[DISEASE]/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
was O
increased O
by O
clonidine O
and O
decreased O
by O
naphazoline O
and O
xylometazoline O
. O

The O
brain B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
concentration B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
of O
NA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
not O
changed O
by O
morphine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
fentanyl B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
but O
one B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_NUMBER[MEASURE]
of O
the O
doses B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
codeine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
( O
45 B_MEASURE/B_LOCATION
mg I_MEASURE/I_LOCATION
/ O
kg B_MEASURE
) O
slightly O
enhanced O
it O
. O

Pentazocine B_TIME[MEASURE]/B_PERSON
dose I_TIME[MEASURE]/I_PERSON
- O
dependently O
decreased O
the O
brain B_MEASURE
level I_MEASURE
of O
NA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O

The O
rate B_MEASURE
of O
NA B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
turnover B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
was O
not O
altered O
by O
analgesics B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
except O
for O
the O
higher B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
dose I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
of O
fentanyl B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
0 B_MEASURE
. O
2 B_MEASURE
mg I_MEASURE
/ O
kg B_MEASURE
) O
following O
which O
the O
disappearance B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O
NA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
from O
the O
brain B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
was O
diminished O
. O

The O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
are O
discussed O
in O
the O
light B_COLOR/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
various B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
and O
non B_DISEASE/B_MEASURE
- O
uniform B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
data I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
from O
the O
literature B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

It O
is O
suggested O
that O
in O
rats B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
the O
brain B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
NA I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
plays O
a O
less O
important B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
function I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
than O
the O
other B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
monoamines B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
in O
the O
behavioural B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activity I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
potent B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPECIES[BIO]
analgesics B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_SPECIES[BIO]
. O

Flurothyl O
seizure B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
thresholds O
in O
mice O
treated O
neonatally O
with O
a O
single O
injection O
of O
monosodium O
glutamate O
( O
MSG O
) O
: O
evaluation O
of O
experimental O
parameters O
in O
flurothyl O
seizure B_DISEASE
testing O
. O

Monosodium O
glutamate O
( O
MSG O
) O
administration O
to O
neonatal O
rodents O
produces O
convulsions B_DISEASE
and O
results O
in O
numerous O
biochemical O
and O
behavioral O
deficits O
. O

These O
studies O
were O
undertaken O
to O
determine O
if O
neonatal O
administration O
of O
MSG O
produced O
permanent O
alterations O
in O
seizure B_DISEASE
susceptibility O
, O
since O
previous O
investigations O
were O
inconclusive O
. O

A O
flurothyl O
ether O
seizure B_DISEASE
screening O
technique O
was O
used O
to O
evaluate O
seizure B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
susceptibility O
in O
adult O
mice O
that O
received O
neonatal O
injections O
of O
MSG O
( O
4 O
mg O
/ O
g O
and O
1 O
mg O
/ O
g O
) O
. O

MSG O
treatment O
resulted O
in O
significant O
reductions O
in O
whole O
brain O
weight O
but O
did O
not O
alter O
seizure B_DISEASE
threshold O
. O

A O
naloxone O
( O
5 O
mg O
/ O
kg O
) O
challenge O
was O
also O
ineffective O
in O
altering O
the O
seizure B_DISEASE
thresholds O
of O
either O
control O
of O
MSG O
- O
treated O
mice O
. O

Flurothyl O
ether O
produced O
hypothermia B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
which O
was O
correlated O
with O
the O
duration O
of O
flurothyl O
exposure O
; O
however O
, O
the O
relationship O
of O
hypothermia B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O
seizure B_DISEASE
induction O
was O
unclear O
. O

Flurothyl O
seizure B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
testing O
proved O
to O
be O
a O
rapid O
and O
reliable O
technique O
with O
which O
to O
evaluate O
seizure B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
susceptibility O
. O

Susceptibility O
to O
seizures B_DISEASE
produced O
by O
pilocarpine O
in O
rats O
after O
microinjection O
of O
isoniazid O
or O
gamma O
- O
vinyl O
- O
GABA O
into O
the O
substantia O
nigra O
. O

Pilocarpine O
, O
given O
intraperitoneally O
to O
rats O
, O
reproduces O
the O
neuropathological O
sequelae O
of O
temporal B_DISEASE
lobe I_DISEASE
epilepsy I_DISEASE
and O
provides O
a O
relevant O
animal O
model O
for O
studying O
mechanisms O
of O
buildup O
of O
convulsive B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
activity O
and O
pathways O
operative O
in O
the O
generalization O
and O
propagation O
of O
seizures B_DISEASE
within O
the O
forebrain O
. O

In O
the O
present O
study O
, O
the O
effects O
of O
manipulating O
the O
activity O
of O
the O
gamma O
- O
aminobutyric O
acid O
( O
GABA O
) O
- O
mediated O
synaptic O
inhibition O
within O
the O
substantia O
nigra O
on O
seizures B_DISEASE
produced O
by O
pilocarpine O
in O
rats O
, O
were O
investigated O
. O

In O
animals O
pretreated O
with O
microinjections O
of O
isoniazid O
, O
150 O
micrograms O
, O
an O
inhibitor O
of O
activity O
of O
the O
GABA O
- O
synthesizing O
enzyme O
, O
L O
- O
glutamic O
acid O
decarboxylase O
, O
into O
the O
substantia O
nigra O
pars O
reticulata O
( O
SNR O
) O
, O
bilaterally O
, O
non O
- O
convulsant O
doses O
of O
pilocarpine O
, O
100 O
and O
200 O
mg O
/ O
kg O
, O
resulted O
in O
severe O
motor O
limbic O
seizures B_DISEASE
and O
status B_DISEASE
epilepticus I_DISEASE
. O

Electroencephalographic O
and O
behavioral O
monitoring O
revealed O
a O
profound O
reduction O
of O
the O
threshold O
for O
pilocarpine O
- O
induced O
convulsions B_DISEASE
. O

Morphological O
analysis O
of O
frontal O
forebrain O
sections O
with O
light O
microscopy O
revealed O
seizure B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
related O
damage O
to O
the O
hippocampal O
formation O
, O
thalamus O
, O
amygdala O
, O
olfactory O
cortex O
, O
substantia O
nigra O
and O
neocortex O
, O
which O
is O
typically O
observed O
with O
pilocarpine O
in O
doses O
exceeding O
350 O
mg O
/ O
kg O
. O

bilateral O
intrastriatal O
injections O
of O
isoniazid O
did O
not O
augment O
seizures B_DISEASE
produced O
by O
pilocarpine O
, O
200 O
mg O
/ O
kg O
. O

Application O
of O
an O
irreversible O
inhibitor O
of O
GABA O
transaminase O
, O
gamma O
- O
vinyl O
- O
GABA O
( O
D O
, O
L O
- O
4 O
- O
amino O
- O
hex O
- O
5 O
- O
enoic O
acid O
) O
, O
5 O
micrograms O
, O
into O
the O
SNR O
, O
bilaterally O
, O
suppressed O
the O
appearance O
of O
electrographic O
and O
behavioral O
seizures B_DISEASE
produced O
by O
pilocarpine O
, O
380 O
mg O
/ O
kg O
. O

This O
treatment O
was O
also O
sufficient O
to O
protect O
animals O
from O
the O
occurrence O
of O
brain B_DISEASE
damage I_DISEASE
. O

Microinjections O
of O
gamma O
- O
vinyl O
- O
GABA O
, O
5 O
micrograms O
, O
into O
the O
dorsal O
striatum O
, O
bilaterally O
, O
failed O
to O
prevent O
the O
development O
of O
convulsions B_DISEASE
produced O
by O
pilocarpine O
, O
380 O
mg O
/ O
kg O
. O

The O
results O
demonstrate O
that O
the O
threshold O
for O
pilocarpine O
- O
induced O
seizures B_DISEASE
in O
rats O
is O
subjected O
to O
the O
regulation O
of O
the O
GABA O
- O
mediated O
synaptic O
inhibition O
within O
the O
substantia O
nigra O
. O

Human O
and O
canine O
ventricular O
vasoactive O
intestinal O
polypeptide O
: O
decrease O
with O
heart B_DISEASE
failure I_DISEASE
. O

vasoactive B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
intestinal I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
polypeptide I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O
VIP B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
is O
a O
systemic B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
and O
coronary B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
vasodilator I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
that O
may O
have O
positive B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
inotropic B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
properties B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Myocardial O
levels O
of O
VIP O
were O
assayed O
before O
and O
after O
the O
development O
of O
heart B_DISEASE
failure I_DISEASE
in O
two O
canine O
models O
. O

In O
the O
first O
, O
cobalt O
cardiomyopathy B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O
induced O
in O
eight O
dogs O
; O
VIP O
( O
by O
radioimmunoassay O
) O
decreased O
from O
35 O
+ O
/ O
- O
11 O
pg O
/ O
mg O
protein O
( O
mean O
+ O
/ O
- O
SD O
) O
to O
5 O
+ O
/ O
- O
4 O
pg O
/ O
mg O
protein O
( O
P O
less O
than O
0 O
. O
05 O
) O
. O

In O
six O
dogs O
with O
doxorubicin O
- O
induced O
heart B_DISEASE
failure I_DISEASE
, O
VIP O
decreased O
from O
31 O
+ O
/ O
- O
7 O
to O
11 O
+ O
/ O
- O
4 O
pg O
/ O
mg O
protein O
( O
P O
less O
than O
0 O
. O
05 O
) O
. O

In O
addition O
, O
VIP O
content O
of O
left O
ventricular O
muscle O
of O
resected O
failing O
hearts O
in O
10 O
patients O
receiving O
a O
heart O
transplant O
was O
compared O
with O
the O
papillary O
muscles O
in O
14 O
patients O
( O
five O
with O
rheumatic B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
disease I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
, O
nine O
with O
myxomatous B_DISEASE
degeneration I_DISEASE
) O
receiving O
mitral O
valve O
prostheses O
. O

The O
lowest O
myocardial O
VIP O
concentration O
was O
found O
in O
the O
hearts O
of O
patients O
with O
coronary B_DISEASE
disease I_DISEASE
( O
one O
patient O
receiving O
a O
transplant O
and O
three O
receiving O
mitral O
prostheses O
) O
( O
6 O
. O
3 O
+ O
/ O
- O
1 O
. O
9 O
pg O
/ O
mg O
protein O
) O
. O

The O
other B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
patients B_PERSON/I_BODY_PART_OR_ORGAN_COMPONENT
undergoing O
transplantation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
had O
an O
average B_MEASURE
ejection I_MEASURE
fraction I_MEASURE
of O
17 B_MEASURE
% I_MEASURE
+ I_MEASURE
/ O
- O
6 B_MEASURE
% I_MEASURE
and O
a O
VIP B_MEASURE
level I_MEASURE
of O
8 B_MEASURE
. O
8 B_MEASURE
+ I_MEASURE
/ O
- O
3 B_MEASURE
. O
9 B_MEASURE
pg I_MEASURE
/ O
mg B_MEASURE
protein I_MEASURE
. O

The O
hearts O
without O
coronary B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
artery I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
disease I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O
average O
ejection O
fraction O
of O
this O
group O
62 O
% O
+ O
/ O
- O
10 O
% O
) O
had O
a O
VIP O
concentration O
of O
14 O
. O
1 O
+ O
/ O
- O
7 O
. O
9 O
pg O
/ O
mg O
protein O
, O
and O
this O
was O
greater O
than O
in O
hearts O
of O
the O
patients O
with O
coronary B_DISEASE
disease I_DISEASE
and O
the O
hearts O
of O
patients O
receiving O
a O
transplant O
( O
P O
less O
than O
0 O
. O
05 O
) O
. O

Myocardial B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
catecholamines I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
were O
also O
determined O
in O
14 B_PERSON/B_SPECIES[BIO]
subjects B_PERSON/I_SPECIES[BIO]
; O
a O
weak B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
correlation I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O
r B_OTHER/B_LOCATION
= O
0 B_MEASURE
. O
57 B_MEASURE
, O
P B_MEASURE
less I_MEASURE
than O
0 B_MEASURE
. O
05 B_MEASURE
) O
between O
the O
tissue B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
concentrations I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
VIP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
norepinephrine B_LOCATION/B_ORGANIZATION
was O
noted O
. O
( O
abstract B_ORGANIZATION/B_LOCATION
TRUNCATED I_ORGANIZATION/I_LOCATION
AT O
250 B_LOCATION/B_ENT
Words I_LOCATION/I_ENT
) O
. O

Non O
- O
invasive O
detection O
of O
coronary B_DISEASE
artery I_DISEASE
disease I_DISEASE
by O
body O
surface O
electrocardiographic O
mapping O
after O
dipyridamole O
infusion O
. O

Electrocardiographic O
changes O
after O
dipyridamole O
infusion O
( O
0 O
. O
568 O
mg O
/ O
kg O
/ O
4 O
min O
) O
were O
studied O
in O
41 O
patients O
with O
coronary B_DISEASE
artery I_DISEASE
disease I_DISEASE
and O
compared O
with O
those O
after O
submaximal O
treadmill O
exercise O
by O
use O
of O
the O
body O
surface O
mapping O
technique O
. O

patients O
were O
divided O
into O
three O
groups O
; O
19 O
patients O
without O
myocardial B_DISEASE/B_LOCATION
infarction I_DISEASE/I_LOCATION
( O
non O
- O
MI B_DISEASE/B_LOCATION
group O
) O
, O
14 O
with O
anterior B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
infarction I_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
( O
ANT B_LOCATION
- I_LOCATION
MI I_LOCATION
) O
and O
eight O
with O
inferior B_DISEASE
infarction I_DISEASE
( O
INF B_LOCATION/B_ORGANIZATION
- I_LOCATION/I_ORGANIZATION
MI I_LOCATION/I_ORGANIZATION
) O
. O

eighty B_NUMBER[MEASURE]
- O
seven B_NUMBER[MEASURE]
unipolar I_NUMBER[MEASURE]
electrocardiograms I_NUMBER[MEASURE]
( O
ECGs B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
distributed O
over O
the O
entire B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
thoracic I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
surface I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
were O
simultaneously O
recorded O
. O

After O
dipyridamole O
, O
ischemic B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
ST O
- O
segment O
depression B_DISEASE_ADJECTIVE[DISEASE]
( O
0 O
. O
05 O
MV O
or O
more O
) O
was O
observed O
in O
84 O
% O
of O
the O
non O
- O
MI B_DISEASE/B_LOCATION
group O
, O
29 O
% O
of O
the O
ANT B_LOCATION
- I_LOCATION
MI I_LOCATION
group O
, O
63 O
% O
of O
the O
INF B_LOCATION/B_ORGANIZATION
- I_LOCATION/I_ORGANIZATION
MI I_LOCATION/I_ORGANIZATION
group O
and O
61 O
% O
of O
the O
total O
population O
. O

exercise O
- O
induced O
ST O
depression B_DISEASE_ADJECTIVE[DISEASE]
was O
observed O
in O
84 O
% O
of O
the O
non O
- O
MI B_DISEASE/B_LOCATION
group O
, O
43 O
% O
of O
the O
ANT B_LOCATION/B_DISEASE
- I_LOCATION/I_DISEASE
MI I_LOCATION/I_DISEASE
group O
, O
38 O
% O
of O
the O
INF B_DISEASE/B_LOCATION
- I_DISEASE/I_LOCATION
MI I_DISEASE/I_LOCATION
group O
and O
61 O
% O
of O
the O
total O
. O

For O
individual O
patients O
, O
there O
were O
no O
obvious O
differences O
between O
the O
body O
surface O
distribution O
of O
ST O
depression B_DISEASE
in O
both O
tests O
. O

The O
increase B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O
pressure B_DISEASE/B_PROTEIN[GENE]
rate B_DISEASE/I_PROTEIN[GENE]
product B_DISEASE/I_PROTEIN[GENE]
after O
dipyridamole B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
was O
significantly O
less B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
than O
that O
during O
the O
treadmill B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
exercise I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
data O
suggest O
that O
the O
dipyridamole O
- O
induced O
myocardial B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
ischemia I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
is O
caused O
by O
the O
inhomogenous O
distribution O
of O
myocardial O
blood O
flow O
. O

We O
conclude O
that O
the O
dipyridamole O
ECG O
test O
is O
as O
useful O
as O
the O
exercise O
ECG O
test O
for O
the O
assessment O
of O
coronary B_DISEASE/B_LOCATION
artery I_DISEASE/I_LOCATION
disease I_DISEASE/I_LOCATION
. O

Bradycardia B_DISEASE
after O
high O
- O
dose O
intravenous O
methylprednisolone O
therapy O
. O

In O
5 O
consecutive O
patients O
with O
rheumatoid B_DISEASE/B_LOCATION
arthritis I_DISEASE/I_LOCATION
who O
received O
intravenous O
high O
- O
dose O
methylprednisolone O
( O
MP O
) O
therapy O
( O
1 O
g O
daily O
for O
2 O
or O
3 O
consecutive O
days O
) O
, O
a O
decline O
in O
pulse O
rate O
was O
observed O
, O
most O
pronounced O
on O
day O
4 O
. O

In O
one O
of O
the O
5 O
patients O
the O
bradycardia B_DISEASE
was O
associated O
with O
complaints O
of O
substernal O
pressure O
. O

reversal B_MEASURE/B_PERSON
to O
normal B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
heart I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
rate I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
was O
found O
on O
day B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
7 I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Electrocardiographic O
registrations O
showed O
sinus B_DISEASE_ADJECTIVE[DISEASE]
bradycardia I_DISEASE_ADJECTIVE[DISEASE]
in O
all O
cases O
. O

No O
significant B_DISEASE_ADJECTIVE[DISEASE]
changes I_DISEASE_ADJECTIVE[DISEASE]
in O
plasma B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
concentrations I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
electrolytes B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
were O
found O
. O

Careful B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
observation I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
patients B_PERSON
receiving O
high B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O
dose B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
MP I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
is O
recommended O
. O

High O
- O
dose O
MP O
may O
be O
contraindicated O
in O
patients O
with O
known O
heart B_DISEASE/B_LOCATION
disease I_DISEASE/I_LOCATION
. O

Two O
cases O
of O
downbeat B_DISEASE
nystagmus I_DISEASE
and O
oscillopsia B_DISEASE
associated O
with O
carbamazepine O
. O

Downbeat B_DISEASE/B_LOCATION
nystagmus I_DISEASE/I_LOCATION
is O
often O
associated O
with O
structural O
lesions O
at O
the O
craniocervical O
junction O
, O
but O
has O
occasionally O
been O
reported O
as O
a O
manifestation O
of O
metabolic O
imbalance O
or O
drug O
intoxication O
. O

We O
recorded O
the O
eye O
movements O
of O
two O
patients O
with O
reversible O
downbeat B_DISEASE
nystagmus I_DISEASE
related O
to O
carbamazepine O
therapy O
. O

The O
nystagmus B_DISEASE
of O
both O
patients O
resolved O
after O
reduction O
of O
the O
serum O
carbamazepine O
levels O
. O

Neuroradiologic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
investigations I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
including O
magnetic B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
resonance I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
imaging I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
scans I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
both O
patients B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
showed O
no O
evidence B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
intracranial B_DISEASE
abnormality I_DISEASE
. O

In O
patients O
with O
downbeat B_DISEASE/B_LOCATION
nystagmus I_DISEASE/I_LOCATION
who O
are O
taking O
anticonvulsant O
medications O
, O
consideration O
should O
be O
given O
to O
reduction O
in O
dose O
before O
further O
investigation O
is O
undertaken O
. O

Improvement O
by O
denopamine O
( O
ta O
- O
064 O
) O
of O
pentobarbital O
- O
induced O
cardiac B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
failure I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
the O
dog O
heart O
- O
lung O
preparation O
. O

The O
efficacy O
of O
denopamine O
, O
an O
orally O
active O
beta O
1 O
- O
adrenoceptor O
agonist O
, O
in O
improving O
cardiac B_DISEASE
failure I_DISEASE
was O
assessed O
in O
dog O
heart O
- O
lung O
preparations O
. O

Cardiac B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
functions I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
depressed O
by O
pentobarbital B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
118 B_MEASURE
+ I_MEASURE
/ O
- O
28 B_MEASURE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mg I_MEASURE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
; O
mean B_MEASURE
value I_MEASURE
+ I_MEASURE
/ O
- O
SD B_MEASURE
) O
such B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
that O
cardiac B_MEASURE
output I_MEASURE
and O
maximum B_MEASURE
rate I_MEASURE
of O
rise B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
of O
left B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ventricular B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
pressure I_MEASURE
( O
LV B_MEASURE/B_PROTEIN[GENE]
dP I_MEASURE/I_PROTEIN[GENE]
/ O
dt B_PROTEIN[GENE]/B_PERSON
max I_PROTEIN[GENE]/I_PERSON
) O
had O
been O
reduced O
by O
about O
35 B_NUMBER[MEASURE]/B_PERSON
% I_NUMBER[MEASURE]/I_PERSON
and O
26 B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
% B_PERSON/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
respective B_PERSON/B_MEASURE
controls I_PERSON/I_MEASURE
were O
improved O
by O
denopamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
10 B_MEASURE
- O
300 B_MEASURE/B_LOCATION
micrograms I_MEASURE/I_LOCATION
) O
in O
a O
dose B_MEASURE
- O
dependent B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
manner I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
. O

With O
100 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
micrograms I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
denopamine I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
almost O
complete B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
restoration B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
cardiac B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
performance I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
attained O
, O
associated O
with O
a O
slight B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
increase I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
heart B_DISEASE/B_GENE
rate I_DISEASE/I_GENE
. O

No O
arrhythmias B_DISEASE
were O
induced O
by O
these O
doses O
of O
denopamine O
. O

The O
results O
warrant O
clinical O
trials O
of O
denopamine O
in O
the O
treatment O
of O
cardiac B_DISEASE/B_LOCATION
failure I_DISEASE/I_LOCATION
. O

Clonazepam O
monotherapy O
for O
epilepsy B_DISEASE
in O
childhood O
. O

sixty O
patients O
( O
age O
- O
range O
one O
month O
to O
14 O
years O
) O
with O
other O
types O
of O
epilepsy B_DISEASE/B_MEASURE
than O
infantile B_DISEASE/B_PERSON
spasms B_DISEASE/I_PERSON
were O
treated O
with O
clonazepam O
. O

disappearance O
of O
seizures B_DISEASE
and O
normalization O
of O
abnormal O
EEG O
with O
disappearance O
of O
seizures B_DISEASE
were O
recognized O
in O
77 O
% O
and O
50 O
% O
, O
respectively O
. O

Seizures B_DISEASE/B_PERSON
disappeared O
in O
71 O
% O
of O
the O
patients O
with O
generalized O
seizures B_DISEASE
and O
89 O
% O
of O
partial O
seizures B_DISEASE/B_LOCATION
. O

Improvement B_DISEASE_ADJECTIVE[DISEASE]
of O
abnormal B_DISEASE
EEG I_DISEASE
was O
noticed O
in O
76 B_MEASURE/B_LOCATION
% I_MEASURE/I_LOCATION
of O
diffuse B_DISEASE_ADJECTIVE[DISEASE]
paroxysms I_DISEASE_ADJECTIVE[DISEASE]
and O
in O
67 B_PERSON/B_MEASURE
% B_PERSON/I_MEASURE
of O
focal B_DISEASE_ADJECTIVE[DISEASE]
paroxysms I_DISEASE_ADJECTIVE[DISEASE]
. O

In O
excellent B_MEASURE/B_PERSON
cases I_MEASURE/I_PERSON
, O
mean B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effective B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dosages B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
0 B_MEASURE
. O
086 B_MEASURE
+ I_MEASURE
/ O
- O
0 B_MEASURE
. O
021 B_MEASURE
mg I_MEASURE
/ O
kg B_MEASURE
/ O
day B_TIME[MEASURE]/B_PERSON
in O
infants B_PERSON
and O
0 B_MEASURE
. O
057 B_MEASURE
+ I_MEASURE
/ O
- O
0 B_MEASURE
. O
022 B_MEASURE
mg I_MEASURE
/ O
kg B_MEASURE
/ O
day B_TIME[MEASURE]/B_PERSON
in O
schoolchildren B_PERSON/B_BIO
, O
this O
difference B_MEASURE
was O
statistically O
significant B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
( O
p B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
less B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
than O
0 B_MEASURE/B_LOCATION
. O
005 B_MEASURE
) O
. O

The O
incidence O
of O
side O
effects O
such O
as O
drowsiness B_DISEASE
and O
ataxia B_DISEASE
was O
only O
5 O
% O
. O

Postmarketing O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
timolol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
hydrochlorothiazide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
antihypertensive I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
therapy I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

A O
postmarketing O
surveillance O
study O
was O
conducted O
to O
determine O
the O
safety O
and O
efficacy O
of O
a O
fixed O
- O
ratio O
combination O
containing O
10 O
mg O
of O
timolol O
maleate O
and O
25 O
mg O
of O
hydrochlorothiazide O
, O
administered O
twice O
daily O
for O
one O
month O
to O
hypertensive B_NUMBER[MEASURE]
patients O
. O

Data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
9 B_MEASURE
, O
037 B_TIME[MEASURE]
patients I_TIME[MEASURE]
were O
collected O
by O
1 B_MEASURE
, O
455 B_MEASURE
participating O
physicians B_PERSON/B_LOCATION
. O

Mean B_DISEASE/B_GENE
systolic I_DISEASE/I_GENE
blood I_DISEASE/I_GENE
pressure I_DISEASE/I_GENE
decreased O
25 B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
mmHg I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
and O
mean O
diastolic B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
blood I_MEASURE/I_BODY_PART_OR_ORGAN_COMPONENT
pressure I_MEASURE/I_BODY_PART_OR_ORGAN_COMPONENT
declined O
15 B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
mmHg I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
after O
one B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
month I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
timolol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
hydrochlorothiazide B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
therapy I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_LOCATION
( O
P B_MEASURE/B_PERSON
less I_MEASURE/I_PERSON
than O
0 B_MEASURE
. O
01 B_MEASURE
, O
both O
comparisons B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
) O
. O

Age B_TIME[MEASURE]/B_PERSON
, O
race B_SPORT[ENT]/B_PERSON
, O
and O
sex B_PERSON/B_MEASURE
appeared O
to O
have O
no O
influence B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
the O
decrease B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O
blood B_DISEASE/B_MEASURE
pressure I_DISEASE/I_MEASURE
. O

The O
antihypertensive O
effect O
of O
the O
drug O
was O
greater O
in O
patients O
with O
more O
severe O
hypertension B_DISEASE
. O

Overall O
, O
1 O
, O
453 O
patients O
experienced O
a O
total O
of O
2 O
, O
658 O
adverse O
events O
, O
the O
most O
common O
being O
fatigue B_DISEASE
, O
dizziness B_DISEASE
, O
and O
weakness B_DISEASE
. O

Treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
590 B_MEASURE
patients I_MEASURE
was O
discontinued O
because O
of O
adverse B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
events I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Salicylate O
nephropathy B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
Gunn O
rat O
: O
potential O
role O
of O
prostaglandins O
. O

We O
examined O
the O
potential O
role O
of O
prostaglandins O
in O
the O
development O
of O
analgesic O
nephropathy B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
Gunn O
strain O
of O
rat O
. O

The O
homozygous O
Gunn O
rats O
have O
unconjugated O
hyperbilirubinemia B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
due O
to O
the O
absence O
of O
glucuronyl O
transferase O
, O
leading O
to O
marked O
bilirubin O
deposition O
in O
renal O
medulla O
and O
papilla O
. O

These O
rats O
are O
also O
highly O
susceptible O
to O
develop O
papillary B_DISEASE
necrosis I_DISEASE
with O
analgesic O
administration O
. O

We O
used O
homozygous B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
( O
jj B_LOCATION/B_PERSON
) O
and O
phenotypically O
normal B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
heterozygous I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
( O
jJ B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
animals B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Four B_NUMBER[MEASURE]/B_ORGANIZATION
groups I_NUMBER[MEASURE]/I_ORGANIZATION
of O
rats B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
n B_OTHER/B_LOCATION
= O
7 B_MEASURE
) O
were O
studied O
: O
jj B_LOCATION/B_PERSON
and O
jJ B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
rats B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
treated O
either O
with O
aspirin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
300 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mg I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
kg O
every O
other B_TIME[MEASURE]
day I_TIME[MEASURE]
or O
sham B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
treated O
. O

After O
one B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
week I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
slices B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
of O
cortex B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
, O
outer B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
and O
inner B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
medulla I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
from O
one B_SPECIES[BIO]/B_SURGICAL_AND_MEDICAL_PROCEDURES[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
kidney I_SPECIES[BIO]/I_SURGICAL_AND_MEDICAL_PROCEDURES[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
incubated O
in O
buffer B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
and O
prostaglandin B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
synthesis I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O
determined O
by O
radioimmunoassay B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
other B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
kidney I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
was O
examined O
histologically O
. O

A O
marked B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
corticomedullary I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
gradient I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
prostaglandin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
synthesis I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
was O
observed O
in O
all O
groups B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

PGE2 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
synthesis I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O
significantly O
higher B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
in O
outer B_BODY_PART_OR_ORGAN_COMPONENT
medulla I_BODY_PART_OR_ORGAN_COMPONENT
, O
but O
not O
cortex B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
or O
inner B_BODY_PART_OR_ORGAN_COMPONENT
medulla I_BODY_PART_OR_ORGAN_COMPONENT
, O
of O
jj B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
( O
38 B_MEASURE
+ I_MEASURE
/ O
- O
6 B_MEASURE/B_PERSON
ng I_MEASURE/I_PERSON
/ O
mg B_MEASURE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
prot I_MEASURE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
than O
jJ B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPECIES[BIO]
rats B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_SPECIES[BIO]
( O
15 B_MEASURE
+ I_MEASURE
/ O
- O
3 B_MEASURE
) O
( O
p B_MEASURE
less I_MEASURE
than O
0 B_MEASURE
. O
01 B_MEASURE
) O
. O

aspirin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
treatment I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
reduced O
PGE2 B_DISEASE/B_GENE
synthesis B_DISEASE/I_GENE
in O
all O
regions B_LOCATION/B_BIO
, O
but O
outer B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
medullary I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
PGE2 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
remained O
higher B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
in O
jj B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
( O
18 B_MEASURE
+ I_MEASURE
/ O
- O
3 B_MEASURE
) O
than O
jJ B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
rats I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
( O
9 B_MEASURE
+ I_MEASURE
/ O
- O
2 B_MEASURE
) O
( O
p B_MEASURE
less I_MEASURE
than O
0 B_MEASURE
. O
05 B_MEASURE
) O
. O

PGF2 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
alpha B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
was O
also O
significantly O
higher B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O
the O
outer B_BODY_PART_OR_ORGAN_COMPONENT
medulla I_BODY_PART_OR_ORGAN_COMPONENT
of O
jj B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
rats I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
with O
and O
without O
aspirin B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
administration I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
p B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
less B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
than O
0 B_MEASURE
. O
05 B_MEASURE
) O
. O

The O
changes O
in O
renal O
prostaglandin O
synthesis O
were O
accompanied O
by O
evidence O
of O
renal B_DISEASE/B_GENE
damage I_DISEASE/I_GENE
in O
aspirin O
- O
treated O
jj O
but O
not O
jJ O
rats O
as O
evidenced O
by O
: O
increased O
incidence O
and O
severity O
of O
hematuria B_DISEASE/B_GENE
( O
p O
less O
than O
0 O
. O
01 O
) O
; O
increased O
serum O
creatinine O
( O
p O
less O
than O
0 O
. O
05 O
) O
; O
and O
increase O
in O
outer O
medullary O
histopathologic O
lesions O
( O
p O
less O
than O
0 O
. O
005 O
compared O
to O
either O
sham O
- O
treated O
jj O
or O
aspirin O
- O
treated O
jJ O
) O
. O

These O
results O
suggest O
that O
enhanced O
prostaglandin O
synthesis O
contributes O
to O
maintenance O
of O
renal O
function O
and O
morphological O
integrity O
, O
and O
that O
inhibition O
of O
prostaglandin O
synthesis O
may O
lead O
to O
pathological B_DISEASE
renal I_DISEASE
medullary I_DISEASE
lesions I_DISEASE
and O
deterioration B_DISEASE
of I_DISEASE
renal I_DISEASE
function I_DISEASE
. O

Prophylactic O
lidocaine O
in O
the O
early O
phase O
of O
suspected O
myocardial B_DISEASE
infarction I_DISEASE
. O

Four O
hundred O
two O
patients O
with O
suspected O
myocardial B_DISEASE/B_LOCATION
infarction I_DISEASE/I_LOCATION
seen O
within O
6 O
hours O
of O
the O
onset O
of O
symptoms O
entered O
a O
double O
- O
blind O
randomized O
trial O
of O
lidocaine O
vs O
placebo O
. O

During O
the O
1 O
hour O
after O
administration O
of O
the O
drug O
the O
incidence O
of O
ventricular B_DISEASE_ADJECTIVE[DISEASE]
fibrillation I_DISEASE_ADJECTIVE[DISEASE]
or O
sustained O
ventricular B_DISEASE
tachycardia I_DISEASE
among O
the O
204 O
patients O
with O
acute O
myocardial B_DISEASE
infarction I_DISEASE
was O
low O
, O
1 O
. O
5 O
% O
. O

Lidocaine O
, O
given O
in O
a O
300 O
mg O
dose O
intramuscularly O
followed O
by O
100 O
mg O
intravenously O
, O
did O
not O
prevent O
sustained O
ventricular B_DISEASE
tachycardia I_DISEASE
, O
although O
there O
was O
a O
significant O
reduction O
in O
the O
number O
of O
patients O
with O
warning O
arrhythmias B_DISEASE
between O
15 O
and O
45 O
minutes O
after O
the O
administration O
of O
lidocaine O
( O
p O
less O
than O
0 O
. O
05 O
) O
. O

The O
average O
plasma O
lidocaine O
level O
10 O
minutes O
after O
administration O
for O
patients O
without O
a O
myocardial B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
infarction I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O
significantly O
higher O
than O
that O
for O
patients O
with O
an O
acute O
infarction B_DISEASE
. O

The O
mean B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
plasma B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
lidocaine B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
level B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
patients B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
beta B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
blocking O
agents B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
no O
different B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O
that O
in O
patients B_PERSON/B_BIO
not O
on O
beta B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
blocking O
agents B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
. O

During O
the O
1 O
- O
hour O
study O
period O
, O
the O
incidence O
of O
central O
nervous O
system O
side O
effects O
was O
significantly O
greater O
in O
the O
lidocaine O
group O
, O
hypotension B_DISEASE
occurred O
in O
11 O
patients O
, O
nine O
of O
whom O
had O
received O
lidocaine O
, O
and O
four O
patients O
died O
from O
asystole B_DISEASE
, O
three O
of O
whom O
had O
had O
lidocaine O
. O

We O
cannot O
advocate O
the O
administration O
of O
lidocaine O
prophylactically O
in O
the O
early O
hours O
of O
suspected O
myocardial B_DISEASE/B_LOCATION
infarction I_DISEASE/I_LOCATION
. O

Evidence O
for O
a O
cholinergic O
role O
in O
haloperidol O
- O
induced O
catalepsy B_DISEASE
. O

experiments O
in O
mice O
tested O
previous O
evidence O
that O
activation O
of O
cholinergic O
systems O
promotes O
catalepsy B_DISEASE
and O
that O
cholinergic O
mechanisms O
need O
to O
be O
intact O
for O
full O
expression O
of O
neuroleptic O
- O
induced O
catalepsy B_DISEASE
. O

Large O
doses O
of O
the O
cholinomimetic O
, O
pilocarpine O
, O
could O
induce O
catalepsy B_DISEASE
when O
peripheral O
cholinergic O
receptors O
were O
blocked O
. O

Low O
doses O
of O
pilocarpine O
caused O
a O
pronounced O
enhancement O
of O
the O
catalepsy B_DISEASE
that O
was O
induced O
by O
the O
dopaminergic O
blocker O
, O
haloperidol O
. O

A O
muscarinic O
receptor O
blocker O
, O
atropine O
, O
disrupted O
haloperidol O
- O
induced O
catalepsy B_DISEASE
. O

Intracranial O
injection O
of O
an O
acetylcholine O
- O
synthesis O
inhibitor O
, O
hemicholinium O
, O
prevented O
the O
catalepsy B_DISEASE
that O
is O
usually O
induced O
by O
haloperidol O
. O

These O
findings O
suggest O
the O
hypothesis O
that O
the O
catalepsy B_DISEASE
that O
is O
produced O
by O
neuroleptics O
such O
as O
haloperidol O
is O
actually O
mediated O
by O
intrinsic O
central O
cholinergic O
systems O
. O

Alternatively O
, O
activation O
of O
central O
cholinergic O
systems O
could O
promote O
catalepsy B_DISEASE/B_ORGANISM_FUNCTION
by O
suppression O
of O
dopaminergic O
systems O
. O

Cardiovascular B_DISEASE
dysfunction I_DISEASE
and O
hypersensitivity B_DISEASE
to O
sodium O
pentobarbital O
induced O
by O
chronic O
barium O
chloride O
ingestion O
. O

Barium O
- O
supplemented O
Long O
- O
Evans O
hooded O
rats O
were O
characterized O
by O
a O
persistent O
hypertension B_DISEASE
that O
was O
evident O
after O
1 O
month O
of O
barium O
( O
100 O
micrograms O
/ O
ml O
mineral O
fortified O
water O
) O
treatment O
. O

Analysis O
of O
in O
vivo O
myocardial O
excitability O
, O
contractility O
, O
and O
metabolic O
characteristics O
at O
16 O
months O
revealed O
other O
significant O
barium O
- O
induced O
disturbances B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
within B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
the B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
cardiovascular B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
system B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
most O
distinctive O
aspect O
of O
the O
barium O
effect O
was O
a O
demonstrated O
hypersensitivity B_DISEASE
of O
the O
cardiovascular O
system O
to O
sodium O
pentobarbital O
. O

Under O
barbiturate B_DISEASE
anesthesia I_DISEASE
, O
virtually O
all O
of O
the O
myocardial B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
contractile B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
indices B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
depressed O
significantly O
in O
barium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
exposed O
rats B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
relative B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
the O
corresponding B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
control I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
fed O
rats B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
lack B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O
a O
similar B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
response I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
to O
ketamine O
and O
xylazine O
anesthesia B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
revealed O
that O
the O
cardiovascular B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
actions I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
sodium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
pentobarbital I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
barium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
treated O
rats B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
linked O
specifically O
to O
this O
anesthetic B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
, O
and O
were O
not O
representative B_PERSON/B_LOCATION
of O
a O
generalized B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
anesthetic I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
response I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Other B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
myocardial B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pathophysiologic B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
metabolic B_DISEASE_ADJECTIVE[DISEASE]
changes I_DISEASE_ADJECTIVE[DISEASE]
induced O
by O
barium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
manifest B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
, O
irrespective B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
of O
the O
anesthetic B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
employed O
. O

The O
contractile B_BODY_PART_OR_ORGAN_COMPONENT/B_MEASURE
element B_BODY_PART_OR_ORGAN_COMPONENT/I_MEASURE
shortening O
velocity B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
cardiac B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
muscle I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
fibers I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
was O
significantly O
slower B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O
both O
groups B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
of O
barium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
treated O
rats B_BIO/B_MEASURE
relative I_BIO/I_MEASURE
to O
the O
control B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
groups I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
, O
irrespective B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
of O
the O
anesthetic B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
regimen I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
. O

Similarly O
, O
significant B_DISEASE_ADJECTIVE[DISEASE]
disturbances I_DISEASE_ADJECTIVE[DISEASE]
in O
myocardial B_DISEASE_ADJECTIVE[DISEASE]/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
energy B_DISEASE_ADJECTIVE[DISEASE]/I_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
metabolism B_DISEASE_ADJECTIVE[DISEASE]/I_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
were O
detected O
in O
the O
barium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
exposed O
rats B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPECIES[BIO]
which O
were O
consistent B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
with O
the O
reduced O
contractile B_BODY_PART_OR_ORGAN_COMPONENT/B_MEASURE
element I_BODY_PART_OR_ORGAN_COMPONENT/I_MEASURE
shortening O
velocity B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

In O
addition B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
the O
excitability B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
the O
cardiac B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
conduction I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
system I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
was O
depressed O
preferentially O
in O
the O
atrioventricular B_BODY_PART_OR_ORGAN_COMPONENT
nodal I_BODY_PART_OR_ORGAN_COMPONENT
region I_BODY_PART_OR_ORGAN_COMPONENT
of O
hearts B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O
barium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
exposed O
rats B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Overall O
, O
the O
altered O
cardiac O
contractility O
and O
excitability O
characteristics O
, O
the O
myocardial O
metabolic B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
disturbances I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
, O
and O
the O
hypersensitivity B_DISEASE
of O
the O
cardiovascular O
system O
to O
sodium O
pentobarbital O
suggest O
the O
existence O
of O
a O
heretofore O
undescribed O
cardiomyopathic B_DISEASE_ADJECTIVE[DISEASE]
disorder I_DISEASE_ADJECTIVE[DISEASE]
induced O
by O
chronic O
barium O
exposure O
. O

These O
experimental B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
findings I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
represent O
the O
first B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
indication I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
that O
life B_TIME[MEASURE]/B_BODY_PART_OR_ORGAN_COMPONENT
- O
long B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
barium B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ingestion B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
may O
have O
significant B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
adverse B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
the O
mammalian B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cardiovascular I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
system I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Propranolol O
antagonism O
of O
phenylpropanolamine O
- O
induced O
hypertension B_DISEASE
. O

Phenylpropanolamine O
( O
PPA O
) O
overdose B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
can O
cause O
severe O
hypertension B_DISEASE
, O
intracerebral B_DISEASE
hemorrhage I_DISEASE
, O
and O
death O
. O

We O
studied O
the O
efficacy O
and O
safety O
of O
propranolol O
in O
the O
treatment O
of O
PPA O
- O
induced O
hypertension B_DISEASE
. O

subjects B_PERSON
received O
propranolol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
either O
by O
mouth B_BODY_PART_OR_ORGAN_COMPONENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
for O
48 B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
hours I_TIME[MEASURE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
before O
PPA B_DISEASE
or O
as O
a O
rapid B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
intravenous I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
infusion I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
after O
PPA B_DISEASE
. O

PPA B_MEASURE/B_DISEASE
, O
75 B_MEASURE
mg O
alone O
, O
increased O
blood B_DISEASE/B_GENE
pressure B_DISEASE/I_GENE
( O
31 B_MEASURE
+ I_MEASURE
/ O
- O
14 B_MEASURE
mm I_MEASURE
Hg I_MEASURE
systolic I_MEASURE
, O
20 B_MEASURE
+ I_MEASURE
/ O
- O
5 B_MEASURE
mm I_MEASURE
Hg I_MEASURE
diastolic I_MEASURE
) O
, O
and O
propranolol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pretreatment I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antagonized O
this O
increase B_DISEASE
( O
12 B_MEASURE
+ I_MEASURE
/ O
- O
10 B_MEASURE
mm I_MEASURE
Hg I_MEASURE
systolic I_MEASURE
, O
10 B_MEASURE
+ O
/ O
- O
7 B_MEASURE
mm I_MEASURE
Hg I_MEASURE
diastolic I_MEASURE
) O
. O

Intravenous B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
propranolol I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
after O
PPA B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
also O
decreased O
blood B_DISEASE/B_GENE
pressure I_DISEASE/I_GENE
. O

Left O
ventricular O
function O
( O
assessed O
by O
echocardiography O
) O
showed O
that O
PPA O
increased O
the O
stroke B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
volume O
30 O
% O
( O
from O
62 O
. O
5 O
+ O
/ O
- O
20 O
. O
9 O
to O
80 O
. O
8 O
+ O
/ O
- O
22 O
. O
4 O
ml O
) O
, O
the O
ejection O
fraction O
9 O
% O
( O
from O
64 O
% O
+ O
/ O
- O
10 O
% O
to O
70 O
% O
+ O
/ O
- O
7 O
% O
) O
, O
and O
cardiac O
output O
14 O
% O
( O
from O
3 O
. O
6 O
+ O
/ O
- O
0 O
. O
6 O
to O
4 O
. O
1 O
+ O
/ O
- O
1 O
. O
0 O
L O
/ O
min O
) O
. O

Intravenous B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
propranolol I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
reversed O
these O
effects B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Systemic B_DISEASE/B_PROTEIN[GENE]
vascular B_DISEASE/I_PROTEIN[GENE]
resistance B_DISEASE/I_PROTEIN[GENE]
was O
increased O
by O
PPA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
28 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
% I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
from O
1710 B_MEASURE
+ I_MEASURE
/ O
- O
200 B_MEASURE
to O
2190 B_MEASURE
+ I_MEASURE
/ O
- O
700 B_MEASURE/B_PERSON
dyne I_MEASURE/I_PERSON
X I_MEASURE/I_PERSON
SEC I_MEASURE/I_PERSON
/ O
cm5 B_MEASURE
) O
and O
was O
further O
increased O
by O
propranolol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
22 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
% I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
( O
to O
2660 B_MEASURE
+ I_MEASURE
/ O
- O
1200 B_TIME[MEASURE]
dyne I_TIME[MEASURE]
X I_TIME[MEASURE]
SEC I_TIME[MEASURE]
/ O
cm5 B_MEASURE
) O
. O

We O
conclude O
that O
PPA B_DISEASE/B_GENE
increases O
blood B_DISEASE/B_PROTEIN[GENE]
pressure B_DISEASE/I_PROTEIN[GENE]
by O
increasing O
systemic B_DISEASE/B_GENE
vascular B_DISEASE/I_GENE
resistance B_DISEASE/I_GENE
and O
cardiac B_MEASURE/B_DISEASE
output B_MEASURE/I_DISEASE
, O
and O
that O
propranolol B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antagonizes I_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
this O
increase B_DISEASE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O
reversing O
the O
effect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
PPA B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
cardiac B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
output B_MEASURE/I_BODY_PART_OR_ORGAN_COMPONENT
. O

That O
propranolol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
antagonizes O
the O
pressor B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
effect I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
of O
PPA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
is O
in O
contrast B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
the O
interaction B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
in O
which O
propranolol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
enhances O
the O
pressor B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effect I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
norepinephrine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O

This O
is O
probably O
because O
PPA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
has O
less B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
beta B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
2 B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
activity B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
than O
does O
norepinephrine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
. O

Mesangial O
function O
and O
glomerular B_DISEASE
sclerosis I_DISEASE
in O
rats O
with O
aminonucleoside O
nephrosis B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

The O
possible O
relationship O
between O
mesangial B_DISEASE/B_GENE
dysfunction I_DISEASE/I_GENE
and O
development O
of O
glomerular B_DISEASE
sclerosis I_DISEASE
was O
studied O
in O
the O
puromycin O
aminonucleoside O
( O
pan O
) O
model O
. O

Five B_NUMBER[MEASURE]/B_PERSON
male I_NUMBER[MEASURE]/I_PERSON
Wistar I_NUMBER[MEASURE]/I_PERSON
rats I_NUMBER[MEASURE]/I_PERSON
received O
repeated O
subcutaneous B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
Pan I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
injections I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
; O
five B_NUMBER[MEASURE]/B_PERSON
controls I_NUMBER[MEASURE]/I_PERSON
received O
saline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
only O
. O

After O
4 O
weeks O
the O
pan O
rats O
were O
severely O
proteinuric B_DISEASE_ADJECTIVE[DISEASE]
( O
190 O
+ O
/ O
- O
80 O
mg O
/ O
24 O
hr O
) O
, O
and O
all O
rats O
were O
given O
colloidal O
carbon O
( O
CC O
) O
intravenously O
. O

At O
5 O
months O
glomerular B_DISEASE/B_GENE
sclerosis I_DISEASE/I_GENE
was O
found O
in O
7 O
. O
6 O
+ O
/ O
- O
3 O
. O
4 O
% O
of O
the O
glomeruli O
of O
pan O
rats O
; O
glomeruli O
of O
the O
controls O
were O
normal O
. O

glomeruli B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
pan B_BIO/B_DISEASE
rats I_BIO/I_DISEASE
contained O
significantly O
more B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
CC B_LOCATION/B_BIO
than O
glomeruli B_BODY_PART_OR_ORGAN_COMPONENT/B_PERSON
of O
controls B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Glomeruli O
with O
sclerosis B_DISEASE
contained O
significantly O
more O
CC O
than O
non O
- O
sclerotic O
glomeruli O
in O
the O
same O
kidneys O
. O

CC B_GENE/B_DISEASE
was O
preferentially O
localized O
within O
the O
sclerotic B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
areas I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
of O
the O
affected B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
glomeruli I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
. O

Since O
mesangial O
CC O
clearance O
from O
the O
mesangium O
did O
not O
change O
during O
chronic O
pan O
treatment O
, O
we O
conclude O
that O
this O
preferential O
CC O
localization O
within O
the O
lesions O
is O
caused O
by O
an O
increased O
CC O
uptake O
shortly O
after O
injection O
in O
apparent O
vulnerable O
areas O
where O
sclerosis B_DISEASE
will O
develop O
subsequently O
. O

Cluster B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
showed O
a O
random B_MEASURE/B_LOCATION
distribution I_MEASURE/I_LOCATION
of O
lesions B_DISEASE
in O
the O
Pan B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
glomeruli I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
in O
concordance B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
with O
the O
random B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
localization I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
mesangial B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
areas I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
with O
dysfunction B_DISEASE
in O
this O
model B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O

Similar O
to O
the O
remnant O
kidney O
model O
in O
pan O
nephrosis B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
the O
development O
of O
glomerular B_DISEASE
sclerosis I_DISEASE
may O
be O
related O
to O
' O
mesangial O
overloading O
. O
' O
. O

relationship O
between O
nicotine O
- O
induced O
seizures B_DISEASE
and O
hippocampal O
nicotinic O
receptors O
. O

A O
controversy B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
has O
existed O
for O
several B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
years I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
concerning O
the O
physiological B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
relevance B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
nicotinic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
receptor I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
measured O
by O
alpha B_PROTEIN[GENE]/B_MEASURE
- O
bungarotoxin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
binding I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Using O
mice O
derived O
from O
a O
classical O
F2 O
and O
backcross O
genetic O
design O
, O
a O
relationship O
between O
nicotine O
- O
induced O
seizures B_DISEASE
and O
alpha O
- O
bungarotoxin O
nicotinic O
receptor O
concentration O
was O
found O
. O

mice O
sensitive O
to O
the O
convulsant O
effects O
of O
nicotine O
had O
greater O
alpha O
- O
bungarotoxin O
binding O
in O
the O
hippocampus O
than O
seizure B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
insensitive O
mice O
. O

The O
binding O
sites O
from O
seizure B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
sensitive O
and O
resistant O
mice O
were O
equally O
affected O
by O
treatment O
with O
dithiothreitol O
, O
trypsin O
or O
heat O
. O

Thus O
it O
appears O
that O
the O
difference O
between O
seizure B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
sensitive O
and O
insensitive O
animals O
may O
be O
due O
to O
a O
difference O
in O
hippocampal O
nicotinic O
receptor O
concentration O
as O
measured O
with O
alpha O
- O
bungarotoxin O
binding O
. O

The O
role O
of O
p O
- O
aminophenol O
in O
acetaminophen O
- O
induced O
nephrotoxicity B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
effect O
of O
bis O
( O
p O
- O
nitrophenyl O
) O
phosphate O
on O
acetaminophen O
and O
p O
- O
aminophenol O
nephrotoxicity B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
and O
metabolism O
in O
Fischer O
344 O
rats O
. O

Acetaminophen O
( O
APAP O
) O
produces O
proximal O
tubular B_DISEASE
necrosis I_DISEASE
in O
Fischer O
344 O
( O
F344 O
) O
rats O
. O

Recently O
, O
p B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
aminophenol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
( O
PAP B_GENE/B_DISEASE
) O
, O
a O
known O
potent B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
nephrotoxicant I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O
was O
identified O
as O
a O
metabolite B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
of O
APAP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
in O
F344 B_SPECIES[BIO]/B_BODY_PART_OR_ORGAN_COMPONENT
rats I_SPECIES[BIO]/I_BODY_PART_OR_ORGAN_COMPONENT
. O

The O
purpose O
of O
this O
study O
was O
to O
determine O
if O
PAP O
formation O
is O
a O
requisite O
step O
in O
APAP O
- O
induced O
nephrotoxicity B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Therefore O
, O
the O
effect O
of O
bis O
( O
p O
- O
nitrophenyl O
) O
phosphate O
( O
BNPP O
) O
, O
an O
acylamidase O
inhibitor O
, O
on O
APAP O
and O
PAP O
nephrotoxicity B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
and O
metabolism O
was O
determined O
. O

BNPP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
( O
1 B_MEASURE/B_LOCATION
to O
8 B_MEASURE
mm I_MEASURE
) O
reduced O
APAP B_DISEASE_ADJECTIVE[DISEASE]
deacetylation I_DISEASE_ADJECTIVE[DISEASE]
and O
covalent B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
binding B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
in O
F344 B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
renal I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
cortical I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
homogenates I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
in O
a O
concentration B_MEASURE/B_LOCATION
- O
dependent B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
manner B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

Pretreatment O
of O
animals O
with O
BNPP O
prior O
to O
APAP O
or O
PAP O
administration O
resulted O
in O
marked O
reduction O
of O
APAP O
( O
900 O
mg O
/ O
kg O
) O
nephrotoxicity B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
but O
not O
PAP O
nephrotoxicity B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

This O
result B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
not O
due B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
to O
altered O
disposition B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
either O
APAP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O
acetylated B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
metabolites I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
plasma B_BODY_PART_OR_ORGAN_COMPONENT/B_GENE
or O
renal B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
cortical I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
and O
hepatic B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
tissue I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O

Rather O
, O
BNPP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
pretreatment I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
reduced O
the O
fraction B_MEASURE
of O
APAP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
excreted O
as O
PAP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
by O
64 B_MEASURE
and O
75 B_MEASURE/B_LOCATION
% I_MEASURE/I_LOCATION
after O
APAP B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
doses I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
of O
750 B_MEASURE
and O
900 B_MEASURE
mg I_MEASURE
/ O
kg B_TIME[MEASURE]
. O

BNPP B_DISEASE/B_GENE
did O
not O
alter O
the O
excretion B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
APAP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
or O
any O
of O
its O
non O
- O
deacetylated O
metabolites B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
nor O
did O
BNPP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
alter O
excretion B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
PAP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
or O
its O
metabolites B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
after O
PAP B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
doses I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
of O
150 B_MEASURE
and O
300 B_MEASURE
mg I_MEASURE
/ O
kg B_TIME[MEASURE]
. O

Therefore O
, O
the O
BNPP O
- O
induced O
reduction O
in O
APAP O
- O
induced O
nephrotoxicity B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
appears O
to O
be O
due O
to O
inhibition O
of O
APAP O
deacetylation O
. O

It O
is O
concluded O
that O
PAP O
formation O
, O
in O
vivo O
, O
accounts O
, O
at O
least O
in O
part O
, O
for O
APAP O
- O
induced O
renal B_DISEASE
tubular I_DISEASE
necrosis I_DISEASE
. O

Morphine O
- O
induced O
seizures B_DISEASE
in O
newborn O
infants O
. O

Two O
neonates O
suffered O
from O
generalized O
seizures B_DISEASE
during O
the O
course O
of O
intravenous O
morphine O
sulfate O
for O
post O
- O
operative O
analgesia O
. O

They O
received O
morphine O
in O
doses O
of O
32 O
micrograms O
/ O
kg O
/ O
hr O
and O
40 O
micrograms O
/ O
kg O
/ O
hr O
larger O
than O
a O
group O
of O
10 O
neonates O
who O
received O
6 O
- O
24 O
micrograms O
/ O
kg O
/ O
hr O
and O
had O
no O
seizures B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O

plasma B_MEASURE
concentrations I_MEASURE
of O
morphine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
these O
neonates B_BIO/B_PERSON
was O
excessive B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
( O
60 B_MEASURE
and O
90 B_MEASURE
mg I_MEASURE
/ O
ml B_TIME[MEASURE]/B_PERSON
) O
. O

Other O
known O
reasons O
for O
seizures B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
were O
ruled O
out O
and O
the O
convulsions B_DISEASE
stopped O
a O
few O
hours O
after O
cessation O
of O
morphine O
and O
did O
not O
reoccur O
in O
the O
subsequent O
8 O
months O
. O

It O
is O
suggested O
that O
post B_DISEASE/B_MEASURE
- O
operative B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
intravenous I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
morphine I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
should O
not O
exceed O
20 B_MEASURE
micrograms I_MEASURE
/ O
kg B_MEASURE
/ O
ml B_MEASURE/B_PERSON
in O
neonates B_PERSON/B_BIO
. O

Indomethacin O
induced O
hypotension B_DISEASE
in O
sodium O
and O
volume O
depleted O
rats O
. O

After O
a O
single B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
oral I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
dose I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
of O
4 B_MEASURE
mg I_MEASURE
/ O
kg B_MEASURE
indomethacin I_MEASURE
( O
IDM B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O
to O
sodium O
and O
volume O
depleted O
rats B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
plasma I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
renin I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
activity I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O
PRA B_LOCATION/B_ORGANIZATION
) O
and O
systolic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
blood B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
pressure B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
fell O
significantly O
within O
four B_TIME[MEASURE]/B_ENT
hours I_TIME[MEASURE]/I_ENT
. O

In O
sodium B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
repleted O
animals B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
indomethacin I_BIO/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
did O
not O
change O
systolic B_MEASURE
blood I_MEASURE
pressure I_MEASURE
( O
BP B_PROTEIN[GENE]/B_DISEASE
) O
although O
plasma B_DISEASE/B_GENE
renin B_DISEASE/I_GENE
activity B_DISEASE/I_GENE
was O
decreased O
. O

Thus O
, O
indomethacin B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
by O
inhibition B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
prostaglandin B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
synthesis I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
may O
diminish O
the O
blood B_MEASURE
pressure I_MEASURE
maintaining O
effect B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
the O
stimulated O
renin B_GENE
- O
angiotensin B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
system B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
sodium B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O
volume B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
depletion I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

On O
the O
antiarrhythmic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
activity I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O
one B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
N I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
- O
substituted O
piperazine B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
derivative I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
trans B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
2 B_MEASURE
- O
amino B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
3 B_NUMBER[MEASURE]
- O
hydroxy B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
1 B_NUMBER[MEASURE]
, O
2 B_NUMBER[MEASURE]
, O
3 B_NUMBER[MEASURE]/B_LOCATION
, O
4 B_NUMBER[MEASURE]
- O
tetrahydroanaphthalene B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
antiarrhythmic B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
activity I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
of O
the O
compound B_PROTEIN[GENE]
N I_PROTEIN[GENE]
- O
( O
trans B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
3 B_MEASURE
- O
hydroxy B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
1 B_MEASURE
, O
2 B_NUMBER[MEASURE]
, O
3 B_NUMBER[MEASURE]/B_LOCATION
, O
4 B_NUMBER[MEASURE]
- O
tetrahydro B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
2 B_MEASURE
- O
naphthyl B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
- O
N B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
- O
( O
3 B_NUMBER[MEASURE]
- O
oxo B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENZYME[GENE]
- O
3 B_MEASURE
- O
phenyl B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
2 B_NUMBER[MEASURE]
- O
methylpropyl B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
- O
piperazine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hydrochloride I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
referred O
to O
as O
P11 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
is O
studied O
on O
anaesthesized B_PERSON
cats I_PERSON
and O
Wistar B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
albino I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
rats I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
as O
well O
as O
on O
non B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
anaesthesized O
rabbits B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Four O
types O
of O
experimental O
arrhythmia B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
are O
used O
- O
- O
with O
BaCl2 O
, O
with O
chloroform O
- O
adrenaline O
, O
with O
strophantine O
G O
and O
with O
aconitine O
. O

The O
compound B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
P11 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
is O
introduced O
in O
doses B_MEASURE/B_LOCATION
of O
0 B_MEASURE/B_LOCATION
. O
25 B_MEASURE
and O
0 B_MEASURE
. O
50 B_MEASURE
mg I_MEASURE
/ O
kg B_MEASURE
intravenously O
and O
10 B_MEASURE
mg I_MEASURE
/ O
kg B_MEASURE
orally O
. O

The O
compound O
manifests O
antiarrhythmic O
activity O
in O
all O
models O
of O
experimental O
arrhythmia B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
used O
, O
causing O
greatest O
inhibition O
on O
the O
arrhythmia B_DISEASE
induced O
by O
chloroform O
- O
adrenaline O
( O
in O
90 O
per O
cent O
) O
and O
with O
BaCl2 O
( O
in O
84 O
per O
cent O
) O
. O

The O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
obtained O
are O
associated O
with O
the O
beta B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
adrenoblocking B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
and O
with O
the O
membrane B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
stabilizing O
action B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
the O
compound B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Recurrent O
subarachnoid B_DISEASE
hemorrhage I_DISEASE
associated O
with O
aminocaproic O
acid O
therapy O
and O
acute B_DISEASE
renal I_DISEASE
artery I_DISEASE
thrombosis I_DISEASE
. O

Case B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
report I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

Epsilon O
aminocaproic O
acid O
( O
EACA O
) O
has O
been O
used O
to O
prevent O
rebleeding O
in O
patients O
with O
subarachnoid B_DISEASE
hemorrhage I_DISEASE
( O
SAH B_DISEASE
) O
. O

Although O
this O
agent O
does O
decrease O
the O
frequency O
of O
rebleeding O
, O
several O
reports O
have O
described O
thrombotic B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
complications O
of O
EACA O
therapy O
. O

These O
complications O
have O
included O
clinical O
deterioration O
and O
intracranial B_DISEASE
vascular I_DISEASE
thrombosis I_DISEASE
in O
patients O
with O
SAH B_DISEASE
, O
arteriolar O
and O
capillary O
fibrin O
thrombi B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
patients O
with O
fibrinolytic O
syndromes O
treated O
with O
EACA O
, O
or O
other O
thromboembolic B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
phenomena I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
. O

Since O
intravascular O
fibrin O
thrombi B_DISEASE
are O
often O
observed O
in O
patients O
with O
fibrinolytic O
disorders O
, O
EACA O
should O
not O
be O
implicated O
in O
the O
pathogenesis O
of O
fibrin O
thrombi B_DISEASE
in O
patients O
with O
disseminated B_DISEASE
intravascular I_DISEASE
coagulation I_DISEASE
or O
other O
' O
consumption B_DISEASE
coagulopathies I_DISEASE
. O
' O
This O
report O
describes O
subtotal O
infarction B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
the O
kidney O
due O
to O
thrombosis B_DISEASE
of I_DISEASE
a I_DISEASE
normal I_DISEASE
renal I_DISEASE
artery I_DISEASE
. O

This O
occlusion O
occurred O
after O
EACA O
therapy O
in O
a O
patient O
with O
SAH B_DISEASE/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
histopathological O
documentation O
of O
recurrent O
SAH B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

The O
corresponding O
clinical O
event O
was O
characterized O
by O
marked O
hypertension B_DISEASE
and O
abrupt O
neurological O
deterioration O
. O

Effect O
of O
vincristine O
sulfate O
on O
Pseudomonas B_DISEASE
infections I_DISEASE
in O
monkeys O
. O

In O
rhesus B_SPECIES[BIO]
monkeys I_SPECIES[BIO]
, O
intravenous B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
challenge I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
with O
0 B_MEASURE/B_LOCATION
. O
6 B_MEASURE
x O
10 B_NUMBER[MEASURE]
( O
10 B_MEASURE
) O
to O
2 B_MEASURE
. O
2 B_MEASURE
x O
10 B_MEASURE
( O
10 B_MEASURE
) O
Pseudomonas B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
aeruginosa I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
organisms I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
caused O
acute B_DISEASE
illness I_DISEASE
of O
4 B_NUMBER[MEASURE]/B_LOCATION
to O
5 B_TIME[MEASURE]
days I_TIME[MEASURE]
' I_TIME[MEASURE]
duration I_TIME[MEASURE]
with O
spontaneous B_DISEASE
recovery I_DISEASE
in O
13 B_NUMBER[MEASURE]/B_PERSON
of O
15 B_MEASURE/B_PERSON
monkeys B_MEASURE/I_PERSON
; O
blood B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
cultures I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
became O
negative B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
3 I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
to O
17 B_SEQUENCE[MEASURE]/B_ENT
days I_SEQUENCE[MEASURE]/I_ENT
after O
challenge B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O

Leukocytosis B_DISEASE_ADJECTIVE[DISEASE]
was O
observed O
in O
all O
monkeys O
. O

Intravenous O
or O
intratracheal O
inoculation O
of O
2 O
. O
0 O
to O
2 O
. O
5 O
mg O
of O
vincristine O
sulfate O
was O
followed O
by O
leukopenia B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
4 O
to O
5 O
days O
. O

Intravenous O
inoculation O
of O
4 O
. O
2 O
x O
10 O
( O
10 O
) O
to O
7 O
. O
8 O
x O
10 O
( O
10 O
) O
pyocin O
type O
6 O
Pseudomonas O
organisms O
in O
monkeys O
given O
vincristine O
sulfate O
4 O
days O
previously O
resulted O
in O
fatal O
infection B_DISEASE
in O
11 O
of O
14 O
monkeys O
, O
whereas O
none O
of O
four O
receiving O
Pseudomonas O
alone O
died O
. O

These O
studies O
suggest O
that O
an O
antimetabolite O
- O
induced O
leukopenia B_DISEASE
predisposes O
to O
severe O
Pseudomonas O
sepsis B_DISEASE
and O
that O
such O
monkeys O
may O
serve O
as O
a O
biological O
model O
for O
study O
of O
comparative O
efficacy O
of O
antimicrobial O
agents O
. O

modification O
by O
propranolol O
of O
cardiovascular O
effects O
of O
induced O
hypoglycaemia B_DISEASE
. O

The O
cardiovascular O
effects O
of O
hypoglycaemia B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O
with O
and O
without O
beta O
- O
blockade O
, O
were O
compared O
in O
fourteen O
healthy O
men O
. O

Eight B_NUMBER[MEASURE]
received O
insulin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
alone O
, O
and O
eight B_NUMBER[MEASURE]
, O
including O
two B_NUMBER[MEASURE]/B_PERSON
of O
the O
original B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
insulin I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
- O
only O
group B_ORGANIZATION/B_PERSON
, O
were O
given O
propranolol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O
insulin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

In O
the O
insulin O
- O
group O
the O
period O
of O
hypoglycaemia B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O
associated O
with O
an O
increase O
in O
heart O
- O
rate O
and O
a O
fall O
in O
diastolic O
blood O
- O
pressure O
. O

In O
the O
propranolol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O
insulin B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
group I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
there O
was O
a O
significant B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
fall I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O
heart B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
- O
rate B_MEASURE/B_ENT
in O
most B_PERSON/B_BIO
subjects I_PERSON/I_BIO
and O
an O
increase B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
diastolic B_MEASURE/B_DISEASE
pressure B_MEASURE/I_DISEASE
. O

typical B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
S I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
- O
T B_PROTEIN[GENE]/B_MEASURE
/ O
T B_LOCATION
changes I_LOCATION
occurred O
in O
the O
insulin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
group B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
but O
in O
none B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
propranolol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O
insulin B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
group I_ORGANIZATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Hypertension B_DISEASE/B_PERSON
in O
diabetics B_PERSON/B_BIO
prone O
to O
hypoglycaemia B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
attacks O
should O
not O
be O
treated O
with O
beta O
- O
blockers O
because O
these O
drugs O
may O
cause O
a O
sharp O
rise O
in O
blood O
- O
pressure O
in O
such O
patients O
. O

Long B_SEQUENCE[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O
term B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
propranolol B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
therapy B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
in O
pregnancy B_PERSON/B_DISEASE
: O
maternal B_PERSON/B_BIO
and O
fetal B_PERSON/B_DISEASE
outcome I_PERSON/I_DISEASE
. O

propranolol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
a O
beta B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
adrenergic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
blocking I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
agent I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
has O
found O
an O
important B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
position I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
practice B_LOCATION/B_EDU[ORGANIZATION]
of O
medicine B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O

Its O
use B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
pregnancy B_PERSON
, O
however O
, O
is O
an O
open B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
question I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O
a O
number B_MEASURE/B_PERSON
of O
detrimental B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
side I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
effects I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
have O
been O
reported O
in O
the O
fetus B_PERSON/B_BIO
and O
neonate B_PERSON/B_BIO
. O

Ten B_NUMBER[MEASURE]
patients I_NUMBER[MEASURE]
and O
12 B_NUMBER[MEASURE]/B_PERSON
pregnancies I_NUMBER[MEASURE]/I_PERSON
are O
reported O
where O
chronic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
propranolol I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
has O
been O
administered O
. O

Five B_PERSON
patients I_PERSON
with O
serial B_DISEASE
pregnancies I_DISEASE
with O
and O
without O
propranolol B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
also O
examined O
. O

maternal B_PERSON
, O
fetal B_PERSON
, O
and O
neonatal B_PERSON
complications I_PERSON
are O
examined O
. O

An O
attempt B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
made O
to O
differentiate O
drug B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
- O
related O
complications B_DISEASE
from O
maternal B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
disease I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
- O
- O
related O
complications B_DISEASE
. O

We O
conclude O
that O
previously O
reported O
hypoglycemia B_DISEASE
, O
hyperbilirubinemia B_DISEASE
, O
polycythemia B_DISEASE
, O
neonatal B_DISEASE
apnea I_DISEASE
, O
and O
bradycardia B_DISEASE
are O
not O
invariable O
and O
cannot O
be O
statistically O
correlated O
with O
chronic O
propranolol O
therapy O
. O

Growth B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
retardation I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
, O
however O
, O
appears O
to O
be O
significant O
in O
both O
of O
our O
series O
. O

Central B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
excitatory I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
actions I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
flurazepam B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O

Toxic B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
actions B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
flurazepam B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
FZP B_PROTEIN[GENE]/B_DISEASE
) O
were O
studied O
in O
cats B_SPECIES[BIO]
, O
mice B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
rats B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

High O
doses O
caused O
an O
apparent O
central O
excitation O
, O
most O
clearly O
seen O
as O
clonic O
convulsions B_DISEASE
, O
superimposed O
on O
general O
depression B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Following O
a O
lethal O
dose O
, O
death O
was O
always O
associated O
with O
convulsions B_DISEASE
. O

comparing O
the O
relative O
sensitivity O
to O
central O
depression B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
and O
excitation O
revealed O
that O
rats O
were O
least O
likely O
to O
have O
convulsions B_DISEASE
at O
doses O
that O
did O
not O
first O
cause O
loss B_DISEASE
of I_DISEASE
consciousness I_DISEASE
, O
while O
cats O
most O
clearly O
showed O
marked O
central O
excitatory O
actions O
. O

signs O
of O
FZP O
toxocity B_DISEASE
in O
cats O
included O
excessive O
salivation B_DISEASE/B_ORGANISM_FUNCTION
, O
extreme O
apprehensive O
behavior O
, O
retching O
, O
muscle B_DISEASE
tremors I_DISEASE
and O
convulsions B_DISEASE
. O

An O
interaction B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
between O
FZP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O
pentylenetetrazol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
PTZ B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O
was O
shown O
by O
pretreating O
mice B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
FZP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
before O
PTZ B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
challenge B_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

As O
a O
function O
of O
dose O
, O
FZP O
first O
protected O
against O
convulsions B_DISEASE
and O
death O
. O

At O
higher O
doses O
, O
however O
, O
convulsions B_DISEASE
again O
emerged O
. O

These O
doses O
of O
FZP O
were O
lower O
than O
those O
that O
would O
alone O
cause O
convulsions B_DISEASE
. O

These O
results O
may O
be O
relevant O
to O
the O
use O
of O
FZP O
in O
clinical O
situations O
in O
which O
there O
is O
increased O
neural O
excitability O
, O
such O
as O
epilepsy B_DISEASE
or O
sedative O
- O
hypnotic O
drug O
withdrawal O
. O

Use O
of O
propranolol O
in O
the O
treatment O
of O
idiopathic B_DISEASE
orthostatic I_DISEASE
hypotension I_DISEASE
. O

Five O
patients O
with O
idiopathic B_DISEASE/B_GENE
orthostatic I_DISEASE/I_GENE
hypotension I_DISEASE/I_GENE
who O
had O
physiologic O
and O
biochemical O
evidence O
of O
severe O
autonomic O
dysfunction O
were O
included O
in O
the O
study O
. O

They O
all O
exhibited O
markedly O
reduced O
plasma O
catecholamines O
and O
plasma O
renin O
activity O
in O
both O
recumbent O
and O
upright O
positions O
and O
had O
marked O
hypersensitivity B_DISEASE
to O
the O
pressor O
effects O
of O
infused O
norepinephrine O
. O

Treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O
propanolol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
administered O
intravenously O
( O
1 B_MEASURE
- O
5 B_TIME[MEASURE]
mg I_TIME[MEASURE]
) O
produced O
increases B_DISEASE_ADJECTIVE[DISEASE]
in O
supine B_BODY_PART_OR_ORGAN_COMPONENT/B_TIME[MEASURE]
and O
upright B_DISEASE/B_GENE
blood I_DISEASE/I_GENE
pressure I_DISEASE/I_GENE
in O
4 B_NUMBER[MEASURE]/B_PERSON
of O
the O
5 B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
individuals I_PERSON/I_BODY_PART_OR_ORGAN_COMPONENT
with O
rises B_DISEASE
ranging O
from O
11 B_MEASURE
/ O
6 B_MEASURE
to O
22 B_MEASURE
/ O
11 B_MEASURE
mmHg I_MEASURE
. O

Chronic B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
oral I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
administration I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
propranolol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
40 B_MEASURE
- O
160 B_MEASURE
mg I_MEASURE
/ O
day B_TIME[MEASURE]
) O
also O
elevated O
the O
blood B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pressures I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
these O
individuals B_PERSON/B_BIO
with O
increases B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
in O
the O
order B_MEASURE/B_PERSON
of O
20 B_MEASURE
- O
35 B_MEASURE
/ O
15 B_MEASURE
- O
25 B_MEASURE
mmg I_MEASURE
being O
observed O
. O

In O
1 O
patient O
, O
marked O
hypertension B_DISEASE
was O
induced O
by O
propranolol O
and O
the O
drug O
had O
to O
be O
withdrawn O
. O

It O
otherwise O
was O
well O
tolerated B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
no O
important B_DISEASE_ADJECTIVE[DISEASE]
side I_DISEASE_ADJECTIVE[DISEASE]
effects I_DISEASE_ADJECTIVE[DISEASE]
were O
observed O
. O

Treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
has O
been O
continued O
in O
3 B_PERSON/B_BIO
individuals I_PERSON/I_BIO
for O
6 B_NUMBER[MEASURE]
- O
13 B_TIME[MEASURE]
months I_TIME[MEASURE]
with O
persistence B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
the O
pressor B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
effect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
, O
although O
there O
appears O
to O
have O
been O
some O
decrease B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O
the O
degree B_MEASURE
of O
response B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
with O
time B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

hemodynamic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
measurements I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
1 B_NUMBER[MEASURE]
of O
the O
patients B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
demonstrated O
an O
increase B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
total B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
peripheral I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
resistance I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
essentially O
no O
change B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O
cardiac B_MEASURE/B_DISEASE
output B_MEASURE/I_DISEASE
following O
propranolol B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
therapy I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

The O
studies O
suggest O
that O
propranolol O
is O
a O
useful O
drug O
in O
selected O
patients O
with O
severe O
idiopathic B_DISEASE
orthostatic I_DISEASE
hypotension I_DISEASE
. O

Total B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
intravenous I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
anesthesia I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
with O
etomidate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

III B_NUMBER[MEASURE]
. O

Some O
observations B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O
adults B_PERSON/B_LOCATION
. O

An O
investigation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
undertaken O
to O
determine O
the O
dosage B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
etomidate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
required O
to O
maintain O
sleep B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
adults B_PERSON/B_LOCATION
undergoing O
surgery B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
under O
regional B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
local I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
anesthesia I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Premedication B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
of O
diazepam B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
10 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mg I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
atropine B_MEASURE
0 I_MEASURE
. O
5 B_MEASURE
mg I_MEASURE
was O
given O
, O
and O
sleep B_DISEASE
was O
induced O
and O
maintained O
by O
intermittent B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
intravenous I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
injections I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
etomidate B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
0 I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O
1 B_MEASURE
/ O
mg B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
kg B_TIME[MEASURE]
, O
given O
whenever O
the O
patient B_PERSON
would O
open O
his O
eyes B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
on O
request B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

A O
mean B_MEASURE
overall I_MEASURE
dose I_MEASURE
of O
etomidate B_MEASURE
17 I_MEASURE
. O
4 B_MEASURE
microgram I_MEASURE
/ O
kg B_MEASURE
/ O
min B_PERSON/B_TIME[MEASURE]
. O
was O
required O
to O
maintain O
sleep B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O
but O
great B_DISEASE
individual I_DISEASE
variation I_DISEASE
occurred O
, O
with O
older B_PERSON
patients I_PERSON
requiring O
less B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
drug I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
. O

The O
investigation O
was O
discontinued O
after O
18 O
patients O
because O
of O
the O
frequency O
and O
intensity O
of O
side O
- O
effects O
, O
particularly O
pain B_DISEASE
and O
myoclonia B_DISEASE
, O
which O
caused O
the O
technique O
to O
be O
abandoned O
in O
two O
cases O
. O

It O
is O
considered O
unlikely O
that O
etomidate O
will O
prove O
to O
be O
the O
hypnotic O
of O
choice O
for O
a O
totally O
intravenous O
anesthetic O
technique O
in O
adults O
because O
of O
the O
high O
incidence O
of O
myoclonia B_DISEASE
after O
prolonged O
administration O
. O

In O
several B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
patients I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
uncontrollable I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
muscle I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
movements I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
persisted O
for O
many B_TIME[MEASURE]/B_ENT
minutes I_TIME[MEASURE]/I_ENT
after O
complete B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
recovery I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
of O
consciousness B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Evidence B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
cardiac B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
beta I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
adrenoceptors B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
man B_PERSON/B_BIO
. O

We O
compared O
the O
effects O
of O
single O
doses O
of O
50 O
mg O
atenolol O
( O
cardioselective O
) O
, O
40 O
mg O
propranolol O
( O
nonselective O
) O
, O
and O
placebo O
on O
both O
exercise O
- O
and O
isoproterenol O
- O
induced O
tachycardia B_DISEASE
in O
two O
experiments O
involving O
nine O
normal O
subjects O
. O

Maximal B_MEASURE/B_PERSON
exercise B_MEASURE/I_PERSON
heart B_MEASURE/I_PERSON
rate B_MEASURE/I_PERSON
was O
reduced O
from O
187 B_MEASURE
+ I_MEASURE
/ O
- O
4 B_MEASURE
( O
SEM B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
) O
after O
placebo B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
146 B_MEASURE
+ I_MEASURE
/ O
- O
7 B_TIME[MEASURE]
bpm I_TIME[MEASURE]
after O
atenolol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
and O
138 B_MEASURE
+ I_MEASURE
/ O
- O
6 B_TIME[MEASURE]
bpm I_TIME[MEASURE]
after O
propranolol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
but O
there O
were O
no O
differences B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O
the O
drugs B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
effects O
on O
isoproterenol O
tachycardia B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
were O
determined O
before O
and O
after O
atropine O
( O
0 O
. O
04 O
mg O
/ O
kg O
IV O
) O
. O

isoproterenol B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
sensitivity I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
was O
determined O
as O
the O
intravenous B_MEASURE
dose I_MEASURE
that O
increased O
heart B_MEASURE
rate I_MEASURE
by O
25 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
bpm I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
CD25 B_GENE/B_MEASURE
) O
and O
this O
was O
increased O
from O
1 B_MEASURE
. O
8 B_MEASURE
+ I_MEASURE
/ O
- O
0 B_MEASURE
. O
3 B_MEASURE
micrograms I_MEASURE
after O
placebo B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
38 B_MEASURE
. O
9 B_MEASURE
+ I_MEASURE
/ O
- O
8 B_MEASURE
. O
3 B_MEASURE
micrograms I_MEASURE
after O
propranolol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
8 B_MEASURE
. O
3 B_MEASURE
+ I_MEASURE
/ O
- O
1 B_MEASURE
. O
7 B_MEASURE
micrograms I_MEASURE
after O
atenolol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
. O

The O
difference B_MEASURE
in O
the O
effects B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
the O
two B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O
significant B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

After O
atropine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
the O
CD25 B_GENE/B_MEASURE
was O
unchanged B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
after O
placebo B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
2 B_MEASURE
. O
3 B_MEASURE
+ I_MEASURE
/ O
- O
0 B_MEASURE
. O
3 B_MEASURE
micrograms I_MEASURE
) O
and O
atenolol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
( O
7 B_MEASURE
. O
7 B_MEASURE
+ I_MEASURE
/ O
- O
1 B_MEASURE
. O
3 B_MEASURE
micrograms I_MEASURE
) O
; O
it O
was O
reduced O
after O
propranolol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
24 B_MEASURE
. O
8 B_MEASURE
+ I_MEASURE
/ O
- O
5 B_MEASURE
. O
0 B_MEASURE
micrograms I_MEASURE
) O
, O
but O
remained O
different B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O
atenolol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
. O

This O
change B_MEASURE
with O
propranolol B_MEASURE
sensitivity I_MEASURE
was O
calculated O
as O
the O
apparent B_MEASURE/B_PERSON
Ka I_MEASURE/I_PERSON
, O
this O
was O
unchanged B_DISEASE_ADJECTIVE[DISEASE]
by O
atropine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
11 B_MEASURE
. O
7 B_MEASURE
+ I_MEASURE
/ O
- O
2 B_MEASURE
. O
1 B_MEASURE
and O
10 B_MEASURE
. O
1 B_MEASURE/B_LOCATION
+ I_MEASURE/I_LOCATION
/ O
- O
2 B_MEASURE
. O
5 B_MEASURE
ml I_MEASURE
/ O
ng B_PERSON/B_MEASURE
) O
. O

These O
data O
are O
consistent O
with O
the O
hypothesis O
that O
exercise O
- O
induced O
tachycardia B_DISEASE
results O
largely O
from O
beta O
1 O
- O
receptor O
activation O
that O
is O
blocked O
by O
both O
cardioselective O
and O
nonselective O
drugs O
, O
whereas O
isoproterenol O
activates O
both O
beta O
1 O
- O
and O
beta O
2 O
- O
receptors O
so O
that O
after O
cardioselective O
blockade O
there O
remains O
a O
beta O
2 O
- O
component O
that O
can O
be O
blocked O
with O
a O
nonselective O
drug O
. O

While O
there O
appear O
to O
be O
beta B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
receptors B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O
the O
human B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
heart I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
, O
their O
physiologic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O
pathologic B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
roles I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
remain O
to O
be O
defined O
. O

hormones O
and O
risk O
of O
breast B_DISEASE
cancer I_DISEASE
. O

This O
paper B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PRODUCT[OBJECT]
reports O
the O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
a O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
50 B_PERSON
menopausal I_PERSON
women I_PERSON
receiving O
hormonal B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
replacement I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
majority B_PERSON
( O
29 O
) O
had O
surgical B_PERSON/B_LOCATION
menopause I_PERSON/I_LOCATION
; O
their O
mean B_TIME[MEASURE]
age I_TIME[MEASURE]
was O
45 B_MEASURE
. O
7 B_MEASURE/B_ENT
years I_MEASURE/I_ENT
. O

It O
was O
hypothesized O
that O
progestins B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
could O
equilibrate O
the O
effects B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
the O
estrogenic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
stimulation I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
on O
the O
mammary B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
and O
endometrial B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
target I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
tissues I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
of O
women B_PERSON/B_BIO
on O
hormonal B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
replacement I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
schedule I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
consisted O
of O
conjugated B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
estrogens I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O
Premarin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O
1 B_MEASURE
. O
25 B_MEASURE
mg I_MEASURE
/ O
day B_TIME[MEASURE]
for O
21 B_TIME[MEASURE]/B_ENT
days I_TIME[MEASURE]/I_ENT
and O
Medroxyprogesterone B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acetate I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
10 I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mg I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
day B_TIME[MEASURE]
for O
10 B_NUMBER[MEASURE]/B_ENT
days I_NUMBER[MEASURE]/I_ENT
in O
each O
month B_TIME[MEASURE]/B_PERSON
. O

The O
mean B_TIME[MEASURE]/B_PERSON
treatment I_TIME[MEASURE]/I_PERSON
period I_TIME[MEASURE]/I_PERSON
was O
18 B_TIME[MEASURE]
months I_TIME[MEASURE]
. O

During O
the O
follow O
- O
up O
period B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
attention B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
was O
paid O
to O
breast B_DISEASE_ADJECTIVE[DISEASE]
modifications I_DISEASE_ADJECTIVE[DISEASE]
as O
evidenced O
by O
symptomatology B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O
physical B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
examination I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
, O
and O
plate B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
thermography I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Mastodynia B_DISEASE_ADJECTIVE[DISEASE]
was O
reported O
by O
21 O
patients O
, O
and O
physical O
examination O
revealed O
a O
light O
increase O
in O
breast O
firmness O
in O
12 O
women O
and O
a O
moderate O
increase O
in O
breast O
nodularity O
in O
2 O
women O
. O

Themography O
confirmed O
the O
existence O
of O
an O
excessive O
breast O
stimulation O
in O
1 O
women O
who O
complained O
of O
moderate O
mastodynia B_DISEASE
and O
in O
5 O
of O
the O
7 O
women O
who O
complained O
of O
severe O
mastodynia B_DISEASE
. O

normalization B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
was O
obtained O
by O
halving O
the O
estrogen B_MEASURE/B_LOCATION
dose B_MEASURE/I_LOCATION
. O

These O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
suggest O
that O
hormonal B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
replacement I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
can O
be O
safely O
prescribed O
if O
the O
following B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
criteria I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
are O
satisfied O
: O
1 B_SEQUENCE[MEASURE]
) O
preliminary B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
evaluation I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
patients B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O
a O
clinical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
, O
metabolic B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O
cytologic B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
mammographic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_EDU[ORGANIZATION]
perspective I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_EDU[ORGANIZATION]
; O
2 B_NUMBER[MEASURE]
) O
cyclic B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
treatment I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
schedule I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
with O
a O
progestative B_MEASURE/B_LOCATION
phase I_MEASURE/I_LOCATION
of O
10 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
days I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
; O
and O
3 B_NUMBER[MEASURE]
) O
periodic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
complete I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
follow I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
- O
up B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
with O
accurate B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
thermographic I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
evaluation I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
breast B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
target I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tissues I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Early O
infections B_DISEASE
in O
kidney O
, O
heart O
, O
and O
liver O
transplant O
recipients O
on O
cyclosporine O
. O

eighty O
- O
one O
renal O
, O
seventeen O
heart O
, O
and O
twenty O
- O
four O
liver O
transplant O
patients O
were O
followed O
for O
infection B_DISEASE
. O

seventeen B_PERSON
renal I_PERSON
patients I_PERSON
received O
azathioprine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
Aza B_SPECIES[BIO]/B_LOCATION
) O
and O
prednisone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O
part B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
a O
randomized B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
trial I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
immunosuppression B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
21 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cyclosporine I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
and O
- O
prednisone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
treated O
renal B_PERSON/B_BIO
transplant I_PERSON/I_BIO
patients I_PERSON/I_BIO
. O

All O
others B_PERSON
received O
cyclosporine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
prednisone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
randomized O
Aza O
patients O
had O
more O
overall O
infections B_DISEASE
( O
P O
less O
than O
0 O
. O
05 O
) O
and O
more O
nonviral O
infections B_DISEASE
( O
P O
less O
than O
0 O
. O
02 O
) O
than O
the O
randomized O
cyclosporine O
patients O
. O

Heart O
and O
liver O
patients O
had O
more O
infections B_DISEASE
than O
cyclosporine O
renal O
patients O
but O
fewer O
infections B_DISEASE
than O
the O
Aza O
renal O
patients O
. O

There O
were O
no O
infectious O
deaths O
in O
renal O
transplant O
patients O
on O
cyclosporine O
or O
Aza O
, O
but O
infection B_DISEASE
played O
a O
major O
role O
in O
3 O
out O
of O
6 O
cardiac O
transplant O
deaths O
and O
in O
8 O
out O
of O
9 O
liver O
transplant O
deaths O
. O

Renal O
patients O
on O
cyclosporine O
had O
the O
fewest O
bacteremias B_DISEASE_ADJECTIVE[DISEASE]
. O

Analysis O
of O
site O
of O
infection B_DISEASE
showed O
a O
preponderance O
of O
abdominal B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
infections I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
in O
liver O
patients O
, O
intrathoracic O
infections B_DISEASE/B_PERSON
in O
heart O
patients O
, O
and O
urinary B_DISEASE/B_PERSON
tract I_DISEASE/I_PERSON
infections I_DISEASE/I_PERSON
in O
renal O
patients O
. O

pulmonary O
infections B_DISEASE
were O
less O
common O
in O
cyclosporine O
- O
treated O
renal O
patients O
than O
in O
Aza O
- O
treated O
patients O
( O
P O
less O
than O
0 O
. O
05 O
) O
. O

Aza O
patients O
had O
significantly O
more O
staphylococcal B_DISEASE
infections I_DISEASE
than O
all O
other O
transplant O
groups O
( O
P O
less O
than O
0 O
. O
005 O
) O
, O
and O
systemic O
fungal B_DISEASE
infections I_DISEASE
occurred O
only O
in O
the O
liver O
transplant O
group O
. O

cytomegalovirus B_VIRUS[BIO]/B_DISEASE
( O
CMV B_VIRUS[BIO]/B_PROTEIN[GENE]
) O
shedding O
or O
serological B_DISEASE_ADJECTIVE[DISEASE]
rises I_DISEASE_ADJECTIVE[DISEASE]
in O
antibody B_MEASURE/B_DISEASE
titer I_MEASURE/I_DISEASE
, O
or O
both O
occurred O
in O
78 B_MEASURE/B_LOCATION
% I_MEASURE/I_LOCATION
of O
cyclosporine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
patients I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
and O
76 B_MEASURE/B_LOCATION
% I_MEASURE/I_LOCATION
of O
Aza B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
patients I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O

Of O
the O
cyclosporine O
patients O
, O
15 O
% O
had O
symptoms O
related O
to O
CMV B_DISEASE
infection I_DISEASE
. O

Serological O
evidence O
for O
Epstein B_DISEASE
Barr I_DISEASE
Virus I_DISEASE
infection I_DISEASE
was O
found O
in O
20 O
% O
of O
65 O
cyclosporine O
patients O
studied O
. O

Three O
had O
associated O
symptoms O
, O
and O
one O
developed O
a O
lymphoma B_DISEASE
. O

Structure O
- O
activity O
and O
dose O
- O
effect O
relationships O
of O
the O
antagonism O
of O
picrotoxin O
- O
induced O
seizures B_DISEASE
by O
cholecystokinin O
, O
fragments O
and O
analogues O
of O
cholecystokinin O
in O
mice O
. O

Intraperitoneal O
administration O
of O
cholecystokinin O
octapeptide O
sulphate O
ester O
( O
CCK O
- O
8 O
- O
SE O
) O
and O
nonsulphated O
cholecystokinin O
octapeptide O
( O
CCK O
- O
8 O
- O
NS O
) O
enhanced O
the O
latency O
of O
seizures B_DISEASE
induced O
by O
picrotoxin O
in O
mice O
. O

Experiments B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
N B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
and O
C B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
terminal B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fragments B_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
revealed O
that O
the O
C B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
terminal B_PROTEIN[GENE]/B_LOCATION
tetrapeptide B_PROTEIN[GENE]/I_LOCATION
( O
CCK B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
5 B_MEASURE/B_LOCATION
- O
8 B_NUMBER[MEASURE]
) O
was O
the O
active B_LOCATION/B_PERSON
centre I_LOCATION/I_PERSON
of O
the O
CCK B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
octapeptide B_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
molecule B_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
analogues B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
CCK I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
8 B_NUMBER[MEASURE]
- O
SE B_LOCATION
and O
CCK B_LOCATION/B_GENE
- O
8 B_SEQUENCE[MEASURE]
- O
NS B_LOCATION
( O
dose B_MEASURE/B_LOCATION
range I_MEASURE/I_LOCATION
0 I_MEASURE/I_LOCATION
. O
2 B_MEASURE
- O
6 B_MEASURE
. O
4 B_MEASURE/B_PERSON
mumol I_MEASURE/I_PERSON
/ O
kg B_MEASURE
) O
and O
caerulein B_MEASURE/B_LOCATION
dose I_MEASURE/I_LOCATION
range I_MEASURE/I_LOCATION
0 I_MEASURE/I_LOCATION
. O
1 B_MEASURE
- O
0 B_MEASURE
. O
8 B_MEASURE/B_PERSON
mumol I_MEASURE/I_PERSON
/ O
kg B_MEASURE
) O
showed O
bell B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
- O
shaped O
dose B_MEASURE/B_LOCATION
- O
effect B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
curves I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O
with O
the O
greatest B_MEASURE
maximum I_MEASURE
inhibition I_MEASURE
for O
CCK B_LOCATION/B_GENE
- O
8 B_NUMBER[MEASURE]
- O
NS B_LOCATION
. O

The O
peptide O
CCK O
- O
5 O
- O
8 O
had O
weak O
anticonvulsant O
activity O
in O
comparison O
to O
the O
octapeptides O
, O
3 O
. O
2 O
mumol O
/ O
kg O
and O
larger O
doses O
of O
the O
reference O
drug O
, O
diazepam O
, O
totally O
prevented O
picrotoxin O
- O
induced O
seizures B_DISEASE
and O
mortality O
. O

The O
maximum B_MEASURE
effect I_MEASURE
of O
the O
peptides B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
tested O
was O
less B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
than O
that O
of O
diazepam B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O

Experiments B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
analogues B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
derivatives B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
CCK B_LOCATION/B_GENE
- O
5 B_NUMBER[MEASURE]
- O
8 B_TIME[MEASURE]/B_LOCATION
demonstrated O
that O
the O
effectiveness B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
the O
beta B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
alanyl B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
derivatives I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
CCK B_LOCATION/B_GENE
- O
5 B_NUMBER[MEASURE]
- O
8 B_TIME[MEASURE]/B_LOCATION
were O
enhanced O
and O
that O
they O
were O
equipotent B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
CCK B_LOCATION/B_PROTEIN[GENE]
- O
8 B_MEASURE
- O
SE B_DISEASE/B_MEASURE
. O

Of O
the O
CCK B_LOCATION/B_GENE
- O
2 B_NUMBER[MEASURE]/B_LOCATION
- O
8 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analogues I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
Ser B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
SO3H B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/B_BACTERIUM[BIO]
) O
7 B_MEASURE
- O
AC B_LOCATION/B_ORGANIZATION
- O
CCK B_LOCATION/B_GENE
- O
2 B_NUMBER[MEASURE]
- O
8 B_NUMBER[MEASURE]
- O
SE B_LOCATION
and O
Thr B_LOCATION/B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]
( O
SO3H B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/B_BACTERIUM[BIO]
) O
7 B_MEASURE
- O
AC B_LOCATION/B_ORGANIZATION
- O
CCK B_LOCATION/B_GENE
- O
2 B_NUMBER[MEASURE]
- O
8 B_NUMBER[MEASURE]
- O
SE B_LOCATION
and O
Hyp B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
( O
SO3H B_LOCATION/B_PROTEIN[GENE]
) O
- O
AC B_LOCATION/B_ORGANIZATION
- O
CCK B_LOCATION/B_GENE
- O
2 B_NUMBER[MEASURE]
- O
8 B_SEQUENCE[MEASURE]/B_LOCATION
- O
SE B_LOCATION
were O
slightly O
more O
active B_DISEASE_ADJECTIVE[DISEASE]
than O
CCK B_LOCATION/B_GENE
- O
8 B_TIME[MEASURE]/B_LOCATION
- O
SE B_LOCATION/B_DISEASE
. O

Vasopressin O
as O
a O
possible O
contributor O
to O
hypertension B_DISEASE
. O

The O
role O
of O
vasopressin O
as O
a O
pressor O
agent O
to O
the O
hypertensive B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
process O
was O
examined O
. O

Vasopressin O
plays O
a O
major O
role O
in O
the O
pathogenesis O
of O
DOCA O
- O
salt O
hypertension B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
since O
the O
elevation O
of O
blood O
pressure O
was O
not O
substantial O
in O
the O
rats O
with O
lithium O
- O
treated O
diabetes B_DISEASE
insipidus I_DISEASE
after O
DOCA O
- O
salt O
treatment O
. O

Administration B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
DDAVP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
which O
has O
antidiuretic B_DISEASE_ADJECTIVE[DISEASE]
action I_DISEASE_ADJECTIVE[DISEASE]
but O
minimal B_TIME[MEASURE]/B_LOCATION
vasopressor I_TIME[MEASURE]/I_LOCATION
effect I_TIME[MEASURE]/I_LOCATION
failed O
to O
increase O
blood B_DISEASE/B_GENE
pressure B_DISEASE/I_GENE
to O
the O
levels B_MEASURE/B_GENE
observed O
after O
administration B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
AVP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O

Furthermore O
, O
the O
pressor O
action O
of O
vasopressin O
appears O
to O
be O
important O
in O
the O
development O
of O
this O
model O
of O
hypertension B_DISEASE
, O
since O
the O
enhanced O
pressor O
responsiveness O
to O
the O
hormone O
was O
observed O
in O
the O
initial O
stage O
of O
hypertension B_DISEASE/B_ORGANISM_FUNCTION
. O

increased O
secretion O
of O
vasopressin O
from O
neurohypophysis O
also O
promotes O
the O
function O
of O
the O
hormone O
as O
a O
pathogenetic O
factor O
in O
hypertension B_DISEASE
. O

An O
unproportional B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
release I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
vasopressin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
compared O
to O
plasma B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
osmolality I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
may O
be O
induced O
by O
the O
absence B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
an O
adjusting O
control B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
angiotensin B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
II B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
forming B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
receptor B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
binding B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
capacity B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
sodium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
balance I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
the O
brain B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
. O

However O
, O
the O
role O
of O
vasopressin O
remains O
to O
be O
determined O
in O
human O
essential O
hypertension B_DISEASE
. O

Toxic B_DISEASE_ADJECTIVE[DISEASE]
hepatitis I_DISEASE_ADJECTIVE[DISEASE]
induced O
by O
disulfiram O
in O
a O
non O
- O
alcoholic O
. O

A O
reversible O
toxic B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
liver B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
damage B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
observed O
in O
a O
non O
- O
alcoholic O
woman O
treated O
with O
disulfiram O
. O

The O
causative B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
relationship I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
proven O
by O
challenge B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Atrial B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
thrombosis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
involving O
the O
heart O
of O
F O
- O
344 O
rats O
ingesting O
quinacrine O
hydrochloride O
. O

Quinacrine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
hydrochloride I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
is O
toxic B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
the O
heart B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
of O
F B_OTHER/B_MEASURE
- O
344 B_MEASURE/B_BIO
rats I_MEASURE/I_BIO
. O

rats O
treated O
with O
500 O
ppm O
quinacrine O
hydrochloride O
in O
the O
diet O
all O
developed O
a O
high O
incidence O
of O
left O
atrial B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
thrombosis I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
. O

The O
lesion O
was O
associated O
with O
cardiac B_DISEASE
hypertrophy I_DISEASE
and O
dilatation O
and O
focal O
myocardial B_DISEASE
degeneration I_DISEASE
. O

rats O
died O
from O
cardiac B_DISEASE
hypertrophy I_DISEASE
with O
severe O
acute O
and O
chronic O
congestion O
of O
the O
lungs O
, O
liver O
, O
and O
other O
organs O
. O

seventy O
percent O
of O
rats O
given O
250 O
ppm O
quinacrine O
hydrochloride O
and O
1 O
, O
000 O
ppm O
sodium O
nitrite O
simultaneously O
in O
the O
diet O
had O
thrombosis B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
the O
atria O
of O
the O
heart O
, O
while O
untreated O
control O
rats O
in O
this O
laboratory O
did O
not O
have O
atrial B_DISEASE/B_PERSON
thrombosis I_DISEASE/I_PERSON
. O

Sodium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
nitrite I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
combination B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
with O
quinacrine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hydrochloride I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
appeared O
to O
have O
no O
additional B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effect I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Alternating B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sinus I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
rhythm I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
intermittent O
sinoatrial B_DISEASE
block I_DISEASE
induced O
by O
propranolol O
. O

Alternating B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
sinus I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
rhythm I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
and O
intermittent O
sinoatrial B_DISEASE
( I_DISEASE
S I_DISEASE
- I_DISEASE
A I_DISEASE
) I_DISEASE
block I_DISEASE
was O
observed O
in O
a O
57 O
- O
year O
- O
old O
woman O
, O
under O
treatment O
for O
angina B_DISEASE
with O
80 O
mg O
propranolol O
daily O
. O

The O
electrocardiogram B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENT
showed O
alternation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O
long B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
and O
short B_DISEASE_ADJECTIVE[DISEASE]
P I_DISEASE_ADJECTIVE[DISEASE]
- O
P B_MEASURE
intervals I_MEASURE
and O
occasional B_DISEASE/B_MEASURE
pauses I_DISEASE/I_MEASURE
. O

These O
pauses B_DISEASE/B_TIME[MEASURE]
were O
always O
preceded O
by O
the O
short B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
P I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
- O
P B_MEASURE
intervals I_MEASURE
and O
were O
usually O
followed O
by O
one B_NUMBER[MEASURE]/B_PERSON
or O
two B_NUMBER[MEASURE]
P I_NUMBER[MEASURE]
- O
P B_TIME[MEASURE]/B_LOCATION
intervals I_TIME[MEASURE]/I_LOCATION
of O
0 B_MEASURE
. O
92 B_MEASURE
- O
0 B_NUMBER[MEASURE]
. O
95 B_MEASURE
s I_MEASURE
representing O
the O
basic B_TIME[MEASURE]/B_PERSON
sinus I_TIME[MEASURE]/I_PERSON
cycle I_TIME[MEASURE]/I_PERSON
. O

Following O
these O
basic O
sinus O
cycles O
, O
alternating B_DISEASE/B_ORGANISM_FUNCTION
rhythm I_DISEASE/I_ORGANISM_FUNCTION
started O
with O
the O
longer O
P O
- O
P O
interval O
. O

The O
long B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
P I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
- O
P B_LOCATION/B_MEASURE
intervals I_LOCATION/I_MEASURE
ranged O
between O
1 B_MEASURE/B_LOCATION
. O
04 B_MEASURE
- O
1 B_MEASURE
. O
12 B_TIME[MEASURE]
s I_TIME[MEASURE]
and O
the O
short B_MEASURE/B_LOCATION
P I_MEASURE/I_LOCATION
- O
P B_MEASURE/B_LOCATION
intervals I_MEASURE/I_LOCATION
between O
0 B_MEASURE/B_LOCATION
. O
80 B_MEASURE
- O
0 B_MEASURE
. O
84 B_MEASURE
s I_MEASURE
, O
respectively O
. O

The O
duration B_MEASURE/B_LOCATION
of O
the O
pauses B_DISEASE/B_TIME[MEASURE]
were O
equal B_MEASURE
or O
almost O
equal B_MEASURE
to O
one B_NUMBER[MEASURE]
short I_NUMBER[MEASURE]
plus O
one B_NUMBER[MEASURE]/B_LOCATION
long I_NUMBER[MEASURE]/I_LOCATION
P I_NUMBER[MEASURE]/I_LOCATION
- O
P B_MEASURE/B_LOCATION
interval I_MEASURE/I_LOCATION
or O
to O
twice O
the O
basic B_MEASURE
sinus I_MEASURE
cycle I_MEASURE
. O

In O
one O
recording O
a O
short O
period O
of O
regular O
sinus O
rhythm O
with O
intermittent O
2 O
/ O
1 O
S B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
A I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
block I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
observed O
. O

This O
short B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
period I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
sinus B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
rhythm I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O
interrupted O
by O
sudden B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
prolongation B_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
the O
P B_OTHER/B_LOCATION
- O
P B_MEASURE/B_LOCATION
interval I_MEASURE/I_LOCATION
starting O
the O
alternative B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
rhythm I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
. O

There O
were O
small B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
changes I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
in O
the O
shape B_MEASURE/B_LOCATION
of O
the O
P B_LOCATION
waves I_LOCATION
and O
P B_PROTEIN[GENE]/B_LOCATION
- O
R B_MEASURE/B_LOCATION
intervals I_MEASURE/I_LOCATION
. O

S B_DISEASE/B_PROTEIN[GENE]
- O
A B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
conduction B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
through O
two B_LOCATION
pathways I_LOCATION
, O
the O
first B_SEQUENCE[MEASURE]/B_LOCATION
with O
2 B_NUMBER[MEASURE]
/ O
1 B_MEASURE
block O
the O
second B_SEQUENCE[MEASURE]/B_PERSON
having O
0 B_MEASURE/B_LOCATION
. O
12 B_MEASURE
- O
0 B_MEASURE
. O
14 B_MEASURE
s I_MEASURE
longer I_MEASURE
conduction I_MEASURE
time I_MEASURE
and O
with O
occasional B_TIME[MEASURE]
2 I_TIME[MEASURE]
/ O
1 B_MEASURE/B_LOCATION
block I_MEASURE/I_LOCATION
was O
proposed O
for O
the O
explanation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
alternating O
P B_OTHER/B_LOCATION
- O
P B_MEASURE
interval I_MEASURE
and O
other B_DISEASE/B_PROTEIN[GENE]
electrocardiographic B_DISEASE/I_PROTEIN[GENE]
features B_DISEASE/I_PROTEIN[GENE]
seen O
. O

atropine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
1 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
mg I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
given O
intravenously O
resulted O
in O
shortening B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
all O
P B_PROTEIN[GENE]/B_LOCATION
- O
P B_MEASURE
intervals I_MEASURE
without O
changing O
the O
rhythm B_DISEASE/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
abnormal O
rhythm O
disappeared O
with O
the O
withdrawal O
of O
propranolol O
and O
when O
the O
drug O
was O
restarted O
a O
2 O
/ O
1 O
S B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
A I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
block I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
seen O
. O

This O
was O
accepted O
as O
evidence O
for O
propranolol O
being O
the O
cause O
of O
this O
conduction B_DISEASE
disorder I_DISEASE
. O

Antitumor O
effect O
, O
cardiotoxicity B_DISEASE
, O
and O
nephrotoxicity B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
doxorubicin O
in O
the O
IgM O
solid O
immunocytoma B_DISEASE
- O
bearing O
Lou O
/ O
M O
/ O
WSL O
rat O
. O

Antitumor O
activity O
, O
cardiotoxicity B_DISEASE
, O
and O
nephrotoxicity B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
induced O
by O
doxorubicin O
were O
studied O
in O
Lou O
/ O
M O
/ O
WSL O
inbred O
rats O
each O
bearing O
a O
transplantable O
solid O
IgM O
immunocytoma B_DISEASE
. O

Animals O
with O
a O
tumor B_DISEASE
( O
diameter O
, O
15 O
. O
8 O
+ O
/ O
- O
3 O
. O
3 O
mm O
) O
were O
treated O
with O
IV O
injections O
of O
doxorubicin O
on O
5 O
consecutive O
days O
, O
followed O
by O
1 O
weekly O
injection O
for O
7 O
weeks O
( O
dose O
range O
, O
0 O
. O
015 O
- O
4 O
. O
0 O
mg O
/ O
kg O
body O
wt O
) O
. O

Tumor B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
regression O
was O
observed O
with O
0 O
. O
5 O
mg O
doxorubicin O
/ O
kg O
. O

Complete O
disappearance O
of O
the O
tumor B_DISEASE
was O
induced O
with O
1 O
. O
0 O
mg O
doxorubicin O
/ O
kg O
. O

Histologic O
evidence O
of O
cardiotoxicity B_DISEASE
scored O
as O
grade O
III O
was O
only O
observed O
at O
a O
dose O
of O
1 O
. O
0 O
mg O
doxorubicin O
/ O
kg O
. O

Light O
microscopic O
evidence O
of O
renal B_DISEASE/B_GENE
damage I_DISEASE/I_GENE
was O
seen O
above O
a O
dose O
of O
0 O
. O
5 O
mg O
doxorubicin O
/ O
kg O
, O
which O
resulted O
in O
albuminuria B_DISEASE
and O
very O
low O
serum O
albumin O
levels O
. O

In O
the O
group B_ORGANIZATION/B_SPECIES[BIO]
that O
received O
1 B_MEASURE
. O
0 B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mg I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
doxorubicin I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
kg B_MEASURE
, O
the O
serum B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
albumin I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
level I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
decreased O
from O
33 B_MEASURE
. O
6 B_MEASURE
+ I_MEASURE
/ O
- O
4 B_MEASURE
. O
1 B_MEASURE
to O
1 B_MEASURE
. O
5 B_MEASURE
+ I_MEASURE
/ O
- O
0 B_MEASURE
. O
5 B_MEASURE
g I_MEASURE
/ O
liter B_MEASURE
. O

Ascites B_DISEASE
and O
hydrothorax B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
were O
observed O
simultaneously O
. O

The O
same O
experiments O
were O
performed O
with O
non O
- O
tumor B_DISEASE
- O
bearing O
rats O
, O
in O
which O
no O
major O
differences O
were O
observed O
. O

In O
conclusion O
, O
antitumor O
activity O
, O
cardiotoxicity B_DISEASE
, O
and O
nephrotoxicity B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
studied O
simultaneously O
in O
the O
same O
Lou O
/ O
M O
/ O
WSL O
rat O
. O

Albuminuria B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
due O
to O
renal B_DISEASE
damage I_DISEASE
led O
to O
extremely O
low O
serum O
albumin O
levels O
, O
so O
ascites B_DISEASE
and O
hydrothorax B_DISEASE
were O
not O
necessarily O
a O
consequence O
of O
the O
observed O
cardiomyopathy B_DISEASE
. O

Intraoperative O
bradycardia B_DISEASE
and O
hypotension B_DISEASE
associated O
with O
timolol O
and O
pilocarpine O
eye O
drops O
. O

A O
69 O
- O
yr O
- O
old O
man O
, O
who O
was O
concurrently O
being O
treated O
with O
pilocarpine O
nitrate O
and O
timolol O
maleate O
eye O
drops O
, O
developed O
a O
bradycardia B_DISEASE
and O
became O
hypotensive B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
during O
halothane O
anaesthesia O
. O

Both O
timolol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
pilocarpine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
subsequently O
identified O
in O
a O
24 B_MEASURE
- O
h B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
collection I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
urine B_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Timolol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O
but O
not O
pilocarpine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
was O
detected O
in O
a O
sample B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
plasma B_BODY_PART_OR_ORGAN_COMPONENT/B_GENE
removed O
during O
surgery B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
; O
the O
plasma B_MEASURE
concentration I_MEASURE
of O
timolol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
( O
2 B_MEASURE
. O
6 B_MEASURE/B_PERSON
ng I_MEASURE/I_PERSON
ml I_MEASURE/I_PERSON
- O
1 B_MEASURE/B_LOCATION
) O
was O
consistent B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
with O
partial B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
beta I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
adrenoceptor B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
blockade I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

It O
is O
postulated O
that O
this O
action O
may O
have O
been O
enhanced O
during O
halothane O
anaesthesia O
with O
resultant O
bradycardia B_DISEASE
and O
hypotension B_DISEASE
. O

Pilocarpine B_PERSON/B_LOCATION
may O
have O
had O
a O
contributory B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
effect I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

Succinylcholine O
apnoea B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
: O
attempted O
reversal O
with O
anticholinesterases O
. O

Anticholinesterases O
were O
administered O
in O
an O
attempt O
to O
antagonize O
prolonged O
neuromuscular B_DISEASE
blockade I_DISEASE
following O
the O
administration O
of O
succinylcholine O
in O
a O
patient O
later O
found O
to O
be O
homozygous O
for O
atypical O
plasma O
cholinesterase O
. O

Edrophonium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
10 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
mg I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O
given O
74 B_TIME[MEASURE]/B_LOCATION
min I_TIME[MEASURE]/I_LOCATION
after O
succinylcholine B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
, O
when O
train B_LOCATION/B_NUMBER[MEASURE]
- O
of O
- O
four B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stimulation B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
characteristic B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
phase B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
II B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
block B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
, O
produced O
partial B_DISEASE_ADJECTIVE[DISEASE]
antagonism I_DISEASE_ADJECTIVE[DISEASE]
which O
was O
not O
sustained O
. O

repeated O
doses B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
edrophonium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O
70 B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mg B_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
neostigmine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
2 B_MEASURE
. O
5 B_MEASURE
mg I_MEASURE
did O
not O
antagonize O
or O
augment O
the O
block B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O

spontaneous B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
respiration I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
recommenced O
200 B_TIME[MEASURE]/B_PERSON
min I_TIME[MEASURE]/I_PERSON
after O
succinylcholine B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
administration I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
. O

It O
is O
concluded O
that O
anticholinesterases O
are O
only O
partially O
effective O
in O
restoring O
neuromuscular O
function O
in O
succinylcholine O
apnoea B_DISEASE
despite O
muscle O
twitch O
activity O
typical O
of O
phase O
II O
block O
. O

Effect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O
doxorubicin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
[ B_MEASURE
omega I_MEASURE
- O
I B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
131 B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
heptadecanoic I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acid I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
myocardial I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
scintigraphy I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
echocardiography B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
dogs B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
effects B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
serial B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
treatment I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
with O
doxorubicin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
dynamic B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
myocardial I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
scintigraphy I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
[ B_MEASURE
omega I_MEASURE
- O
I B_OTHER/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
131 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
] I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
heptadecanoic I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
acid I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O
I B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O
131 B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Ha I_LOCATION/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
, O
and O
on O
global B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
left I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
ventricular B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
function B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
determined O
echocardiographically O
, O
were O
studied O
in O
a O
group B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
nine B_PERSON/B_SPECIES[BIO]
mongrel I_PERSON/I_SPECIES[BIO]
dogs I_PERSON/I_SPECIES[BIO]
. O

Total B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
extractable I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
myocardial I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
lipid I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
was O
compared O
postmortem B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O
a O
group B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
control B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dogs I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
doxorubicin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
treated O
dogs B_BIO/B_PERSON
. O

A O
significant B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
and O
then O
progressive B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
fall I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
global B_DISEASE
LV I_DISEASE
function I_DISEASE
was O
observed O
at O
a O
cumulative B_MEASURE/B_LOCATION
doxorubicin I_MEASURE/I_LOCATION
dose I_MEASURE/I_LOCATION
of O
4 B_MEASURE
mg I_MEASURE
/ O
kg B_MEASURE
. O

A O
significant B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
increase I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O
the O
myocardial B_PROTEIN[GENE]/B_MEASURE
t1 I_PROTEIN[GENE]/I_MEASURE
/ O
2 B_MEASURE
of O
the O
I B_OTHER/B_LOCATION
- O
131 B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
HA I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
observed O
only O
at O
a O
higher B_MEASURE/B_LOCATION
cumulative I_MEASURE/I_LOCATION
dose I_MEASURE/I_LOCATION
, O
10 B_MEASURE
mg I_MEASURE
/ O
kg B_MEASURE
. O

No O
significant B_DISEASE_ADJECTIVE[DISEASE]
alteration I_DISEASE_ADJECTIVE[DISEASE]
in O
total B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
extractable I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
myocardial I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
lipids I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
was O
observed O
between O
control B_PERSON/B_ORGANIZATION
dogs I_PERSON/I_ORGANIZATION
and O
those O
treated O
with O
doxorubicin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Our O
findings O
suggest O
that O
the O
changes O
leading O
to O
an O
alteration O
of O
myocardial O
dynamic O
imaging O
with O
I O
- O
131 O
Ha O
are O
not O
the O
initiating O
factor O
in O
doxorubicin O
cardiotoxicity B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Hemodynamics O
and O
myocardial O
metabolism O
under O
deliberate O
hypotension B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

An O
experimental B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
in O
dogs B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Coronary O
blood O
flow O
, O
cardiac O
work O
and O
metabolism O
were O
studied O
in O
dogs O
under O
sodium O
nitroprusside O
( O
SNP O
) O
and O
trimetaphan O
( O
TMP O
) O
deliberate O
hypotension B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
20 O
% O
and O
40 O
% O
mean O
pressure O
decrease O
from O
baseline O
) O
. O

Regarding O
the O
effects O
of O
drug O
- O
induced O
hypotension B_DISEASE
on O
coronary O
blood O
flow O
, O
aortic O
and O
coronary O
sinus O
metabolic O
data O
( O
pH O
, O
pO2 O
, O
pCO2 O
) O
we O
could O
confirm O
that O
nitroprusside O
hypotension B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
could O
be O
safely O
used O
to O
30 O
% O
mean O
blood O
pressure O
decrease O
from O
control O
, O
trimetaphan O
hypotension B_DISEASE
to O
20 O
% O
mean O
blood O
pressure O
decrease O
. O

cardiac O
work O
was O
significantly O
reduced O
during O
SNP O
hypotension B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Myocardial B_DISEASE/B_PROTEIN[GENE]
O2 B_DISEASE/I_PROTEIN[GENE]
consumption B_DISEASE/I_PROTEIN[GENE]
and O
O2 B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
availability B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
were O
directly O
dependent B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
on O
the O
coronary B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
perfusion B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
. O

Careful B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
invasive I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
monitoring I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
the O
blood B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
pressure I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
blood B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
gases I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
of O
the O
ECG B_DISEASE/B_PROTEIN[GENE]
ST B_DISEASE/I_PROTEIN[GENE]
- O
T B_NUMBER[MEASURE]/B_LOCATION
segment I_NUMBER[MEASURE]/I_LOCATION
is O
mandatory B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Evidence B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
for O
a O
selective B_DISEASE_ADJECTIVE[DISEASE]
brain I_DISEASE_ADJECTIVE[DISEASE]
noradrenergic I_DISEASE_ADJECTIVE[DISEASE]
involvement I_DISEASE_ADJECTIVE[DISEASE]
in O
the O
locomotor B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
stimulant I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
effects I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
of O
amphetamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
rat B_SPECIES[BIO]/B_GENE
. O

Male B_PERSON
rats I_PERSON
received O
the O
noradrenaline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
neurotoxin I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
DSP4 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
50 B_MEASURE
mg I_MEASURE
/ O
kg B_MEASURE
) O
7 B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
days B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
prior B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
to O
injection B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
of O
D B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O
amphetamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
10 B_MEASURE
or O
40 B_MEASURE/B_PERSON
mumol I_MEASURE/I_PERSON
/ O
kg B_MEASURE
i O
. O
p B_MEASURE/B_LOCATION
. O
) O
. O

The O
hyperactivity B_DISEASE
induced O
by O
D O
- O
amphetamine O
( O
10 O
mumol O
/ O
kg O
) O
was O
significantly O
reduced O
by O
DSP4 O
pretreatment O
. O

However O
, O
the O
increased O
rearings O
and O
the O
amphetamine O
- O
induced O
stereotypies B_DISEASE_ADJECTIVE[DISEASE]
were O
not O
blocked O
by O
pretreatment O
with O
DSP4 O
. O

The O
reduction O
of O
amphetamine O
hyperactivity B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
induced O
by O
DSP4 O
was O
blocked O
by O
pretreatment O
with O
the O
noradrenaline O
- O
uptake O
blocking O
agent O
, O
desipramine O
, O
which O
prevents O
the O
neurotoxic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
action O
of O
DSP4 O
. O

The O
present B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
results I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
suggest O
a O
selective B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
involvement I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
central B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
noradrenergic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
neurones B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
in O
the O
locomotor B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
stimulant I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
effect I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
of O
amphetamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O
the O
rat B_SPECIES[BIO]/B_GENE
. O

Accelerated B_DISEASE_ADJECTIVE[DISEASE]
junctional I_DISEASE_ADJECTIVE[DISEASE]
rhythms I_DISEASE_ADJECTIVE[DISEASE]
during O
oral O
verapamil O
therapy O
. O

This O
study O
examined O
the O
frequency O
of O
atrioventricular O
( O
AV O
) O
dissociation O
and O
accelerated B_DISEASE
junctional I_DISEASE
rhythms I_DISEASE
in O
59 O
patients O
receiving O
oral O
verapamil O
. O

Accelerated B_DISEASE/B_PROTEIN[GENE]
junctional B_DISEASE/I_PROTEIN[GENE]
rhythms B_DISEASE/I_PROTEIN[GENE]
and O
AV O
dissociation O
were O
frequent O
in O
patients O
with O
supraventricular B_DISEASE/B_PROTEIN[GENE]
tachyarrhythmias B_DISEASE/I_PROTEIN[GENE]
, O
particularly O
AV O
nodal O
reentry O
. O

verapamil B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
administration I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O
these O
patients B_PERSON/B_BIO
led O
to O
an O
asymptomatic B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
increase I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
activity B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
these O
junctional B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENZYME[GENE]
pacemakers B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENZYME[GENE]
. O

In O
patients O
with O
various O
chest B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
pain I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
syndromes O
, O
verapamil O
neither O
increased O
the O
frequency O
of O
junctional O
rhythms O
nor O
suppressed O
their O
role O
as O
escape O
rhythms O
under O
physiologically O
appropriate O
circumstances O
. O

Interstrain B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
variation I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O
acute B_DISEASE_ADJECTIVE[DISEASE]
toxic I_DISEASE_ADJECTIVE[DISEASE]
response I_DISEASE_ADJECTIVE[DISEASE]
to O
caffeine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
among O
inbred B_PERSON/B_BIO
mice I_PERSON/I_BIO
. O

Acute B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
toxic I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
dosage I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
- O
dependent B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
behavioral I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
effects I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
caffeine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
compared O
in O
adult B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
males B_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O
seven B_LOCATION/B_PERSON
inbred I_LOCATION/I_PERSON
mouse I_LOCATION/I_PERSON
strains I_LOCATION/I_PERSON
( O
A B_OTHER/B_LOCATION
/ O
J B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
, O
BALB B_SPECIES[BIO]/B_PROTEIN[GENE]
/ O
cJ B_DISEASE/B_LOCATION
, O
CBA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
/ O
J B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
C3H B_SPECIES[BIO]/B_LOCATION
/ O
HeJ B_LOCATION/B_DISEASE
, O
C57BL B_BIO/B_PROTEIN[GENE]
/ O
6J B_MEASURE
, O
DBA B_PROTEIN[GENE]/B_DISEASE
/ O
2J B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
SWR B_DISEASE/B_PROTEIN[GENE]
/ O
J B_OTHER/B_PROTEIN[GENE]
) O
. O

C57BL B_MEASURE/B_BIO
/ O
6J B_MEASURE
, O
chosen O
as O
a O
' O
prototypic B_MEASURE/B_GENE
' O
mouse B_SPECIES[BIO]/B_MEASURE
strain I_SPECIES[BIO]/I_MEASURE
, O
was O
used O
to O
determine O
behavioral B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
responses I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
a O
broad B_MEASURE/B_LOCATION
range I_MEASURE/I_LOCATION
( O
5 B_MEASURE
- O
500 B_MEASURE
mg I_MEASURE
/ O
kg B_MEASURE
) O
of O
caffeine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
doses I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Five O
phenotypic O
characteristics O
- O
- O
locomotor O
activity O
, O
righting O
ability O
, O
clonic B_DISEASE/B_GENE
seizure I_DISEASE/I_GENE
induction O
, O
stress O
- O
induced O
lethality O
, O
death O
without O
external O
stress O
- O
- O
were O
scored O
at O
various O
caffeine O
doses O
in O
drug O
- O
naive O
animals O
under O
empirically O
optimized O
, O
rigidly O
constant O
experimental O
conditions O
. O

mice B_BIO/B_PERSON
( O
n B_MEASURE
= O
12 B_NUMBER[MEASURE]
for O
each O
point B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
received O
single B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
IP I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
injections I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
of O
a O
fixed O
volume B_MEASURE
/ O
g B_MEASURE/B_LOCATION
body I_MEASURE/I_LOCATION
weight I_MEASURE/I_LOCATION
of O
physiological B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
saline I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
carrier I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
with O
or O
without O
caffeine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
doses B_MEASURE/B_LOCATION
ranging O
from O
125 B_MEASURE
- O
500 B_MEASURE
mg I_MEASURE
/ O
kg B_MEASURE
. O

Loss B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O
righting O
ability B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
was O
scored O
at O
1 B_NUMBER[MEASURE]
, O
3 B_MEASURE
, O
5 B_SEQUENCE[MEASURE]
min I_SEQUENCE[MEASURE]
post I_SEQUENCE[MEASURE]
dosing I_SEQUENCE[MEASURE]
and O
at O
5 B_TIME[MEASURE]/B_LOCATION
min I_TIME[MEASURE]/I_LOCATION
intervals I_TIME[MEASURE]/I_LOCATION
thereafter O
for O
20 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
min I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O

In O
the O
same O
animals O
the O
occurrence O
of O
clonic B_DISEASE
seizures I_DISEASE
was O
scored O
as O
to O
time O
of O
onset O
and O
severity O
for O
20 O
min O
after O
drug O
administration O
. O

When O
these O
proceeded O
to O
tonic B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
seizures I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
death O
occurred O
in O
less O
than O
20 O
min O
. O

Animals O
surviving O
for O
20 O
min O
were O
immediately O
stressed O
by O
a O
swim O
test O
in O
25 O
degrees O
C O
water O
, O
and O
death O
- O
producing O
tonic B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
seizures B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
were O
scored O
for O
2 O
min O
. O

In O
other B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
animals I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
locomotor I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
activity I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
was O
measured O
15 B_MEASURE
or O
60 B_TIME[MEASURE]
min I_TIME[MEASURE]
after O
caffeine B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
administration I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
. O

By O
any O
single B_MEASURE
behavioral I_MEASURE
criterion I_MEASURE
or O
a O
combination B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
these O
criteria B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
marked B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
differences I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
response B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
to O
toxic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
caffeine I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
doses I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
were O
observed O
between O
strains B_BIO/B_PERSON
. O

These O
results O
indicate O
that O
behavioral O
toxicity B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
testing O
of O
alkylxanthines O
in O
a O
single O
mouse O
strain O
may O
be O
misleading O
and O
suggest O
that O
toxic O
responses O
of O
the O
central O
nervous O
system O
to O
this O
class O
of O
compounds O
are O
genetically O
influenced O
in O
mammals O
. O

Treatment O
of O
ovarian B_DISEASE/B_LOCATION
cancer I_DISEASE/I_LOCATION
with O
a O
combination O
of O
cis O
- O
platinum O
, O
adriamycin O
, O
cyclophosphamide O
and O
hexamethylmelamine O
. O

During O
the O
last O
2 O
1 O
/ O
2 O
years O
, O
38 O
patients O
with O
ovarian B_DISEASE/B_GENE
cancer I_DISEASE/I_GENE
were O
treated O
with O
a O
combination O
of O
cisplatinum O
( O
CPDD O
) O
, O
50 O
mg O
/ O
m2 O
, O
adriamycin O
, O
30 O
mg O
/ O
m2 O
, O
cyclophosphamide O
, O
300 O
mg O
/ O
m2 O
, O
on O
day O
1 O
; O
and O
hexamethylmelamine O
( O
Hmm O
) O
, O
6 O
mg O
/ O
kg O
daily O
, O
for O
14 O
days O
. O

Each O
course B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
repeated O
monthly O
. O

2 B_PERSON
patients I_PERSON
had O
stage B_DISEASE_ADJECTIVE[DISEASE]
II I_DISEASE_ADJECTIVE[DISEASE]
, O
14 B_TIME[MEASURE]/B_DISEASE
stage I_TIME[MEASURE]/I_DISEASE
III I_TIME[MEASURE]/I_DISEASE
and O
22 B_SEQUENCE[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
stage I_SEQUENCE[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
IV I_SEQUENCE[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
disease I_SEQUENCE[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

14 B_MEASURE
of O
the O
38 B_PERSON
patients I_PERSON
were O
previously O
treated O
with O
chemotherapy B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
1 B_MEASURE
with O
radiation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
6 B_NUMBER[MEASURE]
with O
both O
chemotherapy B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O
radiation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
and O
17 B_NUMBER[MEASURE]
did O
not O
have O
any O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
before O
CPDD B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
combination I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
. O

31 B_MEASURE
of O
the O
38 B_MEASURE/B_PERSON
cases I_MEASURE/I_PERSON
( O
81 B_MEASURE
. O
5 B_MEASURE
% I_MEASURE
) O
demonstrated O
objective B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
responses B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
lasting O
for O
2 B_TIME[MEASURE]
months I_TIME[MEASURE]
or O
more B_TIME[MEASURE]/B_LOCATION
. O

These O
responses B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
were O
partial B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O
19 B_NUMBER[MEASURE]
and O
complete B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
12 B_MEASURE
cases I_MEASURE
. O

Hematologic B_DISEASE
toxicity I_DISEASE
was O
moderate O
and O
with O
reversible O
anemia B_DISEASE
developing O
in O
71 O
% O
of O
patients O
. O

Gastrointestinal B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
side I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O
CPDD B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
were O
universal B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Hmm O
gastrointestinal B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
toxicity I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
necessitated O
discontinuation O
of O
the O
drug O
in O
5 O
patients O
. O

severe O
nephrotoxicity B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
observed O
in O
2 O
patients O
but O
was O
reversible O
. O

There O
were O
no O
drug B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
- O
related O
deaths B_DISEASE
. O

Nontraumatic O
dissecting B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
aneurysm I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
the O
basilar O
artery O
. O

A O
case O
of O
nontraumatic O
dissecting B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
aneurysm I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
the O
basilar O
artery O
in O
association O
with O
hypertension B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
smoke O
, O
and O
oral O
contraceptives O
is O
reported O
in O
a O
young O
female O
patient O
with O
a O
locked B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
- I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
syndrome I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

A O
method O
for O
the O
measurement O
of O
tremor B_DISEASE/B_GENE
, O
and O
a O
comparison O
of O
the O
effects O
of O
tocolytic O
beta O
- O
mimetics O
. O

A O
method O
permitting O
measurement O
of O
finger O
tremor B_DISEASE/B_MEASURE
as O
a O
displacement O
- O
time O
curve O
is O
described O
, O
using O
a O
test O
system O
with O
simple O
amplitude O
calibration O
. O

The O
coordinates B_LOCATION/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
inversion B_LOCATION/B_MEASURE
points I_LOCATION/I_MEASURE
of O
the O
displacement B_TIME[MEASURE]/B_LOCATION
- O
time B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
curves B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
transferred O
through O
graphical B_PRODUCT[OBJECT]/B_LOCATION
input I_PRODUCT[OBJECT]/I_LOCATION
equipment I_PRODUCT[OBJECT]/I_LOCATION
to O
punched B_PERSON/B_PRODUCT[OBJECT]
tape I_PERSON/I_PRODUCT[OBJECT]
. O

By O
means O
of O
a O
computer O
program O
, O
periods O
and O
amplitudes O
of O
tremor B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
oscillations O
were O
calculated O
and O
classified O
. O

The O
event B_MEASURE
frequency I_MEASURE
for O
each O
class B_PERSON/B_MEASURE
of O
periods B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
and O
amplitudes B_TIME[MEASURE]/B_ENT
was O
determined O
. O

The O
actions B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O
fenoterol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
hydrobromide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
ritodrin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
HCl B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
placebo B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
given O
to O
10 B_PERSON/B_BIO
healthy I_PERSON/I_BIO
subjects I_PERSON/I_BIO
by O
intravenous B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BODY_PART_OR_ORGAN_COMPONENT
infusion I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_BODY_PART_OR_ORGAN_COMPONENT
in O
a O
double B_NUMBER[MEASURE]/B_PERSON
- O
blind B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
crossover I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
were O
tested O
by O
this O
method B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O

At O
therapeutic O
doses O
both O
substances O
raised O
the O
mean O
tremor B_DISEASE
amplitude O
to O
about O
three O
times O
the O
control O
level O
. O

At O
the O
same B_TIME[MEASURE]/B_LOCATION
time I_TIME[MEASURE]/I_LOCATION
, O
the O
mean B_TIME[MEASURE]
period I_TIME[MEASURE]
within O
each O
class B_PERSON/B_LOCATION
of O
amplitudes B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
shortened O
by O
10 B_MEASURE/B_LOCATION
- O
- O
20 B_TIME[MEASURE]
MS I_TIME[MEASURE]
, O
whereas O
the O
mean B_MEASURE
periods I_MEASURE
calculated O
from O
all O
oscillations B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
together O
did O
not O
change O
significantly O
. O

After O
the O
end O
of O
fenoterol O
- O
hydrobromide O
infusion O
, O
tremor B_DISEASE/B_PROTEIN[GENE]
amplitudes O
decreased O
significantly O
faster O
than O
those O
following O
ritodrin O
- O
HCl O
infusion O
. O

Propylthiouracil O
- O
induced O
hepatic B_DISEASE
damage I_DISEASE
. O

Two O
cases O
of O
propylthiouracil O
- O
induced O
liver B_DISEASE
damage I_DISEASE
have O
been O
observed O
. O

The O
first O
case O
is O
of O
an O
acute O
type O
of O
damage O
, O
proven O
by O
rechallenge O
; O
the O
second O
presents O
a O
clinical O
and O
histologic O
picture O
resembling O
chronic B_DISEASE/B_GENE
active I_DISEASE/I_GENE
hepatitis I_DISEASE/I_GENE
, O
with O
spontaneous O
remission O
. O

Studies O
on O
the O
bradycardia B_DISEASE
induced O
by O
bepridil O
. O

Bepridil O
, O
a O
novel O
active O
compound O
for O
prophylactic O
treatment O
of O
anginal B_DISEASE
attacks I_DISEASE
, O
induced O
persistent O
bradycardia B_DISEASE
and O
a O
non O
- O
specific O
anti O
- O
tachycardial B_DISEASE_ADJECTIVE[DISEASE]
effect O
, O
the O
mechanisms O
of O
which O
were O
investigated O
in O
vitro O
and O
in O
vivo O
. O

In O
vitro B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
perfusion I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
of O
bepridil B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
life B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
- O
support B_LOCATION/B_PERSON
medium I_LOCATION/I_PERSON
for O
isolated B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
sino I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
- O
atrial B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
tissue I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
from O
rabbit B_SPECIES[BIO]
heart I_SPECIES[BIO]
, O
caused O
a O
reduction B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
action B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
potential I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
( O
AP B_DISEASE/B_PROTEIN[GENE]
) O
spike B_MEASURE
frequency I_MEASURE
( O
recorded O
by O
KCl B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
microelectrodes I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
) O
starting O
at O
doses B_MEASURE/B_LOCATION
of O
5 B_MEASURE
X I_MEASURE
10 I_MEASURE
( O
- O
6 B_MEASURE
) O
M B_OTHER/B_MEASURE
. O

This O
effect B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
was O
dose B_MEASURE
- O
dependent B_DISEASE_ADJECTIVE[DISEASE]
up O
to O
concentrations B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
5 B_MEASURE
X I_MEASURE
10 I_MEASURE
( O
- O
5 B_MEASURE
) O
M B_OTHER/B_MEASURE
, O
whereupon B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
blockade I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
of O
sinus B_DISEASE/B_GENE
activity B_DISEASE/I_GENE
set O
in O
. O

Bepridil B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
at O
a O
dose B_MEASURE/B_LOCATION
of O
5 B_MEASURE
X O
10 B_NUMBER[MEASURE]
( O
- O
6 B_MEASURE
) O
M B_OTHER/B_MEASURE
, O
induced O
a O
concomitant B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
reduction I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
AP B_MEASURE/B_DISEASE
amplitude I_MEASURE/I_DISEASE
( O
falling O
from O
71 B_MEASURE
+ I_MEASURE
/ O
- O
8 B_MEASURE
MV I_MEASURE
to O
47 B_MEASURE
+ I_MEASURE
/ O
- O
6 B_MEASURE
MV I_MEASURE
) O
, O
maximum B_MEASURE
systolic I_MEASURE
depolarization I_MEASURE
velocity I_MEASURE
( O
phase B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
0 I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
which O
fell O
from O
1 B_MEASURE
. O
85 B_MEASURE
+ I_MEASURE
/ O
- O
0 B_MEASURE
. O
35 B_MEASURE
V I_MEASURE
/ O
s O
to O
0 B_MEASURE
. O
84 B_MEASURE
+ I_MEASURE
/ O
- O
0 B_MEASURE
. O
28 B_MEASURE
V I_MEASURE
/ O
s B_MEASURE/B_DISEASE
, O
together O
with O
maximum B_MEASURE/B_LOCATION
diastolic I_MEASURE/I_LOCATION
depolarization I_MEASURE/I_LOCATION
velocity I_MEASURE/I_LOCATION
( O
phase B_LOCATION/B_PROTEIN[GENE]
4 I_LOCATION/I_PROTEIN[GENE]
) O
which O
fell O
from O
38 B_MEASURE
+ I_MEASURE
/ O
- O
3 B_MEASURE/B_LOCATION
MV I_MEASURE/I_LOCATION
/ O
s O
to O
24 B_MEASURE
+ I_MEASURE
/ O
- O
5 B_TIME[MEASURE]/B_PERSON
MV I_TIME[MEASURE]/I_PERSON
/ O
s B_MEASURE/B_DISEASE
. O

In O
vivo B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
injection I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
bepridil B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O
a O
dose B_MEASURE/B_LOCATION
of O
5 B_MEASURE
mg I_MEASURE
/ O
kg B_MEASURE
( O
i O
. O
v O
. O
) O
into O
6 B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
anaesthetized I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dogs I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
which O
had O
undergone B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
ablation I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
of O
all O
the O
extrinsic B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
cardiac I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
afferent I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
nerve I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
supply I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
, O
together O
with O
a O
bilateral B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
medullo B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
- O
adrenalectomy B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
, O
caused O
a O
marked B_DISEASE_ADJECTIVE[DISEASE]/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reduction I_DISEASE_ADJECTIVE[DISEASE]/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
heart B_MEASURE/B_DISEASE
rate I_MEASURE/I_DISEASE
which O
fell O
from O
98 B_MEASURE
. O
7 B_MEASURE
+ I_MEASURE
/ O
- O
4 B_MEASURE
. O
2 B_MEASURE
beats I_MEASURE
/ O
min B_TIME[MEASURE]/B_PERSON
to O
76 B_MEASURE
+ I_MEASURE
/ O
- O
5 B_MEASURE
. O
3 B_MEASURE
beats I_MEASURE
/ O
min B_MEASURE/B_PERSON
sustained O
for O
more B_MEASURE
than O
45 B_TIME[MEASURE]
min I_TIME[MEASURE]
. O

It O
is O
concluded O
that O
bepridil B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reduces O
heart B_DISEASE
rate I_DISEASE
by O
acting O
directly O
on O
the O
sinus B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
node I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
. O

This O
effect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
which O
results O
in O
a O
flattening B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
the O
phase B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
0 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
and O
phase B_MEASURE/B_PROTEIN[GENE]
4 I_MEASURE/I_PROTEIN[GENE]
slope I_MEASURE/I_PROTEIN[GENE]
, O
together O
with O
a O
longer B_MEASURE/B_LOCATION
AP I_MEASURE/I_LOCATION
duration I_MEASURE/I_LOCATION
, O
may O
be O
due O
to O
an O
increase B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
the O
time B_MEASURE/B_ENT
constants I_MEASURE/I_ENT
of O
slow B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
inward I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
ionic I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
currents I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
( O
already O
demonstrated O
elsewhere O
) O
, O
but O
also O
to O
an O
increased O
time B_MEASURE
constant I_MEASURE
for O
deactivation B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
the O
outward B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
potassium I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
current I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
( O
ip B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
) O
. O

Hepatitis B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
and O
renal B_DISEASE
tubular I_DISEASE
acidosis I_DISEASE
after O
anesthesia O
with O
methoxyflurane O
. O

A O
69 O
- O
year O
- O
old O
man O
operated O
for O
acute B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
cholecystitis I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
under O
methoxyflurane O
anesthesia O
developed O
postoperatively O
a O
hepatic B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
insufficiency I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
syndrome I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
and O
renal B_DISEASE
tubular I_DISEASE
acidosis I_DISEASE
. O

massive O
bleeding B_DISEASE
appeared O
during O
surgery O
which O
lasted O
for O
six O
hours O
. O

Postoperative B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
evolution I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
under O
supportive B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
therapy I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O
favourable B_DISEASE_ADJECTIVE[DISEASE]
. O

Complete B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
recovery I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
confirmed O
by O
repeated O
controls B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
performed O
over O
a O
period B_MEASURE/B_LOCATION
of O
one B_TIME[MEASURE]
year I_TIME[MEASURE]
after O
surgery B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O

Pituitary O
response O
to O
luteinizing O
hormone O
- O
releasing O
hormone O
during O
haloperidol O
- O
induced O
hyperprolactinemia B_DISEASE
. O

The O
effects B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
a O
6 B_NUMBER[MEASURE]
- O
hour B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
infusion I_TIME[MEASURE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O
haloperidol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
on O
serum B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
prolactin I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
luteinizing B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
hormone I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O
LH B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
levels B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
was O
studied O
in O
a O
group B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
male B_PERSON/B_BIO
subjects I_PERSON/I_BIO
. O

Five B_TIME[MEASURE]/B_ENT
hours I_TIME[MEASURE]/I_ENT
after O
starting O
the O
infusions B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
a O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
pituitary B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
responses I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
to O
LH B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
releasing O
hormone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
LH B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
RH B_PROTEIN[GENE]/B_DISEASE
) O
was O
carried O
out O
. O

Control B_PERSON
patients I_PERSON
received O
infusions B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
0 B_MEASURE
. O
9 B_MEASURE
% I_MEASURE
NaCl I_MEASURE
solution I_MEASURE
. O

During O
the O
course O
of O
haloperidol O
infusions O
, O
significant O
hyperprolactinemia B_DISEASE
was O
found O
, O
together O
with O
an O
abolished O
pituitary O
response O
to O
LH O
- O
RH O
, O
as O
compared O
with O
responses O
of O
control O
subjects O
. O

Antirifampicin O
antibodies O
in O
acute O
rifampicin O
- O
associated O
renal B_DISEASE/B_GENE
failure I_DISEASE/I_GENE
. O

5 O
patients O
with O
acute B_DISEASE
renal I_DISEASE
failure I_DISEASE
( O
3 O
with O
thrombopenia B_DISEASE
and O
hemolysis B_NUMBER[MEASURE]/B_PERSON
) O
induced O
by O
the O
reintroduction O
of O
rifampicin O
are O
described O
. O

No O
correlation B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
found O
between O
the O
severity B_MEASURE
of O
clinical B_DISEASE
manifestations I_DISEASE
and O
the O
total B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
dose I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
taken O
by O
the O
patients B_PERSON
. O

In O
all O
but O
1 B_NUMBER[MEASURE]/B_PERSON
patient I_NUMBER[MEASURE]/I_PERSON
, O
antirifampicin B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
antibodies I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
were O
detected O
. O

antibodies O
suggested O
to O
be O
of O
the O
IgM O
class O
were O
detected O
in O
all O
3 O
patients O
with O
hematological B_DISEASE/B_GENE
disorders I_DISEASE/I_GENE
. O

The O
pattern O
of O
non O
- O
specific O
acute B_DISEASE_ADJECTIVE[DISEASE]
tubular I_DISEASE_ADJECTIVE[DISEASE]
necrosis I_DISEASE_ADJECTIVE[DISEASE]
found O
in O
the O
2 O
biopsied O
patients O
, O
indistinguishable O
from O
that O
of O
ischemic O
origin O
, O
raised O
the O
possibility O
of O
a O
vascular O
- O
mediated O
damage O
. O

In O
3 B_PERSON/B_TIME[MEASURE]
patients I_PERSON/I_TIME[MEASURE]
, O
the O
possibility B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O
a O
triggering O
immunoallergic B_DISEASE_ADJECTIVE[DISEASE]
mechanism I_DISEASE_ADJECTIVE[DISEASE]
is O
discussed O
. O

Cardiovascular O
effects O
of O
hypotension B_DISEASE
induced O
by O
adenosine O
triphosphate O
and O
sodium O
nitroprusside O
on O
dogs O
with O
denervated O
hearts O
. O

Adenosine O
triphosphate O
( O
ATP O
) O
and O
sodium O
nitroprusside O
( O
SNP O
) O
are O
administered O
to O
patients O
to O
induce O
and O
control O
hypotension B_DISEASE
during O
anesthesia O
. O

SNP B_LOCATION/B_ORGANIZATION
is O
authorized O
for O
clinical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
use I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
in O
USA B_LOCATION
and O
UK B_LOCATION
, O
and O
ATP B_GENE/B_DISEASE
is O
clinically O
used O
in O
other B_LOCATION
countries I_LOCATION
such I_LOCATION
as O
Japan B_LOCATION
. O

We O
investigated O
how O
these O
two B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
drugs I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
act O
on O
the O
cardiovascular B_BODY_PART_OR_ORGAN_COMPONENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
systems I_BODY_PART_OR_ORGAN_COMPONENT/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
20 B_PERSON/B_ENT
dogs I_PERSON/I_ENT
whose O
hearts B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
had O
been O
denervated O
by O
a O
procedure B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
we O
had O
devised O
. O

ATP B_ORGANIZATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
10 B_MEASURE/B_ENT
dogs I_MEASURE/I_ENT
) O
or O
SNP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O
10 B_MEASURE/B_ENT
dogs I_MEASURE/I_ENT
) O
was O
administered O
to O
reduce O
mean B_DISEASE
arterial I_DISEASE
pressure I_DISEASE
by O
30 B_MEASURE/B_LOCATION
% I_MEASURE/I_LOCATION
to O
70 B_PERSON/B_MEASURE
% B_PERSON/I_MEASURE
of O
control B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O

Before O
, O
during O
and O
after O
induced O
hypotension B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
we O
measured O
major O
cardiovascular O
parameters O
. O

Hypotension B_DISEASE
induced O
by O
ATP O
was O
accompanied O
by O
significant O
decreases O
in O
mean O
pulmonary O
arterial O
pressure O
( O
p O
less O
than O
0 O
. O
001 O
) O
, O
central O
venous O
pressure O
( O
p O
less O
than O
0 O
. O
001 O
) O
, O
left O
ventricular O
end O
- O
diastolic O
pressure O
( O
p O
less O
than O
0 O
. O
001 O
) O
, O
total O
peripheral O
resistance O
( O
p O
less O
than O
0 O
. O
001 O
) O
, O
rate O
pressure O
product O
( O
p O
less O
than O
0 O
. O
001 O
) O
, O
total O
body O
oxygen O
consumption O
( O
p O
less O
than O
0 O
. O
05 O
) O
, O
and O
heart O
rate O
( O
p O
less O
than O
0 O
. O
001 O
) O
; O
all O
these O
variables O
returned O
normal O
within O
30 O
min O
after O
ATP O
was O
stopped O
. O

cardiac B_PERSON/B_MEASURE
output I_PERSON/I_MEASURE
did O
not O
change B_MEASURE
. O

During O
hypotension B_DISEASE
produced O
by O
SNP O
similar O
decreases O
were O
observed O
in O
mean O
pulmonary O
arterial O
pressure O
( O
p O
less O
than O
0 O
. O
01 O
) O
, O
central O
venous O
pressure O
( O
p O
less O
than O
0 O
. O
001 O
) O
, O
left O
ventricular O
end O
- O
diastolic O
pressure O
( O
p O
less O
than O
0 O
. O
01 O
) O
, O
total O
peripheral O
resistance O
( O
p O
less O
than O
0 O
. O
001 O
) O
, O
rate O
pressure O
product O
( O
p O
less O
than O
0 O
. O
001 O
) O
, O
and O
oxygen O
content O
difference O
between O
arterial O
and O
mixed O
venous O
blood O
( O
p O
less O
than O
0 O
. O
05 O
) O
, O
while O
heart O
rate O
( O
p O
less O
than O
0 O
. O
001 O
) O
and O
cardiac O
output O
( O
p O
less O
than O
0 O
. O
05 O
) O
were O
increased O
. O

recoveries B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
heart B_MEASURE/B_LOCATION
rate B_MEASURE/I_LOCATION
and O
left O
ventricular B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
end I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
- O
diastolic B_MEASURE/B_LOCATION
pressure B_MEASURE/I_LOCATION
were O
not O
shown O
within O
60 B_TIME[MEASURE]
min I_TIME[MEASURE]
after O
SNP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
had O
been O
stopped O
. O

Both O
ATP B_ORGANIZATION/B_LOCATION
and O
SNP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
should O
act O
on O
the O
pacemaker B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
tissue B_PERSON/I_BODY_PART_OR_ORGAN_COMPONENT
of O
the O
heart B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
. O

Comparative B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
: O
Endografine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O
diatrizoate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
, O
Vasurix B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
polyvidone I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O
acetrizoate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
, O
dimer B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
X B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
( O
iocarmate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
) O
and O
Hexabrix B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
ioxaglate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
in O
hysterosalpingography B_SPECIES[BIO]/B_LOCATION
. O

Side B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
effects I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
hysterosalpingography B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O
dimer B_PROTEIN[GENE]
- O
X B_MEASURE/B_DISEASE
, O
Hexabrix B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
Vasurix B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
polyvidone I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O
Endografine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
142 B_MEASURE/B_PERSON
consecutive I_MEASURE/I_PERSON
patients I_MEASURE/I_PERSON
, O
receiving O
one B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_NUMBER[MEASURE]
of O
the O
four B_NUMBER[MEASURE]
tested O
media B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
were O
evaluated O
from O
replies B_PERSON
to O
postal B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
questionnaires I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
Dimer O
- O
X O
group O
had O
a O
higher O
incidence O
of O
nausea B_DISEASE
and O
dizziness B_DISEASE
. O

The O
Endografine O
group O
had O
a O
higher O
incidence O
of O
abdominal B_DISEASE
pain I_DISEASE
. O

These O
differences B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
occur O
especially O
in O
the O
age B_PERSON
groups I_PERSON
under O
30 B_NUMBER[MEASURE]/B_ENT
years I_NUMBER[MEASURE]/I_ENT
. O

Hexabrix O
and O
Vasurix O
polyvidone O
are O
considered O
the O
best O
contrast O
media O
for O
hysterosalpingography O
and O
perhaps O
because O
of O
its O
low O
toxicity B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Hexabrix O
should O
be O
preferred O
. O

Post O
- O
suxamethonium O
pains B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
Nigerian O
surgical O
patients O
. O

contrary O
to O
an O
earlier O
report O
by O
Coxon O
, O
scoline O
pain B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
occurs O
in O
African O
negroes O
. O

Its O
incidence B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
was O
determined O
in O
a O
prospective B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
involving O
a O
total B_MEASURE/B_LOCATION
of O
100 B_MEASURE
Nigerian I_MEASURE
patients I_MEASURE
( O
50 B_LOCATION/B_ENT
out I_LOCATION/I_ENT
- O
patients B_PERSON/B_DISEASE
and O
50 B_MEASURE
in O
- O
patients B_PERSON/B_ORGANIZATION
) O
. O

About O
62 O
% O
of O
the O
out O
- O
patients O
developed O
scoline O
pain B_DISEASE
as O
compared O
with O
about O
26 O
% O
among O
the O
in O
- O
patients O
. O

The O
abolition O
of O
muscle O
fasciculations B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O
by O
0 O
. O
075mg O
/ O
kg O
dose O
of O
Fazadinium O
) O
did O
not O
influence O
the O
occurrence O
of O
scoline O
pain B_DISEASE
. O

Neither O
the O
type O
of O
induction O
agent O
( O
Althesin O
or O
Thiopentone O
) O
nor O
the O
salt O
preparation O
of O
suxamethonium O
used O
( O
chloride O
or O
bromide O
) O
, O
affected O
the O
incidence O
of O
scoline O
pain B_DISEASE
. O

invasive O
carcinoma B_DISEASE
of I_DISEASE
the I_DISEASE
renal I_DISEASE
pelvis I_DISEASE
following O
cyclophosphamide O
therapy O
for O
nonmalignant O
disease O
. O

A O
47 O
- O
year O
- O
old O
woman O
with O
right O
hydroureteronephrosis B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
due O
to O
ureterovesical O
junction O
obstruction O
had O
gross O
hematuria B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
after O
being O
treated O
for O
five O
years O
wtih O
cyclophosphamide O
for O
cerebral B_DISEASE
vasculitis I_DISEASE
. O

A O
right O
nephroureterectomy O
was O
required O
for O
control O
of O
bleeding B_DISEASE
. O

The O
pathology O
specimen O
contained O
clinically O
occult O
invasive O
carcinoma B_DISEASE
of I_DISEASE
the I_DISEASE
renal I_DISEASE
pelvis I_DISEASE
. O

Although O
the O
ability O
of O
cyclophosphamide O
to O
cause O
hemorrhagic B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
cystitis B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
and O
urine O
cytologic O
abnormalities O
indistinguishable O
from O
high O
grade O
carcinoma B_DISEASE
is O
well O
known O
, O
it O
is O
less O
widely O
appreciated O
that O
it O
is O
also O
associated O
with O
carcinoma B_DISEASE
of I_DISEASE
the I_DISEASE
urinary I_DISEASE
tract I_DISEASE
. O

Twenty O
carcinomas B_DISEASE
of I_DISEASE
the I_DISEASE
urinary I_DISEASE
bladder I_DISEASE
and O
one O
carcinoma B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
of I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
the I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
prostate I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
have O
been O
reported O
in O
association O
with O
its O
use O
. O

The O
present O
case O
is O
the O
first O
carcinoma B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
of B_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
the B_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
renal B_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
pelvis B_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
reported O
in O
association O
with O
cyclophosphamide O
treatment O
. O

It O
is O
the O
third O
urinary B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tract I_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cancer I_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reported O
in O
association O
with O
cyclophosphamide O
treatment O
for O
nonmalignant O
disease O
. O

The O
association O
of O
the O
tumor B_DISEASE
with O
preexisting O
hydroureteronephrosis B_DISEASE
suggests O
that O
stasis O
prolonged O
and O
intensified O
exposure O
of O
upper O
urinary O
tract O
epithelium O
to O
cyclophosphamide O
. O

patients O
who O
are O
candidates O
for O
long O
- O
term O
cyclophosphamide O
treatment O
should O
be O
routinely O
evaluated O
for O
obstructive B_DISEASE_ADJECTIVE[DISEASE]
uropathy I_DISEASE_ADJECTIVE[DISEASE]
. O

medial O
changes O
in O
arterial O
spasm B_DISEASE/B_MEASURE
induced O
by O
L O
- O
norepinephrine O
. O

In O
normal B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
rats I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
, O
the O
media B_BODY_PART_OR_ORGAN_COMPONENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
small B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
arteries I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
( O
0 B_MEASURE/B_LOCATION
. O
4 B_MEASURE
- O
- O
0 B_MEASURE
. O
2 B_MEASURE
mm I_MEASURE
in O
diameter B_MEASURE
) O
previously O
was O
shown O
to O
contain O
intracellular B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
vacuoles I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
, O
identified O
ultrastructurally O
as O
herniations B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
one B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
smooth I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
muscle I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
cell I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
into O
another O
. O

The O
hypothesis B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
intense B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
vasoconstriction B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
would O
increase O
the O
number B_MEASURE
of O
such B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
vacuoles B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
has O
been O
tested O
. O

In O
the O
media O
of O
the O
saphenous O
artery O
and O
its O
distal O
branch O
, O
vasoconstriction O
induced O
by O
L O
- O
norepinephrine O
produced O
many O
cell O
- O
to O
- O
cell O
hernias B_PERSON/B_DISEASE
within O
15 O
minutes O
. O

At O
1 B_TIME[MEASURE]/B_LOCATION
day I_TIME[MEASURE]/I_LOCATION
their O
number B_MEASURE/B_PERSON
was O
reduced O
to O
about O
1 B_MEASURE
/ O
10 B_SEQUENCE[MEASURE]
of O
the O
original B_MEASURE/B_ORGANIZATION
number B_MEASURE/I_ORGANIZATION
. O

By O
7 B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
days I_TIME[MEASURE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
the O
vessel B_DISEASE/B_MEASURE
was O
almost O
restored O
to O
normal B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

triple B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
stimulation I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
over O
1 B_NUMBER[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
day I_NUMBER[MEASURE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
induced O
more B_DISEASE
severe I_DISEASE
changes I_DISEASE
in O
the O
media B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
. O

These O
findings B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggest O
that O
smooth B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
muscle I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
are O
susceptible B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O
damage B_DISEASE
in O
the O
course B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
their O
specific B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
function I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
experimental O
data O
are O
discussed O
in O
relation O
to O
medial O
changes O
observed O
in O
other O
instances O
of O
arterial O
spasm B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Endothelial B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
changes I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
that O
developed O
in O
the O
same B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
experimental I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
model I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
were O
described O
in O
a O
previous B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
paper I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

bilateral O
retinal B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
artery B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
choriocapillaris B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
occlusion B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
following O
the O
injection O
of O
long O
- O
acting O
corticosteroid O
suspensions O
in O
combination O
with O
other O
drugs O
: O
I O
. O

Clinical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
studies I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

Two O
well O
- O
documented O
cases O
of O
bilateral O
retinal B_DISEASE/B_PERSON
artery I_DISEASE/I_PERSON
and I_DISEASE/I_PERSON
choriocapillaris I_DISEASE/I_PERSON
occlusions I_DISEASE/I_PERSON
with O
blindness B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
following O
head O
and O
neck O
soft O
- O
tissue O
injection O
with O
methylprednisolone O
acetate O
in O
combination O
with O
lidocaine O
, O
epinephrine O
, O
or O
penicillin O
are O
reported O
. O

One B_PERSON
case I_PERSON
had O
only O
a O
unilateral B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
injection I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
acute O
observations O
included O
hazy O
sensorium O
, O
superior O
gaze O
palsy B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
, O
pupillary B_DISEASE
abnormalities I_DISEASE
, O
and O
conjunctival O
hemorrhages B_DISEASE
with O
edema B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Follow O
- O
up O
changes O
showed O
marked O
visual B_DISEASE
loss I_DISEASE
, O
constricted O
visual O
fields O
, O
optic O
nerve O
pallor O
, O
vascular O
attenuation O
, O
and O
chorioretinal B_DISEASE
atrophy I_DISEASE
. O

The O
literature B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
reviewed O
, O
and O
possible B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
causes I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
are O
discussed O
. O

Abnormalities O
of O
the O
pupil O
and O
visual O
- O
evoked O
potential O
in O
quinine O
amblyopia B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
. O

Total O
blindness B_DISEASE
with O
a O
transient O
tonic B_DISEASE_ADJECTIVE[DISEASE]
pupillary I_DISEASE_ADJECTIVE[DISEASE]
response O
, O
denervation O
supersensitivity O
, O
and O
abnormal O
visual O
- O
evoked O
potentials O
developed O
in O
a O
54 O
- O
year O
- O
old O
man O
after O
the O
use O
of O
quinine O
sulfate O
for O
leg B_DISEASE
cramps I_DISEASE
. O

He O
later O
recovered O
normal B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
visual I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
acuity I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
. O

A O
transient O
tonic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
pupillary I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
response O
, O
denervation O
supersensitivity O
, O
and O
abnormal O
visual O
- O
evoked O
potentials O
in O
quinine O
toxicity B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
to O
our O
knowledge O
, O
have O
not O
been O
previously O
reported O
. O

Suxamethonium O
- O
induced O
jaw B_DISEASE
stiffness I_DISEASE
and O
myalgia B_DISEASE
associated O
with O
atypical O
cholinesterase O
: O
case O
report O
. O

An O
11 B_NUMBER[MEASURE]
- O
year B_TIME[MEASURE]
- O
old B_PERSON
boy I_PERSON
was O
given O
halothane O
, O
nitrous B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
oxide I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
oxygen B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
pancuronium B_MEASURE
0 I_MEASURE
. O
4 B_MEASURE
mg I_MEASURE
and O
suxamethonium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
100 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mg I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
induction B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
anaesthesia B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O

In O
response O
to O
this O
a O
marked O
jaw B_DISEASE
stiffness I_DISEASE
occurred O
which O
lasted O
for O
two O
minutes O
and O
the O
anaesthesia O
were O
terminated O
. O

Four O
hours O
of O
apnoea B_DISEASE
ensued O
and O
he O
suffered O
generalized O
severe O
myalgia B_DISEASE
lasting O
for O
one O
week O
. O

He O
was O
found O
to O
have O
atypical B_DISEASE/B_GENE
plasma I_DISEASE/I_GENE
cholinesterase I_DISEASE/I_GENE
with O
a O
dibucaine B_MEASURE/B_PERSON
number I_MEASURE/I_PERSON
of O
12 B_NUMBER[MEASURE]
, O
indicating O
homozygocity B_DISEASE
. O

This O
was O
verified O
by O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
family B_PERSON/B_LOCATION
. O

The O
case O
shows O
that O
prolonged B_DISEASE
jaw I_DISEASE
rigidity I_DISEASE
and O
myalgia B_DISEASE
may O
occur O
after O
suxamethonium O
in O
patients O
with O
atypical O
cholinesterase O
despite O
pretreatment O
with O
pancuronium O
. O

Indomethacin O
- O
induced O
hyperkalemia B_DISEASE
in O
three O
patients O
with O
gouty B_DISEASE/B_LOCATION
arthritis I_DISEASE/I_LOCATION
. O

We O
describe O
three O
patients O
in O
whom O
severe O
, O
life O
- O
threatening O
hyperkalemia B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
and O
renal B_DISEASE
insufficiency I_DISEASE
developed O
after O
treatment O
of O
acute O
gouty B_DISEASE/B_LOCATION
arthritis I_DISEASE/I_LOCATION
with O
indomethacin O
. O

This O
complication O
may O
result O
from O
an O
inhibition O
of O
prostaglandin O
synthesis O
and O
consequent O
hyporeninemic B_DISEASE
hypoaidosteronism I_DISEASE
. O

careful O
attention O
to O
renal O
function O
and O
potassium O
balance O
in O
patients O
receiving O
indomethacin O
or O
other O
nonsteroidal O
anti O
- O
inflammatory O
agents O
, O
particularly O
in O
those O
patients O
with O
diabetes B_DISEASE_ADJECTIVE[DISEASE]
mellitus I_DISEASE_ADJECTIVE[DISEASE]
or O
preexisting O
renal B_DISEASE
disease I_DISEASE
, O
will O
help O
prevent O
this O
potentially O
serious O
complication O
. O

Etomidate B_MEASURE
: O
a O
foreshortened B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
clinical I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
trial I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

A O
clinical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
evaluation I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
etomidate B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
for O
outpatient B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cystoscopy I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
embarked O
upon O
. O

Unpremedicated B_PERSON
patients I_PERSON
were O
given O
fentanyl B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
microgram I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
kg B_MEASURE
followed O
by O
etomidate B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
0 I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O
3 B_MEASURE
mg I_MEASURE
/ O
kg B_MEASURE
. O

anaesthesia B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
was O
maintained O
with O
intermittent B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
etomidate I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
2 B_NUMBER[MEASURE]
- O
4 B_TIME[MEASURE]/B_LOCATION
mg I_TIME[MEASURE]/I_LOCATION
doses I_TIME[MEASURE]/I_LOCATION
. O

patients B_PERSON
were O
interviewed O
personally O
later O
the O
same B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
day I_TIME[MEASURE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
and O
by O
questionnaire B_NUMBER[MEASURE]/B_LOCATION
three I_NUMBER[MEASURE]/I_LOCATION
to O
four B_NUMBER[MEASURE]/B_ENT
weeks I_NUMBER[MEASURE]/I_ENT
later O
. O

The O
trial B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
discontinued O
after O
20 B_TIME[MEASURE]
cases I_TIME[MEASURE]
because O
of O
an O
unacceptable B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
incidence B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
side B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Venous O
pain B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
occurred O
in O
68 O
% O
of O
patients O
and O
50 O
% O
had O
redness O
, O
pain B_DISEASE
or O
swelling B_DISEASE
related O
to O
the O
injection O
site O
, O
in O
some O
cases O
lasting O
up O
to O
three O
weeks O
after O
anaesthesia O
. O

skeletal O
movements O
occurred O
in O
50 O
% O
of O
patients O
; O
30 O
% O
experienced O
respiratory B_DISEASE
upset I_DISEASE
, O
one O
sufficiently O
severe O
to O
necessitate O
abandoning O
the O
technique O
. O

Nausea B_DISEASE
and O
vomiting B_DISEASE
occurred O
in O
40 O
% O
and O
25 O
% O
had O
disturbing O
emergence O
psychoses B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
. O

Levodopa O
- O
induced O
dyskinesias B_DISEASE
are O
improved O
by O
fluoxetine O
. O

We O
evaluated O
the O
severity O
of O
motor B_DISEASE
disability I_DISEASE
and O
dyskinesias B_DISEASE_ADJECTIVE[DISEASE]
in O
seven O
levodopa O
- O
responsive O
patients O
with O
Parkinson B_DISEASE
' I_DISEASE
s I_DISEASE
disease I_DISEASE
after O
an O
acute O
challenge O
with O
the O
mixed O
dopamine O
agonist O
, O
apomorphine O
, O
before O
and O
after O
the O
administration O
of O
fluoxetine O
( O
20 O
mg O
twice O
per O
day O
) O
for O
11 O
+ O
/ O
- O
1 O
days O
. O

After O
fluoxetine O
treatment O
, O
there O
was O
a O
significant O
47 O
% O
improvement O
( O
p O
< O
0 O
. O
05 O
) O
of O
apomorphine O
- O
induced O
dyskinesias B_DISEASE
without O
modification O
of O
parkinsonian B_DISEASE
motor I_DISEASE
disability I_DISEASE
. O

The O
dyskinesias B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
were O
reduced O
predominantly O
in O
the O
lower O
limbs O
during O
the O
onset O
and O
disappearance O
of O
dystonic B_DISEASE
dyskinesias I_DISEASE
( O
onset O
- O
and O
end O
- O
of O
- O
dose O
dyskinesias B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
) O
and O
in O
the O
upper O
limbs O
during O
choreic B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
mid I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
- I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
dose I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
dyskinesias I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
results O
suggest O
that O
increased O
brain O
serotoninergic O
transmission O
with O
fluoxetine O
may O
reduce O
levodopa O
- O
or O
dopamine O
agonist O
- O
induced O
dyskinesias B_DISEASE
without O
aggravating O
parkinsonian B_DISEASE
motor I_DISEASE
disability I_DISEASE
. O

A O
large O
population O
- O
based O
follow O
- O
up O
study O
of O
trimethoprim O
- O
sulfamethoxazole O
, O
trimethoprim O
, O
and O
cephalexin O
for O
uncommon O
serious O
drug B_DISEASE
toxicity I_DISEASE
. O

We O
conducted O
a O
population O
- O
based O
45 O
- O
day O
follow O
- O
up O
study O
of O
232 O
, O
390 O
people O
who O
were O
prescribed O
trimethoprim O
- O
sulfamethoxazole O
( O
TMP O
- O
SMZ O
) O
, O
266 O
, O
951 O
prescribed O
trimethoprim O
alone O
, O
and O
196 O
, O
397 O
prescribed O
cephalexin O
, O
to O
estimate O
the O
risk O
of O
serious O
liver B_DISEASE
, I_DISEASE
blood I_DISEASE
, I_DISEASE
skin I_DISEASE
, I_DISEASE
and I_DISEASE
renal I_DISEASE
disorders I_DISEASE
resulting O
in O
referral O
or O
hospitalization O
associated O
with O
these O
drugs O
. O

The O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
based O
on O
information B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
recorded O
on O
office B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
computers I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O
selected B_PERSON/B_ORGANIZATION
general I_PERSON/I_ORGANIZATION
practitioners I_PERSON/I_ORGANIZATION
in O
the O
United B_LOCATION/B_ORGANIZATION
Kingdom I_LOCATION/I_ORGANIZATION
, O
together O
with O
a O
review B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
clinical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
records I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
risk O
of O
clinically O
important O
idiopathic O
liver B_DISEASE
disease I_DISEASE
was O
similar O
for O
persons O
prescribed O
TMP O
- O
SMZ O
( O
5 O
. O
2 O
/ O
100 O
, O
000 O
) O
and O
those O
prescribed O
trimethoprim O
alone O
( O
3 O
. O
8 O
/ O
100 O
, O
000 O
) O
. O

The O
risk B_DISEASE/B_MEASURE
for O
those O
prescribed O
cephalexin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
was O
somewhat O
lower B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
( O
2 B_MEASURE
. O
0 B_MEASURE
/ O
100 B_MEASURE
, O
000 B_MEASURE/B_LOCATION
) O
. O

Only O
five O
patients O
experienced O
blood O
disorders O
, O
one O
of O
whom O
was O
exposed O
to O
TMP O
- O
SMZ O
; O
of O
seven O
with O
erythema B_DISEASE
multiforme I_DISEASE
and O
Stevens B_DISEASE
- I_DISEASE
Johnson I_DISEASE
syndrome I_DISEASE
, O
four O
were O
exposed O
to O
TMP O
- O
SMZ O
. O

The O
one O
case O
of O
toxic B_DISEASE
epidermal I_DISEASE
necrolysis I_DISEASE
occurred O
in O
a O
patient O
who O
took O
cephalexin O
. O

Finally O
, O
only O
five O
cases O
of O
acute O
parenchymal O
renal B_DISEASE
disease I_DISEASE
occurred O
, O
none O
likely O
to O
be O
caused O
by O
a O
study O
drug O
. O

We O
conclude O
that O
the O
risk B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O
the O
serious B_DISEASE_ADJECTIVE[DISEASE]
diseases I_DISEASE_ADJECTIVE[DISEASE]
studied O
is O
small B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
for O
the O
three B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
agents I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
compares O
reasonably O
with O
the O
risk B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
many B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
other I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
antibiotics I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Clinical O
safety O
of O
lidocaine O
in O
patients O
with O
cocaine O
- O
associated O
myocardial B_DISEASE/B_LOCATION
infarction I_DISEASE/I_LOCATION
. O

Study O
objective O
: O
To O
evaluate O
the O
safety O
of O
lidocaine O
in O
the O
setting O
of O
cocaine O
- O
induced O
myocardial B_DISEASE
infarction I_DISEASE
( O
MI B_LOCATION/B_DISEASE
) O
. O

Design B_PERSON/B_MEASURE
: O
A O
retrospective B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O
multicenter B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

setting B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
Twenty B_NUMBER[MEASURE]
- O
nine B_NUMBER[MEASURE]/B_LOCATION
university I_NUMBER[MEASURE]/I_LOCATION
, O
university B_LOCATION/B_PERSON
- O
affiliated O
, O
or O
community B_PERSON/B_LOCATION
hospitals I_PERSON/I_LOCATION
during O
a O
6 B_NUMBER[MEASURE]
- O
year B_TIME[MEASURE]
period I_TIME[MEASURE]
( O
total B_MEASURE/B_LOCATION
of O
117 B_NUMBER[MEASURE]/B_LOCATION
cumulative I_NUMBER[MEASURE]/I_LOCATION
hospital I_NUMBER[MEASURE]/I_LOCATION
- O
years B_TIME[MEASURE]/B_LOCATION
) O
. O

participants O
: O
patients O
with O
cocaine O
- O
associated O
MI B_DISEASE/B_LOCATION
who O
received O
lidocaine O
in O
the O
emergency O
department O
. O

Results O
: O
Of O
29 O
patients O
who O
received O
lidocaine O
in O
the O
setting O
of O
cocaine O
- O
associated O
MI B_DISEASE
, O
no O
patient O
died O
; O
exhibited O
bradydysrhythmias B_DISEASE
, O
ventricular B_DISEASE
tachycardia I_DISEASE
, O
or O
ventricular B_DISEASE
fibrillation I_DISEASE
; O
or O
experienced O
seizures B_DISEASE
after O
administration O
of O
lidocaine O
( O
95 O
% O
confidence O
interval O
, O
0 O
% O
to O
11 O
% O
) O
. O

conclusion O
: O
Despite O
theoretical O
concerns O
that O
lidocaine O
may O
enhance O
cocaine O
toxicity B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
the O
use O
of O
lidocaine O
in O
patients O
with O
cocaine O
- O
associated O
MI B_DISEASE/B_LOCATION
was O
not O
associated O
with O
significant O
cardiovascular B_DISEASE_ADJECTIVE[DISEASE]
or I_DISEASE_ADJECTIVE[DISEASE]
central I_DISEASE_ADJECTIVE[DISEASE]
nervous I_DISEASE_ADJECTIVE[DISEASE]
system I_DISEASE_ADJECTIVE[DISEASE]
toxicity I_DISEASE_ADJECTIVE[DISEASE]
. O

Experimental O
progressive O
muscular B_DISEASE
dystrophy I_DISEASE
and O
its O
treatment O
with O
high O
doses O
anabolizing O
agents O
. O

We O
are O
still O
a O
long O
way O
from O
discovering O
an O
unequivocal O
pathogenetic O
interpretation O
of O
progressive O
muscular B_DISEASE
dystrophy I_DISEASE
in O
man O
. O

Noteworthy B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_NUMBER[MEASURE]
efforts I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_NUMBER[MEASURE]
have O
been O
made O
in O
the O
experimental B_LOCATION/B_ORGANIZATION
field I_LOCATION/I_ORGANIZATION
; O
a O
recessive B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
autosomic B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
form B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
found O
in O
the O
mouse B_SPECIES[BIO]/B_DISEASE
seems O
to O
bear O
the O
closest B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
resemblance I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
to O
the O
human B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
form I_SPECIES[BIO]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O
the O
genetic B_LOCATION/B_MEASURE
point I_LOCATION/I_MEASURE
of O
view B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Myopathy B_DISEASE
due O
to O
lack O
of O
vitamin O
E O
and O
myopathy B_DISEASE
induced O
by O
certain O
viruses O
have O
much O
in O
common O
anatomically O
and O
pathologically O
with O
the O
human O
form O
. O

The O
authors O
induced O
myodystrophy B_DISEASE
in O
the O
rat O
by O
giving O
it O
a O
diet O
lacking O
in O
vitamin O
E O
. O

The O
pharmacological B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
characteristics I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
vitamin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
E I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
the O
degenerative B_DISEASE_ADJECTIVE[DISEASE]
changes I_DISEASE_ADJECTIVE[DISEASE]
brought O
about O
by O
its O
deficiency B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
, O
especially O
in O
the O
muscles B_BODY_PART_OR_ORGAN_COMPONENT/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
are O
illustrated O
. O

It O
is O
thus O
confirmed O
that O
the O
histological O
characteristics O
of O
myopathic B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
rat O
muscle O
induced O
experimentally O
are O
extraordinarily O
similar O
to O
those O
of O
human O
myopathy B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
as O
confirmed O
during O
biopsies O
performed O
at O
the O
Orthopaedic O
Traumatological O
Centre O
, O
Florence O
. O

The O
encouraging O
results O
obtained O
in O
various O
authoratative O
departments O
in O
myopathic B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
patients O
by O
using O
anabolizing O
steroids O
have O
encouraged O
the O
authors O
to O
investigate O
the O
beneficial O
effects O
of O
one O
anabolizing O
agent O
( O
Dianabol O
, O
CIBA O
) O
at O
high O
doses O
in O
rats O
rendered O
myopathic B_DISEASE_ADJECTIVE[DISEASE]
by O
a O
diet O
deficient O
in O
vitamin O
E O
. O

In O
this O
way O
they O
obtained O
appreciable O
changes O
in O
body O
weight O
( O
increased O
from O
50 O
to O
70 O
g O
after O
forty O
days O
at O
a O
dose O
of O
5 O
mg O
per O
day O
of O
anabolizing O
agent O
) O
, O
but O
most O
of O
all O
they O
found O
histological O
changes O
due O
to O
' O
regenerative O
' O
changes O
in O
the O
muscle O
tissue O
, O
which O
however O
maintained O
its O
myopathic B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
characteristics O
in O
the O
control O
animals O
that O
were O
not O
treated O
with O
the O
anabolizing O
agent O
. O

The O
authors O
conclude O
by O
affirming O
the O
undoubted O
efficacy O
of O
the O
anabolizing O
steroids O
in O
experimental O
myopathic B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
disease B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
but O
they O
have O
reservations O
as O
to O
the O
transfer O
of O
the O
results O
into O
the O
human O
field O
, O
where O
high O
dosage O
cannot O
be O
carried O
out O
continuously O
because O
of O
the O
effects O
of O
the O
drug O
on O
virility O
; O
because O
the O
tissue O
injury O
too O
often O
occurs O
at O
an O
irreversible O
stage O
vis O
- O
a O
- O
vis O
the O
' O
regeneration O
' O
of O
the O
muscle O
tissue O
; O
and O
finally O
because O
the O
dystrophic O
injurious O
agent O
is O
certainly O
not O
the O
lack O
of O
vitamin O
E O
but O
something O
as O
yet O
unknown O
. O

Paclitaxel B_NUMBER[MEASURE]
3 I_NUMBER[MEASURE]
- O
hour B_MEASURE/B_LOCATION
infusion I_MEASURE/I_LOCATION
given O
alone O
and O
combined O
with O
carboplatin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
preliminary B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
results I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
dose B_MEASURE/B_LOCATION
- O
escalation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
trials I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Paclitaxel O
( O
Taxol O
; O
Bristol O
- O
Myers O
Squibb O
Company O
, O
Princeton O
, O
NJ O
) O
by O
3 O
- O
hour O
infusion O
was O
combined O
with O
carboplatin O
in O
a O
phase O
I O
/ O
II O
study O
directed O
to O
patients O
with O
non B_DISEASE
- I_DISEASE
small I_DISEASE
cell I_DISEASE
lung I_DISEASE
cancer I_DISEASE
. O

carboplatin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
was O
given O
at O
a O
fixed O
target B_MEASURE/B_LOCATION
area I_MEASURE/I_LOCATION
under O
the O
concentration B_MEASURE/B_LOCATION
- O
time B_MEASURE/B_LOCATION
curve I_MEASURE/I_LOCATION
of O
6 B_MEASURE
. O
0 B_MEASURE
by O
the O
Calvert B_PERSON
formula I_PERSON
, O
whereas O
paclitaxel B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
escalated O
in O
patient B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
cohorts B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
from O
150 B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mg I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
m2 B_MEASURE
( O
dose B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
level I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
) O
to O
175 B_MEASURE
, O
200 B_MEASURE
, O
225 B_MEASURE
, O
and O
250 B_MEASURE
mg I_MEASURE
/ O
m2 B_MEASURE/B_LOCATION
. O

The O
225 O
mg O
/ O
m2 O
level O
was O
expanded O
for O
the O
phase O
II O
study O
since O
the O
highest O
level O
achieved O
( O
250 O
mg O
/ O
m2 O
) O
required O
modification O
because O
of O
nonhematologic O
toxicities B_DISEASE
( O
arthralgia B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
and O
sensory B_DISEASE
neuropathy I_DISEASE
) O
. O

Therapeutic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
effects I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
were O
noted O
at O
all O
dose B_MEASURE/B_LOCATION
levels B_MEASURE/I_LOCATION
, O
with O
objective B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
responses I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
17 B_NUMBER[MEASURE]
( O
two B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
complete B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
15 B_DISEASE_ADJECTIVE[DISEASE]
partial I_DISEASE_ADJECTIVE[DISEASE]
regressions I_DISEASE_ADJECTIVE[DISEASE]
) O
of O
41 B_NUMBER[MEASURE]
previously O
untreated B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
patients I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Toxicities B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
compared O
with O
a O
cohort O
of O
patients O
in O
a O
phase O
I O
trial O
of O
paclitaxel O
alone O
at O
identical O
dose O
levels O
. O

Carboplatin O
did O
not O
appear O
to O
add O
to O
the O
hematologic B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
toxicities B_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
observed O
, O
and O
the O
paclitaxel O
/ O
carboplatin O
combination O
could O
be O
dosed O
every O
3 O
weeks O
. O

The O
dose O
- O
dependent O
effect O
of O
misoprostol O
on O
indomethacin O
- O
induced O
renal B_DISEASE
dysfunction I_DISEASE
in O
well O
compensated O
cirrhosis B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Misoprostol O
( O
200 O
micrograms O
) O
has O
been O
shown O
to O
acutely O
counteract O
the O
indomethacin O
- O
induced O
renal B_DISEASE
dysfunction I_DISEASE
in O
well O
compensated O
cirrhotic B_DISEASE
patients O
. O

The O
aim B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
this O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
to O
determine O
if O
the O
prophylactic B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
value I_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
of O
misoprostol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
dose B_MEASURE
- O
dependent B_DISEASE_ADJECTIVE[DISEASE]
. O

parameters O
of O
renal O
hemodynamics O
and O
tubular O
sodium O
and O
water O
handling O
were O
assessed O
by O
clearance O
techniques O
in O
26 O
well O
compensated O
cirrhotic B_DISEASE/B_PERSON
patients O
before O
and O
after O
an O
oral O
combination O
of O
50 O
mg O
of O
indomethacin O
and O
various O
doses O
of O
misoprostol O
. O

The O
200 B_MEASURE
- O
micrograms B_MEASURE
dose I_MEASURE
was O
able B_DISEASE_ADJECTIVE[DISEASE]
to O
totally O
abolish O
the O
deleterious B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
renal I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
effects I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
indomethacin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
whereas O
the O
800 B_MEASURE
- O
micrograms B_MEASURE
dose I_MEASURE
resulted O
in O
significant B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
worsening I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
renal B_DISEASE
hemodynamics I_DISEASE
and O
sodium B_DISEASE
retention I_DISEASE
. O

These O
changes B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
maximal B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O
the O
hour B_BODY_PART_OR_ORGAN_COMPONENT/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
immediately O
after O
medications B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
and O
slowly O
returned O
toward O
base B_LOCATION/B_COLOR
- O
line B_MEASURE/B_ORGANIZATION
levels I_MEASURE/I_ORGANIZATION
thereafter O
. O

These O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggest O
that O
the O
renal B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
protective B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
misoprostol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
dose B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
dependent B_DISEASE_ADJECTIVE[DISEASE]
. O

However O
, O
until O
this O
apparent O
ability O
of O
200 O
micrograms O
of O
misoprostol O
to O
prevent O
the O
adverse O
effects O
of O
indomethacin O
on O
renal O
function O
is O
confirmed O
with O
chronic O
frequent O
dosing O
, O
it O
would O
be O
prudent O
to O
avoid O
nonsteroidal O
anti O
- O
inflammatory O
therapy O
in O
patients O
with O
cirrhosis B_DISEASE/B_LOCATION
. O

increased O
frequency O
and O
severity O
of O
angio B_DISEASE
- I_DISEASE
oedema I_DISEASE
related O
to O
long O
- O
term O
therapy O
with O
angiotensin O
- O
converting O
enzyme O
inhibitor O
in O
two O
patients O
. O

adverse O
reactions O
to O
drugs O
are O
well O
recognized O
as O
a O
cause O
of O
acute O
or O
chronic O
urticaria B_DISEASE
, O
and O
angio B_DISEASE
- I_DISEASE
oedema I_DISEASE
. O

Angiotensin O
- O
converting O
enzyme O
( O
ace O
) O
inhibitors O
, O
used O
to O
treat O
hypertension B_DISEASE
and O
congestive B_DISEASE
heart I_DISEASE
failure I_DISEASE
, O
were O
introduced O
in O
Europe O
in O
the O
middle O
of O
the O
eighties O
, O
and O
the O
use O
of O
these O
drugs O
has O
increased O
progressively O
. O

Soon O
after O
the O
introduction O
of O
ace O
inhibitors O
, O
acute O
bouts O
of O
angio B_DISEASE
- I_DISEASE
oedema I_DISEASE
were O
reported O
in O
association O
with O
the O
use O
of O
these O
drugs O
. O

We O
wish O
to O
draw O
attention O
to O
the O
possibility O
of O
adverse O
reactions O
to O
ace O
inhibitors O
after O
long O
- O
term O
use O
and O
in O
patients O
with O
pre O
- O
existing O
angio B_DISEASE
- I_DISEASE
oedema I_DISEASE
. O

Myoclonus B_DISEASE_ADJECTIVE[DISEASE]
associated O
with O
lorazepam O
therapy O
in O
very O
- O
low O
- O
birth O
- O
weight O
infants O
. O

Lorazepam B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
is O
being O
used O
with O
increasing O
frequency B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O
a O
sedative B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
newborn B_PERSON/B_BIO
and O
the O
young B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
infant I_PERSON/I_BODY_PART_OR_ORGAN_COMPONENT
. O

concern B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
has O
been O
raised O
with O
regard B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
the O
safety B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O
lorazepam B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
in O
this O
age B_MEASURE/B_LOCATION
group B_MEASURE/I_LOCATION
, O
especially O
in O
very B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O
low B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O
birth B_TIME[MEASURE]/B_PERSON
- O
weight B_MEASURE/B_BIO
( O
VLBW B_DISEASE
; O
< O
1 B_MEASURE
, O
500 B_MEASURE
g I_MEASURE
) O
infants B_PERSON/B_BIO
. O

Three O
young O
infants O
, O
all O
of O
birth O
weight O
< O
1 O
, O
500 O
g O
, O
experienced O
myoclonus B_DISEASE
following O
the O
intravenous O
administration O
of O
lorazepam O
. O

The O
potential O
neurotoxic B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects O
of O
the O
drug O
( O
and O
its O
vehicle O
) O
in O
this O
population O
are O
discussed O
. O

injectable B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
lorazepam I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
should O
be O
used O
with O
caution B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
in O
VLBW B_PERSON/B_LOCATION
infants I_PERSON/I_LOCATION
. O

Transvenous O
right O
ventricular O
pacing O
during O
cardiopulmonary O
resuscitation O
of O
pediatric O
patients O
with O
acute O
cardiomyopathy B_DISEASE
. O

We O
describe O
the O
cardiopulmonary O
resuscitation O
efforts O
on O
five O
patients O
who O
presented O
in O
acute O
circulatory B_DISEASE/B_LOCATION
failure I_DISEASE/I_LOCATION
from O
myocardial B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
dysfunction I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Three O
patients O
had O
acute O
viral O
myocarditis B_DISEASE
, O
one O
had O
a O
carbamazepine O
- O
induced O
acute O
eosinophilic B_DISEASE
myocarditis I_DISEASE
, O
and O
one O
had O
cardiac O
hemosiderosis O
resulting O
in O
acute O
cardiogenic B_DISEASE
shock I_DISEASE
. O

All O
patients B_PERSON/B_LOCATION
were O
continuously O
monitored O
with O
central B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
venous I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
and O
arterial B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
catheters B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
in O
addition B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O
routine B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
noninvasive I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
monitoring I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

An O
introducer O
sheath O
, O
a O
pacemaker O
, O
and O
sterile O
pacing O
wires O
were O
made O
readily O
available O
for O
the O
patients O
, O
should O
the O
need O
arise O
to O
terminate O
resistant O
cardiac O
dysrhythmias B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

All O
patients O
developed O
cardiocirculatory O
arrest O
associated O
with O
extreme O
hypotension B_DISEASE
and O
dysrhythmias B_DISEASE
within O
the O
first O
48 O
hours O
of O
their O
admission O
to O
the O
pediatric O
intensive O
care O
unit O
( O
PICU O
) O
. O

Right B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
ventricular I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
pacemaker I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
wires I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
were O
inserted O
in O
all O
of O
them O
during O
cardiopulmonary B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BODY_PART_OR_ORGAN_COMPONENT
resuscitation I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_BODY_PART_OR_ORGAN_COMPONENT
( O
CPR B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O
. O

In O
four B_PERSON/B_MEASURE
patients I_PERSON/I_MEASURE
, O
cardiac B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
pacing I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
was O
used O
, O
resulting O
in O
a O
temporary B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
captured O
rhythm B_DISEASE/B_MEASURE
and O
restoration B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
their O
cardiac B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
output B_MEASURE/I_BODY_PART_OR_ORGAN_COMPONENT
. O

These O
patients O
had O
a O
second O
event O
of O
cardiac B_DISEASE
arrest I_DISEASE
, O
resulting O
in O
death O
, O
within O
10 O
to O
60 O
minutes O
. O

In O
one B_PERSON/B_MEASURE
patient B_PERSON/I_MEASURE
, O
cardiac B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pacing I_PERSON/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
not O
used O
, O
because O
he O
converted O
to O
normal B_DISEASE
sinus I_DISEASE
rhythm I_DISEASE
by O
electrical B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
defibrillation I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
within O
three B_TIME[MEASURE]/B_ENT
minutes I_TIME[MEASURE]/I_ENT
of O
initiating O
CPR B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O

We O
conclude O
that O
cardiac O
pacing O
during O
resuscitative O
efforts O
in O
pediatric O
patients O
suffering O
from O
acute O
myocardial B_DISEASE/B_LOCATION
dysfunction I_DISEASE/I_LOCATION
may O
not O
have O
long O
- O
term O
value O
in O
and O
of O
itself O
; O
however O
, O
if O
temporary O
hemodynamic O
stability O
is O
achieved O
by O
this O
procedure O
, O
it O
may O
provide O
additional O
time O
needed O
to O
institute O
other O
therapeutic O
modalities O
. O

efficacy O
and O
safety O
of O
granisetron O
, O
a O
selective O
5 O
- O
hydroxytryptamine O
- O
3 O
receptor O
antagonist O
, O
in O
the O
prevention O
of O
nausea B_DISEASE
and O
vomiting B_DISEASE
induced O
by O
high O
- O
dose O
cisplatin O
. O

purpose O
: O
To O
assess O
the O
antiemetic O
effects O
and O
safety O
profile O
of O
four O
different O
doses O
of O
granisetron O
( O
Kytril O
; O
SmithKline O
Beecham O
Pharmaceuticals O
, O
Philadelphia O
, O
PA O
) O
when O
administered O
as O
a O
single O
intravenous O
( O
IV O
) O
dose O
for O
prophylaxis O
of O
cisplatin O
- O
induced O
nausea B_DISEASE
and O
vomiting B_DISEASE
. O

patients B_PERSON/B_TIME[MEASURE]
AND O
METHODS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O
One B_NUMBER[MEASURE]
hundred I_NUMBER[MEASURE]
eighty I_NUMBER[MEASURE]
- O
four B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
chemotherapy I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
naive B_PERSON
patients I_PERSON
receiving O
high B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O
dose B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
cisplatin I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O
81 B_MEASURE
to O
120 B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mg I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
m2 B_MEASURE
) O
were O
randomized O
to O
receive O
one B_NUMBER[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
four B_NUMBER[MEASURE]/B_PERSON
granisetron I_NUMBER[MEASURE]/I_PERSON
doses I_NUMBER[MEASURE]/I_PERSON
( O
5 B_NUMBER[MEASURE]
, O
10 B_MEASURE
, O
20 B_MEASURE
, O
or O
40 B_MEASURE
micrograms I_MEASURE
/ O
kg B_MEASURE
) O
administered O
before O
chemotherapy B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

patients O
were O
observed O
on O
an O
inpatient O
basis O
for O
18 O
to O
24 O
hours O
, O
and O
vital O
signs O
, O
nausea B_DISEASE
, O
vomiting B_DISEASE
, O
retching O
, O
and O
appetite O
were O
assessed O
. O

Safety B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analyses I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
included O
incidence B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O
adverse B_DISEASE
experiences I_DISEASE
and O
laboratory B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
parameter B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
changes B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O

Results O
: O
After O
granisetron O
doses O
of O
5 O
, O
10 O
, O
20 O
, O
and O
40 O
micrograms O
/ O
kg O
, O
a O
major O
response O
( O
< O
or O
= O
two O
vomiting B_DISEASE
or O
retching O
episodes O
, O
and O
no O
antiemetic O
rescue O
) O
was O
recorded O
in O
23 O
% O
, O
57 O
% O
, O
58 O
% O
, O
and O
60 O
% O
of O
patients O
, O
respectively O
, O
and O
a O
complete O
response O
( O
no O
vomiting B_DISEASE
or O
retching O
, O
and O
no O
antiemetic O
rescue O
) O
in O
18 O
% O
, O
41 O
% O
, O
40 O
% O
, O
and O
47 O
% O
of O
patients O
, O
respectively O
. O

There O
was O
a O
statistically O
longer O
time O
to O
first O
episode O
of O
nausea B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O
P O
= O
. O
0015 O
) O
and O
vomiting B_DISEASE
( O
P O
= O
. O
0001 O
) O
, O
and O
fewer O
patients O
were O
administered O
additional O
antiemetic O
medication O
in O
the O
10 O
- O
micrograms O
/ O
kg O
dosing O
groups O
than O
in O
the O
5 O
- O
micrograms O
/ O
kg O
dosing O
group O
. O

As O
granisetron B_MEASURE/B_DISEASE
dose I_MEASURE/I_DISEASE
increased O
, O
appetite B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
return I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
increased O
( O
P B_OTHER/B_PROTEIN[GENE]
= O
. O
040 B_MEASURE
) O
. O

Headache B_DISEASE
was O
the O
most O
frequently O
reported O
adverse O
event O
( O
20 O
% O
) O
. O

conclusion O
: O
A O
single O
10 O
- O
, O
20 O
- O
, O
or O
40 O
- O
micrograms O
/ O
kg O
dose O
of O
granisetron O
was O
effective O
in O
controlling O
vomiting B_DISEASE
in O
57 O
% O
to O
60 O
% O
of O
patients O
who O
received O
cisplatin O
at O
doses O
greater O
than O
81 O
mg O
/ O
m2 O
and O
totally O
prevented O
vomiting B_DISEASE
in O
40 O
% O
to O
47 O
% O
of O
patients O
. O

There O
were O
no O
statistically O
significant B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
differences I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
efficacy B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
between O
the O
10 B_MEASURE
- O
micrograms B_MEASURE/B_LOCATION
/ O
kg B_MEASURE/B_PERSON
dose I_MEASURE/I_PERSON
and O
the O
20 B_MEASURE
- O
and O
40 B_MEASURE
- O
micrograms B_MEASURE/B_BIO
/ O
kg B_MEASURE/B_PERSON
doses I_MEASURE/I_PERSON
. O

Granisetron B_PERSON
was O
well O
tolerated O
at O
all O
doses B_TIME[MEASURE]/B_LOCATION
. O

Adverse B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
interaction I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
between O
clonidine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
verapamil B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

objective O
: O
To O
report O
two O
cases O
of O
a O
possible O
adverse O
interaction O
between O
clonidine O
and O
verapamil O
resulting O
in O
atrioventricular B_DISEASE
( I_DISEASE
AV I_DISEASE
) I_DISEASE
block I_DISEASE
in O
both O
patients O
and O
severe O
hypotension B_DISEASE
in O
one O
patient O
. O

Case O
SUMMARIES O
: O
A O
54 O
- O
year O
- O
old O
woman O
with O
hyperaldosteronism B_DISEASE
was O
treated O
with O
verapamil O
480 O
mg O
/ O
d O
and O
spironolactone O
100 O
mg O
/ O
d O
. O

After O
the O
addition O
of O
a O
minimal O
dose O
of O
clonidine O
( O
0 O
. O
15 O
mg O
bid O
) O
, O
she O
developed O
complete O
AV B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
block I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
severe O
hypotension B_DISEASE
, O
which O
resolved O
upon O
cessation O
of O
all O
medications O
. O

A O
65 B_MEASURE
- O
year B_TIME[MEASURE]
- O
old B_PERSON
woman I_PERSON
was O
treated O
with O
extended O
- O
release B_MEASURE/B_LOCATION
verapamil B_MEASURE/I_LOCATION
240 B_MEASURE/I_LOCATION
mg B_MEASURE/I_LOCATION
/ O
d B_OTHER/B_TIME[MEASURE]
. O

After O
the O
addition O
of O
clonidine O
0 O
. O
15 O
mg O
bid O
she O
developed O
complete O
AV B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
block I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
which O
resolved O
after O
all O
therapy O
was O
stopped O
. O

discussion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O
An O
adverse B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
interaction I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
between O
clonidine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
verapamil B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
has O
not O
been O
reported O
previously O
. O

We O
describe O
two B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
such I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
cases I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
and O
discuss O
the O
various B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mechanisms B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
might O
cause O
such O
an O
interaction B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Clinicians B_PERSON
should O
be O
acquainted O
with O
this O
possibly O
fatal B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
interaction I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
between O
two B_NUMBER[MEASURE]/B_PERSON
commonly O
used O
antihypertensive B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
drugs I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

CONCLUSIONS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
: O
caution B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
is O
recommended O
in O
combining O
clonidine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
verapamil B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
therapy I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
, O
even O
in O
patients B_PERSON
who O
do O
not O
have O
sinus B_BODY_PART_OR_ORGAN_COMPONENT/B_PROTEIN[GENE]
or O
AV B_DISEASE
node I_DISEASE
dysfunction I_DISEASE
. O

The O
two B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
drugs I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
may O
act O
synergistically O
on O
both O
the O
AV B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
node I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
and O
the O
peripheral B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
circulation B_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
. O

Pharmacological B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
studies I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
on O
a O
new B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dihydrothienopyridine I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
calcium I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antagonist I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
S B_OTHER/B_LOCATION
- O
312 B_MEASURE
- O
d B_OTHER/B_PROTEIN[GENE]
. O

5th B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
communication I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
: O
anticonvulsant B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
mice B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

S O
- O
312 O
, O
S O
- O
312 O
- O
d O
, O
but O
not O
S O
- O
312 O
- O
l O
, O
L O
- O
type O
calcium O
channel O
antagonists O
, O
showed O
anticonvulsant O
effects O
on O
the O
audiogenic B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
tonic I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
convulsions I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
in O
DBA O
/ O
2 O
mice O
; O
and O
their O
ED50 O
values O
were O
18 O
. O
4 O
( O
12 O
. O
8 O
- O
27 O
. O
1 O
) O
mg O
/ O
kg O
, O
p O
. O
o O
. O
and O
15 O
. O
0 O
( O
10 O
. O
2 O
- O
23 O
. O
7 O
) O
mg O
/ O
kg O
, O
p O
. O
o O
. O
, O
respectively O
, O
while O
that O
of O
flunarizine O
was O
34 O
. O
0 O
( O
26 O
. O
0 O
- O
44 O
. O
8 O
) O
mg O
/ O
kg O
, O
p O
. O
o O
. O

Although O
moderate O
anticonvulsant O
effects O
of O
S O
- O
312 O
- O
d O
in O
higher O
doses O
were O
observed O
against O
the O
clonic O
convulsions B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
induced O
by O
pentylenetetrazole O
( O
85 O
mg O
/ O
kg O
, O
s O
. O
c O
. O
) O
or O
bemegride O
( O
40 O
mg O
/ O
kg O
, O
s O
. O
c O
. O
) O
, O
no O
effects O
were O
observed O
in O
convulsions B_DISEASE
induced O
by O
N O
- O
methyl O
- O
D O
- O
aspartate O
, O
picrotoxin O
, O
or O
electroshock O
in O
Slc O
: O
ddY O
mice O
. O

S O
- O
312 O
- O
d O
may O
be O
useful O
in O
the O
therapy O
of O
certain O
types O
of O
human O
epilepsy B_DISEASE
. O

Transmural O
myocardial B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
infarction B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O
sumatriptan O
. O

For O
sumatriptan B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
tightness B_DISEASE_ADJECTIVE[DISEASE]
in O
the O
chest B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
caused O
by O
an O
unknown B_DISEASE
mechanism I_DISEASE
has O
been O
reported O
in O
3 B_NUMBER[MEASURE]/B_LOCATION
- O
5 B_SEQUENCE[MEASURE]/B_LOCATION
% I_SEQUENCE[MEASURE]/I_LOCATION
of O
users B_PERSON/B_BIO
. O

We O
describe O
a O
47 O
- O
year O
- O
old O
woman O
with O
an O
acute O
myocardial B_DISEASE
infarction I_DISEASE
after O
administration O
of O
sumatriptan O
6 O
mg O
subcutaneously O
for O
cluster B_DISEASE
headache I_DISEASE
. O

The O
patient O
had O
no O
history O
of O
underlying O
ischaemic B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
heart I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
disease I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
or O
Prinzmetal B_DISEASE
' I_DISEASE
s I_DISEASE
angina I_DISEASE
. O

She O
recovered O
without O
complications B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Flumazenil O
induces O
seizures B_DISEASE
and O
death O
in O
mixed O
cocaine O
- O
diazepam O
intoxications O
. O

Study O
hypothesis O
: O
Administration O
of O
the O
benzodiazepine O
antagonist O
flumazenil O
may O
unmask O
seizures B_DISEASE
in O
mixed O
cocaine O
- O
benzodiazepine O
intoxication O
. O

Design B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O
Male B_PERSON
Sprague I_PERSON
- O
Dawley B_PERSON
rats I_PERSON
received O
100 B_MEASURE
mg I_MEASURE
/ O
kg B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cocaine I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
IP I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alone O
, O
5 B_MEASURE
mg I_MEASURE
/ O
kg B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
diazepam I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
alone O
, O
or O
a O
combination B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
diazepam B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
cocaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Three B_TIME[MEASURE]/B_ENT
minutes I_TIME[MEASURE]/I_ENT
later O
, O
groups B_ORGANIZATION/B_PERSON
were O
challenged O
with O
vehicle B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O
flumazenil B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PRODUCT[OBJECT]
5 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PRODUCT[OBJECT]
or O
10 B_MEASURE
mg I_MEASURE
/ O
kg B_MEASURE
IP I_MEASURE
. O

Animal O
behavior O
, O
seizures B_DISEASE/B_ORGANISM_FUNCTION
( O
time O
to O
and O
incidence O
) O
, O
death O
( O
time O
to O
and O
incidence O
) O
, O
and O
cortical O
EEG O
tracings O
were O
recorded O
. O

Interventions B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
Administration B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
flumazenil B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
animals B_PERSON
after O
they O
had O
received O
a O
combination B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
dose I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
cocaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
diazepam B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

RESULTS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O
In O
group B_MEASURE/B_LOCATION
1 I_MEASURE/I_LOCATION
, O
animals B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
received O
cocaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
followed O
by O
vehicle B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

This O
resulted O
in O
100 O
% O
developing O
seizures B_DISEASE
and O
death O
. O

Group B_PERSON/B_ORGANIZATION
2 I_PERSON/I_ORGANIZATION
received O
diazepam B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alone O
followed O
by O
vehicle B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Animals B_BIO/B_NUMBER[MEASURE]
became O
somnolent B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
and O
none B_PERSON/B_NUMBER[MEASURE]
died O
. O

Group B_PERSON/B_ORGANIZATION
3 I_PERSON/I_ORGANIZATION
received O
diazepam B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
followed O
by O
5 B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mg I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
kg B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
flumazenil I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
. O

Animals B_BIO/B_PERSON
became O
somnolent B_DISEASE_ADJECTIVE[DISEASE]
after O
diazepam B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
then O
active B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
after O
flumazenil B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
administration I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

In O
group B_MEASURE
4 I_MEASURE
, O
a O
combination B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
of O
cocaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
diazepam B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
administered O
simultaneously O
. O

This O
resulted O
in O
no O
overt O
or O
EEG O
- O
detectable O
seizures B_DISEASE
and O
a O
50 O
% O
incidence O
of O
death O
. O

Group B_PERSON/B_ORGANIZATION
5 I_PERSON/I_ORGANIZATION
received O
a O
similar B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
combination I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
of O
cocaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
diazepam B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
followed O
later O
by O
5 B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mg I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
kg B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
flumazenil I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
. O

This O
resulted O
in O
an O
increased O
incidence O
of O
seizures B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
90 O
% O
( O
P O
< O
. O
01 O
) O
, O
and O
death O
, O
100 O
% O
( O
P O
< O
or O
= O
. O
01 O
) O
, O
compared O
with O
group O
4 O
. O

Group B_PERSON/B_ORGANIZATION
6 I_PERSON/I_ORGANIZATION
received O
cocaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
diazepam B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
followed O
by O
10 B_MEASURE
mg I_MEASURE
/ O
kg B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
flumazenil I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
. O

This O
also O
resulted O
in O
an O
increased O
incidence O
of O
seizures B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
90 O
% O
( O
P O
< O
or O
= O
. O
01 O
) O
, O
and O
death O
, O
90 O
% O
( O
P O
< O
or O
= O
. O
05 O
) O
, O
compared O
with O
group O
4 O
. O

conclusion O
: O
Flumazenil O
can O
unmask O
seizures B_DISEASE
and O
increase O
the O
incidence O
of O
death O
in O
a O
model O
of O
combined O
cocaine O
- O
diazepam O
intoxications O
. O

mechanisms O
for O
protective O
effects O
of O
free O
radical O
scavengers O
on O
gentamicin O
- O
mediated O
nephropathy B_DISEASE
in O
rats O
. O

Studies O
were O
performed O
to O
examine O
the O
mechanisms O
for O
the O
protective O
effects O
of O
free O
radical O
scavengers O
on O
gentamicin O
( O
GM O
) O
- O
mediated O
nephropathy B_DISEASE
. O

Administration O
of O
GM O
at O
40 O
mg O
/ O
kg O
Sc O
for O
13 O
days O
to O
rats O
induced O
a O
significant O
reduction O
in O
renal O
blood O
flow O
( O
RBF O
) O
and O
inulin O
clearance O
( O
CIn O
) O
as O
well O
as O
marked O
tubular B_DISEASE
damage I_DISEASE
. O

A O
significant O
reduction O
in O
urinary O
guanosine O
3 O
' O
, O
5 O
' O
- O
cyclic O
monophosphate O
( O
cGMP O
) O
excretion O
and O
a O
significant O
increase O
in O
renal O
cortical O
renin O
and O
endothelin O
- O
1 O
contents O
were O
also O
observed O
in O
GM O
- O
mediated O
nephropathy B_DISEASE/B_BIO
. O

superoxide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
dismutase I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
SOD B_GENE
) O
or O
dimethylthiourea B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
( O
DMTU B_LOCATION/B_ORGANIZATION
) O
significantly O
lessened O
the O
GM B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
decrement B_DISEASE_ADJECTIVE[DISEASE]
in O
cin B_DISEASE/B_GENE
. O

The O
SOD B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
induced O
increase B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
glomerular B_MEASURE/B_DISEASE
filtration B_MEASURE/I_DISEASE
rate B_MEASURE/I_DISEASE
was O
associated O
with O
a O
marked B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
improvement I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
RBF B_DISEASE/B_GENE
, O
an O
increase B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
urinary B_DISEASE/B_GENE
cGMP I_DISEASE/I_GENE
excretion I_DISEASE/I_GENE
, O
and O
a O
decrease B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
renal B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
renin I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O
endothelin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
1 B_TIME[MEASURE]/B_LOCATION
content I_TIME[MEASURE]/I_LOCATION
. O

SOD O
did O
not O
attenuate O
the O
tubular B_DISEASE_ADJECTIVE[DISEASE]
damage I_DISEASE_ADJECTIVE[DISEASE]
. O

In O
contrast O
, O
DMTU O
significantly O
reduced O
the O
tubular B_DISEASE
damage I_DISEASE
and O
lipid O
peroxidation O
, O
but O
it O
did O
not O
affect O
renal O
hemodynamics O
and O
vasoactive O
substances O
. O

Neither O
SOD B_LOCATION/B_ORGANIZATION
nor O
DMTU B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
affected O
the O
renal B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
cortical I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
GM I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
content I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
in O
GM B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
treated O
rats B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

These O
results O
suggest O
that O
1 O
) O
both O
SOD O
and O
DMTU O
have O
protective O
effects O
on O
GM O
- O
mediated O
nephropathy B_DISEASE
, O
2 O
) O
the O
mechanisms O
for O
the O
protective O
effects O
differ O
for O
SOD O
and O
DMTU O
, O
and O
3 O
) O
superoxide O
anions O
play O
a O
critical O
role O
in O
GM O
- O
induced O
renal O
vasoconstriction O
. O

Cephalothin O
- O
induced O
immune O
hemolytic B_DISEASE_ADJECTIVE[DISEASE]
anemia I_DISEASE_ADJECTIVE[DISEASE]
. O

A O
patient O
with O
renal B_DISEASE
disease I_DISEASE
developed O
Coombs O
- O
positive O
hemolytic B_DISEASE
anemia I_DISEASE
while O
receiving O
cephalothin O
therapy O
. O

An O
anti B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
cephalothin B_DISEASE/B_GENE
IgG B_DISEASE/I_GENE
antibody B_DISEASE/I_GENE
was O
detected O
in O
the O
patient B_PERSON/B_BIO
' O
s B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
serum I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
in O
the O
eluates B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
from O
her O
erythrocytes B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
. O

In O
addition B_MEASURE/B_LOCATION
, O
nonimmunologic B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
binding I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
normal B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
patient B_PERSON/B_DISEASE
' O
s B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
serum I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
proteins I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
her O
own B_PERSON/B_BIO
and O
cephalothin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
- O
coated O
normal B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
red B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cells B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
was O
demonstrated O
. O

Skin B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
tests B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
and O
in O
vitro B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
lymphocyte I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
stimulation I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
revealed O
that O
the O
patient B_PERSON/B_BIO
was O
sensitized O
to O
cephalothin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
and O
also O
to O
ampicillin O
. O

careful O
investigation O
of O
drug O
- O
induced O
hemolytic B_DISEASE_ADJECTIVE[DISEASE]
anemias I_DISEASE_ADJECTIVE[DISEASE]
reveals O
the O
complexity O
of O
the O
immune O
mechanisms O
involved O
. O

Assessment O
of O
cardiomyocyte O
DNA O
synthesis O
during O
hypertrophy B_DISEASE/B_ORGANISM_FUNCTION
in O
adult O
mice O
. O

The O
ability O
of O
cardiomyocytes O
to O
synthesize O
DNA O
in O
response O
to O
experimentally O
induced O
cardiac B_DISEASE
hypertrophy I_DISEASE
was O
assessed O
in O
adult O
mice O
. O

isoproterenol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
delivered O
by O
osmotic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
minipump I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
implantation I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
in O
adult B_LOCATION/B_PERSON
C3Heb I_LOCATION/I_PERSON
/ O
FeJ B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
mice B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
resulted O
in O
a O
46 B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
% I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
increase I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O
heart B_MEASURE/B_BIO
weight I_MEASURE/I_BIO
and O
a O
19 B_MEASURE
. O
3 B_MEASURE
% I_MEASURE
increase I_MEASURE
in O
cardiomyocyte B_MEASURE/B_DISEASE
area I_MEASURE/I_DISEASE
. O

No O
DNA O
synthesis O
, O
as O
assessed O
by O
autoradiographic O
analysis O
of O
isolated O
cardiomyocytes O
, O
was O
observed O
in O
control O
or O
hypertrophic B_DISEASE/B_ENT
hearts I_DISEASE/I_ENT
. O

A O
survey B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
15 B_MEASURE/B_BIO
independent I_MEASURE/I_BIO
inbred I_MEASURE/I_BIO
strains I_MEASURE/I_BIO
of O
mice B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
revealed O
that O
ventricular B_MEASURE/B_PERSON
cardiomyocyte B_MEASURE/I_PERSON
nuclear B_MEASURE/I_PERSON
number B_MEASURE/I_PERSON
ranged O
from O
3 B_NUMBER[MEASURE]
to O
13 B_MEASURE
% I_MEASURE
mononucleate I_MEASURE
, O
suggesting O
that O
cardiomyocyte B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
terminal B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
differentiation B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
is O
influenced O
directly O
or O
indirectly O
by O
genetic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
background I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

To O
determine O
whether O
the O
capacity O
for O
reactive O
DNA O
synthesis O
was O
also O
subject O
to O
genetic O
regulation O
, O
cardiac B_DISEASE
hypertrophy I_DISEASE
was O
induced O
in O
the O
strains O
of O
mice O
comprising O
the O
extremes O
of O
the O
nuclear O
number O
survey O
. O

These O
data O
indicate O
that O
adult O
mouse O
atrial O
and O
ventricular O
cardiomyocytes O
do O
not O
synthesize O
DNA O
in O
response O
to O
isoproterenol O
- O
induced O
cardiac B_DISEASE_ADJECTIVE[DISEASE]
hypertrophy I_DISEASE_ADJECTIVE[DISEASE]
. O

Central O
cardiovascular O
effects O
of O
AVP O
and O
ANP O
in O
normotensive O
and O
spontaneously O
hypertensive B_DISEASE_ADJECTIVE[DISEASE]
rats O
. O

The O
purpose O
of O
the O
present O
study O
was O
to O
compare O
influence O
of O
central O
arginine O
vasopressin O
( O
AVP O
) O
and O
of O
atrial O
natriuretic O
peptide O
( O
ANP O
) O
on O
control O
of O
arterial O
blood O
pressure O
( O
Map O
) O
and O
heart O
rate O
( O
HR O
) O
in O
normotensive O
( O
WKY O
) O
and O
spontaneously O
hypertensive B_DISEASE
( O
SHR O
) O
rats O
. O

Three B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
series I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
experiments B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
performed O
on O
30 B_MEASURE/B_LOCATION
WKY I_MEASURE/I_LOCATION
and O
30 B_TIME[MEASURE]/B_LOCATION
SHR I_TIME[MEASURE]/I_LOCATION
, O
chronically O
instrumented O
with O
guide B_MEDICAL_DEVICE[OBJECT]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
tubes I_MEDICAL_DEVICE[OBJECT]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
the O
lateral B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
ventricle I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
( O
LV B_PROTEIN[GENE]/B_BODY_PART_OR_ORGAN_COMPONENT
) O
and O
arterial B_BODY_PART_OR_ORGAN_COMPONENT/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
venous B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
catheters I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O

MAP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O
HR B_PROTEIN[GENE]/B_BODY_PART_OR_ORGAN_COMPONENT
were O
monitored O
before O
and O
after O
i O
. O
v B_PROTEIN[GENE]/B_LOCATION
. O
injections B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
either O
vehicle B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
or O
1 B_NUMBER[MEASURE]/B_PRODUCT[OBJECT]
, O
10 B_MEASURE
and O
50 B_MEASURE/B_PERSON
ng I_MEASURE/I_PERSON
of O
AVP B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
25 B_MEASURE
, O
125 B_MEASURE
and O
500 B_MEASURE/B_PERSON
ng I_MEASURE/I_PERSON
of O
ANP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O

sensitivity O
of O
cardiac O
component O
of O
baroreflex O
( O
CCB O
) O
, O
expressed O
as O
a O
slope O
of O
the O
regression O
line O
was O
determined O
from O
relationships O
between O
systolic O
arterial O
pressure O
( O
SAP O
) O
and O
HR O
period O
( O
HRp O
) O
during O
phenylephrine O
( O
Phe O
) O
- O
induced O
hypertension B_DISEASE
and O
sodium O
nitroprusside O
( O
SN O
) O
- O
induced O
hypotension B_DISEASE
. O

CCB B_DISEASE/B_GENE
was O
measured O
before O
and O
after O
administration B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
either O
vehicle B_PRODUCT[OBJECT]/B_LOCATION
, O
AVP B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
ANP B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
or O
both O
peptides O
together O
. O

Increases B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
MAP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
occurred O
after O
LV B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
administration I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
1 B_NUMBER[MEASURE]
, O
10 B_MEASURE
and O
50 B_MEASURE/B_PERSON
ng I_MEASURE/I_PERSON
of O
AVP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O
WKY B_LOCATION
and O
of O
10 B_MEASURE
and O
50 B_MEASURE/B_PERSON
ng I_MEASURE/I_PERSON
in O
SHR B_LOCATION/B_ORGANIZATION
. O

ANP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
did O
not O
cause O
significant B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
changes I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
MAP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O
both O
strains B_BIO
as O
compared O
to O
vehicle B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
, O
but O
it O
abolished O
AVP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
induced O
MAP B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
increase I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
WKY B_LOCATION/B_ORGANIZATION
and O
SHR B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

CCB O
was O
reduced O
in O
WKY O
and O
SHR O
after O
LV O
administration O
of O
AVP O
during O
SN O
- O
induced O
hypotension B_DISEASE
. O

In O
SHR B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
but O
not O
in O
WKY B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
administration I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
ANP B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
AVP B_LOCATION/B_GENE
and O
ANP B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
+ O
AVP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
decreased O
CCB B_DISEASE/B_PROTEIN[GENE]
during O
Phe B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
- O
induced O
MAP B_DISEASE
elevation I_DISEASE
. O

The O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
indicate O
that O
centrally O
applied O
AVP B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
ANP B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
exert O
differential B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
blood B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
pressure I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
baroreflex B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
control B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
heart B_DISEASE
rate I_DISEASE
in O
WKY B_PROTEIN[GENE]
and O
SHR B_LOCATION/B_ORGANIZATION
and O
suggest O
interaction B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O
these O
two B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
peptides I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
blood B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
pressure B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
regulation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
at O
the O
level B_MEASURE/B_LOCATION
of O
central B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
nervous B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
system B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
. O

Cutaneous O
exposure O
to O
warfarin O
- O
like O
anticoagulant O
causing O
an O
intracerebral B_DISEASE
hemorrhage I_DISEASE
: O
a O
case O
report O
. O

A O
case O
of O
intercerebral O
hematoma B_DISEASE
due O
to O
warfarin O
- O
induced O
coagulopathy B_DISEASE
is O
presented O
. O

The O
39 B_NUMBER[MEASURE]
- O
year B_TIME[MEASURE]
- O
old B_PERSON
woman I_PERSON
had O
spread O
a O
warfarin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPECIES[BIO]
- O
type B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
rat I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
poison I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
around O
her O
house B_BODY_PART_OR_ORGAN_COMPONENT
weekly I_BODY_PART_OR_ORGAN_COMPONENT
using O
her O
bare B_PRODUCT[OBJECT]/B_PERSON
hands I_PRODUCT[OBJECT]/I_PERSON
, O
with O
no O
washing B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
post B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
application B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O

Percutaneous O
absorption O
of O
warfarin O
causing O
coagulopathy B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
reported O
three O
times O
in O
the O
past O
, O
is O
a O
significant O
risk O
if O
protective O
measures O
, O
such O
as O
gloves O
, O
are O
not O
used O
. O

An O
adverse O
drug O
interaction O
with O
piroxicam O
, O
which O
she O
took O
occasionally O
, O
may O
have O
exacerbated O
the O
coagulopathy B_DISEASE
. O

Pediatric B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
heart I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_PERSON
transplantation I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_PERSON
without O
chronic B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
maintenance B_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
steroids B_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

From O
1986 B_TIME[MEASURE]
to O
February B_TIME[MEASURE]
1993 I_TIME[MEASURE]
, O
40 B_PERSON/B_ENT
children I_PERSON/I_ENT
aged O
2 B_TIME[MEASURE]
months I_TIME[MEASURE]
to O
18 B_TIME[MEASURE]
years I_TIME[MEASURE]
( O
average B_MEASURE
age I_MEASURE
10 I_MEASURE
. O
4 B_MEASURE
+ I_MEASURE
/ O
- O
5 B_MEASURE
. O
8 B_TIME[MEASURE]
years I_TIME[MEASURE]
) O
underwent O
heart B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
transplantation I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
. O

Indications O
for O
transplantation O
were O
idiopathic B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
cardiomyopathy I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O
52 O
% O
) O
, O
congenital B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
heart I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
disease I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O
35 O
% O
) O
with O
and O
without O
prior O
repair O
( O
71 O
% O
and O
29 O
% O
, O
respectively O
) O
, O
hypertrophic B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
cardiomyopathy I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O
5 O
% O
) O
, O
valvular B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
heart I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
disease I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O
3 O
% O
) O
, O
and O
doxorubicin O
cardiomyopathy B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O
5 O
% O
) O
. O

patients B_PERSON/B_ORGANIZATION
were O
managed O
with O
cyclosporine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
azathioprine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

No O
prophylaxis B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
antilymphocyte B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
globulin I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
used O
. O

steroids B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
were O
given O
to O
39 B_PERSON/B_MEASURE
% B_PERSON/I_MEASURE
of O
patients B_PERSON
for O
refractory B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
rejection B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
but O
weaning B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
was O
always O
attempted O
and O
generally O
successful B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
64 B_TIME[MEASURE]/B_PERSON
% I_TIME[MEASURE]/I_PERSON
) O
. O

Five B_TIME[MEASURE]
patients I_TIME[MEASURE]
( O
14 B_NUMBER[MEASURE]/B_PERSON
% I_NUMBER[MEASURE]/I_PERSON
) O
received O
maintenance B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
steroids I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Four B_NUMBER[MEASURE]
patients I_NUMBER[MEASURE]
died O
in O
the O
perioperative B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
period I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
and O
one B_NUMBER[MEASURE]/B_PERSON
died O
4 B_TIME[MEASURE]/B_LOCATION
months I_TIME[MEASURE]/I_LOCATION
later O
. O

There O
have O
been O
no O
deaths O
related O
to O
rejection O
or O
infection B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Average B_TIME[MEASURE]/B_PERSON
follow I_TIME[MEASURE]/I_PERSON
- O
up B_LOCATION/B_MEASURE
was O
36 B_MEASURE
+ I_MEASURE
/ O
- O
19 B_TIME[MEASURE]/B_PERSON
months I_TIME[MEASURE]/I_PERSON
( O
range B_MEASURE
1 I_MEASURE
to O
65 B_TIME[MEASURE]
months I_TIME[MEASURE]
) O
. O

cumulative B_PERSON/B_LOCATION
survival I_PERSON/I_LOCATION
is O
88 B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
% B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O
5 B_TIME[MEASURE]/B_LOCATION
years I_TIME[MEASURE]/I_LOCATION
. O

In O
patients B_PERSON
less I_PERSON
than O
7 B_TIME[MEASURE]/B_ENT
years I_TIME[MEASURE]/I_ENT
of O
age B_TIME[MEASURE]/B_PERSON
, O
rejection B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O
monitored O
noninvasively O
. O

In O
the O
first B_TIME[MEASURE]/B_LOCATION
postoperative B_TIME[MEASURE]/I_LOCATION
month B_TIME[MEASURE]/I_LOCATION
, O
89 B_NUMBER[MEASURE]/B_PERSON
% I_NUMBER[MEASURE]/I_PERSON
of O
patients B_PERSON
were O
treated O
for O
rejection B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Freedom O
from O
serious O
infections B_DISEASE
was O
83 O
% O
at O
1 O
month O
and O
65 O
% O
at O
1 O
year O
. O

Cytomegalovirus B_PERSON
infections I_PERSON
were O
treated O
successfully O
with O
ganciclovir O
in O
11 O
patients O
. O

No O
impairment B_DISEASE_ADJECTIVE[DISEASE]
of O
growth B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
observed O
in O
children B_PERSON/B_BIO
who O
underwent O
transplantation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
compared O
with O
a O
control B_PERSON/B_BIO
population I_PERSON/I_BIO
. O

Twenty O
- O
one O
patients O
( O
60 O
% O
) O
have O
undergone O
annual O
catheterizations O
and O
no O
sign O
of O
graft O
atherosclerosis B_DISEASE
has O
been O
observed O
. O

Seizures B_DISEASE
occurred O
in O
five O
patients O
( O
14 O
% O
) O
and O
hypertension B_DISEASE
was O
treated O
in O
10 O
patients O
( O
28 O
% O
) O
. O

No O
patient O
was O
disabled O
and O
no O
lymphoproliferative B_DISEASE_ADJECTIVE[DISEASE]
disorder I_DISEASE_ADJECTIVE[DISEASE]
was O
observed O
. O
( O
abstract O
TRUNCATED O
AT O
250 O
Words O
) O
. O

Delirium B_DISEASE
during O
fluoxetine O
treatment O
. O

A O
case B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
report I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

The O
correlation B_MEASURE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O
high B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
serum I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
tricyclic I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
antidepressant I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
concentrations I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
and O
central B_DISEASE
nervous I_DISEASE
system I_DISEASE
side I_DISEASE
effects I_DISEASE
has O
been O
well O
established O
. O

Only O
a O
few B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
reports I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
exist O
, O
however O
, O
on O
the O
relationship B_PERSON/B_MEASURE
between O
the O
serum B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
concentrations I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
selective B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
serotonin I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
reuptake I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
inhibitors I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
SSRIs B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
) O
and O
their O
toxic B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
effects I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
. O

In O
some O
cases O
, O
a O
high O
serum O
concentration O
of O
citalopram O
( O
> O
600 O
nmol O
/ O
L O
) O
in O
elderly O
patients O
has O
been O
associated O
with O
increased O
somnolence B_DISEASE
and O
movement B_DISEASE
difficulties I_DISEASE
. O

widespread O
cognitive B_DISEASE_ADJECTIVE[DISEASE]
disorders I_DISEASE_ADJECTIVE[DISEASE]
, O
such O
as O
delirium B_DISEASE/B_LOCATION
, O
have O
not O
been O
previously O
linked O
with O
high O
blood O
levels O
of O
SSRIs O
. O

In O
this O
report O
, O
we O
describe O
a O
patient O
with O
acute O
hyperkinetic B_DISEASE
delirium I_DISEASE
connected O
with O
a O
high O
serum O
total O
fluoxetine O
( O
fluoxetine O
plus O
desmethylfluoxetine O
) O
concentration O
. O

Pulmonary B_DISEASE
edema I_DISEASE
and O
shock B_DISEASE
after O
high O
- O
dose O
aracytine O
- O
C O
for O
lymphoma B_DISEASE
; O
possible O
role O
of O
TNF O
- O
alpha O
and O
PAF O
. O

Four O
out O
of O
23 O
consecutive O
patients O
treated O
with O
high O
- O
dose O
Ara O
- O
C O
for O
lymphomas B_DISEASE/B_GENE
in O
our O
institution O
developed O
a O
strikingly O
similar O
syndrome O
during O
the O
perfusion O
. O

It O
was O
characterized O
by O
the O
onset O
of O
fever B_DISEASE
, O
diarrhea B_DISEASE
, O
shock B_DISEASE
, O
pulmonary B_DISEASE
edema I_DISEASE
, O
acute B_DISEASE
renal I_DISEASE
failure I_DISEASE
, O
metabolic B_DISEASE
acidosis I_DISEASE
, O
weight B_DISEASE
gain I_DISEASE
and O
leukocytosis B_DISEASE
. O

thorough O
bacteriological O
screening O
failed O
to O
provide O
evidence O
of O
infection B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Sequential B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
biological I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
assays I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
IL B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
1 B_MEASURE
, O
IL B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
2 B_NUMBER[MEASURE]
, O
TNF B_LOCATION
and O
PAF B_GENE
were O
performed O
during O
Ara B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O
C B_MEASURE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
infusion I_MEASURE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O
ten B_NUMBER[MEASURE]/B_PERSON
patients I_NUMBER[MEASURE]/I_PERSON
, O
including O
the O
four B_NUMBER[MEASURE]/B_PERSON
who O
developed O
the O
syndrome B_DISEASE
. O

TNF B_LOCATION/B_ORGANIZATION
and O
PAF B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
activity I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O
found O
in O
the O
serum B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
respectively O
two B_NUMBER[MEASURE]
and O
four B_NUMBER[MEASURE]
of O
the O
cases B_PERSON/B_BIO
, O
but O
not O
in O
the O
six B_BODY_PART_OR_ORGAN_COMPONENT/B_PERSON
controls I_BODY_PART_OR_ORGAN_COMPONENT/I_PERSON
. O

As O
TNF O
and O
PAF O
are O
thought O
to O
be O
involved O
in O
the O
development O
of O
septic O
shock B_DISEASE
and O
adult B_DISEASE
respiratory I_DISEASE
distress I_DISEASE
syndrome I_DISEASE
, O
we O
hypothesize O
that O
high O
- O
dose O
Ara O
- O
C O
may O
be O
associated O
with O
cytokine O
release O
. O

protective O
effect O
of O
clentiazem O
against O
epinephrine O
- O
induced O
cardiac B_DISEASE
injury I_DISEASE
in O
rats O
. O

We O
investigated O
the O
effects O
of O
clentiazem O
, O
a O
1 O
, O
5 O
- O
benzothiazepine O
calcium O
antagonist O
, O
on O
epinephrine O
- O
induced O
cardiomyopathy B_DISEASE
in O
rats O
. O

With O
2 O
- O
week O
chronic O
epinephrine O
infusion O
, O
16 O
of O
30 O
rats O
died O
within O
4 O
days O
, O
and O
severe O
ischemic B_DISEASE
lesions I_DISEASE
and O
fibrosis B_DISEASE
of O
the O
left O
ventricles O
were O
observed O
. O

In O
epinephrine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
treated O
rats B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
left O
atrial B_BODY_PART_OR_ORGAN_COMPONENT
and O
left O
ventricular B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
papillary B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
muscle B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
contractile B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
responses B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
to O
isoproterenol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
reduced O
, O
but O
responses B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O
calcium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
normal B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O
enhanced B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
compared O
to O
controls B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
. O

Left O
ventricular B_BODY_PART_OR_ORGAN_COMPONENT
alpha I_BODY_PART_OR_ORGAN_COMPONENT
and O
beta B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
adrenoceptor I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
densities I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
were O
also O
reduced O
compared O
to O
controls B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
. O

Treatment O
with O
clentiazem O
prevented O
epinephrine O
- O
induced O
death O
( O
P O
< O
. O
05 O
) O
, O
and O
attenuated O
the O
ventricular O
ischemic B_DISEASE
lesions I_DISEASE
and O
fibrosis B_DISEASE
, O
in O
a O
dose O
- O
dependent O
manner O
. O

Left O
atrial B_BODY_PART_OR_ORGAN_COMPONENT
and O
left O
ventricular B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
papillary B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
muscle B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
contractile B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
responses B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
isoproterenol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
reduced O
compared O
to O
controls B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
in O
groups B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPECIES[BIO]
treated O
with O
clentiazem B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alone O
, O
but O
combined O
with O
epinephrine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
clentiazem B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
restored O
left B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
atrial I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
responses I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
and O
enhanced O
left B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
ventricular I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
papillary I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
responses I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O
isoproterenol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

On O
the O
other B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hand I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
clentiazem I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
did O
not O
prevent O
epinephrine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
down B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
regulation B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE_EXPRESSION_ADJECTIVE[GENE]
of O
alpha B_PROTEIN[GENE]
and O
beta B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
adrenoceptors I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Interestingly O
, O
clentiazem B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
infused O
alone O
, O
resulted O
in O
decreased O
adrenergic B_DISEASE/B_MEASURE
receptor I_DISEASE/I_MEASURE
densities I_DISEASE/I_MEASURE
in O
the O
left B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
ventricle I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O

Clentiazem B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
also O
did O
not O
prevent O
the O
enhanced O
responses B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
to O
calcium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
seen O
in O
the O
epinephrine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
treated O
animals B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
although O
the O
high B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
dose I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
of O
clentiazem B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
partially O
attenuated O
the O
maximal B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
response B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
calcium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
compared O
to O
epinephrine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
treated O
animals B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

In O
conclusion O
, O
clentiazem O
attenuated O
epinephrine O
- O
induced O
cardiac B_DISEASE
injury I_DISEASE
, O
possibly O
through O
its O
effect O
on O
the O
adrenergic O
pathway O
. O

Kaliuretic O
effect O
of O
L O
- O
dopa O
treatment O
in O
parkinsonian B_DISEASE/B_PERSON
patients O
. O

Hypokalemia B_DISEASE
, O
sometimes O
severe O
, O
was O
observed O
in O
some O
L O
- O
dopa O
- O
treated O
parkinsonian B_DISEASE
patients O
. O

The O
influence O
of O
L O
- O
dopa O
on O
the O
renal O
excretion O
of O
potassium O
was O
studied O
in O
3 O
patients O
with O
hypokalemia B_DISEASE/B_GENE
and O
in O
5 O
normokalemic O
patients O
by O
determination O
of O
renal O
plasma O
flow O
, O
glomerular O
filtration O
rate O
, O
plasma O
concentration O
of O
potassium O
and O
sodium O
as O
well O
as O
urinary O
excretion O
of O
potassium O
, O
sodium O
and O
aldosterone O
. O

L B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
DOPA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
intake I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
was O
found O
to O
cause O
an O
increased O
excretion B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
of O
potassium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
sometimes O
also O
of O
sodium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
in O
the O
hypokalemic B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
but O
not O
in O
the O
normokalemic B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
patients I_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
. O

This O
effect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
on O
the O
renal B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
function I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
could O
be O
prohibited O
by O
the O
administration B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
a O
peripheral B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
DOPA I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
decarbodylase I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
inhibitor I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

It O
is O
not O
known O
why O
this O
effect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
occurred O
in O
some O
individuals B_PERSON/B_BIO
but O
not O
in O
others B_PERSON/B_BIO
, O
but O
our O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
indicate O
a O
correlation B_MEASURE/B_LOCATION
between O
aldosterone B_DISEASE
production I_DISEASE
and O
this O
renal B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
effect I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
L B_PROTEIN[GENE]/B_MEASURE
- O
DOPA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O

cocaine O
induced O
myocardial B_DISEASE_ADJECTIVE[DISEASE]
ischemia I_DISEASE_ADJECTIVE[DISEASE]
. O

We O
report O
a O
case O
of O
myocardial B_DISEASE
ischemia I_DISEASE
induced O
by O
cocaine O
. O

The O
ischemia B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
probably O
induced O
by O
coronary B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
artery B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
spasm B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
reversed O
by O
nitroglycerin O
and O
calcium O
blocking O
agents O
. O

Doxorubicin O
- O
induced O
cardiotoxicity B_DISEASE
monitored O
by O
ECG O
in O
freely O
moving O
mice O
. O

A O
new B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
model I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
test O
potential B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
protectors I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

In O
laboratory O
animals O
, O
histology O
is O
most O
commonly O
used O
to O
study O
doxorubicin O
- O
induced O
cardiotoxicity B_DISEASE
. O

However O
, O
for O
monitoring O
during O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
, O
large B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
numbers I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
animals B_BIO/B_PERSON
are O
needed O
. O

Recently O
we O
developed O
a O
new B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
method I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
to O
measure O
ECG B_DISEASE
values I_DISEASE
in O
freely O
moving O
mice B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O
telemetry B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

With O
this O
model B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
we O
investigated O
the O
effect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
chronic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
doxorubicin I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
administration I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
on O
the O
ECG B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O
freely O
moving O
BALB B_SPECIES[BIO]/B_PROTEIN[GENE]
/ O
c B_MEASURE/B_PERSON
mice I_MEASURE/I_PERSON
and O
the O
efficacy B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
ICRF B_LOCATION
- O
187 B_MEASURE
as O
a O
protective B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
agent I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
ST B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
interval B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
significantly O
widened O
from O
15 B_MEASURE
. O
0 B_MEASURE
+ I_MEASURE
/ O
- O
1 B_MEASURE
. O
5 B_MEASURE
to O
56 B_MEASURE
. O
8 B_MEASURE
+ I_MEASURE
/ O
- O
11 B_MEASURE
. O
8 B_MEASURE
MS I_MEASURE
in O
week B_TIME[MEASURE]
10 I_TIME[MEASURE]
( O
7 B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
weekly I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
doses I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
of O
4 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
mg I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
/ O
kg B_TIME[MEASURE]
doxorubicin I_TIME[MEASURE]
given O
i O
. O
v B_PROTEIN[GENE]/B_LOCATION
. O
plus O
3 B_TIME[MEASURE]/B_ENT
weeks I_TIME[MEASURE]/I_ENT
of O
observation B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
. O

The O
ECG B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
the O
control B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
animals I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
did O
not O
change O
during O
the O
entire B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

After O
sacrifice O
the O
hearts O
of O
doxorubicin O
- O
treated O
animals O
were O
enlarged O
and O
the O
atria O
were O
hypertrophic B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
. O

As O
this O
schedule O
exerted O
more O
toxicity B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
than O
needed O
to O
investigate O
protective O
agents O
, O
the O
protection O
of O
ICRF O
- O
187 O
was O
determined O
using O
a O
dose O
schedule O
with O
lower O
general O
toxicity B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
( O
6 O
weekly O
doses O
of O
4 O
mg O
/ O
kg O
doxorubicin O
given O
i O
. O
v O
. O
plus O
2 O
weeks O
of O
observation O
) O
. O

On O
this O
schedule B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O
the O
animals B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
' I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
hearts I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
appeared O
normal B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
after O
sacrifice B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
and O
ICRF B_MEASURE/B_PROTEIN[GENE]
- O
187 B_NUMBER[MEASURE]
( O
50 B_MEASURE
mg I_MEASURE
/ O
kg B_MEASURE
given O
i O
. O
p B_MEASURE/B_LOCATION
. O
1 B_MEASURE
h O
before O
doxorubicin B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
) O
provided O
almost O
full B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
protection B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
. O

These O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
were O
confirmed O
by O
histology B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O

The O
results O
indicate O
that O
this O
new O
model O
is O
very O
sensitive O
and O
enables O
monitoring O
of O
the O
development O
of O
cardiotoxicity B_DISEASE
with O
time O
. O

These O
findings O
result O
in O
a O
model O
that O
allows O
the O
testing O
of O
protectors O
against O
doxorubicin O
- O
induced O
cardiotoxicity B_DISEASE
as O
demonstrated O
by O
the O
protection O
provided O
by O
ICRF O
- O
187 O
. O

epinephrine B_DISEASE
dysrhythmogenicity I_DISEASE
is O
not O
enhanced O
by O
subtoxic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
bupivacaine I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
dogs B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Since O
bupivacaine O
and O
epinephrine O
may O
both O
precipitate O
dysrhythmias B_DISEASE
, O
circulating O
bupivacaine O
during O
regional O
anesthesia O
could O
potentiate O
dysrhythmogenic O
effects O
of O
epinephrine O
. O

We O
therefore O
examined O
whether O
bupivacaine O
alters O
the O
dysrhythmogenicity O
of O
subsequent O
administration O
of O
epinephrine O
in O
conscious O
, O
healthy O
dogs O
and O
in O
anesthetized O
dogs O
with O
myocardial B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
infarction B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Forty B_NUMBER[MEASURE]/B_LOCATION
- O
one B_NUMBER[MEASURE]/B_PERSON
conscious I_NUMBER[MEASURE]/I_PERSON
dogs I_NUMBER[MEASURE]/I_PERSON
received O
10 B_MEASURE
micrograms I_MEASURE
. O
kg B_MEASURE
- O
1 B_MEASURE
. O
min B_MEASURE/B_PERSON
- O
1 B_MEASURE/B_LOCATION
epinephrine I_MEASURE/I_LOCATION
. O

seventeen O
animals O
responded O
with O
ventricular B_DISEASE
tachycardia I_DISEASE
( O
VT B_PROTEIN[GENE]/B_DISEASE
) O
within O
3 O
min O
. O

After O
3 B_MEASURE
h O
, O
these O
responders B_PERSON/B_SPECIES[BIO]
randomly O
received O
1 B_MEASURE/B_LOCATION
or O
2 B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mg I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
kg B_MEASURE
bupivacaine I_MEASURE
or O
saline O
over O
5 B_TIME[MEASURE]/B_BODY_PART_OR_ORGAN_COMPONENT
min I_TIME[MEASURE]/I_BODY_PART_OR_ORGAN_COMPONENT
, O
followed O
by O
10 B_MEASURE
micrograms I_MEASURE
. O
kg B_MEASURE/B_PERSON
- O
1 B_MEASURE
. O
min B_MEASURE/B_PERSON
- O
1 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
epinephrine I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

In O
the O
bupivacaine B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
groups I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
, O
epinephrine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
caused O
fewer B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
prodysrhythmic I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
than O
without O
bupivacaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

VT B_DISEASE/B_PERSON
appeared O
in O
fewer O
dogs O
and O
at O
a O
later O
time O
, O
and O
there O
were O
more O
sinoatrial O
beats O
and O
less O
ectopies O
. O

epinephrine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
shortened O
QT B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
less B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
after O
bupivacaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
than O
in O
control B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
animals I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

One O
day O
after O
experimental O
myocardial B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
infarction B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
six O
additional O
halothane O
- O
anesthetized O
dogs O
received O
4 O
micrograms O
. O
kg O
- O
1 O
. O
min O
- O
1 O
epinephrine O
until O
VT B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
appeared O
. O

After O
45 B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
min I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
1 B_MEASURE
mg I_MEASURE
/ O
kg B_MEASURE
bupivacaine I_MEASURE
was O
injected O
over O
5 B_TIME[MEASURE]/B_LOCATION
min B_TIME[MEASURE]/I_LOCATION
, O
again O
followed O
by O
4 B_MEASURE
micrograms I_MEASURE
. O
kg B_MEASURE/B_LOCATION
- O
1 B_MEASURE
. O
min B_MEASURE/B_PERSON
- O
1 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
epinephrine I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

In O
these O
dogs B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
the O
prodysrhythmic B_DISEASE_ADJECTIVE[DISEASE]
response I_DISEASE_ADJECTIVE[DISEASE]
to O
epinephrine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
also O
mitigated O
by O
preceding O
bupivacaine B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O

Bupivacaine O
antagonizes O
epinephrine O
dysrhythmogenicity O
in O
conscious O
dogs O
susceptible O
to O
VT B_DISEASE
and O
in O
anesthetized O
dogs O
with O
spontaneous O
postinfarct O
dysrhythmias B_DISEASE
. O

There O
is O
no O
evidence B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
that O
systemic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
subtoxic I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
bupivacaine I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
administration I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
enhances O
the O
dysrhythmogenicity B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
subsequent B_DISEASE/B_PROTEIN[GENE]
epinephrine B_DISEASE/I_PROTEIN[GENE]
. O

Milk B_DISEASE
- I_DISEASE
alkali I_DISEASE
syndrome I_DISEASE
induced O
by O
1 O
, O
25 O
( O
OH O
) O
2D O
in O
a O
patient O
with O
hypoparathyroidism B_DISEASE/B_LOCATION
. O

Milk B_DISEASE
- I_DISEASE
alkali I_DISEASE
syndrome I_DISEASE
was O
first O
described O
70 O
years O
ago O
in O
the O
context O
of O
the O
treatment O
of O
peptic B_DISEASE/B_BIO
ulcer B_DISEASE/I_BIO
disease B_DISEASE/I_BIO
with O
large O
amounts O
of O
calcium O
and O
alkali O
. O

Although O
with O
current O
ulcer B_DISEASE/B_PERSON
therapy O
( O
H O
- O
2 O
blockers O
, O
omeprazole O
, O
and O
sucralfate O
) O
, O
the O
frequency O
of O
milk B_DISEASE
- I_DISEASE
alkali I_DISEASE
syndrome I_DISEASE
has O
decreased O
significantly O
, O
the O
classic O
triad O
of O
hypercalcemia B_DISEASE
, O
alkalosis B_DISEASE/B_BACTERIUM[BIO]
, O
and O
renal B_DISEASE
impairment I_DISEASE
remains O
the O
hallmark O
of O
the O
syndrome O
. O

Milk B_DISEASE/B_PERSON
- I_DISEASE/I_PERSON
alkali I_DISEASE/I_PERSON
syndrome I_DISEASE/I_PERSON
can O
present O
serious O
and O
occasionally O
life O
- O
threatening O
illness O
unless O
diagnosed O
and O
treated O
appropriately O
. O

This O
article O
presents O
a O
patient O
with O
hypoparathyroidism B_DISEASE/B_GENE
who O
was O
treated O
with O
calcium O
carbonate O
and O
calcitriol O
resulting O
in O
two O
admissions O
to O
the O
hospital O
for O
milk B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
- I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
alkali I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
syndrome I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

The O
patient B_PERSON/B_DISEASE
was O
successfully O
treated O
with O
intravenous B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pamidronate I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
his O
first B_SEQUENCE[MEASURE]/B_PERSON
admission I_SEQUENCE[MEASURE]/I_PERSON
and O
with O
hydrocortisone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
the O
second B_SEQUENCE[MEASURE]/B_LOCATION
. O

This O
illustrates O
intravenous O
pamidronate O
as O
a O
valuable O
therapeutic O
tool O
when O
milk B_DISEASE/B_PERSON
- I_DISEASE/I_PERSON
alkali I_DISEASE/I_PERSON
syndrome I_DISEASE/I_PERSON
presents O
as O
hypercalcemic B_DISEASE/B_LOCATION
emergency I_DISEASE/I_LOCATION
. O

Famotidine O
- O
associated O
delirium B_DISEASE
. O

A O
series B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
six B_ENT/B_PERSON
cases I_ENT/I_PERSON
. O

Famotidine O
is O
a O
histamine O
H2 O
- O
receptor O
antagonist O
used O
in O
inpatient O
settings O
for O
prevention O
of O
stress O
ulcers B_DISEASE
and O
is O
showing O
increasing O
popularity O
because O
of O
its O
low O
cost O
. O

Although O
all O
of O
the O
currently O
available O
H2 O
- O
receptor O
antagonists O
have O
shown O
the O
propensity O
to O
cause O
delirium B_DISEASE
, O
only O
two O
previously O
reported O
cases O
have O
been O
associated O
with O
famotidine O
. O

The O
authors O
report O
on O
six O
cases O
of O
famotidine O
- O
associated O
delirium B_DISEASE
in O
hospitalized O
patients O
who O
cleared O
completely O
upon O
removal O
of O
famotidine O
. O

The O
pharmacokinetics B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
famotidine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
reviewed O
, O
with O
no O
change B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
in O
its O
metabolism B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
in O
the O
elderly B_TIME[MEASURE]/B_PERSON
population I_TIME[MEASURE]/I_PERSON
seen O
. O

The O
implications B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
using O
famotidine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
in O
elderly B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
persons I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
discussed O
. O

Encephalopathy B_DISEASE
during O
amitriptyline O
therapy O
: O
are O
neuroleptic B_DISEASE
malignant I_DISEASE
syndrome I_DISEASE
and O
serotonin B_DISEASE
syndrome I_DISEASE
spectrum O
disorders O
. O

This O
report O
describes O
a O
case O
of O
encephalopathy B_DISEASE
developed O
in O
the O
course O
of O
amitriptyline O
therapy O
, O
during O
a O
remission O
of O
unipolar B_DISEASE
depression I_DISEASE
. O

This O
patient O
could O
have O
been O
diagnosed O
as O
having O
either O
neuroleptic B_DISEASE
malignant I_DISEASE
syndrome I_DISEASE
( O
NMS B_LOCATION
) O
or O
serotonin B_DISEASE
syndrome I_DISEASE
( O
SS B_LOCATION
) O
. O

The O
major B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
determinant I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
of O
the O
symptoms B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
may O
have O
been O
dopamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
serotonin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
imbalance I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
the O
central B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
nervous I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
system I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
NMS B_DISEASE/B_GENE
- O
like O
encephalopathy B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
develops O
in O
association O
with O
the O
use O
of O
antidepressants O
indicates O
that O
NMS B_LOCATION
and O
SS B_DISEASE
are O
spectrum O
disorders O
induced O
by O
drugs O
with O
both O
antidopaminergic O
and O
serotonergic O
effects O
. O

genetic O
separation O
of O
tumor B_DISEASE_ADJECTIVE[DISEASE]
growth O
and O
hemorrhagic B_DISEASE_ADJECTIVE[DISEASE]
phenotypes O
in O
an O
estrogen O
- O
induced O
tumor B_DISEASE
. O

chronic O
administration O
of O
estrogen O
to O
the O
Fischer O
344 O
( O
F344 O
) O
rat O
induces O
growth O
of O
large O
, O
hemorrhagic B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
pituitary B_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
tumors B_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
. O

Ten O
weeks O
of O
diethylstilbestrol O
( O
Des O
) O
treatment O
caused O
female O
F344 O
rat O
pituitaries O
to O
grow O
to O
an O
average O
of O
109 O
. O
2 O
+ O
/ O
- O
6 O
. O
3 O
mg O
( O
mean O
+ O
/ O
- O
SE O
) O
versus O
11 O
. O
3 O
+ O
/ O
- O
1 O
. O
4 O
mg O
for O
untreated O
rats O
, O
and O
to O
become O
highly O
hemorrhagic B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
. O

The O
same B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
DES I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treatment I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
produced O
no O
significant B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
growth B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
8 B_MEASURE
. O
9 B_MEASURE
+ I_MEASURE
/ O
- O
0 B_MEASURE
. O
5 B_MEASURE
mg I_MEASURE
for O
treated O
females B_PERSON/B_BIO
versus O
8 B_MEASURE
. O
7 B_MEASURE
+ I_MEASURE
/ O
- O
1 B_MEASURE
. O
1 B_MEASURE
for O
untreated B_PERSON/B_BIO
females I_PERSON/I_BIO
) O
or O
morphological B_DISEASE/B_ORGANISM_FUNCTION
changes I_DISEASE/I_ORGANISM_FUNCTION
in O
Brown B_PERSON/B_LOCATION
Norway I_PERSON/I_LOCATION
( O
BN B_MEASURE/B_DISEASE
) O
rat B_BIO/B_BODY_PART_OR_ORGAN_COMPONENT
pituitaries I_BIO/I_BODY_PART_OR_ORGAN_COMPONENT
. O

An O
F1 B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hybrid B_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
F344 B_LOCATION/B_PERSON
and O
BN B_MEASURE/B_DISEASE
exhibited O
significant B_DISEASE/B_MEASURE
pituitary I_DISEASE/I_MEASURE
growth I_DISEASE/I_MEASURE
after O
10 B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
weeks I_TIME[MEASURE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
DES B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
treatment I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANISM_FUNCTION
with O
an O
average B_MEASURE
mass I_MEASURE
of O
26 B_MEASURE
. O
3 B_MEASURE
+ I_MEASURE
/ O
- O
0 B_MEASURE
. O
7 B_MEASURE
mg I_MEASURE
compared O
with O
8 B_MEASURE
. O
6 B_MEASURE
+ I_MEASURE
/ O
- O
0 B_MEASURE
. O
9 B_MEASURE
mg I_MEASURE
for O
untreated B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
rats I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O

surprisingly O
, O
the O
F1 O
hybrid O
tumors B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
were O
not O
hemorrhagic B_DISEASE_ADJECTIVE[DISEASE]
and O
had O
hemoglobin O
content O
and O
outward O
appearance O
identical O
to O
that O
of O
BN O
. O

Expression B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
of O
both O
growth B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
and O
morphological B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
changes B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
is O
due O
to O
multiple B_DISEASE/B_GENE
genes I_DISEASE/I_GENE
. O

However O
, O
while O
Des O
- O
induced O
pituitary O
growth O
exhibited O
quantitative O
, O
additive O
inheritance O
, O
the O
hemorrhagic B_DISEASE
phenotype O
exhibited O
recessive O
, O
epistatic O
inheritance O
. O

Only O
5 O
of O
the O
160 O
F2 O
pituitaries O
exhibited O
the O
hemorrhagic B_DISEASE_ADJECTIVE[DISEASE]
phenotype O
; O
36 O
of O
the O
160 O
F2 O
pituitaries O
were O
in O
the O
F344 O
range O
of O
mass O
, O
but O
31 O
of O
these O
were O
not O
hemorrhagic B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
, O
indicating O
that O
the O
hemorrhagic B_DISEASE_ADJECTIVE[DISEASE]
phenotype O
is O
not O
merely O
a O
consequence O
of O
extensive O
growth O
. O

The O
hemorrhagic B_DISEASE/B_NUMBER[MEASURE]
F2 O
pituitaries O
were O
all O
among O
the O
most O
massive O
, O
indicating O
that O
some O
of O
the O
genes O
regulate O
both O
phenotypes O
. O

increased O
expression O
of O
neuronal O
nitric O
oxide O
synthase O
in O
bladder O
afferent O
pathways O
following O
chronic O
bladder B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
irritation I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Immunocytochemical O
techniques O
were O
used O
to O
examine O
alterations O
in O
the O
expression O
of O
neuronal O
nitric O
oxide O
synthase O
( O
NOS O
) O
in O
bladder O
pathways O
following O
acute O
and O
chronic O
irritation B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
the I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
urinary I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tract I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
rat O
. O

Chemical O
cystitis B_DISEASE
was O
induced O
by O
cyclophosphamide O
( O
CYP O
) O
which O
is O
metabolized O
to O
acrolein O
, O
an O
irritant O
eliminated O
in O
the O
urine O
. O

Injection B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
CYP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
( O
n B_MEASURE/B_PROTEIN[GENE]
= O
10 B_MEASURE
, O
75 B_MEASURE
mg I_MEASURE
/ O
kg B_TIME[MEASURE]
, O
i O
. O
p B_MEASURE/B_LOCATION
. O
) O
2 B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BODY_LOCATION_OR_REGION[BODY_PART_OR_ORGAN_COMPONENT]
hours B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_BODY_LOCATION_OR_REGION[BODY_PART_OR_ORGAN_COMPONENT]
prior B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_BODY_LOCATION_OR_REGION[BODY_PART_OR_ORGAN_COMPONENT]
to O
perfusion B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BODY_PART_OR_ORGAN_COMPONENT
( O
acute B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treatment I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
of O
the O
animals B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
increased O
Fos B_GENE
- O
immunoreactivity B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
IR B_PROTEIN[GENE]/B_LOCATION
) O
in O
neurons B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
in O
the O
dorsal B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
commissure I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
dorsal B_BODY_PART_OR_ORGAN_COMPONENT
horn I_BODY_PART_OR_ORGAN_COMPONENT
, O
and O
autonomic B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
regions I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
of O
spinal B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
segments B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
( O
L1 B_PROTEIN[GENE]
- O
L2 B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
L6 B_PROTEIN[GENE]
- O
S1 B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
which O
receive O
afferent B_BODY_PART_OR_ORGAN_COMPONENT
inputs I_BODY_PART_OR_ORGAN_COMPONENT
from O
the O
bladder B_BODY_PART_OR_ORGAN_COMPONENT
, O
urethra B_BODY_PART_OR_ORGAN_COMPONENT
, O
and O
ureter B_BODY_PART_OR_ORGAN_COMPONENT
. O

Fos B_GENE
- O
IR B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
spinal B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
cord B_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
was O
not O
changed O
in O
rats B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receiving O
chronic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
CYP I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treatment I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
n B_PROTEIN[GENE]/B_LOCATION
= O
15 B_MEASURE
, O
75 B_MEASURE
mg I_MEASURE
/ O
kg B_TIME[MEASURE]
, O
i O
. O
p B_MEASURE/B_LOCATION
. O
, O
every O
3rd B_TIME[MEASURE]/B_PERSON
day I_TIME[MEASURE]/I_PERSON
for O
2 B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
weeks I_TIME[MEASURE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
) O
. O

In O
control B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
animals I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
and O
in O
animals B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treated O
acutely O
with O
CYP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
, O
only O
small B_MEASURE/B_LOCATION
numbers I_MEASURE/I_LOCATION
of O
NOS B_GENE/B_DISEASE
- O
IR B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_PROTEIN[GENE]
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_PROTEIN[GENE]
( O
0 B_MEASURE/B_LOCATION
. O
5 B_MEASURE
- O
0 B_MEASURE
. O
7 B_MEASURE
cell I_MEASURE
profiles I_MEASURE
/ O
sections B_LOCATION/B_MEASURE
) O
were O
detected O
in O
the O
L6 B_PROTEIN[GENE]
- O
S1 B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
dorsal B_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
root B_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
ganglia B_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
( O
DRG B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
) O
. O

Chronic B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
CYP B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
administration B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
significantly O
( O
P B_MEASURE/B_LOCATION
< I_MEASURE/I_LOCATION
or O
= O
. O
002 B_MEASURE
) O
increased O
bladder B_MEASURE/B_DISEASE
weight B_MEASURE/I_DISEASE
by O
60 B_NUMBER[MEASURE]/B_LOCATION
% I_NUMBER[MEASURE]/I_LOCATION
and O
increased O
( O
7 B_NUMBER[MEASURE]
- O
to O
11 B_NUMBER[MEASURE]
- O
fold B_TIME[MEASURE]
) O
the O
numbers B_MEASURE
of O
NOS B_GENE/B_DISEASE
- O
immunoreactive B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
( O
IR B_PROTEIN[GENE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
afferent B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
neurons I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
in O
the O
L6 B_PROTEIN[GENE]
- O
S1 B_DISEASE/B_PROTEIN[GENE]
DRG B_DISEASE/I_PROTEIN[GENE]
. O

A O
small B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
increase I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
( O
1 B_MEASURE
. O
5 B_MEASURE
- O
fold B_MEASURE
) O
also O
occurred O
in O
the O
L1 B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
DRG I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
but O
no O
change B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
was O
detected O
in O
the O
L2 B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
L5 B_PROTEIN[GENE]/B_DISEASE
DRG I_PROTEIN[GENE]/I_DISEASE
. O

bladder B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
afferent I_BIO/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cells I_BIO/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
in O
the O
L6 B_PROTEIN[GENE]
- O
S1 B_DISEASE/B_LOCATION
DRG B_DISEASE/I_LOCATION
labeled O
by O
Fluorogold B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O
40 B_PROTEIN[GENE]
microliters I_PROTEIN[GENE]
) O
injected O
into O
the O
bladder B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
wall I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
did O
not O
exhibit O
NOS B_LOCATION
- O
IR B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
control B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
animals I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
; O
however O
, O
following O
chronic B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
CYP I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
administration I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
, O
a O
significant B_MEASURE/B_PERSON
percentage I_MEASURE/I_PERSON
of O
bladder B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_PERSON
afferent I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_PERSON
neurons I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_PERSON
were O
NOS B_GENE/B_DISEASE
- O
IR B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
L6 B_PROTEIN[GENE]/B_BODY_PART_OR_ORGAN_COMPONENT
( O
19 B_MEASURE
. O
8 B_MEASURE
+ I_MEASURE
/ O
- O
4 B_MEASURE
. O
6 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
and O
S1 B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
25 B_MEASURE
. O
3 B_MEASURE
+ I_MEASURE
/ O
- O
2 B_MEASURE
. O
9 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
. O

These O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
indicate O
that O
neuronal B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gene I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expression I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
visceral B_DISEASE/B_SPECIES[BIO]
sensory B_DISEASE/I_SPECIES[BIO]
pathways B_DISEASE/I_SPECIES[BIO]
can O
be O
upregulated O
by O
chemical B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
irritation B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
afferent B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
receptors I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
in O
the O
urinary B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
tract I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
and O
/ O
or O
that O
pathological B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
changes B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
in O
the O
urinary B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
tract I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
can O
initiate O
chemical B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
signals B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
alter O
the O
chemical B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
properties B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
visceral B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
afferent I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
neurons I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O

Effects O
of O
a O
new O
calcium O
antagonist O
, O
CD O
- O
832 O
, O
on O
isoproterenol O
- O
induced O
myocardial B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
ischemia I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
dogs O
with O
partial O
coronary B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
stenosis I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Effects O
of O
CD O
- O
832 O
on O
isoproterenol O
( O
ISO O
) O
- O
induced O
myocardial B_DISEASE
ischemia I_DISEASE
were O
studied O
in O
dogs O
with O
partial O
coronary B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
stenosis B_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
the O
left O
circumflex O
coronary O
artery O
and O
findings O
were O
compared O
with O
those O
for O
nifedipine O
or O
diltiazem O
. O

In O
the O
presence O
of O
coronary B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
artery B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stenosis B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
3 O
- O
min O
periods O
of O
intracoronary O
ISO O
infusion O
( O
10 O
ng O
/ O
kg O
/ O
min O
) O
increased O
heart O
rate O
and O
maximal O
rate O
of O
left O
ventricular O
pressure O
rise O
, O
which O
resulted O
in O
a O
decrease O
in O
percentage O
segmental O
shortening O
and O
ST O
- O
segment O
elevation O
of O
the O
epicardial O
electrocardiogram O
. O

After O
the O
control O
ISO O
infusion O
with O
stenosis B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
was O
performed O
, O
equihypotensive O
doses O
of O
CD O
- O
832 O
( O
3 O
and O
10 O
micrograms O
/ O
kg O
/ O
min O
, O
n O
= O
7 O
) O
, O
nifedipine O
( O
1 O
and O
3 O
micrograms O
/ O
kg O
/ O
min O
, O
n O
= O
9 O
) O
or O
diltiazem O
( O
10 O
and O
30 O
micrograms O
/ O
kg O
/ O
min O
, O
n O
= O
7 O
) O
were O
infused O
5 O
min O
before O
and O
during O
the O
second O
and O
third O
ISO O
infusion O
. O

Both O
CD B_LOCATION
- O
832 B_MEASURE
and O
diltiazem B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
but O
not O
nifedipine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
significantly O
reduced O
the O
increase B_DISEASE_ADJECTIVE[DISEASE]
in O
heart B_DISEASE/B_PROTEIN[GENE]
rate B_DISEASE/I_PROTEIN[GENE]
induced O
by O
ISO B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
infusion I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O

In O
contrast O
to O
nifedipine O
, O
CD O
- O
832 O
( O
10 O
micrograms O
/ O
kg O
/ O
min O
) O
prevented O
the O
decrease O
in O
percentage O
segmental O
shortening O
from O
32 O
+ O
/ O
- O
12 O
% O
to O
115 O
+ O
/ O
- O
26 O
% O
of O
the O
control O
value O
( O
P O
< O
. O
01 O
) O
and O
ST O
- O
segment O
elevation O
from O
5 O
. O
6 O
+ O
/ O
- O
1 O
. O
0 O
MV O
to O
1 O
. O
6 O
+ O
/ O
- O
1 O
. O
3 O
MV O
( O
P O
< O
. O
01 O
) O
at O
3 O
min O
after O
ISO O
infusion O
with O
stenosis B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O

Diltiazem O
( O
30 O
micrograms O
/ O
kg O
/ O
min O
) O
also O
prevented O
the O
decrease O
in O
percentage O
segmental O
shortening O
from O
34 O
+ O
/ O
- O
14 O
% O
to O
63 O
+ O
/ O
- O
18 O
% O
of O
the O
control O
value O
( O
P O
< O
. O
05 O
) O
and O
ST O
- O
segment O
elevation O
from O
4 O
. O
7 O
+ O
/ O
- O
0 O
. O
7 O
MV O
to O
2 O
. O
1 O
+ O
/ O
- O
0 O
. O
7 O
MV O
( O
P O
< O
. O
01 O
) O
at O
3 O
min O
after O
ISO O
infusion O
with O
stenosis B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O

These O
data O
show O
that O
CD O
- O
832 O
improves O
myocardial B_DISEASE_ADJECTIVE[DISEASE]
ischemia I_DISEASE_ADJECTIVE[DISEASE]
during O
ISO O
infusion O
with O
stenosis B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
suggest O
that O
the O
negative O
chronotropic O
property O
of O
CD O
- O
832 O
plays O
a O
major O
role O
in O
the O
beneficial O
effects O
of O
CD O
- O
832 O
. O

The O
effect O
of O
recombinant O
human O
insulin O
- O
like O
growth O
factor O
- O
I O
on O
chronic O
puromycin O
aminonucleoside O
nephropathy B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
rats O
. O

We O
recently O
demonstrated O
that O
recombinant O
hGH O
exacerbates O
renal O
functional O
and O
structural O
injury O
in O
chronic O
puromycin O
aminonucleoside O
( O
pan O
) O
nephropathy B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
an O
experimental O
model O
of O
glomerular B_DISEASE
disease I_DISEASE
. O

Therefore O
, O
we O
examined O
whether O
recombinant O
human O
( O
rh O
) O
IGF O
- O
I O
is O
a O
safer O
alternative O
for O
the O
treatment O
of O
growth B_DISEASE/B_GENE
failure I_DISEASE/I_GENE
in O
rats O
with O
chronic O
pan O
nephropathy B_DISEASE
. O

The O
glomerulopathy B_DISEASE
was O
induced O
by O
seven O
serial O
injections O
of O
pan O
over O
12 O
wk O
. O

Experimental B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
animals I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
( O
n B_MEASURE/B_LOCATION
= O
6 B_MEASURE
) O
received O
rhIGF B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- O
I B_OTHER/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
400 B_MEASURE/B_LOCATION
micrograms I_MEASURE/I_LOCATION
/ O
d B_OTHER/B_TIME[MEASURE]
, O
whereas O
control B_PERSON/B_BIO
rats I_PERSON/I_BIO
( O
n B_LOCATION
= O
6 B_MEASURE
) O
received O
the O
vehicle B_PRODUCT[OBJECT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

rhIGF O
- O
I O
improved O
weight O
gain O
by O
14 O
% O
( O
p O
< O
0 O
. O
05 O
) O
, O
without O
altering O
hematocrit O
or O
blood O
pressure O
in O
rats O
with O
renal B_DISEASE/B_GENE
disease I_DISEASE/I_GENE
. O

Urinary O
protein O
excretion O
was O
unaltered O
by O
rhIGF O
- O
I O
treatment O
in O
rats O
with O
chronic O
pan O
nephropathy B_DISEASE
. O

After O
12 O
wk O
, O
the O
inulin O
clearance O
was O
higher O
in O
rhIGF O
- O
I O
- O
treated O
rats O
, O
0 O
. O
48 O
+ O
/ O
- O
0 O
. O
08 O
versus O
0 O
. O
24 O
+ O
/ O
- O
0 O
. O
06 O
mL O
/ O
min O
/ O
100 O
g O
of O
body O
weight O
in O
untreated O
pan O
nephropathy B_DISEASE/B_LOCATION
animals O
, O
p O
< O
0 O
. O
05 O
. O

The O
improvement O
in O
GFR O
was O
not O
associated O
with O
enhanced O
glomerular B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
hypertrophy I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
or O
increased O
segmental O
glomerulosclerosis B_DISEASE/B_MEASURE
, O
tubulointerstitial B_DISEASE
injury I_DISEASE
, O
or O
renal O
cortical O
malondialdehyde O
content O
. O

In O
rats O
with O
pan O
nephropathy B_DISEASE
, O
administration O
of O
rhIGF O
- O
I O
increased O
IGF O
- O
I O
and O
GH O
receptor O
gene O
expression O
, O
without O
altering O
the O
steady O
state O
level O
of O
IGF O
- O
I O
receptor O
mRNA O
. O

In O
normal O
rats O
with O
intact O
kidneys O
, O
rhIGF O
- O
I O
administration O
( O
n O
= O
4 O
) O
did O
not O
alter O
weight O
gain O
, O
blood O
pressure O
, O
proteinuria B_DISEASE/B_GENE
, O
GFR O
, O
glomerular O
planar O
area O
, O
renal O
cortical O
malondialdehyde O
content O
, O
or O
glomerular O
or O
tubulointerstitial B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
damage B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
, O
compared O
with O
untreated O
animals O
( O
n O
= O
4 O
) O
. O

rhIGF B_GENE/B_MEASURE
- O
I O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
reduced O
the O
steady B_GENE/B_LOCATION
state I_GENE/I_LOCATION
renal I_GENE/I_LOCATION
IGF I_GENE/I_LOCATION
- O
I O
mRNA B_MEASURE/B_LOCATION
level B_MEASURE/I_LOCATION
but O
did O
not O
modify O
gene B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
expression B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
of O
the O
IGF B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
I O
or O
GH B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
receptors I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

We O
conclude O
that O
: O
1 O
) O
administration O
of O
rhIGF O
- O
I O
improves O
growth O
and O
GFR O
in O
rats O
with O
chronic O
pan O
nephropathy B_DISEASE
and O
2 O
) O
unlike O
rhGH O
, O
long O
- O
term O
use O
of O
rhIGF O
- O
I O
does O
not O
worsen O
renal O
functional O
and O
structural O
injury O
in O
this O
disease O
model O
. O

Nefiracetam O
( O
DM O
- O
9384 O
) O
reverses O
apomorphine O
- O
induced O
amnesia B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
a O
passive O
avoidance O
response O
: O
delayed O
emergence O
of O
the O
memory O
retention O
effects O
. O

Nefiracetam O
is O
a O
novel O
pyrrolidone O
derivative O
which O
attenuates O
scopolamine O
- O
induced O
learning B_DISEASE
and I_DISEASE
post I_DISEASE
- I_DISEASE
training I_DISEASE
consolidation I_DISEASE
deficits I_DISEASE
. O

Given O
that O
apomorphine O
inhibits O
passive O
avoidance O
retention O
when O
given O
during O
training O
or O
in O
a O
defined O
10 O
- O
12h O
post O
- O
training O
period O
, O
we O
evaluated O
the O
ability O
of O
nefiracetam O
to O
attenuate O
amnesia B_DISEASE_ADJECTIVE[DISEASE]
induced O
by O
dopaminergic O
agonism O
. O

A O
step O
- O
down O
passive B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
avoidance I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
paradigm I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
employed O
and O
nefiracetam B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
3 B_MEASURE
mg I_MEASURE
/ O
kg B_MEASURE
) O
and O
apomorphine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
0 B_MEASURE
. O
5 B_MEASURE
mg I_MEASURE
/ O
kg B_MEASURE
) O
were O
given O
alone O
or O
in O
combination B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
during O
training B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
and O
at O
the O
10 B_MEASURE/B_LOCATION
- O
12h B_TIME[MEASURE]/B_LOCATION
post I_TIME[MEASURE]/I_LOCATION
- O
training B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
period I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
consolidation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O

Co B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
administration B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
nefiracetam B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
apomorphine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
during O
training B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_TIME[MEASURE]
or O
10h B_TIME[MEASURE]/B_LOCATION
thereafter O
produced O
no O
significant B_DISEASE_ADJECTIVE[DISEASE]
anti I_DISEASE_ADJECTIVE[DISEASE]
- O
amnesic B_DISEASE
effect I_DISEASE
. O

However O
, O
administration O
of O
nefiracetam O
during O
training O
completely O
reversed O
the O
amnesia B_DISEASE_ADJECTIVE[DISEASE]
induced O
by O
apomorphine O
at O
the O
10h O
post O
- O
training O
time O
and O
the O
converse O
was O
also O
true O
. O

These O
effects B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
not O
mediated O
by O
a O
dopaminergic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENZYME[GENE]
mechanism B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENZYME[GENE]
as O
nefiracetam B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
at O
millimolar B_MEASURE
concentrations I_MEASURE
, O
failed O
to O
displace O
either O
[ O
3H B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] O
SCH B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
23390 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
or O
[ B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
3H I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
] I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
spiperone I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
binding I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
from O
D1 B_PROTEIN[GENE]
or O
D2 B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
dopamine I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
receptor I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
subtypes I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
respectively O
. O

It O
is O
suggested O
that O
nefiracetam B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
augments O
molecular B_DISEASE/B_GENE
processes I_DISEASE/I_GENE
in O
the O
early B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stages B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
events B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
which O
ultimately O
lead O
to O
consolidation B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
memory B_DISEASE
. O

Phenytoin O
encephalopathy B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
as O
probable O
idiosyncratic O
reaction O
: O
case O
report O
. O

A O
case O
of O
phenytoin O
( O
DPH O
) O
encephalopathy B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O
increasing O
seizures B_DISEASE
and O
EEG O
and O
mental O
changes O
is O
described O
. O

Despite O
adequate B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
oral I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANISM_FUNCTION
dosage I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANISM_FUNCTION
of O
DPH B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
( O
5 B_MEASURE
mg I_MEASURE
/ O
kg B_MEASURE
/ O
daily O
) O
the O
plasma B_MEASURE/B_DISEASE
level I_MEASURE/I_DISEASE
was O
very O
low B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
( O
2 B_MEASURE
. O
8 B_MEASURE
microgramg I_MEASURE
/ O
ml B_MEASURE/B_PERSON
) O
. O

The O
encephalopathy B_DISEASE
was O
probably O
an O
idiosyncratic O
and O
not O
toxic O
or O
allergic O
reaction O
. O

In O
fact O
the O
concentration O
of O
free O
DPH O
was O
normal O
, O
the O
patient O
presented O
a O
retarded O
morbilliform O
rash B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
during O
DPH O
treatment O
, O
the O
protidogram O
was O
normal O
, O
and O
an O
intradermic O
DPH O
injection O
had O
no O
local O
effect O
. O

The O
authors O
conclude O
that O
in O
a O
patient O
starting O
DPH O
treatment O
an O
unexpected O
increase O
in O
seizures B_DISEASE
, O
with O
EEG O
and O
mental O
changes O
occurring O
simultaneously O
, O
should O
alert O
the O
physician O
to O
the O
possible O
need O
for O
eliminating O
DPH O
from O
the O
therapeutic O
regimen O
, O
even O
if O
plasma O
concentrations O
are O
low O
. O

Prevention O
and O
treatment O
of O
endometrial B_DISEASE
disease I_DISEASE
in O
climacteric O
women O
receiving O
oestrogen O
therapy O
. O

The O
treatment O
regimens O
are O
described O
in O
74 O
patients O
with O
endometrial B_DISEASE/B_LOCATION
disease I_DISEASE/I_LOCATION
among O
850 O
climacteric O
women O
receiving O
oestrogen O
therapy O
. O

Cystic O
hyperplasia B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
associated O
with O
unopposed O
oestrogen O
therapy O
without O
progestagen O
. O

Two O
courses O
of O
21 O
days O
of O
5 O
mg O
norethisterone O
daily O
caused O
reversion O
to O
normal O
in O
all O
57 O
cases O
of O
cystic O
hyperplasia B_DISEASE
and O
6 O
of O
the O
8 O
cases O
of O
atypical O
hyperplasia B_DISEASE
. O

4 O
cases O
of O
endometrial B_DISEASE/B_PERSON
carcinoma I_DISEASE/I_PERSON
referred O
from O
elsewhere O
demonstrated O
the O
problems O
of O
inappropriate O
and O
unsupervised O
unopposed O
oestrogen O
therapy O
and O
the O
difficulty O
in O
distinguishing O
severe O
hyperplasia B_DISEASE
from O
malignancy B_DISEASE
. O

Cyclical O
low O
- O
dose O
oestrogen O
therapy O
with O
7 O
- O
- O
13 O
days O
of O
progestagen O
does O
not O
seem O
to O
increase O
the O
risk O
of O
endometrial B_DISEASE
hyperplasia I_DISEASE
or O
carcinoma B_DISEASE/B_ORGANISM_FUNCTION
. O

Effects O
of O
exercise O
on O
the O
severity O
of O
isoproterenol O
- O
induced O
myocardial B_DISEASE
infarction I_DISEASE
. O

The O
effect O
of O
exercise O
on O
the O
severity O
of O
isoproterenol O
- O
induced O
myocardial B_DISEASE
infarction I_DISEASE
was O
studied O
in O
male O
rats O
. O

ninety B_NUMBER[MEASURE]
- O
three B_NUMBER[MEASURE]
rats I_NUMBER[MEASURE]
were O
randomly O
divided O
into O
three B_MEASURE/B_LOCATION
groups B_MEASURE/I_LOCATION
. O

The O
exercise B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O
isoproterenol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
( O
E B_OTHER/B_LOCATION
- O
1 B_NUMBER[MEASURE]/B_LOCATION
) O
and O
exercise B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
control I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
EC B_LOCATION
) O
groups B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
exercised O
daily O
for O
thirty B_TIME[MEASURE]
days I_TIME[MEASURE]
on O
a O
treadmill B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
at O
1 B_MEASURE
mph I_MEASURE
, O
2 B_TIME[MEASURE]/B_LOCATION
% I_TIME[MEASURE]/I_LOCATION
grade I_TIME[MEASURE]/I_LOCATION
while O
animals B_BIO/B_PERSON
of O
the O
sedentary B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
isoproterenol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
S B_OTHER/B_LOCATION
- O
I B_OTHER/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
group B_ORGANIZATION/B_LOCATION
remained O
sedentary B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
. O

Eight B_PERSON/B_ENT
animals I_PERSON/I_ENT
were O
assigned O
to O
the O
sedentary B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
control I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O
SC B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
group B_ORGANIZATION/B_LOCATION
which O
remained O
sedentary B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
throughout O
the O
experimental B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
period I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Forty B_NUMBER[MEASURE]
- O
eight B_NUMBER[MEASURE]/B_ENT
hours I_NUMBER[MEASURE]/I_ENT
after O
the O
final B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
exercise I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
period I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
, O
S B_OTHER/B_LOCATION
- O
I B_OTHER/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
E B_OTHER/B_LOCATION
- O
I O
animals B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
received O
a O
single B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
subcutaneous I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
injection I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
of O
isoproterenol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
250 B_MEASURE
mg I_MEASURE
/ O
kg B_MEASURE
body I_MEASURE
weight I_MEASURE
) O
. O

Animals B_BIO/B_PERSON
of O
the O
S B_OTHER/B_LOCATION
- O
I O
group B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
exhibited O
significantly O
( O
PP B_MEASURE/B_PERSON
less I_MEASURE/I_PERSON
than O
0 B_MEASURE/B_LOCATION
. O
05 B_MEASURE
) O
greater B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mortality I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O
the O
effects B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O
isoproterenol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
than O
animals B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
E B_OTHER/B_LOCATION
- O
I B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
group I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
. O

Serum B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
CPK B_MEASURE/B_DISEASE
activity I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
for O
E B_OTHER/B_PROTEIN[GENE]
- O
I O
animals B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
significantly O
( O
p B_MEASURE
less I_MEASURE
than O
0 B_MEASURE
. O
05 B_MEASURE
) O
greater B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
than O
for O
animals B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
S B_OTHER/B_LOCATION
- O
I O
and O
EC B_PROTEIN[GENE]/B_LOCATION
groups I_PROTEIN[GENE]/I_LOCATION
twenty I_PROTEIN[GENE]/I_LOCATION
hours I_PROTEIN[GENE]/I_LOCATION
following O
isoproterenol B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
injection I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
. O

No O
statistically O
significant B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
differences I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
were O
observed O
between O
the O
two B_NUMBER[MEASURE]/B_PERSON
isoproterenol I_NUMBER[MEASURE]/I_PERSON
treated O
groups B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
severity B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O
the O
induced B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
lesions I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
changes B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
heart B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
weight I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
, O
or O
heart B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
weight I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
to O
body B_MEASURE/B_PERSON
weight I_MEASURE/I_PERSON
ratios I_MEASURE/I_PERSON
. O

The O
results O
indicated O
that O
exercise O
reduced O
the O
mortality O
associated O
with O
the O
effects O
of O
large O
dosages O
of O
isoproterenol O
but O
had O
little O
on O
the O
severity O
of O
the O
infarction B_DISEASE
. O

Human O
corticotropin O
- O
releasing O
hormone O
and O
thyrotropin O
- O
releasing O
hormone O
modulate O
the O
hypercapnic B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
ventilatory O
response O
in O
humans O
. O

Human B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
corticotropin I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
releasing O
hormone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O
hCRH B_GENE/B_LOCATION
) O
and O
thyrotropin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O
releasing O
hormone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
( O
TRH B_GENE/B_LOCATION
) O
are O
known O
to O
stimulate O
ventilation B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
after O
i O
. O
v B_PROTEIN[GENE]/B_LOCATION
. O
administration B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
humans B_PERSON/B_SPECIES[BIO]
. O

In O
a O
placebo B_LOCATION/B_PERSON
- O
controlled O
, O
single B_NUMBER[MEASURE]/B_LOCATION
- O
blind B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
we O
aimed O
to O
clarify O
if O
both O
peptides B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
act O
by O
altering O
central B_DISEASE
chemosensitivity I_DISEASE
. O

Two B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
subsequent I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
CO2 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
- O
rebreathing O
tests B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
performed O
in O
healthy B_TIME[MEASURE]/B_LOCATION
young B_TIME[MEASURE]/I_LOCATION
volunteers B_TIME[MEASURE]/I_LOCATION
. O

During O
the O
first B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
test I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
0 I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O
9 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
NaCl I_MEASURE/I_PERSON
was O
given O
i O
. O
v B_PROTEIN[GENE]/B_LOCATION
. O
; O
during O
the O
second B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SEQUENCE[MEASURE]
test B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_SEQUENCE[MEASURE]
200 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_SEQUENCE[MEASURE]
micrograms B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_SEQUENCE[MEASURE]
of O
hCRH B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O
n B_MEASURE/B_LOCATION
= O
12 B_MEASURE
) O
or O
400 B_MEASURE/B_LOCATION
micrograms I_MEASURE/I_LOCATION
of O
TRH B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O
n B_OTHER/B_MEASURE
= O
6 B_MEASURE
) O
was O
administered O
i O
. O
v B_PROTEIN[GENE]/B_MEASURE
. O
Nine B_PERSON/B_LOCATION
subjects I_PERSON/I_LOCATION
received O
0 B_MEASURE
. O
9 B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
% I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
NaCl I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
i O
. O
v B_PROTEIN[GENE]/B_MEASURE
. O
during O
both O
rebreathing O
manoeuvres B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O

The O
CO2 B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
- O
response B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
curves I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
for O
the O
two B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tests I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
compared O
within O
the O
same B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
subject I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

In O
the O
hCRH B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
group I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
a O
marked O
parallel B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
shift I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
the O
CO2 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
- O
response B_MEASURE
curve I_MEASURE
to O
the O
left B_BODY_PART_OR_ORGAN_COMPONENT/B_MEASURE
was O
observed O
after O
hCRH B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
( O
P B_OTHER/B_PROTEIN[GENE]
< O
0 B_MEASURE
. O
01 B_MEASURE
) O
. O

The O
same B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
effect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
occurred O
following O
TRH B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
but O
was O
less O
striking B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
P B_PROTEIN[GENE]/B_LOCATION
= O
0 B_MEASURE
. O
05 B_MEASURE
) O
. O

hCRH B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
TRH B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
caused O
a O
reduction B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O
the O
CO2 B_MEASURE/B_DISEASE
threshold B_MEASURE/I_DISEASE
. O

The O
CO2 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
- O
response B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
curves I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
in O
the O
control B_PERSON/B_ORGANIZATION
group I_PERSON/I_ORGANIZATION
were O
nearly O
identical B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
. O

The O
results O
indicate O
an O
additive O
effect O
of O
both O
releasing O
hormones O
on O
the O
hypercapnic B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
ventilatory O
response O
in O
humans O
, O
presumably O
independent O
of O
central O
chemosensitivity O
. O

Lamivudine O
is O
effective O
in O
suppressing O
hepatitis B_DISEASE
B I_DISEASE
virus O
DNA O
in O
Chinese O
hepatitis O
B O
surface O
antigen O
carriers O
: O
a O
placebo O
- O
controlled O
trial O
. O

Lamivudine O
is O
a O
novel O
2 O
' O
, O
3 O
' O
- O
dideoxy O
cytosine O
analogue O
that O
has O
potent O
inhibitory O
effects O
on O
hepatitis B_DISEASE/B_GENE
B I_DISEASE/I_GENE
virus O
replication O
in O
vitro O
and O
in O
vivo O
. O

We O
performed O
a O
single B_PERSON/B_MEASURE
- O
blind B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
placebo B_LOCATION/B_PERSON
- O
controlled O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
assess O
its O
effectiveness B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O
safety B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
in O
Chinese B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hepatitis I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
B I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
surface I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antigen I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
HBsAg B_DISEASE/B_GENE
) O
carriers B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Forty B_NUMBER[MEASURE]
- O
two B_NUMBER[MEASURE]
Chinese I_NUMBER[MEASURE]
HBsAg I_NUMBER[MEASURE]
carriers I_NUMBER[MEASURE]
were O
randomized O
to O
receive O
placebo B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
6 B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
patients B_PERSON/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
or O
lamivudine O
orally O
in O
dosages B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
25 B_MEASURE
mg I_MEASURE
, O
100 B_MEASURE
mg I_MEASURE
, O
or O
300 B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mg I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
daily O
( O
12 B_NUMBER[MEASURE]
patients I_NUMBER[MEASURE]
for O
each O
dosage B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
) O
. O

The O
drug B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
given O
for O
4 B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
weeks I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
. O

The O
patients B_PERSON/B_BIO
were O
closely O
monitored O
clinically O
, O
biochemically O
, O
and O
serologically O
up O
to O
4 B_TIME[MEASURE]/B_ENT
weeks I_TIME[MEASURE]/I_ENT
after O
drug B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
treatment I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
. O

All O
36 O
patients O
receiving O
lamivudine O
had O
a O
decrease O
in O
hepatitis B_DISEASE
B I_DISEASE
virus O
( O
HBV O
) O
DNA O
values O
of O
> O
90 O
% O
( O
P O
< O
. O
001 O
compared O
with O
placebo O
) O
. O

Although O
25 B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
mg I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
of O
lamivudine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
was O
slightly O
less O
effective B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
than O
100 B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mg I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
P B_MEASURE/B_PROTEIN[GENE]
= B_MEASURE/I_PROTEIN[GENE]
. O
011 B_MEASURE
) O
and O
300 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
mg I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O
P B_LOCATION/B_PERSON
= I_LOCATION/I_PERSON
. O
005 B_MEASURE
) O
, O
it O
still O
induced O
94 B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
% B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
suppression B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
HBV B_DISEASE/B_GENE
DNA I_DISEASE/I_GENE
after O
the O
fourth B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
week I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
therapy B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O

HBV B_PERSON/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
DNA I_PERSON/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
values I_PERSON/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
returned O
to O
pretreatment B_MEASURE/B_PERSON
levels I_MEASURE/I_PERSON
within O
4 B_TIME[MEASURE]/B_ENT
weeks I_TIME[MEASURE]/I_ENT
of O
cessation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
therapy B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

There O
was O
no O
change O
in O
the O
hepatitis B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
B B_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
e O
antigen O
status O
or O
in O
aminotransferase O
levels O
. O

No O
serious B_DISEASE_ADJECTIVE[DISEASE]
adverse I_DISEASE_ADJECTIVE[DISEASE]
events I_DISEASE_ADJECTIVE[DISEASE]
were O
observed O
. O

In O
conclusion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O
a O
4 B_NUMBER[MEASURE]
- O
week B_MEASURE/B_LOCATION
course I_MEASURE/I_LOCATION
of O
lamivudine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
was O
safe B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
effective B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O
suppression B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
HBV B_DISEASE/B_GENE
DNA I_DISEASE/I_GENE
in O
Chinese B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
HBsAg I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
carriers I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
suppression B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
was O
> B_DISEASE_ADJECTIVE[DISEASE]
90 I_DISEASE_ADJECTIVE[DISEASE]
% I_DISEASE_ADJECTIVE[DISEASE]
but O
reversible B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
. O

Studies B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
long B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O
term B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_TIME[MEASURE]
lamivudine B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_TIME[MEASURE]
administration B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_TIME[MEASURE]
should O
be O
performed O
to O
determine O
if O
prolonged O
suppression B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
HBV B_DISEASE/B_GENE
DNA I_DISEASE/I_GENE
can O
be O
achieved O
. O

Population O
- O
based O
study O
of O
risk O
of O
venous B_DISEASE
thromboembolism I_DISEASE
associated O
with O
various O
oral O
contraceptives O
. O

Background O
: O
Four O
studies O
published O
since O
December O
, O
1995 O
, O
reported O
that O
the O
incidence O
of O
venous B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
thromboembolism I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
( O
VTE B_LOCATION/B_ORGANIZATION
) O
was O
higher O
in O
women O
who O
used O
oral O
contraceptives O
( O
OCs O
) O
containing O
the O
third O
- O
generation O
progestagens O
gestodene O
or O
desogestrel O
than O
in O
users O
of O
OCs O
containing O
second O
- O
generation O
progestagens O
. O

However O
, O
confounding B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
and O
bias B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O
the O
design B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
these O
studies B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
may O
have O
affected O
the O
findings B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
aim O
of O
our O
study O
was O
to O
re O
- O
examine O
the O
association O
between O
risk O
of O
VTE B_DISEASE
and O
OC O
use O
with O
a O
different O
study O
design O
and O
analysis O
to O
avoid O
some O
of O
the O
bias O
and O
confounding O
of O
the O
earlier O
studies O
. O

METHODS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O
We O
used O
computer B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
records I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
patients B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O
143 B_LOCATION/B_PERSON
general I_LOCATION/I_PERSON
practices I_LOCATION/I_PERSON
in O
the O
UK B_LOCATION
. O

The O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
based O
on O
the O
medical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
records I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
about O
540 B_MEASURE
, O
000 B_TIME[MEASURE]
women I_TIME[MEASURE]
born O
between O
1941 B_MEASURE
and O
1981 B_MEASURE
. O

All O
women O
who O
had O
a O
recorded O
diagnosis O
of O
deep B_DISEASE/B_LOCATION
- I_DISEASE/I_LOCATION
vein I_DISEASE/I_LOCATION
thrombosis I_DISEASE/I_LOCATION
, O
venous B_DISEASE
thrombosis I_DISEASE
not O
otherwise O
specified O
, O
or O
pulmonary O
embolus O
during O
the O
study O
period O
, O
and O
who O
had O
been O
treated O
with O
an O
anticoagulant O
were O
identified O
as O
potential O
cases O
of O
VTE B_DISEASE
. O

We O
did O
a O
cohort O
analysis O
to O
estimate O
and O
compare O
incidence O
of O
VTE B_DISEASE/B_LOCATION
in O
users O
of O
the O
main O
OC O
preparations O
, O
and O
a O
nested O
case O
- O
control O
study O
to O
calculate O
the O
odds O
ratios O
of O
VTE B_DISEASE
associated O
with O
use O
of O
different O
types O
of O
OC O
, O
after O
adjustment O
for O
potential O
confounding O
factors O
. O

In O
the O
case B_PERSON/B_MEASURE
- O
control B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
, O
we O
matched O
cases B_PERSON
to O
controls B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O
exact B_TIME[MEASURE]
year I_TIME[MEASURE]
of O
birth B_TIME[MEASURE]/B_PERSON
, O
practice B_LOCATION/B_PERSON
, O
and O
current B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
use B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
OCs B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

We O
used O
a O
multiple B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
logistic I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
regression I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
model I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
that O
included O
body B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
- O
mass B_MEASURE/B_LOCATION
index I_MEASURE/I_LOCATION
, O
number B_MEASURE/B_LOCATION
of O
cycles B_TIME[MEASURE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
change O
in O
type B_MEASURE/B_DISEASE
of O
OC B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
prescribed O
within O
3 B_TIME[MEASURE]/B_LOCATION
months I_TIME[MEASURE]/I_LOCATION
of O
the O
event B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O
previous B_DISEASE/B_PERSON
pregnancy I_DISEASE/I_PERSON
, O
and O
concurrent B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
disease B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

findings O
: O
85 O
women O
met O
the O
inclusion O
criteria O
for O
VTE B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O
two O
of O
whom O
were O
users O
of O
progestagen O
- O
only O
OCs O
. O

Of O
the O
83 O
cases O
of O
VTE B_DISEASE
associated O
with O
use O
of O
combined O
OCs O
, O
43 O
were O
recorded O
as O
deep B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
- I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
vein I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
thrombosis I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
, O
35 O
as O
pulmonary O
thrombosis B_DISEASE
, O
and O
five O
as O
venous B_DISEASE/B_PERSON
thrombosis I_DISEASE/I_PERSON
not O
otherwise O
specified O
. O

The O
crude O
rate O
of O
VTE B_DISEASE
per O
10 O
, O
000 O
woman O
- O
years O
was O
4 O
. O
10 O
in O
current O
users O
of O
any O
OC O
, O
3 O
. O
10 O
in O
users O
of O
second O
- O
generation O
OCs O
, O
and O
4 O
. O
96 O
in O
users O
of O
third O
- O
generation O
preparations O
. O

After O
adjustment O
for O
age O
, O
the O
rate O
ratio O
of O
VTE B_DISEASE
in O
users O
of O
third O
- O
generation O
relative O
to O
second O
- O
generation O
OCs O
was O
1 O
. O
68 O
( O
95 O
% O
CI O
1 O
. O
04 O
- O
2 O
. O
75 O
) O
. O

Logistic O
regression O
showed O
no O
significant O
difference O
in O
the O
risk O
of O
VTE B_DISEASE/B_GENE
between O
users O
of O
third O
- O
generation O
and O
second O
- O
generation O
OCs O
. O

Among O
users O
of O
third O
- O
generation O
progestagens O
, O
the O
risk O
of O
VTE B_DISEASE
was O
higher O
in O
users O
of O
desogestrel O
with O
20 O
g O
ethinyloestradiol O
than O
in O
users O
of O
gestodene O
or O
desogestrel O
with O
30 O
g O
ethinyloestradiol O
. O

With O
all O
second O
- O
generation O
OCs O
as O
the O
reference O
, O
the O
odds O
ratios O
for O
VTE B_DISEASE/B_LOCATION
were O
3 O
. O
49 O
( O
1 O
. O
21 O
- O
10 O
. O
12 O
) O
for O
desogestrel O
plus O
20 O
g O
ethinyloestradiol O
and O
1 O
. O
18 O
( O
0 O
. O
66 O
- O
2 O
. O
17 O
) O
for O
the O
other O
third O
- O
generation O
progestagens O
. O

interpretation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O
The O
previously O
reported O
increase B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O
odds B_DISEASE
ratio I_DISEASE
associated O
with O
third B_SEQUENCE[MEASURE]
- O
generation B_PERSON
OCs I_PERSON
when O
compared O
with O
second B_SEQUENCE[MEASURE]
- O
generation B_PERSON/B_TIME[MEASURE]
products B_PERSON/I_TIME[MEASURE]
is O
likely B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O
have O
been O
the O
result B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
residual B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
confounding I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O
age B_TIME[MEASURE]/B_PERSON
. O

The O
increased O
odds B_MEASURE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
ratio O
associated O
with O
products B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
containing O
20 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
micrograms I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
ethinyloestradiol I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O
desogestrel B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
compared O
with O
the O
30 B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
micrograms B_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
product B_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
biologically O
implausible B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
, O
and O
is O
likely B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O
be O
the O
result B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
preferential B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
prescribing I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
, O
thus O
, O
confounding O
. O

Mk O
- O
801 O
augments O
pilocarpine O
- O
induced O
electrographic O
seizure B_DISEASE
but O
protects O
against O
brain B_DISEASE
damage I_DISEASE
in O
rats O
. O

1 B_NUMBER[MEASURE]
. O

The O
authors O
examined O
the O
anticonvulsant O
effects O
of O
Mk O
- O
801 O
on O
the O
pilocarpine O
- O
induced O
seizure B_DISEASE
model O
. O

Intraperitoneal O
injection O
of O
pilocarpine O
( O
400 O
mg O
/ O
kg O
) O
induced O
tonic B_DISEASE
and I_DISEASE
clonic I_DISEASE
seizure I_DISEASE
. O

Scopolamine O
( O
10 O
mg O
/ O
kg O
) O
and O
pentobarbital O
( O
5 O
mg O
/ O
kg O
) O
prevented O
development O
of O
pilocarpine O
- O
induced O
behavioral O
seizure B_DISEASE
but O
Mk O
- O
801 O
( O
0 O
. O
5 O
mg O
/ O
kg O
) O
did O
not O
. O

2 B_NUMBER[MEASURE]
. O

An O
electrical O
seizure B_DISEASE
measured O
with O
hippocampal O
EEG O
appeared O
in O
the O
pilocarpine O
- O
treated O
group O
. O

Scopolamine O
and O
pentobarbital O
blocked O
the O
pilocarpine O
- O
induced O
electrographic O
seizure B_DISEASE
, O
Mk O
- O
801 O
treatment O
augmented O
the O
electrographic O
seizure B_DISEASE
induced O
by O
pilocarpine O
. O

3 B_NUMBER[MEASURE]
. O

Brain B_DISEASE_ADJECTIVE[DISEASE]
damage I_DISEASE_ADJECTIVE[DISEASE]
was O
assessed O
by O
examining O
the O
hippocampus O
microscopically O
. O

Pilocarpine O
produced O
neuronal B_DISEASE
death I_DISEASE
in O
the O
hippocampus O
, O
which O
showed O
pyknotic O
changes O
. O

Pentobarbital O
, O
scopolamine O
and O
Mk O
- O
801 O
protected O
the O
brain B_DISEASE_ADJECTIVE[DISEASE]
damage I_DISEASE_ADJECTIVE[DISEASE]
by O
pilocarpine O
, O
though O
in O
the O
Mk O
- O
801 O
- O
treated O
group O
, O
the O
pyramidal O
cells O
of O
hippocampus O
appeared O
darker O
than O
normal O
. O

In O
all O
treatments B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
, O
granule B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
of O
the O
dentate B_BODY_PART_OR_ORGAN_COMPONENT/B_GENE
gyrus I_BODY_PART_OR_ORGAN_COMPONENT/I_GENE
were O
not O
affected O
. O

4 B_NUMBER[MEASURE]
. O

These O
results O
indicate O
that O
status B_DISEASE
epilepticus I_DISEASE
induced O
by O
pilocarpine O
is O
initiated O
by O
cholinergic O
overstimulation O
and O
propagated O
by O
glutamatergic O
transmission O
, O
the O
elevation O
of O
which O
may O
cause O
brain B_DISEASE
damage I_DISEASE
through O
an O
excitatory O
NMDA O
receptor O
- O
mediated O
mechanism O
. O

Paclitaxel O
, O
5 O
- O
fluorouracil O
, O
and O
folinic O
acid O
in O
metastatic O
breast B_DISEASE/B_LOCATION
cancer I_DISEASE/I_LOCATION
: O
BRE O
- O
26 O
, O
a O
phase O
II O
trial O
. O

5 O
- O
Fluorouracil O
plus O
folinic O
acid O
and O
paclitaxel O
( O
Taxol O
; O
Bristol O
- O
Myers O
Squibb O
Company O
, O
Princeton O
, O
NJ O
) O
are O
effective O
salvage O
therapies O
for O
metastatic O
breast B_DISEASE/B_LOCATION
cancer I_DISEASE/I_LOCATION
patients O
. O

Paclitaxel O
and O
5 O
- O
fluorouracil O
have O
additive O
cytotoxicity B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
MCF O
- O
7 O
cell O
lines O
. O

We O
performed O
a O
phase O
II O
trial O
of O
paclitaxel O
175 O
mg O
/ O
m2 O
over O
3 O
hours O
on O
day O
I O
followed O
by O
folinic O
acid O
300 O
mg O
over O
1 O
hour O
before O
5 O
- O
fluorouracil O
350 O
mg O
/ O
m2 O
on O
days O
1 O
to O
3 O
every O
28 O
days O
( O
TFL O
) O
in O
women O
with O
metastatic O
breast B_DISEASE/B_LOCATION
cancer I_DISEASE/I_LOCATION
. O

Analysis O
is O
reported O
on O
37 O
patients O
with O
a O
minimum O
of O
6 O
months O
follow O
- O
up O
who O
received O
a O
total O
of O
192 O
cycles O
of O
TFL O
: O
nine O
cycles O
( O
5 O
% O
) O
were O
associated O
with O
grade O
3 O
/ O
4 O
neutropenia B_DISEASE
requiring O
hospitalization O
; O
seven O
( O
4 O
% O
) O
cycles O
in O
two O
patients O
required O
granulocyte O
colony O
- O
stimulating O
factor O
due O
to O
neutropenia B_DISEASE
; O
no O
patient O
required O
platelet O
transfusions O
. O

Grade O
3 O
/ O
4 O
nonhematologic O
toxicities B_DISEASE
were O
uncommon O
. O

Among O
the O
34 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
patients I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
evaluable I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
for O
response B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O
there O
were O
three B_MEASURE
complete I_MEASURE
responses I_MEASURE
( O
9 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
and O
18 B_NUMBER[MEASURE]
partial I_NUMBER[MEASURE]
responses I_NUMBER[MEASURE]
( O
53 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
for O
an O
overall B_MEASURE
response I_MEASURE
rate I_MEASURE
of O
62 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
. O

Of O
the O
19 B_PERSON
evaluable I_PERSON
patients I_PERSON
with O
prior B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
doxorubicin I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
exposure I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
11 B_NUMBER[MEASURE]
( O
58 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
responded O
compared O
with O
nine B_MEASURE/B_PERSON
of O
15 B_NUMBER[MEASURE]/B_PERSON
( O
60 B_MEASURE/B_LOCATION
% I_MEASURE/I_LOCATION
) O
without O
prior B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
doxorubicin I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O

plasma B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
paclitaxel I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
concentrations I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
measured O
at O
the O
completion B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
paclitaxel B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
infusion I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
at O
24 B_MEASURE/B_SPORT[ENT]
hours I_MEASURE/I_SPORT[ENT]
in O
19 B_PERSON/B_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]
patients B_PERSON/I_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]
. O

TFL O
is O
an O
active O
, O
well O
- O
tolerated O
regimen O
in O
metastatic O
breast B_DISEASE/B_LOCATION
cancer I_DISEASE/I_LOCATION
. O

efficacy O
and O
proarrhythmia B_DISEASE_ADJECTIVE[DISEASE]
with O
the O
use O
of O
d O
, O
l O
- O
sotalol O
for O
sustained O
ventricular B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
tachyarrhythmias B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

This O
study O
prospectively O
evaluated O
the O
clinical O
efficacy O
, O
the O
incidence O
of O
torsades B_DISEASE
de I_DISEASE
pointes I_DISEASE
, O
and O
the O
presumable O
risk O
factors O
for O
torsades B_DISEASE
de I_DISEASE
pointes I_DISEASE
in O
patients O
treated O
with O
d O
, O
l O
- O
sotalol O
for O
sustained O
ventricular B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
tachyarrhythmias I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

eighty O
- O
one O
consecutive O
patients O
( O
54 O
with O
coronary B_DISEASE_ADJECTIVE[DISEASE]
artery I_DISEASE_ADJECTIVE[DISEASE]
disease I_DISEASE_ADJECTIVE[DISEASE]
, O
and O
20 O
with O
dilated B_DISEASE
cardiomyopathy I_DISEASE
) O
with O
inducible O
sustained O
ventricular B_DISEASE
tachycardia I_DISEASE
or O
ventricular B_DISEASE
fibrillation I_DISEASE
received O
oral O
d O
, O
l O
- O
sotalol O
to O
prevent O
induction O
of O
the O
ventricular B_DISEASE
tachyarrhythmia I_DISEASE
. O

During O
oral B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
loading I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
with O
d B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O
l B_PROTEIN[GENE]/B_MEASURE
- O
sotalol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
continuous B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
electrocardiographic I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
( O
ECG B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O
monitoring B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
performed O
. O

Those O
patients O
in O
whom O
d O
, O
l O
- O
sotalol O
prevented O
induction O
of O
ventricular B_DISEASE
tachycardia I_DISEASE
or O
ventricular B_DISEASE
fibrillation I_DISEASE
were O
discharged O
with O
the O
drug O
and O
followed O
up O
on O
an O
outpatient O
basis O
for O
21 O
+ O
/ O
- O
18 O
months O
. O

induction O
of O
the O
ventricular B_DISEASE
tachyarrhythmia I_DISEASE
was O
prevented O
by O
oral O
d O
, O
l O
- O
sotalol O
in O
35 O
( O
43 O
% O
) O
patients O
; O
the O
ventricular B_DISEASE
tachyarrhythmia I_DISEASE
remained O
inducible O
in O
40 O
( O
49 O
% O
) O
patients O
; O
and O
two O
( O
2 O
. O
5 O
% O
) O
patients O
did O
not O
tolerate O
even O
40 O
mg O
of O
d O
, O
l O
- O
sotalol O
once O
daily O
. O

Four O
( O
5 O
% O
) O
patients O
had O
from O
torsades B_DISEASE
de I_DISEASE
pointes I_DISEASE
during O
the O
initial O
oral O
treatment O
with O
d O
, O
l O
- O
sotalol O
. O

Neither O
ECG O
[ O
sinus O
- O
cycle O
length O
( O
SCL O
) O
, O
QT O
or O
QTc O
interval O
, O
or O
U O
wave O
] O
nor O
clinical O
parameters O
identified O
patients O
at O
risk O
for O
torsades B_DISEASE
de I_DISEASE
pointes I_DISEASE
. O

However O
, O
the O
oral O
dose O
of O
d O
, O
l O
- O
sotalol O
was O
significantly O
lower O
in O
patients O
with O
torsades B_DISEASE/B_LOCATION
de I_DISEASE/I_LOCATION
pointes I_DISEASE/I_LOCATION
( O
200 O
+ O
/ O
- O
46 O
vs O
. O
328 O
+ O
/ O
- O
53 O
mg O
/ O
day O
; O
p O
= O
0 O
. O
0017 O
) O
. O

Risk O
factors O
associated O
with O
the O
development O
of O
torsades B_DISEASE
de I_DISEASE
pointes I_DISEASE
were O
the O
appearance O
of O
an O
U O
wave O
( O
p O
= O
0 O
. O
049 O
) O
, O
female O
gender O
( O
p O
= O
0 O
. O
015 O
) O
, O
and O
significant O
dose O
- O
corrected O
changes O
of O
SCL O
, O
QT O
interval O
, O
and O
QTc O
interval O
( O
p O
< O
0 O
. O
05 O
) O
. O

During O
follow O
- O
up O
, O
seven O
( O
20 O
% O
) O
patients O
had O
a O
nonfatal O
ventricular B_DISEASE/B_LOCATION
tachycardia I_DISEASE/I_LOCATION
recurrence O
, O
and O
two O
( O
6 O
% O
) O
patients O
died O
suddenly O
. O

One O
female O
patient O
with O
stable O
cardiac B_DISEASE
disease I_DISEASE
had O
recurrent O
torsades B_DISEASE
de I_DISEASE
pointes I_DISEASE
after O
2 O
years O
of O
successful O
treatment O
with O
d O
, O
l O
- O
sotalol O
. O

Torsades B_DISEASE_ADJECTIVE[DISEASE]
de I_DISEASE_ADJECTIVE[DISEASE]
pointes I_DISEASE_ADJECTIVE[DISEASE]
occurred O
early O
during O
treatment O
even O
with O
low O
doses O
of O
oral O
d O
, O
l O
- O
sotalol O
. O

pronounced O
changes O
in O
the O
surface O
ECG O
( O
cycle O
length O
, O
QT O
, O
and O
QTc O
) O
in O
relation O
to O
the O
dose O
of O
oral O
d O
, O
l O
- O
sotalol O
might O
identify O
a O
subgroup O
of O
patients O
with O
an O
increased O
risk O
for O
torsades B_DISEASE
de I_DISEASE
pointes I_DISEASE
. O

Other O
ECG O
parameters O
before O
the O
application O
of O
d O
, O
l O
- O
sotalol O
did O
not O
identify O
patients O
at O
increased O
risk O
for O
torsades B_DISEASE
de I_DISEASE
pointes I_DISEASE
. O

Recurrence O
rates O
of O
ventricular B_DISEASE
tachyarrhythmias I_DISEASE
are O
high O
despite O
complete O
suppression O
of O
the O
arrhythmia B_DISEASE
during O
programmed O
stimulation O
. O

Therefore O
programmed O
electrical B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
stimulation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
in O
the O
case B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
of O
d B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O
l B_PROTEIN[GENE]/B_DISEASE
- O
sotalol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
seems O
to O
be O
of O
limited B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
prognostic I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
value I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

chronic O
hyperprolactinemia B_DISEASE
and O
changes O
in O
dopamine O
neurons O
. O

The O
tuberoinfundibular B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
dopaminergic I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
TIDA B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
system B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
is O
known O
to O
inhibit O
prolactin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O
PRL B_PROTEIN[GENE]/B_LOCATION
) O
secretion B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O

In O
young B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENT
animals I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENT
this O
system B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENZYME[GENE]
responds O
to O
acute B_DISEASE_ADJECTIVE[DISEASE]
elevations I_DISEASE_ADJECTIVE[DISEASE]
in O
serum B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
PRL I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
by O
increasing O
its O
activity B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O

However O
, O
this O
responsiveness B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
is O
lost O
in O
aging O
rats B_BIO/B_PERSON
with O
chronically O
high B_DISEASE
serum I_DISEASE
PRL I_DISEASE
levels I_DISEASE
. O

The O
purpose O
of O
this O
study O
was O
to O
induce O
hyperprolactinemia B_DISEASE
in O
rats O
for O
extended O
periods O
of O
time O
and O
examine O
its O
effects O
on O
dopaminergic O
systems O
in O
the O
brain O
. O

Hyperprolactinemia B_DISEASE/B_PROTEIN[GENE]
was O
induced O
by O
treatment O
with O
haloperidol O
, O
a O
dopamine O
receptor O
antagonist O
, O
and O
Palkovits O
' O
microdissection O
technique O
in O
combination O
with O
high O
- O
performance O
liquid O
chromatography O
was O
used O
to O
measure O
neurotransmitter O
concentrations O
in O
several O
areas O
of O
the O
brain O
. O

After O
6 O
months O
of O
hyperprolactinemia B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
dopamine O
( O
Da O
) O
concentrations O
in O
the O
median O
eminence O
( O
ME O
) O
increased O
by O
84 O
% O
over O
the O
control O
group O
. O

Nine O
months O
of O
hyperprolactinemia B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
produced O
a O
50 O
% O
increase O
in O
Da O
concentrations O
in O
the O
ME O
over O
the O
control O
group O
. O

However O
, O
Da O
response O
was O
lost O
if O
a O
9 O
- O
month O
long O
haloperidol O
- O
induced O
hyperprolactinemia B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O
followed O
by O
a O
1 O
1 O
/ O
2 O
month O
- O
long O
extremely O
high O
increase O
in O
serum O
PRL O
levels O
produced O
by O
implantation O
of O
MMQ O
cells O
under O
the O
kidney O
capsule O
. O

There O
was O
no O
change O
in O
the O
levels O
of O
Da O
, O
norepinephrine O
( O
NE O
) O
, O
serotonin O
( O
5 O
- O
HT O
) O
, O
or O
their O
metabolites O
in O
the O
arcuate O
nucleus O
( O
AN O
) O
, O
medial O
preoptic O
area O
( O
MPA O
) O
, O
caudate O
putamen O
( O
CP O
) O
, O
substantia O
nigra O
( O
SN O
) O
, O
and O
zona O
incerta O
( O
ZI O
) O
, O
except O
for O
a O
decrease O
in O
5 O
- O
hydroxyindoleacetic O
acid O
( O
5 O
- O
HIAA O
) O
in O
the O
AN O
after O
6 O
- O
months O
of O
hyperprolactinemia B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
an O
increase O
in O
Da O
concentrations O
in O
the O
AN O
after O
9 O
- O
months O
of O
hyperprolactinemia B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

These O
results O
demonstrate O
that O
hyperprolactinemia B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
specifically O
affects O
TIDA O
neurons O
and O
these O
effects O
vary O
, O
depending O
on O
the O
duration O
and O
intensity O
of O
hyperprolactinemia B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

The O
age B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
related O
decrease B_DISEASE_ADJECTIVE[DISEASE]
in O
hypothalamic B_GENE
dopamine I_GENE
function I_GENE
may O
be O
associated O
with O
increases B_DISEASE_ADJECTIVE[DISEASE]
in O
PRL B_DISEASE
secretion I_DISEASE
. O

Treatment O
- O
related O
disseminated O
necrotizing O
leukoencephalopathy B_DISEASE
with O
characteristic O
contrast O
enhancement O
of O
the O
white O
matter O
. O

This O
report O
describes O
unique O
contrast O
enhancement O
of O
the O
white O
matter O
on O
T1 O
- O
weighted O
magnetic O
resonance O
images O
of O
two O
patients O
with O
disseminated O
necrotizing O
leukoencephalopathy B_DISEASE
, O
which O
developed O
from O
acute B_DISEASE_ADJECTIVE[DISEASE]
lymphoblastic I_DISEASE_ADJECTIVE[DISEASE]
leukemia I_DISEASE_ADJECTIVE[DISEASE]
treated O
with O
high O
- O
dose O
methotrexate O
. O

In O
both O
patients B_PERSON/B_LOCATION
, O
the O
enhancement B_DISEASE_ADJECTIVE[DISEASE]
was O
more O
pronounced O
near O
the O
base B_LOCATION/B_MEASURE
of O
the O
brain B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
than O
at O
the O
vertex B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
. O

Necropsy O
of O
the O
first O
case O
revealed O
loss B_DISEASE
of I_DISEASE
myelination I_DISEASE
and O
necrosis B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
the O
white O
matter O
. O

possible O
mechanisms O
causing O
such O
a O
leukoencephalopathy B_DISEASE_ADJECTIVE[DISEASE]
are O
discussed O
. O

Thrombotic B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
complications O
in O
acute B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
promyelocytic B_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
leukemia B_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
during O
all O
- O
trans O
- O
retinoic O
acid O
therapy O
. O

A O
case O
of O
acute B_DISEASE
renal I_DISEASE
failure I_DISEASE
, O
due O
to O
occlusion B_DISEASE
of I_DISEASE
renal I_DISEASE
vessels I_DISEASE
in O
a O
patient O
with O
acute B_DISEASE
promyelocytic I_DISEASE
leukemia I_DISEASE
( O
APL B_DISEASE
) O
treated O
with O
all O
- O
trans O
- O
retinoic O
acid O
( O
ATRA O
) O
and O
tranexamic O
acid O
has O
been O
described O
recently O
. O

We O
report O
a O
case O
of O
acute B_DISEASE/B_GENE
renal I_DISEASE/I_GENE
failure I_DISEASE/I_GENE
in O
an O
APL B_DISEASE/B_MEASURE
patient O
treated O
with O
ATRA O
alone O
. O

This O
case O
further O
supports O
the O
concern O
about O
thromboembolic B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
complications O
associated O
with O
ATRA O
therapy O
in O
APL B_DISEASE/B_MEASURE
patients O
. O

The O
patients O
, O
a O
43 O
- O
year O
- O
old O
man O
, O
presented O
all O
the O
signs O
and O
symptoms O
of O
APL B_DISEASE/B_GENE
and O
was O
included O
in O
a O
treatment O
protocol O
with O
ATRA O
. O

After O
10 O
days O
of O
treatment O
, O
he O
developed O
acute B_DISEASE
renal I_DISEASE
failure I_DISEASE
that O
was O
completely O
reversible O
after O
complete O
remission O
of O
APL B_DISEASE
was O
achieved O
and O
therapy O
discontinued O
. O

We O
conclude O
that O
ATRA O
is O
a O
valid O
therapeutic O
choice O
for O
patients O
with O
APL B_DISEASE/B_LOCATION
, O
although O
the O
procoagulant O
tendency O
is O
not O
completely O
corrected O
. O

Thrombotic B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
events O
, O
however O
, O
could O
be O
avoided O
by O
using O
low O
- O
dose O
heparin O
. O

Pupillary O
changes O
associated O
with O
the O
development O
of O
stimulant O
- O
induced O
mania B_DISEASE/B_LOCATION
: O
a O
case O
report O
. O

A O
30 O
- O
year O
- O
old O
cocaine O
- O
dependent O
man O
who O
was O
a O
subject O
in O
a O
study O
evaluating O
the O
anticraving O
efficacy O
of O
the O
stimulant O
medication O
diethylpropion O
( O
DEP O
) O
became O
manic B_DISEASE
during O
his O
second O
week O
on O
the O
study O
drug O
. O

Pupillometric O
changes O
while O
on O
DEP O
, O
especially O
changes O
in O
the O
total O
power O
of O
pupillary B_DISEASE
oscillation I_DISEASE
, O
were O
dramatically O
different O
than O
those O
observed O
in O
the O
eight O
other O
study O
subjects O
who O
did O
not O
become O
manic B_DISEASE/B_PERSON
. O

The O
large O
changes O
in O
total O
power O
of O
pupillary B_DISEASE/B_PROTEIN[GENE]
oscillation B_DISEASE/I_PROTEIN[GENE]
occurred O
a O
few O
days O
before O
the O
patient O
became O
fully O
manic B_DISEASE/B_PERSON
. O

Such O
medication O
- O
associated O
changes O
in O
the O
total O
power O
of O
pupillary B_DISEASE/B_PROTEIN[GENE]
oscillation B_DISEASE/I_PROTEIN[GENE]
might O
be O
of O
utility O
in O
identifying O
persons O
at O
risk O
for O
manic B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
like O
adverse O
effects O
during O
the O
medical O
use O
of O
psychomotor O
stimulants O
or O
sympathomimetic O
agents O
. O

Fetal B_DISEASE_ADJECTIVE[DISEASE]
risks I_DISEASE_ADJECTIVE[DISEASE]
due I_DISEASE_ADJECTIVE[DISEASE]
to O
warfarin O
therapy B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
during O
pregnancy B_DISEASE/B_ORGANISM_FUNCTION
. O

Two B_PERSON/B_BIO
mothers I_PERSON/I_BIO
with O
heart B_DISEASE
valve I_DISEASE
prosthesis I_DISEASE
were O
treated O
with O
warfarin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
during O
pregnancy B_DISEASE/B_PERSON
. O

In O
the O
first B_TIME[MEASURE]/B_LOCATION
case I_TIME[MEASURE]/I_LOCATION
a O
caesarean B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
section I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O
done O
one B_TIME[MEASURE]/B_LOCATION
week B_TIME[MEASURE]/I_LOCATION
after O
replacement B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O
warfarin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
with O
heparin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
baby O
died O
of O
cerebral B_DISEASE
and I_DISEASE
pulmonary I_DISEASE
hemorrhage I_DISEASE
. O

The O
second B_PERSON/B_LOCATION
mother I_PERSON/I_LOCATION
had O
a O
male B_PERSON
infant I_PERSON
by O
caesarean B_TIME[MEASURE]/B_PERSON
section B_TIME[MEASURE]/I_PERSON
. O

The O
baby O
showed O
warfarin O
- O
induced O
embryopathy B_DISEASE
with O
nasal B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
hypoplasia I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
and O
stippled B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
epiphyses I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O
chondrodysplasia B_DISEASE/B_PROTEIN[GENE]
punctata B_DISEASE/I_PROTEIN[GENE]
) O
. O

Nasal B_DISEASE
hypoplasia I_DISEASE
with O
or O
without O
stippled B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
epiphyses I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
has O
now O
been O
reported O
in O
11 O
infants O
born O
to O
mothers O
treated O
with O
warfarin O
during O
the O
first O
trimester O
, O
and O
a O
causal O
association O
is O
probable O
. O

In O
view B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
risks B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O
both O
mother B_PERSON/B_BIO
and O
fetus B_PERSON
in O
women B_PERSON
with O
prosthetic B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
cardiac I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
valves I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
it O
is O
recommended O
that O
therapeutic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
abortion I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
be O
advised O
as O
the O
first B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alternative I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
negative B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
mucosal I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
potential I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
: O
separating O
central B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
and O
peripheral B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
effects B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
of O
NSAIDs B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
man B_PERSON/B_BIO
. O

objective O
: O
We O
wanted O
to O
test O
whether O
assessment O
of O
both O
a O
central O
pain B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
related O
signal O
( O
chemo O
- O
somatosensory O
evoked O
potential O
, O
CSSEP O
) O
and O
a O
concomitantly O
recorded O
peripheral O
signal O
( O
negative O
mucosal O
potential O
, O
NMP O
) O
allows O
for O
separation O
of O
central O
and O
peripheral O
effects O
of O
NSAIDs O
. O

For O
this O
purpose O
, O
experimental O
conditions O
were O
created O
in O
which O
NSAIDs O
had O
previously O
been O
observed O
to O
produce O
effects O
on O
phasic O
and O
tonic O
pain B_DISEASE
by O
either O
central O
or O
peripheral O
mechanisms O
. O

METHODS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O
According O
to O
a O
double B_MEASURE/B_COLOR
- O
blind B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
randomised O
, O
controlled O
, O
threefold B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
cross O
- O
over O
design B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
18 B_PERSON
healthy I_PERSON
subjects I_PERSON
( O
11 B_PERSON/B_MEASURE
males I_PERSON/I_MEASURE
, O
7 B_PERSON
females I_PERSON
; O
mean B_TIME[MEASURE]/B_PERSON
age B_TIME[MEASURE]/I_PERSON
26 B_TIME[MEASURE]/I_PERSON
years B_TIME[MEASURE]/I_PERSON
) O
received O
either O
placebo B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
400 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
mg I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
ibuprofen I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O
or O
800 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mg I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ibuprofen I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Phasic O
pain B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
was O
applied O
by O
means O
of O
short O
pulses O
of O
CO2 O
to O
the O
nasal O
mucosa O
( O
stimulus O
duration O
500 O
MS O
, O
interval O
approximately O
60 O
s O
) O
, O
and O
tonic O
pain B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O
induced O
in O
the O
nasal O
cavity O
by O
means O
of O
dry O
air O
of O
controlled O
temperature O
, O
humidity O
and O
flow O
rate O
( O
22 O
degrees O
C O
, O
0 O
% O
relative O
humidity O
, O
145 O
ml O
. O
s O
- O
1 O
) O
. O

Both O
CSSEPs O
as O
central O
and O
NMPs O
as O
peripheral O
correlates O
of O
pain B_DISEASE/B_GENE
were O
obtained O
in O
response O
to O
the O
CO2 O
stimuli O
. O

Additionally O
, O
the O
subjects O
rated O
the O
intensity O
of O
both O
phasic O
and O
tonic O
pain B_DISEASE
by O
means O
of O
visual O
analogue O
scales O
. O

Results O
: O
As O
described O
earlier O
, O
administration O
of O
ibuprofen O
was O
followed O
by O
a O
decrease O
in O
tonic O
pain B_DISEASE/B_MEASURE
but O
- O
relative O
to O
placebo O
- O
an O
increase O
in O
correlates O
of O
phasic O
pain B_DISEASE
, O
indicating O
a O
specific O
effect O
of O
ibuprofen O
on O
the O
interaction O
between O
the O
pain B_DISEASE_ADJECTIVE[DISEASE]
stimuli O
under O
these O
special O
experimental O
conditions O
. O

Based O
on O
the O
similar B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
behaviour I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
CSSEP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
NMP B_DISEASE
, O
it O
was O
concluded O
that O
the O
pharmacological B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
process B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
underlying O
this O
phenomenon B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
was O
localised O
in O
the O
periphery B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
. O

By O
means B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
simultaneous B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
recording I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
interrelated B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
peripheral B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
and O
central B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
electrophysiologic B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
correlates B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
of O
nociception B_DISEASE
, O
it O
was O
possible B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
separate B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
central B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
and O
peripheral B_LOCATION
effects I_LOCATION
of O
an O
NSAID B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
major O
advantage O
of O
this O
pain B_DISEASE/B_SPECIES[BIO]
model O
is O
the O
possibility O
of O
obtaining O
peripheral O
pain B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
- O
related O
activity O
directly O
using O
a O
non O
- O
invasive O
technique O
in O
humans O
. O

Effect O
of O
D O
- O
Glucarates O
on O
basic O
antibiotic O
- O
induced O
renal B_DISEASE
damage I_DISEASE
in O
rats O
. O

Dehydrated B_PERSON
rats O
regularly O
develop O
acute B_DISEASE
renal I_DISEASE
failure I_DISEASE
following O
single O
injection O
of O
aminoglycoside O
antibiotics O
combined O
with O
dextran O
or O
of O
antibiotics O
only O
. O

Oral O
administration O
of O
2 O
, O
5 O
- O
di O
- O
O O
- O
acetyl O
- O
D O
- O
glucaro O
- O
1 O
, O
4 O
- O
6 O
, O
3 O
- O
dilactone O
protected O
rats O
against O
renal B_DISEASE
failure I_DISEASE
induced O
by O
kanamycin O
- O
dextran O
. O

The O
protective B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
effect I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
was O
prevalent B_DISEASE_ADJECTIVE[DISEASE]
among O
D B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
glucarates B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O
and O
also O
to O
other B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
saccharic I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
acid I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
hexauronic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
acids I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
hexaaldonic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
acids I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O
although O
to O
a O
lesser B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
degree I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
, O
but O
not O
to O
a O
hexaaldose B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
, O
sugar B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
alcohols I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
substances B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
inthe O
TCA B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
cycle I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
other B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acidic I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
compounds I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

D O
- O
Glucarates O
were O
effective O
against O
renal B_DISEASE
damage I_DISEASE
induced O
by O
peptide O
antibiotics O
as O
well O
as O
various O
aminoglycoside O
antibitocis O
. O

dose B_MEASURE/B_LOCATION
- O
responses B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
observed O
in O
the O
protective B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
effect I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
D B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
Glucarates B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O

With O
a O
D O
- O
glucarate O
of O
a O
fixed O
size O
of O
dose O
, O
approximately O
the O
same O
degree O
of O
protection O
was O
obtained O
against O
renal B_DISEASE
damages I_DISEASE
induced O
by O
different O
basic O
antibiotics O
despite O
large O
disparities O
in O
administration O
doses O
of O
different O
antibiotics O
. O

D O
- O
Glucarates O
had O
the O
ability O
to O
prevent O
renal B_DISEASE
damage I_DISEASE
but O
not O
to O
cure O
it O
. O

rats O
excreted O
acidic O
urine O
when O
they O
were O
spared O
from O
renal B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
lesions B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
by O
monosaccharides O
. O

The O
reduction O
effect O
of O
D O
- O
glucarates O
against O
nephrotoxicity B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
basic O
antibiotics O
was O
discussed O
. O

acute O
severe O
depression B_DISEASE
following O
peri O
- O
operative O
ondansetron O
. O

A O
41 O
- O
year O
- O
old O
woman O
with O
a O
strong O
history O
of O
postoperative B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
nausea I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
vomiting I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
presented O
for O
abdominal O
hysterectomy O
3 O
months O
after O
a O
previous O
anaesthetic O
where O
ondansetron O
prophylaxis O
had O
been O
used O
. O

She O
had O
developed O
a O
severe O
acute O
major B_DISEASE
depression I_DISEASE
disorder I_DISEASE
almost O
immediately O
thereafter O
, O
possibly O
related O
to O
the O
use O
of O
a O
serotonin O
antagonist O
. O

Nine O
years O
before O
she O
had O
experienced O
a O
self O
- O
limited O
puerperal O
depressive B_DISEASE
episode I_DISEASE
. O

Anaesthesia O
with O
a O
propofol O
infusion O
and O
avoidance O
of O
serotonin O
antagonists O
provided O
a O
nausea B_DISEASE
- O
free O
postoperative O
course O
without O
exacerbation O
of O
the O
depression B_DISEASE
disorder I_DISEASE
. O

Hypertensive B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
response O
during O
dobutamine O
stress O
echocardiography O
. O

Among O
3 O
, O
129 O
dobutamine O
stress O
echocardiographic O
studies O
, O
a O
hypertensive B_DISEASE_ADJECTIVE[DISEASE]
response O
, O
defined O
as O
systolic O
blood O
pressure O
( O
BP O
) O
> O
or O
= O
220 O
mm O
Hg O
and O
/ O
or O
diastolic O
BP O
> O
or O
= O
110 O
mm O
Hg O
, O
occurred O
in O
30 O
patients O
( O
1 O
% O
) O
. O

patients O
with O
this O
response O
more O
often O
had O
a O
history O
of O
hypertension B_DISEASE
and O
had O
higher O
resting O
systolic O
and O
diastolic O
BP O
before O
dobutamine O
infusion O
. O

continuously O
nebulized O
albuterol O
in O
severe O
exacerbations O
of O
asthma B_DISEASE/B_LOCATION
in O
adults O
: O
a O
case O
- O
controlled O
study O
. O

A O
retrospective O
, O
case O
- O
controlled O
analysis O
comparing O
patients O
admitted O
to O
a O
medical O
intensive O
care O
unit O
with O
severe O
exacerbations O
of O
asthma B_DISEASE/B_LOCATION
who O
received O
continuously O
nebulized O
albuterol O
( O
CNA O
) O
versus O
intermittent O
albuterol O
( O
INA O
) O
treatments O
is O
reported O
. O

Forty O
matched O
pairs O
of O
patients O
with O
asthma B_DISEASE/B_LOCATION
are O
compared O
. O

CNA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
was O
administered O
for O
a O
mean B_MEASURE/B_LOCATION
of O
11 B_MEASURE
+ I_MEASURE
/ O
- O
10 B_TIME[MEASURE]
hr I_TIME[MEASURE]
. O

The O
incidence O
of O
cardiac B_DISEASE
dysrhythmias I_DISEASE
was O
similar O
between O
groups O
. O

Symptomatic O
hypokalemia B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
did O
not O
occur O
. O

CNA B_PERSON
patients I_PERSON
had O
higher B_DISEASE_ADJECTIVE[DISEASE]
heart I_DISEASE_ADJECTIVE[DISEASE]
rates I_DISEASE_ADJECTIVE[DISEASE]
during O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
, O
which O
may O
reflect O
severity B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O
illness B_DISEASE
. O

The O
incidence B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
intubation B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O
similar B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O

We O
conclude O
that O
CNA B_LOCATION/B_ORGANIZATION
and O
INA B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
demonstrated O
similar B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
profiles B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
regard B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
safety B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
morbidity B_DISEASE
, O
and O
mortality B_DISEASE
. O

Paraplegia B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
following O
intrathecal O
methotrexate O
: O
report O
of O
a O
case O
and O
review O
of O
the O
literature O
. O

A O
patient O
who O
developed O
paraplegia B_DISEASE
following O
the O
intrathecal O
instillation O
of O
methotrexate O
is O
discribed O
. O

The O
ten B_NUMBER[MEASURE]
previously O
reported O
cases B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
this O
unusual B_DISEASE
complication I_DISEASE
are O
reviewed O
. O

The O
following O
factors O
appear O
to O
predispose O
to O
the O
development O
of O
this O
complication O
: O
abnormal O
cerebrospinal O
dynamics O
related O
to O
the O
presence O
of O
central B_DISEASE
nervous I_DISEASE
system I_DISEASE
leukemia I_DISEASE
, O
and O
epidural O
cerebrospinal O
leakage O
; O
elevated O
cerebrospinal O
fluid O
methothexate O
concentration O
related O
to O
abnormal O
cerebrospinal O
fluid O
dynamics O
and O
to O
inappropriately O
high O
methotrexate O
doses O
based O
on O
body O
surface O
area O
calculations O
in O
older O
children O
and O
adults O
; O
the O
presence O
of O
neurotoxic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
preservatives O
in O
commercially O
available O
methotrexate O
preparations O
and O
diluents O
; O
and O
the O
use O
of O
methotrexate O
diluents O
of O
unphysiologic O
pH O
, O
ionic O
content O
and O
osmolarity O
. O

The O
role O
of O
methotrexate O
contaminants O
, O
local O
folate B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
deficiency B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
cranial O
irradiation O
in O
the O
pathogenesis O
of O
intrathecal O
methotrexate O
toxicity B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
unclear O
. O

The O
incidence O
of O
neurotoxicity B_DISEASE
may O
be O
reduced O
by O
employing O
lower O
doses O
of O
methotrexate O
in O
the O
presence O
of O
central B_DISEASE
nervous I_DISEASE
system I_DISEASE
leukemia I_DISEASE
, O
in O
older O
children O
and O
adults O
, O
and O
in O
the O
presence O
of O
epidural O
leakage O
. O

Only O
preservative B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
free B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
methotrexate I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
in O
Elliott B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
' I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
s I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
B I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
solution I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
at O
a O
concentration B_MEASURE/B_LOCATION
of O
not O
more B_MEASURE
than O
1 B_MEASURE
mg I_MEASURE
/ O
ml B_MEASURE/B_PERSON
should O
be O
used O
for O
intrathecal B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
administration I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
. O

periodic O
monitoring O
of O
cerebruspinal O
fluid O
methotrexate O
levels O
may O
be O
predictive O
of O
the O
development O
of O
serious O
neurotoxicity B_DISEASE
. O

Hyperosmolar B_DISEASE
nonketotic I_DISEASE
coma I_DISEASE
precipitated O
by O
lithium O
- O
induced O
nephrogenic B_DISEASE
diabetes I_DISEASE
insipidus I_DISEASE
. O

A O
45 O
- O
year O
- O
old O
man O
, O
with O
a O
10 O
- O
year O
history O
of O
manic B_DISEASE
depression I_DISEASE
treated O
with O
lithium O
, O
was O
admitted O
with O
hyperosmolar B_DISEASE
, I_DISEASE
nonketotic I_DISEASE
coma I_DISEASE
. O

He O
gave O
a O
five O
- O
year O
history O
of O
polyuria B_DISEASE
and O
polydipsia B_DISEASE
, O
during O
which O
time O
urinalysis O
had O
been O
negative O
for O
glucose O
. O

After O
recovery O
from O
hyperglycaemia B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
he O
remained O
polyuric B_DISEASE_ADJECTIVE[DISEASE]
despite O
normal O
blood O
glucose O
concentrations O
; O
water O
deprivation O
testing O
indicated O
nephrogenic B_DISEASE
diabetes I_DISEASE
insipidus I_DISEASE
, O
likely O
to O
be O
lithium O
- O
induced O
. O

We O
hypothesize O
that O
when O
this O
man O
developed O
type B_DISEASE
2 I_DISEASE
diabetes I_DISEASE
, O
chronic O
polyuria B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
due O
to O
nephrogenic B_DISEASE
diabetes I_DISEASE
insipidus I_DISEASE
was O
sufficient O
to O
precipitate O
hyperosmolar O
dehydration B_DISEASE
. O

Effects B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
intracoronary B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
infusion I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANISM_FUNCTION
of O
cocaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
left B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
ventricular I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
systolic I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
and O
diastolic B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
function I_MEASURE/I_BODY_PART_OR_ORGAN_COMPONENT
in O
humans B_PERSON/B_SPECIES[BIO]
. O

Background O
: O
In O
dogs O
, O
a O
large O
amount O
of O
intravenous O
cocaine O
causes O
a O
profound O
deterioration B_DISEASE
of I_DISEASE
left I_DISEASE
ventricular I_DISEASE
( I_DISEASE
LV I_DISEASE
) I_DISEASE
systolic I_DISEASE
function I_DISEASE
and O
an O
increase O
in O
LV O
end O
- O
diastolic O
pressure O
. O

This O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
done O
to O
assess O
the O
influence B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
a O
high B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
intracoronary B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cocaine B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
concentration B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
LV B_BODY_PART_OR_ORGAN_COMPONENT
systolic I_BODY_PART_OR_ORGAN_COMPONENT
and O
diastolic B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
function I_MEASURE/I_BODY_PART_OR_ORGAN_COMPONENT
in O
humans B_PERSON/B_SPECIES[BIO]
. O

methods O
AND O
Results O
: O
In O
20 O
patients O
( O
14 O
men O
and O
6 O
women O
aged O
39 O
to O
72 O
years O
) O
referred O
for O
cardiac O
catheterization O
for O
the O
evaluation O
of O
chest B_DISEASE/B_LOCATION
pain I_DISEASE/I_LOCATION
, O
we O
measured O
heart O
rate O
, O
systemic O
arterial O
pressure O
, O
LV O
pressure O
and O
its O
first O
derivative O
( O
dP O
/ O
dt O
) O
, O
and O
LV O
volumes O
and O
ejection O
fraction O
before O
and O
during O
the O
final O
2 O
to O
3 O
minutes O
of O
a O
15 O
- O
minute O
intracoronary O
infusion O
of O
saline O
( O
n O
= O
10 O
, O
control O
subjects O
) O
or O
cocaine O
hydrochloride O
1 O
mg O
/ O
min O
( O
n O
= O
10 O
) O
. O

No O
variable B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
changed O
with O
saline B_LOCATION/B_MEASURE
. O

With O
cocaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
the O
drug B_MEASURE/B_DISEASE
concentration I_MEASURE/I_DISEASE
in O
blood B_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]
obtained O
from O
the O
coronary B_DISEASE/B_PERSON
sinus I_DISEASE/I_PERSON
was O
3 B_MEASURE
. O
0 B_MEASURE
+ I_MEASURE
/ O
- O
0 B_MEASURE
. O
4 B_MEASURE
( O
mean B_MEASURE
+ O
/ O
- O
SD B_MEASURE/B_DISEASE
) O
mg B_LOCATION/B_MEASURE
/ O
L B_OTHER/B_MEASURE
, O
similar B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
magnitude B_MEASURE/B_LOCATION
to O
the O
blood B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
cocaine I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
concentration I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
reported O
in O
abusers B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
dying O
of O
cocaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
intoxication I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

cocaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
induced O
no O
significant B_MEASURE
change I_MEASURE
in O
heart B_DISEASE/B_PROTEIN[GENE]
rate B_DISEASE/I_PROTEIN[GENE]
, O
LV B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
DP I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
/ O
dt B_PROTEIN[GENE]/B_DISEASE
( O
positive B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O
negative B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
, O
or O
LV B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
end I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
diastolic B_MEASURE/B_LOCATION
volume I_MEASURE/I_LOCATION
, O
but O
it O
caused O
an O
increase B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
systolic B_BODY_PART_OR_ORGAN_COMPONENT/B_MEASURE
and O
mean B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
arterial I_MEASURE/I_BODY_PART_OR_ORGAN_COMPONENT
pressures I_MEASURE/I_BODY_PART_OR_ORGAN_COMPONENT
, O
LV B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
end I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
diastolic B_MEASURE/B_LOCATION
pressure I_MEASURE/I_LOCATION
, O
and O
LV B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
end I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
systolic B_MEASURE
volume I_MEASURE
, O
as O
well O
as O
a O
decrease B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
LV B_MEASURE/B_DISEASE
ejection I_MEASURE/I_DISEASE
fraction I_MEASURE/I_DISEASE
. O

conclusions O
: O
In O
humans O
, O
the O
intracoronary O
infusion O
of O
cocaine O
sufficient O
in O
amount O
to O
achieve O
a O
high O
drug O
concentration O
in O
coronary O
sinus O
blood O
causes O
a O
deterioration B_DISEASE
of I_DISEASE
LV I_DISEASE
systolic I_DISEASE
and I_DISEASE
diastolic I_DISEASE
performance I_DISEASE
. O

ascending O
dose B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
tolerance B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
of O
intramuscular B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
carbetocin I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
administered O
after O
normal B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
vaginal I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
birth I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
. O

Objective B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
To O
determine O
the O
maximum B_MEASURE
tolerated I_MEASURE
dose I_MEASURE
( O
MTD B_MEASURE/B_DISEASE
) O
of O
carbetocin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
( O
a O
long O
- O
acting O
synthetic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analogue I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
oxytocin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
) O
, O
when O
administered O
immediately O
after O
vaginal B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
delivery I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANISM_FUNCTION
at O
term B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
. O

materials B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
AND O
METHODS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
Carbetocin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
was O
given O
as O
an O
intramuscular B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
injection I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
immediately O
after O
the O
birth B_PERSON/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
the O
infant B_PERSON/B_BIO
in O
45 B_PERSON
healthy I_PERSON
women I_PERSON
with O
normal B_DISEASE/B_ORGANISM_FUNCTION
singleton I_DISEASE/I_ORGANISM_FUNCTION
pregnancies I_DISEASE/I_ORGANISM_FUNCTION
who O
delivered O
vaginally O
at O
term B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_TIME[MEASURE]
. O

dosage B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
groups I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
15 B_MEASURE
, O
30 B_MEASURE
, O
50 B_MEASURE
, O
75 B_MEASURE
, O
100 B_MEASURE
, O
125 B_MEASURE
, O
150 B_MEASURE
, O
175 B_MEASURE
or O
200 B_MEASURE/B_LOCATION
microg I_MEASURE/I_LOCATION
carbetocin I_MEASURE/I_LOCATION
were O
assigned O
to O
blocks B_LOCATION/B_ORGANIZATION
of O
three B_NUMBER[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
women I_NUMBER[MEASURE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
according O
to O
the O
continual B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
reassessment I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
method I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O
CRM B_DISEASE/B_LOCATION
) O
. O

RESULTS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O
All O
dosage B_PERSON/B_ORGANIZATION
groups I_PERSON/I_ORGANIZATION
consisted O
of O
three B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_NUMBER[MEASURE]
women I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_NUMBER[MEASURE]
, O
except O
those O
with O
100 B_MEASURE
microg I_MEASURE
( O
n B_OTHER/B_MEASURE
= O
6 B_MEASURE
) O
and O
200 B_MEASURE
microg I_MEASURE
( O
n B_OTHER/B_MEASURE
= O
18 B_MEASURE
) O
. O

Recorded O
were O
dose O
- O
limiting O
adverse O
events O
: O
hyper B_DISEASE
- I_DISEASE
or I_DISEASE
hypotension I_DISEASE
( O
three O
) O
, O
severe O
abdominal B_DISEASE
pain I_DISEASE
( O
0 O
) O
, O
vomiting B_DISEASE
( O
0 O
) O
and O
retained B_DISEASE
placenta I_DISEASE
( O
four O
) O
. O

serious O
adverse O
events O
occurred O
in O
seven O
women O
: O
six O
cases O
with O
blood B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
loss B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
> O
or O
= O
1000 O
ml O
, O
four O
cases O
of O
manual O
placenta O
removal O
, O
five O
cases O
of O
additional O
oxytocics O
administration O
and O
five O
cases O
of O
blood O
transfusion O
. O

Maximum O
blood B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
loss I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
was O
greatest O
at O
the O
upper O
and O
lower O
dose O
levels O
, O
and O
lowest O
in O
the O
70 O
- O
125 O
microg O
dose O
range O
. O

Four O
out O
of O
six O
cases O
with O
blood B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
loss B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
> O
or O
= O
1000 O
ml O
occurred O
in O
the O
200 O
microg O
group O
. O

The O
majority B_MEASURE
of O
additional B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
administration I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
oxytocics B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
( O
4 B_MEASURE
/ O
5 B_MEASURE
) O
and O
blood B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
transfusion I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
3 B_MEASURE
/ O
5 B_MEASURE
) O
occurred O
in O
the O
dose B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
groups I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
200 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
microg I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O

All O
retained O
placentae B_DISEASE/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
found O
in O
the O
group B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
200 B_NUMBER[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
microg I_NUMBER[MEASURE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Conclusion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O
The O
MTD B_MEASURE
was O
calculated O
to O
be O
at O
200 B_MEASURE/B_LOCATION
microg I_MEASURE/I_LOCATION
carbetocin I_MEASURE/I_LOCATION
. O

Heparin O
- O
induced O
thrombocytopenia B_DISEASE
, O
paradoxical O
thromboembolism B_DISEASE
, O
and O
other O
side O
effects O
of O
heparin O
therapy O
. O

Although O
several B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_NUMBER[MEASURE]
new I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_NUMBER[MEASURE]
anticoagulant I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_NUMBER[MEASURE]
drugs I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_NUMBER[MEASURE]
are O
in O
development B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O
heparin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
remains O
the O
drug B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
choice B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
for O
most B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
anticoagulation I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
needs I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
. O

The O
clinical B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
effects I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
of O
heparin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
meritorious B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
, O
but O
side B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
effects I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
do O
exist O
. O

Important O
untoward O
effects O
of O
heparin O
therapy O
including O
heparin O
- O
induced O
thrombocytopenia B_DISEASE
, O
heparin O
- O
associated O
osteoporosis B_DISEASE
, O
eosinophilia B_DISEASE
, O
skin B_DISEASE
reactions I_DISEASE
, O
allergic B_DISEASE
reactions I_DISEASE
other O
than O
thrombocytopenia B_DISEASE
and O
alopecia B_DISEASE
will O
be O
discussed O
in O
this O
article O
. O

Nonopaque O
crystal O
deposition O
causing O
ureteric B_DISEASE
obstruction I_DISEASE
in O
patients O
with O
HIV O
undergoing O
indinavir O
therapy O
. O

objective O
: O
We O
describe O
the O
unique O
CT O
features O
of O
ureteric B_DISEASE/B_LOCATION
calculi I_DISEASE/I_LOCATION
in O
six O
HIV B_DISEASE/B_PERSON
- I_DISEASE/I_PERSON
infected I_DISEASE/I_PERSON
patients O
receiving O
indinavir O
, O
the O
most O
commonly O
used O
HIV O
protease O
inhibitor O
, O
which O
is O
associated O
with O
an O
increased O
incidence O
of O
urolithiasis B_DISEASE
. O

conclusion O
: O
Ureteric B_DISEASE
obstruction I_DISEASE
caused O
by O
precipitated O
indinavir O
crystals O
may O
be O
difficult O
to O
diagnose O
with O
unenhanced O
CT O
. O

The O
calculi B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
are O
not O
opaque B_DISEASE_ADJECTIVE[DISEASE]
, O
and O
secondary B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
signs I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O
obstruction B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
may O
be O
absent B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
or O
minimal B_DISEASE_ADJECTIVE[DISEASE]
and O
should O
be O
sought O
carefully O
. O

Images O
may O
need O
to O
be O
obtained O
using O
i O
. O
v O
. O
contrast O
material O
to O
enable O
diagnosis O
of O
ureteric B_DISEASE
stones I_DISEASE
or I_DISEASE
obstruction I_DISEASE
in O
patients O
with O
HIV B_DISEASE
infection I_DISEASE
who O
receive O
indinavir O
therapy O
. O

Ischemic B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
colitis B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
sumatriptan O
use O
. O

Sumatriptan B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
succinate I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O
a O
serotonin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
1 B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
( O
5 B_MEASURE
- O
hydroxytryptamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O
1 B_TIME[MEASURE]/B_PERSON
) O
receptor B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
agonist I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O
is O
an O
antimigraine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
drug I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
is O
reported O
to O
act O
by O
selectively O
constricting O
intracranial B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
arteries I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
. O

Recently O
, O
vasopressor B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
responses I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
that O
are O
distinct B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
from O
the O
cranial B_DISEASE/B_MEASURE
circulation I_DISEASE/I_MEASURE
have O
been O
demonstrated O
to O
occur O
in O
the O
systemic B_BODY_PART_OR_ORGAN_COMPONENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
pulmonary B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
, O
and O
coronary B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
circulations I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O

cases O
have O
been O
published O
of O
coronary B_DISEASE
vasospasm I_DISEASE
, O
myocardial B_DISEASE
ischemia I_DISEASE
, O
and O
myocardial B_DISEASE
infarction I_DISEASE
occurring O
after O
sumatriptan O
use O
. O

We O
report O
on O
the O
development O
of O
8 O
serious O
cases O
of O
ischemic B_DISEASE
colitis I_DISEASE
in O
patients O
with O
migraine B_DISEASE/B_LOCATION
treated O
with O
sumatriptan O
. O

Pallidotomy B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
with O
the O
gamma B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
knife I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_PERSON
: O
a O
positive B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
experience I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
. O

51 O
patients O
with O
medically O
refractory O
Parkinson B_DISEASE
' I_DISEASE
s I_DISEASE
disease I_DISEASE
underwent O
stereotactic O
posteromedial O
pallidotomy O
between O
August O
1993 O
and O
February O
1997 O
for O
treatment O
of O
bradykinesia B_DISEASE
, O
rigidity B_DISEASE
, O
and O
L O
- O
DOPA O
- O
induced O
dyskinesias B_DISEASE
. O

In O
29 B_TIME[MEASURE]
patients I_TIME[MEASURE]
, O
the O
pallidotomies B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
were O
performed O
with O
the O
Leksell B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
Gamma I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
knife I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
in O
22 B_MEASURE
they O
were O
performed O
with O
the O
standard B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BODY_PART_OR_ORGAN_COMPONENT
radiofrequency I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_BODY_PART_OR_ORGAN_COMPONENT
( O
RF B_LOCATION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
) O
method B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Clinical O
assessment O
as O
well O
as O
blinded O
ratings O
of O
Unified O
Parkinson B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
' I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
s I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
Disease I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
rating O
Scale O
( O
UPDRS O
) O
scores O
were O
carried O
out O
pre O
- O
and O
postoperatively O
. O

Mean B_MEASURE/B_PERSON
follow O
- O
up O
time B_TIME[MEASURE]
is O
20 B_MEASURE
. O
6 B_TIME[MEASURE]
months I_TIME[MEASURE]
( O
range B_MEASURE/B_LOCATION
6 I_MEASURE/I_LOCATION
- O
48 B_MEASURE
) O
and O
all O
except O
4 B_NUMBER[MEASURE]
patients I_NUMBER[MEASURE]
have O
been O
followed O
more B_TIME[MEASURE]
than O
one B_TIME[MEASURE]/B_LOCATION
year I_TIME[MEASURE]/I_LOCATION
. O

85 O
percent O
of O
patients O
with O
dyskinesias B_DISEASE
were O
relieved O
of O
symptoms O
, O
regardless O
of O
whether O
the O
pallidotomies O
were O
performed O
with O
the O
Gamma O
knife O
or O
radiofrequency O
methods O
. O

About O
2 O
/ O
3 O
of O
the O
patients O
in O
both O
Gamma O
knife O
and O
radiofrequency O
groups O
showed O
improvements O
in O
bradykinesia B_DISEASE/B_MEASURE
and O
rigidity B_DISEASE
, O
although O
when O
considered O
as O
a O
group O
neither O
the O
Gamma O
knife O
nor O
the O
radiofrequency O
group O
showed O
statistically O
significant O
improvements O
in O
UPDRS O
scores O
. O

One O
patient O
in O
the O
Gamma O
knife O
group O
( O
3 O
. O
4 O
% O
) O
developed O
a O
homonymous B_DISEASE
hemianopsia I_DISEASE
9 O
months O
following O
treatment O
and O
5 O
patients O
( O
27 O
. O
7 O
% O
) O
in O
the O
radiofrequency O
group O
became O
transiently O
confused O
postoperatively O
. O

No O
other B_DISEASE
complications I_DISEASE
were O
seen O
. O

Gamma O
knife O
pallidotomy O
is O
as O
effective O
as O
radiofrequency O
pallidotomy O
in O
controlling O
certain O
of O
the O
symptoms O
of O
Parkinson B_DISEASE
' I_DISEASE
s I_DISEASE
disease I_DISEASE
. O

It O
may O
be O
the O
only O
practical O
technique O
available O
in O
certain O
patients O
, O
such O
as O
those O
who O
take O
anticoagulants O
, O
have O
bleeding B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
diatheses O
or O
serious O
systemic O
medical O
illnesses O
. O

It O
is O
a O
viable B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
option I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
for O
other B_PERSON
patients I_PERSON
as O
well O
. O

Centrally O
mediated O
cardiovascular B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
effects I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
of O
intracisternal B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
application I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
carbachol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
anesthetized B_PERSON/B_BIO
rats I_PERSON/I_BIO
. O

The O
pressor B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
response B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
to O
the O
intracisternal B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
( O
i O
. O
c O
. O
) O
injection B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
of O
carbachol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
1 B_PROTEIN[GENE]/B_LOCATION
mug B_PROTEIN[GENE]/I_LOCATION
) O
in O
anesthetized B_SPECIES[BIO]
rats I_SPECIES[BIO]
was O
analyzed O
. O

This O
response O
was O
significantly O
reduced O
by O
the O
intravenous O
( O
i O
. O
v O
. O
) O
injection O
of O
guanethidine O
( O
5 O
mg O
) O
, O
hexamethonium O
( O
10 O
mg O
) O
or O
phentolamine O
( O
5 O
mg O
) O
, O
and O
Conversely O
, O
potentiated O
by O
i O
. O
v O
. O
desmethylimipramine O
( O
0 O
. O
3 O
mg O
) O
, O
while O
propranolol O
( O
0 O
. O
5 O
mg O
) O
i O
. O
v O
. O
selectively O
inhibited O
the O
enlargement B_DISEASE
of I_DISEASE
pulse I_DISEASE
pressure I_DISEASE
and O
the O
tachycardia B_DISEASE
following O
i O
. O
c O
. O
carbachol O
( O
1 O
mug O
) O
. O

On O
the O
other B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
hand I_TIME[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
the O
pressor B_DISEASE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
response I_DISEASE/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
i O
. O
c B_DISEASE/B_LOCATION
. O
carbachol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
1 B_TIME[MEASURE]
mug I_TIME[MEASURE]
) O
was O
almost O
completely O
blocked O
by O
i O
. O
c B_DISEASE/B_LOCATION
. O
atropine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
3 B_MEASURE
mug I_MEASURE
) O
or O
hexamethonium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
( O
500 B_MEASURE
mug I_MEASURE
) O
, O
and O
significantly O
reduced O
by O
i O
. O
c B_DISEASE/B_LOCATION
. O
chlorpromazine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
50 B_MEASURE
mug I_MEASURE
) O
but O
significantly O
potentiated O
by O
i O
. O
c B_DISEASE/B_LOCATION
. O
desmethylimipramine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
30 B_MEASURE
mug I_MEASURE
) O
. O

The O
pressor B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
response B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
to O
i O
. O
c B_DISEASE/B_LOCATION
. O
carbachol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
1 B_PROTEIN[GENE]
mug I_PROTEIN[GENE]
) O
remained O
unchanged B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
after O
sectioning O
of O
the O
bilateral B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
cervical I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
vagal I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
nerves I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
but O
disappeared O
after O
sectioning O
of O
the O
spinal B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
cord I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
( O
C7 B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
C8 B_MEASURE/B_PROTEIN[GENE]
) O
. O

From O
the O
above B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
result I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
it O
is O
suggested O
that O
the O
pressor B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
response B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
to O
i O
. O
c B_DISEASE/B_LOCATION
. O
carbachol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ortral I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
peripheral B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
adrenergic I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
mechanisms I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
and O
that O
the O
sympathetic B_BODY_PART_OR_ORGAN_COMPONENT
trunk I_BODY_PART_OR_ORGAN_COMPONENT
is O
the O
main B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
pathway I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
. O

Neuroleptic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
malignant I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
syndrome I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
methylphenidate O
. O

A O
1 O
- O
year O
- O
old O
female O
presented O
with O
neuroleptic B_DISEASE
malignant I_DISEASE
syndrome I_DISEASE
probably O
caused O
by O
methylphenidate O
. O

She O
had O
defects O
in O
the O
supratentorial O
brain O
including O
the O
basal O
ganglia O
and O
the O
striatum O
( O
multicystic B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
encephalomalacia B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
) O
due O
to O
severe O
perinatal O
hypoxic B_DISEASE
- I_DISEASE
ischemic I_DISEASE
encephalopathy I_DISEASE
, O
which O
was O
considered O
to O
be O
a O
possible O
predisposing O
factor O
causing O
neuroleptic B_DISEASE
malignant I_DISEASE
syndrome I_DISEASE
. O

A O
dopaminergic B_DISEASE_ADJECTIVE[DISEASE]
blockade I_DISEASE_ADJECTIVE[DISEASE]
mechanism I_DISEASE_ADJECTIVE[DISEASE]
generally O
is O
accepted O
as O
the O
pathogenesis B_DISEASE
of O
this O
syndrome B_DISEASE
. O

However O
, O
methylphenidate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
is O
a O
dopamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
agonist I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
via O
the O
inhibition B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
of O
uptake B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
dopamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
therefore O
dopaminergic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
systems B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
in O
the O
brainstem B_BODY_PART_OR_ORGAN_COMPONENT
( O
mainly O
the O
midbrain B_BODY_PART_OR_ORGAN_COMPONENT
) O
and O
the O
spinal B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
cord I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
were O
unlikely B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O
participate O
in O
the O
onset B_DISEASE_ADJECTIVE[DISEASE]
of O
this O
syndrome B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

A O
relative B_MEASURE/B_PROTEIN[GENE]
gamma B_MEASURE/I_PROTEIN[GENE]
- O
aminobutyric B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acid I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
ergic B_DISEASE_ADJECTIVE[DISEASE]
deficiency I_DISEASE_ADJECTIVE[DISEASE]
might O
occur O
because O
diazepam B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
a O
gamma B_PROTEIN[GENE]
- O
aminobutyric B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acid I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
mimetic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
agent I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
was O
strikingly O
effective B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O

This O
is O
the O
first O
reported O
patient O
with O
neuroleptic B_DISEASE
malignant I_DISEASE
syndrome I_DISEASE
probably O
caused O
by O
methylphenidate O
. O

Differential B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
17alpha B_MEASURE/B_PROTEIN[GENE]
- O
ethinylestradiol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
the O
neutral B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
acidic B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pathways B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
bile B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
salt B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
synthesis B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
in O
the O
rat B_BODY_PART_OR_ORGAN_COMPONENT/B_GENE
. O

Effects B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
17alpha B_MEASURE/B_PERSON
- O
ethinylestradiol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
EE B_LOCATION/B_ORGANIZATION
) O
on O
the O
neutral B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
acidic B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
biosynthetic B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pathways B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
bile B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
salt I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O
BS B_LOCATION
) O
synthesis B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
were O
evaluated O
in O
rats B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
an O
intact B_DISEASE
enterohepatic I_DISEASE
circulation I_DISEASE
and O
in O
rats B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
long B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O
term B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
bile B_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
diversion B_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
to O
induce O
BS B_DISEASE
synthesis I_DISEASE
. O

For O
this O
purpose B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
bile B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
salt I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pool I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
composition I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
synthesis B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
of O
individual B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
BS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
in O
vivo B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
hepatic B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activities B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
expression B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
levels I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
of O
cholesterol B_MEASURE
7alpha I_MEASURE
- O
hydroxylase B_ENZYME[GENE]
( O
CYP7A B_GENE/B_LOCATION
) O
, O
and O
sterol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
27 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
- O
hydroxylase B_ENZYME[GENE]
( O
CYP27 B_LOCATION/B_ORGANIZATION
) O
, O
as O
well O
as O
of O
other B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
enzymes I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
involved O
in O
BS B_DISEASE/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
synthesis B_DISEASE/I_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
, O
were O
analyzed O
in O
rats B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treated O
with O
EE B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O
5 B_MEASURE
mg I_MEASURE
/ O
kg B_MEASURE
, O
3 B_TIME[MEASURE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
days B_TIME[MEASURE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
or O
its O
vehicle B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O

BS B_MEASURE/B_PROTEIN[GENE]
pool I_MEASURE/I_PROTEIN[GENE]
size I_MEASURE/I_PROTEIN[GENE]
was O
decreased O
by O
27 B_LOCATION
% I_LOCATION
but O
total B_LOCATION/B_MEASURE
BS B_LOCATION/I_MEASURE
synthesis B_LOCATION/I_MEASURE
was O
not O
affected O
by O
EE B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
in O
intact B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
rats I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

synthesis B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
cholate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
reduced O
by O
68 B_NUMBER[MEASURE]/B_PERSON
% I_NUMBER[MEASURE]/I_PERSON
in O
EE B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
treated O
rats B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
while O
that O
of O
chenodeoxycholate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
increased O
by O
60 B_NUMBER[MEASURE]/B_LOCATION
% I_NUMBER[MEASURE]/I_LOCATION
. O

The O
recently O
identified O
Delta22 B_PROTEIN[GENE]/B_MEASURE
- O
isomer B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
of O
beta B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
- O
muricholate B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
contributed O
for O
5 B_MEASURE
. O
4 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
and O
18 B_MEASURE
. O
3 B_MEASURE
% I_MEASURE
( O
P B_PROTEIN[GENE]/B_LOCATION
< O
0 B_MEASURE
. O
01 B_MEASURE
) O
to O
the O
pool B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
in O
control B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
and O
EE B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
treated O
rats B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
respectively O
, O
but O
could O
not O
be O
detected O
in O
bile B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
after O
exhaustion B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O
the O
pool B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

A O
clear B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
reduction B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
BS B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
synthesis I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
was O
found O
in O
bile B_BODY_PART_OR_ORGAN_COMPONENT
- O
diverted O
rats B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treated O
with O
EE B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
yet O
biliary B_MEASURE/B_PROTEIN[GENE]
BS B_MEASURE/I_PROTEIN[GENE]
composition B_MEASURE/I_PROTEIN[GENE]
was O
only O
minimally O
affected O
. O

Activity B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
CYP7A B_GENE
was O
decreased O
by O
EE B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
in O
both O
intact B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
and O
bile B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
- O
diverted O
rats B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
whereas O
the O
activity B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
of O
the O
CYP27 B_GENE/B_BIO
was O
not O
affected O
. O

Hepatic B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
mRNA I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
levels I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
of O
CYP7A B_GENE
were O
significantly O
reduced O
by O
EE B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
bile B_BODY_PART_OR_ORGAN_COMPONENT/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
diverted O
rats B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
only O
; O
CYP27 B_PERSON/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mRNA I_PERSON/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
levels I_PERSON/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
not O
affected O
by O
EE B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O

In O
addition B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
, O
mRNA B_GENE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
levels B_GENE/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
sterol B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
12alpha I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
hydroxylase B_ENZYME[GENE]
and O
lithocholate B_MEASURE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
6beta I_MEASURE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
hydroxylase B_ENZYME[GENE]
were O
increased O
by O
bile B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
diversion I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
and O
suppressed O
by O
EE B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O

This O
study O
shows O
that O
17alpha O
- O
ethinylestradiol O
( O
EE O
) O
- O
induced O
intrahepatic B_DISEASE
cholestasis I_DISEASE
in O
rats O
is O
associated O
with O
selective O
inhibition O
of O
the O
neutral O
pathway O
of O
bile O
salt O
( O
BS O
) O
synthesis O
. O

Simultaneous B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
impairment B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
other B_ENZYME[GENE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
enzymes B_ENZYME[GENE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
BS B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
biosynthetic I_BODY_PART_OR_ORGAN_COMPONENT/I_BIO
pathways I_BODY_PART_OR_ORGAN_COMPONENT/I_BIO
may O
contribute O
to O
overall B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
effects B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
of O
EE B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
on O
BS B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
synthesis B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

Glibenclamide O
- O
sensitive O
hypotension B_DISEASE
produced O
by O
helodermin O
assessed O
in O
the O
rat O
. O

The O
effects B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
helodermin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O
a O
basic B_MEASURE
35 I_MEASURE
- O
amino B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENZYME[GENE]
acid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENZYME[GENE]
peptide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENZYME[GENE]
isolated O
from O
the O
venom B_BODY_PART_OR_ORGAN_COMPONENT/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
a O
lizard B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
salivary I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
gland I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
, O
on O
arterial B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
blood B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pressure B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
heart B_DISEASE
rate I_DISEASE
were O
examined O
in O
the O
rat B_SPECIES[BIO]/B_GENE
, O
focusing O
on O
the O
possibility B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
that O
activation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
of O
ATP B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
sensitive I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
K I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
+ O
( O
K B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
ATP B_PROTEIN[GENE]/B_LOCATION
) O
) O
channels B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
is O
involved O
in O
the O
responses B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O

The O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
were O
also O
compared O
with O
those O
of O
vasoactive B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
intestinal I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
polypeptide I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
( O
VIP B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
. O

Helodermin O
produced O
hypotension B_DISEASE
in O
a O
dose O
- O
dependent O
manner O
with O
approximately O
similar O
potency O
and O
duration O
to O
VIP O
. O

Hypotension B_DISEASE
induced O
by O
both O
peptides O
was O
significantly O
attenuated O
by O
glibenclamide O
, O
which O
abolished O
a O
levcromakalim O
- O
produced O
decrease O
in O
arterial O
blood O
pressure O
. O

Oxyhemoglobin O
did O
not O
affect O
helodermin O
- O
induced O
hypotension B_DISEASE
, O
whereas O
it O
shortened O
the O
duration O
of O
acetylcholine O
( O
ACh O
) O
- O
produced O
hypotension B_DISEASE
. O

These O
findings O
suggest O
that O
helodermin O
- O
produced O
hypotension B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
is O
partly O
attributable O
to O
the O
activation O
of O
glibenclamide O
- O
sensitive O
K O
+ O
channels O
( O
K O
( O
ATP O
) O
channels O
) O
, O
which O
presumably O
exist O
on O
arterial O
smooth O
muscle O
cells O
. O

EDRF O
( O
endothelium O
- O
derived O
relaxing O
factor O
) O
/ O
nitric O
oxide O
does O
not O
seem O
to O
play O
an O
important O
role O
in O
the O
peptide O
- O
produced O
hypotension B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Long O
- O
term O
efficacy O
and O
adverse O
event O
of O
nifedipine O
sustained O
- O
release O
tablets O
for O
cyclosporin O
A O
- O
induced O
hypertension B_DISEASE
in O
patients O
with O
psoriasis B_DISEASE/B_LOCATION
. O

Thirteen O
psoriatic B_DISEASE/B_MEASURE
patients O
with O
hypertension B_DISEASE
during O
the O
course O
of O
cyclosporin O
A O
therapy O
were O
treated O
for O
25 O
months O
with O
a O
calcium O
channel O
blocker O
, O
sustained O
- O
release O
nifedipine O
, O
to O
study O
the O
clinical O
antihypertensive O
effects O
and O
adverse O
events O
during O
treatment O
with O
both O
drugs O
. O

Seven O
of O
the O
13 O
patients O
had O
exhibited O
a O
subclinical O
hypertensive B_DISEASE_ADJECTIVE[DISEASE]
state O
before O
cyclosporin O
A O
therapy O
. O

Both O
systolic B_BODY_PART_OR_ORGAN_COMPONENT/B_MEASURE
and O
diastolic B_MEASURE/B_DISEASE
blood B_MEASURE/I_DISEASE
pressures B_MEASURE/I_DISEASE
of O
these O
13 B_PERSON
patients I_PERSON
were O
decreased O
significantly O
after O
4 B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
weeks I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
nifedipine B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
therapy I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
and O
blood B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pressure I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
maintained O
within O
the O
normal B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
range B_MEASURE/I_BODY_PART_OR_ORGAN_COMPONENT
thereafter O
for O
25 B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
months I_TIME[MEASURE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

The O
adverse O
events O
during O
combined O
therapy O
with O
cyclosporin O
A O
and O
nifedipine O
included O
an O
increase O
in O
blood O
urea O
nitrogen O
levels O
in O
9 O
of O
the O
13 O
patients O
and O
development O
of O
gingival B_DISEASE
hyperplasia I_DISEASE
in O
2 O
of O
the O
13 O
patients O
. O

Our O
findings O
indicate O
that O
sustained O
- O
release O
nifedipine O
is O
useful O
for O
hypertensive B_DISEASE/B_LOCATION
psoriatic I_DISEASE/I_LOCATION
patients O
under O
long O
- O
term O
treatment O
with O
cyclosporin O
A O
, O
but O
that O
these O
patients O
should O
be O
monitored O
for O
gingival B_DISEASE
hyperplasia I_DISEASE
. O

